PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Shaw, JW; Bennett, B; Trigg, A; DeRosa, M; Taylor, F; Kiff, C; Ntais, D; Noon, K; King, MT; Cocks, K				Shaw, James W.; Bennett, Bryan; Trigg, Andrew; DeRosa, Michael; Taylor, Fiona; Kiff, Christopher; Ntais, Dionysios; Noon, Katie; King, Madeleine T.; Cocks, Kim			A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions	VALUE IN HEALTH			English	Article						cost-effectiveness; European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions; EQ-5D-3L; EQ-5D-5L; nivolumab; quality-adjusted life-years	DISCRETE-CHOICE EXPERIMENTS; PSYCHOMETRIC PROPERTIES; HEALTH STATES; POPULATION; PATIENT; QALYS; VALIDATION; VALUATION; QLU-C10D; EUROQOL	Objectives: There is growing interest in condition-specific preference measures, including the European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions (QLU-C10D). This research assessed the implications of using utility indices on the basis of the EQ-5D-3L, a mapping of EQ-5D-3L to the EQ-5D-5L, and the QLU-C10D, and compared their psychometric properties. Methods: Data were taken from 8 phase 3 randomized controlled trials of nivolumab with or without ipilimumab for the treatment of solid tumors. Utilities for progression-related states were calculated using the UK and English value sets and incremental quality-adjusted life-years (QALYs) derived from established UK cost-effectiveness models. The psychometric properties of the utility indices were assessed using pooled trial data. Results: Compared with the EQ-5D-3L index, the mapped EQ-5D-5L index yielded an average of 6% more and the QLU-C10D index an average of 2% fewer incremental QALYs for nivolumab versus comparators. All indices could differentiate between groups defined by performance status, cancer stage, or self-reported health status at baseline and detect meaningful changes in performance status, tumor response, health status, and quality of life over approximately 12 weeks of treatment. Conclusions: The lower QALY yield of the QLU-C10D was balanced by evidence of greater validity and responsiveness. Benefits gained from using the QLU-C10D may be apparent when treatments affect targeted symptoms and functional aspects, including sleep, bowel function, appetite, nausea, and fatigue. The observed differences in QALYs may not be sufficiently large to affect health technology assessment decisions.	[Shaw, James W.] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ USA; [Bennett, Bryan; Kiff, Christopher; Ntais, Dionysios; Noon, Katie] Bristol Myers Squibb Pharmaceut Ltd, Uxbridge, Middx, England; [Trigg, Andrew; Cocks, Kim] Adelphi Values Ltd, Patient Ctr Outcomes, Bollington, England; [DeRosa, Michael; Taylor, Fiona] Adelphi Values, Patient Ctr Outcomes, Boston, MA USA; [King, Madeleine T.] Univ Sydney, Sch Psychol, Sydney, NSW, Australia		Shaw, JW (通讯作者)，3401 Princeton Pike, Lawrenceville, NJ 08648 USA.	james.shaw@bms.com			Bristol Myers SquibbBristol-Myers Squibb	This study was supported by Bristol Myers Squibb.	Alava MH, 2018, VALUE HEALTH, V21, P49, DOI 10.1016/j.jval.2017.09.004; Ali S, 2012, BRIT MED BULL, V103, P21, DOI 10.1093/bmb/lds020; Arnesen T, 2005, HEALTH ECON, V14, P39, DOI 10.1002/hec.895; Attema AE, 2013, EUR J HEALTH ECON, V14, pS53, DOI 10.1007/s10198-013-0508-x; Bennett B, 2021, 2021 VIRT EUR ACAD M; BOYD NF, 1990, MED DECIS MAKING, V10, P58, DOI 10.1177/0272989X9001000109; Bozzani FM, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-43; Brazier JE, 2019, VALUE HEALTH, V22, P62, DOI 10.1016/j.jval.2018.12.001; Bryan Stirling, 2004, Eur J Health Econ, V5, P199, DOI 10.1007/s10198-004-0241-6; Buchholz I, 2018, PHARMACOECONOMICS, V36, P645, DOI 10.1007/s40273-018-0642-5; Cha AS, 2019, QUAL LIFE RES, V28, P3065, DOI 10.1007/s11136-019-02249-y; Coens C, 2020, LANCET ONCOL, V21, pE83, DOI 10.1016/S1470-2045(19)30790-9; Cohen J., 1988, STAT POWER ANAL BEHA; Danish Medicines Council, 2021, DAN MED COUNC METH G; Devlin NJ, 2018, HEALTH ECON, V27, P7, DOI 10.1002/hec.3564; Devlin NJ, 2017, J Cancer Policy, V11, P19, DOI 10.1016/j.jcpo.2016.09.005; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Dolan P, 1996, J HEALTH ECON, V15, P209, DOI 10.1016/0167-6296(95)00038-0; Epskamp S, 2018, PSYCHOL METHODS, V23, P617, DOI 10.1037/met0000167; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Foygel R., 2010, ADV NEURAL INFORM PR; Gamper EM, 2020, QUAL LIFE RES, V29, P2485, DOI 10.1007/s11136-020-02536-z; Garbuszus JM, READSTATA13 IMPORT V; Gries KS, 2016, VALUE HEALTH, V19, P218, DOI 10.1016/j.jval.2015.11.012; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hernandez-Alava M, 2017, METHODS MAPPING EQ 5; Hernandez-Alava M, 2018, STATA J, V18, P395, DOI 10.1177/1536867X1801800207; Hernandez-Alava M, 2017, J HEALTH ECON, V55, P139, DOI 10.1016/j.jhealeco.2017.06.013; Jansen SJT, 2000, MED DECIS MAKING, V20, P62, DOI 10.1177/0272989X0002000108; Jiang R, 2018, 40 ANN M SOC MED SOC; Jiang R, 2019, 36 PLEN M EUROQOL GR; Karimi M, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0678-9; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Kemmler G, 2019, QUAL LIFE RES, V28, P3197, DOI 10.1007/s11136-019-02283-w; Khan I, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0455-1; Kim TH, 2013, QUAL LIFE RES, V22, P2245, DOI 10.1007/s11136-012-0331-3; King MT, 2016, QUAL LIFE RES, V25, P625, DOI 10.1007/s11136-015-1217-y; King MT, 2018, PHARMACOECONOMICS, V36, P225, DOI 10.1007/s40273-017-0582-5; Krabbe PFM, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-31; Lenert LA, 1998, MED DECIS MAKING, V18, P76, DOI 10.1177/0272989X9801800115; Lorgelly PK, 2017, QUAL LIFE RES, V26, P1163, DOI 10.1007/s11136-016-1443-y; Lovett R, STUDY WILL MEASURE P; Marti-Pastor M, 2018, POPUL HEALTH METR, V16, DOI 10.1186/s12963-018-0170-8; McTaggart-Cowan Helen, 2019, MDM Policy Pract, V4, p2381468319842532, DOI 10.1177/2381468319842532; Mulhern B, 2018, PHARMACOECONOMICS, V36, P699, DOI 10.1007/s40273-018-0628-3; National Institute for Health and Care Excellence, POS STAT US EQ 5D 5L; National Institute for Health and Care Excellence, TA483 NIH CAR EXC; National Institute for Health and Care Excellence, GUID METH TECHN APPR; Norman R, 2019, HEALTH ECON, V28, P1385, DOI 10.1002/hec.3950; Norman R, 2010, QUAL LIFE RES, V19, P499, DOI 10.1007/s11136-010-9609-5; Oppe M., 2015, EQ 5D 3L USER GUIDE; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Pennington B, 2019, PHARMACOECONOMICS, V37, P75, DOI 10.1007/s40273-018-0701-y; Perelman J, METHODOLOGICAL GUIDE; Pickard AS, 2018, VALUE HEALTH, V21, pS387, DOI 10.1016/j.jval.2018.09.2298; Pickard AS, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-70; Pickard AS, 2019, VALUE HEALTH, V22, P931, DOI 10.1016/j.jval.2019.02.009; Pickard AS, 2013, EUR J HEALTH ECON, V14, P697, DOI 10.1007/s10198-012-0421-8; Pickard AS, 2017, 34 PLEN M EUR GROUP; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robinson A, 2017, MED DECIS MAKING, V37, P273, DOI 10.1177/0272989X16668343; Rowen D, 2017, PHARMACOECONOMICS, V35, pS11, DOI 10.1007/s40273-017-0544-y; Ryan M, 2001, QUAL HEALTH CARE, V10, pI55; Shaw JW, 2019, VALUE HEALTH, V22, pS922; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sully K, 2019, EUR J HAEMATOL, V103, P500, DOI 10.1111/ejh.13316; Thompson AJ, 2020, PHARMACOECONOMICS, V38, P575, DOI 10.1007/s40273-020-00893-8; Ubel PA, 2003, QUAL LIFE RES, V12, P599, DOI 10.1023/A:1025119931010; van Hout B, VALUE HEALTH; van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008; Versteegh MM, 2012, VALUE HEALTH, V15, P504, DOI 10.1016/j.jval.2011.12.003; WASSERMAN S, 1988, J EDUC STAT, V13, P75; Weyler EJ, 2011, HEALTH SERV RES, V46, P1562, DOI 10.1111/j.1475-6773.2011.01268.x; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Yang F, 2019, VALUE HEALTH, V22, P45, DOI 10.1016/j.jval.2018.05.008; Yfantopoulos JN, 2017, EUR J HEALTH ECON, V18, P519, DOI 10.1007/s10198-016-0807-0; Zhao LC, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014719	77	0	0	4	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	NOV	2021	24	11					1651	1659		10.1016/j.jval.2021.05.022		OCT 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	XF1GI	34711366				2022-04-28	WOS:000723825200013
J	Reed, SD; Yang, JC; Gonzalez, JM; Johnson, FR				Reed, Shelby D.; Yang, Jui-Chen; Gonzalez, Juan Marcos; Johnson, F. Reed			Quantifying Value of Hope	VALUE IN HEALTH			English	Article						discrete-choice experiment; hope; patient preferences; value assessment	DISCRETE-CHOICE EXPERIMENT; HEALTH ECONOMICS APPROACH; WILLINGNESS-TO-PAY; DEFINING ELEMENTS; DURABLE SURVIVAL; RISK; PREFERENCES; BANKRUPTCY	Background: 'Hope' is a construct in patient-centered value frameworks, but few studies have attempted to measure the value of hope separately from treatment-related gains in quality of life and survival to support its application in economic evaluation. Objective: To generate quantitative information on the "value of hope". Methods: We designed a discrete-choice experiment in which treatment alternatives varied the probability of achieving 10 year survival, expected survival as the weighted sum of short-term and long-term survival, health status, and out-of-pocket cost. Two-hundred patients with cancer or history of cancer recruited by Cancer Support Community each completed 10 choice questions. We used mixed-logit and latent-class models to analyze the choice data. Results: Relative to fixed survival periods of two, three or five years with 0% chance of 10-year survival, participants positively valued treatments with 5% and 10% chances of 10-year survival. However, participants negatively valued a 20% chance of 10 year survival that required an offsetting 80% chance of shorter survival. This finding was particularly strong when expected survival was two years. Compared to a 0% chance, dollar-equivalent values of 5% and 10% chances of long-term survival were $5,975 and $12,421, respectively, independent of health status or expected survival. The corresponding value for 20% versus 0% chance of long-term survival was negative. Latent-class analysis revealed 4 groups with distinct preference patterns. Conclusions: Our findings affirm positive value for hope independent of expected survival and health status. However, this finding does not universally hold in all situations nor across all groups.	[Reed, Shelby D.; Yang, Jui-Chen; Gonzalez, Juan Marcos; Johnson, F. Reed] Duke Univ, Preference Evaluat Res Grp, Duke Clin Res Inst, Durham, NC 27706 USA		Reed, SD (通讯作者)，Duke Clin Res Inst, 200 Morris St, Durham, NC 27701 USA.	shelby.reed@duke.edu		Gonzalez, Juan Marcos/0000-0002-5386-0907	PhRMA Foundation	This work was supported by an unrestricted grant from the PhRMA Foundation 2018 Value Assessment Initiative.	Bansback N, 2012, J HEALTH ECON, V31, P306, DOI 10.1016/j.jhealeco.2011.11.004; Ben-Aharon O, 2018, JAMA ONCOL, V4, P326, DOI 10.1001/jamaoncol.2017.4445; Cherny NI, 2019, J CLIN ONCOL, V37, P336, DOI 10.1200/JCO.18.00729; Damschroder LJ, 2007, JUDGM DECIS MAK, V2, P96; Everest L, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6803; Feuz C, 2012, J MED IMAGING RADIAT, V43, P168, DOI 10.1016/j.jmir.2011.10.002; Fischer B, 2018, J HEALTH ECON, V60, P30, DOI 10.1016/j.jhealeco.2018.06.001; Garrison LP, 2018, VALUE HEALTH, V21, P124, DOI 10.1016/j.jval.2017.12.006; Garrison LP, 2017, VALUE HEALTH, V20, P213, DOI 10.1016/j.jval.2016.12.005; Hauber AB, 2016, VALUE HEALTH, V19, P300, DOI 10.1016/j.jval.2016.04.004; Hauber B, 2020, PATIENT PREFER ADHER, V14, P2093, DOI 10.2147/PPA.S248295; Johnson FR, 2019, VALUE HEALTH, V22, P157, DOI 10.1016/j.jval.2018.07.876; Kuhfeld W.F., MARKETING RES METHOD; KUHFELD WF, 1994, J MARKETING RES, V31, P545, DOI 10.2307/3151882; Lakdawalla DN, 2018, VALUE HEALTH, V21, P131, DOI 10.1016/j.jval.2017.12.007; Lakdawalla DN, 2012, HEALTH AFFAIR, V31, P676, DOI 10.1377/hlthaff.2011.1300; Louviere J.J., 2000, STATED CHOICE METHOD; Nekolaichuk Cheryl L, 2004, Palliat Support Care, V2, P243; Ozdemir S, 2009, J HEALTH ECON, V28, P894, DOI 10.1016/j.jhealeco.2009.04.004; Ramsey S, 2013, HEALTH AFFAIR, V32, P1143, DOI 10.1377/hlthaff.2012.1263; Schnipper LE, 2016, J CLIN ONCOL, V34, P2925, DOI 10.1200/JCO.2016.68.2518; Shafrin J, 2017, VALUE HEALTH, V20, P217, DOI 10.1016/j.jval.2016.11.028; Shrime MG, 2018, VALUE HEALTH, V21, P95, DOI 10.1016/j.jval.2017.07.006; Smith GL, 2019, J NATL COMPR CANC NE, V17, P1184, DOI 10.6004/jnccn.2019.7305; Van Houtven G, 2011, MED DECIS MAKING, V31, P469, DOI 10.1177/0272989X10386116	25	2	2	4	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	OCT	2021	24	10					1511	1519		10.1016/j.jval.2021.04.1284		SEP 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	WE3WV	34593175	Bronze			2022-04-28	WOS:000705561100016
J	Ludwig, K; Ramos-Goni, JM; Oppe, M; Kreimeier, S; Greiner, W				Ludwig, Kristina; Ramos-Goni, Juan M.; Oppe, Mark; Kreimeier, Simone; Greiner, Wolfgang			To What Extent Do Patient Preferences Differ From General Population Preferences?	VALUE IN HEALTH			English	Article						discrete choice experiment; EQ-5D-5L; general population preferences; health-related quality of life; patient preferences; valuation	VALUE SET; HEALTH; VALUATION; EQ-5D; UTILITIES; VALUES	Objectives: In some countries including Germany, value sets based on general population preferences are not acceptable for decision-makers in healthcare because the impact of the reference group-general population versus patients-on utility decrements is questioned. The objective of this study was to explore potential differences in patient versus general population health preferences and a way of combining both preferences in economic evaluation. Methods: EQ-5D-5L general population preferences were available from national value sets in Germany and Spain. Patient preferences were obtained by conducting discrete choice experiments with patients with rheumatism and patients with diabetes mellitus in Germany and Spain using an online panel. The econometric approach was based on the conditional logit framework. Latent values were anchored using the national value sets. Results: A total of 1700 patients (Germany, n = 937; Spain, n = 763) were included in the analysis. In both countries, patients gave more importance to mobility, self-care, or usual activities and less importance to pain/discomfort and anxiety/ depression than the general population. The size of these differences was larger in Germany than in Spain. In Germany, preferences reported by both patient groups were more similar than in Spain. Conclusion: Patient preferences differ from preferences derived from the general population. In contrast to the general population, patients gave more importance to the functional dimensions than to symptoms in both countries. The extent of the differences depends on the disease and the country. For countries preferring patient preferences, a possible way of incorporating the patient perspective in health state valuation was suggested and needs to be further explored.	[Ludwig, Kristina; Ramos-Goni, Juan M.; Kreimeier, Simone; Greiner, Wolfgang] Bielefeld Univ, Sch Publ Hlth, Dept Hlth Econ & Hlth Care Management, Bielefeld, Germany; [Ramos-Goni, Juan M.; Oppe, Mark] Maths Hlth BV, Rotterdam, Netherlands		Ludwig, K (通讯作者)，Bielefeld Univ, Dept Hlth Econ & Hlth Care Management, POB 10 01 31, D-33501 Bielefeld, Germany.	kristina.ludwig@uni-bielefeld.de		Kreimeier, Simone/0000-0002-4832-7833	European Union's Horizon 2020 research and innovation program (H2020) of the European Commission; IMPACT HTA [779312]	This research was funded by the European Union's Horizon 2020 research and innovation program (H2020) of the European Commission and undertaken under the auspices of IMPACT HTA (grant number 779312; www.impact-hta.eu).	Badia X, 2001, MED DECIS MAKING, V21, P7, DOI 10.1177/0272989X0102100102; Badia X, 1998, PHARMACOECONOMICS, V13, P687, DOI 10.2165/00019053-199813060-00005; Brazier J., 2017, MEASURING VALUING HL; Brazier J, 2005, APPL HEALTH ECON HEA, V4, P201, DOI 10.2165/00148365-200504040-00002; Drummond MF, METHODS EC EVALUATIO, V2nd; Gandhi M, 2017, QUAL LIFE RES, V26, P3353, DOI 10.1007/s11136-017-1683-5; Greiner W, 2005, Eur J Health Econ, V6, P124, DOI 10.1007/s10198-004-0264-z; Greiner W, 2014, Z EVIDENZ FORTBILD Q, V108, P120, DOI 10.1016/j.zefq.2014.02.004; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Institut fur Qualitat und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2017, ALLGEMEINE METHODEN; Kennedy-Martin M, 2020, EUR J HEALTH ECON, V21, P1245, DOI 10.1007/s10198-020-01195-8; Knies S, 2009, PHARMACOECONOMICS, V27, P767, DOI 10.2165/11314120-000000000-00000; Ludwig K, 2018, PHARMACOECONOMICS, V36, P663, DOI 10.1007/s40273-018-0615-8; Mulhern B, 2013, VALUE HEALTH, V16, P104, DOI 10.1016/j.jval.2012.09.001; Negrin MA, 2006, HEALTH ECON, V15, P363, DOI 10.1002/hec.1056; Oppe M., 2017, EUROQOL WORKING PAPE; Oppe M, 2014, VALUE HEALTH, V17, P445, DOI 10.1016/j.jval.2014.04.002; Peeters Y, 2010, VALUE HEALTH, V13, P306, DOI 10.1111/j.1524-4733.2009.00610.x; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Radoschewski M, 2000, BUNDESGESUNDHEITSBLA, V43, P165; Ramos-Goni JM, 2020, PHARMACOECONOMICS, V38, P653, DOI 10.1007/s40273-020-00909-3; Ramos-Goni JM, 2018, VALUE HEALTH, V21, P596, DOI 10.1016/j.jval.2017.10.023; Rowen D, 2017, PHARMACOECONOMICS, V35, pS11, DOI 10.1007/s40273-017-0544-y; Suarez-Almazor ME, 2001, J RHEUMATOL, V28, P648; Wang P, 2014, PATIENT, V7, P329, DOI 10.1007/s40271-014-0059-y; Wille N, 2010, QUAL LIFE RES, V19, P875, DOI 10.1007/s11136-010-9648-y; Zentner A, 2006, GESUNDH QUAL, V11, P368, DOI 10.1055/s-2006-927192	27	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	SEP	2021	24	9					1343	1349		10.1016/j.jval.2021.02.012		AUG 2021	7	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	UG5RC	34452715	hybrid, Green Published			2022-04-28	WOS:000689308300015
J	Hambraeus, J; Ehsanian, R; Cheng, DS; McKenna, MJ; McCormick, ZL				Hambraeus, Johan; Ehsanian, Reza; Cheng, David S.; McKenna, Michael J.; McCormick, Zachary L.			Inadequate Selection and Treatment Results in Poor Outcomes and Lack of Cost-Effectiveness	VALUE IN HEALTH			English	Letter							LOW-BACK-PAIN; RADIOFREQUENCY DENERVATION; CLINICAL-FEATURES; LUMBAR FACET; JOINT PAIN; TRIALS; DESIGN		[Hambraeus, Johan] Umea Univ, Dept Epidemiol & Global Hlth, Umea, Sweden; [Hambraeus, Johan] Smartkliniken Eques Indolor, Vallentuna, Sweden; [Ehsanian, Reza] Univ New Mexico, Sch Med, Dept Orthopaed & Rehabil, Div Phys Med & Rehabil, Albuquerque, NM 87131 USA; [Cheng, David S.] Univ Southern Calif, Dept Neurol Surg, Los Angeles, CA 90007 USA; [McCormick, Zachary L.] Univ Utah, Div Phys Med & Rehabil, 590 Wakara Way, Salt Lake City, UT 84108 USA		McCormick, ZL (通讯作者)，Univ Utah, Div Phys Med & Rehabil, 590 Wakara Way, Salt Lake City, UT 84108 USA.	zmccormi@gmail.com		Cheng, David/0000-0001-6074-2637; Hambraeus, Johan/0000-0001-6571-5830			Ares JD, 2020, PAIN PRACT, V20, P889, DOI 10.1111/papr.12928; Bogduk N., 2013, PRACTICE GUIDELINES; Burnham RS, 2009, ARCH PHYS MED REHAB, V90, P201, DOI 10.1016/j.apmr.2008.07.021; Maas ET, 2020, VALUE HEALTH, V23, P585, DOI 10.1016/j.jval.2019.12.009; McCormick ZL, 2018, PAIN MED, V19, P2127, DOI 10.1093/pm/pny046; Provenzano DA, 2018, REGION ANESTH PAIN M, V43, P68, DOI 10.1097/AAP.0000000000000699; Provenzano DA, 2020, REGION ANESTH PAIN M, V45, P84, DOI 10.1136/rapm-2019-100905; Schneider BJ, 2020, PAIN MED, V21, P1122, DOI 10.1093/pm/pnz349; SCHWARZER AC, 1994, SPINE, V19, P1132, DOI 10.1097/00007632-199405001-00006; SCHWARZER AC, 1995, ANN RHEUM DIS, V54, P100, DOI 10.1136/ard.54.2.100; van Kuijk SMJ, 2018, PAIN PRACT, V18, P292, DOI 10.1111/papr.12673; Vorobeychik Y, 2017, JAMA-J AM MED ASSOC, V318, P2254, DOI 10.1001/jama.2017.16386	12	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	AUG	2021	24	8					1234	1235		10.1016/j.jval.2020.11.024		AUG 2021	2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TY1SX	34372989				2022-04-28	WOS:000683567300017
J	Webber, CM; Chen, AL; Gebben, DJ; Saha, A; Tarver, ME				Webber, Christina M.; Chen, Allen L.; Gebben, David J.; Saha, Anindita; Tarver, Michelle E.			Measuring Patient Preferences at the FDA Center for Devices and Radiological Health: Reflections and Projections	VALUE IN HEALTH			English	Article						FDA; medical devices; patient preference; regulatory		Objectives: Patient preference information (PPI) is a way to incorporate the patient voice in the evaluation of medical devices. The US Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) has been working to encourage the voluntary inclusion of PPI throughout the medical device lifecycle for nearly a decade. This article reflects CDRH's efforts to encourage collection of PPI and offers perspectives on the future of PPI in the evaluation of medical devices. Methods: CDRH regulatory guidance, public meetings, and collaborations relating to PPI were explored. Results: Since 2012 when CDRH issued guidance on how PPI can be used as scientific evidence in the benefit-risk regulatory submission, CDRH has issued 5 subsequent guidance documents expanding on the use of PPI in medical device evaluations. CDRH remains committed to advancing the science and application of PPI in the medical device ecosystem through many collaborations with professional organizations, patient advocacy groups, and academic institutions. By hosting and actively participating in multiple scientific and regulatory public meetings and conferences, CDRH fosters a continuous learning environment where the experience of using PPI in regulatory submissions can be shared. A September 2020 meeting cosponsored by FDA and International Society for Pharmacoeconomics and Outcomes Research (ISPOR) discussed the state of PPI in regulatory applications and beyond. Conclusion: This article describes these pivotal events that have helped to increase the use of PPI in medical device evaluation as well as discusses future applications of PPI.	[Webber, Christina M.; Chen, Allen L.; Gebben, David J.; Saha, Anindita; Tarver, Michelle E.] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD USA; [Gebben, David J.] Calvin Univ, Dept Econ, Grand Rapids, MI USA		Tarver, ME (通讯作者)，10903 New Hampshire Ave,Bldg 66 Room 5608, Silver Spring, MD 20993 USA.	michelle.tarver@fda.hhs.gov		Webber, Christina/0000-0001-8318-7007			Benz HL, 2019, PATIENT, V12, P553, DOI 10.1007/s40271-019-00396-5; Bocell F, 2020, ISPOR M MAY 2020 VIR ISPOR M MAY 2020 VIR; Gwinn K, 2019, NEUROLOGY, V92; Ho M, 2016, VALUE HEALTH, V19, P746, DOI 10.1016/j.jval.2016.02.019; Ho MP, 2015, SURG ENDOSC, V29, P2984, DOI 10.1007/s00464-014-4044-2; Janssen EM, 2018, EXPERT REV MED DEVIC, V15, P385, DOI 10.1080/17434440.2018.1470505; Li TJ, 2020, EYE, V34, P205, DOI 10.1038/s41433-019-0676-8; McMurry-Heath M, FDA BRINGS PAT PROC FDA BRINGS PAT PROC; Medical Device Innovation Consortium (MDIC), MDICS 2020 PAT ENG F MDICS 2020 PAT ENG F; Medical Device Innovation Consortium (MDIC), PAT PREF HEART FAIL PAT PREF HEART FAIL; Medical Device Innovation Consortium (MDIC), BEST PRACTICES COMMU; Medical Device Innovation Consortium (MDIC), 2015, PAT CTR BEN RISK PCB PAT CTR BEN RISK PCB; Truelove C, 2020, VALUE OUTCOMES SPOTL, V6, P11; US Food and Drug Admiistration, BEN RISK FACT CONS D BEN RISK FACT CONS D; US Food and Drug Administration, PAT ENG ADV COMM M A PAT ENG ADV COMM M A; US Food and Drug Administration, PUBL M US PAT PREF I PUBL M US PAT PREF I; US Food and Drug Administration, PAT PREF INF PPI MED PAT PREF INF PPI MED; US Food and Drug Administration, 2020, PAT PREF INF VOL SUB; US Food and Drug Administration, LIST PAT PREF SENS P LIST PAT PREF SENS P; US Food and Drug Administration, FACT CONS REG BEN RI FACT CONS REG BEN RI; US Food and Drug Administration, CONS UNC MAK BEN RIS CONS UNC MAK BEN RIS; US Food and Drug Administration, PUBL WORKSH THE PAT PUBL WORKSH THE PAT; US Food and Drug Administration, VIRT PUBL M MED DEV VIRT PUBL M MED DEV; US Food and Drug Administration, ADV US PAT PREF INF ADV US PAT PREF INF; US Food and Drug Administration, FACT CONS MAK BEN RI FACT CONS MAK BEN RI	25	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUL	2021	24	7					1024	1029		10.1016/j.jval.2021.01.009		JUL 2021	6	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TE7UB	34243826				2022-04-28	WOS:000670212100013
J	Acharya, M; Zorn, KK; Simonson, ME; Bimali, M; Moore, GW; Martin, BC				Acharya, M.; Zorn, K. K.; Simonson, M. E.; Bimali, M.; Moore, G. W.; Martin, B. C.			STATEWIDE TRENDS IN GENETIC TESTING FOR HEREDITARY CANCERS IN ARKANSAS 2013-2018	VALUE IN HEALTH			English	Meeting Abstract									[Acharya, M.; Moore, G. W.; Martin, B. C.] Univ Arkansas Med Sci, Coll Pharm, Little Rock, AR 72205 USA; [Zorn, K. K.; Simonson, M. E.] Univ Arkansas Med Sci, Coll Med, Little Rock, AR 72205 USA; [Bimali, M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH14	S101	S101					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400440
J	Ahdesmaki, O; Ainsworth, C; Bell, J; Hawe, E				Ahdesmaki, O.; Ainsworth, C.; Bell, J.; Hawe, E.			ONGOING SLRS WHEN CONSIDERING HTA SUBMISSIONS: REWARDS AND AVOIDABLE PITFALLS	VALUE IN HEALTH			English	Meeting Abstract									[Ahdesmaki, O.; Ainsworth, C.; Bell, J.; Hawe, E.] RTI Hlth Solut, Manchester, Lancs, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS7	S174	S174					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401018
J	Al-Shaibi, S; Abushanab, D; Alhersh, E; Kaddoura, R; Rouf, PA; Al-Badriyeh, D				Al-Shaibi, S.; Abushanab, D.; Alhersh, E.; Kaddoura, R.; Rouf, Abdul P.; Al-Badriyeh, D.			THE USE OF IBUPROFEN, INCLUDING VERSUS INDOMETHACIN OR PARACETAMOL/ACETAMINOPHEN, FOR THE CLOSURE OF PATENT DUCTUS ARTERIOSUS IN PRETERM INFANTS. A SYSTEMATIC REVIEW OF META-ANALYSES	VALUE IN HEALTH			English	Meeting Abstract									[Al-Shaibi, S.; Alhersh, E.; Al-Badriyeh, D.] Qatar Univ, Doha, Qatar; [Abushanab, D.; Kaddoura, R.; Rouf, Abdul P.] Hamad Med Corp, Doha, Qatar									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV6	S67	S68					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400295
J	Armstrong, A; Reich, K; Warren, RB; Taieb, V; Fahrbach, K; Kazmierska, P; Betts, M; Neupane, B; Kiri, S; Gordon, K				Armstrong, A.; Reich, K.; Warren, R. B.; Taieb, V; Fahrbach, K.; Kazmierska, P.; Betts, M.; Neupane, B.; Kiri, S.; Gordon, K.			COMPARATIVE EFFICACY OF BIMEKIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Armstrong, A.] Keck Sch Med USC, Dermatol, Los Angeles, CA USA; [Reich, K.] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Ctr Translat Res Inflammatory Skin Dis, Hamburg, Germany; [Warren, R. B.] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England; [Taieb, V; Kiri, S.] UCB Pharma, Slough, Berks, England; [Fahrbach, K.; Betts, M.; Neupane, B.] Evidera, Waltham, MA USA; [Kazmierska, P.] Evidera, London, Lon, England; [Gordon, K.] Med Coll Wisconsin, Milwaukee, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PBI3	S14	S14					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400056
J	Ashaye, A; Shah, R; Corman, S; Dalal, MR; Fox, C; Trumper, L				Ashaye, A.; Shah, R.; Corman, S.; Dalal, M. R.; Fox, C.; Trumper, L.			REAL-WORLD COSTS OF FRONT-LINE TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA IN FRANCE, GERMANY, AND THE UNITED KINGDOM	VALUE IN HEALTH			English	Meeting Abstract									[Ashaye, A.; Dalal, M. R.] Millennium Pharmaceut Inc, Cambridge, MA USA; [Shah, R.; Corman, S.] Pharmerit, Bethesda, MD USA; [Fox, C.] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Trumper, L.] Georg August Univ, Univ Med, Gottingen, Germany									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN62	S30	S30					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400125
J	Sotomayor, MC; Alvis-Zakzuk, N; Mejia, FS; Moyano, L; Alvis-Zakzuk, NR; De la Rosa, FG; Wilchez, JP; Arias, MJ; Alvis-Guzman, N				Carrasquilla Sotomayor, M.; Alvis-Zakzuk, N.; Salcedo Mejia, F.; Moyano, L.; Alvis-Zakzuk, N. R.; Gomez De la Rosa, F.; Paz Wilchez, J.; Jerez Arias, M.; Alvis-Guzman, N.			BURDEN OF DISEASE IN YOUNG POPULATION OF A COLOMBIAN HEALTH INSURANCE COMPANY	VALUE IN HEALTH			English	Meeting Abstract									[Carrasquilla Sotomayor, M.] ALZAK Fdn, Bogota, Cun, Colombia; [Alvis-Zakzuk, N.] Univ Costa CUC, Barranquilla, Atl, Colombia; [Salcedo Mejia, F.; Gomez De la Rosa, F.] ALZAK Fdn, Cartagena, Bol, Colombia; [Moyano, L.; Alvis-Zakzuk, N. R.] ALZAK Fdn, Cartagena De Indias, Bol, Colombia; [Paz Wilchez, J.] Univ Cartagena Clin Crecer, MUTUALSER EPS, Cartagena De Indias, Colombia; [Jerez Arias, M.] Fdn SERSOCIAL, Cartagena, Colombia; [Alvis-Guzman, N.] Univ Cartagena, ALZAK Fdn, Cartagena, Bol, Colombia				Alvis-Guzman, Nelson/D-4913-2013; Zakzuk, Nelson J. Alvis/AAV-3171-2021	Alvis-Guzman, Nelson/0000-0001-9458-864X; 				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU20	S148	S148					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400646
J	Chen, I; Berlin, HM; Boag, W; Sontag, D; Szolovits, P; Kamble, P; Wang, S; Elomaa, K; Luo, M				Chen, I; Berlin, H. M.; Boag, W.; Sontag, D.; Szolovits, P.; Kamble, P.; Wang, S.; Elomaa, K.; Luo, M.			APPLYING MACHINE LEARNING TO LARGE DATABASES TO PREDICT NONRESPONSE TO CONVENTIONAL TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS	VALUE IN HEALTH			English	Meeting Abstract									[Chen, I; Berlin, H. M.; Boag, W.; Sontag, D.; Szolovits, P.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Kamble, P.; Wang, S.; Luo, M.] Takeda Pharmaceut, Cambridge, MA USA; [Elomaa, K.] Takeda Oy, Helsinki, Finland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PGI27	S99	S99					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400430
J	Chen, YF; Chen, M; Trask, P				Chen, Y. F.; Chen, M.; Trask, P.			EVALUATION OF THE ITEM-LEVEL PSYCHOMETRIC PROPERTIES OF EORTC QLQ-C30 AND QLQ-LC13 FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)	VALUE IN HEALTH			English	Meeting Abstract									[Chen, Y. F.; Chen, M.; Trask, P.] Genentech Inc, San Francisco, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN204	S57	S58					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400249
J	Choong, C; Chinthammit, C; Chen, Y				Choong, C.; Chinthammit, C.; Chen, Y.			COMORBIDITY PROFILE OF ADULTS DIAGNOSED WITH EOSINOPHILIC ESOPHAGITIS IN US ELECTRONIC MEDICAL RECORDS AND MEDICAL CLAIMS	VALUE IN HEALTH			English	Meeting Abstract									[Choong, C.; Chinthammit, C.; Chen, Y.] Eli Lilly & Co, Indianapolis, IN 46285 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PGI18	S97	S97					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400422
J	Crawford, S; Kelley, M; Choy, B; Miano, MA; Grosso, R; Pronovost, PJ; Padula, W				Crawford, S.; Kelley, M.; Choy, B.; Miano, M. A.; Grosso, R.; Pronovost, P. J.; Padula, W.			THE COST-UTILITY OF REMOTE PULSE-OXIMETER MONITORING OF COVID19 PATIENTS	VALUE IN HEALTH			English	Meeting Abstract									[Crawford, S.; Kelley, M.; Padula, W.] Univ Southern Calif, Los Angeles, CA 90007 USA; [Choy, B.] Univ Southern Calif, Honolulu, HI USA; [Miano, M. A.; Grosso, R.; Pronovost, P. J.] Univ Hosp, Cleveland, OH USA				Padula, Bill/AGB-4625-2022					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN21	S109	S109					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400474
J	Dai, L				Dai, L.			TWO-WEEK-WAIT REFERRAL AND MORTALITY OF UTERUS CANCER	VALUE IN HEALTH			English	Meeting Abstract									[Dai, L.] Univ Aberdeen, Aberdeen, Abe, Scotland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN135	S44	S44					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400187
J	Dierick, K				Dierick, K.			CAN A REUSABLE SURGICAL FACE MASK BRING HEALTH ECONOMIC AND ECOLOGICAL BENEFIT TO A HEALTH SYSTEM UPON THE OUTBREAK OF AN EMERGING PATHOGEN?	VALUE IN HEALTH			English	Meeting Abstract									[Dierick, K.] Verdickt, Zavemtem, Belgium									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS12	S175	S175					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401022
J	Dispenzieri, A; Zonder, J; Hoffman, J; Wong, SW; Liedtke, M; Abonour, R; D'Souza, A; Lee, C; Cote, S; Nair, S; Potluri, R; Weiss, BM; Vermeulen, J; Lam, A; Mehra, M				Dispenzieri, A.; Zonder, J.; Hoffman, J.; Wong, S. W.; Liedtke, M.; Abonour, R.; D'Souza, A.; Lee, C.; Cote, S.; Nair, S.; Potluri, R.; Weiss, B. M.; Vermeulen, J.; Lam, A.; Mehra, M.			REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS: ANALYSIS OF THE OPTUM US ELECTRONIC HEALTH RECORDS (EHR) AND COMMERCIAL CLAIMS DATABASE	VALUE IN HEALTH			English	Meeting Abstract									[Dispenzieri, A.] Mayo Clin, Rochester, MN USA; [Zonder, J.] Barbara Ann Karmanos Canc Inst, Detroit, MI USA; [Hoffman, J.] Sylvester Comprehens Canc Ctr, Miami, FL USA; [Wong, S. W.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Liedtke, M.] Stanford Univ, Stanford, CA 94305 USA; [Abonour, R.] Indiana Canc Pavil, Indianapolis, IN USA; [D'Souza, A.] Froedtert & Med Coll Wisconsin Canc Ctr, Milwaukee, WI USA; [Lee, C.; Cote, S.; Lam, A.] Janssen Global Serv, Raritan, NJ USA; [Nair, S.] Janssen Pharmaceut NV, Beerse, Belgium; [Potluri, R.] SmartAnalyst Inc, New York, NY USA; [Weiss, B. M.; Vermeulen, J.; Mehra, M.] Janssen Global Med Affairs, Horsham, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO78	S212	S212					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401193
J	Do, L; Ollendorf, D; Synnott, P; Ma, S				Do, L.; Ollendorf, D.; Synnott, P.; Ma, S.			BRIDGING THE GAP: ALIGNING ECONOMIC RESEARCH WITH DISEASE BURDEN	VALUE IN HEALTH			English	Meeting Abstract									[Do, L.; Ollendorf, D.; Synnott, P.; Ma, S.] Tufts Med Ctr, Boston, MA 02111 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU4	S145	S145					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400632
J	Ezekekwu, E				Ezekekwu, E.			EXAMINING THE USE OF SEDATIVE DRUGS IN THE US. WORKING POPULATION	VALUE IN HEALTH			English	Meeting Abstract									[Ezekekwu, E.] Univ Louisville, Louisville, KY 40292 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG16	S90	S90					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400391
J	Ferrari, A; Manetti, S; Giannini, A; Simoncini, T; Vainieri, M				Ferrari, A.; Manetti, S.; Giannini, A.; Simoncini, T.; Vainieri, M.			ASSESSING UNWARRANTED VARIATION IN MINIMALLY-INVASIVE SURGERY FOR PELVIC ORGAN PROLAPSE IN TUSCANY, ITALY: A CASE STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Ferrari, A.; Manetti, S.; Vainieri, M.] St Anna Sch Adv Studies, MeS Lab, Pisa, PI, Italy; [Giannini, A.; Simoncini, T.] Univ Pisa, Pisa, Italy				Giannini, Andrea/AAE-9490-2022					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSU14	S226	S226					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401255
J	Gajra, A; Zettler, M; Russell, ACG; Feinberg, B				Gajra, A.; Zettler, M.; Russell, Graham A. C.; Feinberg, B.			APPLICATION OF AUGMENTED INTELLIGENCE (AI) IN ONCOLOGY: A PHYSICIAN PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Gajra, A.; Russell, Graham A. C.; Feinberg, B.] Cardinal Hlth, Dublin, OH USA; [Zettler, M.] Cardinal Hlth, Falls Church, VA USA				Feinberg, Bruce/AAX-9378-2021	Feinberg, Bruce/0000-0001-9267-9994				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN189	S54	S55					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400235
J	Guo, J; Yang, J; Muzumdar, J; Park, T				Guo, J.; Yang, J.; Muzumdar, J.; Park, T.			CONTENT ANALYSIS OF FDA WARNING LETTERS FOR FRAUDULENT COVID-19 CLAIMS USING THE ECONOMIC, CLINICAL, HUMANISTIC OUTCOMES (ECHO) MODEL	VALUE IN HEALTH			English	Meeting Abstract									[Guo, J.] St Johns Univ, Valley Stream, NY USA; [Yang, J.; Park, T.] St Johns Univ, Queens, NY USA; [Muzumdar, J.] St Johns Univ, Jamaica, NY 11439 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN56	S116	S116					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400506
J	Haris, GA; Li, P; Bian, J; Guo, Y; Shao, H				Haris, Alipour G.; Li, P.; Bian, J.; Guo, Y.; Shao, H.			COMPUTABLE PHENOTYPES (CPS) FOR IDENTIFYING INDIVIDUALS WITH MULTI-MORBIDITY FROM REAL-WORLD DATA (RWD): A SYSTEMATIC LITERATURE REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Haris, Alipour G.; Bian, J.; Guo, Y.] Univ Florida, Gainesville, FL USA; [Li, P.] Univ Florida, Beijing 11, Peoples R China; [Shao, H.] Univ Florida, Coll Pharm, Gainesville, FL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU25	S149	S149					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400648
J	Harricharan, S; Kee, A; Grieve, S; Brokars, J; Forsythe, A; Copher, R				Harricharan, S.; Kee, A.; Grieve, S.; Brokars, J.; Forsythe, A.; Copher, R.			SYSTEMATIC LITERATURE REVIEW OF TREATMENT PATTERNS, LONG-TERM EFFICACY, AND SAFETY OF DASATINIB THERAPY FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA	VALUE IN HEALTH			English	Meeting Abstract									[Harricharan, S.; Grieve, S.] Purple Squirrel Econ, Montreal, PQ, Canada; [Kee, A.; Brokars, J.; Copher, R.] Bristol Myers Squibb, Princeton, NJ USA; [Forsythe, A.] Purple Squirrel Econ, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN25	S23	S23					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400092
J	Hernandez, K; Paredes, D; Lenz, R				Hernandez, K.; Paredes, D.; Lenz, R.			A SCOPING REVIEW OF CONSEQUENCES OF UNTREATED STROKE: ECONOMIC BURDEN DUE TO COVID-19?	VALUE IN HEALTH			English	Meeting Abstract									[Hernandez, K.] Lenz Consultores, Independencia, RM, Chile; [Paredes, D.] Univ Andres Bello, Inst Salud Publ, Santiago, RM, Chile; [Paredes, D.; Lenz, R.] Lenz Consultores, Santiago, RM, Chile; [Lenz, R.] Univ Nacl Andres Bello, Santiago, RM, Chile									0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS28	S218	S218					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401217
J	Ito, T; Sanford, D; Tomuleasa, C; Hsiao, HH; Olivera, LJE; Enjeti, AK; Conca, AG; del Castillo, TB; Girshova, L; Martelli, MP; Guvenc, B; Bui, CN; Delgado, A; Duan, Y; Guijarro, BG; Llamas, C; Lee, JH				Ito, T.; Sanford, D.; Tomuleasa, C.; Hsiao, H. H.; Enciso Olivera, L. J.; Enjeti, A. K.; Gimenez Conca, A.; Bernal del Castillo, T.; Girshova, L.; Martelli, M. P.; Guvenc, B.; Bui, C. N.; Delgado, A.; Duan, Y.; Garbayo Guijarro, B.; Llamas, C.; Lee, J. H.			PATTERNS OF HEALTHCARE RESOURCE UTILIZATION (HRU) IN UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) RECEIVING FIRST-LINE SYSTEMIC TREATMENT OR BEST SUPPORTIVE CARE (BSC): A MULTICENTER INTERNATIONAL STUDY (CURRENT)	VALUE IN HEALTH			English	Meeting Abstract									[Ito, T.] Kansai Med Univ, Hirakata, Osaka, Japan; [Sanford, D.] Univ British Columbia, Div Hematol, Leukemia Bone Marrow Transplant Program BC, Vancouver, BC, Canada; [Tomuleasa, C.] Ion Chiricuta Clin Canc Ctr, Dept Hematol, Cluj Napoca, Romania; [Hsiao, H. H.] Kaohsiung Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Kaohsiung, Taiwan; [Hsiao, H. H.] Kaohsiung Med Univ, Kaohsiung, Taiwan; [Enciso Olivera, L. J.] Inst Nacl Cancerol, Bogota, Colombia; [Enjeti, A. K.] Calvary Mater Newcastle, Waratah, Australia; [Enjeti, A. K.] NSW Hlth Pathol, Waratah, Australia; [Gimenez Conca, A.] Hosp Italiano Buenos Aires, Sect Hematol, Buenos Aires, DF, Argentina; [Bernal del Castillo, T.] Univ Hosp Cent Asturias, Oviedo, Spain; [Girshova, L.] Minist Hlth Russian Federat, Fed State Budgetary Inst Almazov Natl Med Res Ctr, St Petersburg, Russia; [Martelli, M. P.] Univ Perugia, Santa Maria Misericordia Hosp, Sect Hematol & Clin Immunol, Dept Med & Surg, Perugia, Italy; [Guvenc, B.] Cukurova Univ, Dept Hematol, Adana, Turkey; [Bui, C. N.; Duan, Y.; Llamas, C.] AbbVie Inc, N Chicago, IL USA; [Delgado, A.] AbbVie Inc, Singapore, Singapore; [Garbayo Guijarro, B.] AbbVie Inc, Madrid, Spain; [Lee, J. H.] Univ Ulsan, Coll Med, Dept Hematol, Seoul, South Korea; [Lee, J. H.] Asan Med Ctr, Seoul, South Korea				Enjeti, Anoop/M-1198-2019; Bernal, Teresa/AAS-9731-2021; Enjeti, Anoop/F-4867-2011	Enjeti, Anoop/0000-0001-8069-090X; Bernal, Teresa/0000-0002-2338-513X; 				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN237	S64	S64					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400279
J	Jay, J; Fernandez, E; Slade, A; Patterson, J; Nadpara, P; Mays, DP; Carroll, NV				Jay, J.; Fernandez, E.; Slade, A.; Patterson, J.; Nadpara, P.; Mays, D. P.; Carroll, N., V			OPIOID UTILIZATION IN CANCER SURVIVORS: A SYSTEMATIC LITERATURE REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Jay, J.] Virginia Commonwealth Univ, Fulton, MD USA; [Fernandez, E.] Monument Analyt, Richmond, VA USA; [Slade, A.; Patterson, J.; Nadpara, P.; Mays, D. P.; Carroll, N., V] Virginia Commonwealth Univ, Richmond, VA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN129	S43	S43					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400181
J	Jiang, J; Nazarey, P; Kuharic, M; Athavale, A; Fan, T; Silber, A; Abilash, V; Hadker, N; Sharpe, E; Cazzetta, S				Jiang, J.; Nazarey, P.; Kuharic, M.; Athavale, A.; Fan, T.; Silber, A.; Abilash, V; Hadker, N.; Sharpe, E.; Cazzetta, S.			EVALUATING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH AND WITHOUT CROHN?S PERIANAL FISTULAS (CPF) USING THE EUROQOL FIVE-DIMENSION (EQ-5D-5L) QUESTIONNAIRE IN A REAL-WORLD US SETTING	VALUE IN HEALTH			English	Meeting Abstract									[Jiang, J.] Takeda Pharmaceut USA Inc, Cambridge, MA USA; [Nazarey, P.; Kuharic, M.; Fan, T.; Cazzetta, S.] Takeda Pharmaceut USA Inc, Lexington, MA USA; [Athavale, A.; Silber, A.; Abilash, V; Hadker, N.; Sharpe, E.] Trinity Life Sci, Waltham, MA USA						Takeda Pharmaceuticals USA, Inc.Takeda Pharmaceutical Company Ltd	Takeda Pharmaceuticals USA, Inc.		0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PGI22	S98	S98					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400426
J	Jin, Y; Yang, B				Jin, Y.; Yang, B.			ACUTE HEALTHCARE UTILIZATION AND COSTS AFTER INITIATING FIRST-LINE TARGETED THERAPY FOR METASTATIC LUNG CANCER IN THE US	VALUE IN HEALTH			English	Meeting Abstract									[Jin, Y.; Yang, B.] Roche Diagnost, Santa Clara, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN163	S50	S50					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400214
J	Kharroubi, S				Kharroubi, S.			VALUATION OF PREFERENCE-BASED MEASURES: COULD BORROWING STRENGTH FROM EXISTING COUNTRIES' VALUATIONS PRODUCE BETTER ESTIMATES	VALUE IN HEALTH			English	Meeting Abstract									[Kharroubi, S.] Amer Univ Beirut, Beirut, Lebanon									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS95	S190	S190					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401092
J	Khor, S; Vodicka, E; Carlson, J				Khor, S.; Vodicka, E.; Carlson, J.			THE POTENTIAL COST-EFFECTIVENESS OF USING COMMUNITY PHARMACIES TO INCREASE HUMAN PAPILLOMAVIRUS VACCINATION RATES IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Khor, S.; Vodicka, E.; Carlson, J.] Univ Washington, Seattle, WA 98195 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN18	S108	S108					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400472
J	Le Dissez, C; Jocelyn, D; Hammes, F; Buesch, K; Maurel, F; de Zarate, IBO				Le Dissez, C.; Jocelyn, D.; Hammes, F.; Buesch, K.; Maurel, F.; de Zarate, Beitia Ortiz, I			BURDEN OF AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY (AADC-D) IN FRANCE WITH A FOCUS ON PATIENT SYMPTOMS AND MOTOR MILESTONES DEVELOPMENT	VALUE IN HEALTH			English	Meeting Abstract									[Le Dissez, C.; Jocelyn, D.; Maurel, F.] IQVIA, Courbevoie, France; [Hammes, F.; de Zarate, Beitia Ortiz, I] PTC Therapeut France, Paris 75, France; [Buesch, K.] PTC Therapeut Switzerland GmbH, Zug, Switzerland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO2	S197	S197					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401125
J	Manetti, S; Guidotti, E; Vainieri, M				Manetti, S.; Guidotti, E.; Vainieri, M.			USING REAL-WORLD EVIDENCE (RWE) AND A MULTI-STAKEHOLDER APPROACH TO ASSESS THE MULTIDIMENSIONAL IMPACT OF A NEW DIAGNOSTIC DEVICE FOR THE EARLY IDENTIFICATION OF SEPSIS IN THE ITALIAN NATIONAL HEALTH SYSTEM	VALUE IN HEALTH			English	Meeting Abstract									[Manetti, S.; Vainieri, M.] St Anna Sch Adv Studies, MeS Lab, Pisa, Italy; [Guidotti, E.] St Anna Sch Adv Studies, MeS Lab, Lucca, LU, Italy									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMD12	S125	S125					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400547
J	Negi, H; Agrawal, R; Vieira, J; Ryan, J; Thakur, D; Viana, R				Negi, H.; Agrawal, R.; Vieira, J.; Ryan, J.; Thakur, D.; Viana, R.			HUMANISTIC AND ECONOMIC BURDEN IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (A)over-cap- A REVIEW OF THE LITERATURE	VALUE IN HEALTH			English	Meeting Abstract									[Negi, H.; Agrawal, R.; Thakur, D.] Novartis Healthcare Pvt Ltd, Hyderabad, AP, India; [Vieira, J.; Ryan, J.] Novartis Pharmaceut UK Ltd, London, England; [Viana, R.] Novartis Pharma AG, Basel, Switzerland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN231	S63	S63					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400273
J	Nikkel, L; Tran, L; Jennings, J; Hollenbeak, CS				Nikkel, L.; Tran, L.; Jennings, J.; Hollenbeak, C. S.			COST-EFFECTIVENESS OF PRE-OPERATIVE SPINAL IMAGING FOR SUSPECTED STIFF OR HYPERMOBILE SPINE BEFORE TOTAL HIP ARTHROPLASTY	VALUE IN HEALTH			English	Meeting Abstract									[Nikkel, L.] Penn State Univ, Hershey, PA USA; [Tran, L.] Penn State Univ, State Coll, PA USA; [Jennings, J.] Centura Hlth Phys Grp, Denver, CO USA; [Hollenbeak, C. S.] Penn State Univ, University Pk, PA 16802 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSU7	S225	S225					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401248
J	Norman, J; Hasegawa, N; Blackall, M; Heinzman, A; Brandt, B; Poepsel, T; Kaul, R; Newton, B; McCullough, E; McKown, S				Norman, J.; Hasegawa, N.; Blackall, M.; Heinzman, A.; Brandt, B.; Poepsel, T.; Kaul, R.; Newton, B.; McCullough, E.; McKown, S.			DISPLAY OF JAPANESE LANGUAGE FEATURES WITHIN ECOA MEASURES: CHALLENGES AND RECOMMENDATIONS	VALUE IN HEALTH			English	Meeting Abstract									[Norman, J.] RWS Life Sci, Nottingham, Ngm, England; [Hasegawa, N.; Blackall, M.] RWS Life Sci, Chicago, IL USA; [Heinzman, A.] RWS Life Sci, Denver, CT USA; [Brandt, B.] RWS Life Sci, East Hartford, IL USA; [Poepsel, T.; Kaul, R.; Newton, B.; McCullough, E.; McKown, S.] RWS Life Sci, E Hartford, CT USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS1	S173	S173					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401013
J	Patel, A; Hallock, C; Fusco, N; Cadarette, SM; Mody, L				Patel, A.; Hallock, C.; Fusco, N.; Cadarette, S. M.; Mody, L.			EVALUATION OF ARTIFICIAL INTELLIGENCE WITHIN DISTILLERSR SOFTWARE AS A SECOND REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Patel, A.; Mody, L.] Xcenda LLC, Tampa, FL USA; [Hallock, C.; Fusco, N.; Cadarette, S. M.] Xcenda LLC, Palm Harbor, FL USA									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS101	S191	S191					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401097
J	Pesa, J; Liberman, JN; Petrillo, M; Ruetsch, C				Pesa, J.; Liberman, J. N.; Petrillo, M.; Ruetsch, C.			EARLY IMPACT OF COVID-19 PANDEMIC ON ANTIPSYCHOTIC MEDICATION USE AMONG PATIENTS WITH SCHIZOPHRENIA	VALUE IN HEALTH			English	Meeting Abstract									[Pesa, J.; Petrillo, M.] Janssen Sci Affairs, Titusville, NJ USA; [Liberman, J. N.; Ruetsch, C.] Hlth Analyt LLC, Columbia, MD USA									0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH26	S132	S132					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400578
J	Platzbecker, U; Garcia-Manero, G; Komrokji, RS; Tang, D; Ito, R; Fabre, S; Zhang, G; Ha, X; Mantovani, E; Miteva, D; Zinger, T; Fenaux, P				Platzbecker, U.; Garcia-Manero, G.; Komrokji, R. S.; Tang, D.; Ito, R.; Fabre, S.; Zhang, G.; Ha, X.; Mantovani, E.; Miteva, D.; Zinger, T.; Fenaux, P.			CHANGES IN TRANSFUSION BURDEN (TB), HEMOGLOBIN (HB), SERUM FERRITIN (SF), AND IRON CHELATION THERAPY (ICT) USE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH RING SIDEROBLASTS TREATED WITH LUSPATERCEPT FROM THE MEDALIST STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Platzbecker, U.] Leipzig Univ Hosp, Leipzig, Germany; [Garcia-Manero, G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Komrokji, R. S.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Tang, D.; Fabre, S.; Zhang, G.; Ha, X.; Mantovani, E.] Bristol Myers Squibb, Princeton, NJ USA; [Ito, R.] Bristol Myers Squibb, Chatham, NJ USA; [Miteva, D.; Zinger, T.] Celgene Int Sarl, Boudry, Switzerland; [Fenaux, P.] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN3	S19	S19					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400075
J	Porter, K; Fischer, R; Peay, H				Porter, K.; Fischer, R.; Peay, H.			DECISION-MAKING AND BENEFIT-RISK TRADEOFFS FOR DUCHENNE MUSCULAR DYSTROPHY TREATMENT	VALUE IN HEALTH			English	Meeting Abstract									[Porter, K.; Peay, H.] RTI Int, Res Triangle Pk, NC USA; [Fischer, R.] Parent Project Muscular Dystrophy, Hackensack, NJ USA					Porter, Kristie/0000-0002-1278-0329; Peay, Holly/0000-0002-3053-7453; Porter, Katherine/0000-0002-5544-8369				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMS24	S142	S142					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400621
J	Priest, J; Germain, G; Laliberte, F; Duh, MS; Mahendran, M; Fakih, I; Oglesby, A				Priest, J.; Germain, G.; Laliberte, F.; Duh, M. S.; Mahendran, M.; Fakih, I; Oglesby, A.			REAL-WORLD HEALTHCARE COSTS OF PATIENTS RECEIVING DOLUTEGRAVIR/LAMIVUDINE AND OTHER SINGLE TABLET REGIMENS FOR THE TREATMENT OF HIV-1 IN THE US	VALUE IN HEALTH			English	Meeting Abstract									[Priest, J.] ViiV Healthcare, Durham, NC USA; [Germain, G.; Laliberte, F.] Grp Anal Ltee, Montreal, PQ, Canada; [Duh, M. S.] Anal Grp, Boston, MA USA; [Mahendran, M.; Fakih, I] Anal Grp Inc, Montreal, PQ, Canada; [Oglesby, A.] ViiV Healthcare, Res Triangle Pk, NC USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN15	S107	S108					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400469
J	Rajagopalan, K; Mahadik, B				Rajagopalan, K.; Mahadik, B.			PREVALENCE OF COVID-19 VS. SEASONAL INFLUENZA: A POPULATION-BASED NATIONAL SURVEY OF US ADULTS	VALUE IN HEALTH			English	Meeting Abstract									[Rajagopalan, K.; Mahadik, B.] An L It Iks Inc, Framingham, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN35	S112	S112					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400488
J	Reed, S; Yang, JC; Gonzalez, J; Johnson, FR				Reed, S.; Yang, J. C.; Gonzalez, J.; Johnson, F. R.			VALUING HOPE WITH CANCER TREATMENTS INDEPENDENT OF SURVIVAL GAINS	VALUE IN HEALTH			English	Meeting Abstract									[Reed, S.; Yang, J. C.; Johnson, F. R.] Duke Clin Res Inst, Durham, NC USA; [Gonzalez, J.] Duke Clin Res Inst, Cary, NC USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN203	S57	S57					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400248
J	Rumpakis, J				Rumpakis, J.			THROUGH THE PATIENT'S EYES: A PRESBYOPIA PATIENT JOURNEY SURVEY	VALUE IN HEALTH			English	Meeting Abstract									[Rumpakis, J.] Practice Resource Management Inc, Lake Oswego, OR USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSS10	S221	S222					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401234
J	Serrano, D; Barnes, G; Podger, L; Song, J; Tang, B				Serrano, D.; Barnes, G.; Podger, L.; Song, J.; Tang, B.			PSYCHOMETRIC VALIDATION OF THE EORTC QLQ-HCC18 IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE HEPATOCELLULAR CARCINOMA	VALUE IN HEALTH			English	Meeting Abstract									[Serrano, D.; Podger, L.] Pharmerit Int, Bethesda, MD USA; [Barnes, G.] BeiGene Ltd, Jenkintown, PA USA; [Song, J.] BeiGene Ltd, Ridgefield Pk, NJ USA; [Tang, B.] BeiGene Ltd, Collegeville, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN192	S55	S55					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400238
J	Shah, C; Onukwugha, E; Zafari, Z; Villalonga, OE; Park, JE; Slejko, JF				Shah, C.; Onukwugha, E.; Zafari, Z.; Villalonga, Olives E.; Park, J. E.; Slejko, J. F.			ECONOMIC BURDEN OF COMORBIDITIES AMONG COPD PATIENTS EXPERIENCING ACUTE EXACERBATIONS: AN ANALYSIS OF A COMMERCIALLY INSURED POPULATION	VALUE IN HEALTH			English	Meeting Abstract									[Shah, C.; Onukwugha, E.; Zafari, Z.; Villalonga, Olives E.; Park, J. E.; Slejko, J. F.] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS8	S214	S214					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401200
J	Sharma, D; Deering, K; Loustau, P; Culler, M; Allas, S; Weiss, B; Mitchell, D; Astolfi, D; Mannstadt, M				Sharma, D.; Deering, K.; Loustau, P.; Culler, M.; Allas, S.; Weiss, B.; Mitchell, D.; Astolfi, D.; Mannstadt, M.			METHODS TO IDENTIFY PATIENTS WITH CHRONIC HYPOPARATHYROIDISM IN THE UNITED STATES (US) USING CLAIMS DATA	VALUE IN HEALTH			English	Meeting Abstract									[Sharma, D.; Deering, K.] EPI Q Inc, Oak Brook, IL USA; [Loustau, P.; Culler, M.; Weiss, B.] Amolyt Pharma, Cambridge, MA USA; [Allas, S.] Amolyt Pharma, Ecully, France; [Mitchell, D.; Mannstadt, M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; [Mitchell, D.; Mannstadt, M.] Harvard Med Sch, Boston, MA 02115 USA; [Astolfi, D.] Hypoparathyroid Assoc Representat, Wescosville, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO43	S205	S205					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401160
J	Skroumpelos, A; Freddi, M; Akcicek, H; Cohen, J; Driessen, MT				Skroumpelos, A.; Freddi, M.; Akcicek, H.; Cohen, J.; Driessen, M. T.			SCENARIO ANALYSES ON MAJOR IMPACTFUL AND UNCERTAIN INPUTS OF THE COST-EFFECTIVENESS MODEL OF FREMANEZUMAB FROM A HEALTHCARE SYSTEM PERSPECTIVE IN ENGLAND	VALUE IN HEALTH			English	Meeting Abstract									[Skroumpelos, A.; Akcicek, H.; Driessen, M. T.] Teva Pharmaceut, Amsterdam, Netherlands; [Freddi, M.] Strategen, Winchester, Hants, England; [Cohen, J.] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND29	S164	S164					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400713
J	Tomazos, I; Levy, A; Faria, C				Tomazos, I; Levy, A.; Faria, C.			PRELIMINARY CHARACTERIZATION OF ECULIZUMAB TREATMENT PATTERNS, PRECEDING DISEASE TRIGGERS AND SUPPORTIVE THERAPIES IN ATYPICAL HEMOLYTIC UREMIC SYNDROME: A US CLAIMS DATABASE ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Tomazos, I; Faria, C.] Alex Pharmaceut Inc, Boston, MA USA; [Levy, A.] Dalhousie Univ, Halifax, NS, Canada						Alexion Pharmaceuticals, Inc.	Sponsor: Alexion Pharmaceuticals, Inc.		0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO77	S212	S212					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401192
J	Truong, B; Qian, J				Truong, B.; Qian, J.			COMPARATIVE EFFECTIVENESS IN MEDICATION ADHERENCE BETWEEN VIDEO-OBSERVED THERAPY AND DIRECTLY-OBSERVED THERAPY IN TUBERCULOSIS-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Truong, B.] Auburn Univ, Auburn, AL 36849 USA; [Qian, J.] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN4	S106	S106					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400463
J	Vega-Hernandez, G; MacGregor, G; Lopez, A; Daly, C; Rubin, JL				Vega-Hernandez, G.; MacGregor, G.; Lopez, A.; Daly, C.; Rubin, J. L.			MODELLING SURVIVAL OF PEOPLE WITH CYSTIC FIBROSIS (PWCF) AGED >= 12 YEARS HOMOZYGOUS FOR THE F508DEL MUTATION TREATED WITH IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND IVACAFTOR (IVA/TEZ/ELX)	VALUE IN HEALTH			English	Meeting Abstract									[Vega-Hernandez, G.; Daly, C.] Vertex Pharmaceut Europe Ltd, London, Lon, England; [MacGregor, G.] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland; [Lopez, A.; Rubin, J. L.] Vertex Pharmaceut Inc, Boston, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS31	S218	S218					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401220
J	Walker, T; Nixon, F; Albrow, R				Walker, T.; Nixon, F.; Albrow, R.			ASSESSMENT OF PROGNOSTIC AND PREDICTIVE TESTS BY THE NICE DIAGNOSTICS ASSESSMENT PROGRAMME	VALUE IN HEALTH			English	Meeting Abstract									[Walker, T.; Nixon, F.; Albrow, R.] Natl Inst Hlth & Care Excellence, Manchester, Lancs, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS80	S187	S187					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401081
J	Wang, Y; Rui, M; Cao, YD; Fei, Z; Ma, AX; Li, HC				Wang, Y.; Rui, M.; Cao, Y. D.; Fei, Z.; Ma, A. X.; Li, H. C.			COST-EFFECTIVENESS ANALYSIS OF THE THIRD-LINE TREATMENT OF REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Wang, Y.; Rui, M.; Cao, Y. D.; Fei, Z.; Ma, A. X.; Li, H. C.] China Pharmaceut Univ, Nanjing, Peoples R China									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN52	S28	S28					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400116
J	Goldstine, J; Knox, K; Beekman, J; Cobussen-Boekhorst, H; Conti, A; Gray, M; Inglese, G; England, A; Rodriguez, G; Stanley, J; Vaughn, S; Howlett, SE; Rockwood, K				Goldstine, Jimena; Knox, Kari; Beekman, Joke; Cobussen-Boekhorst, Hanny; Conti, Alessio; Gray, Mikel; Inglese, Gary; England, Amanda; Rodriguez, Gianna; Stanley, Justin; Vaughn, Stephanie; Howlett, Susan E.; Rockwood, Kenneth			A Patient-Centric Tool to Facilitate Goal Attainment Scaling in Neurogenic Bladder and Bowel Dysfunction: Path to Individualization	VALUE IN HEALTH			English	Article						goal attainment scaling; neurogenic lower urinary tract dysfunction		Objectives: People with neurogenic bladder and/or bowel dysfunction experience diverse challenges that can be difficult to evaluate with standardized outcome measures. Goal attainment scaling (GAS) is an individualized, patient-centric outcome measure that enables patients/caregivers to identify and track their own treatment goals. Because creating goals de novo can be cumbersome, we aimed to develop a neurogenic bladder/bowel dysfunction goal menu to facilitate goal attainment scaling uptake and use. Methods: We conducted a workshop with 6 expert clinicians to develop an initial menu. Individual interviews with 12 people living with neurogenic bladder and/or bowel dysfunction and 2 clinician panels with 5 additional experts aided us in refining the menu. A thematic framework analysis identified emergent themes for analysis and reporting. Results: Interview participants were adults (median = 36 years, range 25-58), most with spinal cord injury (75%; 9/12). Of 24 goals identified initially, 2 (8%) were not endorsed and were removed, and 3 goals were added. Most participants listed "Impact on Life" goals (eg, Exercise, Emotional Well-Being) among their 5 most important goals (58%; 35/60). Three main themes emerged: challenges posed by incontinence, limitations on everyday life, and need for personalized care. Conclusions: We developed a clinical outcome assessment tool following a multistep process of representative stakeholder engagement. This patient-centric tool consists of 25 goals specific to people living with neurogenic bladder and/or bowel dysfunction. Asking people what matters most to them can identify important constructs that clinicians might have overlooked.	[Goldstine, Jimena; Inglese, Gary] Hollister Inc, Libertyville, IL USA; [Knox, Kari; England, Amanda; Stanley, Justin; Howlett, Susan E.; Rockwood, Kenneth] DGI Clin Inc, 1730 Market St, Halifax, NS B3J 3N9, Canada; [Beekman, Joke] Sint Maartensklin, Nijmegen, Netherlands; [Cobussen-Boekhorst, Hanny] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands; [Conti, Alessio] Univ Turin, Turin, Italy; [Gray, Mikel] Univ Virginia, Charlottesville, VA USA; [Rodriguez, Gianna] Michigan Med, Ann Arbor, MI USA; [Vaughn, Stephanie] Calif State Univ Fullerton, Fullerton, CA 92634 USA; [Howlett, Susan E.; Rockwood, Kenneth] Dalhousie Univ, Div Geriatr Med, Halifax, NS, Canada; [Howlett, Susan E.] Dalhousie Univ, Dept Pharmacol, Halifax, NS, Canada		Stanley, J (通讯作者)，DGI Clin Inc, 1730 Market St, Halifax, NS B3J 3N9, Canada.	justin@dgiclinical.com	Cobussen-Boekhorst, Hanny/ABE-6297-2021	Cobussen-Boekhorst, Hanny/0000-0002-5820-014X; Conti, Alessio/0000-0003-4301-8924	Hollister Incorporated	This study was funded by Hollister Incorporated.	Clark R, 2016, TRANSL ANDROL UROL, V5, P22, DOI 10.3978/j.issn.2223-4683.2015.12.05; Coggrave Maureen, 2008, Br J Nurs, V17, P962; Cotterill N, 2018, NEUROUROL URODYNAM, V37, P46, DOI 10.1002/nau.23289; Gabbe BJ, 2016, INJURY, V47, P1847, DOI 10.1016/j.injury.2016.06.012; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Harris CJ, 2016, CURR OPIN UROL, V26, P290, DOI 10.1097/MOU.0000000000000290; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Lattimore S, 69 BLEED DIS C; Patel DP, 2016, NEUROUROL URODYNAM, V35, P8, DOI 10.1002/nau.22673; Patrick DL, 2011, VALUE HEALTH, V14, P978, DOI 10.1016/j.jval.2011.06.013; Pellatt GC, 2008, BR J NURS, V17, P908; Pellatt Glynis Collis, 2008, Br J Nurs, V17, P908; Qi Zhengyan, 2018, Curr Gastroenterol Rep, V20, P47, DOI 10.1007/s11894-018-0655-4; Recht M, 2016, HAEMOPHILIA, V22, P825, DOI 10.1111/hae.13066; Roberts JC, 2018, HAEMOPHILIA, V24, pE199, DOI 10.1111/hae.13454; Rockwood K, 2010, CLIN PHARMACOL THER, V88, P446, DOI 10.1038/clpt.2010.68; Rockwood K, 2013, CAN J NEUROL SCI, V40, P564, DOI 10.1017/S0317167100014670; Rohn EJ, 2019, J SPINAL CORD MED, V42, P469, DOI 10.1080/10790268.2018.1517471; Schops TF, 2015, BJU INT, V115, P33, DOI 10.1111/bju.13085; Streiner DL., 2014, HLTH MEASUREMENT SCA, V5 edn; Turner-Stokes L, 2018, EUR J PHYS REHAB MED, V54, P605, DOI 10.23736/S1973-9087.17.04808-0; Turner-Stokes L, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002230; Turner-Stokes L, 2009, CLIN REHABIL, V23, P362, DOI 10.1177/0269215508101742; US Food and Drug Administration, GUID IND PAT REP OUT; Vahdat S, 2014, IRAN RED CRESCENT ME, V16, DOI 10.5812/ircmj.12454; Yip AM, 1998, GERONTOLOGIST, V38, P735	26	1	1	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAR	2021	24	3					413	420		10.1016/j.jval.2020.10.023		FEB 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QM9NG	33641776	Green Published, hybrid			2022-04-28	WOS:000622099500014
J	Rowen, D; Keetharuth, AD; Poku, E; Wong, R; Pennington, B; Wailoo, A				Rowen, Donna; Keetharuth, Anju D.; Poku, Edith; Wong, Ruth; Pennington, Becky; Wailoo, Allan			A Review of the Psychometric Performance of Selected Child and Adolescent Preference-Based Measures Used to Produce Utilities for Child and Adolescent Health	VALUE IN HEALTH			English	Review						adolescents; children; CHU9D; EQ-5D-Y-3L; HUI2; HUI3; paediatric; QALYs; utilities		Objective: This review examined the psychometric performance of 4 generic child- and adolescent-specific preference-based measures that can be used to produce utilities for child and adolescent health. Methods: A systematic search was undertaken to identify studies reporting the psychometric performance of the Child Health Utility (CHU9D), EQ-5D-Y (3L or 5L), and Health Utilities Index Mark 2 (HUI2) or Mark 3 (HUI3) in children and/or adolescents. Data were extracted to assess known-group validity, convergent validity, responsiveness, reliability, acceptability, and feasibility. Data were extracted separately for the dimensions and utility index where this was reported. Results: The review included 76 studies (CHU9D n = 12, EQ-5D-Y-3L n = 20, HUI2 n = 26,HUI3 n = 43), which varied considerably across conditions and sample size. EQ-5D-Y-3L had the largest amount of evidence of good psychometric performance in proportion to the number of studies examining performance. The majority of the evidence related to EQ5D-Y-3L was based on dimensions. CHU9D was assessed in fewer studies, but the majority of studies found evidence of good psychometric performance. Evidence for HUI2 and HUI3 was more mixed, but the studies were more limited in sample size and statistical power, which was likely to have affected performance. Conclusions: The heterogeneity of published studies means that the evidence is based on studies across a range of countries, populations and conditions, using different study designs, different languages, different value sets and different statistical techniques. Evidence for CHU9D in particular is based on a limited number of studies. The findings raise concerns about the comparability of self-report and proxy-report responses to generate utility values for children and adolescents.	[Rowen, Donna; Keetharuth, Anju D.; Poku, Edith; Wong, Ruth; Pennington, Becky; Wailoo, Allan] Univ Sheffield, Sch Hlth & Related Res, 30 Regent St, Sheffield S1 4DA, S Yorkshire, England		Rowen, D (通讯作者)，Univ Sheffield, Sch Hlth & Related Res, 30 Regent St, Sheffield S1 4DA, S Yorkshire, England.	d.rowen@sheffield.ac.uk		Keetharuth, Anju/0000-0001-8889-6806	National Institute of Health and Care Excellence Excellence Decision Support Unit; National Institute for Health Research Policy Research Program [PR-PRU-1217-20401]	This research was funded by National Institute of Health and Care Excellence Excellence Decision Support Unit and the National Institute for Health Research Policy Research Program, conducted through the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions, PR-PRU-1217-20401.	Anthoine Emmanuelle, 2014, Health Qual Life Outcomes, V12, P176, DOI 10.1186/s12955-014-0176-2; Astrom M, 2018, QUAL LIFE RES, V27, P2859, DOI 10.1007/s11136-018-1985-2; Banks BA, 2008, J PEDIAT HEMATOL ONC, V30, P292, DOI 10.1097/MPH.0b013e3181647bda; Barr RD, 1997, INT J ONCOL, V11, P333; Belfort MB, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-12; Bergfors S, 2015, ACTA PAEDIATR, V104, P167, DOI 10.1111/apa.12863; Boran P, 2011, PEDIATR BLOOD CANCER, V56, P812, DOI 10.1002/pbc.22835; Boulton M, 2006, DEV MED CHILD NEUROL, V48, P656, DOI 10.1017/S0012162206001381; Burstrom K, 2014, ACTA PAEDIATR, V103, P426, DOI 10.1111/apa.12557; Canaway AG, 2013, QUAL LIFE RES, V22, P173, DOI 10.1007/s11136-012-0119-5; Chen G, 2019, QUAL LIFE RES, V28, P163, DOI 10.1007/s11136-018-2032-z; Chen G, 2015, PHARMACOECONOMICS, V33, P1013, DOI 10.1007/s40273-015-0286-7; Chen G, 2015, VALUE HEALTH, V18, P432, DOI 10.1016/j.jval.2015.02.014; Cheng AK, 2000, JAMA-J AM MED ASSOC, V284, P850, DOI 10.1001/jama.284.7.850; de Sonneville-Koedoot C, 2015, J COMMUN DISORD, V58, P106, DOI 10.1016/j.jcomdis.2015.10.006; de Sonneville-Koedoot C, 2014, J FLUENCY DISORD, V42, P1, DOI 10.1016/j.jfludis.2014.09.001; Devlin NJ, 2017, APPL HEALTH ECON HEA, V15, P127, DOI 10.1007/s40258-017-0310-5; Dickerson JF, 2018, QUAL LIFE RES, V27, P447, DOI 10.1007/s11136-017-1728-9; Eidt-Koch D, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-55; Feeny D, 2004, SOC SCI MED, V58, P799, DOI 10.1016/S0277-9536(03)00254-5; Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006; Finch AP, 2018, EUR J HEALTH ECON, V19, P557, DOI 10.1007/s10198-017-0902-x; Francis A, 2019, ARCH DIS CHILD, V104, P134, DOI 10.1136/archdischild-2018-314934; Frew EJ, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0526-1; Furber G, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0218-4; Furlong W, 2012, PEDIATR BLOOD CANCER, V59, P717, DOI 10.1002/pbc.24096; Glaser AW, 1999, EUR J CANCER, V35, P256, DOI 10.1016/S0959-8049(98)00367-0; Hernandez G, 2015, QUAL LIFE RES, V24, P174; Hsu CN, 2018, INT J QUAL HEALTH C, V30, P298, DOI 10.1093/intqhc/mzy011; Hu R L, 1988, Zhonghua Shen Jing Jing Shen Ke Za Zhi, V21, P362; Janse AJ, 2008, ACTA PAEDIATR, V97, P1118, DOI 10.1111/j.1651-2227.2008.00847.x; Jelsma J, 2010, INT J REHABIL RES, V33, P172, DOI 10.1097/MRR.0b013e32832bb0f7; Kennedy CR, 1999, INT J CANCER, P106; Kennes J, 2002, DEV MED CHILD NEUROL, V44, P240, DOI 10.1017/S0012162201002018; Kim SK, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0922-y; Kind P, 2015, QUAL LIFE RES, V24, P2519, DOI 10.1007/s11136-015-0971-1; Klaassen RJ, 2010, CANCER-AM CANCER SOC, V116, P1602, DOI 10.1002/cncr.24888; Klaassen RJ, 2010, CANCER-AM CANCER SOC, V116, P1608, DOI 10.1002/cncr.24883; Kreimeier S, 2018, VALUE HEALTH, V21, P1291, DOI 10.1016/j.jval.2018.05.002; Kulkarni AV, 2010, J NEUROSURG-PEDIATR, V6, P11, DOI 10.3171/2010.3.PEDS09358; Kulpeng W, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-122; Kwon J, 2018, MED DECIS MAKING, V38, P277, DOI 10.1177/0272989X17732990; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Le Gales C, 1999, INT J CANCER, P112; Lee JM, 2011, MED CARE, V49, P924, DOI 10.1097/MLR.0b013e318216592c; Livingston MH, 2008, DEV MED CHILD NEUROL, V50, P696, DOI 10.1111/j.1469-8749.2008.03053.x; Longworth L, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18090; Loof E, 2019, ACTA PAEDIATR, V108, P1492, DOI 10.1111/apa.14709; Lovett RES, 2015, EAR HEARING, V36, P14, DOI 10.1097/AUD.0000000000000087; Lynch FL, 2016, MED CARE, V55, P1089, DOI 10.1097/MLR.0000000000000581; Mattera M, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-1006-8; Mayoral K, 2017, QUAL LIFE RES, V26, P71; McCabe C, 2005, HEALTH ECON, V14, P231, DOI 10.1002/hec.925; Michalos A, 2014, ENCY QUALITY LIFE WE; Mok WKY, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/s12955-014-0144-x; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Morrow AM, 2012, CHILD CARE HLTH DEV, V38, P186, DOI 10.1111/j.1365-2214.2011.01240.x; NICE, 2013, GUID METH TECHN APPR; Oluboyede Y, 2019, VALUE HEALTH, V22, P348, DOI 10.1016/j.jval.2018.10.001; Oluboyede Y, 2013, EUR J HEALTH ECON, V14, P11, DOI 10.1007/s10198-011-0340-0; Page LAF, 2015, INT J PAEDIATR DENT, V25, P349, DOI 10.1111/ipd.12177; Penn A, 2011, J PEDIAT HEMATOL ONC, V33, P592, DOI 10.1097/MPH.0b013e31821388c0; Perez-Sousa MA, 2018, QUAL LIFE RES, V27, P2305, DOI 10.1007/s11136-018-1893-5; Petersen KD, 2018, PATIENT, V11, P29, DOI 10.1007/s40271-017-0265-5; Petrou S, 2013, CHILD CARE HLTH DEV, V39, P345, DOI 10.1111/j.1365-2214.2012.01368.x; Ramos-Goni JM, 2020, PHARMACOECONOMICS, V38, P653, DOI 10.1007/s40273-020-00909-3; Ratcliffe J, 2016, SOC SCI MED, V157, P48, DOI 10.1016/j.socscimed.2016.03.042; Ratcliffe J, 2015, APPL HEALTH ECON HEA, V13, P485, DOI 10.1007/s40258-015-0184-3; Ratcliffe J, 2012, VALUE HEALTH, V15, P730, DOI 10.1016/j.jval.2012.04.005; Ratcliffe J, 2012, PHARMACOECONOMICS, V30, P713, DOI 10.2165/11597900-000000000-00000; Ratcliffe J, 2012, QUAL LIFE RES, V21, P717, DOI 10.1007/s11136-011-9971-y; Ratcliffe J, 2011, APPL HEALTH ECON HEA, V9, P15, DOI 10.2165/11536960-000000000-00000; Ravens-Sieberer U, 2010, QUAL LIFE RES, V19, P887, DOI 10.1007/s11136-010-9649-x; Rhodes ET, 2012, J PEDIATR-US, V160, DOI 10.1016/j.jpeds.2011.11.026; Robles N, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0271-z; Roposch Andreas, 2011, J Bone Joint Surg Am, V93, pe145, DOI 10.2106/JBJS.J.01623; Rosenbaum PL, 2007, DEV MED CHILD NEUROL, V49, P516, DOI 10.1111/j.1469-8749.2007.00516.x; Rowen D, 2020, PHARMACOECONOMICS, V38, P325, DOI 10.1007/s40273-019-00873-7; Rowen D, 2018, VALUE HEALTH, V21, P1234, DOI 10.1016/j.jval.2018.03.016; Sach TH, 2017, VALUE HEALTH, V20, pA406, DOI 10.1016/j.jval.2017.08.051; Scalone L, 2011, EPIDEMIOL BIOSTAT PU, V8, P331; Scott D, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0590-3; Smith-Olinde L, 2008, QUAL LIFE RES, V17, P943, DOI 10.1007/s11136-008-9358-x; Speechley KN, 1999, INT J CANCER, P95; Stade BC, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-81; Stevens K, 2012, VALUE HEALTH, V15, P1092, DOI 10.1016/j.jval.2012.07.011; Stevens K, 2012, PHARMACOECONOMICS, V30, P729, DOI 10.2165/11599120-000000000-00000; Stevens KJ, 2012, PEDIATR CRIT CARE ME, V13, P387, DOI 10.1097/PCC.0b013e318238969a; Sung L, 2004, J CLIN EPIDEMIOL, V57, P1161, DOI 10.1016/j.jclinepi.2004.05.003; Sung L, 2003, BRIT J CANCER, V88, P1185, DOI 10.1038/sj.bjc.6600895; Tan EJ, 2018, QUAL LIFE RES, V27, P2851, DOI 10.1007/s11136-018-1932-2; TATSUOKA H, 1989, J COMP NEUROL, V290, P343, DOI 10.1002/cne.902900304; Tilford JM, 2012, PHARMACOECONOMICS, V30, P661, DOI 10.2165/11597200-000000000-00000; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Trevino RP, 2013, J OBES, V2013, DOI 10.1155/2013/206074; Trudel JG, 1998, QUAL LIFE RES, V7, P421, DOI 10.1023/A:1008857920624; Ungar WJ, 2012, PHARMACOECONOMICS, V30, P697, DOI 10.2165/11597890-000000000-00000; Verrips GHW, 2001, J CLIN EPIDEMIOL, V54, P475, DOI 10.1016/S0895-4356(00)00317-6; Wille N, 2010, QUAL LIFE RES, V19, P875, DOI 10.1007/s11136-010-9648-y; Wolke D, 2013, J PEDIATR-US, V163, P1020, DOI 10.1016/j.jpeds.2013.04.030; Wong CKH, 2019, EUR J HEALTH ECON, V20, P647, DOI 10.1007/s10198-018-1026-7; Xu F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089222	102	7	7	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAR	2021	24	3					443	460		10.1016/j.jval.2020.09.012		FEB 2021	18	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QM9NG	33641779	Green Accepted, Bronze			2022-04-28	WOS:000622099500017
J	Amiri, S; McDonell, MG; Denney, JT; Buchwald, D; Amram, O				Amiri, Solmaz; McDonell, Michael G.; Denney, Justin T.; Buchwald, Dedra; Amram, Ofer			Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis	VALUE IN HEALTH			English	Article						medication-assisted treatment; 2-step floating catchment area; RUCA; Area Deprivation Index; Integrated Nested Laplace Approximation; GIS		Objectives: To measure access to opioid treatment programs (OTPs) and office-based buprenorphine treatment (OBBTs) at the smallest geographic unit for which the Census Bureau publishes demographic and socioeconomic data (ie, block group) and to explore disparities in access to treatment across the rural-urban and area deprivation continua across the United States. Methods: Access to OTPs and OBBTs at the block group in 2019 was quantified using an innovative 2-step floating catchment area technique that accounts for the supply of treatment facilities relative to the population size, proximity of facilities relative to the location of population in block groups, and time as a barrier within catchments. Block groups were stratified into tertiles based on the rural-urban continuum codes (metropolitan, micropolitan, small town, or rural) and area deprivation index (least-deprived, middle-deprived, most-deprived). The Integrated Nested Laplace Approximation approach was used for statistical analysis. Results: Across the United States, 3329 block groups corresponding to 2 915 949 adults lacked access to OTPs within a 2-hour drive of their community and 130 block groups corresponding to 86 605 adults did not have access to OBBTs. Disparities in access to treatment were observed across the urban-rural and area deprivation continua including (1) lowest mean access score to OBBTs were found among most-deprived small towns, and (2) lower mean access score to OTPs were found among micropolitan and small towns. Conclusions: The results of this study revealed disparities in access to medication-assisted treatment. The findings call for creative initiatives and local and regional policies to develop to mitigate access problems.	[Amiri, Solmaz; Amram, Ofer] Washington State Univ, Dept Nutr & Exercise Physiol, Elson S Floyd Coll Med, Spokane, WA USA; [McDonell, Michael G.] Washington State Univ, Elson S Floyd Coll Med, Behav Hlth Innovat, Spokane, WA USA; [Denney, Justin T.] Washington State Univ, Dept Sociol, Pullman, WA 99164 USA; [Buchwald, Dedra] Washington State Univ, Inst Res & Educ Adv Community Hlth, Elson S Floyd Coll Med, Spokane, WA USA; [Amram, Ofer] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA		Amiri, S (通讯作者)，WSU Hlth Sci Spokane Nutr & Exercise Physiol, 412 E Spokane Falls Blvd, Spokane, WA 99202 USA.	solmaz.amiri@wsu.edu			State of Washington Initiative Measure [171]	This investigation was supported in part by funds provided for medical and biological research by the State of Washington Initiative Measure No.171.	Abraham AJ, 2020, NEUROTHERAPEUTICS, V17, P55, DOI 10.1007/s13311-019-00814-4; Amiri S, 2020, AM J DRUG ALCOHOL AB, V46, P78, DOI 10.1080/00952990.2019.1620261; Amiri S, 2018, J SUBST ABUSE TREAT, V93, P26, DOI 10.1016/j.jsat.2018.07.006; Anderson TJ, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1053-3; Andrilla CHA, 2018, AM J PREV MED, V54, pS208, DOI 10.1016/j.amepre.2018.02.006; Askari MS, 2020, J SUBST ABUSE TREAT, V114, DOI 10.1016/j.jsat.2020.108028; Association of American Medical Colleges, 2017 STAT PHYS WORKF; Barnett ML, 2019, HEALTH AFFAIR, V38, P2048, DOI 10.1377/hlthaff.2019.00859; Basu S, 2019, JAMA INTERN MED, V179, P506, DOI 10.1001/jamainternmed.2018.7624; Beardsley K, 2003, J SUBST ABUSE TREAT, V25, P279, DOI 10.1016/S0740-5472(03)00188-0; Blangiardo M, 2015, SPATIAL AND SPATIO-TEMPORAL BAYESIAN MODELS WITH R-INLA, P1, DOI 10.1002/9781118950203; Blangiardo M, 2013, SPAT SPATIO-TEMPORAL, V7, P39, DOI 10.1016/j.sste.2013.07.003; Brooks RG, 2002, ACAD MED, V77, P790, DOI 10.1097/00001888-200208000-00008; Centers for Medicare & Medicaid Services US Department of Health and Human Services, REV PAYM POL PHYS SC; Cummings JR, 2017, JAMA PSYCHIAT, V74, P476, DOI 10.1001/jamapsychiatry.2017.0303; Gong G, 2019, HEALTH AFFAIR, V38, P2003, DOI 10.1377/hlthaff.2019.00722; Grimm CA, GEOGRAPHIC DISPARITI; Guagliardo Mark F, 2004, Int J Health Geogr, V3, P3; Handley TE, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0249-0; Henning-Smith C, 2017, MED CARE, V55, P823, DOI 10.1097/MLR.0000000000000761; Jones CM, 2019, ADDICTION, V114, P471, DOI 10.1111/add.14436; Jones CW, 2018, J SUBST ABUSE TREAT, V93, P19, DOI 10.1016/j.jsat.2018.07.008; Kelly J, HIV AIDS RURAL COMMU; Kind AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMp1802313; Knighton Andrew J, 2016, EGEMS (Wash DC), V4, P1238, DOI 10.13063/2327-9214.1238; Look KA, 2019, RES SOC ADMIN PHARM, V15, P404, DOI 10.1016/j.sapharm.2018.06.006; Luo W, 2003, ENVIRON PLANN B, V30, P865, DOI 10.1068/b29120; McGrail MR, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0880-6; Minozzi S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001333.pub4; National Institutes of Health, OV DEATH RAT; Nielsen S, 2017, JAMA-J AM MED ASSOC, V317, P967, DOI 10.1001/jama.2017.0001; Rising, 2019, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20190920.981503/full/, DOI 10.1377/HBLOG20190920.981503/FULL, DOI 10.1377/HB1OG20190920.981503/FULL]; Rosenblum A, 2011, J ENVIRON PUBLIC HEA, V2011, DOI 10.1155/2011/948789; SAMHSA, 2020, KEY SUBSTANCE USE ME; Schrodle B, 2011, ENVIRONMETRICS, V22, P725, DOI 10.1002/env.1065; Schuurman N, 2010, CAN GEOGR-GEOGR CAN, V54, P29, DOI 10.1111/j.1541-0064.2009.00301.x; Shi L, 2005, PUBLIC HEALTH, V119, P699, DOI 10.1016/j.puhe.2004.12.007; Shi LY, 2005, SOC SCI MED, V61, P65, DOI 10.1016/j.socscimed.2004.11.056; Shi LY, 2005, AM J PUBLIC HEALTH, V95, P674, DOI 10.2105/AJPH.2003.031716; Singh GK, 2003, AM J PUBLIC HEALTH, V93, P1137, DOI 10.2105/AJPH.93.7.1137; Skillman S, 2017, WASHINGTON STATES PH; Spetz J, 2019, JAMA-J AM MED ASSOC, V321, P1407, DOI 10.1001/jama.2019.0834; Substance Abuse and Mental Health Service Administration, OP TREATM PROGR DIR; Substance Abuse and Mental Health Services Administration, DAT SUBST AB TREATM; Substance Abuse and Mental Health Services Administration, UND FIN RUL PAT LIM; Substance Abuse and Mental Health Services Administration, 2018, MED COV MED ASS TREA; Substance Abuse and Mental Health Services Administration, HHS PUBL; Substance Abuse and Mental Health Services Administration, 2018, NAT SURV SUBST AB TR; Substance Abuse and Mental Health Services Administration US Department of Health and Human Services, FAC ADD AM SURG GEN; Thomas CP, 2017, DRUG ALCOHOL DEPEN, V181, P213, DOI 10.1016/j.drugalcdep.2017.10.002; United States Census Bureau, STAND HIER CENS GEOG; United States Census Bureau, 2017, AM COMMUNITY SURVEY; United States Department of Agriculture, POP MIGR; US Department of Health and Human Services, 2016, FAC ADD AM SURG GEN; Warner TD, 2005, COMMUNITY MENT HLT J, V41, P21, DOI 10.1007/s10597-005-2597-1; Whelan PJ, 2012, J NEUROSCI RURAL PRA, V3, P45, DOI 10.4103/0976-3147.91934; Wolff K., 2005, ENCY FORENSIC LEGAL; WWAMI Rural Health Research Center, RUR URB COMM AR COD	58	8	8	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	FEB	2021	24	2					188	195		10.1016/j.jval.2020.08.2098		JAN 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QJ1VI	33518025	Bronze			2022-04-28	WOS:000619478100006
J	Boersma, C; Postma, MJ				Boersma, Cornelis; Postma, Maarten J.			Health Economics of Vaccines: From Current Practice to Future Perspectives	VALUE IN HEALTH			English	Editorial Material							COST-EFFECTIVENESS; VACCINATION; VARICELLA		[Boersma, Cornelis; Postma, Maarten J.] Univ Groningen, Dept Hlth Sci, Univ Med Ctr Groningen, Groningen, Netherlands; [Boersma, Cornelis] Open Univ Netherlands, Dept Management Sci, Heerlen, Netherlands; [Boersma, Cornelis; Postma, Maarten J.] Hlth Ecore Ltd, Zeist, Netherlands; [Postma, Maarten J.] Univ Groningen, Dept Pharm, Groningen, Netherlands; [Postma, Maarten J.] Univ Groningen, Dept Econ Econometr & Finance, Groningen, Netherlands; [Postma, Maarten J.] Univ Airlangga, Dept Pharmacol & Therapy, Surabaya, Indonesia; [Postma, Maarten J.] Univ Padjadjaran, Ctr Excellence Higher Educ Pharmaceut Care Innova, Bandung, Indonesia		Postma, MJ (通讯作者)，Univ Groningen, Dept Hlth Sci, Illegaliteitslaan 29, NL-9727EB Groningen, Netherlands.	m.j.postma@rug.nl		Postma, Maarten/0000-0002-6306-3653; Boersma, Cornelis/0000-0002-1190-2638			Annemans L, 2021, VALUE HEALTH, V24, P105, DOI 10.1016/j.jval.2020.09.005; Atkins KE, 2018, LANCET INFECT DIS, V18, pE204, DOI 10.1016/S1473-3099(17)30478-4; Baguelin M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0452-y; Barnighausen T, 2014, LANCET GLOB HEALTH, V2, pE251, DOI 10.1016/S2214-109X(13)70170-0; Beck E, 2021, VALUE HEALTH, V24, P91, DOI 10.1016/j.jval.2020.09.004; Christensen H, 2020, EUR J HEALTH ECON, V21, P297, DOI 10.1007/s10198-019-01129-z; de Boer PT, 2021, VALUE HEALTH, V24, P19, DOI 10.1016/j.jval.2020.10.011; de Boer PT, 2015, EBIOMEDICINE, V2, P1302, DOI 10.1016/j.ebiom.2015.09.014; Dolk FCK, 2021, VALUE HEALTH, V24, P11, DOI 10.1016/j.jval.2020.10.013; Health Technology Assessment international, HTAS CRIT ROL EARL A; Jit M, 2021, VALUE HEALTH, V24, P61, DOI 10.1016/j.jval.2020.07.012; Jit M, 2014, LANCET GLOB HEALTH, V2, pE406, DOI 10.1016/S2214-109X(14)70237-2; Joint Committee of Vaccination and Immunization, STAT INFL VACC 2021; Luyten J, 2021, VALUE HEALTH, V24, P41, DOI 10.1016/j.jval.2020.07.011; Mauskopf J, 2021, VALUE HEALTH, V24, P86, DOI 10.1016/j.jval.2020.06.018; Portnoy A, 2021, VALUE HEALTH, V24, P67, DOI 10.1016/j.jval.2020.08.2097; Rafferty TERS, 2021, VALUE HEALTH, V24, P50, DOI 10.1016/j.jval.2020.10.004; Rozenbaum MH, 2008, EXPERT REV VACCINES, V7, P753, DOI 10.1586/14760584.7.6.753; Schlander Michael, 2016, J Mark Access Health Policy, V4, DOI 10.3402/jmahp.v4.33039; Scholz SM, 2021, VALUE HEALTH, V24, P32, DOI 10.1016/j.jval.2020.05.022; Sim SY, 2021, VALUE HEALTH, V24, P70, DOI 10.1016/j.jval.2020.07.010; Ultsch B, 2016, PHARMACOECONOMICS, V34, P227, DOI 10.1007/s40273-015-0335-2; Verguet S, 2016, PHARMACOECONOMICS, V34, P913, DOI 10.1007/s40273-016-0414-z; Watts E, 2021, VALUE HEALTH, V24, P78, DOI 10.1016/j.jval.2020.07.009; Zeevat F, 2021, VALUE HEALTH, V24, P3, DOI 10.1016/j.jval.2020.11.002	25	3	3	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JAN	2021	24	1					1	2		10.1016/j.jval.2020.11.006		JAN 2021	2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QC0YJ	33431140	Green Published, Bronze			2022-04-28	WOS:000614560000001
J	van Hout, BA; Shaw, JW				van Hout, Ben A.; Shaw, James W.			Mapping EQ-5D-3L to EQ-5D-5L	VALUE IN HEALTH			English	Article						algorithms; EQ-5D-3L; EQ-5D-5L; mapping		Objectives: The original 3-level EQ-5D (EQ-5D-3L) includes 5 dimensions with 3 levels of problems per dimension. Since 2010, a more sensitive version with 5 levels of problems per dimension (EQ-5D-5L) has become available. Population value sets have been developed for both versions of the questionnaire. The objective of this research was to develop a mapping function to link EQ-5D-3L responses to value sets for the EQ-5D-5L. Methods: Various algorithms were developed to link EQ-5D-3L and EQ-5D-5L responses using data from an observational study including members of 10 subgroups (N = 3580) who completed both versions of the questionnaire. Nonparametric and ordinal logistic regression models were fit to the data and compared using Akaike's information criterion (AIC) as well as the mean absolute error and root mean squared error of predictions. Results were contrasted qualitatively and quantitatively with those of an alternative copula-based approach. Results: Including indicants of problems for other EQ-5D-3L dimensions as regressors in the modeling yielded the greatest improvement in prediction accuracy. Adding age and gender lowered the AIC without improving predictions, while including a latent factor lowered the AIC further and slightly improved predictive accuracy. Models that conditioned on problems in other EQ-5D-3L dimensions yielded more accurate predictions than the alternative copula-based approach in subgroups defined by age and gender. Conclusion: We present novel algorithms to map EQ-5D-3L responses to EQ-5D-5L value sets. The recommended approach is based on an ordinal logistic regression that disregards age and gender and accounts for unobserved heterogeneity using a latent factor.	[van Hout, Ben A.] Univ Sheffield, Sheffield, S Yorkshire, England; [Shaw, James W.] Bristol Meyers Squibb, Lawrenceville, NJ USA		van Hout, BA (通讯作者)，Univ Sheffield, Sch Hlth & Related Res, 113 West Court,2 Mappin St, Sheffield S1 4DT, S Yorkshire, England.	b.a.vanhout@sheffield.ac.uk			EuroQol foundation	The work of Dr van Hout was supported by a grant from the EuroQol foundation. Dr Shaw did not receive any financial sup-port for this research.	Buchholz I, 2018, PHARMACOECONOMICS, V36, P645, DOI 10.1007/s40273-018-0642-5; Devlin NJ, 2018, HEALTH ECON, V27, P7, DOI 10.1002/hec.3564; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hernandez-Alava M, 2017, METHODS MAPPING EQ 5; Hernandez-Alava M, 2018, STATA J, V18, P395, DOI 10.1177/1536867X1801800207; Hernandez-Alava M, 2017, J HEALTH ECON, V55, P139, DOI 10.1016/j.jhealeco.2017.06.013; Khan I, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0455-1; Pickard AS, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-70; Shaw JW, COMP GENERIC CONDITI; Shaw JW, 2020, 25 ANN INT M INT SOC; Thompson AJ, 2020, PHARMACOECONOMICS, V38, P575, DOI 10.1007/s40273-020-00893-8; van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	13	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	SEP	2021	24	9					1285	1293		10.1016/j.jval.2021.03.009		AUG 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	UG5RC	34452708	Bronze			2022-04-28	WOS:000689308300008
J	Matza, LS; Stewart, KD; Lloyd, AJ; Rowen, D; Brazier, JE				Matza, Louis S.; Stewart, Katie D.; Lloyd, Andrew J.; Rowen, Donna; Brazier, John E.			Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations	VALUE IN HEALTH			English	Article						cost-utility analysis; health state utilities; health state vignettes; time trade-off; utility assessment; vignette-based methods	HEALTH STATE UTILITIES; PREFERENCE-BASED MEASURES; ISPOR GOOD PRACTICES; ADJUSTED LIFE YEARS; WILLINGNESS-TO-PAY; QUALITY-OF-LIFE; OUTCOMES; EVENTS; IMPACT; VALUATION	Health technology assessment agencies often prefer that utilities used to calculate quality-adjusted life years in cost-utility analyses (CUAs) are derived using standardized methods, such as generic preference-based measures completed by patients in clinical trials. However, there are situations when no standardized approach is feasible or appropriate for a specific medical condition or treatment that must be represented in a CUA. When this occurs, vignette-based methods are often used to estimate utilities. A vignette (sometimes called a "scenario," "health state description," "health state vignette," or "health state") is a description of a health state that is valued in a preference elicitation task to obtain a utility estimate. This method is sometimes the only feasible way to estimate utilities representing a concept that is important for a CUA. Consequently, vignette-based studies continue to be conducted and published, with the resulting utilities used in economic models to inform decision making about healthcare resource allocation. Despite the potential impact of vignette-based utilities on medical decision making, there is no published guidance or review of this methodology. This article provides recommendations for researchers, health technology assessment reviewers, and policymakers who may be deciding whether to use vignette-based methods, designing a vignette study, using vignette-based utilities in a CUA, or evaluating a CUA that includes vignette-based utilities. Recommendations are provided on: (A) when to use vignette-based utilities, (B) methods for developing vignettes, (C) valuing vignettes, (D) use of vignette-based utilities in models, and (E) limitations of vignette methods.	[Matza, Louis S.; Stewart, Katie D.] Evidera, Patient Ctr Res Grp, Bethesda, MD USA; [Lloyd, Andrew J.] Acaster Lloyd Consulting, London, England; [Rowen, Donna; Brazier, John E.] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England		Matza, LS (通讯作者)，7101 Wisconsin Ave,Suite 1400, Bethesda, MD 20814 USA.	louis.matza@evidera.com		Brazier, John/0000-0001-8645-4780			Ara R, 2017, PHARMACOECONOMICS, V35, pS67, DOI 10.1007/s40273-017-0549-6; Aristides M, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0377-3; Arnesen Trude, 2004, J Health Serv Res Policy, V9, P43, DOI 10.1258/135581904322716111; Beale RC, 2017, ISPOR 20 ANN EUR C 4; Bilir S Pinar, 2018, Eur Endocrinol, V14, P80, DOI 10.17925/EE.2018.14.2.80; Boye KS, 2019, J MED ECON, V22, P806, DOI 10.1080/13696998.2019.1609482; Boye KS, 2011, EUR J HEALTH ECON, V12, P219, DOI 10.1007/s10198-010-0224-8; Brazier JE, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16320; Brazier J, 2019, VALUE HEALTH, V22, P267, DOI 10.1016/j.jval.2019.01.004; Brazier J, 2017, PHARMACOECONOMICS, V35, pS21, DOI 10.1007/s40273-017-0545-x; Brennan VK, 2013, PHARMACOECONOMICS, V31, P677, DOI 10.1007/s40273-013-0066-1; Carlsson KS, 2017, HAEMOPHILIA, V23, P894, DOI 10.1111/hae.13322; Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x; DALY E, 1993, BRIT MED J, V307, P836, DOI 10.1136/bmj.307.6908.836; Davies EW, 2018, PATIENT PREFER ADHER, V12, P1079, DOI 10.2147/PPA.S160662; Davies EW, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0266-9; Donaldson C, 1997, SOC SCI MED, V44, P699, DOI 10.1016/S0277-9536(96)00215-8; Evans Marc, 2013, J Med Econ, V16, P1357, DOI 10.3111/13696998.2013.846262; Faris C, 2018, JAMA FACIAL PLAST SU, V20, P480, DOI 10.1001/jamafacial.2018.0866; Feeny D, 2005, ASSESSING QUALITY LI, V2nd, P405; Finch AP, 2019, VALUE HEALTH, V22, P50, DOI 10.1016/j.jval.2018.07.001; Fordham BA, 2015, PATIENT PREFER ADHER, V9, P1561, DOI 10.2147/PPA.S90425; GERARD K, 1993, J CLIN EPIDEMIOL, V46, P77, DOI 10.1016/0895-4356(93)90011-O; Hadi M, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0903-6; Hall F, 2019, QUAL LIFE RES, V28, P1191, DOI 10.1007/s11136-019-02117-9; Hamilton DW, 2018, CLIN OTOLARYNGOL, V43, P117, DOI 10.1111/coa.12906; Healthcare Improvement Scotland (HIS), 2018, 81 HIS SDG, P60; Healthcare Improvement Scotland (HIS), 2018, ADV STAT 009 18 WHAT, P7; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Higgins A, 2014, VALUE HEALTH, V17, P877, DOI 10.1016/j.jval.2014.08.2670; Hixson-Wallace JA, 2001, CLIN APPL THROMB-HEM, V7, P33, DOI 10.1177/107602960100700108; Horsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54; Institute for Quality and Efficiency in Health Care (IQWiG), 2017, GEN METH, V5.0, P274; Karnon J, 2008, CURR MED RES OPIN, V24, P1609, DOI 10.1185/03007990802077442; Krassioukov A, 2018, MED DEVICES-EVID RES, V11, P345, DOI 10.2147/MDER.S165778; Kuppermann M, 1997, MED DECIS MAKING, V17, P42, DOI 10.1177/0272989X9701700105; LAUPACIS A, 1993, J BONE JOINT SURG AM, V75A, P1619, DOI 10.2106/00004623-199311000-00006; Lenert LA, 2004, SCHIZOPHR RES, V71, P155, DOI 10.1016/j.schres.2003.10.010; Lloyd A, 2008, DIABETIC MED, V25, P618, DOI 10.1111/j.1464-5491.2008.02430.x; Lloyd A, 2006, BRIT J CANCER, V95, P683, DOI 10.1038/sj.bjc.6603326; Lloyd A, 2015, ISPOR 18 ANN EUR C N; Lloyd A, 2019, BRIT J OPHTHALMOL, V103, P1610, DOI 10.1136/bjophthalmol-2018-313089; Lloyd AJ, 2018, VALUE HEALTH, V21, P449, DOI 10.1016/j.jval.2017.09.015; Lloyd AJ, 2017, CURR MED RES OPIN, V33, P23, DOI 10.1080/03007995.2016.1232704; Longworth L, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18090; Longworth L, 2013, VALUE HEALTH, V16, P202, DOI 10.1016/j.jval.2012.10.010; Lourenco RD, 2017, PHARMACOECONOMICS, V35, P347, DOI 10.1007/s40273-016-0470-4; MacKeigan LD, 1999, MED DECIS MAKING, V19, P113, DOI 10.1177/0272989X9901900201; Matza LS, 2007, QUAL LIFE RES, V16, P1251, DOI 10.1007/s11136-007-9226-0; Matza LS, 2020, J MED ECON, V23, P978, DOI 10.1080/13696998.2020.1776719; Matza LS, 2020, EUR J HEALTH ECON, V21, P397, DOI 10.1007/s10198-019-01136-0; Matza LS, 2020, DIABETES THER, V11, P319, DOI 10.1007/s13300-019-00718-8; Matza LS, 2019, J MED ECON, V22, P567, DOI 10.1080/13696998.2019.1584108; Matza LS, 2019, QUAL LIFE RES, V28, P2359, DOI 10.1007/s11136-019-02163-3; Matza LS, 2019, EUR J HEALTH ECON, V20, P819, DOI 10.1007/s10198-019-01036-3; Matza LS, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2648-7; Matza LS, 2017, QUAL LIFE RES, V26, P1785, DOI 10.1007/s11136-017-1519-3; Matza LS, 2017, VALUE HEALTH, V20, P507, DOI 10.1016/j.jval.2016.10.007; Matza LS, 2015, EUR J HEALTH ECON, V16, P1005, DOI 10.1007/s10198-014-0649-6; Matza LS, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0772-9; Matza LS, 2014, PATIENT PREFER ADHER, V8, P997, DOI 10.2147/PPA.S62776; Matza LS, 2014, EUR J HEALTH ECON, V15, P7, DOI 10.1007/s10198-012-0443-2; Matza LS, 2013, PATIENT PREFER ADHER, V7, P855, DOI 10.2147/PPA.S44947; MORRIS LS, 1993, CLIN THER, V15, P593; Nafees B, 2017, ASIA-PAC J CLIN ONCO, V13, pE195, DOI 10.1111/ajco.12477; National Institute for Health and Care Excellence (NICE), 2017, EL TREATM TYP 1 GAUC, V28, P44; NICE (National Institute for Health and Clinical Excellence), 2013, PROC METH GUID GUID, P93; Ock M, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0660-3; Oppe M, 2016, PHARMACOECONOMICS, V34, P993, DOI 10.1007/s40273-016-0404-1; PBAC, 2016, GUID PREP SUBM PHARM; Prosser LA, 2004, PEDIATRICS, V113, P283, DOI 10.1542/peds.113.2.283; Rajan Narayan, 2016, Value Health Reg Issues, V9, P67, DOI 10.1016/j.vhri.2015.11.006; Rencz F, 2016, BRIT J DERMATOL, V175, P593, DOI 10.1111/bjd.14647; Revicki DA, 1996, INT CLIN PSYCHOPHARM, V11, P101, DOI 10.1097/00004850-199611020-00004; Revicki DA, 1998, J AFFECT DISORDERS, V48, P25, DOI 10.1016/S0165-0327(97)00117-1; Rowen D, 2018, MED DECIS MAKING, V38, P699, DOI 10.1177/0272989X18784291; Rowen D, 2012, MED DECIS MAKING, V32, P31, DOI 10.1177/0272989X11408435; SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3; Saigal S, 1999, JAMA-J AM MED ASSOC, V281, P1991, DOI 10.1001/jama.281.21.1991; Saigal S, 2003, ARCH PEDIAT ADOL MED, V157, P261, DOI 10.1001/archpedi.157.3.261; Scottish Medicines Consortium (SMC), 2020, GUID SUBM CO COMPL N; Scottish Medicines Consortium (SMC), 2016, 11101511 SMC, P10; Secnik K, 2005, MED DECIS MAKING, V25, P56, DOI 10.1177/0272989X04273140; Shikiar R, 2004, VALUE HEALTH, V7, P204, DOI 10.1111/j.1524-4733.2004.72252.x; Shingler S, 2015, J MED ECON, V18, P45, DOI 10.3111/13696998.2014.971158; Smith P, 2011, OXFORD HDB HLTH EC, P788; Swinburn P, 2012, J Med Econ, V15, P681, DOI 10.3111/13696998.2012.670175; The International Society of Pharmacoeconomics and Outcomes Research (ISPOR), 2019, PHARM GUID WORLD; Tosh JC, 2011, VALUE HEALTH, V14, P102, DOI 10.1016/j.jval.2010.10.015; Wailoo AJ, 2017, VALUE HEALTH, V20, P18, DOI 10.1016/j.jval.2016.11.006; Wolowacz SE, 2016, VALUE HEALTH, V19, P704, DOI 10.1016/j.jval.2016.06.001	91	7	7	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24	6					812	821		10.1016/j.jval.2020.12.017		JUN 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SP8AF	34119079	hybrid, Green Accepted			2022-04-28	WOS:000659884900009
J	Alkofide, H; Almesned, R; Alnoghaimshi, L; Alkherb, Z; Alhindi, G; Korayem, G				Alkofide, H.; Almesned, R.; Alnoghaimshi, L.; Alkherb, Z.; Alhindi, G.; Korayem, G.			CARDIOVASCULAR OUTCOMES ASSOCIATED WITH CORONAVIRUS DISEASE 2019 (COVID-19): A SYSTEMATIC REVIEW AND META-ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Alkofide, H.; Almesned, R.; Alnoghaimshi, L.; Alkherb, Z.] King Saud Univ, Riyadh, Saudi Arabia; [Alhindi, G.] KSP, Riyadh, Saudi Arabia; [Korayem, G.] Princess Nourah Bint Abdulrahman Univ, Riyadh, Saudi Arabia									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV40	S74	S74					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400323
J	Alnijadi, A; Li, M; Wu, J; Lu, K				Alnijadi, A.; Li, M.; Wu, J.; Lu, K.			THE IMPACT OF COST RELATED MEDICATION NONADHERENCE ON HEALTHCARE UTILIZATION AND PATIENT-REPORTED OUTCOMES AMONG ELDERLY MEDICARE BENEFICIARIES ON ANTIDEPRESSANTS	VALUE IN HEALTH			English	Meeting Abstract									[Alnijadi, A.; Lu, K.] Univ South Carolina, Columbia, SC 29208 USA; [Li, M.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Wu, J.] Presbyterian Coll, Clinton, SC USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG25	S91	S91					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400398
J	Atallah, EL; Maegawa, R; Latremouille-Viau, D; Rossi, C; Guerin, A; Wu, E; Patwardhan, P				Atallah, E. L.; Maegawa, R.; Latremouille-Viau, D.; Rossi, C.; Guerin, A.; Wu, E.; Patwardhan, P.			COST OF CHRONIC MYELOID LEUKEMIA CARE AMONG PATIENTS IN ADVANCED PHASES OR ON LATER LINES OF THERAPY IN CHRONIC PHASE IN THE UNITED STATES FROM A COMMERCIAL AND MEDICARE PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Atallah, E. L.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Maegawa, R.; Patwardhan, P.] Novartis Pharmaceut, E Hanover, NJ USA; [Latremouille-Viau, D.; Rossi, C.; Guerin, A.] Anal Grp Inc, Montreal, PQ, Canada; [Wu, E.] Anal Grp Inc, Boston, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN50	S28	S28					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400114
J	Brook, R; Kleinman, NL; Beren, IA				Brook, R.; Kleinman, N. L.; Beren, I. A.			TRENDS IN ABSENCE TIME AND PAYMENTS DUE TO LONG- AND SHORT-TERM DISABILITY AND WORKERS' COMPENSATION FOR EMPLOYEES WITH MULTIPLE SCLEROSIS IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Brook, R.] Better Hlth Worldwide NPRT NASP, Newfoundland, NJ USA; [Kleinman, N. L.; Beren, I. A.] WorkPartners LLC, Loveland, CO USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSY28	S233	S233					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401284
J	Challagulla, S; Lee, P; Giafis, N; Manceur, AM; Fakih, I; Emond, B; Iyengar, R				Challagulla, S.; Lee, P.; Giafis, N.; Manceur, A. M.; Fakih, I; Emond, B.; Iyengar, R.			EFFECT OF EARLIER USE OF IBRUTINIB ON HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Challagulla, S.] Pharmacyclics LLC, Fremont, CA USA; [Lee, P.; Giafis, N.; Iyengar, R.] Pharmacyclics LLC, Sunnyvale, CA USA; [Manceur, A. M.; Fakih, I; Emond, B.] Anal Grp Inc, Montreal, PQ, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN95	S37	S37					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400154
J	Chikermane, S; Trivedi, MV; Sharma, M; Abughosh, SM; Aparasu, RR; Johnson, ML				Chikermane, S.; Trivedi, M., V; Sharma, M.; Abughosh, S. M.; Aparasu, R. R.; Johnson, M. L.			DOSE-DEPENDENT RELATION BETWEEN METFORMIN AND THE RISK OF HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE (HR+/HER2-) BREAST CANCER AMONG POSTMENOPAUSAL WOMEN WITH TYPE-2 DIABETES	VALUE IN HEALTH			English	Meeting Abstract									[Chikermane, S.; Trivedi, M., V; Abughosh, S. M.; Aparasu, R. R.; Johnson, M. L.] Univ Houston, Houston, TX USA; [Sharma, M.] Univ Mississippi, University, MS 38677 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN130	S43	S43					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400182
J	Cong, M; Liu, M; Ouyang, J; Dunne, S; Vicidomina, B; Nigam, S				Cong, M.; Liu, M.; Ouyang, J.; Dunne, S.; Vicidomina, B.; Nigam, S.			THE HEALTHCARE EFFECTS OF THE OCHSNER HYPERTENSION DIGITAL MEDICINE PROGRAM	VALUE IN HEALTH			English	Meeting Abstract									[Cong, M.; Liu, M.; Ouyang, J.; Dunne, S.; Vicidomina, B.; Nigam, S.] Blue Cross Blue Shield Louisiana, Baton Rouge, LA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV45	S75	S75					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400328
J	Dalal, G; Youn, JH; Kariki, E; Bromiley, PA; Luetchens, S; Cootes, TF; Payne, K				Dalal, G.; Youn, J. H.; Kariki, E.; Bromiley, P. A.; Luetchens, S.; Cootes, T. F.; Payne, K.			DESIGNING A COMPLEX INTERVENTION USING EARLY MODEL-BASED COST-EFFECTIVENESS ANALYSIS: A CASE STUDY OF AN ARTIFICIAL INTELLIGENCE-BASED ALGORITHM TO IDENTIFY VERTEBRAL FRAGILITY FRACTURES	VALUE IN HEALTH			English	Meeting Abstract									[Dalal, G.; Youn, J. H.; Bromiley, P. A.; Cootes, T. F.; Payne, K.] Univ Manchester, Manchester, Lancs, England; [Kariki, E.] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England; [Luetchens, S.] Optasia Med Ltd, Manchester, Lancs, England					Dalal, Garima/0000-0002-4073-4215				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMD5	S123	S124					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400541
J	Dayma, M; Markan, R; Sawhney, B; Kathe, N				Dayma, M.; Markan, R.; Sawhney, B.; Kathe, N.			HEALTH-RELATED QUALITY OF LIFE OF HPV-RELATED CANCER PATIENTS IN THE UNITED STATES: 2010-2018	VALUE IN HEALTH			English	Meeting Abstract									[Dayma, M.] Complete HEOR Solut CHEORS, Nimbahera, RJ, India; [Markan, R.; Sawhney, B.; Kathe, N.] Complete HEOR Solut CHEORS, N Wales, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN235	S63	S64					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400277
J	DiBenedetti, D; Mansfield, C; Myers, K; Satram, S; Reyes, C				DiBenedetti, D.; Mansfield, C.; Myers, K.; Satram, S.; Reyes, C.			UNDERSTANDING PATIENT EXPERIENCES WITH CHRONIC HEPATITIS B VIRUS (CHBV) AND ITS TREATMENTS	VALUE IN HEALTH			English	Meeting Abstract									[DiBenedetti, D.; Mansfield, C.; Myers, K.] RTI Hlth Solut, Res Triangle Pk, NC USA; [Satram, S.; Reyes, C.] Vir Biotechnol, San Francisco, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN72	S119	S119					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400522
J	Ding, W; Ma, Y; Ma, C; Ma, A; Tang, W				Ding, W.; Ma, Y.; Ma, C.; Ma, A.; Tang, W.			LIFETIME COST ESTIMATION OF HUMAN PAPILLOMAVIRUS RELATED DISEASES IN CHINA: A MODELLING STUDY USING REAL-WORLD DATA	VALUE IN HEALTH			English	Meeting Abstract									[Ding, W.; Ma, Y.; Ma, A.; Tang, W.] China Pharmaceut Univ, Nanjing, Peoples R China; [Ma, C.] Southeast Univ, Nanjing, Peoples R China									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN26	S110	S110					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400479
J	Enright, D; Panzer, A; Chambers, J				Enright, D.; Panzer, A.; Chambers, J.			DO US COMMERCIAL HEALTH PLANS CITE ICER REPORTS IN THEIR SPECIALTY DRUG COVERAGE POLICIES? AN EMPIRICAL ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Enright, D.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Davie, FL USA; [Panzer, A.; Chambers, J.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA 02111 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS48	S181	S181					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401052
J	Etges, AP; Ogliari, L; Souza, JS; Zanotto, B; Bertoglio, CR; Polanczyk, CA				Etges, A. P.; Ogliari, L.; Souza, J. S.; Zanotto, B.; Bertoglio, Cardoso R.; Polanczyk, C. A.			A TOOL PROPOSAL FOR MEASURING COSTS USING TIME-DRIVEN ACTIVITY-BASED COSTING FOR THE ISCHEMIC STROKE CARE PATHWAY	VALUE IN HEALTH			English	Meeting Abstract									[Etges, A. P.; Zanotto, B.; Polanczyk, C. A.] Natl Hlth Technol Assessment Inst, Porto Alegre, RS, Brazil; [Ogliari, L.; Souza, J. S.] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil; [Bertoglio, Cardoso R.] Moinhos Vento Hosp, Porto Alegre, RS, Brazil									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND21	S162	S162					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400706
J	Fenske, C; Rosettie, K; Ferrufino, C; Borns, M; Atiya, B; Johnson, N; Wehler, E				Fenske, C.; Rosettie, K.; Ferrufino, C.; Borns, M.; Atiya, B.; Johnson, N.; Wehler, E.			BUDGET IMPACT OF BARICITINIB FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS WITH AN INADEQUATE RESPONSE TO TOPICAL TREATMENTS	VALUE IN HEALTH			English	Meeting Abstract									[Fenske, C.; Borns, M.; Atiya, B.; Johnson, N.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Rosettie, K.] IQVIA, Everett, WA USA; [Ferrufino, C.] IQVIA, Falls Church, VA USA; [Wehler, E.] IQVIA, Plymouth Meeting, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSY4	S229	S229					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401266
J	Halioua, B; Zetlaoui, J; Astruc, A; Harrizi, M; Bombezin-Domino, A; Radoszycki, L				Halioua, B.; Zetlaoui, J.; Astruc, A.; Harrizi, M.; Bombezin-Domino, A.; Radoszycki, L.			POST-LOCKDOWN IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS AFFECTED BY CHRONIC DISEASES IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Halioua, B.] GEM Resopso, Paris, France; [Zetlaoui, J.; Harrizi, M.; Bombezin-Domino, A.; Radoszycki, L.] Carenity, Paris 75, France; [Astruc, A.] Univ Sorbonne Paris Nord, Bobigny, France									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU63	S155	S156					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400678
J	Hauser, R; Huff, K; Friedman, HS; Navaratnam, P; Xiao, H; Gricar, J				Hauser, R.; Huff, K.; Friedman, H. S.; Navaratnam, P.; Xiao, H.; Gricar, J.			A REAL-WORLD ASSESSMENT OF THE TREATMENT PATTERNS, HEALTH RESOURCE UTILIZATION AND OUTCOMES ASSOCIATED WITH ESOPHAGEAL CANCER IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Hauser, R.] Vidence LLC, Boca Raton, FL USA; [Huff, K.] Bristol Myers Squibb Pharmaceut Corp, Lawrence Township, NJ USA; [Friedman, H. S.; Navaratnam, P.] DataMed Solut LLC, New York, NY USA; [Xiao, H.; Gricar, J.] Bristol Myers Squibb, Lawrenceville, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN9	S20	S20					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400080
J	Hernandez, F; Nakajima, K; de Oliveira, RW; Julian, G				Hernandez, F.; Nakajima, K.; de Oliveira, R. W.; Julian, G.			REAL WORLD EVIDENCE TO SUPPORT REGULATORY DECISIONS: FRAMEWORKS FOR LATIN AMERICAN AGENCIES	VALUE IN HEALTH			English	Meeting Abstract									[Hernandez, F.] IQVIA Colombia, Bogota, Colombia; [Nakajima, K.; de Oliveira, R. W.; Julian, G.] IQVIA Brasil, Sao Paulo, SP, Brazil									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS115	S193	S194					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401109
J	Hong, N; Lin, W; Li, X; Zhang, Q; Yang, Y; Guo, Q				Hong, N.; Lin, W.; Li, X.; Zhang, Q.; Yang, Y.; Guo, Q.			BUILDING CANCER KNOWLEDGE GRAPH FOR CLINICAL DECISION SUPPORT APPLICATIONS	VALUE IN HEALTH			English	Meeting Abstract									[Hong, N.; Li, X.; Zhang, Q.; Yang, Y.] Digital Hlth China Technol Co Ltd, Beijing, Peoples R China; [Lin, W.; Guo, Q.] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China									0	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN187	S54	S54					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400233
J	Iwasaki, K; Nakano, K; Mori, M; Igarashi, A				Iwasaki, K.; Nakano, K.; Mori, M.; Igarashi, A.			CHANGES IN COST OF ORAL ANTIDIABETIC DRUGS BY INTRODUCTION OF FORMULARIES IN JAPAN: A SIMULATION USING HEALTH INSURANCE CLAIMS DATABASE	VALUE IN HEALTH			English	Meeting Abstract									[Iwasaki, K.] Milliman, Chiyoda Ku, Tokyo 13, Japan; [Nakano, K.; Mori, M.] DeSC Healthcare, Tokyo, Japan; [Igarashi, A.] Yokohama City Univ, Yokohama, Kanagawa, Japan									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB8	S78	S79					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400344
J	Khandker, R; Chekani, F; Limone, B; Thiel, E				Khandker, R.; Chekani, F.; Limone, B.; Thiel, E.			IMPACT OF BIPOLAR DISORDER TREATMENT DISCONTINUATION ON HEALTHCARE UTILIZATION AND COSTS IN THE REAL-WORLD SETTING	VALUE IN HEALTH			English	Meeting Abstract									[Khandker, R.; Chekani, F.] Merck & Co Inc, N Wales, PA USA; [Limone, B.] IBM Watson Hlth, Cambridge, MA USA; [Thiel, E.] IBM Watson Hlth, Ann Arbor, MI USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH54	S137	S137					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400600
J	Kim, E; Raimundo, K; Marcum, ZA; Veenstra, DL				Kim, E.; Raimundo, K.; Marcum, Z. A.; Veenstra, D. L.			ELEMENTS OF VALUE FOR GENE THERAPY: A SYSTEMATIC REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Kim, E.; Marcum, Z. A.; Veenstra, D. L.] Univ Washington, Seattle, WA 98195 USA; [Raimundo, K.] Genentech Inc, San Francisco, CA 94080 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		ED2	S6	S6					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400023
J	Kinchen, T; Jordan, JC; Soleimani, S; Holloway, J; Ouyang, J; Vicidomina, B; Nigam, S				Kinchen, T.; Jordan, J. C., Jr.; Soleimani, S.; Holloway, J.; Ouyang, J.; Vicidomina, B.; Nigam, S.			BLUE CROSS BLUE SHIELD OF LOUISIANA APPROACH USING NATURAL LANGUAGE PROCESSING AND MACHINE LEARNING TO PREDICT THE RISK OF HOSPITALIZATIONS (ROH) FOR MEDICAID PATIENTS	VALUE IN HEALTH			English	Meeting Abstract									[Kinchen, T.; Jordan, J. C., Jr.; Soleimani, S.; Holloway, J.; Ouyang, J.; Vicidomina, B.; Nigam, S.] Blue Cross Blue Shield Louisiana, Baton Rouge, LA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS91	S189	S189					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401089
J	Lau, O; Vadlamudi, N				Lau, O.; Vadlamudi, N.			IMMUNOGENICITY AND SAFETY OF THE COVID-19 VACCINES COMPARED TO CONTROLS IN HEALTHY ADULTS: A SYSTEMATIC REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Lau, O.; Vadlamudi, N.] Univ British Columbia, Vancouver, BC, Canada									0	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN5	S106	S106					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400464
J	Mark, K; Manchanda, P; Rubinstein, J				Mark, K.; Manchanda, P.; Rubinstein, J.			CLINICAL RESTRICTIONS IN CARDIAC HEALTH TECHNOLOGY ASSESSMENTS	VALUE IN HEALTH			English	Meeting Abstract									[Mark, K.] Decis Resources Grp, Gurugram, HR, India; [Manchanda, P.; Rubinstein, J.] Decis Resources Grp, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV38	S75	S76					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400331
J	O'Mahony, C; Murphy, KD; O'Brien, GL; Hanan, T; Mullen, L; Aherne, J; Keane, M; Donnelan, P; Davey, C; Browne, H; Malee, K; Byrne, S				O'Mahony, C.; Murphy, K. D.; O'Brien, G. L.; Hanan, T.; Mullen, L.; Aherne, J.; Keane, M.; Donnelan, P.; Davey, C.; Browne, H.; Malee, K.; Byrne, S.			A COST COMPARISON STUDY TO REVIEW COMMUNITY VERSUS ACUTE HOSPITAL MODELS OF NURSING CARE DELIVERED TO ONCOLOGY PATIENTS	VALUE IN HEALTH			English	Meeting Abstract									[O'Mahony, C.; Murphy, K. D.; O'Brien, G. L.; Byrne, S.] Univ Coll Cork, Cork, CO, Ireland; [Hanan, T.; Mullen, L.] Natl Canc Control Programme, Dublin, Ireland; [Aherne, J.] Leading Edge Grp, Cork, Ireland; [Keane, M.; Donnelan, P.; Davey, C.] Univ Hosp Galway, Galway, Ireland; [Browne, H.] Community Healthcare West, Galway, Ireland; [Malee, K.] Dept Publ Hlth Nursing, Galway, Ireland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN102	S38	S38					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400160
J	Peng, ZY; Yang, CT; Ou, HT; Kuo, S				Peng, Z. Y.; Yang, C. T.; Ou, H. T.; Kuo, S.			REAL-WORLD COST-EFFECTIVENESS OF SGLT-2 INHIBITORS VERSUS DPP-4 INHIBITORS FOR TYPE 2 DIABETES: A MODELING STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Peng, Z. Y.; Yang, C. T.] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, Taoyuan, Taiwan; [Ou, H. T.] Natl Cheng Kung Univ, Dept Pharm, Coll Med, Tainan, Taiwan; [Kuo, S.] Univ Michigan, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB11	S79	S79					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400347
J	Rege, S; Holmes, HM; Aparasu, RR				Rege, S.; Holmes, H. M.; Aparasu, R. R.			ANTIMUSCARINIC PRESCRIBING CASCADE WITH ACETYLCHOLINESTERASE INHIBITOR USE AMONG A NATIONAL COHORT OF OLDER ADULTS WITH ALZHEIMER'S DISEASE	VALUE IN HEALTH			English	Meeting Abstract									[Rege, S.] Pharmerit Int, Bethesda, MD USA; [Holmes, H. M.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA; [Aparasu, R. R.] Univ Houston, Coll Pharm, Pharmaceut Hlth Outcomes & Policy, Houston, TX 77030 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH20	S131	S131					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400574
J	Safarudin, R; Alabaku, O; Alheraki, SZM; Sambamoorthi, U				Safarudin, R.; Alabaku, O.; Alheraki, S. Z. M.; Sambamoorthi, U.			EXPLAINING COGNITIVE IMPAIRMENT AMONG ADULTS WITH CHRONIC PAIN: NON-LINEAR DECOMPOSITION ANALYSIS OF 2015 MEPS DATA	VALUE IN HEALTH			English	Meeting Abstract									[Safarudin, R.; Sambamoorthi, U.] West Virginia Univ, Sch Pharm, Dept Pharmaceut Syst & Policy, Morgantown, WV 26506 USA; [Alabaku, O.] Univ Pittsburgh, Sch Pharm, PharmD Program, Pittsburgh, PA USA; [Alheraki, S. Z. M.] West Virginia Univ Hosp, Dept Emergency Med, Morgantown, WV USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS26	S177	S177					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401032
J	Sands-Lincoln, M; Huang, H; Jackson, GP; Wang, S				Sands-Lincoln, M.; Huang, H.; Jackson, G. P.; Wang, S.			TOWARDS A BETTER UNDERSTANDING OF COVID-19 AMONG YOUNG ADULTS AGES 18-24	VALUE IN HEALTH			English	Meeting Abstract									[Sands-Lincoln, M.; Huang, H.; Wang, S.] IBM Watson Hlth, San Francisco, CA USA; [Jackson, G. P.] IBM Watson Hlth, Cambridge, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN81	S121	S121					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400529
J	Thode, R; Solanki, GS; Aggarwal, A; Belekar, V; Lakkakula, U; Goyal, R				Thode, R.; Solanki, G. S.; Aggarwal, A.; Belekar, V; Lakkakula, U.; Goyal, R.			A COMPARISON OF NOS AND ROBINS-I TOOLS FOR QUALITY ASSESSMENT OF OBSERVATIONAL STUDIES	VALUE IN HEALTH			English	Meeting Abstract									[Thode, R.; Solanki, G. S.; Aggarwal, A.; Belekar, V] IQVIA, Gurgaon, India; [Lakkakula, U.] IQVIA, Hyderabad, Andhra Pradesh, India; [Goyal, R.] IQVIA, Mumbai, Maharashtra, India									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND54	S169	S169					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400737
J	Vasudevan, A; Boyd, M; Robert, N; Espirito, J				Vasudevan, A.; Boyd, M.; Robert, N.; Espirito, J.			CONCORDANCE OF CLINICAL VS. ALGORITHM BASED LINE OF THERAPY DETERMINATION IN LUNG CANCER	VALUE IN HEALTH			English	Meeting Abstract									[Vasudevan, A.] Ontada, Plano, TX USA; [Boyd, M.] Ontada, Irving, TX USA; [Robert, N.] Ontada, The Woodlands, TX USA; [Espirito, J.] Ontada, The Woodlands, TX USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN233	S63	S63					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400275
J	Zettler, M; Feinberg, B; Jeune-Smith, Y; Gajra, A				Zettler, M.; Feinberg, B.; Jeune-Smith, Y.; Gajra, A.			THE IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON CANCER CARE: A SURVEY OF COMMUNITY ONCOLOGISTS	VALUE IN HEALTH			English	Meeting Abstract									[Zettler, M.] Cardinal Hlth, Falls Church, VA USA; [Feinberg, B.; Jeune-Smith, Y.; Gajra, A.] Cardinal Hlth, Dublin, OH USA				Feinberg, Bruce/AAX-9378-2021	Feinberg, Bruce/0000-0001-9267-9994				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS35	S178	S178					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401039
J	Zhang, Q; O'Hara, M; McCormick, C; Lingohr-Smith, M; Borentain, S; Mathews, M; Lin, J				Zhang, Q.; O'Hara, M.; McCormick, C.; Lingohr-Smith, M.; Borentain, S.; Mathews, M.; Lin, J.			PATIENT PROFILES AND HOSPITAL RE-ENCOUNTERS OF PATIENTS WITH A HOSPITAL EMERGENCY DEPARTMENT VISIT OR INPATIENT ADMISSION FOR MAJOR DEPRESSIVE DISORDER	VALUE IN HEALTH			English	Meeting Abstract									[Zhang, Q.; O'Hara, M.; McCormick, C.; Borentain, S.; Mathews, M.] Janssen Global Serv LLC, Titusville, NJ USA; [Lingohr-Smith, M.] Novosys Hlth, Basking Ridge, NJ USA; [Lin, J.] Novosys Hlth, Martinsville, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH2	S128	S128					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400558
J	Zhou, LL; Bhattacharjee, S; Kwoh, CK; Malone, DC; Tighe, PJ; Reisfield, GM; Slack, M; Wilson, DL; Lo-Ciganic, WH				Zhou, Lili; Bhattacharjee, Sandipan; Kwoh, C. Kent; Malone, Daniel C.; Tighe, Patrick J.; Reisfield, Gary M.; Slack, Marion; Wilson, Debbie L.; Lo-Ciganic, Wei-Hsuan			Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries	VALUE IN HEALTH			English	Article						gabapentinoids; health expenditures; Medicare; opioids; trajectories	LOW-BACK-PAIN; CANCER PAIN; PREGABALIN; COSTS; OLDER; PRESCRIPTIONS; COMBINATION; DULOXETINE; MANAGEMENT; DIVERSION	Objectives: Little is known about relationships between opioid- and gabapentinoid-use patterns and healthcare expenditures that may be affected by pain management and risk of adverse outcomes. This study examined the association between patients' opioid and gabapentinoid prescription filling/refilling trajectories and direct medical expenditures in US Medicare. Methods: This cross-sectional study included a 5% national sample (2011-2016) of fee-for-service beneficiaries with fibromyalgia, low back pain, neuropathy, or osteoarthritis newly initiating opioids or gabapentinoids. Using group-based multitrajectory modeling, this study identified patients' distinct opioid and gabapentinoid (OPI-GABA) dose and duration patterns, based on standardized daily doses, within a year of initiating opioids and/or gabapentinoids. Concurrent direct medical expenditures within the same year were estimated using inverse probability of treatment weighted multivariable generalized linear regression, adjusting for sociodemographic and health status factors. Results: Among 67 827 eligible beneficiaries (mean age +/- SD = 63.6 +/- 14.8 years, female = 65.8%, white = 77.1%), 11 distinct trajectories were identified (3 opioid-only, 4 gabapentinoid-only, and 4 concurrent OPI-GABA trajectories). Compared with opioid-only early discontinuers ($13 830, 95% confidence interval = $13 643-14 019), gabapentinoid-only early discontinuers and consistent low-dose and moderate-dose gabapentinoid-only users were associated with 11% to 23% lower health expenditures (adjusted mean expenditure = $10 607-$11 713). Consistent low-dose opioid-only users, consistent high-dose opioid-only users, consistent low-dose OPI-GABA users, consistent low-dose opioid and high-dose gabapentinoid users, and consistent high-dose opioid and moderate-dose gabapentinoid users were associated with 14% to 106% higher healthcare expenditures (adjusted mean expenditure = $15 721-$28 464). Conclusions: Dose and duration patterns of concurrent OPI-GABA varied substantially among fee-for-service Medicare beneficiaries. Consistent opioid-only users and all concurrent OPI-GABA users were associated with higher healthcare expenditures compared to opioid-only discontinuers.	[Zhou, Lili; Slack, Marion] Univ Arizona, Dept Pharm Practice & Sci, Tucson, AZ USA; [Zhou, Lili; Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, Tucson, AZ USA; [Bhattacharjee, Sandipan] Univ Texas Austin, Hlth Outcome Div, Austin, TX 78712 USA; [Kwoh, C. Kent] Univ Arizona, Dept Med, Tucson, AZ USA; [Malone, Daniel C.] Univ Utah, Dept Pharmacotherapy, Salt Lake City, UT USA; [Tighe, Patrick J.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Reisfield, Gary M.] Univ Florida, Dept Psychiat, Div Addict Med, Gainesville, FL 32611 USA; [Reisfield, Gary M.] Univ Florida, Dept Psychiat, Div Forens Psychiat, Gainesville, FL 32611 USA; [Reisfield, Gary M.] Univ Florida, Dept Anesthesiol, Div Addict Med, Gainesville, FL USA; [Reisfield, Gary M.] Univ Florida, Dept Anesthesiol, Div Forens Psychiat, Gainesville, FL USA; [Wilson, Debbie L.; Lo-Ciganic, Wei-Hsuan] Univ Florida, Dept Pharmaceut Outcomes & Policy, POB 100496,1225 Ctr Dr, Gainesville, FL 32610 USA; [Lo-Ciganic, Wei-Hsuan] Univ Florida, Ctr Drug Evaluat & Safety, Gainesville, FL USA		Lo-Ciganic, WH (通讯作者)，Univ Florida, Dept Pharmaceut Outcomes & Policy, POB 100496,1225 Ctr Dr, Gainesville, FL 32610 USA.	wlociganic@cop.ufl.edu		Wilson, Debbie/0000-0002-1640-5497	National Institute on Aging of the National Institutes of Health (NIH), United States [1R21AG060308-01A1]	This work was supported by grant 1R21AG060308-01A1 from the National Institute on Aging of the National Institutes of Health (NIH), United States.	Abrahamsson T, 2017, DRUG ALCOHOL DEPEN, V174, P58, DOI 10.1016/j.drugalcdep.2017.01.013; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Bonnet U, 2017, EUR NEUROPSYCHOPHARM, V27, P1185, DOI 10.1016/j.euroneuro.2017.08.430; Campbell CI, 2010, AM J PUBLIC HEALTH, V100, P2541, DOI 10.2105/AJPH.2009.180646; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Drugs@ fda, FDA AP; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Enke O, 2018, CAN MED ASSOC J, V190, pE786, DOI 10.1503/cmaj.171333; Gomes T, 2018, ANN INTERN MED, V169, P732, DOI 10.7326/M18-1136; Gomes T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002396; Goodman CW, 2017, NEW ENGL J MED, V377, P411, DOI 10.1056/NEJMp1704633; Gore M, 2012, SPINE, V37, pE668, DOI 10.1097/BRS.0b013e318241e5de; Ip Q, 2018, EPILEPSY RES, V139, P107, DOI 10.1016/j.eplepsyres.2017.11.022; Johansen ME, 2018, JAMA INTERN MED, V178, P292, DOI 10.1001/jamainternmed.2017.7856; Jones BL, 2007, SOCIOL METHOD RES, V35, P542, DOI 10.1177/0049124106292364; Jones BL, 2013, SOCIOL METHOD RES, V42, P608, DOI 10.1177/0049124113503141; Keskinbora K, 2007, J PAIN SYMPTOM MANAG, V34, P183, DOI 10.1016/j.jpainsymman.2006.11.013; Kesselheim AS, 2011, HEALTH AFFAIR, V30, P2318, DOI 10.1377/hlthaff.2011.0370; Kim SC, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0530-8; Le T Kim, 2012, J Pain Res, V5, P23, DOI 10.2147/JPR.S27275; Lo-Ciganic WH, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0968; Lo-Ciganic WH, 2016, J GEN INTERN MED, V31, P1052, DOI 10.1007/s11606-016-3747-6; Lo-Ciganic WH, 2016, ADDICTION, V111, P892, DOI 10.1111/add.13270; Mack Alicia, 2003, J Manag Care Pharm, V9, P559; Margolis JM, 2010, AM J MANAG CARE, V16, P447; Marlow NM, 2018, PAIN PRACT, V18, P154, DOI 10.1111/papr.12585; Meara E, 2016, NEW ENGL J MED, V375, P44, DOI 10.1056/NEJMsa1514387; Mues KE, 2017, CLIN EPIDEMIOL, V9, P267, DOI 10.2147/CLEP.S105613; Nagin DS, 2018, STAT METHODS MED RES, V27, P2015, DOI 10.1177/0962280216673085; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Peckham AM, 2018, DRUG SAFETY, V41, P213, DOI 10.1007/s40264-017-0595-1; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021; Sadosky A, 2015, J DIABETES COMPLICAT, V29, P212, DOI 10.1016/j.jdiacomp.2014.10.013; Schaefer C, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-71; Shanthanna H, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002369; Shinde S, 2015, SUPPORT CARE CANCER, V23, P695, DOI 10.1007/s00520-014-2415-9; Smith RV, 2016, ADDICTION, V111, P1160, DOI 10.1111/add.13324; Smith RV, 2015, AM J PSYCHIAT, V172, P487, DOI 10.1176/appi.ajp.2014.14101272; Thakur M, 2014, NAT REV RHEUMATOL, V10, P374, DOI 10.1038/nrrheum.2014.47; Twisk J, 2012, J CLIN EPIDEMIOL, V65, P1078, DOI 10.1016/j.jclinepi.2012.04.010; Wallach JD, 2018, JAMA-J AM MED ASSOC, V319, P776, DOI 10.1001/jama.2017.21897; Zhou LL, 2021, ADDICTION, V116, P819, DOI 10.1111/add.15189; Zhou LL, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010083	45	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	FEB	2021	24	2					196	205		10.1016/j.jval.2020.12.001		JAN 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QJ1VI	33518026	Bronze, Green Accepted			2022-04-28	WOS:000619478100007
J	Garrison, LP; Pezalla, E; Towse, A; Yang, HB; Faust, E; Wu, EQ; Li, NX; Sawyer, EK; Recht, M				Garrison, Louis P.; Pezalla, Ed; Towse, Adrian; Yang, Hongbo; Faust, Elizabeth; Wu, Eric Q.; Li, Nanxin; Sawyer, Eileen K.; Recht, Michael			Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations	VALUE IN HEALTH			English	Article						cost; gene therapy; hemophilia; valoctocogene roxaparvovec; value assessment	HEALTH-CARE EXPENDITURES; FACTOR-IX; UNITED-STATES; FOLLOW-UP; PROPHYLAXIS; EFFICACY; SAFETY; ANTITHROMBIN; MANAGEMENT; INHIBITORS	Gene therapy for hemophilia is designed to produce health gains for patients over many years. Rewarding that value creation on the basis of a one-time treatment implies a large upfront cost. This cost can only be justified by long-term health benefits and being cost-effective compared with conventional treatments. Yet, uncertainties about the long-term benefits make it challenging to assess clinical and economic value of gene therapies at launch. We identify and discuss key methodological challenges in assessing the value of gene therapy for hemophilia, including the immaturity of evidence on the durability of benefits, lack of definition and valuation of cure for chronic diseases, absence of randomized controlled trials, limitations of traditional quality of life measures in hemophilia, approach for qualifying cost-savings compared with current treatments, and choice of perspective. The Institute for Clinical and Economic Review has developed a framework for assessing single or short-term therapies (ICER-SST) and has applied it in hemophilia. After reviewing this framework and its application, we recommend the following when assessing the value of hemophilia gene therapies: (1) leveraging expert clinical opinion to justify assumptions on the durability of benefits; (2) using external synthetic controls and lead-in, self-controlled trials to assess comparative effectiveness; (3) addressing limitations of traditional quality of life measures through the use of modified utility collection approaches; (4) adjusting cost offsets from gene therapies with caution; (5) considering outcome-based contracting to address uncertainties about prices and long-term outcomes; and (6) presenting societal and healthcare sys-tem perspectives in parallel.	[Garrison, Louis P.] Univ Washington, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Dept Pharm, Seattle, WA 98195 USA; [Pezalla, Ed] Enlightenment Bioconsult LLC, Wethersfield, CT USA; [Towse, Adrian] Off Hlth Econ, London, England; [Yang, Hongbo; Faust, Elizabeth; Wu, Eric Q.] Anal Grp Inc, Boston, MA USA; [Li, Nanxin; Sawyer, Eileen K.] UniQure Inc, Lexington, MA USA; [Recht, Michael] Amer Thrombosis & Hemostasis Network, Rochester, NY USA		Garrison, LP (通讯作者)，Univ Washington, Dept Pharm, Hlth Sci Bldg,H375,1959 NE Pacific St,Box 357630, Seattle, WA 98195 USA.	lgarrison@uw.edu			uniQure Inc, Lexington, MA, USA	This study was funded by uniQure Inc, Lexington, MA, USA.	Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0; [Anonymous], GENE THERAPY UNDERST; Cook K, 2020, J MED ECON, V23, P501, DOI 10.1080/13696998.2020.1721508; Devlin NJ, 2017, APPL HEALTH ECON HEA, V15, P127, DOI 10.1007/s40258-017-0310-5; Drummond MF, 2019, VALUE HEALTH, V22, P661, DOI 10.1016/j.jval.2019.03.012; Garrison LP, 2019, J MANAG CARE SPEC PH, V25, P793, DOI 10.18553/jmcp.2019.18378; George LA, 2017, NEW ENGL J MED, V377, P2215, DOI 10.1056/NEJMoa1708538; George LA, 2019, BLOOD, V134, DOI 10.1182/blood-2019-124091; Ginn SL, 2018, J GENE MED, V20, DOI 10.1002/jgm.3015; Goswami R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00297; Grigore B, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0186-3; Guh S, 2012, HAEMOPHILIA, V18, P276, DOI 10.1111/j.1365-2516.2011.02713.x; Guh S, 2012, HAEMOPHILIA, V18, P268, DOI 10.1111/j.1365-2516.2011.02692.x; Hacker MR, 2001, HAEMOPHILIA, V7, P392, DOI 10.1046/j.1365-2516.2001.00534.x; Hampson G, 2018, J COMP EFFECT RES, V7, P15, DOI 10.2217/cer-2017-0068; Herzog RW, 2020, MOL THER, V28, P341, DOI 10.1016/j.ymthe.2020.01.007; Iorio A, 2018, HAEMOPHILIA, V24, pE167, DOI 10.1111/hae.13504; Konkle B, 2020, J THROMB HAEMOST, V18, P3074, DOI 10.1111/jth.15023; Lakdawalla DN, 2018, VALUE HEALTH, V21, P131, DOI 10.1016/j.jval.2017.12.007; Li M, 2019, VALUE HEALTH, V22, P777, DOI 10.1016/j.jval.2019.02.002; Manco-Johnson MJ, 2007, NEW ENGL J MED, V357, P535, DOI 10.1056/NEJMoa067659; Mannucci PM, 2017, EUR J INTERN MED, V43, P16, DOI 10.1016/j.ejim.2017.05.012; Meijer K, 62 ASH ANN M EXP; Miesbach W, 2018, BLOOD, V131, P1022, DOI 10.1182/blood-2017-09-804419; Nathwani AC, 2014, NEW ENGL J MED, V371, P1994, DOI 10.1056/NEJMoa1407309; Nathwani AC, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-118334; Nathwani AC, 2011, NEW ENGL J MED, V365, P2357, DOI 10.1056/NEJMoa1108046; Noone D, 2021, HAEMOPHILIA, V27, P12, DOI 10.1111/hae.14218; O'Hara J, 2021, HAEMOPHILIA, V27, P245, DOI 10.1111/hae.14278; Oldenburg J, 2017, NEW ENGL J MED, V377, P809, DOI 10.1056/NEJMoa1703068; Pasi KJ, 2017, NEW ENGL J MED, V377, P819, DOI [10.1056/NEJMoa1616569, 10.1056/NEJMoa1708483]; Pasi KJ, 2020, NEW ENGL J MED, V382, P29, DOI 10.1056/NEJMoa1908490; Peel A, 2018, APPL HEALTH ECON HEA, V16, P819, DOI 10.1007/s40258-018-0415-5; Pipe S, 2019, BLOOD, V134, DOI 10.1182/blood-2019-128765; Pipe SW, 2021, HAEMOPHILIA, V27, P114, DOI 10.1111/hae.14027; Puetz J, 2014, HAEMOPHILIA, V20, P25, DOI 10.1111/hae.12229; Ragni MV, 2015, NEW ENGL J MED, V373, P389, DOI 10.1056/NEJMcibr1505657; Recht M, 62 ASH ANN M EXP; Roberts JC, 2018, HAEMOPHILIA, V24, pE199, DOI 10.1111/hae.13454; Roth DA, 2001, BLOOD, V98, P3600, DOI 10.1182/blood.V98.13.3600; Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195; Schrijvers LH, 2016, HAEMOPHILIA, V22, P499, DOI 10.1111/hae.12904; Srivastava A, 2020, HAEMOPHILIA, V26, P1, DOI 10.1111/hae.14046; Thorlund K, 2020, CLIN EPIDEMIOL, V12, P457, DOI 10.2147/CLEP.S242097; Thornburg CD, 2017, PATIENT PREFER ADHER, V11, P1677, DOI 10.2147/PPA.S139851; Towse A, 2019, VALUE HEALTH, V22, P677, DOI 10.1016/j.jval.2019.03.013; Von Drygalski A, 2019, BLOOD ADV, V3, P3241, DOI 10.1182/bloodadvances.2019000811; Wight J, 2003, HAEMOPHILIA, V9, P418, DOI 10.1046/j.1365-2516.2003.00780.x	48	0	0	5	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	NOV	2021	24	11					1628	1633		10.1016/j.jval.2021.05.008		OCT 2021	6	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	XF1GI	34711363	Bronze			2022-04-28	WOS:000723825200010
J	Keller, E; Newman, JE; Ortmann, A; Jorm, LR; Chambers, GM				Keller, Elena; Newman, Jade E.; Ortmann, Andreas; Jorm, Louisa R.; Chambers, Georgina M.			How Much Is a Human Life Worth? A Systematic Review	VALUE IN HEALTH			English	Review						revealed preference; stated preference; systematic review; value of statistical life; VSL; willingness to pay	WILLINGNESS-TO-PAY; MORTALITY RISK REDUCTIONS; STATISTICAL LIFE; STATED-PREFERENCE; COST-EFFECTIVENESS; DISCRETE-CHOICE; AIR-POLLUTION; HEALTH-RISKS; CONTINGENT VALUATION; ECONOMIC VALUATION	Objectives: To systematically review studies eliciting monetary value of a statistical life (VSL) estimates within, and across, different sectors and other contexts; compare the reported estimates; and critically review the elicitation methods used. Methods: In June 2019, we searched the following databases to identify methodological and empirical studies: Cochrane Library, Compendex, Embase, Environment Complete, Informit, ProQuest, PubMed, Scopus, and Web of Science. We used the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines for reporting and a modified Consolidated Health Economic Evaluation Reporting Standards checklist to assess the quality of included studies. Results: We identified 1455 studies, of which we included 120 in the systematic review. A stated-preference approach was used in 76 articles, with 51%, 41%, and 8% being contingent valuation studies, discrete-choice experiments, or both, respectively. A revealed-preference approach was used in 43 articles, of which 74% were based on compensating-wage differentials. The human capital approach was used in only 1 article. We assessed most publications (87%) as being of high quality. Estimates for VSL varied substantially by context (sector, developed/developing country, socio-economic status, etc), with the median of midpoint purchasing power parity-adjusted estimates of 2019 US$5.7 million ($6.8 million, $8.7 million, and $5.3 million for health, labor market, and transportation safety sectors, respectively). Conclusions: The large variation observed in published VSLs depends mainly on the context rather than the method used. We found higher median values for labor markets and developed countries. It is important that health economists and policymakers use context-specific VSL estimates. Methodological innovation and standardization are needed to maximize comparability of VSL estimates within, and across, sectors and methods.	[Keller, Elena; Newman, Jade E.; Jorm, Louisa R.; Chambers, Georgina M.] Ctr Big Data Res Hlth, Sydney, NSW, Australia; [Keller, Elena; Newman, Jade E.; Chambers, Georgina M.] Natl Perinatal Epidemiol & Stat Unit, Sydney, NSW, Australia; [Ortmann, Andreas] Univ New South Wales, Sch Business, New South Wales, Australia; [Jorm, Louisa R.] Univ New South Wales, Hlth Serv & Outcomes Unit, Sydney, NSW, Australia		Keller, E (通讯作者)，Univ New South Wales, Ctr Big Data Res Hlth, Sydney, NSW 2052, Australia.	e.keller@unsw.edu.au		Keller, Elena/0000-0002-4790-482X	Australian National Health and Medical Research CouncilNational Health and Medical Research Council (NHMRC) of Australia [APP1104543]; University of New South Wales School of Women's and Children's Health	This study was supported by an Australian National Health and Medical Research Council project grant (APP1104543) and a scholarship from the University of New South Wales School of Women's and Children's Health.	Abdallah N.M., 2016, INT J TRAFFIC TRANSP, V5, P10; Abelson P, ESTABLISHING MONETAR; Adamowicz W, 2011, J ENVIRON ECON MANAG, V61, P213, DOI 10.1016/j.jeem.2010.10.003; Adamson GD, 2018, FERTIL STERIL, V110, P1067, DOI 10.1016/j.fertnstert.2018.06.039; Adler MD, 2014, J HEALTH ECON, V35, P82, DOI 10.1016/j.jhealeco.2014.02.001; Aiken DV, 2009, REV LAW ECON, V5, P293, DOI 10.2202/1555-5879.1230; Alberini A, MEASURING EC VALUE E; Alberini A, 2018, J HEALTH ECON, V57, P249, DOI 10.1016/j.jhealeco.2017.08.004; Alberini A, 2013, ECOL ECON, V94, P143, DOI 10.1016/j.ecolecon.2013.07.012; Alberini A, 2012, J AIR WASTE MANAGE, V62, P783, DOI 10.1080/10962247.2012.676594; Alberini A, 2011, ENVIRON RESOUR ECON, V49, P511, DOI 10.1007/s10640-010-9444-8; Allen E, 2006, REPORT EPA WORK GROU; Alolayan MA, 2017, ENVIRON RESOUR ECON, V66, P629, DOI 10.1007/s10640-015-9958-1; Andersson H, 2016, J ENVIRON ECON MANAG, V75, P41, DOI 10.1016/j.jeem.2015.11.001; Andersson H, 2013, ENVIRON RESOUR ECON, V56, P437, DOI 10.1007/s10640-013-9644-0; Andersson H, 2009, ACCIDENT ANAL PREV, V41, P286, DOI 10.1016/j.aap.2008.11.009; [Anonymous], Our Principles; [Anonymous], PPP conversion factor, GDP (LCU per international $)-Iran, Islamic Rep; Antoniou C, 2017, J TRANSP SAF SECUR, V9, P347, DOI 10.1080/19439962.2016.1212444; Antoniou C, 2014, EUR TRANSP RES REV, V6, P31, DOI 10.1007/s12544-013-0103-3; Arigoni Ortiz Ramon, 2009, Rev. Bras. Econ., V63, P3, DOI 10.1590/S0034-71402009000100001; Balmford B, 2019, RESOUR ENERGY ECON, V57, P68, DOI 10.1016/j.reseneeco.2019.04.005; Bellavance F, 2009, J HEALTH ECON, V28, P444, DOI 10.1016/j.jhealeco.2008.10.013; Benkhalifa A, 2016, J EC COOP DEV, V37, P1; Benkhalifa A, 2013, ECON BULL, V33, P3023; Blomquist GC, 2011, RESOUR ENERGY ECON, V33, P410, DOI 10.1016/j.reseneeco.2010.05.004; Bockarjova M, VALUATION FLOOD RISK; Cameron M, 2010, ENVIRON DEV ECON, V15, P395, DOI 10.1017/S1355770X10000069; Cameron TA, 2013, J ENVIRON ECON MANAG, V65, P87, DOI 10.1016/j.jeem.2012.05.008; Cameron TA, 2010, J RISK UNCERTAINTY, V41, P245, DOI 10.1007/s11166-010-9106-9; Carlsson F, 2010, RISK ANAL, V30, P975, DOI 10.1111/j.1539-6924.2010.01399.x; Chambers J, 2016, NZ SOCIOL, V31, P73; Chanel O, 2014, J ENVIRON ECON POLIC, V3, P67, DOI 10.1080/21606544.2013.863743; Chanel O, 2013, ECOL ECON, V85, P198, DOI 10.1016/j.ecolecon.2012.03.004; Chaturabong P, 2011, TRANSPORT RES REC, P56, DOI 10.3141/2239-07; Chestnut LG, 2012, CONTEMP ECON POLICY, V30, P399, DOI 10.1111/j.1465-7287.2011.00269.x; Clough P, 2015, APPROACHES VALUING I; Cole MA, 2009, J RISK UNCERTAINTY, V39, P161, DOI 10.1007/s11166-009-9077-x; Courard-Hauri D, 2012, J BENEFIT-COST ANAL, V3, DOI 10.1515/2152-2812.1099; Cropper L, 2009, VALUING MORTALITY MO; Cropper M, 2011, ANNU REV RESOUR ECON, V3, P313, DOI 10.1146/annurev.resource.012809.103949; Davis DS, 2001, KENNEDY INST ETHIC J, V11, P239, DOI 10.1353/ken.2001.0023; Dekker T, 2011, ENVIRON RESOUR ECON, V49, P597, DOI 10.1007/s10640-011-9456-z; DeLeire T, 2013, INT ECON REV, V54, P279, DOI 10.1111/j.1468-2354.2012.00733.x; Desaigues B, 2011, ECOL INDIC, V11, P902, DOI 10.1016/j.ecolind.2010.12.006; Dixit VV, 2017, TRANSPORT RES C-EMER, V77, P161, DOI 10.1016/j.trc.2017.01.011; Doucouliagos C, 2012, J HEALTH ECON, V31, P197, DOI 10.1016/j.jhealeco.2011.10.001; Doucouliagos H, 2014, J HEALTH ECON, V33, P67, DOI 10.1016/j.jhealeco.2013.10.010; Evans MF, 2010, J ENVIRON ECON MANAG, V59, P260, DOI 10.1016/j.jeem.2009.11.004; Fifer S, 2014, TRANSPORT RES A-POL, V61, P164, DOI 10.1016/j.tra.2013.12.010; Finkel AM, LIMITS SELF INTEREST; Flugel S, 2019, ACCIDENT ANAL PREV, V122, P63, DOI 10.1016/j.aap.2018.09.028; Gentry EP, 2016, J HEALTH ECON, V46, P90, DOI 10.1016/j.jhealeco.2016.01.011; George B, 2001, PHARMACOECONOMICS, V19, P1103, DOI 10.2165/00019053-200119110-00004; Gerking S, 2014, J ENVIRON ECON MANAG, V68, P20, DOI 10.1016/j.jeem.2013.11.010; Ghadi M, 2018, PERIODICA POLYTECHNI, V46, P129; Goucher J, 2012, LABOUR ECON, V19, P27, DOI 10.1016/j.labeco.2011.06.014; Grisolia JM, 2018, SOC SCI MED, V211, P164, DOI 10.1016/j.socscimed.2018.06.011; Grune-Yanoff T, 2009, J ECON METHODOL, V16, P109, DOI 10.1080/13501780902940703; Guardado JR, 2019, INT ECON REV, V60, P133, DOI 10.1111/iere.12347; Guignet D, 2015, RISK ANAL, V35, P501, DOI 10.1111/risa.12282; Guo XQ, 2009, ENVIRON RESOUR ECON, V42, P187, DOI 10.1007/s10640-008-9217-9; Gyrd-Hansen D, 2016, J HEALTH ECON, V49, P184, DOI 10.1016/j.jhealeco.2016.07.002; Hammitt JK, 2018, J ENVIRON ECON MANAG, V87, P165, DOI 10.1016/j.jeem.2017.06.006; Hammitt JK, 2011, J BENEFIT-COST ANAL, V2, DOI 10.2202/2152-2812.1009; Hammitt JK, 2010, J RISK UNCERTAINTY, V40, P57, DOI 10.1007/s11166-009-9086-9; Haninger K, 2011, RISK ANAL, V31, P1363, DOI 10.1111/j.1539-6924.2011.01617.x; Harrison G.W., 2008, HDB EXPT EC RESULTS, V1, P752, DOI DOI 10.1016/S1574-0722(07)00081-9; Hein L., 2016, J ENV ASSESS POLICY, V18, P1; Hensher DA, 2011, J CHOICE MODEL, V4, P70, DOI 10.1016/S1755-5345(13)70058-7; Hensher DA, 2009, TRANSPORT RES A-POL, V43, P692, DOI 10.1016/j.tra.2009.06.001; Hersch J, 2010, J HUM RESOUR, V45, P749; Hintermann B, 2010, APPL ECON, V42, P1085, DOI 10.1080/00036840802260940; Hoffmann S, 2017, J BENEFIT-COST ANAL, V8, P251, DOI 10.1017/bca.2017.16; Hoffmann S, 2012, RESOUR ENERGY ECON, V34, P493, DOI 10.1016/j.reseneeco.2012.04.005; Hoyos D, 2010, ECOL ECON, V69, P1595, DOI 10.1016/j.ecolecon.2010.04.011; Huang DS, 2018, J ENVIRON PLANN MAN, V61, P2207, DOI 10.1080/09640568.2017.1389701; Hultkrantz L, 2012, HEALTH POLICY, V108, P302, DOI 10.1016/j.healthpol.2012.09.007; Husereau D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1049; Inflation (CPI), ORG EC COOP DEV; Jones-Lee M, 2015, J RISK UNCERTAINTY, V51, P1, DOI 10.1007/s11166-015-9221-8; Kluve J., 2008, SOZIAL FORTSCHR, V10-11, P279; Kniesner TJ, 2014, J RISK UNCERTAINTY, V48, P187, DOI 10.1007/s11166-014-9192-1; Kniesner TJ, 2012, REV ECON STAT, V94, P74, DOI 10.1162/REST_a_00229; Kniesner TJ, 2010, J RISK UNCERTAINTY, V40, P15, DOI 10.1007/s11166-009-9084-y; Kochi I, 2011, ENV EC, V2, P17; Kochi I, 2006, ENVIRON RESOUR ECON, V34, P385, DOI 10.1007/s10640-006-9000-8; Kochi I, 2011, J BENEFIT-COST ANAL, V2, DOI 10.2202/2152-2812.1079; Kremer M, 2011, Q J ECON, V126, P145, DOI 10.1093/qje/qjq010; Kruger NA, 2009, J HEALTH ECON, V28, P563, DOI 10.1016/j.jhealeco.2009.01.002; Kuchyna P, 2015, PROC ECON FINANC, V25, P378, DOI 10.1016/S2212-5671(15)00748-0; Lakdawalla DN, 2021, VALUE HEALTH, V24, P244, DOI 10.1016/j.jval.2020.10.003; Lakdawalla DN, 2010, J HEALTH ECON, V29, P333, DOI 10.1016/j.jhealeco.2010.02.006; Lavetti K, 2020, J BUS ECON STAT, V38, P165, DOI 10.1080/07350015.2018.1470000; Laxminarayan R, 2014, VACCINE, V32, P5065, DOI 10.1016/j.vaccine.2014.07.003; Le H, DERIVING ACCIDENT CO; Lee SH, 2016, ENERG POLICY, V92, P111, DOI 10.1016/j.enpol.2016.01.035; Lee YJ, 2011, J ENVIRON MANAGE, V92, P603, DOI 10.1016/j.jenvman.2010.09.028; Leiter AM, 2011, EUR J HEALTH ECON, V12, P331, DOI 10.1007/s10198-010-0240-8; Leiter AM, 2009, ENVIRON RESOUR ECON, V42, P169, DOI 10.1007/s10640-008-9214-z; Leon G, 2017, AM ECON J-APPL ECON, V9, P202, DOI 10.1257/app.20160140; Li SJ, 2012, J APPL ECONOMET, V27, P34, DOI 10.1002/jae.1161; Liao CH, 2009, VALUE HEALTH, V12, pS74, DOI 10.1111/j.1524-4733.2009.00632.x; Lindhjem H, 2011, RISK ANAL, V31, P1381, DOI 10.1111/j.1539-6924.2011.01694.x; Liou JL, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091620; [刘文歌 Liu Wenge], 2013, [交通运输系统工程与信息, Journal of Transporation Systems Engineering & Information Technology], V13, P137; Liu WG, 2011, P 1 INT C TRANSP INF, DOI [10.1061/41177(415)134, DOI 10.1061/41177(415)134]; Mahmud M, 2009, APPL ECON, V41, P171, DOI 10.1080/00036840600994252; Majumder A, 2017, INDIAN J LAB EC, V60, P527; Majumder A, 2017, IIM KOZHIKODE SOC MA, V6, P110, DOI 10.1177/2277975216678546; Mangham LJ, 2009, HEALTH POLICY PLANN, V24, P151, DOI 10.1093/heapol/czn047; Mardones C, 2018, LAT AM RES REV, V53, P815, DOI 10.25222/larr.61; Gonzalez RM, 2018, TRANSPORTATION, V45, P499, DOI 10.1007/s11116-016-9736-0; Masterman CJ, 2018, J BENEFIT-COST ANAL, V9, P407, DOI 10.1017/bca.2018.20; Milligan C, 2014, ACCIDENT ANAL PREV, V71, P236, DOI 10.1016/j.aap.2014.05.026; Miyazato N., 2011, JAPANESE EC, V38, P65; Mofadal AIA, 2015, ACCIDENT ANAL PREV, V78, P201, DOI 10.1016/j.aap.2015.02.022; Mohamed HA, 2015, ADV MANAGEMENT APPL, V5, P43; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Mon EE, 2018, ACCIDENT ANAL PREV, V118, P18, DOI 10.1016/j.aap.2018.05.018; Morisugi M, 2016, WORLD C TRANSP RES J; Mouter N, 2017, TRANSPORT RES A-POL, V106, P333, DOI 10.1016/j.tra.2017.10.003; Munro A, 2018, J REGIONAL SCI, V58, P635, DOI 10.1111/jors.12381; Musters AM, 2011, HUM REPROD, V26, P2425, DOI 10.1093/humrep/der177; Nelson J, 2009, ENVIRON RESOUR ECON, V42, P345, DOI 10.1007/s10640-008-9253-5; Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158; NEUMANN PJ, 1994, MED CARE, V32, P686, DOI 10.1097/00005650-199407000-00003; Niroomand N, 2017, J SAFETY RES, V62, P81, DOI 10.1016/j.jsr.2017.06.006; Niroomand N, 2016, ACCIDENT ANAL PREV, V91, P216, DOI 10.1016/j.aap.2016.03.004; Norman R, 2013, AUST NZ J PUBL HEAL, V37, P17, DOI 10.1111/1753-6405.12005; Nunthasen K, 2018, ADV SCI LETT, V24, P2320, DOI 10.1166/asl.2018.10944; O'Brien J, 2018, J RISK UNCERTAINTY, V57, P51, DOI 10.1007/s11166-018-9285-3; Ohno E, 2012, 52 C EUR REG SCI ASS; Organisation for Economic Co-operation and Development, MORT RISK VAL ENV HL; Parada-Contzen M, 2013, EMPIR ECON, V45, P1073, DOI 10.1007/s00181-012-0660-7; Parada-Contzen MV, 2019, RISK ANAL, V39, P2369, DOI 10.1111/risa.13329; Polat S, 2014, SAFETY SCI, V70, P153, DOI 10.1016/j.ssci.2014.05.018; Porfiriev B, 2014, INT J DISAST RISK RE, V7, P91, DOI 10.1016/j.ijdrr.2013.12.007; Qin XZ, 2013, CHINA AGR ECON REV, V5, P373, DOI 10.1108/CAER-06-2011-0065; Rafiq M, 2010, PAK DEV REV, V49, P823; Reynaud A, 2016, ENVIRON MODEL ASSESS, V21, P603, DOI 10.1007/s10666-016-9500-z; Rheinberger CM, 2018, J ENVIRON ECON MANAG, V89, P285, DOI 10.1016/j.jeem.2018.04.002; Rheinberger CM, 2011, ENVIRON RESOUR ECON, V49, P121, DOI 10.1007/s10640-010-9427-9; Robinson LA, 2021, RISK ANAL, V41, P761, DOI 10.1111/risa.13561; Robinson LA, 2019, J BENEFIT-COST ANAL, V10, P15, DOI 10.1017/bca.2018.26; Robinson LA, 2016, HEALTH ECON, V25, P1039, DOI 10.1002/hec.3214; Robinson LA, 2015, RISK ANAL, V35, P1086, DOI 10.1111/risa.12366; Robinson LA, 2010, J HOMEL SECUR EMERG, V7; Rohlfs C, 2016, J RISK UNCERTAINTY, V52, P163, DOI 10.1007/s11166-016-9238-7; Rohlfs C, 2015, AM ECON J-ECON POLIC, V7, P331, DOI 10.1257/pol.20110309; Rohlfs C, 2012, J BENEFIT-COST ANAL, V3, DOI 10.1515/2152-2812.1107; Roldos Maria Isabel, 2017, Int J MCH AIDS, V6, P1, DOI 10.21106/ijma.166; Rouwendal J, 2010, TRANSPORT RES B-METH, V44, P136, DOI 10.1016/j.trb.2009.04.006; Ryan M, 1997, APPL ECON, V29, P841, DOI 10.1080/000368497326499; Scasny M, 2012, INT J ENV RES PUB HE, V9, P4760, DOI 10.3390/ijerph9124760; Schaffner S, 2010, RESOUR ENERGY ECON, V32, P15, DOI 10.1016/j.reseneeco.2009.06.001; Scotton CR, 2013, J BENEFIT-COST ANAL, V4, P39, DOI 10.1515/jbca-2012-0015; Scotton CR, 2011, RESOUR ENERGY ECON, V33, P381, DOI 10.1016/j.reseneeco.2010.06.001; Shanmugam KR, 2011, EC RES INT, V2011, P1; Sliupas ~ T, 2017, P 21 INT SCI C TRANS; Svensson M, 2009, J RISK UNCERTAINTY, V39, P65, DOI 10.1007/s11166-009-9070-4; Svensson M, 2009, ACCIDENT ANAL PREV, V41, P430, DOI 10.1016/j.aap.2009.01.005; Tekesin C, 2014, INT J ENV RES PUB HE, V11, P6890, DOI 10.3390/ijerph110706890; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Tsai WJ, 2011, ENVIRON RESOUR ECON, V49, P425, DOI 10.1007/s10640-010-9440-z; U.S. Environmental Protection Agency National Center for Environmental Economics, 2010, VAL MORT RISK RED EN; Vallejo-Torres L, 2016, VALUE HEALTH, V19, P558, DOI 10.1016/j.jval.2016.02.020; van den Wijngaard L, 2015, HUM REPROD, V30, P331, DOI 10.1093/humrep/deu307; van Wee B, 2013, TRANSPORTATION, V40, P295, DOI 10.1007/s11116-012-9425-6; Veisten K, 2013, RES TRANSP ECON, V43, P50, DOI 10.1016/j.retrec.2012.12.009; Viscusi WK, 2018, J BENEFIT-COST ANAL, V9, P205, DOI 10.1017/bca.2017.21; Viscusi WK, 2018, ECON REC, V94, P1, DOI 10.1111/1475-4932.12396; Viscusi WK, 2017, J BENEFIT-COST ANAL, V8, P226, DOI 10.1017/bca.2017.12; Viscusi WK, 2017, J RISK UNCERTAINTY, V54, P103, DOI 10.1007/s11166-017-9255-1; Viscusi WK, 2015, J BENEFIT-COST ANAL, V6, P187, DOI 10.1017/bca.2015.3; Viscusi WK, 2015, J RISK UNCERTAINTY, V51, P53, DOI 10.1007/s11166-015-9219-2; Viscusi WK, 2014, HEALTH ECON, V23, P384, DOI 10.1002/hec.2919; Viscusi WK, 2012, J ECON SURV, V26, P763, DOI 10.1111/j.1467-6419.2011.00707.x; Viscusi WK, 2010, J RISK UNCERTAINTY, V40, P1, DOI 10.1007/s11166-009-9083-z; Viscusi WK, 2003, J RISK UNCERTAINTY, V27, P5, DOI 10.1023/A:1025598106257; Viscusi WK, 2014, ROLE PUBLICATION SEL; Viscusi WK, 2008, J EC FINANCE, V32, P311, DOI DOI 10.1007/S12197-008-9030-X; Vitaliano DF, 2019, INT J ECON BUS, V26, P217, DOI 10.1080/13571516.2018.1512187; Wang Hua, 2014, FRONTIERS EC CHINA, V9, P183; Wardman M, 2004, TRANSPORT RES D-TR E, V9, P1, DOI 10.1016/S1361-9209(03)00042-7; Wijnen W, 2009, EVAL PROGRAM PLANN, V32, P326, DOI 10.1016/j.evalprogplan.2009.06.015; Yaduma N, 2013, ENVIRON RESOUR ECON, V54, P361, DOI 10.1007/s10640-012-9598-7; Yang Z, 2016, ACCIDENT ANAL PREV, V95, P308, DOI 10.1016/j.aap.2016.04.026; Yusof MFM, 2013, J SOC TRANSP TRAFFIC, V2, P30; Zan H, 2017, J CONSUM POLICY, V40, P157, DOI 10.1007/s10603-017-9347-y; Zhang J, 2013, WATER RESOUR RES, V49, P6286, DOI 10.1002/wrcr.20447	191	1	1	6	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	OCT	2021	24	10					1531	1541		10.1016/j.jval.2021.04.003		SEP 2021	11	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	WE3WV	34593177	Bronze			2022-04-28	WOS:000705561100018
J	Rowen, D; Powell, P; Mukuria, C; Carlton, J; Norman, R; Brazier, J				Rowen, Donna; Powell, Philip; Mukuria, Clara; Carlton, Jill; Norman, Richard; Brazier, John			Deriving a Preference-Based Measure for People With Duchenne Muscular Dystrophy From the DMD-QoL	VALUE IN HEALTH			English	Article						condition-specific preference based measure; DMD-QoL; Duchenne muscular dystrophy; utilities; QALYs	DISCRETE-CHOICE EXPERIMENT; QUALITY-OF-LIFE; CLASSIFICATION-SYSTEM; MIXED METHODS; R PACKAGE; HEALTH; MULTIATTRIBUTE; EQ-5D-5L	Objectives: This study generates a preference-based measure for capturing the quality of life of people with Duchenne muscular dystrophy (DMD) from a new measure of quality of life, DMD-QoL. Methods: A health state classification system was derived from the DMD-QoL based on psychometric performance of items, factor analysis, and item response theory analysis. Preferences for health states described by the classification system were elicited using an online discrete choice experiment survey with life years as an additional attribute, from members of the UK general population (n =1043). Discrete choice experiment data was modeled using a conditional fixed-effects logit model and utility estimates were directly anchored on the 1 to 0 full health-dead scale. Results: The health state classification system has 8 dimensions: mobility, difficulty using hands, difficulty breathing, pain, tiredness, worry, participation, and feeling good about yourself. The standard model had mostly statistically significant coefficients and reflected the instrument's monotonic structure. However, 2 dimensions had inconsistent coefficients (where utility increased as health worsened) and a consistent model was estimated that merged adjacent inconsistent severity levels. The best state defined by the classification system has a value of 1 and the worst state has a value of 20.559. Conclusion: The modeled results enable DMD-QoL-8D utility values to be generated using DMD-QoL or DMD-QoL-8D data to generate QALYs for people with DMD. QALYs can then be used to inform economic models of the cost-effectiveness of interventions in DMD. Future research comparing the psychometric performance of DMD-QoL-8D to existing generic preference-based measures, including EQ-5D-5L, is recommended.	[Rowen, Donna; Powell, Philip; Mukuria, Clara; Carlton, Jill; Brazier, John] Univ Sheffield, Sch Hlth & Related Res ScHARR, Sheffield, S Yorkshire, England; [Norman, Richard] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia		Rowen, D (通讯作者)，Univ Sheffield Regent Court, Sch Hlth & Related Res ScHARR, 30 Regent St, Sheffield S1 4DA, S Yorkshire, England.	d.rowen@sheffield.ac.uk		Brazier, John/0000-0001-8645-4780	Project HERCULES consortium; Duchenne UK; PfizerPfizer; PTC Therapeutics; RocheRoche Holding; Summit Therapeutics plc; Sarepta Therapeutics Inc; Wave Lifesciences USA Inc; Solid Biosciences; Catabasis Pharmaceuticals; Santhera Therapeutics	This study was funded by Project HERCULES consortium. The Project HERCULES consortium is funded by Duchenne UK, Pfizer, PTC Therapeutics, Roche, Summit Therapeutics plc, Sarepta Therapeutics Inc, Wave Lifesciences USA Inc, Solid Biosciences, Catabasis Pharmaceuticals, and Santhera Therapeutics.	Bahrampour M, 2020, EUR J HEALTH ECON, V21, P983, DOI 10.1007/s10198-020-01189-6; Bann CM, 2015, NEUROLOGY, V84, P1034, DOI 10.1212/WNL.0000000000001336; Bansback N, 2012, J HEALTH ECON, V31, P306, DOI 10.1016/j.jhealeco.2011.11.004; Brazier J.., 2016, MEASURING VALUING HL, V2; Brazier JE, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16320; Brazier JE, 2004, MED CARE, V42, P851, DOI 10.1097/01.mlr.0000135827.18610.0d; Brazier JE, 2020, MED CARE, V58, P557, DOI 10.1097/MLR.0000000000001325; Choi SW, 2011, J STAT SOFTW, V39, P1; Choice Metrics, 2018, NGEN SOFTW EXP DES; COOK RD, 1980, TECHNOMETRICS, V22, P315, DOI 10.2307/1268315; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006; Flores D, 2020, EUR J HEALTH ECON, V21, P1015, DOI 10.1007/s10198-020-01197-6; Johnson FR, 2019, VALUE HEALTH, V22, P157, DOI 10.1016/j.jval.2018.07.876; Jonker MF, 2018, VALUE HEALTH, V21, P767, DOI 10.1016/j.jval.2017.10.002; Kennedy-Martin M, 2020, EUR J HEALTH ECON, V21, P1245, DOI 10.1007/s10198-020-01195-8; Landfeldt E, 2020, EUR J EPIDEMIOL, V35, P643, DOI 10.1007/s10654-020-00613-8; Lue YJ, 2017, DISABIL REHABIL, V39, P1408, DOI 10.1080/09638288.2016.1196398; Mair P, 2007, R J STAT SOFTW, V20; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Mukuria C, 2015, VALUE HEALTH, V18, P846, DOI 10.1016/j.jval.2015.07.004; Mulhern B, 2019, PHARMACOECONOMICS, V37, P29, DOI 10.1007/s40273-018-0714-6; Mulhern BJ, 2020, MED CARE, V58, P566, DOI 10.1097/MLR.0000000000001324; NICE, 2013, GUID METH TECHN APPR; Norman R, 2016, QUAL LIFE RES, V25, P637, DOI 10.1007/s11136-015-1115-3; Norman R, 2019, HEALTH ECON, V28, P1385, DOI 10.1002/hec.3950; Norman R, 2014, MED DECIS MAKING, V34, P773, DOI 10.1177/0272989X13503499; Norman R, 2013, APPL HEALTH ECON HEA, V11, P287, DOI 10.1007/s40258-013-0035-z; Orme B, 1998, SAWTHOOTH SOFTWARE R, V10; Payne K, 2011, VALUE HEALTH, V14, P121, DOI 10.1016/j.jval.2010.10.007; Powell PA, 2021, NEUROLOGY, V96, pE2438, DOI 10.1212/WNL.0000000000011896; Powell PA, 2020, HEALTH QUAL LIFE OUT, V18, DOI 10.1186/s12955-020-01511-z; Powell PA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023685; R Core Team, 2016, R LANG ENV STAT COMP; Revelle W., 2018, PSYCH PROCEDURES PER; Rosseel Y, 2012, J STAT SOFTW, V48, P1, DOI 10.18637/jss.v048.i02; Rowen D, 2020, PHARMACOECONOMICS, V38, P325, DOI 10.1007/s40273-019-00873-7; Rowen D, 2018, VALUE HEALTH, V21, P1234, DOI 10.1016/j.jval.2018.03.016; Rowen D, 2018, MED DECIS MAKING, V38, P699, DOI 10.1177/0272989X18784291; Rowen D, 2017, PHARMACOECONOMICS, V35, pS11, DOI 10.1007/s40273-017-0544-y; Rowen D, 2011, VALUE HEALTH, V14, P721, DOI 10.1016/j.jval.2011.01.004; Stark AE, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.10.45; Stevens K, 2012, PHARMACOECONOMICS, V30, P729, DOI 10.2165/11599120-000000000-00000; Straub V, 2018, NEUROMUSCULAR DISORD, V28, P690, DOI 10.1016/j.nmd.2018.05.013; Szabo SM, 2020, QUAL LIFE RES, V29, P593, DOI 10.1007/s11136-019-02355-x; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Uttley L, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-1062-0; Uzark K, 2012, PEDIATRICS, V130, pE1559, DOI 10.1542/peds.2012-0858; van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008; Wong SH, 2015, EUR J HUM GENET, V23, P1294, DOI 10.1038/ejhg.2014.301; Wright BD, 1994, RASCH MEASUREMENT T, V8, P370	52	1	1	3	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	OCT	2021	24	10					1499	1510		10.1016/j.jval.2021.03.007		SEP 2021	12	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	WE3WV	34593174	Green Accepted, hybrid			2022-04-28	WOS:000705561100015
J	Grimm, SE; Pouwels, X; Ramaekers, BLT; van Ravesteyn, NT; Sankatsing, VDV; Grutters, J; Joore, MA				Grimm, Sabine E.; Pouwels, Xavier; Ramaekers, Bram L. T.; van Ravesteyn, Nicolien T.; Sankatsing, Valerie D. V.; Grutters, Janneke; Joore, Manuela A.			Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation	VALUE IN HEALTH			English	Article						decision science; health economics; uncertainty; value of information	EXPECTED VALUE; UNCERTAINTY; FRAMEWORK; DESIGN; AGE	Objectives: Value of information (VOI) analysis can support health technology assessment decision making, but it is a long way from being standard use. The objective of this study was to understand barriers to the implementation of VOI analysis and propose actions to overcome these. Methods: We performed a process evaluation of VOI analysis use within decision making on tomosynthesis versus digital mammography for use in the Dutch breast cancer population screening. Based on steering committee meeting attendance and regular meetings with analysts, we developed a list of barriers to VOI use, which were analyzed using an established diffusion model. We proposed actions to address these barriers. Barriers and actions were discussed and validated in a workshop with stakeholders representing patients, clinicians, regulators, policy advisors, researchers, and the industry. Results: Consensus was reached on groups of barriers, which included characteristics of VOI analysis itself, stakeholder's attitudes, analysts' and policy makers' skills and knowledge, system readiness, and implementation in the organization. Observed barriers did not only pertain to VOI analysis itself but also to formulating the objective of the assessment, economic modeling, and broader aspects of uncertainty assessment. Actions to overcome these barriers related to organizational changes, knowledge transfer, cultural change, and tools. Conclusions: This in-depth analysis of barriers to implementation of VOI analysis and resulting actions and tools may be useful to health technology assessment organizations that wish to implement VOI analysis in technology assessment and research prioritization. Further research should focus on application and evaluation of the proposed actions in real-world assessment processes.	[Grimm, Sabine E.; Ramaekers, Bram L. T.; Joore, Manuela A.] Maastricht Univ, Med Ctr, Sch Publ Hlth & Primary Care, Dept Clin Epidemiol & Med Technol Assessment, P Debyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands; [Pouwels, Xavier] Univ Twente, Fac Behav Management & Social Sci, Dept Hlth Technol & Res Serv, Enschede, Netherlands; [van Ravesteyn, Nicolien T.; Sankatsing, Valerie D. V.] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Grutters, Janneke] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Nijmegen, Netherlands		Grimm, SE (通讯作者)，Maastricht Univ, Med Ctr, Sch Publ Hlth & Primary Care, Dept Clin Epidemiol & Med Technol Assessment, P Debyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands.	sabine.grimm@mumc.nl	Pouwels, Xavier/AAQ-2092-2021	Pouwels, Xavier/0000-0003-3563-0013; Joore, Manuela/0000-0002-5649-6768	Netherlands Organisation for Health Research and Development (ZonMW)Netherlands Organization for Health Research and Development [1520020521, 531002051]	This project was supported by The Netherlands Organisation for Health Research and Development (ZonMW), project numbers: 1520020521 and 531002051. The views and opinions expressed in the study are those of the individual authors and should not be attributed to a specific organization.	Al M, ONZEKERHEID VALUE IN; [Anonymous], RES RECOMMENDATIONS; [Anonymous], GUIDELINES SUBMISSIO; [Anonymous], PROCEDURE BEOORDELIN; [Anonymous], WIE VOEREN BEVOLKING; Badgett RG, 2005, MILBANK Q, V83, P177, DOI 10.1111/j.0887-378X.2005.340_1.x; Bennette CS, 2016, MED DECIS MAKING, V36, P641, DOI 10.1177/0272989X16636847; Bindels J, 2016, PHARMACOECONOMICS, V34, P315, DOI 10.1007/s40273-015-0346-z; Briggs A, 2006, DECISION MODELLING H; Briggs AH, 2012, MED DECIS MAKING, V32, P722, DOI 10.1177/0272989X12458348; Carlson JJ, 2018, CANCER MED-US, V7, P4251, DOI 10.1002/cam4.1657; Carlson JJ, 2013, MED DECIS MAKING, V33, P463, DOI 10.1177/0272989X13484388; Chalkidou K, 2008, HEALTH AFFAIR, V27, P1642, DOI 10.1377/hlthaff.27.6.1642; Chalmers I, 2009, LANCET, V374, P86, DOI 10.1016/S0140-6736(09)60329-9; Claxton K, 1996, HEALTH ECON, V5, P513, DOI 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9; Claxton K, 2002, LANCET, V360, P711, DOI 10.1016/S0140-6736(02)09832-X; Davis C, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4530; de Gelder R, 2015, INT J CANCER, V137, P165, DOI 10.1002/ijc.29364; Eckermann S, 2007, HEALTH ECON, V16, P195, DOI 10.1002/hec.1161; Eckermann S, 2010, PHARMACOECONOMICS, V28, P699, DOI 10.2165/11537370-000000000-00000; Felli JC, 1998, MED DECIS MAKING, V18, P95, DOI 10.1177/0272989X9801800117; Fleurence RL, 2020, VALUE HEALTH, V23, P287, DOI 10.1016/j.jval.2020.01.003; Gagliardi AR, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0399-1; Ghabri S, 2018, PHARMACOECONOMICS, V36, P127, DOI 10.1007/s40273-017-0603-4; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; Grimm SE, 2020, PHARMACOECONOMICS, V38, P205, DOI 10.1007/s40273-019-00855-9; Grimm SE, 2017, PHARMACOECONOMICS, V35, P1287, DOI 10.1007/s40273-017-0562-9; Gyawali B, 2019, JAMA INTERN MED, V179, P906, DOI 10.1001/jamainternmed.2019.0462; HABBEMA JDF, 1985, COMPUT METH PROG BIO, V20, P79, DOI 10.1016/0169-2607(85)90048-3; Heath A, 2020, MED DECIS MAKING, V40, P314, DOI 10.1177/0272989X20912402; Kunst N, 2020, VALUE HEALTH, V23, P734, DOI 10.1016/j.jval.2020.02.010; Lipska I, 2015, CLIN PHARMACOL THER, V98, P489, DOI 10.1002/cpt.198; Makady A, 2019, HEALTH POLICY, V123, P267, DOI 10.1016/j.healthpol.2018.09.016; Meisel ZF, 2019, SUBST ABUSE TREAT PR, V14, DOI 10.1186/s13011-019-0199-0; Minelli C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001882; Morgan DL, 2007, J MIX METHOD RES, V1, P48, DOI 10.1177/2345678906292462; Pouwels XGLV, 2019, VALUE HEALTH, V22, P799, DOI 10.1016/j.jval.2018.11.010; Raiffa H., 1968, DECISION ANAL INTRO; Ramos IC, 2013, MED DECIS MAKING, V33, P472, DOI 10.1177/0272989X12468616; Ritchie J., 2003, DESIGNING SELECTING; Rothery C, 2020, VALUE HEALTH, V23, P277, DOI 10.1016/j.jval.2020.01.004; Sabry-Grant C, 2019, PHARMACOECONOMICS, V37, P953, DOI 10.1007/s40273-019-00793-6; Sankatsing VDV, 2020, RADIOLOGY, V297, P40, DOI 10.1148/radiol.2020192505; Sankatsing VDV, 2015, INT J CANCER, V137, P1990, DOI 10.1002/ijc.29572; Steuten L, 2013, PHARMACOECONOMICS, V31, P25, DOI 10.1007/s40273-012-0008-3; Strong M, SAVI SHEFFIELD ACCEL; Thompson M S, 1981, Med Decis Making, V1, P165, DOI 10.1177/0272989X8100100206; Tuffaha H, 2021, PHARMACOECON-OPEN, V5, P139, DOI 10.1007/s41669-020-00227-6; van Asselt MBA, 2008, J RISK RES, V11, P281, DOI 10.1080/13669870801990806; Walker S, 2012, VALUE HEALTH, V15, P570, DOI 10.1016/j.jval.2011.12.013	50	0	0	4	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	AUG	2021	24	8					1126	1136		10.1016/j.jval.2021.03.013		AUG 2021	11	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TY1SX	34372978	Green Published, hybrid			2022-04-28	WOS:000683567300006
J	Laberge, M; Coulibaly, LP; Berthelot, S; da Silva, RB; Guertin, JR; Strumpf, E; Poirier, A; Zomahoun, HTV; Poder, TG				Laberge, Maude; Coulibaly, Lucien P.; Berthelot, Simon; da Silva, Roxane Borges; Guertin, Jason R.; Strumpf, Erin; Poirier, Annie; Zomahoun, Herve Tchala Vignon; Poder, Thomas G.			Development and Validation of an Instrument to Measure Health-Related Out-of-Pocket Costs: The Cost for Patients Questionnaire	VALUE IN HEALTH			English	Article						cost measurement; Delphi process; patient perspective; questionnaire development; questionnaire validation; test-retest	SYSTEMATIC REVIEWS; FINANCIAL TOXICITY; CARE UTILIZATION; CANCER; RELIABILITY; AGREEMENT; BURDEN; IMPACT; KAPPA; DIARY	Objective: The growth of healthcare spending is a major concern for insurers and governments but also for patients whose health problems may result in costs going beyond direct medical costs. To develop a comprehensive tool to measure direct and indirect costs of a health condition for patients and their families to various outpatient contexts. Methods: We conducted a content and face validation including results of a systematic review to identify the items related to direct and indirect costs for patients or their families and an online Delphi to determine the cost items to retain. We conducted a pilot test-retest with 18 naive participants and analyzed data calculating intraclass correlation and kappa coefficients. Results: An initial list of 34 items was established from the systematic review. Each round of the Delphi panel incorporated feedback from the previous round until a strong consensus was achieved. After 4 rounds of the Delphi to reach consensus on items to be included and wording, the questionnaire had a total of 32 cost items. For the test-retest, kappa coefficients ranged from -0.11 to 1.00 (median = 0.86), and intraclass correlation ranged from -0.02 to 0.99 (median = 0.62). Conclusions: A rigorous process of content and face development was implemented for the Cost for Patients Questionnaire, and this study allowed to set a list of cost elements to be considered from the patient's perspective. Additional research including a test-retest with a larger sample will be part of a subsequent validation strategy.	[Laberge, Maude] Univ Laval, Fac Adm, Dept Operat & Decis Syst, 2325,Rue Terrasse 2519, Quebec City, PQ G1V 0A6, Canada; [Guertin, Jason R.; Zomahoun, Herve Tchala Vignon] Univ Laval, Dept Social & Prevent Med, Quebec City, PQ, Canada; [Berthelot, Simon; Poirier, Annie] Univ Laval, Fac Med, Dept Med Familiale & Med Urgence, Quebec City, PQ, Canada; [Zomahoun, Herve Tchala Vignon] Univ Laval, Hlth & Social Serv Syst, Knowledge Translat & Implementat Component Quebec, Quebec City, PQ, Canada; [Laberge, Maude; Berthelot, Simon; Guertin, Jason R.; Poirier, Annie] Univ Laval, CHU Quebec, Ctr Rech, Axe Sante Populat & Prat Optim Sante, Quebec City, PQ, Canada; [Coulibaly, Lucien P.] Univ Sherbrooke, Fac Lettres & Sci Humaines, Sherbrooke, PQ, Canada; [Coulibaly, Lucien P.] Univ Sherbrooke, Ctr Rech Vieillissement, Sherbrooke, PQ, Canada; [da Silva, Roxane Borges; Poder, Thomas G.] Univ Montreal, Ecole Sante Publ, Dept Gest Evaluat & Polit Sante, Montreal, PQ, Canada; [da Silva, Roxane Borges] Univ Montreal, Ctr Rech Sante Publ, Montreal, PQ, Canada; [Strumpf, Erin; Zomahoun, Herve Tchala Vignon] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Strumpf, Erin; Zomahoun, Herve Tchala Vignon] McGill Univ, Dept Econ, Montreal, PQ, Canada; [Laberge, Maude; Poirier, Annie; Zomahoun, Herve Tchala Vignon] Univ Laval, Ctr Rech Sante Durable, Vitam, Quebec City, PQ, Canada; [Poder, Thomas G.] Inst Univ Sante Mentale Montreal, Ctr Rech, Montreal, PQ, Canada		Laberge, M (通讯作者)，Univ Laval, Fac Adm, Dept Operat & Decis Syst, 2325,Rue Terrasse 2519, Quebec City, PQ G1V 0A6, Canada.	laberge@fsa.ulaval.ca					Biondo PD, 2008, SUPPORT CARE CANCER, V16, P935, DOI 10.1007/s00520-007-0348-2; Booto Ekionea J., 2011, RECHERCHES QUALITATI, V29, P168; Bowling A, 2005, J PUBLIC HEALTH-UK, V27, P281, DOI 10.1093/pubmed/fdi031; Brouwer WBF, 2005, PHARMACOECONOMICS, V23, P105, DOI 10.2165/00019053-200523020-00002; Caffrey M, 2019, AM J MANAG CARE, V25, P88168; Canadian Institutes of Health Research, STRAT PAT OR RES PAT; Chernyak N, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-303; Cunningham Peter J, 2009, Issue Brief (Commonw Fund), V63, P1; Dalkey NC, 1975, DELPHI METHOD TECHNI, P236; de Souza JA, 2017, CANCER-AM CANCER SOC, V123, P476, DOI 10.1002/cncr.30369; de Souza JA, 2014, CANCER-AM CANCER SOC, V120, P3245, DOI 10.1002/cncr.28814; Delbecq AL., 1975, GROUP TECHNIQUES PRO, p10, 89; Drummond MF, 2015, METHOD EC EVALUATION; Fathollahzade Abazar, 2015, Asian Pac J Cancer Prev, V16, P1621; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; Fox M, 2009, HEALTH SERV RES, V44, P1662, DOI 10.1111/j.1475-6773.2009.00993.x; Goossens MEJB, 2000, J CLIN EPIDEMIOL, V53, P688, DOI 10.1016/S0895-4356(99)00177-8; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hoogendoorn M, 2009, INT J TECHNOL ASSESS, V25, P588, DOI 10.1017/S0266462309990432; Hulsemann JL, 2006, RHEUMATOL INT, V26, P704, DOI 10.1007/s00296-005-0070-7; Hutchison Brian, 2013, Healthc Policy, V9, P12; INESSS, GUID SOUM DEM INESSS GUID SOUM DEM INESSS; JACOBY A, 1993, EPILEPSY RES, V16, P83, DOI 10.1016/0920-1211(93)90042-6; Kim DD, 2020, PHARMACOECONOMICS, V38, P1135, DOI 10.1007/s40273-020-00942-2; Lamoureux EL, 2006, OPHTHAL EPIDEMIOL, V13, P121, DOI 10.1080/09286580500536781; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Longo CJ, 2006, SUPPORT CARE CANCER, V14, P1077, DOI 10.1007/s00520-006-0088-8; Mason SJ, 2018, BJU INT, V122, P760, DOI 10.1111/bju.14368; Mokkink L., COSMIN METHODOLOGY S; Mokkink LB, 2018, QUAL LIFE RES, V27, P1171, DOI 10.1007/s11136-017-1765-4; Neumann P. J., 2016, Cost-effectiveness in health and medicine; Peersman W, 2014, EUR J PUBLIC HEALTH, V24, P91, DOI 10.1093/eurpub/ckt079; Poder TG, 2021, VALIDATED TOOLS MEAS, DOI [10.1007/s40271-021-00527-x, DOI 10.1007/S40271-021-00527-X]; Prinsen CAC, 2018, QUAL LIFE RES, V27, P1147, DOI 10.1007/s11136-018-1798-3; Rattray J, 2007, J CLIN NURS, V16, P234, DOI 10.1111/j.1365-2702.2006.01573.x; Sable-Smith B., INSULINS HIGH COST L; Schweikert B, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-187; Sim J, 2005, PHYS THER, V85, P257; Stabile M, 2006, HLTH SERVICES RESTRU, P83; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; Stockwell DC, 2016, J PATIENT SAF, V12, P180, DOI 10.1097/PTS.0000000000000139; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Thorn JC, 2018, VALUE HEALTH, V21, P640, DOI 10.1016/j.jval.2017.06.011; Topp J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-032859; VALLERAND RJ, 1989, CAN PSYCHOL, V30, P662, DOI 10.1037/h0079856; van den Brink M, 2005, INT J TECHNOL ASSESS, V21, P298, DOI 10.1017/S0266462305050397; Van Houtven CH, 2010, ONCOLOGIST, V15, P883, DOI 10.1634/theoncologist.2010-0005; Verguet S, 2016, PHARMACOECONOMICS, V34, P913, DOI 10.1007/s40273-016-0414-z; Tran VT, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-68	50	0	0	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	AUG	2021	24	8					1172	1181		10.1016/j.jval.2021.03.016		AUG 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TY1SX	34372983	Green Published, hybrid			2022-04-28	WOS:000683567300011
J	Murchu, EO; Teljeur, C; Hayes, C; Harrington, P; Moran, P; Ryan, M				Murchu, Eamon O.; Teljeur, Conor; Hayes, Catherine; Harrington, Patricia; Moran, Patrick; Ryan, Mairin			Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland	VALUE IN HEALTH			English	Article						cost-effectiveness analysis; HIV prevention; pre-exposure prophylaxis; PrEP	UNITED-STATES; HIV; MEN; SEX; PREVENTION; PEOPLE; ERA	Objectives: To estimate the cost-effectiveness of introducing a publicly funded pre-exposure prophylaxis (PrEP) program in Ireland. Methods: We constructed a state-transition Markov model. This was a cross-sectional population model that tracked all HIV negative men who have sex with men (MSM) in Ireland over their lifetime. Access to a publicly funded PrEP program (medications 1 frequent monitoring) in high-risk MSM was compared with no PrEP. The primary outcome measure was the incremental cost-effectiveness ratio (ICER). Results: In the base case, introducing a PrEP program was considered cost saving and provided significant health benefits to the population. Univariate sensitivity analysis demonstrated that PrEP efficacy and HIV incidence had the greatest impact on cost-effectiveness. Including an increase in sexually transmitted infections had a negligible impact on the results. Efficacy was a significant driver in the model. PrEP was cost saving at all efficacy values above 60%, and at the lowest reported efficacy in MSM (44% in the iPrEX trial), the ICER was & euro;4711/QALY (highly cost-effective). Event-based dosing (administration during high-risk periods only) was associated with additional cost savings. We estimated that 1705 individuals (95% CI: 617-3452) would join the program in year 1. The incremental budget impact was & euro;1.5m (95% CI: & euro;0.5m to & euro;3m) in the first year and & euro;5.4m over 5 years (95% CI: & euro;1.8m to & euro;11.5m), with 173 cases of HIV averted over 5 years. Conclusion: We found that the introduction of a PrEP program would be considered cost saving in the first cost-effectiveness analysis of its kind in Ireland.	[Murchu, Eamon O.; Teljeur, Conor; Harrington, Patricia; Moran, Patrick; Ryan, Mairin] Hlth Informat & Qual Author, Dublin 7, Ireland; [Murchu, Eamon O.; Hayes, Catherine; Moran, Patrick] Trinity Coll Dublin, Inst Populat Hlth, Dublin, Ireland; [Ryan, Mairin] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Trinity Hlth Sci, Dublin, Ireland		Murchu, EO (通讯作者)，Hlth Informat & Qual Author, Dublin 7, Ireland.	eomurchu@hiqa.ie	Catherine, Hayes/D-3864-2016	Catherine, Hayes/0000-0002-1576-4623; Moran, Patrick/0000-0003-4476-569X			[Anonymous], 2018, TREEAGE PRO; Ara R, 2010, VALUE HEALTH, V13, P509, DOI 10.1111/j.1524-4733.2010.00700.x; Central Statistics Office, 2018, AG SPEC MORT AG GROU; Croxford S, 2017, LANCET PUBLIC HEALTH, V2, pE35, DOI 10.1016/S2468-2667(16)30020-2; Department of Health, HLTH IR SURV 2017; Department of Health and the HSE Sexual Health and Crisis Pregnancy Programme, 2006, IR STUD SEX HLTH REL; Desai K, 2008, AIDS, V22, P1829, DOI 10.1097/QAD.0b013e32830e00f5; Durand-Zaleski I, 2016, J INT AIDS SOC, V19; ECDC, HIV AIDS SURV EUR 20; EUNETHTA (European Network for Health Technology Assessment), 2015, METH HLTH EC EV A GU; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Grohskopf LA, 2013, JAIDS-J ACQ IMM DEF, V64, P79, DOI 10.1097/QAI.0b013e31828ece33; Grulich AE, 2018, LANCET HIV, V5, pE629, DOI 10.1016/S2352-3018(18)30215-7; Health Information and Quality Authority (HIQA), 2019, HLTH TECHNOLOGY ASSE; Health Information and Quality Authority (HIQA), HLTH TECHNOLOGY ASSE; Health Information Quality Assessment (HIQA), GUID EC EV HLTH TECH; Health Protection Surveillance Centre (HPSC), 2017, ANN EPIDEMIOLOGICAL; Health Protection Surveillance Centre (HPSC), 2019, ANN EPIDEMIOLOGICAL; Hosek SG, 2013, JAIDS-J ACQ IMM DEF, V62, P447, DOI 10.1097/QAI.0b013e3182801081; HSE, 2017, POS ANT THER ALL PEO; Juusola JL, 2012, ANN INTERN MED, V156, P541, DOI [10.7326/0003-4819-156-8-201204170-00004, 10.7326/0003-4819-156-8-201204170-00001]; MacFadden DR, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20791; McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2; Miners A, 2014, LANCET HIV, V1, pE32, DOI 10.1016/S2352-3018(14)70018-9; Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273; Mutua G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033103; Nakagawa F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125018; NHS, IMPL HIV PREP SCOTL; Nichols BE., 2016, TOP ANTIVIR MED, V24, P456; Nichols BE, 2016, LANCET INFECT DIS, V16, P1423, DOI 10.1016/S1473-3099(16)30311-5; ODonnell K, 2015, MEN WHO HAVE SEX MEN; ODonnell K, MISI 2015 FINDINGS M; Ong KJ, 2017, EUROSURVEILLANCE, V22, P15, DOI 10.2807/1560-7917.ES.2017.22.42.17-00192; Orr J., 2017, IRISH LONGITUDINAL S; Schneider K, 2014, CLIN INFECT DIS, V58, P1027, DOI 10.1093/cid/cit946; Traeger MW, 2018, CLIN INFECT DIS, V67, P676, DOI 10.1093/cid/ciy182	36	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUL	2021	24	7					948	956		10.1016/j.jval.2021.02.005		JUL 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TE7UB	34243838	Green Published			2022-04-28	WOS:000670212100005
J	Achter, E; Shen, Y; Goldgrub, R; Kendall, R; Shah, D				Achter, E.; Shen, Y.; Goldgrub, R.; Kendall, R.; Shah, D.			A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC BURDEN OF HOSPITALIZED ADULTS WITH COVID-19 IN EUROPE AND ASIA	VALUE IN HEALTH			English	Meeting Abstract									[Achter, E.] ICON Plc, Boston, MA USA; [Shen, Y.] ICON Plc, Cambridge, MA USA; [Goldgrub, R.] ICON Plc, Vancouver, BC, Canada; [Kendall, R.] ICON Plc, Toronto, ON, Canada; [Shah, D.] ICON Plc, New York, NY USA									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN32	S111	S111					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400485
J	Adler, LA; Childress, A; Cloutier, M; Gagnon-Sanschagrin, P; Davidson, M; Kinkead, F; Guerin, A; Lefebvre, P; Schein, J				Adler, L. A.; Childress, A.; Cloutier, M.; Gagnon-Sanschagrin, P.; Davidson, M.; Kinkead, F.; Guerin, A.; Lefebvre, P.; Schein, J.			ECONOMIC BURDEN OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) AMONG ADULTS IN THE UNITED STATES: A SOCIETAL PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Adler, L. A.] NYU, Grossman Sch Med, New York, NY USA; [Childress, A.] Ctr Psychiat & Behav Med, Las Vegas, NV USA; [Cloutier, M.; Gagnon-Sanschagrin, P.; Davidson, M.; Kinkead, F.; Guerin, A.; Lefebvre, P.] Anal Grp Inc, Montreal, PQ, Canada; [Schein, J.] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH4	S128	S128					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400560
J	Averell, C; Germain, G; Laliberte, F; MacKnight, S; Jung, Y; Duh, MS; Abbott, C				Averell, C.; Germain, G.; Laliberte, F.; MacKnight, S.; Jung, Y.; Duh, M. S.; Abbott, C.			REAL-WORLD ADHERENCE TO SINGLE-INHALER FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL VERSUS MULTIPLE-INHALER TRIPLE THERAPY AMONG ASTHMA PATIENTS IN THE US	VALUE IN HEALTH			English	Meeting Abstract									[Averell, C.] GlaxoSmithKline, Res Triangle Pk, NC USA; [Germain, G.; Laliberte, F.; MacKnight, S.; Jung, Y.] Grp Anal Ltee, Montreal, PQ, Canada; [Duh, M. S.] Anal Grp Inc, Boston, MA USA; [Abbott, C.] GlaxoSmithKline, Durham, NC USA						 [HO-18-18555/208189]	GSK-sponsored (Study HO-18-18555/208189)		0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PB2	S13	S13					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400051
J	Azmi, S; Barnes, G; Xuan, D; Tang, B				Azmi, S.; Barnes, G.; Xuan, D.; Tang, B.			HEALTH RELATED QUALITY OF LIFE (HRQOL) REVIEW IN PATIENTS WITH OVARIAN CANCER: A SYSTEMATIC LITERATURE REVIEW (SLR)	VALUE IN HEALTH			English	Meeting Abstract									[Azmi, S.; Tang, B.] BeiGene Ltd, Emeryville, CA USA; [Barnes, G.] BeiGene Ltd, Jenkintown, PA USA; [Xuan, D.] Ceres Hlth Res Consulting, Littleton, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN222	S61	S61					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400265
J	Calixto, OJ; Salguedo, MG; Bello, JM; Saavedra, GP; Beltran, OA; Quitian, RH				Calixto, O. J.; Salguedo, Madrid G.; Bello, J. M.; Saavedra, G. P.; Beltran, Ostos A.; Quitian, Reyes H.			HEALTHCARE RELATED COSTS WITH BIOLOGICAL THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN RHEUMATOLOGY DEPARTMENT FROM TERTIARY HOSPITAL FROM BOGOTA, COLOMBIA	VALUE IN HEALTH			English	Meeting Abstract									[Calixto, O. J.; Salguedo, Madrid G.; Beltran, Ostos A.] Univ Mil Nueva Granada, Bogota, Cun, Colombia; [Bello, J. M.; Saavedra, G. P.] Hosp Mil Cent, Bogota, Colombia; [Quitian, Reyes H.] Pontificia Univ Javeriana, Bogota, Colombia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMS30	S143	S144					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400626
J	Carr, D; Macaulay, R				Carr, D.; Macaulay, R.			THE NEW SMC ULTRA-ORPHAN PATHWAY: HTA BEST PRACTICE FOR VERY RARE DISEASES?	VALUE IN HEALTH			English	Meeting Abstract									[Carr, D.] Precis Advisors, Kingston, England; [Macaulay, R.] Precis Advisors, London, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		SM4	S241	S241					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401320
J	Choon-Quinones, M; Hose, D; Kalo, Z; Jakab, I; Yucel, E; Zelei, T; Harousseau, JL; Durie, B; Keown, P; Barnett, M				Choon-Quinones, M.; Hose, D.; Kalo, Z.; Jakab, I; Yucel, E.; Zelei, T.; Harousseau, J. L.; Durie, B.; Keown, P.; Barnett, M.			PATIENT CAREGIVER PREFERENCES IN TREATMENT DECISION MAKING IN MULTIPLE MYELOMA - RESULTS OF A TARGETED LITERATURE REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Choon-Quinones, M.] Int Myeloma Fdn, Arisdorf, Switzerland; [Hose, D.] Vrije Univ Brussel, Brussels, Belgium; [Kalo, Z.; Jakab, I; Zelei, T.] Syreon Res Inst, Budapest, Hungary; [Yucel, E.] Bristol Myers Squibb, Princeton, NJ USA; [Harousseau, J. L.] Univ Nantes, Nantes, France; [Durie, B.] Int Myeloma Fdn, North Hollywood, CA USA; [Keown, P.; Barnett, M.] Univ British Columbia, Vancouver, BC, Canada				Kalo, Zoltan/G-7582-2011	Kalo, Zoltan/0000-0001-7762-2607				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN142	S45	S45					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400193
J	Chua, B; Ma, Y; Asjes, C; Lim, A; Mohseni, M; Wee, HL				Chua, B.; Ma, Y.; Asjes, C.; Lim, A.; Mohseni, M.; Wee, H. L.			BARRIERS TO AND FACILITATORS OF CERVICAL CANCER SCREENING AMONG WOMEN IN SOUTHEAST ASIA: A SYSTEMATIC REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Chua, B.; Mohseni, M.; Wee, H. L.] Natl Univ Singapore, Singapore, Singapore; [Ma, Y.; Asjes, C.] Becton Dickinson Holdings Pte Ltd, Singapore, Singapore; [Lim, A.] KK Womens & Childrens Hosp, Singapore, Singapore									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN150	S47	S47					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400201
J	De Guzman, K; Snoswell, C; Caffery, LJ; Smith, AC				De Guzman, K.; Snoswell, C.; Caffery, L. J.; Smith, A. C.			IS TELEHEALTH IN PRIMARY CARE COST-EFFECTIVE? A SYSTEMATIC REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[De Guzman, K.; Smith, A. C.] Univ Queensland, Ctr Online Hlth, Brisbane, Qld, Australia; [Snoswell, C.] Univ Queensland, Woolloongabba, Qld, Australia; [Caffery, L. J.] Univ Queensland, Brisbane, Qld, Australia				Smith, Anthony C./E-9538-2010	Smith, Anthony C./0000-0002-7756-5136				0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS81	S188	S188					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401082
J	Guo, H; Zheng, T; Lin, Y; Zhang, Z; Wang, D; Zhao, X; Liu, Y; Tan, B; Yang, P; Tian, Y; Fan, L; Li, Y; Zhao, Q				Guo, H.; Zheng, T.; Lin, Y.; Zhang, Z.; Wang, D.; Zhao, X.; Liu, Y.; Tan, B.; Yang, P.; Tian, Y.; Fan, L.; Li, Y.; Zhao, Q.			USING A NEW POWERED STAPLING SYSTEM WITH GRIPPING SURFACE TECHNOLOGY IS ASSOCIATED WITH BETTER INTRAOPERATIVE OUTCOMES AMONG PATIENTS WITH GASTRIC CARCINOMA	VALUE IN HEALTH			English	Meeting Abstract									[Guo, H.; Zheng, T.; Lin, Y.; Zhang, Z.; Wang, D.; Zhao, X.; Liu, Y.; Tan, B.; Yang, P.; Tian, Y.; Fan, L.; Li, Y.; Zhao, Q.] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PGI9	S96	S96					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400416
J	Hari, P; Nguyen, A; Pelletier, C; Hege, K; McGarvey, N; Gitlin, M; Parikh, K				Hari, P.; Nguyen, A.; Pelletier, C.; Hege, K.; McGarvey, N.; Gitlin, M.; Parikh, K.			ESTIMATION OF POST-INFUSION COSTS OF CARE FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVED IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN THE KARMMA CLINICAL TRIAL	VALUE IN HEALTH			English	Meeting Abstract									[Hari, P.] Med Coll Wisconsin, Div Hematol Oncol, Brookfield, WI USA; [Nguyen, A.; McGarvey, N.; Gitlin, M.] BluePath Solut, Los Angeles, CA USA; [Pelletier, C.; Hege, K.; Parikh, K.] Bristol Myers Squibb, Princeton, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN58	S29	S30					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400121
J	Hjalte, F; Norlin, J; Kellerborg, K; Odin, P				Hjalte, F.; Norlin, J.; Kellerborg, K.; Odin, P.			RESOURCE USE AT DIFFERENT LEVELS OF SEVERITY OF PARKINSON'S DISEASE IN A SWEDISH SETTING	VALUE IN HEALTH			English	Meeting Abstract									[Hjalte, F.; Norlin, J.; Kellerborg, K.] Swedish Inst Hlth Econ, Lund, Sweden; [Odin, P.] Skane Univ Hosp, Malmo, Sweden									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND30	S164	S164					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400714
J	Holanda, P; De Santana, CS; Senna, T; Carmo, L; Alexandre, RF				Holanda, P.; Salgado De Santana, C.; Senna, T.; Carmo, L.; Alexandre, R. F.			BUDGET IMPACT ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM	VALUE IN HEALTH			English	Meeting Abstract									[Holanda, P.; Senna, T.; Carmo, L.; Alexandre, R. F.] Pfizer Inc, Sao Paulo, Brazil; [Salgado De Santana, C.] Pfizer Inc, Santos, SP, Brazil									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PGI14	S96	S97					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400419
J	Jayasekera, J; Mandelblatt, J; Schechter, C				Jayasekera, J.; Mandelblatt, J.; Schechter, C.			THE DEVELOPMENT AND VALIDATION OF A SIMULATION MODEL-BASED CLINICAL DECISION TOOL TO SUPPORT ONCOLOGY PRACTICE	VALUE IN HEALTH			English	Meeting Abstract									[Jayasekera, J.; Mandelblatt, J.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA; [Jayasekera, J.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA; [Schechter, C.] Albert Einstein Coll Med, Bronx, NY 10467 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN23	S22	S22					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400090
J	Jiang, J; Li, D; Horrow, J; Tamada, H; Kahl, A; Hariharan, V; Avinav, A; Liu, X; Li, X				Jiang, J.; Li, D.; Horrow, J.; Tamada, H.; Kahl, A.; Hariharan, V; Avinav, A.; Liu, X.; Li, X.			ANTIPLATELET TREATMENT PATTERNS FOR SECONDARY STROKE PREVENTION IN THE UNITED KINGDOM	VALUE IN HEALTH			English	Meeting Abstract									[Jiang, J.; Li, D.; Tamada, H.; Kahl, A.; Liu, X.; Li, X.] Bristol Myers Squibb Co, Princeton, NJ USA; [Horrow, J.] Bristol Myers Squibb Co, Lawrenceville, NJ USA; [Hariharan, V; Avinav, A.] Mu Sigma Inc, Bangalore, Karnataka, India									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV42	S74	S74					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400325
J	Kachroo, K; Keerthan, R; Gopalan, G; Sharma, J				Kachroo, K.; Keerthan, R.; Gopalan, G.; Sharma, J.			HEALTH TECHNOLOGY ASSESSMENT REPORT ON CLINICAL EFFECTIVENESS OF CONTINUOUS POSITIVE PRESSURE VENTILATION WITH HELMET VERSUS STANDARD THERAPY IN PATIENTS WITH RESPIRATORY FAILURE	VALUE IN HEALTH			English	Meeting Abstract									[Kachroo, K.; Keerthan, R.; Gopalan, G.; Sharma, J.] Kalam Inst Hlth Technol, Visakhapatnam, Andhra Pradesh, India									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS29	S218	S218					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401218
J	Kumar, A; Lutsey, PL; St Peter, WL; Schommer, JC; Farley, JF				Kumar, A.; Lutsey, P. L.; St Peter, W. L.; Schommer, J. C.; Farley, J. F.			TRENDS IN PRESCRIPTION OF P2Y12 INHIBITORS FOLLOWING REVASCULARIZATION IN CORONARY HEART DISEASE	VALUE IN HEALTH			English	Meeting Abstract									[Kumar, A.] Univ Minnesota, Coll Pharm, St Paul, MN 55108 USA; [Lutsey, P. L.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; [St Peter, W. L.; Schommer, J. C.; Farley, J. F.] Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV53	S76	S77					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400335
J	Leo, CG; Mincarone, P; Mammucci, P; Pisani, AR; Ferrari, C; Rubini, G				Leo, C. G.; Mincarone, P.; Mammucci, P.; Pisani, A. R.; Ferrari, C.; Rubini, G.			ECONOMIC AND HEALTHCARE IMPACT OF LUNG PERFUSION SCINTIGRAPHY IN DIAGNOSIS OF SUBJECTS WITH A SUSPECT OF ACUTE PULMONARY EMBOLISM	VALUE IN HEALTH			English	Meeting Abstract									[Leo, C. G.] CNR, Inst Clin Physiol, Lecce, LE, Italy; [Mincarone, P.] CNR, Inst Res Populat & Social Policies, Brindisi, Italy; [Mammucci, P.; Pisani, A. R.; Ferrari, C.; Rubini, G.] Univ Aldo Moro Bari, DIM, Nucl Med Sect, Bari, Italy				Mincarone, Pierpaolo/B-8603-2015	Mincarone, Pierpaolo/0000-0002-8452-5642				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV29	S72	S72					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400315
J	Lylyk, P; Cirio, J; Toranzo, C; Aiello, EC; Paredes, D; Valencia, J				Lylyk, P.; Cirio, J.; Toranzo, C.; Aiello, E. C.; Paredes, D.; Valencia, J.			BUDGET IMPACT ANALYSIS OF THE INCORPORATION OF MECHANICAL THROMBECTOMY WITH STENT RETRIEVERS AFTER THROMBOLYSIS IN ISCHEMIC-STROKE WITH LARGE VESSEL OCCLUSION IN OBRAS SOCIALES AND EMPRESAS DE MEDICINA PREPAGA IN ARGENTINA	VALUE IN HEALTH			English	Meeting Abstract									[Lylyk, P.; Toranzo, C.] ENERI Equipo Neurocirugia Endovasc & Radiol Inter, Buenos Aires, DF, Argentina; [Lylyk, P.; Toranzo, C.] Clin La Sagrada Familia, Buenos Aires, DF, Argentina; [Cirio, J.] Clin La Sagrada Familia, Acute Stroke Unit, Buenos Aires, B, Argentina; [Cirio, J.] ENERI, Dept Neurol, Buenos Aires, B, Argentina; [Paredes, D.] Medtronic, Hlth Econ & Reimbursement, Santiago, RM, Chile; [Valencia, J.] Medtronic, Miami, FL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND28	S163	S164					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400712
J	Martin, A; Way, N; Jaffe, DH; Maculaitis, M				Martin, A.; Way, N.; Jaffe, D. H.; Maculaitis, M.			EHEALTH USE AMONG TYPE 2 DIABETICS: PRE-COVID ASSOCIATIONS WITH PATIENT ACTIVATION, PREVENTIVE BEHAVIORS, AND HEALTH OUTCOMES	VALUE IN HEALTH			English	Meeting Abstract									[Martin, A.] Kantar Hlth, Burlingame, CA USA; [Way, N.] Kantar Hlth, San Mateo, CA USA; [Jaffe, D. H.] Kantar Hlth, Tel Aviv, Israel; [Maculaitis, M.] Kantar Hlth, Red Bank, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB43	S85	S85					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400372
J	Navaratnam, P; Hong, SH; Friedman, HS; Gricar, J				Navaratnam, P.; Hong, S. H.; Friedman, H. S.; Gricar, J.			REAL-WORLD ASSESSMENT OF THE TREATMENT PATTERNS, HEALTHCARE RESOURCE USE, AND SURVIVAL OUTCOMES ASSOCIATED WITH NON-RESECTABLE ADVANCED ESOPHAGEAL CANCERS IN SOUTH KOREA	VALUE IN HEALTH			English	Meeting Abstract									[Navaratnam, P.; Friedman, H. S.] DataMed Solut LLC, New York, NY USA; [Hong, S. H.] Seoul Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, Seoul, South Korea; [Gricar, J.] Bristol Myers Squibb, Lawrenceville, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN154	S48	S48					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400205
J	Nepomuceno, T; Silva, WM; Gomes, SDF; Rodriguez, TFO				Nepomuceno, T.; Silva, W. M.; Gomes, S. D. F.; Rodriguez, T. F. O.			COMPARATIVE NETWORK EFFICIENCY ANALYSIS OF BRAZIL RESPONSE TO COVID-19 AT STATE LEVEL	VALUE IN HEALTH			English	Meeting Abstract									[Nepomuceno, T.] Univ Fed Pernambuco, Jaboatao Das Guararapes, PE, Brazil; [Silva, W. M.; Rodriguez, T. F. O.] Univ Fed Pernambuco, Recife, PE, Brazil; [Gomes, S. D. F.] Univ Fed Alagoas, Penedo, Brazil									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS13	S175	S175					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401023
J	Patel, I; Miller, MK; Hoque, S; Heng, B; Fitzpatrick, C; Attarabeen, O				Patel, I; Miller, M. K.; Hoque, S.; Heng, B.; Fitzpatrick, C.; Attarabeen, O.			KNOWLEDGE ABOUT NOVEL OPIOIDS AND NALAXONE USE ATTITUDES AMONG PHARMD STUDENTS	VALUE IN HEALTH			English	Meeting Abstract									[Patel, I; Miller, M. K.; Hoque, S.; Fitzpatrick, C.; Attarabeen, O.] Marshall Univ, Huntington, WV USA; [Heng, B.] Kings Daughters Med Ctr, Ashland, KY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS102	S191	S191					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401098
J	Punch, D; Davis, JS; Hahn, R; Gill, R; Hsiao, C; Kara, R				Punch, D.; Davis, J. S.; Hahn, R.; Gill, R.; Hsiao, C.; Kara, R.			VALUE OF A COMPREHENSIVE OPHTHALMOLOGY CUSTOM PACK IN A CANADIAN SETTING	VALUE IN HEALTH			English	Meeting Abstract									[Punch, D.] Kensington Eye Inst, Mississauga, ON, Canada; [Davis, J. S.; Hahn, R.] KJT Grp Inc, Honeoye Falls, NY USA; [Gill, R.] Alcon Canada Inc, Mississauga, ON, Canada; [Hsiao, C.; Kara, R.] Alcon Inc, Ft Worth, TX USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS17	S176	S176					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401027
J	Rigg, J; Doyle, OM; McDonogh, N; Leavitt, N; Kreter, B; Vanstraelen, K; Son, A				Rigg, J.; Doyle, O. M.; McDonogh, N.; Leavitt, N.; Kreter, B.; Vanstraelen, K.; Son, A.			FINDING UNDIAGNOSED PATIENTS WITH HEPATITIS C VIRUS: AN APPLICATION OF ARTIFICIAL INTELLIGENCE TO US AMBULATORY ELECTRONIC MEDICAL RECORDS	VALUE IN HEALTH			English	Meeting Abstract									[Rigg, J.; Doyle, O. M.; McDonogh, N.] IQVIA, London, England; [Leavitt, N.] IQVIA, Plymouth Meeting, PA USA; [Kreter, B.; Son, A.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA; [Vanstraelen, K.] Gilead Sci Inc, Uxbridge, Middx, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PPM7	S196	S196					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401119
J	Rosario, BL; Huang, H; Jackson, GP; Kolt, B; Wang, S				Rosario, B. L.; Huang, H.; Jackson, G. P.; Kolt, B.; Wang, S.			DEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH POST TRAUMATIC STRESS DISORDER (PTSD) DURING THE COVID-19 PANDEMIC	VALUE IN HEALTH			English	Meeting Abstract									[Rosario, B. L.; Jackson, G. P.; Kolt, B.; Wang, S.] IBM Watson Hlth, Cambridge, MA USA; [Huang, H.] IBM Watson Hlth, Rochester, MN USA				Huang, Hu/A-8145-2012	Huang, Hu/0000-0002-4384-3804				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH24	S132	S132					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400577
J	Samaksha, PB; Puvvada, RK				Samaksha, P. B.; Puvvada, R. K.			EVALUATION OF SYMPTOMS OF DEPRESSION AMONGST PEOPLE WITH SUBSTANCE USE DURING COVID-19 LOCKDOWN IN INDIA: A CROSS-SECTIONAL STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Samaksha, P. B.] JSS Coll Pharm, Mysuru, India; [Puvvada, R. K.] La Trobe Univ, Melbourne, Vic, Australia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH19	S131	S131					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400573
J	Sharma, D; Deering, K; Sundaram, M; Daly, K; Huang, Q				Sharma, D.; Deering, K.; Sundaram, M.; Daly, K.; Huang, Q.			IMPACT OF TREATMENT AND PATIENT ATTRIBUTES ON ONCOLOGISTS DECISION-MAKING IN FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE UNITED STATES (US)	VALUE IN HEALTH			English	Meeting Abstract									[Sharma, D.; Deering, K.] EPI Q Inc, Oak Brook, IL USA; [Sundaram, M.] Janssen Sci Affairs LLC, N Wales, PA USA; [Daly, K.] Janssen Global Serv LLC, Raritan, NJ USA; [Huang, Q.] Janssen Sci Affairs LLC, Horsham, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN164	S50	S50					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400215
J	Velez, F; Huang, D; Hallock, C; Mody, L				Velez, F.; Huang, D.; Hallock, C.; Mody, L.			BUDGET IMPACT OF RESET-O WITH TREATMENT-AS-USUAL (TAU) VS TAU ALONE FOR THE TREATMENT OF OPIOID USE DISORDER (OUD) OVER 5 YEARS	VALUE IN HEALTH			English	Meeting Abstract									[Velez, F.] Pear Therapeut, Boston, MA USA; [Huang, D.; Hallock, C.; Mody, L.] Xcenda LLC, Palm Harbor, FL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH5	S128	S129					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400561
J	Wang, J; Lang, Y; Kong, L; Zhang, Y; Du, Q; Qiu, Y; Zhou, H				Wang, J.; Lang, Y.; Kong, L.; Zhang, Y.; Du, Q.; Qiu, Y.; Zhou, H.			EFFECTIVENESS AND SAFETY OF TERIFLUNOMIDE IN PATIENTS WITH MULTIPLE SCLEROSIS: A REAL-WORLD STUDY FROM WEST CHINA HOSPITAL, CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Wang, J.; Lang, Y.; Kong, L.; Zhang, Y.; Du, Q.; Qiu, Y.; Zhou, H.] West China Hosp, Chengdu, Peoples R China									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO8	S198	S198					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401130
J	Wilk, N				Wilk, N.			TRANSPARENCY HELPED A SMALL PHARMACEUTICAL COMPANY TO HAVE THE PRICE OF THEIR DRUG WITH FEW MILLION EURO ANNUAL REVENUE IN POLAND PRACTICALLY INCREASED BY 168% BY THE MINISTER OF HEALTH - A CASE STUDY OF PUBLICLY AVAILABLE DOCUMENTS FROM ADMINISTRATIVE PROCEEDINGS ON NOVO-HELISEN DEPOT	VALUE IN HEALTH			English	Meeting Abstract									[Wilk, N.] Fdn Transparency & Predictabil Adm Decis, Krakow, MA, Poland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS25	S217	S217					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401214
J	Wirtz, H; Hepp, Z; McKay, C; Timmons, J; Bloudek, B; Bloudek, L; Galsky, MD				Wirtz, H.; Hepp, Z.; McKay, C.; Timmons, J.; Bloudek, B.; Bloudek, L.; Galsky, M. D.			ESTIMATED PREVALENCE OF TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN CANADA USING SIMULATION MODELING	VALUE IN HEALTH			English	Meeting Abstract									[Wirtz, H.] Seagen Inc, Sammamish, WA USA; [Hepp, Z.] Seagen Inc, Bothell, WA USA; [McKay, C.] Astellas Pharma Inc, Northbrook, IL USA; [Timmons, J.; Bloudek, B.; Bloudek, L.] Curta Inc, Seattle, WA USA; [Galsky, M. D.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN118	S41	S41					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400172
J	Xu, R; Shen, L; Qin, Y; Qin, S; Yin, X; Liu, B; Tanasanvimon, S; Zhou, C; Zhang, W; Zhou, L				Xu, R.; Shen, L.; Qin, Y.; Qin, S.; Yin, X.; Liu, B.; Tanasanvimon, S.; Zhou, C.; Zhang, W.; Zhou, L.			QUALITY-OF-LIFE (QOL) RESULTS FROM THE PHASE 3 RAINBOW-ASIA STUDY OF RAMUCIRUMAB PLUS PACLITAXEL (RAM/PTX) VERSUS PLACEBO PLUS PACLITAXEL (PBO/PTX) IN PATIENTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (AGC)	VALUE IN HEALTH			English	Meeting Abstract									[Xu, R.] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China; [Shen, L.] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China; [Qin, Y.] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Qin, S.] Nanjing Chinese Med Univ, Nanjing Bayi Hosp, Ctr Canc, Nanjing, Peoples R China; [Yin, X.] Hunan Canc Hosp, Changsha, Peoples R China; [Liu, B.] Nanjing Univ, Nanjing Drum Tower Hosp, Sch Med, Affiliated Hosp, Nanjing, Peoples R China; [Tanasanvimon, S.] King Chulalongkorn Mem Hosp, Bangkok, Thailand; [Zhou, C.; Zhang, W.; Zhou, L.] Eli Lilly & Co, Shanghai, Peoples R China									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN13	S21	S21					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400083
J	Yang, H; Kukaswadia, A; Gaudet, V; Sharma, A; Barbeau, M				Yang, H.; Kukaswadia, A.; Gaudet, V; Sharma, A.; Barbeau, M.			SWITCH PATTERNS AMONG PATIENTS CLAIMING ANTIFUNGAL THERAPIES FOR ONYCHOMYCOSIS IN CANADA	VALUE IN HEALTH			English	Meeting Abstract									[Yang, H.; Kukaswadia, A.] IQVIA Solut Canada Inc, Mississauga, ON, Canada; [Gaudet, V; Barbeau, M.] Bausch Hlth Canada Inc, Laval, PQ, Canada; [Sharma, A.] IQVIA Solut Canada Inc, Ottawa, ON, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN61	S117	S117					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400511
J	Zhang, Y; Bian, J; Huo, J; Shuang, Y; Guo, Y; Shao, H				Zhang, Y.; Bian, J.; Huo, J.; Shuang, Y.; Guo, Y.; Shao, H.			COMPARING THE DOWNSTREAM COSTS AND HEALTHCARE UTILIZATION ASSOCIATED WITH THE USE OF LOW-DOSE COMPUTED TOMOGRAPHY (LDCT) IN LUNG CANCER SCREENING IN PATIENTS WITH AND WITHOUT ALZHEIMERA'S DISEASE AND RELATED DEMENTIAS (ADRD)	VALUE IN HEALTH			English	Meeting Abstract									[Zhang, Y.; Bian, J.; Shuang, Y.; Guo, Y.; Shao, H.] Univ Florida, Gainesville, FL USA; [Huo, J.] Bristol Myers Squibb, Princeton, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN84	S35	S35					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400145
J	Zhang, Y; Hsieh, MC; Nauman, E; Callison, K; Tackett, S; Shi, L				Zhang, Y.; Hsieh, M. C.; Nauman, E.; Callison, K.; Tackett, S.; Shi, L.			RISK FACTORS OF TREATMENT DELAY AMONG NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN LOUISIANA	VALUE IN HEALTH			English	Meeting Abstract									[Zhang, Y.] Tulane Univ, Sch Publ Hlth & Trop Med, Metairie, LA USA; [Hsieh, M. C.] Louisiana State Univ, Hlth Sci Ctr New Orleans, New Orleans, LA USA; [Nauman, E.] Louisiana Publ Hlth Inst, New Orleans, LA USA; [Callison, K.; Shi, L.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA; [Tackett, S.] Intuit Surg, Sunnyvale, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN199	S56	S57					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400244
J	Galekop, MMJ; Uyl-de Groot, CA; Redekop, WK				Galekop, Milanne M. J.; Groot, Carin A. Uyl-de; Redekop, W. Ken			A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults	VALUE IN HEALTH			English	Review						nutrition; personalized; cost-effectiveness; systematic review	LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; DIABETES PREVENTION PROGRAM; CRITERIA DECISION-ANALYSIS; HEALTH-CARE DECISIONS; QUALITY-OF-LIFE; ECONOMIC EVALUATIONS; CLINICAL-TRIAL; OLDER-ADULTS; RISK-FACTORS	Objectives: Important links between dietary patterns and diseases have been widely applied to establish nutrition in-terventions. However, knowledge about between-person heterogeneity regarding the benefits of nutrition intervention can be used to personalize the intervention and thereby improve health outcomes and efficiency. We performed a systematic review of cost-effectiveness analyses (CEAs) of interventions with a personalized nutrition (PN) component to assess their methodology and findings. Methods: A systematic search (March 2019) was performed in 5 databases: EMBASE, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google Scholar. CEAs involving interventions in adults with a PN component were included; CEAs focusing on clinical nutrition or undernutrition were excluded. The CHEERS checklist was used to assess the quality of CEAs. Results: We identified 49 eligible studies among 1792 unique records. Substantial variation in methodology was found. Most studies (91%) focused only on psychological concepts of PN such as behavior and preferences. Thirty-four CEAs were trial-based, 13 were modeling studies, and 4 studies were both trial- and model-based. Thirty-two studies used qualityadjusted life year as an outcome measure. Different time horizons, comparators, and modeling assumptions were applied, leading to differences in costs/quality-adjusted life years. Twenty-eight CEAs (49%) concluded that the intervention was cost-effective, and 75% of the incremental cost-utility ratios were cost-effective given a willingness-to-pay threshold of $50 000 per quality-adjusted life year. Conclusions: Interventions with PN components are often evaluated using various types of models. However, most PN interventions have been considered cost-effective. More studies should examine the cost-effectiveness of PN interventions that combine psychological and biological concepts of personalization.	[Galekop, Milanne M. J.; Groot, Carin A. Uyl-de; Redekop, W. Ken] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands		Galekop, MMJ (通讯作者)，Burgemeester Oudlaan 50, NL-3062 PA Rotterdam, Netherlands.	galekop@eshpm.eur.nl			European UnionEuropean Commission [818318]	This work was supported by grant No.818318 from the European Union's Horizon 2020 research and innovation program (project named PREVENTOMICS).	Ackermann RT, 2006, DIABETES CARE, V29, P1237, DOI 10.2337/dc05-1709; Alouki K, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/2159890; Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Bandurska E, 2019, MED SCI MONITOR, V25, P2879, DOI 10.12659/MSM.913358; Befort CA, 2010, EAT BEHAV, V11, P11, DOI 10.1016/j.eatbeh.2009.08.002; Bell CM, 2006, BMJ-BRIT MED J, V332, P699, DOI 10.1136/bmj.38737.607558.80; Biesiekierski JR, 2019, NUTRIENTS, V11, P10; Boyers D, 2015, OBES RES CLIN PRACT, V9, P310, DOI 10.1016/j.orcp.2015.03.001; Bray GA, 1999, DIABETES CARE, V22, P623; Broekhuizen Karen, 2015, BMC Res Notes, V8, P317, DOI 10.1186/s13104-015-1282-x; Bush CL, 2020, J AM COLL NUTR, V39, P5, DOI 10.1080/07315724.2019.1685332; Caro JJ, 2004, DIABETIC MED, V21, P1229, DOI 10.1111/j.1464-5491.2004.01330.x; Celis-Morales C, 2017, INT J EPIDEMIOL, V46, P578, DOI 10.1093/ije/dyw186; Chatterton ML, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5504-8; Corso PS, 2002, MED DECIS MAKING, V22, pS92, DOI 10.1177/027298902237713; Cutler GJ, 2012, BRIT J NUTR, V108, P349, DOI 10.1017/S0007114511005435; Dalziel K, 2007, HEALTH PROMOT INT, V22, P271, DOI 10.1093/heapro/dam027; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; de Toro-Martin J, 2017, NUTRIENTS, V9, P1, DOI DOI 10.3390/nu9080913; Diabet Prevention Program Res Grp, 2003, DIABETES CARE, V26, P2518, DOI 10.2337/diacare.26.9.2518; DPP Res Grp, 2002, DIABETES CARE, V25, P2165; Drummond M, 2016, VALUE HEALTH, V19, pA836, DOI 10.1016/j.jval.2016.08.558; Eddy DM, 2005, ANN INTERN MED, V143, P251, DOI 10.7326/0003-4819-143-4-200508160-00006; Emmons KM, 2005, CANCER EPIDEM BIOMAR, V14, P1453, DOI 10.1158/1055-9965.EPI-04-0620; Eriksson J, 1999, DIABETOLOGIA, V42, P793, DOI 10.1007/s001250051229; Ethgen O, 2016, OSTEOPOROSIS INT, V27, P301, DOI 10.1007/s00198-015-3319-3; Fischer ARH, 2016, EUR J PUBLIC HEALTH, V26, P640, DOI 10.1093/eurpub/ckw045; Flodgren Gerd, 2017, Cochrane Database Syst Rev, V11, pCD000984, DOI 10.1002/14651858.CD000984.pub3; Franz MJ, 1995, J AM DIET ASSOC, P1018; Freijer K, 2014, ISPOR CONNECT, V20, P10; Galani C, 2007, INT J PUBLIC HEALTH, V52, P372, DOI 10.1007/s00038-007-7014-9; Gillespie P, 2017, EUR J HEALTH ECON, V18, P321, DOI 10.1007/s10198-016-0777-2; Glasgow RE, 1997, PATIENT EDUC COUNS, V32, P175, DOI 10.1016/S0738-3991(97)00039-6; Glechner A, 2018, PRIM CARE DIABETES, V12, P393, DOI 10.1016/j.pcd.2018.07.003; Goldfield GS, 2001, INT J OBESITY, V25, P1843, DOI 10.1038/sj.ijo.0801838; Herman PM, 2014, J OCCUP ENVIRON MED, V56, P171, DOI 10.1097/JOM.0000000000000066; Herman WH, 2005, ANN INTERN MED, V142, P323, DOI 10.7326/0003-4819-142-5-200503010-00007; Holt RI, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22650; Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010; Icks A, 2007, DIABETIC MED, V24, P473, DOI 10.1111/j.1464-5491.2007.02108.x; KAPLAN RM, 1987, J GEN INTERN MED, V2, P220, DOI 10.1007/BF02596443; Kaplan RM, 1987, HEALTH PROMOT INT, V2, P331; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEIGH JP, 1992, ARCH INTERN MED, V152, P1201, DOI 10.1001/archinte.152.6.1201; Lenoir-Wijnkoop I, 2011, Br J Nutr, V105, P157, DOI 10.1017/S0007114510003041; Lindgren P, 2003, PREV MED, V36, P403, DOI 10.1016/S0091-7435(02)00060-9; Lindgren P, 2007, INT J TECHNOL ASSESS, V23, P177, DOI 10.1017/S0266462307070286; Livingstone KM, 2015, GENES NUTR, V10; Lorefalt B, 2011, J NUTR HEALTH AGING, V15, P92, DOI 10.1007/s12603-011-0019-3; Marsh K, 2016, VALUE HEALTH, V19, P125, DOI 10.1016/j.jval.2015.12.016; McConnon A, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-206; Milte R, 2016, J REHABIL MED, V48, P378, DOI 10.2340/16501977-2070; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Muir KR, 2009, BMJ-BRIT MED J, V339, P610; Ohlhorst SD, 2013, ADV NUTR, V4, P579, DOI 10.3945/an.113.004176; Olsen J, 2005, INT J TECHNOL ASSESS, V21, P194, DOI 10.1017/S0266462305050269; Ordovas JM, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2173; Organisation for Economic Co-operation and Development, PPPS EXCHANGE RATES; Organisation for Economic Co-operation and Development, INFLATION CPI INDICA, DOI [10.1787/eee82-6e-en, DOI 10.1787/EEE82-6E-EN]; Palmer AJ, 2004, CLIN THER, V26, P304, DOI 10.1016/S0149-2918(04)90029-X; Palmer Andrew J, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P393, DOI 10.1586/14737167.4.4.393; Price RJG, 2006, J HUM NUTR DIET, V19, P139, DOI 10.1111/j.1365-277X.2006.00676.x; Pritchard DA, 1999, J EPIDEMIOL COMMUN H, V53, P311, DOI 10.1136/jech.53.5.311; Ramachandran A, 2007, DIABETES CARE, V30, P2548, DOI 10.2337/dc07-0150; Redman LM, 2017, JMIR MHEALTH UHEALTH, V5, P32, DOI 10.2196/mhealth.8228; Robertson C, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18350; Saha S, 2010, INT J ENV RES PUB HE, V7, P3150, DOI 10.3390/ijerph7083150; Schorling E, 2017, PUBLIC HEALTH NUTR, V20, P1993, DOI 10.1017/S1368980017000593; Schulz DN, 2014, J MED INTERNET RES, V16, P383, DOI 10.2196/jmir.3159; Segal L, 1998, HEALTH PROMOT INT, V13, P197, DOI 10.1093/heapro/13.3.197; Sharma Y, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0736-0; Sherwood NE, 2006, INT J OBESITY, V30, P1565, DOI 10.1038/sj.ijo.0803295; Sikand G, 2000, J AM DIET ASSOC, V100, P218, DOI 10.1016/S0002-8223(00)00066-3; Smith KJ, 2016, PREV MED, V87, P103, DOI 10.1016/j.ypmed.2016.02.036; Speed C, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14520; Steptoe A, 2003, BRIT MED J, V326, P855, DOI 10.1136/bmj.326.7394.855; Sukhanova A, 2009, INT J BEHAV NUTR PHY, V6, DOI 10.1186/1479-5868-6-92; Swinburn BA, 2001, DIABETES CARE, V24, P619, DOI 10.2337/diacare.24.4.619; Tai BWB, 2016, VALUE HEALTH, V19, P903, DOI 10.1016/j.jval.2016.05.010; Thielen FW, 2016, EXPERT REV PHARM OUT, V16, P705, DOI 10.1080/14737167.2016.1246962; Thokala P, 2016, VALUE HEALTH, V19, P1, DOI 10.1016/j.jval.2015.12.003; Toobert DJ, 2007, INT J BEHAV NUTR PHY, V4, DOI 10.1186/1479-5868-4-1; Tremmel M, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040435; Troyer JL, 2010, J AM DIET ASSOC, V110, P1840, DOI 10.1016/j.jada.2010.09.013; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; van der Pols-Vijlbrief R, 2017, CLIN NUTR, V36, P1498, DOI 10.1016/j.clnu.2016.09.030; van Dongen JM, 2012, SCAND J WORK ENV HEA, V38, P393, DOI 10.5271/sjweh.3275; van Mastrigt GAPG, 2016, EXPERT REV PHARM OUT, V16, P689, DOI 10.1080/14737167.2016.1246960; van Rijckevorsel-Scheele J, 2019, CLIN INTERV AGING, V14, P643, DOI 10.2147/CIA.S190425; Walsh TS, 2015, JAMA INTERN MED, V175, P901, DOI 10.1001/jamainternmed.2015.0822; Walters K, 2017, HEALTH TECHNOL ASSES, V21, DOI 10.3310/hta21730; Wang DD, 2018, LANCET DIABETES ENDO, V6, P416, DOI 10.1016/S2213-8587(18)30037-8; Whigham L, 2015, J HUM NUTR DIET, V28, P687, DOI 10.1111/jhn.12318; WHO, OB OV; Wijnen BFM, 2016, EXPERT REV PHARM OUT, V16, P723, DOI 10.1080/14737167.2016.1246961; Wikipedia, COHENS KAPPA; Wyers CE, 2013, OSTEOPOROSIS INT, V24, P151, DOI 10.1007/s00198-012-2009-7; Wyers CE, 2018, J GERONTOL A-BIOL, V73, P1429, DOI 10.1093/gerona/gly030; Wylie-Rosett J, 2001, J AM DIET ASSOC, V101, P1155, DOI 10.1016/S0002-8223(01)00284-X; Wylie-Rosett J, 2006, CURR OPIN LIPIDOL, V17, P37, DOI 10.1097/01.mol.0000203890.27267.eb; XE Currency Converter, USD US DOLLAR; Zimmet PZ, 2014, LANCET DIABETES ENDO, V2, P56, DOI 10.1016/S2213-8587(13)70112-8; Zwaap J, 2015, COST EFFECTIVENSS PR	103	5	5	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAR	2021	24	3					325	335		10.1016/j.jval.2020.12.006		FEB 2021	11	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QM9NG	33641765	hybrid, Green Published			2022-04-28	WOS:000622099500003
J	Koldehoff, A; Danner, M; Civello, D; Rhiem, K; Stock, S; Muller, D				Koldehoff, Andreas; Danner, Marion; Civello, Daniele; Rhiem, Kerstin; Stock, Stephanie; Mueller, Dirk			Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review	VALUE IN HEALTH			English	Review						breast cancer; cost-effectiveness; genetic testing; ovarian cancer	HEREDITARY BREAST; WOMEN; HEALTH; BRCA1; RISK; CARRIERS; SURGERY; MODEL	Background: Targeted genetic testing is a tool to identify women at increased risk of gynaecological cancer. Objective: This systematic review evaluates the results and quality of cost-effectiveness modeling studies that assessed targeted genetic-based screen-and-treat strategies to prevent breast and ovarian cancer. Methods: Using MEDLINE and databases of the Centre for Reviews and Dissemination, we searched for health economic modeling evaluations of targeted genetic-based screen-and-treat strategies to prevent inheritable breast and ovarian cancer (until August 2020). The incremental cost-effectiveness ratios (ICERs) were compared. Methodological variations were addressed by evaluating the model conceptualizations, the modeling techniques, parameter estimation and uncertainty, and transparency and validation of the models. Additionally, the reporting quality of each study was assessed. Results: Eighteen studies met our inclusion criteria. From a payer perspective, the ICERs of (1) BRCA screening for high-risk women without cancer ranged from dominating the no test strategy to an ICER of $21 700/quality-adjusted life years (QALY). In studies that evaluated (2) BRCA cascade screening (ie, screening of women with cancer plus their unaffected relatives) compared with no test, the ICERs were between $6500/QALY and $50 200/QALY. Compared with BRCA alone, (3) multigene testing in women without cancer had an ICER of $51 800/QALY (one study), while for (4) multigene-cascade screening the ICERs were $15 600/QALY, $56.500/QALY, and $69 600/QALY for women in the United Kingdom, Norway, and the United States, respectively (2 studies). More recently published studies showed a higher methodological and reporting quality. Conclusions: Targeted BRCA or multiple gene screening is likely to be cost-effective. Methodological variations could be decreased by the development of a reference model, which may serve as a tool for validation of present and future cost-effectiveness models.	[Koldehoff, Andreas] Ruhr Univ Bochum RUB, Dept Anaesthesiol, Bochum, Germany; [Danner, Marion] Univ Hosp Schleswig Holstein, SHARE TO CARE Team, Dept Gen Pediat, Kiel, Germany; [Civello, Daniele; Stock, Stephanie; Mueller, Dirk] Univ Hosp Cologne AoR, Cologne Inst Hlth Econ & Clin Epidemiol, Gleueler Str 176-178, D-50935 Cologne, Germany; [Rhiem, Kerstin] Fac Med, Ctr Integrated Oncol CIO, Ctr Familial Breast & Ovarian Canc, Cologne, Germany; [Rhiem, Kerstin] Univ Hosp Cologne AoR, Cologne, Germany		Muller, D (通讯作者)，Univ Hosp Cologne AoR, Cologne Inst Hlth Econ & Clin Epidemiol, Gleueler Str 176-178, D-50935 Cologne, Germany.	dirk.mueller@uk-koeln.de					American Cancer Society, BREAST CANC RISK FAC; Asphaug L, 2019, MDM POLICY PRACT, V4; Balmana J, 2004, INT J CANCER, V112, P647, DOI 10.1002/ijc.20458; Breheny N, 2005, GENOMICS SOC POLICY, V1, P67; Caro JJ, 2012, VALUE HEALTH, V15, P796, DOI 10.1016/j.jval.2012.06.012; D'Andrea E, 2016, GENET MED, V18, P1171, DOI 10.1038/gim.2016.29; Ramos MCD, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052000643, 10.11606/s1518-8787.2018052000643]; Domchek SM, 2010, JAMA-J AM MED ASSOC, V304, P967, DOI 10.1001/jama.2010.1237; Eccleston A, 2017, VALUE HEALTH, V20, P567, DOI 10.1016/j.jval.2017.01.004; Eddy DM, 2012, MED DECIS MAKING, V32, P733, DOI 10.1177/0272989X12454579; European Commission, INC MORT 2002; Fischer C, 2013, J MED GENET, V50, P360, DOI 10.1136/jmedgenet-2012-101415; German Consortium of Familial Breast and Ovarian Cancer, MOL DIAGN COST COV; Holland ML, 2009, VALUE HEALTH, V12, P207, DOI 10.1111/j.1524-4733.2008.00418.x; Hurry M, 2020, INT J TECHNOL ASSESS, V36, P104, DOI 10.1017/S0266462319003519; Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010; Kohler JN, 2017, EUR J HUM GENET, V25, P662, DOI 10.1038/ejhg.2017.10; Kwon JS, 2019, GYNECOL ONCOL, V152, P459, DOI 10.1016/j.ygyno.2018.10.014; Kwon JS, 2010, J CLIN ONCOL, V28, P4214, DOI 10.1200/JCO.2010.28.0719; Li YH, 2017, VALUE HEALTH, V20, P547, DOI 10.1016/j.jval.2017.01.006; Luengo-Fernandez R, 2013, LANCET ONCOL, V14, P1165, DOI 10.1016/S1470-2045(13)70442-X; Metcalfe K, 2019, BRIT J CANCER, V121, P15, DOI 10.1038/s41416-019-0446-1; Moya-Alarcon C, 2019, CLIN TRANSL ONCOL, V21, P1076, DOI 10.1007/s12094-018-02026-2; Muller D, 2019, EUR J HEALTH ECON, V20, P739, DOI 10.1007/s10198-019-01038-1; Muller, APPL HLTH EC HLTH PO; National Health Service (NHS), PRED GEN TESTS CANC; National Institure for Clinical Excellence (NICE), 2015, FAM BREAST CANC CLAS; Norum J, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2018-000328; Park J, 2019, INQUIRY-J HEALTH CAR, V56, DOI 10.1177/0046958019880696; Pouwels XGLV, 2017, BREAST CANCER RES TR, V165, P485, DOI 10.1007/s10549-017-4374-6; PRISMA, TRANSP REP SYST REV; Puhan MA, 2007, J CLIN EPIDEMIOL, V60, P1029, DOI 10.1016/j.jclinepi.2007.03.001; Regier DA, 2018, VALUE HEALTH, V21, P1043, DOI 10.1016/j.jval.2018.06.010; Shemilt I, 2010, EVID POLICY, V6, P51, DOI 10.1332/174426410X482999; Sun L, 2019, JAMA ONCOL, V5, P1718, DOI 10.1001/jamaoncol.2019.3323; Tengs T.O., 2000, DIS MANAG CLIN OUTCO, V2, P15; Tuffaha HW, 2018, GENET MED, V20, P985, DOI 10.1038/gim.2017.231; United Healthcare, GEN TEST HER CANC PO; US Department of Health and Human Services. National Institutes of Health, CANC STAT FACTS FEM; Wainberg S, 2004, CANCER EPIDEM BIOMAR, V13, P1989; WHO-World Health Organization. WHO Commission on Macroeconomics and Health, 2001, MACROECONOMICS HLTH; Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017; World Health Organization, BREAST CANC PREV CON	43	3	3	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	FEB	2021	24	2					303	312		10.1016/j.jval.2020.09.016		JAN 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QJ1VI	33518037	Bronze			2022-04-28	WOS:000619478100018
J	Shao, H; Laxy, M; Gregg, EW; Albright, A; Zhang, P				Shao, Hui; Laxy, Michael; Gregg, Edward W.; Albright, Ann; Zhang, Ping			Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes	VALUE IN HEALTH			English	Article						cost-effectiveness; diabetes; glycemic control; microsimulation		Objectives: This study aims to estimate the national impact and cost-effectiveness of the 2018 American College of Physicians (ACP) guidance statements compared to the status quo. Methods: Survey data from the 2011-2016 National Health and Nutrition Examination were used to generate a national representative sample of individuals with diagnosed type 2 diabetes in the United States. Individuals with A1c <6.5% on antidiabetic medications are recommended to deintensify their A1c level to 7.0% to 8.0% (group 1); individuals with A1c 6.5% to 8.0% and a life expectancy of <10 years are recommended to deintensify their A1c level >8.0% (group 2); and individuals with A1c >8.0% and a life expectancy of >10 years are recommended to intensify their A1c level to 7.0% to 8.0% (group 3). We used a Markov-based simulation model to evaluate the lifetime cost-effectiveness of following the ACP recommended A1c level. Results: 14.41 million (58.1%) persons with diagnosed type 2 diabetes would be affected by the new guidance statements. Treatment deintensification would lead to a saving of $363 600 per quality-adjusted life-year (QALY) lost for group 1 and a saving of $118 300 per QALY lost for group 2. Intensifying treatment for group 3 would lead to an additional cost of $44 600 per QALY gain. Nationally, the implementation of the guidance would add 3.2 million life-years and 1.1 million QALYs and reduce healthcare costs by $47.7 billion compared to the status quo. Conclusions: Implementing the new ACP guidance statements would affect a large number of persons with type 2 diabetes nationally. The new guidance is cost-effective.	[Shao, Hui; Laxy, Michael; Gregg, Edward W.; Albright, Ann; Zhang, Ping] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA; [Shao, Hui] Univ Florida, Coll Pharm, Dept Pharmaceut Outcomes & Policy, Gainesville, FL USA; [Laxy, Michael] Helmholtz Zentrum Munchen, Inst Hlth Econ & Hlth Care Management, Munich, Germany; [Gregg, Edward W.] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England		Shao, H (通讯作者)，Coll Pharm, Dept Pharmaceut Outcomes & Policy, 1225 Ctr Dr, Gainesville, FL 32610 USA.	hui.shao@cop.ufl.edu					American Diabetes Association, 2015, Clin Diabetes, V33, P97, DOI 10.2337/diaclin.33.2.97; Centers for Disease Control and Prevention, 2012, NAT HLTH INT SURV; Centers for Disease Control and Prevention, 2020, NATL DIABETES STAT R; Chamberlain JJ, 2016, ANN INTERN MED, V164, P542, DOI 10.7326/M15-3016; Coffey JT, 2002, DIABETES CARE, V25, P2238, DOI 10.2337/diacare.25.12.2238; Dieleman JL, 2016, JAMA-J AM MED ASSOC, V316, P2627, DOI 10.1001/jama.2016.16885; Flavin P, DIAGNOSIS MANAGEMENT; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Gerstein HC, 2011, NEW ENGL J MED, V364, P818, DOI 10.1056/NEJMoa1006524; Hayward RA, 2015, NEW ENGL J MED, V372, P2197, DOI 10.1056/NEJMoa1414266; Herman WH, 2005, ANN INTERN MED, V142, P323, DOI 10.7326/0003-4819-142-5-200503010-00007; Herman WH, 2012, DIABETES CARE, V35, P723, DOI 10.2337/dc11-1468; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; Hoerger TJ, 2009, VALIDATION CDC RTI D; Holman RR, 2017, NEW ENGL J MED, V377, P1228, DOI 10.1056/NEJMoa1612917; Husereau Don, 2013, Cost Eff Resour Alloc, V11, P6, DOI 10.1186/1478-7547-11-6; Ismail-Beigi F, 2010, LANCET, V376, P419, DOI 10.1016/S0140-6736(10)60576-4; Kirkman MS, 2012, DIABETES CARE, V35, P2650, DOI 10.2337/dc12-1801; Laiteerapong N, 2018, ANN INTERN MED, V168, P170, DOI 10.7326/M17-0537; Leal J, 2009, EUR HEART J, V30, P834, DOI 10.1093/eurheartj/ehn567; Lin J, 2017, DIABETES CARE; Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827; McGuire H, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1575; Menke A, 2013, EPIDEMIOLOGY, V24, P773, DOI 10.1097/EDE.0b013e31829ef01a; Miller ME, 2014, DIABETES CARE, V37, P634, DOI 10.2337/dc13-1545; National Institute for Health and Care Excellence, TYPE 2 DIABETES ADUL; Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158; Palmer AJ, 2018, VALUE HEALTH, V21, P724, DOI 10.1016/j.jval.2018.02.002; Qaseem A, 2018, ANN INTERN MED, V168, P569, DOI 10.7326/M17-0939; Reaven PD, 2019, NEW ENGL J MED, V380, P2215, DOI 10.1056/NEJMoa1806802; Riddle MC, 2010, DIABETES CARE, V33, P983, DOI 10.2337/dc09-1278; Shao H, 2019, DIABETES CARE, V42, P2136, DOI 10.2337/dc19-0381; Shao H, 2019, PHARMACOECONOMICS, V37, P921, DOI 10.1007/s40273-019-00775-8; Stevens RJ, 2001, CLIN SCI, V101, P671, DOI 10.1042/CS20000335; The Management of Type 2 Diabetes Mellitus in Primary Care Work Group, VA DOD CLIN PRACTICE; United States Census Bureau, POPULATION STAT 2017; Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI 10.1056/NEJMoa1812389; Zhang B, 2011, J CLIN OUTCOMES MANA, V18, P455; Zhuo XH, 2013, AM J PREV MED, V45, P253, DOI 10.1016/j.amepre.2013.04.017; Zinman B, 2015, NEW ENGL J MED, V373, P2117, DOI 10.1056/NEJMoa1504720; Zoungas S, 2009, DIABETES CARE, V32, P2068, DOI 10.2337/dc09-0959	41	0	0	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	FEB	2021	24	2					227	235		10.1016/j.jval.2020.09.010		JAN 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QJ1VI	33518029	Bronze			2022-04-28	WOS:000619478100010
J	Degeling, K; Corcoran, NM; Pereira-Salgado, A; Hamid, AA; Siva, S; IJzerman, MJ				Degeling, Koen; Corcoran, Niall M.; Pereira-Salgado, Amanda; Hamid, Anis A.; Siva, Shankar; IJzerman, Maarten J.			Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer	VALUE IN HEALTH			English	Article						active monitoring; active surveillance; cost-effectiveness; cost-utility; discrete-event simulation; health economics; localized prostate cancer; modeling; radiation therapy; radical prostatectomy; radiotherapy; simulation	DISCRETE-EVENT SIMULATION	Objectives: To estimate the lifetime health and economic outcomes of selecting active surveillance (AS), radical prostatectomy (RP), or radiation therapy (RT) as initial management for low-or favorable-risk localized prostate cancer. Methods: A discrete-event simulation model was developed using evidence from published randomized trials. Health outcomes were measured in life-years and quality-adjusted life-years (QALYs). Costs were included from a public payer perspective in Australian dollars. Outcomes were discounted at 5% over a lifetime horizon. Probabilistic and scenario analyses quantified parameter and structural uncertainty. Results: A total of 60% of patients in the AS arm eventually received radical treatment (surgery or radiotherapy) compared with 90% for RP and 91% for RT. Although AS resulted in fewer treatment-related complications, it led to increased clinical progression (AS 40.7%, RP 17.6%, RT 19.9%) and metastatic disease (AS 13.4%, RP 6.1%, RT 7.0%). QALYs were 10.88 for AS, 11.10 for RP, and 11.13 for RT. Total costs were A$17 912 for AS, A$15 609 for RP, and A$15 118 for RT. At a willingness to pay of A$20 000/QALY, RT had a 61.4% chance of being cost-effective compared to 38.5% for RP and 0.1% for AS. Conclusions: Although AS resulted in fewer and delayed treatment-related complications, it was not found to be a cost-effective strategy for favorable-risk localized prostate cancer over a lifetime horizon because of an increase in the number of patients developing metastatic disease. RT was the dominant strategy yielding higher QALYs at lower cost although differences compared with RP were small.	[Degeling, Koen; Pereira-Salgado, Amanda; IJzerman, Maarten J.] Univ Melbourne, Canc Hlth Serv Res, Ctr Canc Res Fac Med, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia; [Degeling, Koen; Pereira-Salgado, Amanda; IJzerman, Maarten J.] Univ Melbourne, Canc Hlth Serv Res, Melbourne Sch Populat & Global Hlth, Ctr Hlth Policy,Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia; [Corcoran, Niall M.; Hamid, Anis A.] Univ Melbourne, Dept Surg, Melbourne, Vic, Australia; [Siva, Shankar] Univ Melbourne, Sir Peter Mac Callum Dept Oncol, Melbourne, Vic, Australia; [Corcoran, Niall M.] Frankston Hosp, Dept Urol, Frankston, Australia; [Corcoran, Niall M.] Royal Melbourne Hosp, Div Urol, Melbourne, Vic, Australia; [Siva, Shankar] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia; [IJzerman, Maarten J.] Peter MacCallum Canc Ctr, Dept Canc Res, Melbourne, Vic, Australia		Degeling, K (通讯作者)，Univ Melbourne, Canc Hlth Serv Res, Ctr Canc Res UMCCR, Level 10,305,Grattan St, Melbourne, Vic 3000, Australia.	koen.degeling@unimelb.edu.au	IJzerman, Maarten/Q-8963-2016	IJzerman, Maarten/0000-0001-5788-5805	Prostate Cancer Research Alliance; Movember Foundation; Australian GovernmentAustralian GovernmentCGIAR	This work was part of the PRostatE CancEr Prognosis and Treatment (PRECEPT) program funded by the Prostate Cancer Research Alliance, which is a joint initiative between the Movember Foundation and the Australian Government.	Basto M, 2016, BJU INT, V117, P930, DOI 10.1111/bju.13317; Caro JJ, 2010, VALUE HEALTH, V13, P1056, DOI 10.1111/j.1524-4733.2010.00775.x; Degeling K, 2019, MED DECIS MAKING, V39, P57, DOI 10.1177/0272989X18814770; Degeling K, 2018, CANCER EPIDEMIOL, V57, P60, DOI 10.1016/j.canep.2018.09.008; Degeling K, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0437-y; Diels J, 2015, QUAL LIFE RES, V24, P591, DOI 10.1007/s11136-014-0794-5; Gordon LG, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2017.10.024; Gravis G, 2018, EUR UROL, V73, P847, DOI 10.1016/j.eururo.2018.02.001; Guyot P, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-9; Hamdy FC, 2020, HEALTH TECHNOL ASSES, V24, P1, DOI 10.3310/hta24370; Karnon J, 2012, VALUE HEALTH, V15, P821, DOI 10.1016/j.jval.2012.04.013; Lane A, 2016, BJU INT, V118, P869, DOI 10.1111/bju.13582; Magnus A, 2019, MDM POLICY PRACT, V4; Maoui M, 2021, DIAGN INTERV IMAG, V102, P93, DOI 10.1016/j.diii.2020.05.007; Morgan SC, 2018, J CLIN ONCOL, V36, P3411, DOI 10.1200/JCO.18.01097; Mottet N, 2021, EUR UROL, V79, P243, DOI 10.1016/j.eururo.2020.09.042; Noble SM, 2020, BRIT J CANCER, V123, P1063, DOI 10.1038/s41416-020-0978-4; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Sanda MG, 2018, J UROLOGY, V199, P683, DOI 10.1016/j.juro.2017.11.095; Sanghera S, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07276-4; Sharma V, 2019, J UROLOGY, V202, P966, DOI 10.1097/JU.0000000000000345; Thomsen FB, 2014, J SURG ONCOL, V109, P830, DOI 10.1002/jso.23584; Watson E, 2016, BJU INT, V117, pE10, DOI 10.1111/bju.13122	23	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	DEC	2021	24	12					1737	1745		10.1016/j.jval.2021.06.004		NOV 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	XC7VG	34838271	hybrid, Green Published			2022-04-28	WOS:000722217200004
J	Caro, JJ; Moller, J; Santhirapala, V; Gill, H; Johnston, J; El-Boghdadly, K; Santhirapala, R; Kelly, P; McGuire, A				Caro, J. Jaime; Moller, Jorgen; Santhirapala, Vatshalan; Gill, Harpreet; Johnston, Jessica; El-Boghdadly, Kariem; Santhirapala, Ramai; Kelly, Paul; McGuire, Alistair			Predicting Hospital Resource Use During COVID-19 Surges: A Simple but Flexible Discretely Integrated Condition Event Simulation of Individual Patient-Hospital Trajectories	VALUE IN HEALTH			English	Article						capacity; COVID-19; hospital resources; individual simulation; patient trajectories; DICE	DICE SIMULATION; VALIDATION; DEATHS; DEMAND; UK	Objectives: To assist with planning hospital resources, including critical care (CC) beds, for managing patients with COVID-19. Methods: An individual simulation was implemented in Microsoft Excel using a discretely integrated condition event simulation. Expected daily cases presented to the emergency department were modeled in terms of transitions to and from ward and CC and to discharge or death. The duration of stay in each location was selected from trajectory-specific distributions. Daily ward and CC bed occupancy and the number of discharges according to care needs were forecast for the period of interest. Face validity was ascertained by local experts and, for the case study, by comparing forecasts with actual data. Results: To illustrate the use of the model, a case study was developed for Guy's and St Thomas' Trust. They provided inputs for January 2020 to early April 2020, and local observed case numbers were fit to provide estimates of emergency department arrivals. A peak demand of 467 ward and 135 CC beds was forecast, with diminishing numbers through July. The model tended to predict higher occupancy in Level 1 than what was eventually observed, but the timing of peaks was quite close, especially for CC, where the model predicted at least 120 beds would be occupied from April 9, 2020, to April 17, 2020, compared with April 7, 2020, to April 19, 2020, in reality. The care needs on discharge varied greatly from day to day. Conclusions: The DICE simulation of hospital trajectories of patients with COVID-19 provides forecasts of resources needed with only a few local inputs. This should help planners understand their expected resource needs.	[Caro, J. Jaime; Gill, Harpreet; McGuire, Alistair] London Sch Econ & Polit Sci, Dept Hlth Policy, London, England; [Caro, J. Jaime; Moller, Jorgen] Evidera, London, England; [Santhirapala, Vatshalan] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA 02115 USA; [Gill, Harpreet; Johnston, Jessica; El-Boghdadly, Kariem; Santhirapala, Ramai; Kelly, Paul] Guys & St Thomas NHS Fdn Trust, Dept Theatres Anaesthesia & Perioperat Care, London, England		Caro, JJ (通讯作者)，39 Bypass Rd, Lincoln, MA 01773 USA.	jaime.caro@evidera.com	El-Boghdadly, Kariem/P-5011-2017	El-Boghdadly, Kariem/0000-0002-9912-717X	European UnionEuropean Commission [779312]	This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 779312. The views expressed in this article are those of the authors and not necessarily those of the European Commission.	Abdollahi E, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01705-8; Amar P, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9090299; Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5; Augustin M, 2020, EUROSURVEILLANCE, V25, P6, DOI 10.2807/1560-7917.ES.2020.25.21.2000531; Badr HS, 2020, LANCET INFECT DIS, V20, P1247, DOI 10.1016/S1473-3099(20)30553-3; Bertozzi AL, 2020, P NATL ACAD SCI USA, V117, P16732, DOI 10.1073/pnas.2006520117; Booton RD, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-041536; Briggs AH, 2012, VALUE HEALTH, V15, P835, DOI 10.1016/j.jval.2012.04.014; Caro JJ, 2020, VALUE HEALTH, V23, P1049, DOI 10.1016/j.jval.2020.03.009; Caro JJ, 2016, PHARMACOECONOMICS, V34, P665, DOI 10.1007/s40273-016-0394-z; Caro JJ, 2005, PHARMACOECONOMICS, V23, P323, DOI 10.2165/00019053-200523040-00003; Chowdhury R, 2020, EUR J EPIDEMIOL, V35, P389, DOI 10.1007/s10654-020-00649-w; Clark A, 2020, LANCET GLOB HEALTH, V8, P1003, DOI 10.1016/S2214-109X(20)30264-3; Currie CSM, 2020, J SIMUL, V14, P83, DOI 10.1080/17477778.2020.1751570; Dagpunar JS, 2020, INFECT DIS MODEL, V5, P525, DOI 10.1016/j.idm.2020.07.002; Davies NG, 2020, LANCET PUBLIC HEALTH, V5, pE375, DOI 10.1016/S2468-2667(20)30133-X; Deng Q, 2020, J MED INTERNET RES, V22, DOI 10.2196/21173; Eddy DM, 2012, VALUE HEALTH, V15, P843, DOI 10.1016/j.jval.2012.04.012; Edejer TTT, 2020, LANCET GLOB HEALTH, V8, pE1372, DOI 10.1016/S2214-109X(20)30383-1; Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7; Ghabri S, 2020, VALUE HEALTH, V23, P461, DOI 10.1016/j.jval.2019.12.003; Giannakeas V, 2020, ANN INTERN MED, V173, P407, DOI 10.7326/M20-1169; Hartono P, 2020, INFORM MED UNLOCKED, V20; Hick JL, 2014, CHEST, V146, pE1S, DOI 10.1378/chest.14-0733; Hilton J, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008031; Hoertel N, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1001-6; Holmdahl I, 2020, NEW ENGL J MED, V383, P303, DOI 10.1056/NEJMp2016822; Jarvis CI, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01597-8; Jewell NP, 2020, JAMA-J AM MED ASSOC, V323, P1893, DOI 10.1001/jama.2020.6585; Jewell NP, 2020, ANN INTERN MED, V173, P226, DOI 10.7326/M20-1565; Jones JH, 2020, AM J HUM BIOL, V32, DOI 10.1002/ajhb.23512; Kaxiras E, 2020, J MED INTERNET RES, V22, DOI 10.2196/20912; Kennedy DM, 2020, J CLIN VIROL, V128, DOI [10.1016/j.jcv.2020.104440, DOI 10.1016/J.JCV.2020.104440]; Killeen GF, 2020, INFECT DIS MODEL, V5, P442, DOI 10.1016/j.idm.2020.06.006; Kucharski AJ, 2020, LANCET INFECT DIS, V20, P1151, DOI 10.1016/S1473-3099(20)30457-6; Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Lee C, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110090; Lewnard JA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1923; Liu Y, 2020, LANCET, V395, pE47, DOI 10.1016/S0140-6736(20)30462-1; Mahmood I, 2020, J SIMUL, DOI 10.1080/17477778.2020.1800422; Mangiarotti S, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000990; Manrique-Abril F. G., 2020, Revista de Salud Publica, V22, DOI 10.15446/rsap.V22.85977; Meehan MT, 2020, PAEDIATR RESPIR REV, V35, P64, DOI 10.1016/j.prrv.2020.06.014; Moghadas SM, 2020, P NATL ACAD SCI USA, V117, P9122, DOI 10.1073/pnas.2004064117; Moller J, 2019, PHARMACOECONOMICS, V37, P1341, DOI 10.1007/s40273-019-00840-2; Moller J, 2017, PHARMACOECONOMICS, V35, P1103, DOI 10.1007/s40273-017-0534-0; Overton CE, 2020, INFECT DIS MODEL, V5, P409, DOI 10.1016/j.idm.2020.06.008; Pacheco-Barrios K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239175; Pencina MJ, 2020, NEW ENGL J MED, V382, P1583, DOI 10.1056/NEJMp2000589; Perc M, 2020, FRONT PHYS-LAUSANNE, V8, DOI 10.3389/fphy.2020.00127; Perkins TA, 2020, P NATL ACAD SCI USA, V117, P22597, DOI 10.1073/pnas.2005476117; Poletto C, 2020, LANCET DIGIT HEALTH, V2, pE498, DOI 10.1016/S2589-7500(20)30196-5; Rainisch G, 2020, INT J INFECT DIS, V96, P376, DOI 10.1016/j.ijid.2020.05.043; Roques L, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00274; Shan Bai, 2020, International Journal of Simulation and Process Modelling, V15, P268; Shoukat A, 2020, CAN MED ASSOC J, V192, pE489, DOI 10.1503/cmaj.200457; Silva PCL, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110088; Soubeyrand S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238410; Sperrin M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1464; Struben J, 2020, SYST DYNAM REV, V36, P247, DOI 10.1002/sdr.1660; Stutt ROJH, 2020, P ROY SOC A-MATH PHY, V476, DOI 10.1098/rspa.2020.0376; Tuite AR, 2020, CAN MED ASSOC J, V192, pE497, DOI 10.1503/cmaj.200476; Upadhyay S, 2020, J HLTH CARE FINANCE, V46, P53; Vespignani A, 2020, NAT REV PHYS, V2, P279, DOI 10.1038/s42254-020-0178-4; Wang PP, 2020, CHAOS SOLITON FRACT, V140, DOI 10.1016/j.chaos.2020.110214; Wang PP, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110058; Weissman GE, 2020, ANN INTERN MED, V173, P21, DOI 10.7326/M20-1260; Wells CR, 2020, LANCET INFECT DIS, V20, P1123, DOI 10.1016/S1473-3099(20)30315-7; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Wong JB, 2020, ANN INTERN MED, V173, P396, DOI 10.7326/M20-1956; Wood RM, 2020, HEALTH CARE MANAG SC, V23, P315, DOI 10.1007/s10729-020-09511-7; Zhao ZY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00735-x	73	1	1	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	NOV	2021	24	11					1570	1577		10.1016/j.jval.2021.05.023		OCT 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	XF1GI	34711356	Green Published, Bronze			2022-04-28	WOS:000723825200003
J	Fanning, L; Woods, E; Hornung, CJ; Perrett, KP; Tang, MMLK; Dalziel, K				Fanning, Laura; Woods, Ekaterina; Hornung, Catherine J.; Perrett, Kirsten P.; Tang, Mimi L. K.; Dalziel, Kim			Cost-Effectiveness of Food Allergy Interventions in Children: A Systematic Review of Economic Evaluations	VALUE IN HEALTH			English	Review						cost-effectiveness; cow's milk allergy; egg allergy; food allergy; peanut allergy; pediatric	COWS MILK ALLERGY; HYDROLYZED CASEIN FORMULA; LACTOBACILLUS-RHAMNOSUS GG; AMINO-ACID FORMULA; PEANUT ORAL IMMUNOTHERAPY; MANAGING INFANTS; PREVENTION; MANAGEMENT; DIAGNOSIS	Objectives: To identify published economic evaluations of interventions aimed at preventing, diagnosing, or treating food allergies in children. Methods: We examined economic evaluations published from 2000 to 2019. Data analyzed included: food allergy type, study population/setting, intervention/comparator, and economic evaluation details. Quality assessment used reporting and economic modeling checklists. Two reviewers simultaneously undertook article screening, data extraction, and quality assessment. Results: 17 studies were included: 8 peanut allergy (PA) studies, 8 cow's milk allergy (CMA) studies, and 1 egg allergy (EA) study. All PA studies reported incremental costs per quality-adjusted life-year gained for diagnostic strategies, management pathways for peanut exposure, and immunotherapies. Immunotherapies rendered inconsistent cost-effectiveness results. CMA studies reported costs per symptom-free day or probability of developing CMA tolerance. Cost-effectiveness of extensively hydrolyzed casein formula for CMA treatment was consistently demonstrated. Early introduction of cooked egg in first year of life dominated all EA prevention strategies. Quality assessment showed average noncompliance for 3.5 items/study (range 0-11) for modeling methods and 3.4 items/study (range 0-8) for reporting quality. Key quality concerns included limited justification for model choice, evidence base for model parameters, source of utility values, and representation of uncertainty. Conclusion: Recent cost-effectiveness literature of interventions in PA, CMA, and EA is limited and diverse. Interventions for diagnosis and treatment of CMA and prevention of EA were generally cost-effective; however, results for PA were variable and dependent on effectiveness and utility values used. There is a need to expand economic evaluation of interventions for childhood food allergy and to improve methods and reporting.	[Fanning, Laura; Woods, Ekaterina; Dalziel, Kim] Univ Melbourne, Ctr Hlth Policy, Melbourne Sch Global & Populat Hlth, Hlth Econ Grp, Level 4,207 Bouverie St, Melbourne, Vic, Australia; [Fanning, Laura; Woods, Ekaterina; Hornung, Catherine J.; Perrett, Kirsten P.; Tang, Mimi L. K.; Dalziel, Kim] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Fanning, Laura] Monash Univ, Ctr Hlth Econ, Monash Business Sch, Melbourne, Vic, Australia; [Perrett, Kirsten P.; Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia; [Perrett, Kirsten P.; Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia		Dalziel, K (通讯作者)，Univ Melbourne, Ctr Hlth Policy, Melbourne Sch Global & Populat Hlth, Hlth Econ Grp, Level 4,207 Bouverie St, Melbourne, Vic, Australia.	kim.dalziel@unimelb.edu.au	Perrett, Kirsten/P-8813-2019	Perrett, Kirsten/0000-0002-5683-996X; Tang, Mimi/0000-0002-3839-5293	Australian National Health and Medical Research Council, Centre for Research ExcellenceNational Health and Medical Research Council (NHMRC) of Australia [APP1134812]	This work was supported by an Australian National Health and Medical Research Council, Centre for Research Excellence grant number APP1134812.	Aimmune Therapeutics, AR101 PEAN ALL; Allergy and Anaphylaxis Australia, FOOD ALL QUAL LIF ST; Asaria M, 2018, ALLERGY, V73, P269, DOI 10.1111/all.13254; Asthma and Allergy Foundation of America, MY LIF FOOD ALL PAR; Australasian Society of Clinical Immunology and Allergy, SCIA ACT PLAN 1 AID; Australasian Society of Clinical Immunology and Allergy, SCIA GUID INF FEED A; Canani RB, 2013, J PEDIATR-US, V163, P771, DOI 10.1016/j.jpeds.2013.03.008; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; DBV Technologies, DEV PROGR VIASK PEAN; de Morais MB, 2016, J MED ECON, V19, P1207, DOI 10.1080/13696998.2016.1211390; Dhami S, 2017, ALLERGY, V72, P1597, DOI 10.1111/all.13201; Drummond M, 1997, HEALTH POLICY, V40, P199, DOI 10.1016/S0168-8510(97)00901-9; Fleischer DM, 2019, JAMA-J AM MED ASSOC, V321, P946, DOI 10.1001/jama.2019.1113; Food Standards Australia New Zealand, FOOD ALL FOOD INT; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Guest JF, 2018, CURR MED RES OPIN, V34, P1539, DOI 10.1080/03007995.2017.1400962; Guest JF, 2016, CLINICOECONOMIC OUTC, V8, P629, DOI 10.2147/CEOR.S113448; Guest JF, 2015, CLINICOECONOMIC OUTC, V7, P583, DOI 10.2147/CEOR.S89347; Guest JF, 2016, CLINICOECONOMIC OUTC, V8, P307, DOI 10.2147/CEOR.S105748; Guest JF, 2015, CLINICOECONOMIC OUTC, V7, P325, DOI 10.2147/CEOR.S80130; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; Gupta RS, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-1235; Hsiao KC, 2017, LANCET CHILD ADOLESC, V1, P97, DOI 10.1016/S2352-4642(17)30041-X; Husereau D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1049; Institute for Clinical and Economic Review, 2019, REV VAL OR IMM EP IM; Koplin JJ, 2016, J ALLERGY CLIN IMMUN, V138, P1131, DOI 10.1016/j.jaci.2016.04.011; Kunst NR, 2019, J ALLERGY CLIN IMMUN, V143, P1243, DOI 10.1016/j.jaci.2018.10.050; Lindvik H, 2017, CLIN EXP ALLERGY, V47, P785, DOI 10.1111/cea.12899; Luthra S., 2019, KAISER HLTH NEWS; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; National Institute for Health and Clinical Excellence, 2011, FOOD ALL CHILDR YOUN; Natsume O, 2017, LANCET, V389, P276, DOI 10.1016/S0140-6736(16)31418-0; Nilsson C, 2020, PEDIAT ALLERG IMM-UK, V31, P186, DOI 10.1111/pai.13110; Ovcinnikova O, 2015, CLINICOECONOMIC OUTC, V7, P145, DOI 10.2147/CEOR.S75071; Philips Z, 2006, PHARMACOECONOMICS, V24, P355, DOI 10.2165/00019053-200624040-00006; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Savage J, 2016, J ALLER CL IMM-PRACT, V4, P196, DOI 10.1016/j.jaip.2015.11.024; Shaker M, 2018, ALLERGY, V73, P1707, DOI 10.1111/all.13446; Shaker M, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3242; Shaker M, 2018, ALLERGY, V73, P2214, DOI 10.1111/all.13565; Shaker M, 2019, ANN ALLERG ASTHMA IM, V122, P79, DOI 10.1016/j.anai.2018.06.035; Shaker M, 2018, J ALLER CL IMM-PRACT, V6, P2073, DOI 10.1016/j.jaip.2018.04.036; Shaker MS, 2017, J ALLER CL IMM-PRACT, V5, P1707, DOI 10.1016/j.jaip.2017.04.016; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Simon D, 2019, INT ARCH ALLERGY IMM, V180, P291, DOI 10.1159/000504364; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Taylor RR, 2012, PEDIAT ALLERG IMM-UK, V23, P240, DOI 10.1111/j.1399-3038.2011.01262.x; Umasunthar T, 2013, CLIN EXP ALLERGY, V43, P1333, DOI 10.1111/cea.12211; US Food and Drug Administration, FDA APPR 1 DRUG TREA; Vickery BP, 2018, NEW ENGL J MED, V379, P1991, DOI 10.1056/NEJMoa1812856; Wong L, 2019, CURR OPIN ALLERGY CL, V19, P236, DOI 10.1097/ACI.0000000000000532	51	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	SEP	2021	24	9					1360	1376		10.1016/j.jval.2021.02.010		AUG 2021	17	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	UG5RC	34452717				2022-04-28	WOS:000689308300017
J	van Oostrum, I; Ouwens, M; Remiro-Azocar, A; Baio, G; Postma, MJ; Buskens, E; Heeg, B				van Oostrum, Ilse; Ouwens, Mario; Remiro-Azocar, Antonio; Baio, Gianluca; Postma, Maarten J.; Buskens, Erik; Heeg, Bart			Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs	VALUE IN HEALTH			English	Article						additive hazards; general population mortality; incremental life-years; parametric modeling	COST-EFFECTIVENESS; LIFE EXPECTANCY; RHEUMATOID-ARTHRITIS; ECONOMIC-EVALUATION; CROSS-VALIDATION; FOLLOW-UP; CANCER; PREDNISONE; MELPHALAN; EVALUATE	Objectives: Survival extrapolation of trial outcomes is required for health economic evaluation. Generally, all-cause mortality (ACM) is modeled using standard parametric distributions, often without distinguishing disease-specific/excess mortality and general population background mortality (GPM). Recent National Institute for Health and Care Excellence guidance (Technical Support Document 21) recommends adding GPM hazards to disease-specific/excess mortality hazards in the log-likelihood function ("internal additive hazards"). This article compares alternative extrapolation approaches with and without GPM adjustment. Methods: Survival extrapolations using the internal additive hazards approach (1) are compared to no GPM adjustment (2), applying GPM hazards once ACM hazards drop below GPM hazards (3), adding GPM hazards to ACM hazards (4), and pro-portional hazards for ACM versus GPM hazards (5). The fit, face validity, mean predicted life-years, and corresponding uncertainty measures are assessed for the active versus control arms of immature and mature (30-and 75-month follow-up) multiple myeloma data and mature (64-month follow-up) breast cancer data. Results: The 5 approaches yielded considerably different outcomes. Incremental mean predicted life-years vary most in the immature multiple myeloma data set. The lognormal distribution (best statistical fit for approaches 1-4) produces survival increments of 3.5 (95% credible interval: 1.4-5.3), 8.5 (3.1-13.0), 3.5 (1.3-5.4), 2.9 (1.1-4.5), and 1.6 (0.4-2.8) years for approaches 1 to 5, respectively. Approach 1 had the highest face validity for all data sets. Uncertainty over parametric distributions was comparable for GPM-adjusted approaches 1, 3, and 4, and much larger for approach 2. Conclusion: This study highlights the importance of GPM adjustment, and particularly of incorporating GPM hazards in the log-likelihood function of standard parametric distributions.	[van Oostrum, Ilse; Heeg, Bart] Ingress Hlth, Weena 316-318, NL-3012 NJ Rotterdam, Netherlands; [van Oostrum, Ilse; Postma, Maarten J.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands; [Ouwens, Mario] AstraZeneca, Molndal, Sweden; [Remiro-Azocar, Antonio; Baio, Gianluca] UCL, Dept Stat Sci, London, England; [Postma, Maarten J.; Buskens, Erik] Univ Groningen, Dept Econ Econometr & Finance, Fac Econ & Business, Groningen, Netherlands; [Buskens, Erik] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands		van Oostrum, I (通讯作者)，Ingress Hlth, Weena 316-318, NL-3012 NJ Rotterdam, Netherlands.	ivoostrum92@gmail.com		Postma, Maarten/0000-0002-6306-3653; buskens, erik/0000-0002-6463-1106; Remiro-Azocar, Antonio/0000-0002-2877-2315			Aballea S, 2007, CANCER-AM CANCER SOC, V109, P1082, DOI 10.1002/cncr.22512; Andersson TML, 2013, STAT MED, V32, P5286, DOI 10.1002/sim.5943; [Anonymous], 2016, GUID PREP SUBM PHARM; Baio G, 2020, J STAT SOFTW, V95, P1, DOI 10.18637/jss.v095.i14; Barton P, 2004, HEALTH TECHNOL ASSES, V8, P1; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Bell F.C, 2005, SSA PUB; Burkner PC, 2017, J STAT SOFTW, V80, P1, DOI 10.18637/jss.v080.i01; Canadian Agency for Drugs and Technologies in Health, 2017, GUID EC EV HLTH TECH, V4th; Carpenter B, 2017, J STAT SOFTW, V76, P1, DOI 10.18637/jss.v076.i01; Chambers D, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14390; Chen YF, 2006, HEALTH TECHNOL ASSES, V10, P1, DOI 10.3310/hta10420; Chu PC, 2008, VALUE HEALTH, V11, P1102, DOI 10.1111/j.1524-4733.2008.00350.x; Fang CT, 2007, QJM-INT J MED, V100, P97, DOI 10.1093/qjmed/hcl141; Grant A, 2008, HEALTH TECHNOL ASSES, V12, P1; Guyot P, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-9; Hind D, 2007, HEALTH TECHNOL ASSES, V11, P1; Hisashige A, 2008, BRIT J CANCER, V99, P1232, DOI 10.1038/sj.bjc.6604666; Howard DH, 2009, HEALTH ECON, V18, P1381, DOI 10.1002/hec.1434; Hwang JS, 1999, STAT MED, V18, P1627, DOI 10.1002/(SICI)1097-0258(19990715)18:13<1627::AID-SIM159>3.3.CO;2-4; Jackson C, 2017, MED DECIS MAKING, V37, P377, DOI 10.1177/0272989X16639900; Latimer N, 2013, NICE DSU TECHNICAL S; Latimer NR, 2013, MED DECIS MAKING, V33, P743, DOI 10.1177/0272989X12472398; Main C, 2010, HEALTH TECHNOL ASSES, V14, P27, DOI 10.3310/hta14suppl2/04; Messori A, 1999, ONCOL REP, V6, P1135; Mitchell M. B., ENGAUGE DIGITIZER SO; National Institute for Health and Care Excellence (NICE), 2018, COMM PAP FIN APPR DE; National Institute for Health and Care Excellence (NICE), COMM PAP FIN APPR DE; Ouwens MJNM, 2010, RES SYNTH METHODS, V1, P258, DOI 10.1002/jrsm.25; Peek GJ, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14350; Plummer M, 2008, BIOSTATISTICS, V9, P523, DOI 10.1093/biostatistics/kxm049; Ravi P, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0065-8; Rodgers M, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13600; Rutherford M., 2020, NICE DSU TECHNICAL S; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; San Miguel JF, 2013, J CLIN ONCOL, V31, P448, DOI 10.1200/JCO.2012.41.6180; Soikkeli F, 2019, VALUE HEALTH, V22, P1012, DOI 10.1016/j.jval.2019.03.017; Stan Development Team, RSTAN R INT STAN R P; van der Linde A, 2005, STAT NEERL, V59, P45; Vehtari A, 2017, STAT COMPUT, V27, P1413, DOI 10.1007/s11222-016-9696-4; Viscomi S, 2006, ANN ONCOL, V17, P167, DOI 10.1093/annonc/mdj050; Watanabe S, 2010, J MACH LEARN RES, V11, P3571	42	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	SEP	2021	24	9					1294	1301		10.1016/j.jval.2021.03.008		AUG 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	UG5RC	34452709	Green Published, hybrid			2022-04-28	WOS:000689308300009
J	Rome, BN; Lee, CC; Gagne, JJ; Kesselheim, AS				Rome, Benjamin N.; Lee, ChangWon C.; Gagne, Joshua J.; Kesselheim, Aaron S.			Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017	VALUE IN HEALTH			English	Article						generic drugs; prescription drug pricing	PRESCRIPTION DRUGS; MEDICATION ADHERENCE; MARKET EXCLUSIVITY; BRAND-NAME; PHARMACEUTICALS; COMPETITION; COUPONS; TRENDS	Objectives: In the United States, brand-name prescription drugs remain expensive until market exclusivity ends and lower cost generics become available. Delayed generic drug uptake may increase spending and worsen medication adherence and patient outcomes. We assessed recent trends and factors associated with generic uptake. Methods: Among 227 drugs facing new generic competition from 2012 to 2017, we used a national claims database to measure generic uptake in the first and second year after generic entry, defined as the proportion of claims for a generic version of the drug. Using linear regression, we evaluated associations between generic uptake and key drug characteristics . Results: Mean generic uptake was 66.1% (standard deviation 22.1%) in the first year and 82.7% (standard deviation 21.6%) in the second year after generic entry. From 2012 to 2017 generic uptake decreased 4.3% per year in the first year (95% confidence interval, 2.8%-5.8%, P <.001) and 3.2%/year in the second year (95% confidence interval, 1.2%-5.1%). Generic uptake was lower for injected than oral drugs in the first year (38.5% vs 70.0%, P <.001) and second year (50.3% vs 86.9%, P < .001). In the second year, generic uptake was higher among drugs with an authorized generic (86.1 vs 80.1%, P = .045) and those with $3 generic competitors (87.7% vs 78.6%, P = .055). Conclusion: Early generic uptake decreased over the past several years. This trend may adversely affect patients and increase prescription drug spending. Policies are needed to encourage generic competition, particularly among injected drugs administered in a hospital or clinic setting.	[Rome, Benjamin N.; Lee, ChangWon C.; Gagne, Joshua J.; Kesselheim, Aaron S.] Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA; [Rome, Benjamin N.; Lee, ChangWon C.; Gagne, Joshua J.; Kesselheim, Aaron S.] Harvard Med Sch, Boston, MA 02115 USA		Rome, BN (通讯作者)，Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	brome@bwh.harvard.edu			Anthem Public Policy Institute; Arnold Ventures; Harvard-MIT Center for Regulatory Science	This work was funded by a grant from Anthem Public Policy Institute. Dr Kesselheim was also supported by Arnold Ventures and the Harvard-MIT Center for Regulatory Science.	Aitken M, ORPHAN DRUGS US EXCL; Aitken ML, 2013, NBER WORK PAP SER; Berndt ER, 2007, HEALTH AFFAIR, V26, P790, DOI 10.1377/hlthaff.26.3.790; Bureau of Labor Statistics, DAT TABL CALC SUBJ; Choudhry NK, 2014, AM HEART J, V167, P51, DOI 10.1016/j.ahj.2013.09.014; Cole AL, 2018, HEALTH AFFAIR, V37, P738, DOI 10.1377/hlthaff.2017.1684; Conti RM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.14141; Dafny L, 2017, AM ECON J-ECON POLIC, V9, P91, DOI 10.1257/pol.20150588; Darrow JJ, 2020, JAMA-J AM MED ASSOC, V323, P164, DOI 10.1001/jama.2019.20288; Dave CV, 2017, NEW ENGL J MED, V377, P2597, DOI 10.1056/NEJMc1711899; Federal Trade Commission, AUTHORIZED GENERIC D; First Databank, NTR; Frosch DL, 2010, AM J PUBLIC HEALTH, V100, P24, DOI 10.2105/AJPH.2008.153767; Glass G, 2005, NAT REV DRUG DISCOV, V4, P953, DOI 10.1038/nrd1906; Grabowski H, 2016, J MED ECON, V19, P836, DOI 10.1080/13696998.2016.1176578; Grabowski Henry, 2014, J Med Econ, V17, P207, DOI 10.3111/13696998.2013.873723; Hyman Phelps, NTR; IQVIA Institute for Human Data Science, NTR; Kesselheim AS, 2017, JAMA INTERN MED, V177, P1658, DOI 10.1001/jamainternmed.2017.4329; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Lanthier M, 2013, HEALTH AFFAIR, V32, P1433, DOI 10.1377/hlthaff.2012.0541; Luo J, 2018, JAMA INTERN MED, V178, P721, DOI 10.1001/jamainternmed.2018.0989; Luo J, 2016, JAMA INTERN MED, V176, P1317, DOI 10.1001/jamainternmed.2016.3384; Oner ZG, 2018, AAPS PHARMSCITECH, V19, P2450, DOI 10.1208/s12249-018-1073-5; Rome BN, 2021, CLIN PHARMACOL THER, V109, P367, DOI 10.1002/cpt.1983; Ross JS, 2013, NEW ENGL J MED, V369, P1188, DOI 10.1056/NEJMp1301993; Sacks CA, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.7344; Saha A, 2006, INT J ECON BUS, V13, P15, DOI 10.1080/13571510500519905; Schwartz LM, 2019, JAMA-J AM MED ASSOC, V321, P80, DOI 10.1001/jama.2018.19320; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shrank WH, 2010, HEALTH AFFAIR, V29, P1383, DOI 10.1377/hlthaff.2009.0424; SSR Health, NTR; Uhl K., 2017, FDA VOICES PERSPECTI; US Food and Drug Adminstration, BREAKTHROUGH THERAPY; US Food and Drug Adminstration, NTR; US Food and Drug Adminstration, NTR; Vokinger KN, 2017, JAMA INTERN MED, V177, P1665, DOI 10.1001/jamainternmed.2017.4650; Wang B, 2015, JAMA INTERN MED, V175, P635, DOI 10.1001/jamainternmed.2014.7968; Wang Bo, 2013, Virtual Mentor, V15, P960, DOI 10.1001/virtualmentor.2013.15.11.pfor1-1311; Warraich HJ, 2018, JAMA INTERN MED, V178, P719, DOI 10.1001/jamainternmed.2018.0990	40	1	1	4	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24	6					804	811		10.1016/j.jval.2020.12.020		JUN 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SP8AF	34119078				2022-04-28	WOS:000659884900008
J	Roydhouse, JK; Mishra-Kalyani, PS; Bhatnagar, V; Gutman, R; King-Kallimanis, BL; Sridhara, R; Kluetz, PG				Roydhouse, Jessica K.; Mishra-Kalyani, Pallavi S.; Bhatnagar, Vishal; Gutman, Roee; King-Kallimanis, Bellinda L.; Sridhara, Rajeshwari; Kluetz, Paul G.			Does Knowledge of Treatment Assignment Affect Patient Report of Symptoms, Function, and Health Status? An Evaluation Using Multiple Myeloma Trials	VALUE IN HEALTH			English	Article						bias; cancer; clinical trial; open-label; patient-reported outcomes	CLINICAL-TRIALS; RANDOMIZED-TRIALS; PROPENSITY SCORE; MISSING-DATA; BIAS; OUTCOMES; ASSOCIATION; IMPUTATION; SURVIVAL; DISEASE	Objectives: Unblinded trials are common in oncology, but patient knowledge of treatment assignment may bias response to questionnaires. We sought to ascertain the extent of possible bias arising from patient knowledge of treatment assignment. Methods: This is a retrospective analysis of data from 2 randomized trials in multiple myeloma, 1 double-blind and 1 open label. We compared changes in patient reports of symptoms, function, and health status from prerandomization (screening) to baseline (pretreatment but postrandomization) across control and investigational arms in the 2 trials. Changes from prerandomization scores at similar to 2 and 6 months on treatment were evaluated only across control arms to avoid comparisons between 2 different experimental drugs. All scores were on 0- to 100-point scales. Inverse probability weighting, entropy balancing, and multiple imputation using propensity score splines were used to compare score changes across similar groups of patients. Results: Minimal changes from screening were seen at baseline in all arms. In the control arm, mean changes of <7 points were seen for all domains at 2 and 6 months. The effect of unblinding at 6 months in social function was a decline of less than 6 points (weighting: -3.09; 95% confidence interval -8.41 to 2.23; balancing: -4.55; 95% confidence interval -9.86 to 0.76; imputation: -5.34; 95% confidence interval -10.64 to -0.04). Conclusion: In this analysis, we did not find evidence to suggest that there was a meaningful differential effect on how patients reported their symptoms, function or health status after knowing their treatment assignment.	[Roydhouse, Jessica K.] US FDA, Off Hematol & Oncol Prod, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA; [Roydhouse, Jessica K.] Univ Tasmania, Menzies Inst Med Res, 17 Liverpool St, Hobart, Tas 7000, Australia; [Mishra-Kalyani, Pallavi S.; Sridhara, Rajeshwari] US FDA, Off Biostat, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA; [Bhatnagar, Vishal; King-Kallimanis, Bellinda L.; Kluetz, Paul G.] US FDA, Oncol Ctr Excellence, Rockville, MD 20857 USA; [Gutman, Roee] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI 02912 USA		Roydhouse, JK (通讯作者)，Univ Tasmania, Menzies Inst Med Res, 17 Liverpool St, Hobart, Tas 7000, Australia.	jessica.roydhouse@utas.edu.au	Gutman, Roee/J-2355-2014	Gutman, Roee/0000-0001-7095-3016			AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Armijo-Olivo S, 2017, AM J PHYS MED REHAB, V96, P34, DOI 10.1097/PHM.0000000000000521; Atkinson TM, 2017, JAMA ONCOL, V3, P738, DOI 10.1001/jamaoncol.2016.3328; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Bello S, 2014, J CLIN EPIDEMIOL, V67, P1059, DOI 10.1016/j.jclinepi.2014.05.007; Berkman N, 2014, AHRQ PUBLICATION, V14-EHC050-EF; Cortes JE, 2019, LANCET ONCOL, V20, P984, DOI 10.1016/S1470-2045(19)30150-0; Dore DD, 2013, J CLIN EPIDEMIOL, V66, pS42, DOI 10.1016/j.jclinepi.2013.02.014; Fayers PMAN, 2001, EORTC QLQ C30 SCORIN, V3rd; Fiero MH, 2019, LANCET ONCOL, V20, pE582, DOI 10.1016/S1470-2045(19)30335-3; Food and Drug Administration, DIS DOC PAT FOC DRUG; Food and Drug Administration, 2009, GUID IND PAT REP OUT; Greifer N., 2019, PACKAGE WEIGHTIT; Gutman R, 2015, STAT MED, V34, P3381, DOI 10.1002/sim.6532; Hainmueller J, 2013, J STAT SOFTW, P54; Hainmueller J, 2012, POLIT ANAL, V20, P25, DOI 10.1093/pan/mpr025; Harvey RA, 2017, PHARMACOEPIDEM DR S, V26, P368, DOI 10.1002/pds.4121; Hrobjartsson A, 2014, INT J EPIDEMIOL, V43, P1272, DOI 10.1093/ije/dyu115; Hrobjartsson A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1119; Imbens GW, 2015, CAUSAL INFERENCE FOR STATISTICS, SOCIAL, AND BIOMEDICAL SCIENCES: AN INTRODUCTION, P1, DOI 10.1017/CBO9781139025751; Kanapuru B, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e14024; King-Kallimanis BL, 2020, QUAL LIFE RES, V29, P1903, DOI 10.1007/s11136-020-02448-y; Kluetz PG, 2016, CLIN CANCER RES, V22, P1553, DOI 10.1158/1078-0432.CCR-15-2035; Larkin J, 2018, J CLIN ONCOL, V36, P383, DOI 10.1200/JCO.2016.71.8023; Levy C, 2019, HEALTH SERV RES, V54, P1346, DOI 10.1111/1475-6773.13195; LITTLE RJA, 1988, J BUS ECON STAT, V6, P287, DOI 10.2307/1391878; Little RJA, 2019, STAT ANAL MISSING DA, V3rd; Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730; Lunceford JK, 2004, STAT MED, V23, P2937, DOI 10.1002/SIM.1903; Morimoto T, 2015, J CARDIOL, V66, P466, DOI 10.1016/j.jjcc.2015.05.018; Nuesch E, 2009, ARTHRIT RHEUM-ARTHR, V61, P1633, DOI 10.1002/art.24894; Osoba D, 2005, EUR J CANCER, V41, P280, DOI 10.1016/j.ejca.2004.10.017; Page MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159267; Pe M, 2018, LANCET ONCOL, V19, pE459, DOI 10.1016/S1470-2045(18)30418-2; Roydhouse JK, 2019, JAMA ONCOL, V5, P457, DOI 10.1001/jamaoncol.2018.6205; Roydhouse JK, 2019, JNCI-J NATL CANCER I, V111, P459, DOI 10.1093/jnci/djy181; Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908; Rubin DB., 1987, MULTIPLE IMPUTATION; Savovic J, 2018, AM J EPIDEMIOL, V187, P1113, DOI 10.1093/aje/kwx344; Schulz KF, 2002, ANN INTERN MED, V136, P254, DOI 10.7326/0003-4819-136-3-200202050-00022; Schulz KF, 2002, LANCET, V359, P696, DOI 10.1016/S0140-6736(02)07816-9; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD	44	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24	6					822	829		10.1016/j.jval.2020.12.015		JUN 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SP8AF	34119080				2022-04-28	WOS:000659884900010
J	Aggarwal, S; Kumar, S; Bela, A; Topaloglu, H				Aggarwal, S.; Kumar, S.; Bela, A.; Topaloglu, H.			HOSPITAL LENGTH OF STAY, TOTAL COSTS AND COMORBIDITIES IN PATIENTS WITH ACUTE PERICARDITIS: ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE	VALUE IN HEALTH			English	Meeting Abstract									[Aggarwal, S.; Bela, A.; Topaloglu, H.] NOVEL Hlth Strategies, Chevy Chase, MD USA; [Kumar, S.] NOVEL Hlth Strategies, Columbia, MD USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV27	S71	S72					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400313
J	Alexander, W; Jensen, I; Srivastava, K; Hathway, J; Cyr, P; Batt, K				Alexander, W.; Jensen, I; Srivastava, K.; Hathway, J.; Cyr, P.; Batt, K.			ECONOMIC IMPACT OF UTILIZING EPTACOG BETA FOR THE ON-DEMAND TREATMENT OF BLEEDING EVENTS AMONG HEMOPHILIA PATIENTS WITH INHIBITORS	VALUE IN HEALTH			English	Meeting Abstract									[Alexander, W.] Aoede Associates, Athens, TX USA; [Jensen, I; Hathway, J.; Cyr, P.] PrecisionHEOR, Boston, MA USA; [Srivastava, K.] PrecisionHEOR, Brighton, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PBI11	S16	S16					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400064
J	Chen, WH; Panter, C; Park, J; Mason, B; Findley, A; Arbuckle, R; Svedsater, H; Chauhan, D				Chen, W. H.; Panter, C.; Park, J.; Mason, B.; Findley, A.; Arbuckle, R.; Svedsater, H.; Chauhan, D.			QUALITATIVE STUDY TO UNDERSTAND THE PATIENT EXPERIENCE OF KNEE OSTEOARTHRITIS (OA) AND ASSESS THE CONTENT VALIDITY OF THE KNEE INJURY AND OSTEOARTHRITIS OUTCOME SCORE (KOOS) AND HIP DISABILITY AND OSTEOARTHRITIS OUTCOME SCORE (HOOS) MEASURES	VALUE IN HEALTH			English	Meeting Abstract									[Chen, W. H.; Park, J.] GSK, Collegeville, PA USA; [Panter, C.; Mason, B.; Findley, A.; Arbuckle, R.] Adelphi Values Ltd, Bollington, England; [Svedsater, H.; Chauhan, D.] GSK, Brentford, England									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMS29	S143	S143					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400625
J	Chen, Z; Babcock, A; Sanogo, V; Xiao, H; Diaby, V				Chen, Z.; Babcock, A.; Sanogo, V; Xiao, H.; Diaby, V			PREDICTORS OF 30-DAY READMISSION AND HOSPITALIZATION COSTS OF PATIENTS WITH HEPATIC ENCEPHALOPATHY IN THE US FROM 2010 TO 2014	VALUE IN HEALTH			English	Meeting Abstract									[Chen, Z.; Babcock, A.; Diaby, V] Univ Florida, Gainesville, FL USA; [Xiao, H.] Bristol Myers Squibb Co, Lawrenceville, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND43	S167	S167					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400727
J	Christen, P; Conteh, L				Christen, P.; Conteh, L.			HOW ARE MATHEMATICAL MODELS OF VACCINE PREVENTABLE DISEASES USED, OR NOT, BY DECISION MAKERS AT A GLOBAL LEVEL?	VALUE IN HEALTH			English	Meeting Abstract									[Christen, P.] Imperial Coll London, London, England; [Conteh, L.] LSE, London, England									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN69	S118	S119					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400519
J	Divino, V				Divino, V			CHARACTERISTICS OF PATIENTS DIAGNOSED WITH CORONAVIRUS DISEASE 2019 (COVID-19) ACROSS THE THREE WAVES IN THE US: A CLAIMS-BASED STUDY USING A LARGE NATIONAL SAMPLE	VALUE IN HEALTH			English	Meeting Abstract									[Divino, V] IQVIA, Falls Church, VA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		IN2	S10	S10					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400038
J	English, B; Munetsi, R; Chrysos, A				English, B.; Munetsi, R.; Chrysos, A.			COST-EFFECTIVENESS ANALYSIS OF USING HYPOXIC STORED RED BLOOD CELLS TO REDUCE THE FREQUENCY OF BLOOD TRANSFUSIONS	VALUE IN HEALTH			English	Meeting Abstract									[English, B.; Munetsi, R.; Chrysos, A.] Initiate Consultancy, London, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO29	S202	S203					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401149
J	Gala, K; Lodaya, K; Marinaro, X; Zhang, X; Hayashida, DK; Munson, S; D'Souza, F				Gala, K.; Lodaya, K.; Marinaro, X.; Zhang, X.; Hayashida, D. K.; Munson, S.; D'Souza, F.			COMPARING MORTALITY IN CARDIAC PATIENT SURGICAL CLUSTERS WITH MACHINE LEARNING CLUSTERS IN THE NATIONAL INPATIENT SAMPLE	VALUE IN HEALTH			English	Meeting Abstract									[Gala, K.] Deborah Heart & Lung Ctr, Browns Mills, NJ USA; [Lodaya, K.; Marinaro, X.; Zhang, X.; Hayashida, D. K.; Munson, S.; D'Souza, F.] Boston Strateg Partners Inc, Boston, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		ML1	S10	S11					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400041
J	Gebremariam, G				Gebremariam, G.			EVALUATION OF HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT A TERTIARY CARE HOSPITAL IN ETHIOPIA	VALUE IN HEALTH			English	Meeting Abstract									[Gebremariam, G.] Addis Ababa Univ, Addis Ababa, Ethiopia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB1	S78	S78					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400340
J	Giocanti-Auregan, A; Lanar, S; Lewis, HB; Latibeaudiere, D; Williams, A; Mirt, DM; Kotecha, A; Paris, LP; Van den Brande, I; Chi, GC; Gentile, B				Giocanti-Auregan, A.; Lanar, S.; Lewis, H. B.; Latibeaudiere, D.; Williams, A.; Mirt, Dabic M.; Kotecha, A.; Paris, L. P.; Van den Brande, I; Chi, G. C.; Gentile, B.			UNDERSTANDING THE PATIENT EXPERIENCE WITH ANTI-VEGF INTRAVITREAL INJECTIONS AND THE IMPACT ON TREATMENT MAINTENANCE: A QUALITATIVE INTERVIEW STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Giocanti-Auregan, A.] Avicenne Hosp, Bobigny 75, France; [Lanar, S.] ICON Plc, Lyon, France; [Lewis, H. B.; Latibeaudiere, D.; Williams, A.] ICON Plc, London, England; [Mirt, Dabic M.; Paris, L. P.; Van den Brande, I] F Hoffmann La Roche, Basel, Switzerland; [Kotecha, A.] Roche Prod Ltd, Welwyn Garden City, Herts, England; [Chi, G. C.; Gentile, B.] Genentech Inc, San Francisco, CA 94080 USA									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSS12	S222	S222					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401236
J	Guan, H; Liu, Y; Feng, Y; He, Y; Liu, J				Guan, H.; Liu, Y.; Feng, Y.; He, Y.; Liu, J.			COST-OFFSET ANALYSIS OF DAPAGLIFLOZIN IN TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) IN CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Guan, H.] PKU China Ctr Hlth Econim Res, Beijing, Peoples R China; [Liu, Y.; He, Y.] IQVIA, Shanghai, Peoples R China; [Feng, Y.; Liu, J.] IQVIA, Beijing, Peoples R China									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV34	S73	S73					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400319
J	Hernandez, F; van der Werf, L; Kashiura, D; Julian, G				Hernandez, F.; van der Werf, L.; Kashiura, D.; Julian, G.			TRANSITION TO VALUE BASED HEALTHCARE IN LATIN AMERICA: A SITUATION ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Hernandez, F.] IQVIA Colombia, Bogota, Colombia; [van der Werf, L.] IQVIA Colombia, No Aplica, Cun, Colombia; [Kashiura, D.; Julian, G.] IQVIA Brasil, Sao Paulo, SP, Brazil									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS31	S177	S178					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401035
J	Hsu, LI; Palanca-Wessels, MC; Stecher, M; Siadak, M; Surinach, A; Arndorfer, S; DeBusk, K				Hsu, L., I; Palanca-Wessels, M. C.; Stecher, M.; Siadak, M.; Surinach, A.; Arndorfer, S.; DeBusk, K.			CHARACTERISTICS AND TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH METASTATIC COLORECTAL CANCER IN THE UNITED STATES: A HEALTHCARE CLAIMS DATABASE ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Hsu, L., I; Palanca-Wessels, M. C.; Stecher, M.; Siadak, M.; DeBusk, K.] Seagen Inc, Bothell, WA USA; [Surinach, A.; Arndorfer, S.] Genesis Res, Hoboken, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN157	S48	S49					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400208
J	Kelley, M; Wadwa, P; Buckingham, B; Thankamony, A; Campbell, F; Weinzimer, S; Mauras, N; DiMeglio, L; Denvir, L; Davis, N; Ghatak, A; Besser, R; Fox, DS				Kelley, M.; Wadwa, P.; Buckingham, B.; Thankamony, A.; Campbell, F.; Weinzimer, S.; Mauras, N.; DiMeglio, L.; Denvir, L.; Davis, N.; Ghatak, A.; Besser, R.; Fox, D. S.			IDENTIFYING PREFERENCES FOR CLOSED-LOOP INSULIN SYSTEMS AMONG CHILDREN WITH TYPE 1 DIABETES AND THEIR PARENTS: A DISCRETE CHOICE EXPERIMENT	VALUE IN HEALTH			English	Meeting Abstract									[Kelley, M.] Univ Southern Calif, Santa Monica, CA USA; [Wadwa, P.] Univ Colorado, Aurora, CO USA; [Buckingham, B.] Stanford Univ, Palo Alto, CA 94304 USA; [Thankamony, A.] Univ Cambridge, Cambridge, England; [Campbell, F.] St James Univ Hosp, Leeds, W Yorkshire, England; [Weinzimer, S.] Yale Univ, New Haven, CT USA; [Mauras, N.] Nemours Childrens Clin, Jacksonville, FL USA; [DiMeglio, L.] Indiana Univ, Indianapolis, IN 46204 USA; [Denvir, L.] Nottingham Childrens Hosp, Nottingham, Notts, England; [Davis, N.] Southampton Childrens Hosp, Southampton, Hants, England; [Ghatak, A.] Alder Hey Childrens Hosp, Liverpool, Merseyside, England; [Besser, R.] Oxford Univ Hosp NHS Fdn Trust, Oxford, Oxon, England; [Fox, D. S.] Univ Southern Calif, Los Angeles, CA 90007 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PR3	S196	S197					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401122
J	Kumar, A; Berg, H; Rivers, Z; Mandic, PK; Yang, J; Farley, JF				Kumar, A.; Berg, H.; Rivers, Z.; Mandic, Karaca P.; Yang, J.; Farley, J. F.			COST-EFFECTIVENESS ANALYSIS OF PHARMACOGENETIC TESTING IN OPIOID ANALGESIA IN PEDIATRIC POPULATION UNDERGOING SURGERY	VALUE IN HEALTH			English	Meeting Abstract									[Kumar, A.] Univ Minnesota, Coll Pharm, St Paul, MN 55108 USA; [Berg, H.; Rivers, Z.; Farley, J. F.] Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA; [Mandic, Karaca P.; Yang, J.] Univ Minnesota, Carlson Sch Management, Minneapolis, MN 55455 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS15	S175	S175					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401025
J	Ladouceur, M; Colby, C; Okala, S; Yue, B				Ladouceur, M.; Colby, C.; Okala, S.; Yue, B.			ROBUSTNESS OF EXTERNAL CONTROL ARM: WHEN TO USE THEM	VALUE IN HEALTH			English	Meeting Abstract									[Ladouceur, M.] Evidera, Verdun, PQ, Canada; [Colby, C.] Evidera, Oakland, CA USA; [Okala, S.] Evidera, London, England; [Yue, B.] Evidera, Orlando, FL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		EM3	S7	S7					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400028
J	Lanzkron, S; Crook, N; Wu, J; Hussain, S; Curtis, RG; Robertson, D; Baker, JR; Nugent, D; Soni, A; Roberts, J; Ullman, MM; Nguyen, A; Agodoa, I; Nichol, M				Lanzkron, S.; Crook, N.; Wu, J.; Hussain, S.; Curtis, R. G.; Robertson, D.; Baker, J. R.; Nugent, D.; Soni, A.; Roberts, J.; Ullman, M. M.; Nguyen, A.; Agodoa, I; Nichol, M.			HEALTH-RELATED QUALITY OF LIFE IN PERSONS WITH SICKLE CELL DISEASE	VALUE IN HEALTH			English	Meeting Abstract									[Lanzkron, S.; Hussain, S.] Johns Hopkins Sch Med, Baltimore, MD USA; [Crook, N.; Baker, J. R.; Nugent, D.; Soni, A.] Ctr Inherited Blood Disorders, Orange, CA USA; [Wu, J.; Nichol, M.] Univ Southern Calif, Los Angeles, CA 90007 USA; [Curtis, R. G.] Factor VIII Comp, Berkeley, CA USA; [Robertson, D.] Maryland Sickle Cell Dis Assoc Inc, Columbia, MD USA; [Roberts, J.] Bleeding & Clotting Disorders Inst, Peoria, IL USA; [Ullman, M. M.] Univ Texas Hlth Sci Ctr Houston, Gulf States Hemophilia & Thrombophilia Ctr, Houston, TX 77030 USA; [Nguyen, A.; Agodoa, I] Global Blood Therapeut, San Francisco, CA USA				Lanzkron, Sophie/AAD-7584-2022	Lanzkron, Sophie/0000-0002-2878-0251				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO66	S209	S210					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401181
J	Liu, Y; Mathur, M; de Groot, A				Liu, Y.; Mathur, M.; de Groot, A.			TRENDS IN THE ADOPTION OF DIFFERENT SURGICAL APPROACHES ACROSS SPECIALTIES: A NATIONAL STUDY FROM 2013 TO 2019	VALUE IN HEALTH			English	Meeting Abstract									[Liu, Y.; de Groot, A.] Intuit Surg, Sunnyvale, CA USA; [Mathur, M.] Intuit Surg, Union City, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSU16	S226	S227					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401257
J	Macaulay, R				Macaulay, R.			IS THE CANCER DRUGS FUND FUNCTIONING AS ANTICIPATED?	VALUE IN HEALTH			English	Meeting Abstract									[Macaulay, R.] Precis Advisors, London, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN180	S52	S52					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400226
J	Mesa, R; Hudgens, S; Floden, L; Palmer, J; Gupta, V; McLornan, DP; McMullin, MF; Kiladjian, JJ; Foltz, L; Platzbecker, U; Fox, ML; Mead, AJ; Ross, DM; Oh, ST; Perkins, A; Leahy, MF; Deheshi, S; Donahue, R; Klencke, BJ; Verstovsek, S				Mesa, R.; Hudgens, S.; Floden, L.; Palmer, J.; Gupta, V; McLornan, D. P.; McMullin, M. F.; Kiladjian, J. J.; Foltz, L.; Platzbecker, U.; Fox, M. L.; Mead, A. J.; Ross, D. M.; Oh, S. T.; Perkins, A.; Leahy, M. F.; Deheshi, S.; Donahue, R.; Klencke, B. J.; Verstovsek, S.			BEYOND A BINARY ENDPOINT: LONGITUDINAL AND INDIVIDUAL SYMPTOM ANALYSES FROM THE SIMPLIFY-1 STUDY DEMONSTRATE CLINICALLY COMPARABLE SYMPTOMATIC BENEFIT OF MOMELOTINIB TO RUXOLITINIB IN JAK INHIBITOR NAIVE MYELOFIBROSIS PATIENTS	VALUE IN HEALTH			English	Meeting Abstract									[Mesa, R.] UT Hlth San Antonio MD Anderson, Boerne, TX USA; [Hudgens, S.; Floden, L.] Clin Outcomes Solut, Tucson, AZ USA; [Palmer, J.] Mayo Clin, Phoenix, AZ USA; [Gupta, V] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada; [McLornan, D. P.] Guys & St Thomas NHS Fdn Trust, London, England; [McMullin, M. F.] Queens Univ, Belfast City Hosp Trust, Belfast, Antrim, North Ireland; [Kiladjian, J. J.] Hop St Louis, Paris, France; [Kiladjian, J. J.] Univ Paris, Paris, France; [Foltz, L.] Univ British Columbia, St Pauls Hosp, Vancouver, BC, Canada; [Platzbecker, U.] Leipzig Univ Hosp, Leipzig, Germany; [Fox, M. L.] Hosp Univ Vall dHebron, Dept Hematol, Barcelona, Spain; [Mead, A. J.] MRC Weatherall Inst Mol Med, Oxford, England; [Ross, D. M.] Flinders Med Ctr, Adelaide, SA, Australia; [Ross, D. M.] Univ Adelaide, Adelaide, SA, Australia; [Oh, S. T.] Washington Univ, Sch Med, St Louis, MO USA; [Perkins, A.] Monash Univ, Malvern, SA, Australia; [Leahy, M. F.] Univ Western Australia, Perth, WA, Australia; [Deheshi, S.] Sierra Oncol, Vancouver, BC, Canada; [Donahue, R.; Klencke, B. J.] Sierra Oncol, Vancouver, BC, Canada; [Verstovsek, S.] MD Anderson Canc Ctr, Houston, TX USA									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN19	S22	S22					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400087
J	Moon, R; Rosenthal, N; Brown, H				Moon, R.; Rosenthal, N.; Brown, H.			TREATMENT JOURNEY OF COVID-19 PATIENTS IN HOSPITAL SETTINGS	VALUE IN HEALTH			English	Meeting Abstract									[Moon, R.] Premier Inc, Ocoee, FL USA; [Rosenthal, N.; Brown, H.] Premier Inc, Charlotte, NC USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		IN1	S9	S10					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400037
J	Noto, S; Wake, M; Mishiro, I; Hammer-Helmich, L; Moriguchi, Y; Fujikawa, K; Fernandez, J				Noto, S.; Wake, M.; Mishiro, I; Hammer-Helmich, L.; Moriguchi, Y.; Fujikawa, K.; Fernandez, J.			EFFECTS OF ANTIDEPRESSANTS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER; A SECONDARY ANALYSIS USING PERFORM-J STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Noto, S.] Niigata Univ Hlth & Welf, Niigata, Japan; [Wake, M.; Mishiro, I; Fujikawa, K.; Fernandez, J.] Takeda Pharmaceut Co Ltd, Tokyo, Japan; [Hammer-Helmich, L.] H Lundbeck & Co AS, Valby, Denmark; [Moriguchi, Y.] Lundbeck Japan KK, Tokyo, Japan									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH3	S128	S128					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400559
J	Paly, V; Mohr, P; Larkin, J; Middleton, M; Youn, JH; Remiro-Azocar, A; Baio, G; Moshyk, A; Kotapati, S; Hamilton, M; Kurt, M				Paly, V; Mohr, P.; Larkin, J.; Middleton, M.; Youn, J. H.; Remiro-Azocar, A.; Baio, G.; Moshyk, A.; Kotapati, S.; Hamilton, M.; Kurt, M.			ASSESSING THE IMPACT OF MODELING NON-DISEASE-RELATED MORTALITY ON LONG-TERM SURVIVORSHIP RATES IN PREVIOUSLY UNTREATED ADVANCED MELANOMA: A CASE STUDY FROM CHECKMATE 067	VALUE IN HEALTH			English	Meeting Abstract									[Paly, V] ICON Plc, New York, NY USA; [Mohr, P.] Elbe Klinikum Buxtehude, Buxtehude, NY, Germany; [Larkin, J.] Royal Marsden NHS Fdn Trust, London, England; [Middleton, M.] Univ Oxford, Oxford, England; [Youn, J. H.] ICON Plc, Marlow, Bucks, England; [Remiro-Azocar, A.; Baio, G.] UCL, London, Sry, England; [Moshyk, A.; Kotapati, S.; Hamilton, M.] Bristol Myers Squibb, Princeton, NJ USA; [Kurt, M.] Bristol Myers Squibb, Lawrenceville, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN193	S55	S55					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400239
J	Salmasi, S; Hoegg, T; Safari, A; De Vera, M; Lynd, LD; Koehoorn, M; Barry, A; Andrade, J; Loewen, P				Salmasi, S.; Hoegg, T.; Safari, A.; De Vera, M.; Lynd, L. D.; Koehoorn, M.; Barry, A.; Andrade, J.; Loewen, P.			THE RANDOM EFFECTS WARFARIN DAYS' SUPPLY (REWARDS) MODEL: DEVELOPMENT AND VALIDATION OF A NOVEL METHOD TO ESTIMATE EXPOSURE TO WARFARIN USING ADMINISTRATIVE DATA	VALUE IN HEALTH			English	Meeting Abstract									[Salmasi, S.; Hoegg, T.; Safari, A.; De Vera, M.; Lynd, L. D.; Koehoorn, M.; Barry, A.; Andrade, J.; Loewen, P.] Univ British Columbia, Vancouver, BC, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		SM1	S241	S241					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401317
J	Samaksha, PB; Kishor, M; Ramesh, M				Samaksha, P. B.; Kishor, M.; Ramesh, M.			IMPACT OF CLINICAL PHARMACIST INTERVENTION IN PATIENTS WITH BIPOLAR AFFECTIVE DISORDER IN SOUTH INDIA	VALUE IN HEALTH			English	Meeting Abstract									[Samaksha, P. B.] JSS Coll Pharm, Mysuru, KA, India; [Kishor, M.] JSS Med Coll, Mysore, Karnataka, India; [Ramesh, M.] JSS Coll Pharm, Mysore, Karnataka, India									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH50	S136	S136					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400596
J	Soloman, N; Amin, M; Helfgott, SM; Hu, A; Huston, K; Leonard, J; Milligan, K; Milligan, S; Singh, JA; Tesser, J; Edgerton, C				Soloman, N.; Amin, M.; Helfgott, S. M.; Hu, A.; Huston, K.; Leonard, J.; Milligan, K.; Milligan, S.; Singh, J. A.; Tesser, J.; Edgerton, C.			GOUT MANAGEMENT AFTER PEGLOTICASE IN US CLINICAL PRACTICE; OBSERVATIONS FROM TRIO HEALTH AND THE AMERICAN RHEUMATOLOGY NETWORK	VALUE IN HEALTH			English	Meeting Abstract									[Soloman, N.; Tesser, J.] Arizona Arthrit, Phoenix, AZ USA; [Amin, M.; Hu, A.; Leonard, J.] Arizona Arthrit & Rheumatol Associates, Phoenix, AZ USA; [Helfgott, S. M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Huston, K.] Ctr Rheumat Dis & Allergy Immunol, Kansas City, MO USA; [Milligan, K.] Trio Hlth Advisory, La Jolla, CA USA; [Milligan, S.] Trio Hlth Analyt, Louisville, CO USA; [Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA; [Edgerton, C.] Articularis Healthcare, Summerville, SC USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMS5	S138	S139					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400605
J	Xie, J; Wang, Y; Xu, Y; Garrison, LP				Xie, J.; Wang, Y.; Xu, Y.; Garrison, L. P.			HEALTH UTILITIES AMONG PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM): AN ANALYSIS OF PATIENT HEALTH-RELATED QUALITY OF LIFE IN THE EXPLORER-HCM TRIAL	VALUE IN HEALTH			English	Meeting Abstract									[Xie, J.; Wang, Y.] Anal Grp Inc, Los Angeles, CA USA; [Xu, Y.] MyoKardia Inc, Brisbane, CA USA; [Garrison, L. P.] Univ Washington, Seattle, WA 98195 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV51	S76	S76					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400334
J	Zhang, Y; Batech, M; Lamy, FX; Pan, X				Zhang, Y.; Batech, M.; Lamy, F. X.; Pan, X.			ECONOMIC BURDEN IN PATIENTS WITH METASTATIC CERVICAL CANCER: A TRUVEN MARKETSCAN DATABASE STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Zhang, Y.] Univ Mississippi, Oxford, MS USA; [Batech, M.; Lamy, F. X.] Merck KGaA, Darmstadt, Germany; [Pan, X.] EMD Serono Res & Dev Inst Inc, Billerica, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN100	S38	S38					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400158
J	Zhao, S; Browning, J; Wang, J				Zhao, S.; Browning, J.; Wang, J.			USING MACHINE LEARNING TO CLASSIFY PATIENTS ON OPIOID USE	VALUE IN HEALTH			English	Meeting Abstract									[Zhao, S.; Browning, J.; Wang, J.] Univ Tennessee, Coll Pharm, Memphis, TN USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG35	S93	S93					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400404
J	Epstein, D				Epstein, David			Nutrition Economics: Celebrating Cross-Disciplinary Collaboration	VALUE IN HEALTH			English	Editorial Material							PREVENTION; IMPACT; FOOD		[Epstein, David] Univ Granada, Dept Appl Econ, Campus Cartuja, Granada 18071, Spain		Epstein, D (通讯作者)，Univ Granada, Dept Appl Econ, Campus Cartuja, Granada 18071, Spain.	davidepstein@ugr.es					AIELLO LC, 1995, CURR ANTHROPOL, V36, P199, DOI 10.1086/204350; Bray GA, 1999, DIABETES CARE, V22, P623; Caro JJ, 2014, VALUE HEALTH, V17, P174, DOI 10.1016/j.jval.2014.01.003; Culyer AJ, 1997, BEING REASONABLE EC; Fan HL, 2021, VALUE HEALTH, V24, P317, DOI 10.1016/j.jval.2020.06.017; Galekop MMJ, 2021, VALUE HEALTH, V24, P325, DOI 10.1016/j.jval.2020.12.006; Garnett T, 2018, FOOD CLIM RES NETW, P34; Lenoir-Wijnkoop I, 2013, BRIT J NUTR, V109, P777, DOI 10.1017/S0007114512005107; Lenoir-Wijnkoop I, 2011, Br J Nutr, V105, P157, DOI 10.1017/S0007114510003041; Mankoff R., 2014, NEW YORKER; Rodriguez-Mireles S, 2021, VALUE HEALTH, V24, P336, DOI 10.1016/j.jval.2020.12.005; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; Wrangham R., 2009, CATCHING FIRE COOKIN	13	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAR	2021	24	3					313	316		10.1016/j.jval.2020.12.004		FEB 2021	4	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QM9NG	33641763	Bronze			2022-04-28	WOS:000622099500001
J	Snoswell, CL; Rahja, M; Lalor, AF				Snoswell, Centaine L.; Rahja, Miia; Lalor, Aislinn F.			A Systematic Review and Meta-Analysis of Change in Health-Related Quality of Life for Interactive Telehealth Interventions for Patients With Asthma	VALUE IN HEALTH			English	Review						adherence; asthma; digital health; quality of life; telehealth; telemedicine	SELF-MANAGEMENT; USUAL CARE; LONG-TERM; CHILDREN; OUTCOMES; EPIDEMIOLOGY; VALIDATION; EDUCATION; ADULTS	Objectives: Asthma is one of the most common major noncommunicable diseases in the world and affects individuals of all ages. Medication is used to achieve and maintain quality of life (QOL) for people with asthma. Telehealth interventions offer optimized and personalized symptom monitoring with timely treatment adjustment and the potential to increase medication adherence for individuals with asthma. This study examines and synthesizes the available data on the change in the QOL for patients with asthma who use interactive telehealth interventions, and identifies the most effective telehealth modalities used for intervention in this area. Methods: Literature searches were conducted in 5 databases in November 2018 for studies measuring a change in QOL for patients with asthma. Study QOL outcomes, where possible, were pooled in a meta-analysis. Results: Seventeen publications (describing 16 studies) comprising 2015 patients were included. Based on a meta-analysis, interactive telehealth interventions can improve QOL outcomes for people living with asthma, although the improved effects may be small: web portals (0.51, 95% confidence interval [CI] -0.00 to 1.03), interactive smartphone apps (0.30, 95% CI -0.16 to 0.76) and remote monitoring (standardized mean difference 0.20, 95% CI -0.11 to 0.52).. Intervention delivery modalities identified include interactive web portals, smartphone apps, and remote monitoring programs. Conclusions: The findings provide a comprehensive overview of the available literature on interactive telehealth interventions, including interactive web portals, smartphone apps, and remote monitoring programs. These findings demonstrated that a positive change in QOL can be attributed to these interventions and provide evidence for the implementation of telehealth interventions for individuals with asthma.	[Snoswell, Centaine L.] Univ Queensland, Ctr Online Hlth, Brisbane, Qld, Australia; [Snoswell, Centaine L.] Univ Queensland, Ctr Hlth Serv Res, Brisbane, Qld, Australia; [Snoswell, Centaine L.] Princess Alexandra Hosp, Pharm Dept, Brisbane, Qld, Australia; [Rahja, Miia] Flinders Univ S Australia, Flinders Hlth & Med Res Inst, Adelaide, SA, Australia; [Lalor, Aislinn F.] Monash Univ, Sch Primary & Allied Hlth Care, Rehabil Ageing & Independent Living RAIL Res Ctr, Melbourne, Vic, Australia; [Lalor, Aislinn F.] Monash Univ, Sch Primary & Allied Hlth Care, Dept Occupat Therapy, Melbourne, Vic, Australia		Snoswell, CL (通讯作者)，Univ Queensland, Ctr Hlth Serv Res, Ctr Online Hlth, Ground Floor,Bldg 33, Brisbane, Qld 4102, Australia.	c.snoswell@uq.edu.au	Snoswell, Centaine L./G-3668-2016	Snoswell, Centaine L./0000-0002-4298-9369; Rahja, Miia/0000-0003-0845-5459; Lalor, Aislinn/0000-0002-9772-5272	NHMRCNational Health and Medical Research Council (NHMRC) of Australia; Bupa Health Foundation; NSW Ministry of Health; Department of Health, WA; University of Notre Dame Australia;  [9100002]	A very sincere thank you to Assistant Professor Tracy Comans and Ms Monica Taylor for their suggestions that improved this manuscript. This research is conducted for the NHMRC Partnership Centre for Health System Sustainability (Grant ID #: 9100002) administered by the Australian Institute of Health Innovation, Macquarie University. Along with the NHMRC, the funding partners in this research collaboration are The Bupa Health Foundation; NSW Ministry of Health; Department of Health, WA; and The University of Notre Dame Australia. Their generous support is gratefully acknowledged. Although the NHMRC, The Bupa Health Foundation, NSW Ministry of Health, Department of Health, WA, and The University of Notre Dame Australia have provided in-kind and financial support for this research, they have not reviewed the content and are not responsible for any injury, loss or damage however arising from the use of, or reliance on, the information provided herein. The published material is solely the responsibility of the authors and does not reflect the views of the NHMRC or its funding partners.	Ahmed S, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5866; Araujo L, 2012, J INVEST ALLERG CLIN, V22, P28; Chan DS, 2007, PEDIATRICS, V119, P569, DOI 10.1542/peds.2006-1884; Chan DS, 2003, AM J HEALTH-SYST PH, V60, P1976, DOI 10.1093/ajhp/60.19.1976; Chongmelaxme B, 2019, J ALLER CL IMM-PRACT, V7, P199, DOI 10.1016/j.jaip.2018.07.015; Croisant S, 2014, ADV EXP MED BIOL, V795, P17, DOI 10.1007/978-1-4614-8603-9_2; Deschildre A, 2012, EUR RESPIR J, V39, P290, DOI 10.1183/09031936.00185310; Dharmage SC, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00246; Dunne M, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.PA336; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Global Asthma Network, 2018, GLOB ASTHM REP 2018; Halterman JS, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2017.4938; Iribarren SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170581; Jan RL, 2007, TELEMED J E-HEALTH, V13, P257, DOI 10.1089/tmj.2006.0053; Jiang XC, 2019, J MED INTERNET RES, V21, DOI 10.2196/13166; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Kim MY, 2016, ASIA PAC ALLERGY, V6, P174, DOI 10.5415/apallergy.2016.6.3.174; Labrique AB, 2013, GLOB HEALTH-SCI PRAC, V1, P160, DOI 10.9745/GHSP-D-13-00031; Liu WT, 2011, EUR RESPIR J, V37, P310, DOI 10.1183/09031936.00000810; McLean G, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0248-7; McLean S, 2011, CAN MED ASSOC J, V183, pE733, DOI 10.1503/cmaj.101146; Mesko Bertalan, 2017, Mhealth, V3, P38, DOI 10.21037/mhealth.2017.08.07; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Morrison D, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.2814; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Council Australia, AUSTR ASTHM HDB VERS; Ogrinc G, 2016, J AM COLL SURGEONS, V222, P317, DOI 10.1016/j.jamcollsurg.2015.07.456; Park JW, 2000, J ASTHMA ALLERGY CLI, V20, P467; Rasmussen LM, 2005, J ALLERGY CLIN IMMUN, V115, P1137, DOI 10.1016/j.jaci.2005.03.030; Rikkers-Mutsaerts ERVM, 2012, PEDIATR PULM, V47, P1170, DOI 10.1002/ppul.22575; Ryan D, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1756; Snoswell CL, EFFECT DIGITAL HLTH; Steinhubl SR, 2013, JAMA-J AM MED ASSOC, V310, P2395, DOI 10.1001/jama.2013.281078; van der Meer V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027108; van der Meer V, 2009, ANN INTERN MED, V151, P110, DOI 10.7326/0003-4819-151-2-200907210-00008; van Gaalen JL, 2013, J MED INTERNET RES, V15, P40, DOI 10.2196/jmir.2640; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WHOQOL Group, 1993, MEAS QUAL LIF DEV WO; Willems DCM, 2008, J EVAL CLIN PRACT, V14, P600, DOI 10.1111/j.1365-2753.2007.00936.x; World Health Organization, 2013, ACT PLAN PREV CONTR; Zairina E, 2016, RESPIROLOGY, V21, P867, DOI 10.1111/resp.12773	44	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	FEB	2021	24	2					291	302		10.1016/j.jval.2020.09.006		JAN 2021	12	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QJ1VI	33518036	Bronze			2022-04-28	WOS:000619478100017
J	Zeevat, F; Crepey, P; Dolk, FCK; Postma, AJ; Breeveld-Dwarkasing, VNA; Postma, MJ				Zeevat, Florian; Crepey, Pascal; Dolk, F. Christiaan K.; Postma, Arjan J.; Breeveld-Dwarkasing, Vidya N. A.; Postma, Maarten J.			Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program	VALUE IN HEALTH			English	Article						cost-effectiveness; influenza; quadrivalent influenza vaccine; vaccination		Objectives: As of 2019, quadrivalent influenza vaccine (QIV) has replaced trivalent influenza vaccine (TIV) in the national immunization program in The Netherlands. Target groups are individuals of 601 years of age and those with chronic diseases. The objective was to estimate the incremental break-even price of QIV over TIV at a threshold of (sic)20 000 per quality-adjusted life-year (QALY). Methods: An age-structured compartmental dynamic model was adapted for The Netherlands to assess health outcomes and associated costs of vaccinating all individuals at higher risk for influenza with QIV instead of TIV over the seasons 2010 to 2018. Influenza incidence rates were derived from a global database. Other parameters (probabilities, QALYs and costs) were extracted from the literature and applied according to Dutch guidelines. A threshold of (sic)20 000 per QALY was applied to estimate the incremental break-even prices of QIV versus TIV. Sensitivity analyses were performed to test the robustness of the model outcomes. Results: Retrospectively, vaccination with QIV instead of TIV could have prevented on average 9500 symptomatic influenza cases, 2130 outpatient visits, 84 hospitalizations, and 38 deaths per year over the seasons 2010 to 2018. This translates into 385 QALYs and 398 life-years potentially gained. On average, totals of (sic)431 527 direct and (sic)2 388 810 indirect costs could have been saved each year. Conclusion: Using QIV over TIV during the influenza seasons 2010 to 2018 would have been cost-effective at an incremental price of maximally (sic)3.81 (95% confidence interval, (sic)3.26-4.31). Sensitivity analysis showed consistent findings on the incremental break-even price in the same range.	[Zeevat, Florian; Postma, Maarten J.] Univ Groningen, Dept Hlth Sci, Univ Med Ctr, Groningen, Netherlands; [Crepey, Pascal] Univ Rennes, Dept Quantitat Methods Publ Hlth, Rennes, France; [Dolk, F. Christiaan K.; Postma, Maarten J.] Univ Groningen, Unit PharmacoTherapy Epidemiol & Econ, Dept Pharm, Groningen, Netherlands; [Postma, Arjan J.] Asc Acad, Groningen, Netherlands; [Breeveld-Dwarkasing, Vidya N. A.] Sanofi, Amsterdam, Netherlands; [Postma, Maarten J.] Univ Groningen, Dept Econ Econometr & Finance, Fac Econ & Business, Groningen, Netherlands		Zeevat, F (通讯作者)，Univ Med Ctr Groningen, Dept Hlth Sci, Antonius Deusinglaan, NL-19713 AV Groningen, Netherlands.	f.zeevat@rug.nl	Crépey, Pascal/G-5422-2011	Crépey, Pascal/0000-0003-1852-0752; Zeevat, Florian/0000-0001-6427-4172; Postma, Maarten/0000-0002-6306-3653	Sanofi Pasteur, The Netherlands	This study was funded by Sanofi Pasteur, The Netherlands.	Backer JA, 2019, EPIDEMICS-NETH, V26, P77, DOI 10.1016/j.epidem.2018.10.001; Baguelin M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0452-y; Bedford T, 2014, ELIFE, V3, DOI 10.7554/eLife.01914; Blokhuis, KAMERBRIEF VERDER ME; Boersma C, 2010, VALUE HEALTH, V13, P853, DOI 10.1111/j.1524-4733.2010.00736.x; Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375; Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases (NCIRD), TYP INFL VIR SEAS IN; Chit A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133606; Chit A, 2015, VACCINE, V33, P734, DOI 10.1016/j.vaccine.2014.10.079; Clements KM, 2014, HUM VACC IMMUNOTHER, V10, P1171, DOI 10.4161/hv.28221; Crepey P, 2015, INFLUENZA OTHER RESP, V9, P39, DOI 10.1111/irv.12318; de Boer PT, 2016, VALUE HEALTH, V19, P964, DOI 10.1016/j.jval.2016.05.012; Dolk C, 2016, PHARMACOECONOMICS, V34, P1299, DOI 10.1007/s40273-016-0443-7; Dutch Health Council (Gezondheidsraad), 2014, GRIP GRIEP; Friesema IHM, 2009, VACCINE, V27, P6353, DOI 10.1016/j.vaccine.2009.05.042; Garcia A, 2016, HUM VACC IMMUNOTHER, V12, P2269, DOI 10.1080/21645515.2016.1182275; Hakkaart-van Roijen L., 2016, DUTCH NATL HEAL CARE, P1; Heins M., 2018, NIVEL MONITOR VACCIN; Heins M, 2017, MONITOR VACCINATIEGR; Henry C, 2018, TRENDS IMMUNOL, V39, P70, DOI 10.1016/j.it.2017.08.003; Hooiveld Heins M, 2017, MONITOR VACCINATIEGR; Houweling H, 2010, VACCINE, V28, P2924, DOI 10.1016/j.vaccine.2010.02.021; Korevaar J., 2016, MONITOR VACCINATIEGR; Meier G, 2015, J MED ECON, V18, P746, DOI 10.3111/13696998.2015.1044456; Miksch F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221564; Netea MG, 2008, FEMS IMMUNOL MED MIC, V52, P118, DOI 10.1111/j.1574-695X.2007.00353.x; Pitman R, 2012, MED DECIS MAKING, V32, P712, DOI 10.1177/0272989X12454578; Reukers D.F.M., 2018, ANN REPORT SURVEILLA; Rijksinstituut voor Volksgezondheid en Milieu, 2018, MAATR GRIEP SEIZ 201; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Teirlinck AC, 2017, ANN REPORT SURVEILLA; Tewawong N, 2017, INFECT GENET EVOL, V47, P35, DOI 10.1016/j.meegid.2016.11.010; Thommes EW, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1193-4; Tsuzuki S, 2018, VACCINE, V36, P624, DOI 10.1016/j.vaccine.2017.12.058; Uhart M, 2016, HUM VACC IMMUNOTHER, V12, P2259, DOI 10.1080/21645515.2016.1180490; Van Bellinghen LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098437; van den Wijngaard CC, 2010, AM J PUBLIC HEALTH, V100, P2248, DOI 10.2105/AJPH.2009.168245; van Dissel JT, ADVIES BAO N A V 55E; van Lier A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153106; Vijaykrishna D, 2015, ELIFE, V4, DOI 10.7554/eLife.05055; Willem L, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2699-8; World Health Organization, WHO GUID STAND EC EV; Yang MC, 2017, HUM VACC IMMUNOTHER, V13, P81, DOI 10.1080/21645515.2016.1225636; You JHS, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0618-9	44	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JAN	2021	24	1					3	10		10.1016/j.jval.2020.11.002		JAN 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QC0YJ	33431150	Green Published, hybrid			2022-04-28	WOS:000614560000002
J	Duarte, F				Duarte, Fabian			Encouraging Mammograms Using Behavioral Economics: A Randomized Controlled Trial in Chile	VALUE IN HEALTH			English	Article						barriers to screening; behavioral economics; mammography; women's health	SCREENING MAMMOGRAPHY; PROMOTE MAMMOGRAPHY; PRIMARY-CARE; INTERVENTIONS; WOMEN; COST	Objectives: This article illustrates the effect of a direct mail campaign that used insights from behavioral economics and psychology to increase the number of free mammograms in Chilean women aged 50 years or older. Methods: We hypothesized 4 barriers in obtaining a mammogram based on previous literature and focus group analysis. A behavioral economic approach providing incentives was used to help overcome these barriers. We accessed a unique data set, which comprised 12 000 women 50 years old or older, with private health insurance who have not had a mammogram for 24 or more months. We conducted a randomized controlled trial with 8 treatments, each involving a specific combination of messages. Results: The intervention overall led to a 167% increase in the use of free mammograms, a 1.13% to 3.03% average increase from the control to treatment groups, respectively. Regarding barriers, we found that all messages were effective, with a slightly larger and persistent effect for the less complex ones in terms of information. This finding illustrates the benefits of keeping the message simple. Conclusions: Finally, these results suggest a successful public policy for increasing use of free mammography programs. Moreover, they are potentially transferable because the study considered decision-making heuristics that are not specific to one culture or social context.	[Duarte, Fabian] Univ Chile, Econ Dept, Diagonal Paraguay 257, Santiago 8330015, Chile; [Duarte, Fabian] Millennium Nucleus Social Dev, Santiago, Chile		Duarte, F (通讯作者)，Univ Chile, Econ Dept, Diagonal Paraguay 257, Santiago 8330015, Chile.; Duarte, F (通讯作者)，Millennium Nucleus Social Dev, Santiago, Chile.	fabduarte@fen.uchile.cl			Fondecyt IniciacionComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT [11140162]; National Commission for Science and Technological Research; National Fund for Scientific and Technological Development program	This work was financially supported by Fondecyt Iniciacion grant number 11140162. The National Commission for Science and Technological Research was a Chilean government agency that aims to support research through competitive funding with annual calls for projects. One of these funds is the National Fund for Scientific and Technological Development program. Financial support for this project was awarded from the 2014 annual call, which consisted of $150 000 for 3 years and was assigned to the principal investigator, Fabian Duarte.	Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; Bleyer A, 2012, NEW ENGL J MED, V367, P1998, DOI 10.1056/NEJMoa1206809; Cialdini RB., 2007, INFLUENCE PSYCHOL PE; Elder JP, 1999, AM J PREV MED, V17, P275, DOI 10.1016/S0749-3797(99)00094-X; Gigerenzer G, 2009, B WORLD HEALTH ORGAN, V87, P567, DOI 10.2471/BLT.09.069872; Golman R, 2017, J ECON LIT, V55, P96, DOI 10.1257/jel.20151245; Iyengar SS, 2000, J PERS SOC PSYCHOL, V79, P995, DOI 10.1037//0022-3514.79.6.995; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Johannesson M, 1998, HEALTH ECON, V7, P1, DOI 10.1002/(SICI)1099-1050(199802)7:1<1::AID-HEC327>3.0.CO;2-U; KAHNEMAN D, 1979, COGNITION, V7, P409, DOI 10.1016/0010-0277(79)90024-6; Karlan D, 2016, MANAGE SCI, V62, P3393, DOI 10.1287/mnsc.2015.2296; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Legler J, 2002, CANCER EPIDEM BIOMAR, V11, P59; Luoto J, 2014, J DEV ECON, V110, P13, DOI 10.1016/j.jdeveco.2014.02.010; Madrian BC, 2001, Q J ECON, V116, P1149, DOI 10.1162/003355301753265543; Mandelblatt JS, 2009, ANN INTERN MED, V151, P738, DOI 10.7326/0003-4819-151-10-200911170-00010; Meissner HI, 2004, CANCER-AM CANCER SOC, V101, P1107, DOI 10.1002/cncr.20507; Ministerio de Desarrollo Social y Familia (MIDEPLAN), CASEN 2017 ENC CAR S; Ministerio de Economia Fomento y Turismo Servicio Nacional de Turismo (SERNATUR), 2012, MEDCOMP TUR INT; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; O'Donoghue T, 1999, AM ECON REV, V89, P103, DOI 10.1257/aer.89.1.103; Pop-Eleches C, 2011, AIDS, V25, P825, DOI 10.1097/QAD.0b013e32834380c1; Puschel K, 2010, FAM PRACT, V27, P85, DOI 10.1093/fampra/cmp080; Puschel K, 2011, BREAST, V20, pS40, DOI 10.1016/j.breast.2011.02.002; Puschel K, 2010, CANCER EPIDEM BIOMAR, V19, P2254, DOI 10.1158/1055-9965.EPI-10-0313; Slater JS, 2005, CANCER EPIDEM BIOMAR, V14, P2346, DOI 10.1158/1055-9965.EPI-05-0034; Slovic P., 2002, HEURISTICS BIASES PS, P397, DOI DOI 10.1017/CBO9780511808098.025; Sohl SJ, 2007, PREV MED, V45, P252, DOI 10.1016/j.ypmed.2007.06.009; Sullivan PS, 2004, JAIDS-J ACQ IMM DEF, V35, P511, DOI 10.1097/00126334-200404150-00009; URBAN N, 1994, AM J PUBLIC HEALTH, V84, P50, DOI 10.2105/AJPH.84.1.50; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; Weedon-Fekjaer H, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3701	32	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	OCT	2021	24	10					1463	1469		10.1016/j.jval.2021.04.1275		SEP 2021	7	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	WE3WV	34593169				2022-04-28	WOS:000705561100010
J	Ayala, A; Forjaz, MJ; Ramallo-Farina, Y; Martin-Fernandez, J; Garcia-Perez, L; Bilbao, A				Ayala, Alba; Forjaz, Maria Joao; Ramallo-Farina, Yolanda; Martin-Fernandez, Jesus; Garcia-Perez, Lidia; Bilbao, Amaia			Response Mapping Methods to Estimate the EQ-5D-5L From the Western Ontario McMaster Universities Osteoarthritis in Patients With Hip or Knee Osteoarthritis	VALUE IN HEALTH			English	Article						Bayesian networks; EQ-5D-5L; osteoarthritis; response mapping; WOMAC	QUALITY-OF-LIFE; OUTCOME MEASURES; CLINICAL MEASURES; HEALTH UTILITIES; WOMAC; VALIDITY; SCORES; INDEX	Objectives: The mapping technique can estimate generic preference-based measure scores through a specific measure that cannot be used in economic evaluations. This study compared 2 response mapping methods to estimate EQ-5D-5L scores using the Western Ontario McMaster Universities Osteoarthritis (WOMAC). Methods: The sample consisted of 758 patients with the hip or knee osteoarthritis recruited in baseline. Bayesian networks (BN) and multinomial logistic regression (ML) were used as response mapping models. Predictions were obtained using the 6-month follow-up as a validation sample. The mean absolute error, mean squared error, deviation from the root mean squared error and intraclass correlation coefficient were calculated as precision measures. Results: There was 5.5% of missing data, which was removed. The mean age was 69.6 years (standard deviation = 10.5), with 61.6% of women. The BN model presented lower mean absolute error, mean squared error, root mean squared error and higher intraclass correlation coefficient than the ML model. Only the WOMAC items pain and physical function items were related with the EQ-5D-5L dimensions. Conclusion: BN response mapping models are more robust methods, with better prediction results, than ML models. The BN model also provided a graphic representation of the dependency relationships between the EQ-5D-5L dimensions and the different WOMAC items that could be useful in the clinical investigation of patients with hip or knee osteoarthritis.	[Ayala, Alba] Univ Carlos III Madrid, Madrid, Spain; [Forjaz, Maria Joao] Inst Hlth Carlos III, Natl Epidemiol Ctr, Madrid, Spain; [Ramallo-Farina, Yolanda; Garcia-Perez, Lidia] Fdn Canaria Inst Invest Sanitaria Canarias FIISC, Tenerife, Spain; [Martin-Fernandez, Jesus] Madrid Hlth Serv, Primary Healthcare Management, Oeste Multiprofess Teaching Unit Primary & Commun, Madrid, Spain; [Bilbao, Amaia] Basurto Univ Hosp, Res Unit, Osakidetza Basque Hlth Serv, Bilbao, Spain; [Ayala, Alba; Ramallo-Farina, Yolanda; Martin-Fernandez, Jesus; Garcia-Perez, Lidia; Bilbao, Amaia] Hlth Serv Res Network Chron Dis REDISSEC, Baracaldo, Spain; [Bilbao, Amaia] Kronikgune Inst Hlth Serv Res, Baracaldo, Spain		Ayala, A (通讯作者)，Univ Carlos III Madrid, Sch Law & Social Sci, Dept Stat, C Madrid 126, Getafe 28903, Madrid, Spain.	aayala@est-econ.uc3m.es	Martín-Fernández, Jesús/U-1006-2019; Forjaz, Maria João/AAI-3797-2020; García-Pérez, Lidia/C-6364-2011	Martín-Fernández, Jesús/0000-0001-9545-1549; Forjaz, Maria João/0000-0003-3935-962X; García-Pérez, Lidia/0000-0002-5626-8116	Carlos III Health InstituteInstituto de Salud Carlos III [PI13/00560, PI13/00518, PI13/00648]; European Regional Development FundEuropean Commission	This study was supported by grants from the Carlos III Health Institute (Refs: PI13/00560, PI13/00518 and PI13/00648) and the European Regional Development Fund.	Alava MH, 2014, MED DECIS MAKING, V34, P919, DOI 10.1177/0272989X13500720; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ALTMAN RD, 1991, J RHEUMATOL, V18, P10; Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011; Barton GR, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-51; Bellamy N, 2002, J RHEUMATOL, V29, P2473; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bilbao A, 2020, VALUE HEALTH, V23, P379, DOI 10.1016/j.jval.2019.09.2755; Bilbao A, 2018, QUAL LIFE RES, V27, P2897, DOI 10.1007/s11136-018-1929-x; Borgelt C, 2009, GRAPHICAL MODELS REP; Brazier JE, 2010, EUR J HEALTH ECON, V11, P215, DOI 10.1007/s10198-009-0168-z; Conner-Spady BL, 2015, QUAL LIFE RES, V24, P1775, DOI 10.1007/s11136-014-0910-6; Costa J, 2019, J HEALTH PSYCHOL, V24, P153, DOI 10.1177/1359105316649785; Dakin H, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0857-3; Dakin H, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-151; Escobar A, 2002, CLIN RHEUMATOL, V21, P466, DOI 10.1007/s100670200117; Friedman N, 1996, PROCEEDINGS OF THE THIRTEENTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE AND THE EIGHTH INNOVATIVE APPLICATIONS OF ARTIFICIAL INTELLIGENCE CONFERENCE, VOLS 1 AND 2, P1277; Grootendorst P, 2007, J RHEUMATOL, V34, P534; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hiligsmann M, 2013, MEDICOGRAPHIA, V35, P197; Hiligsmann M, 2013, SEMIN ARTHRITIS RHEU, V43, P303, DOI 10.1016/j.semarthrit.2013.07.003; Kharroubi SA, 2015, MED DECIS MAKING, V35, P351, DOI 10.1177/0272989X15575285; Kiadaliri AA, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0547-y; Kleiber Beverly, 2005, Psychiatry (Edgmont), V2, P12; Le QA, 2014, QUAL LIFE RES, V23, P459, DOI 10.1007/s11136-013-0517-3; Le QA, 2011, MED CARE, V49, P451, DOI 10.1097/MLR.0b013e318207e9a8; Ramos-Goni JM, 2013, STATA J, V13, P474, DOI 10.1177/1536867X1301300303; Margaritis D, LEARNING BAYESIAN NE; Mukaka MM, 2012, MALAWI MED J, V24, P69; Mukuria C, 2019, APPL HEALTH ECON HEA, V17, P295, DOI 10.1007/s40258-019-00467-6; Nagarajan R, 2013, BAYESIAN NETWORKS R, P125; National Institute for Health and Care Excellence, 2013, GUID METH TECHN APPR; Oemar M, EQ 5D 5L USER GUIDE; Pearl J., 1985, BAYESIAN NETWORKS MO; Petrou S, 2016, QUAL LIFE RES, V25, P275, DOI 10.1007/s11136-015-1082-8; Petrou S, 2015, PHARMACOECONOMICS, V33, P985, DOI [10.1007/s40273-015-0319-2, 10.1017/S0266462315000379]; Petrou S, 2015, PHARMACOECONOMICS, V33, P993, DOI 10.1007/s40273-015-0312-9; Price AJ, 2019, HEALTH TECHNOL ASSES, V23; Ramos-Goni JM, 2018, VALUE HEALTH, V21, P596, DOI 10.1016/j.jval.2017.10.023; Rasanen P, 2006, INT J TECHNOL ASSESS, V22, P235, DOI 10.1017/S0266462306051051; Rowen D, 2011, NICE DSU TECHNICAL S; Sacristan JA, 2004, MED CLIN-BARCELONA, V122, P379; Scutari M., 2012, R PACKAGE VERSION; Wailoo A, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-37; Wailoo AJ, 2017, VALUE HEALTH, V20, P18, DOI 10.1016/j.jval.2016.11.006; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Xie F, 2007, ARTHRIT RHEUM-ARTHR, V57, P1043, DOI 10.1002/art.22883; Xie F, 2010, VALUE HEALTH, V13, P873, DOI 10.1111/j.1524-4733.2010.00770.x; Young MK, 2013, QUAL LIFE RES, V22, P1065, DOI 10.1007/s11136-012-0231-6	49	0	0	5	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24	6					874	883		10.1016/j.jval.2021.01.003		JUN 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SP8AF	34119086				2022-04-28	WOS:000659884900016
J	Gc, VS; Iglesias, CP; Erdem, S; Hassan, L; Manca, A				Gc, V. S.; Iglesias, C. P.; Erdem, S.; Hassan, L.; Manca, A.			PATIENTS' PREFERENCES FOR A WEARABLE DIGITAL HEALTH TECHNOLOGY TO SUPPORT SELF-MANAGEMENT OF CHRONIC KIDNEY DISEASE	VALUE IN HEALTH			English	Meeting Abstract									[Gc, V. S.; Iglesias, C. P.; Manca, A.] Univ York, York, Yor, England; [Erdem, S.] Univ Stirling, Stirling, Scotland; [Hassan, L.] Univ Manchester, Manchester, Lancs, England				Gc, Vijay/E-7443-2011	Gc, Vijay/0000-0003-0365-2605				0	0	0	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PUK21	S237	S237		10.1016/j.jval.2021.04.1189		JUN 2021	1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401301
J	Alzahrani, S; Almeziny, M; Narang, A; Mohamed, O				Alzahrani, S.; Almeziny, M.; Narang, A.; Mohamed, O.			A COST-COMPARATIVE ANALYSIS OF OUTPATIENT USE OF INTRAVENOUS FERRIC CARBOXYMALTOSE VERSUS INTRAVENOUS IRON SUCROSE IN A MAJOR TERTIARY CARE HOSPITAL IN SAUDI ARABIA	VALUE IN HEALTH			English	Meeting Abstract									[Alzahrani, S.; Almeziny, M.] Prince Sultan Mil Med City, Riyadh, Saudi Arabia; [Narang, A.] IQVIA, Delhi, DL, India; [Mohamed, O.] IQVIA, Dubai, DU, U Arab Emirates									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG11	S89	S89					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400387
J	Blauvelt, A; Shi, N; Somani, N; Kern, S; Atiya, B; Burge, R; Ridenour, T; Zhu, B; Zimmerman, N; Murage, M				Blauvelt, A.; Shi, N.; Somani, N.; Kern, S.; Atiya, B.; Burge, R.; Ridenour, T.; Zhu, B.; Zimmerman, N.; Murage, M.			COMPARISON OF SWITCHING PATTERNS AMONG PATIENTS WITH PSORIASIS USING IXEKIZUMAB OR SECUKINUMAB IN REAL-WORLD SETTINGS	VALUE IN HEALTH			English	Meeting Abstract									[Blauvelt, A.] Oregon Med Res Ctr, Portland, IN USA; [Shi, N.; Zimmerman, N.] IBM Watson Hlth, Acton, MA USA; [Somani, N.; Kern, S.; Atiya, B.; Burge, R.; Ridenour, T.; Zhu, B.; Murage, M.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Burge, R.] Univ Cincinnati, Div Pharmaceut Sci, Indianapolis, IN USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PBI17	S17	S18					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400070
J	Cai, K; Devine, B				Cai, K.; Devine, B.			A THRESHOLD ANALYSIS OF THE COST-EFFECTIVENESS OF ADJUNCTIVE INCLISIRAN THERAPY FOR ASCVD PATIENTS WITH LDL >= 70 MG/DL ON MAXIMALLY TOLERATED STATIN THERAPY	VALUE IN HEALTH			English	Meeting Abstract									[Cai, K.; Devine, B.] Univ Washington, Seattle, WA 98195 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV24	S71	S71					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400310
J	Chen, JV; Klein, TM; Mudd, P				Chen, J., V; Klein, T. M.; Mudd, P.			COST EFFECTIVENESS OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Chen, J., V; Klein, T. M.] Med Decis Modeling Inc, Indianapolis, IN USA; [Mudd, P.] Urovant Sci, Durham, NC USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PUK6	S235	S235					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401290
J	Chitnis, A; Wolf, S; Vanderkarr, M; Quintana, J; Gador, LV; Holy, CE; Lambert, S				Chitnis, A.; Wolf, S.; Vanderkarr, M.; Quintana, J.; Gador, L., V; Holy, C. E.; Lambert, S.			SURGICAL TREATMENT, REOPERATIONS, AND COMPLICATIONS AMONG PATIENTS WITH CLAVICLE FRACTURE IN ENGLAND	VALUE IN HEALTH			English	Meeting Abstract									[Chitnis, A.] Johnson & Johnson, New Brunswick, NJ USA; Mu Sigma, Bangalore, Karnataka, India; [Wolf, S.] Synthes GmbH, Zuchwil, Switzerland; [Vanderkarr, M.] DePuy Synthes Inc, Bay Village, OH USA; [Quintana, J.] Johnson & Johnson, Madrid M, Spain; [Gador, L., V] Johnson & Johnson Med GmbH, Norderstedt, Germany; [Lambert, S.] NHS, London, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMD15	S125	S126					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400549
J	Clerc, E; Salzberger, T; Cano, S; Afolalu, E; Chrea, C				Clerc, E.; Salzberger, T.; Cano, S.; Afolalu, E.; Chrea, C.			PSYCHOMETRIC VALIDATION OF NEW SCALES EXPANDING CONCEPTUAL COVERAGE OF THE ABOUTTM-PERCEIVED RISK: PERCEIVED SOCIAL RISK AND PERCEIVED PRACTICAL RISK	VALUE IN HEALTH			English	Meeting Abstract									[Clerc, E.; Afolalu, E.; Chrea, C.] Philip Morris Prod SA, Neuchatel, NE, Switzerland; [Salzberger, T.] Univ Econ & Business, Vienna, Austria; [Cano, S.] Modus Outcomes, Stotfold, England									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS108	S192	S192					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401103
J	Dai, L				Dai, L.			IMPACTS OF INCOME RESOURCES ON INFORMAL CARE USAGE IN ENGLAND	VALUE IN HEALTH			English	Meeting Abstract									[Dai, L.] Univ Aberdeen, Aberdeen, Abe, Scotland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS57	S183	S183					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401060
J	Domsic, RT; Vampola, CL; Stassek, L; Pokrzywinski, R; Furst, D; Chung, LS; Steen, V; Mayes, MD; Shah, A; Molitor, J; Nagaraja, V; Oliver, K; Benton, W; Khanna, D				Domsic, R. T.; Vampola, C. L.; Stassek, L.; Pokrzywinski, R.; Furst, D.; Chung, L. S.; Steen, V; Mayes, M. D.; Shah, A.; Molitor, J.; Nagaraja, V; Oliver, K.; Benton, W.; Khanna, D.			QUALITATIVE INTERVIEWS TO ASSESS THE CONTENT VALIDITY OF A NOVEL RAYNAUD DIARY IN PATIENTS WITH SYSTEMIC SCLEROSIS	VALUE IN HEALTH			English	Meeting Abstract									[Domsic, R. T.] Univ Pittsburgh, Dept Med, 930 Scaife Hall, Pittsburgh, PA USA; [Vampola, C. L.; Oliver, K.] Eicos Sci, San Mateo, CA USA; [Stassek, L.] Evidera, Seattle, WA USA; [Pokrzywinski, R.] EVIDERA, Bethesda, MD USA; [Furst, D.] Univ Calif Los Angeles, Los Angeles, CA USA; [Chung, L. S.] Stanford Univ, Palo Alto, CA 94304 USA; [Steen, V] Georgetown Univ, Med Ctr, Washington, DC 20007 USA; [Mayes, M. D.] Univ Texas Houston, Houston, TX USA; [Shah, A.] Johns Hopkins Univ Hosp, Baltimore, MD USA; [Molitor, J.] Univ Minnesota, Minneapolis, MN USA; [Nagaraja, V; Khanna, D.] Univ Michigan, Ann Arbor, MI 48109 USA; [Benton, W.] Eicos Sci, Redwood City, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO62	S208	S209					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401177
J	Edgerton, C; Frick, A; Helfgott, SM; Huston, K; Singh, JA; Soloman, N				Edgerton, C.; Frick, A.; Helfgott, S. M.; Huston, K.; Singh, J. A.; Soloman, N.			EXPERIENCE WITH APREMILAST IN TREATMENT OF PSORIATIC ARTHRITIS IN US CLINICAL PRACTICE; ASSESSMENTS FROM TRIO HEALTH AND THE AMERICAN RHEUMATOLOGY NETWORK (ARN)	VALUE IN HEALTH			English	Meeting Abstract									[Edgerton, C.] Articularis Healthcare, Summerville, SC USA; [Frick, A.] Trio Hlth, La Mirada, CA USA; [Helfgott, S. M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Huston, K.] Ctr Rheumat Dis & Allergy Immunol, Kansas City, MO USA; [Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA; [Soloman, N.] Arizona Arthrit, Phoenix, AZ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSY12	S231	S231					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401273
J	Garcia-Rivera, E; Ruiz, K; Miranda, E; Mejia, L; Pinzon, A; Marques-Goyco, C; Quijada, J; Monsanto, H; Orengo, J				Garcia-Rivera, E.; Ruiz, K.; Miranda, E.; Mejia, L.; Pinzon, A.; Marques-Goyco, C.; Quijada, J.; Monsanto, H.; Orengo, J.			PREVALENCE AND CO-PREVALENCE OF COMORBIDITIES AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS LIVING IN PUERTO RICO, USA	VALUE IN HEALTH			English	Meeting Abstract									[Garcia-Rivera, E.] Univ Puerto Rico, Carolina, PR USA; [Ruiz, K.] Univ Puerto Rico, San Juan, PR 00936 USA; [Miranda, E.; Mejia, L.; Marques-Goyco, C.; Quijada, J.; Monsanto, H.; Orengo, J.] Merck & Co Inc, Kenilworth, NJ USA; [Pinzon, A.] MSD IA Corp CL Branch, Santiago, Chile									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB18	S81	S81					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400354
J	Gilardino, R; Guarin, D; Marquez, MCB; Forero, JC				Gilardino, R.; Guarin, D.; Bustos Marquez, M. C.; Forero, J. C.			VALUE-BASED PRICING IN COLOMBIA: THE DEVIL IS IN THE DETAILS	VALUE IN HEALTH			English	Meeting Abstract									[Gilardino, R.] HE Xperts Consulting LLC, Miami, FL USA; [Guarin, D.] Merck, Kenilworth, NJ USA; [Bustos Marquez, M. C.; Forero, J. C.] Amgen Inc, Bogota, CUN, Colombia				Gilardino, Ramiro/AGX-6637-2022	Gilardino, Ramiro/0000-0002-9238-7729				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU43	S152	S152					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400662
J	Grabner, M; Burchard, J; Nguyen, C; Chung, H; Gangan, N; Boniface, J; Zupancic, JAF; Stanek, E				Grabner, M.; Burchard, J.; Nguyen, C.; Chung, H.; Gangan, N.; Boniface, J.; Zupancic, J. A. F.; Stanek, E.			COST-EFFECTIVENESS OF A PROTEOMIC TEST FOR PRETERM BIRTH PREDICTION	VALUE IN HEALTH			English	Meeting Abstract									[Grabner, M.; Nguyen, C.; Chung, H.; Gangan, N.; Stanek, E.] HealthCore Inc, Wilmington, DE USA; [Burchard, J.; Boniface, J.] Sera Prognost, Salt Lake City, UT USA; [Zupancic, J. A. F.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH7	S100	S100					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400435
J	Graham, C				Graham, C.			A NEW APPROACH TO SURVIVAL CURVE TAIL CORRECTIONS: THE AGE-MATCHED LIFE TABLE (AMLT) METHOD	VALUE IN HEALTH			English	Meeting Abstract									[Graham, C.] RTI Hlth Solut, Durham, NC USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU55	S154	S154					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400670
J	Holub, A; Kr, S; Ray, B; Holy, CE; Leopold, J; Daccach, J; Hoeffel, D; Coplan, P				Holub, A.; Kr, S.; Ray, B.; Holy, C. E.; Leopold, J.; Daccach, J.; Hoeffel, D.; Coplan, P.			PATIENT AND PROVIDER FACTORS ASSOCIATED WITH ASEPTIC LOOSENING FOLLOWING CEMENTED PRIMARY KNEE TOTAL ARTHROPLASTY	VALUE IN HEALTH			English	Meeting Abstract									[Holub, A.; Holy, C. E.; Leopold, J.; Daccach, J.; Hoeffel, D.; Coplan, P.] Johnson & Johnson, New Brunswick, NJ USA; [Kr, S.; Ray, B.] Mu Sigma, Bangalore, Karnataka, India									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMS17	S141	S141					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400615
J	Karkare, S; Zhdanava, M; Nash, A; Pilon, D; Morrison, L; Shah, A; Lefebvre, P; Joshi, K				Karkare, S.; Zhdanava, M.; Nash, A.; Pilon, D.; Morrison, L.; Shah, A.; Lefebvre, P.; Joshi, K.			CHARACTERISTICS OF REAL-WORLD COMMERCIALLY INSURED PATIENTS WITH TREATMENT-RESISTANT DEPRESSION INITIATED ON ESKETAMINE NASAL SPRAY OR CONVENTIONAL THERAPIES	VALUE IN HEALTH			English	Meeting Abstract									[Karkare, S.; Nash, A.; Joshi, K.] Janssen Sci Affairs LLC, Titusville, NJ USA; [Zhdanava, M.; Pilon, D.; Morrison, L.; Shah, A.; Lefebvre, P.] Anal Grp Inc, Montreal, PQ, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH30	S133	S133					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400580
J	Khan, H				Khan, H.			PROTOCATECHUIC ACID INDUCED PHARMACOLOGICAL POSTCONDITIONING AMELIORATES CEREBRAL ISCHEMIA REPERFUSION INJURY IN MICE BY MODULATION OF NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR PATHWAY	VALUE IN HEALTH			English	Meeting Abstract									[Khan, H.] Chitkara Univ, Rajpura, PB, India									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND55	S169	S169					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400738
J	Khurana, L; Reed, DL; Hutchin, J; Lima, V; Arnera, V; Cascade, E				Khurana, L.; Reed, D. L.; Hutchin, J.; Lima, V; Arnera, V; Cascade, E.			STATE OF BYOD: LESSONS IN ACCEPTABILITY AND COMPLIANCE FROM 35 TRIALS	VALUE IN HEALTH			English	Meeting Abstract									[Khurana, L.] ERT, Boston, MA USA; [Reed, D. L.; Arnera, V] ERT, Geneva, MA, Switzerland; [Hutchin, J.] ERT, Pittsburgh, PA USA; [Lima, V; Cascade, E.] ERT, Medford, MA USA									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU61	S155	S155					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400676
J	Leung, L; Kurt, M; Singh, P; Kim, I; Donnellan, G; Kanters, S				Leung, L.; Kurt, M.; Singh, P.; Kim, I; Donnellan, G.; Kanters, S.			DISEASE-FREE SURVIVAL (DFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADULTS WITH RESECTABLE ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER: A CORRELATION META-ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Leung, L.; Donnellan, G.; Kanters, S.] Evidinno Outcomes Res Inc, Vancouver, BC, Canada; [Kurt, M.; Singh, P.; Kim, I] Bristol Myers Squibb, Lawrenceville, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		AI3	S1	S1					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400004
J	Lin, D; Pilon, D; Benson, C; Morrison, L; Shah, A; Lafeuille, MH; Lefebvre, P				Lin, D.; Pilon, D.; Benson, C.; Morrison, L.; Shah, A.; Lafeuille, M. H.; Lefebvre, P.			ASSESSMENT OF PATIENT OUT-OF-POCKET COSTS FOR ANTIPSYCHOTIC TREATMENTS AMONG MEDICAID BENEFICIARIES WITH SCHIZOPHRENIA	VALUE IN HEALTH			English	Meeting Abstract									[Lin, D.; Benson, C.] Janssen Sci Affairs LLC, Titusville, NJ USA; [Pilon, D.; Morrison, L.; Shah, A.; Lafeuille, M. H.; Lefebvre, P.] Anal Grp Inc, Montreal, PQ, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH7	S129	S129					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400563
J	Liu, X; Dou, G; Rui, W; Li, L; Yu, M; Zhan, L				Liu, X.; Dou, G.; Rui, W.; Li, L.; Yu, M.; Zhan, L.			TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION AND DIRECT MEDICAL COSTS OF CHRONIC URTICARIA IN CHINA: BASED A NATIONAL CLAIM DATABASE	VALUE IN HEALTH			English	Meeting Abstract									[Liu, X.; Dou, G.; Rui, W.; Zhan, L.] Lilly Suzhou Pharmaceut Co Ltd, Shanghai, Peoples R China; [Li, L.; Yu, M.] Beijing Brainpower Pharma Consulting Co Ltd, Beijing, Peoples R China									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSY3	S229	S229					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401265
J	Marques, RP; Heudtlass, P; Godinho, AR; Pais, HL; Quintela, A; Lopes, DJP; Martins, AP				Marques, R. P.; Heudtlass, P.; Godinho, A. R.; Pais, H. L.; Quintela, A.; Lopes, da Cruz J. P.; Martins, A. P.			CETUXIMAB VERSUS BEVACIZUMAB IN METASTATIC COLORECTAL CANCER: A COMPARATIVE EFFECTIVENESS AND PATIENT-REPORTED OUTCOMES MULTICOHORT STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Marques, R. P.; Pais, H. L.; Quintela, A.; Lopes, da Cruz J. P.] Ctr Hosp Univ Lisboa Norte, Lisbon, Portugal; [Heudtlass, P.; Godinho, A. R.] Ctr Hlth Evaluat & Res, Lisbon, Portugal; [Martins, A. P.] Univ Lisbon, Fac Pharm, Lisbon, Portugal									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN18	S21	S21					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400086
J	Mathur, H; Jaiswal, H; Farinella, M; Rubinstein, J				Mathur, H.; Jaiswal, H.; Farinella, M.; Rubinstein, J.			IDENTIFICATION OF KEY DRIVERS OF PBAC DEFERRED DECISIONS AND THE NUMBER OF SUBMISSIONS NEEDED TO REACH A POSITIVE RECOMMENDATION	VALUE IN HEALTH			English	Meeting Abstract									[Mathur, H.; Jaiswal, H.] Decis Resources Grp, Gurugram, HR, India; [Farinella, M.; Rubinstein, J.] Decis Resources Grp, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS58	S183	S183					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401061
J	McClelland, T; Adunlin, G				McClelland, T.; Adunlin, G.			EARLY-ONSET COLORECTAL CANCER IN THE UNITED STATES: A NARRATIVE REVIEW OF THE EVIDENCE	VALUE IN HEALTH			English	Meeting Abstract									[McClelland, T.] Samford Univ, Birmingham, AL USA; [Adunlin, G.] Samford Univ, Chelsea, AL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN5	S19	S19					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400077
J	Menis, M; Whitaker, BI; Jiao, Y; Lo, AC; Wernecke, M; MaCurdy, TE; Kelman, JA; Anderson, SA; Forshee, RA				Menis, M.; Whitaker, B., I; Jiao, Y.; Lo, A. C.; Wernecke, M.; MaCurdy, T. E.; Kelman, J. A.; Anderson, S. A.; Forshee, R. A.			OUTPATIENT TRANSFUSIONS AND OCCURRENCE OF TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD (TACO) AMONG US MEDICARE BENEFICIARIES AGES 65 AND OLDER, DURING 2011-2018	VALUE IN HEALTH			English	Meeting Abstract									[Menis, M.; Whitaker, B., I; Anderson, S. A.; Forshee, R. A.] US FDA, Silver Spring, MD USA; [Jiao, Y.; Lo, A. C.; Wernecke, M.] Acumen LLC, Burlingame, CA USA; [MaCurdy, T. E.] Stanford Univ, Dept Econ, Palo Alto, CA 94304 USA; [Kelman, J. A.] CMS, Baltimore, MD USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS23	S216	S217					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401212
J	Mestouri, A; Maalem, A; Kooli, A				Mestouri, A.; Maalem, A.; Kooli, A.			EFFECTIVENESS OF SACUBITRIL/VALSARTAN VERSUS ENALAPRIL IN REDUCING MORTALITY AND HOSPITALIZATIONS COSTS FROM AN ALGERIAN HOSPITAL PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Mestouri, A.; Maalem, A.] Novartis Algeria, Algiers, Algeria; [Kooli, A.] Novartis Pharma Serv, Les Berges Du Lac 1, Tunisia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV33	S72	S73					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400318
J	Mohan, A; Majd, Z; Paranjpe, R; Vadhariya, A; Serna, O; Abughosh, SM				Mohan, A.; Majd, Z.; Paranjpe, R.; Vadhariya, A.; Serna, O.; Abughosh, S. M.			PERSISTENCE TO WARFARIN AMONG PATIENTS WITH ATRIAL FIBRILLATION AND COMORBID HYPERTENSION, DIABETES AND HYPERLIPIDEMIA	VALUE IN HEALTH			English	Meeting Abstract									[Mohan, A.; Majd, Z.] Univ Houston, Coll Pharm, Houston, TX 77030 USA; [Paranjpe, R.] Boston Sci, Boston, MA USA; [Vadhariya, A.] Eli Lilly & Co, Pittsburgh, PA USA; [Serna, O.] CareAllies, Houston, TX USA; [Abughosh, S. M.] Univ Houston, Houston, TX USA				Paranjpe, Rutugandha/AFU-1080-2022					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV57	S77	S77					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400338
J	Moussa, M; Shabana, A; Eldin, DS; Ali, HM; Mohamed, M; Sheweta, S; Elsisi, GH				Moussa, M.; Shabana, A.; Salah Eldin, D.; Ali, H. M.; Mohamed, M.; Sheweta, S.; Elsisi, G. H.			A COST EFFECTIVENESS STUDY OF PERCUTANEOUS CORONARY INTERVENTION VERSUS CORONARY ARTERY BYPASS GRAFTING IN EGYPT FOR PATIENTS WITH PREVIOUSLY UNTREATED THREE-VESSEL OR LEFT MAIN CORONARY ARTERY DISEASE: MARKOV MODEL	VALUE IN HEALTH			English	Meeting Abstract									[Moussa, M.] Elaraby Hosp, Tanta, Egypt; [Shabana, A.] VACSERA, Cairo, Egypt; [Salah Eldin, D.; Sheweta, S.] HTA Off, Cairo, Egypt; [Ali, H. M.] VACSERA, Giza, Egypt; [Mohamed, M.] AXA, Cairo, Egypt; [Elsisi, G. H.] Egyptian Minist Hlth & Populat, Cairo, Egypt									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV13	S69	S69					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400300
J	Osenenko, K; Deighton, A; Szabo, S				Osenenko, K.; Deighton, A.; Szabo, S.			CHALLENGES IN THE ESTIMATION OF BIRTH PREVALENCE FOR RARE DISEASES: A CASE STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Osenenko, K.; Deighton, A.; Szabo, S.] Broadstreet Hlth Econ & Outcomes Res, Vancouver, BC, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO34	S203	S203					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401152
J	Rong, Y; Ramachandran, S; Pittman, E; Bhattacharya, K; Bentley, JP; Banahan, B; Kirby, T; Drone, S				Rong, Y.; Ramachandran, S.; Pittman, E.; Bhattacharya, K.; Bentley, J. P.; Banahan, B., III; Kirby, T.; Drone, S.			RISK FACTORS FOR SEVERE OUTCOMES IN COVID-19 CONFIRMED OR SUSPECTED BENEFICIARIES ENROLLED IN MISSISSIPPI MEDICAID	VALUE IN HEALTH			English	Meeting Abstract									[Rong, Y.; Ramachandran, S.] Univ Mississippi, Oxford, MS USA; [Pittman, E.; Bentley, J. P.] Univ Mississippi, University, MS 38677 USA; [Bhattacharya, K.] Univ Mississippi, Sch Pharm, Dept Pharm Adm, University, MS 38677 USA; [Banahan, B., III] Univ Mississippi, Ctr Pharmaceut Mkt & Management, University, MS 38677 USA; [Kirby, T.] Mississippi Div Medicaid, Off Governor, Jackson, MS USA; [Drone, S.] Mississippi Div Medicaid, Off Informat Technol Management iTECH, Jackson, MS USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN40	S112	S112					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400491
J	Russell-Smith, TA; Chadda, S; Le Reun, C; Doogan, E; Bajko, P				Russell-Smith, T. A.; Chadda, S.; Le Reun, C.; Doogan, E.; Bajko, P.			A PARAMETRIC ANALYSIS OF OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) WHO HAVE RECEIVED HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)	VALUE IN HEALTH			English	Meeting Abstract									[Russell-Smith, T. A.] Pfizer Inc, New York, NY USA; [Chadda, S.; Doogan, E.; Bajko, P.] Genesis Res, Newcastle Upon Tyne, Tyne & Wear, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSU17	S227	S227					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401258
J	Sadosky, A; Ambegaonkar, AJ				Sadosky, A.; Ambegaonkar, A. J.			REAL WORLD EVIDENCE TO SUPPORT THE CLINICAL EFFECTIVENESS OF MULTIPLE SCLEROSIS THERAPIES: A US PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Sadosky, A.] APPERTURE LLC, Westerly, RI USA; [Ambegaonkar, A. J.] APPERTURE LLC, Marlboro, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND4	S158	S158					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400690
J	Samaksha, PB; Ramesh, M; Kishor, M				Samaksha, P. B.; Ramesh, M.; Kishor, M.			IMPACT OF CLINICAL PHARMACIST-INITIATED MEDICATION INFORMATION SERVICES AMONG PSYCHIATRIC PATIENTS	VALUE IN HEALTH			English	Meeting Abstract									[Samaksha, P. B.] JSS Coll Pharm, Mysuru, KA, India; [Ramesh, M.] JSS Coll Pharm, Mysore, Karnataka, India; [Kishor, M.] JSS Med Coll, Mysore, Karnataka, India									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH44	S135	S135					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400591
J	Shankar, S; Buendia, O				Shankar, S.; Buendia, O.			HEALTHCARE RESOURCE UTILISATION AND COSTS SAVED WITH EARLIER DIAGNOSIS OF BEHCETS DISEASE: USING UK PRIMARY CARE ELECTRONIC HEALTH RECORDS	VALUE IN HEALTH			English	Meeting Abstract									[Shankar, S.; Buendia, O.] Mendelian, London, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO14	S200	S200					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401136
J	Shao, Y; Hong, D; Stoecker, C; Nauman, E; Bazzano, A; Kabagambe, E; Hu, G; Yoshida, Y; Fonseca, V; Katzmarzyk, P; Nigam, S; Carton, T; Gugel, J; Shi, L				Shao, Y.; Hong, D.; Stoecker, C.; Nauman, E.; Bazzano, A.; Kabagambe, E.; Hu, G.; Yoshida, Y.; Fonseca, V; Katzmarzyk, P.; Nigam, S.; Carton, T.; Gugel, J.; Shi, L.			THE IMPACT OF REIMBURSEMENT FOR NON-FACE-TO-FACE CHRONIC CARE MANAGEMENT ON HEALTH OUTCOMES AND HEALTH CARE UTILIZATION AMONG PATIENTS WITH TYPE 2 DIABETES IN LOUISIANA	VALUE IN HEALTH			English	Meeting Abstract									[Shao, Y.] Tulane Univ, Sch Publ Hlth & Trop Med, River Ridge, LA USA; [Hong, D.; Stoecker, C.; Bazzano, A.; Shi, L.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA; [Nauman, E.; Carton, T.] Louisiana Publ Hlth Inst, New Orleans, LA USA; [Kabagambe, E.] Ochsner Hlth, New Orleans, LA USA; [Hu, G.; Katzmarzyk, P.] Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA; [Yoshida, Y.; Fonseca, V; Gugel, J.] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Nigam, S.] Blue Cross & Blue Shield Louisiana, Baton Rouge, LA USA									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		RE4	S239	S239					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401308
J	Shi, L; Luck, J				Shi, L.; Luck, J.			DOSE MEDICAID EXPANSION PROVIDE AFFORDABILITY OF HELATHCARE SERVICE FOR ASTHMA POPULATION	VALUE IN HEALTH			English	Meeting Abstract									[Shi, L.; Luck, J.] Oregon State Univ, Corvallis, OR 97331 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		HP4	S8	S8					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400032
J	Siskou, O; Koutsovasilis, A; Doupis, J; Karagkouni, I; Konstantakopoulou, O; Galanis, P; Kaitelidou, D				Siskou, O.; Koutsovasilis, A.; Doupis, J.; Karagkouni, I; Konstantakopoulou, O.; Galanis, P.; Kaitelidou, D.			BUDGET IMPACT ANALYSIS OF A FLASH GLYCOSE MONITORING TECHNOLOGY IN GREECE	VALUE IN HEALTH			English	Meeting Abstract									[Siskou, O.; Karagkouni, I; Konstantakopoulou, O.; Galanis, P.; Kaitelidou, D.] Natl & Kapodistrian Univ Athens, Dept Nursing, Ctr Hlth Serv Management & Evaluat, Athens, Greece; [Koutsovasilis, A.] St Panteleimon Gen Hosp Nikaia, Ctr Diabet, Piraeus, Greece; [Doupis, J.] Iatriko Palaiou Falirou Med Ctr, Diabet Dept, Athens, Greece; [Doupis, J.] Iatriko Palaiou Falirou Med Ctr, Clin Res Ctr, Athens, Greece									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB21	S81	S81					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400355
J	Stephenson, B; Chertow, G; Yang, Y; Rosenbaum, D				Stephenson, B.; Chertow, G.; Yang, Y.; Rosenbaum, D.			HOSPITALIZATION IN PATIENTS RECEIVING MAINTENANCE DIALYSIS WITH HYPERPHOSPHATEMIA RANDOMIZED TO TENAPANOR OR SEVELAMER	VALUE IN HEALTH			English	Meeting Abstract									[Stephenson, B.] Ardelyx, San Francisco, CA USA; [Chertow, G.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Yang, Y.; Rosenbaum, D.] Ardelyx, Fremont, CA USA					Chertow, Glenn/0000-0002-7599-0534				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PUK2	S234	S234					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401286
J	Yu, M; Duan, X; Wang, J; Zhang, XJ; Yu, F				Yu, M.; Duan, X.; Wang, J.; Zhang, X. J.; Yu, F.			DISEASE BURDEN OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Yu, M.; Duan, X.] Beijing North Med & Hlth Econ Res Ctr, Beijing, Peoples R China; [Wang, J.; Zhang, X. J.; Yu, F.] Xian Janssen Pharmaceut Ltd, Beijing, Peoples R China									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN109	S39	S40					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400166
J	Gravesteijn, B; Krijkamp, E; Busschbach, J; Geleijnse, G; Helmrich, IR; Bruinsma, S; van Lint, C; van Veen, E; Steyerberg, E; Verhoef, K; van Saase, J; Lingsma, H; de Jong, RB				Gravesteijn, Benjamin; Krijkamp, Eline; Busschbach, Jan; Geleijnse, Geert; Helmrich, Isabel Retel; Bruinsma, Sophie; van Lint, Celine; van Veen, Ernest; Steyerberg, Ewout; Verhoef, Kees; van Saase, Jan; Lingsma, Hester; de Jong, Rob Baatenburg		Value Based Operation Room Triage	Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study	VALUE IN HEALTH			English	Article						healthcare planning; COVID-19; population health; prioritization; simulation model; surgery delay	CANCER SURVIVAL; BLADDER-CANCER; BREAST-CANCER; SURGERY; OUTCOMES; IMPACT; RESECTION; DELAY; CARCINOMA; THERAPY	Objectives: Coronavirus disease 2019 has put unprecedented pressure on healthcare systems worldwide, leading to a reduction of the available healthcare capacity. Our objective was to develop a decision model to estimate the impact of postponing semielective surgical procedures on health, to support prioritization of care from a utilitarian perspective. Methods: A cohort state-transition model was developed and applied to 43 semielective nonpediatric surgical procedures commonly performed in academic hospitals. Scenarios of delaying surgery from 2 weeks were compared with delaying up to 1 year and no surgery at all. Model parameters were based on registries, scientific literature, and the World Health Organization Global Burden of Disease study. For each surgical procedure, the model estimated the average expected disability-adjusted life-years (DALYs) per month of delay. Results: Given the best available evidence, the 2 surgical procedures associated with most DALYs owing to delay were bypass surgery for Fontaine III/IV peripheral arterial disease (0.23 DALY/month, 95% confidence interval [CI]: 0.13-0.36) and trans aortic valve implantation (0.15 DALY/month, 95% CI: 0.09-0.24). The 2 surgical procedures with the least DALYs were placing a shunt for dialysis (0.01, 95% CI: 0.005-0.01) and thyroid carcinoma resection (0.01, 95% CI: 0.01-0.02). Conclusion: Expected health loss owing to surgical delay can be objectively calculated with our decision model based on best available evidence, which can guide prioritization of surgical procedures to minimize population health loss in times of scarcity. The model results should be placed in the context of different ethical perspectives and combined with capacity management tools to facilitate large-scale implementation.	[Gravesteijn, Benjamin; Geleijnse, Geert] Erasmus MC, Dept Otorhinolaryngol ENT, Rotterdam, Netherlands; [Gravesteijn, Benjamin; Helmrich, Isabel Retel; van Veen, Ernest; Steyerberg, Ewout; Lingsma, Hester; de Jong, Rob Baatenburg] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Krijkamp, Eline] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Krijkamp, Eline; Busschbach, Jan] Erasmus MC, Dept Med Psychol, Rotterdam, Netherlands; [Krijkamp, Eline; Busschbach, Jan] Erasmus MC, Netherlands Inst Hlth Sci, Rotterdam, Netherlands; [Bruinsma, Sophie; van Lint, Celine] Erasmus MC, Dept Qual & Patient Care, Rotterdam, Netherlands; [van Veen, Ernest] Erasmus MC, Dept Intens Care, Rotterdam, Netherlands; [Steyerberg, Ewout] Leiden Univ, Dept Biostat, Med Ctr, Leiden, Netherlands; [Verhoef, Kees] Erasmus MC, Dept Surg Oncol & Gastrointestinal Surg, Rotterdam, Netherlands; [van Saase, Jan] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands		Krijkamp, E (通讯作者)，Erasmus MC, Rotterdam, Netherlands.	e.krijkamp@erasmusmc.nl	Gravesteijn, Benjamin Yaël/AAN-9524-2020	Gravesteijn, Benjamin Yaël/0000-0001-8096-5803	Society for Medical Decision Making fellowship by the Gordon and Betty Moore Foundation, Palo Alto, CA, United States [GBMF7853]	Eline Krijkamp was supported by the Society for Medical Decision Making fellowship through a grant (GBMF7853) by the Gordon and Betty Moore Foundation, Palo Alto, CA, United States. Support for this study was solely from institutional and/or departmental sources.	Alarid-Escudero F, COHORT STATE TRANSIT; Alarid-Escudero F, 2019, PHARMACOECONOMICS, V37, P1329, DOI 10.1007/s40273-019-00837-x; [Anonymous], 2018, R LANGUAGE ENV STAT; Auneau-Enjalbert L, 2020, QUAL LIFE RES, V29, P959, DOI 10.1007/s11136-019-02372-w; Badalato GM, 2012, BJU INT, V110, P1471, DOI 10.1111/j.1464-410X.2012.11116.x; Biddison LD, 2014, CHEST, V146, pE145S, DOI 10.1378/chest.14-0742; Bleicher RJ, 2016, JAMA ONCOL, V2, P330, DOI 10.1001/jamaoncol.2015.4508; Bonow RO, 2015, CIRCULATION, V131, P969, DOI 10.1161/CIRCULATIONAHA.115.014846; Brewster DC, 2006, ANN SURG, V244, P426, DOI 10.1097/01.sla.0000234893.88045.dc; Brunner M, 2004, EUR HEART J, V25, P88, DOI 10.1016/j.ehj.2003.10.022; CBS, MORTALITY PROBABILIT; Centers for Disease Control and Prevention, ETHICAL CONSIDERATIO; Chang HJ, 2004, AM J PUBLIC HEALTH, V94, P562, DOI 10.2105/AJPH.94.4.562; Chen EY, 2021, J GASTROINTEST CANC, V52, P169, DOI 10.1007/s12029-020-00372-5; Chung JH, 2014, ANN THORAC SURG, V97, P224, DOI 10.1016/j.athoracsur.2013.08.039; Clegg LX, 2009, CANCER CAUSE CONTROL, V20, P417, DOI 10.1007/s10552-008-9256-0; D'Agostino A, 2020, LANCET PSYCHIAT, V7, P385, DOI 10.1016/S2215-0366(20)30133-4; Davies L, 2010, ARCH OTOLARYNGOL, V136, P440, DOI 10.1001/archoto.2010.55; Elliott JH, 2017, J CLIN EPIDEMIOL, V91, P23, DOI 10.1016/j.jclinepi.2017.08.010; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FEIN DA, 1994, HEAD NECK-J SCI SPEC, V16, P358, DOI 10.1002/hed.2880160410; Feltrim MIZ, 2014, TRANSPL P, V46, P3060, DOI 10.1016/j.transproceed.2014.07.022; Garner RT, 1967, MORAL PHILOS SYSTEMA; Ginsberg Robert J., 1995, Annals of Thoracic Surgery, V60, P615, DOI 10.1016/0003-4975(95)00537-U; Global Burden of Disease Collaborative Network, 2017, GLOBAL BURDEN DIS ST; Harahsheh AS, 2020, J PEDIATR-US, V222, P261, DOI 10.1016/j.jpeds.2020.04.052; Haruna A, 2010, CHEST, V138, P635, DOI 10.1378/chest.09-2836; Holtzman A, 2017, ACTA ONCOL, V56, P484, DOI 10.1080/0284186X.2016.1253863; Howard DPJ, 2015, CIRCULATION, V132, P1805, DOI 10.1161/CIRCULATIONAHA.115.016424; Huang CE, 2017, ONCOTARGET, V8, P79876, DOI 10.18632/oncotarget.20180; Hunink M, 2003, DECISION MAKING HLTH; Integrated Cancer Center Netherlands, CANCERS; Jain A, 2020, J BONE JOINT SURG AM, V102, DOI 10.2106/JBJS.20.00602; Jakola AS, 2012, JAMA-J AM MED ASSOC, V308, P1881, DOI 10.1001/jama.2012.12807; Janssen MWW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196427; Kann BH, 2019, RADIOTHER ONCOL, V134, P44, DOI 10.1016/j.radonc.2019.01.027; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Kim WR, 2018, AM J TRANSPLANT, V18, P172, DOI 10.1111/ajt.14559; Kirkegard J, 2019, EJSO-EUR J SURG ONC, V45, P1901, DOI 10.1016/j.ejso.2019.05.029; KLARMAN HE, 1968, MED CARE, V6, P48, DOI 10.1097/00005650-196801000-00005; KONSTANTINIDES S, 1995, HERZ KREISLAUF, V27, P354; Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5; Lee CT, 2006, J UROLOGY, V175, P1262, DOI 10.1016/S0022-5347(05)00644-0; Lee JN, 2014, J SURG ONCOL, V110, P468, DOI 10.1002/jso.23589; Lim C, 2018, J HEPATOL, V68, P100, DOI 10.1016/j.jhep.2017.09.017; MacCormick AD, 2006, MED DECIS MAKING, V26, P255, DOI 10.1177/0272989X06288680; Mazzone E, 2019, CLIN GENITOURIN CANC, V17, P105, DOI 10.1016/j.clgc.2018.11.003; Mikkola R, 2010, WORLD J SURG, V34, P266, DOI 10.1007/s00268-009-0324-8; Morse E, 2018, OTOLARYNG HEAD NECK, V159, P283, DOI 10.1177/0194599818758020; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Muluk SC, 2001, J VASC SURG, V33, P251, DOI 10.1067/mva.2001.112210; Murphy MM, 2009, CANCER-AM CANCER SOC, V115, P3979, DOI 10.1002/cncr.24433; Nakano R, 2018, SURGERY, V164, P219, DOI 10.1016/j.surg.2018.03.006; New York State Department of Health, 2015, VENTILATOR ALLOCATIO; Noorbakhsh A, 2014, J NEUROSURG, V120, P31, DOI 10.3171/2013.9.JNS13877; Nyboe C, LONG TERM MORTALITY; NZA, ANALYSE GEVOLGEN COR; Office of the Assistant Secretary for Preparedness US Department of Health and Human Services, 2017, PANDEMIC INFLUENZA P; Oudhoff JP, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-164; Pedregal-Mallo D, 2018, EUR ARCH OTO-RHINO-L, V275, P2071, DOI 10.1007/s00405-018-5027-z; Pettitt D, 2016, J STEM CELL RES THER, V6; PIEHLER JM, 1977, ARCH SURG-CHICAGO, V112, P26; Qadan M, 2020, ANN SURG, V272, pE20, DOI 10.1097/SLA.0000000000003963; Redden MD, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010651.pub2; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Ruys AT, 2014, HPB, V16, P469, DOI 10.1111/hpb.12156; Salenger R, 2020, ANN THORAC SURG, V110, P2020, DOI 10.1016/j.athoracsur.2020.04.018; Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8; Scott SWM, 2016, EUR J VASC ENDOVASC, V52, P444, DOI 10.1016/j.ejvs.2016.05.008; Shalowitz DI, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.11.1050; Shalowitz DI, 2016, GYNECOL ONCOL, V142, P30, DOI 10.1016/j.ygyno.2016.04.026; Shin DW, 2013, ANN SURG ONCOL, V20, P2468, DOI 10.1245/s10434-013-2957-y; Siebert U, 2012, MED DECIS MAKING, V32, P690, DOI 10.1177/0272989X12455463; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Soran A, 2018, ANN SURG ONCOL, V25, P3141, DOI 10.1245/s10434-018-6494-6; Sorensen VR, 2016, TRANSPLANTATION, V100, P2160, DOI 10.1097/TP.0000000000001002; Stewart JM, 2016, CAN J SURG, V59, P223, DOI 10.1503/cjs.014315; Stouthard MEA, 2000, EUR J PUBLIC HEALTH, V10, P24, DOI 10.1093/eurpub/10.1.24; Sud A, 2020, ANN ONCOL, V31, P1065, DOI 10.1016/j.annonc.2020.05.009; Tan WS, 2020, UROL ONCOL-SEMIN ORI, V38, DOI 10.1016/j.urolonc.2019.11.008; Toner E, HEALTH SERV J; Torgerson DJ, 1999, BRIT MED J, V319, P914, DOI 10.1136/bmj.319.7214.914; van Harten MC, 2014, ORAL ONCOL, V50, P282, DOI 10.1016/j.oraloncology.2013.12.018; Vergano M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02891-w; Verwaal VJ, 2008, ANN SURG ONCOL, V15, P2426, DOI 10.1245/s10434-008-9966-2; Wang JJ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017552; Warner L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002027.pub2; World Health Organization, DISABILITY ADJUSTED; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; Zorginstituut Nederland, GUIDELINE CONDUCTING	91	4	4	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAY	2021	24	5					648	657		10.1016/j.jval.2020.12.010		APR 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	RU9KC	33933233	hybrid, Green Published			2022-04-28	WOS:000645457500007
J	Towse, A; Chalkidou, K; Firth, I; Kettler, H; Silverman, R				Towse, Adrian; Chalkidou, Kalipso; Firth, Isobel; Kettler, Hannah; Silverman, Rachel			How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?	VALUE IN HEALTH			English	Article						Advance Market Commitment; COVID-19; global health; vaccines; value-based pricing	PANDEMIC INFLUENZA; ECONOMIC-ANALYSIS; EQUILIBRIUM; IMPACT	The potential health and economic value of a vaccine for coronavirus disease (COVID-19) is self-evident given nearly 2 million deaths, ?collateral? loss of life as other conditions go untreated, and massive economic damage. Results from the first licensed products are very encouraging; however, there are important reasons why we will likely need second and third generation vaccines. Dedicated incentives and funding focused explicitly on nurturing and advancing competing second and third generation vaccines are essential. This article proposes a collaborative, market-based financing mechanism for the world to incentivize and pay for the development of, and provide equitable access to, second and third generation COVID-19 vaccines. Specifically, we propose consideration of a Benefit-Based Advance Market Commitment (BBAMC). The BBAMC uses health technology assessment to determine value-based prices to guarantee overall market revenues, not revenue for any specific product or company. The poorest countries would not pay a value-based price but a discounted ?tail-price.? Innovators must agree to supply them at this tail price or to facilitate technology transfer to local licensees at low or zero cost to enable them to supply at this price. We expect these purchases to be paid for in full or large part by global donors. The BBAMC therefore sets prices in relation to value, protects intellectual property rights, encourages competition, and ensures all populations get access to vaccines, subject to agreed priority allocation rules.	[Towse, Adrian; Firth, Isobel] Off Hlth Econ, 7th Floor Southside,105 Victoria St, London SW1E 6QT, England; [Chalkidou, Kalipso; Silverman, Rachel] Ctr Global Dev, London, England; [Kettler, Hannah] Imperial Coll, London, England; [Kettler, Hannah] PATH, Seattle, WA USA		Towse, A (通讯作者)，Off Hlth Econ, 7th Floor Southside,105 Victoria St, London SW1E 6QT, England.	atowse@ohe.org					AcceleratingHT, ACC HLTH TECHN INC D; AstraZeneca, ASTRAZENECA TAK NEXT; AVERCH H, 1962, AM ECON REV, V52, P1052; Bach PB, BLOOMBERG OPINION; Berkeley S., GAVI COVAX AMC EXPLA; Beutels P, 2008, HEALTH ECON, V17, P1317, DOI 10.1002/hec.1339; Center for Global Development, SUMM BBAMC SLID FORM; CEPI, COVAX CEPIS RESP COV; Cernuschi T, 2011, B WORLD HEALTH ORGAN, V89, P913, DOI 10.2471/BLT.11.087700; Chaturvedi A, 2011, M&SOM-MANUF SERV OP, V13, P227, DOI 10.1287/msom.1100.0319; Cohen JT, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20200518.966027/full/, DOI 10.1377/HBLOG20200518.966027/FULL]; Council of Economic Advisers, 2019, MIT IMP PAND INFL VA; Dalberg Global Development Advisors, 2013, ADV MARK COMM PNEUM; Duke Global Health Innovation Center, 2020, LAUNCH SCAL SPEED; Garrison LP, 2018, VALUE HEALTH, V21, P161, DOI 10.1016/j.jval.2017.12.009; Garthwaite C., THEWASHINGTONPOST; GAVI, 2018, ADV MARK COMM PNEUM; Gavi, 2020, PRESS REL GAV SIGNS; Gavi, 2020, PRESS REL NEW COLL M; GAVI, COVID 19 VACC GLOB A; GAVI, EB VACC PURCH COMM G; Glennerster R., 2004, STRONG MED CREATING; Gorvett Z, WHY MOST COVID 19 DE; Gov.UK, JCVI UPD INT ADV PRI; GSK, SAN GSK JOIN FORC UN; Hollis A, IRPP POLICY OPTIONS; Hopkins Johns, J HOPKINS CORONAVIRU; International Monetary Fund, IMF BLOG; Kettler R, 2020, RACE DEV VACCINE COV; Kremer M, 1998, Q J ECON, V113, P1137, DOI 10.1162/003355398555865; Kremer M, 2005, BRIEFING NOTE ADV PU; Kremer M, 2020, W28168 NBER; Kremer M, 2020, AEA PAP P, V110, P269, DOI 10.1257/pandp.20201017; Kupferschmidt K, SCI MAG; Levine R, MAKING MARKETS VACCI; Lloyd S, 2020, 183 CGD, V183; Ma SY, 2020, VALUE HEALTH, V23, P1405, DOI 10.1016/j.jval.2020.06.002; Mauskopf J, 2018, VALUE HEALTH, V21, P1133, DOI 10.1016/j.jval.2018.08.005; McDonnell A, CGD BLOG; McLean KA, 2016, VACCINE, V34, P5410, DOI 10.1016/j.vaccine.2016.08.019; Mossialos E., 2020, TIMES; Neumann PJ, 2021, HEALTH AFFAIR, V40, P53, DOI 10.1377/hlthaff.2020.01548; Peel M, FINANCIAL TIMES; Pfizer, PFIZ BIONTECH CO DEV; Policy Cures, 2020, G IND 2019 NEGL DIS, DOI 11150341/G-Finder2019.pdf; Scannell J., FINANCIAL TIMES; Shretta R, COVID 19 VACCINE WE; Silverman R., 2020, MOND MORN VACC BREAK; Silverman R, 2020, RACE COVID 19 VACCIN; Silverman R., 2020, UNPACKING BLACK BOX; Slaoui M, 2020, NEW ENGL J MED, V383, P1701, DOI 10.1056/NEJMp2027405; Smith RD, 2005, J HEALTH ECON, V24, P1055, DOI 10.1016/j.jhealeco.2005.02.003; Smith RD, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4571; Snyder CM, 2020, HEALTH AFFAIR, V39, P1633, DOI 10.1377/hlthaff.2020.00646; The Boston Consulting Group, ADV MARK COMM PIL PN; The DELVE initiative, 6 DELVE; The Economist Intelligence Unit, COVID 19 HLTH FUND T; The National Academies of Sciences Engineering and Medicine., 2020, FRAM EQ ALL COVID 19; Towse A, 2005, B WORLD HEALTH ORGAN, V83, P301; Towse A., 2020, FINANCING SCALING IN; Towse A, NEW WAY DRIVE COVID; Towse A, LEAV 1 US BEN BAS AD; Towse A, BLUEPR MARK DRIV VAL; Weintraub A, FIERCE PHARM; World Health Organization, 2019, WHO GUID STAND EC EV; World Health Organization, SAGE WORK GROUP COV; World Health Organization, ADV MARK COMM VACC; World Health Organization, FAIR ALL MECH COVID; Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7	69	2	2	4	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAY	2021	24	5					625	631		10.1016/j.jval.2020.12.008		APR 2021	7	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	RU9KC	33933230	hybrid, Green Published			2022-04-28	WOS:000645457500004
J	Zhao, JD; Jin, HJ; Li, X; Jia, JG; Zhang, C; Zhao, HJ; Ma, WR; Wang, ZZ; He, Y; Lee, J; Zhang, DL; Yin, B; Zheng, WW; Wang, HY; Pennington, M				Zhao, Jidi; Jin, Huajie; Li, Xun; Jia, Jianguo; Zhang, Chao; Zhao, Huijuan; Ma, Wuren; Wang, Zhuozhu; He, Yi; Lee, Jimmy; Zhang, Donglan; Yin, Bo; Zheng, Weiwei; Wang, Haiyin; Pennington, Mark			Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies	VALUE IN HEALTH			English	Article						COVID-19; cost-effectiveness analysis; DALY; disease burden; movement restriction policies; timing		Objectives: Movement restriction policies (MRPs) are effective in preventing/delaying COVID-19 transmission but are associated with high societal cost. This study aims to estimate the health burden of the first wave of COVID-19 in China and the cost-effectiveness of early versus late implementation of MRPs to inform preparation for future waves. Methods: The SEIR (susceptible, exposed, infectious, and recovered) modeling framework was adapted to simulate the health and cost outcomes of initiating MRPs at different times: rapid implementation (January 23, the real-world scenario), delayed by 1 week, delayed by 2 weeks, and delayed by 4 weeks. The end point was set as the day when newly confirmed cases reached zero. Two costing perspectives were adopted: healthcare and societal. Input data were obtained from official statistics and published literature. The primary outcomes were disability-adjusted life-years, cost, and net monetary benefit. Costs were reported in both Chinese renminbi (RMB) and US dollars (USD) at 2019 values. Results: The first wave of COVID-19 in China resulted in 38 348 disability adjusted life-years lost (95% CI 19 417-64 130) and 2639 billion RMB losses (95% CI 1347-4688). The rapid implementation strategy dominated all other delayed strategies. This conclusion was robust to all scenarios tested. At a willingness-to-pay threshold of 70 892 RMB (the national annual GDP per capita) per disability-adjusted life-year saved, the probability for the rapid implementation to be the optimal strategy was 96%. Conclusions: Early implementation of MRPs in response to COVID-19 reduced both the health burden and societal cost and thus should be used for future waves of COVID-19.	[Zhao, Jidi] East China Normal Univ, Coll Econ & Management, Dept Publ Adm, Shanghai, Peoples R China; [Jin, Huajie; Pennington, Mark] Neurosci Kings Coll London, Inst Psychiat Psychol & Neurosci, Hlth Serv & Populat Res Dept, Kings Hlth Econ, London, England; [Li, Xun; Zhang, Chao; Zhao, Huijuan; Ma, Wuren; Zhang, Donglan; Zheng, Weiwei] Fudan Univ, Sch Publ Hlth, Dept Environm Hlth, Shanghai, Peoples R China; [Jia, Jianguo] Tongji Univ, Dev Inst, Shanghai, Peoples R China; [Wang, Zhuozhu] Zhejiang Univ, Hangzhou, Zhejiang, Peoples R China; [He, Yi] Curtin Univ Technol, Bentley, WA, Australia; [Lee, Jimmy] Univ Calif Los Angeles, Los Angeles, CA USA; [Yin, Bo] Fudan Univ, Huashan Hosp, Shanghai, Peoples R China; [Wang, Haiyin] Shanghai Hlth Dev Res Ctr, Hlth Technol Assessment Res Dept, Shanghai, Peoples R China		Zheng, WW (通讯作者)，130 Dongan Rd, Shanghai 200032, Peoples R China.; Wang, HY (通讯作者)，181 Xinbei Rd, Shanghai 201199, Peoples R China.	weiweizheng@fudan.edu.cn; why0522@126.com			National Social Science Foundation of China [18BGL235]; Shanghai Municipal Commission of Health and the Family Foundation for Young Talents [2017YQ023]; Fourth Round of Shanghai ThreeYear Action Plan on Public Health Discipline and Talent Program: EvidenceBased Public Health and Health Economics [15GWZK0901]	This work was supported by National Social Science Foundation of China (No. 18BGL235) , Shanghai Municipal Commission of Health and the Family Foundation for Young Talents (2017YQ023) , and Fourth Round of Shanghai ThreeYear Action Plan on Public Health Discipline and Talent Program: EvidenceBased Public Health and Health Economics (No. 15GWZK0901) .	[Anonymous], CHINA NETWORK NEWS; Awata S, 2007, INT PSYCHOGERIATR, V19, P77, DOI 10.1017/S1041610206004212; Baidu, MOBILE POPULATION MI; Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418; Department of Health Statistics and Information Systems WHO, WHO METHODS DATA SOU; Emery JC, 2020, ELIFE, V9, DOI 10.7554/eLife.58699; Feng ZJ, 2020, CHINA CDC WEEKLY, V2, P113, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003; Fidler DP, 2007, J LAW MED ETHICS, V35, P616, DOI 10.1111/j.1748-720X.2007.00185.x; First Affiliated Hospital of Zhejiang University School of Medicine, HDB COVID 19 PREVENT; Fodor Z., 2020, WHY INTEGRAL EQUATIO; Gaunt ER, 2011, J CLIN VIROL, V52, P215, DOI 10.1016/j.jcv.2011.07.017; Global Initiative for Chronic Obstructive Lung Disease, GOLD COVID 19 GUIDAN; Health Commission of Hubei Province, COVID 19 B; Hou C, 2020, J MED VIROL, V92, P841, DOI 10.1002/jmv.25827; Hubei Statistics Bureau, 2019, HUBEI NATL EC SOCIAL; Husereau D, 2013, PHARMACOECONOMICS, V31, P361, DOI 10.1007/s40273-013-0032-y; Jin HJ, 2021, B WORLD HEALTH ORGAN, V99, P112, DOI 10.2471/BLT.20.267112; Lai SJ, 2020, NATURE, V585, P410, DOI 10.1038/s41586-020-2293-x; Lee K, 2009, GLOB INST, P1; Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7; Louise P., 2020, EVIDENCE BASED COST, DOI [10.1101/2020.04.20.20054726, DOI 10.1101/2020.04.20.20054726]; Ministry of Finance of the People's Republic of China, FINANCIAL SUPPORT NO; Mubayi A, 2010, MATH BIOSCI ENG, V7, P687, DOI 10.3934/mbe.2010.7.687; National Bureau of Statistics of China, 2019, CHIN STAT YB; National Institute for Health and Care Excellence, GUID METH TECHN APPR; Organization of Economic Cooperation and Development, EXCHANGE RATES; Piguillem F., 2020, EIEF WORKING PAPERS; Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6; Salamatbakhsh M, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7899-2; Scally G, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1932; Teacher R, COSTS BENEFITS CORON; The National Health Commission of the People's Republic of China, LATEST STAT COVID 19; The National Health Commission of the People's Republic of China, GUIDANCE INFECT PREV, V7th; Thunstrom L, 2020, J BENEFIT-COST ANAL, V11, P179, DOI 10.1017/bca.2020.12; Worldometer, WORLD POPULATION; Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9; Yang ZF, 2020, J THORAC DIS, V12, P165, DOI 10.21037/jtd.2020.02.64	37	10	10	7	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAY	2021	24	5					615	624		10.1016/j.jval.2020.12.009		APR 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	RU9KC	33933229	Green Published, Bronze			2022-04-28	WOS:000645457500003
J	Ciarametaro, M; Houghton, K; Wamble, D; Dubois, R				Ciarametaro, Michael; Houghton, Katherine; Wamble, David; Dubois, Robert			The Dollar or Disease Burden: Caps on Healthcare Spending May Save Money, but at What "Cost" to Patients?	VALUE IN HEALTH			English	Article						budget caps; capitation; health spending; prospective payment	LANDSCAPE; MEDICAID	Objectives: Various strategies to address healthcare spending and medical costs continue to be debated and implemented in the United States. To date, these efforts have failed to adequately contain the growth of healthcare cost. An alternative strategy that has elicited rising interest among policymakers is budget caps. As budget caps become more prevalent, it is important to identify which features are needed to ensure success, both in terms of cost reduction and health improvement. Methods: We explored the impacts of different features of budget caps by comparing hypothetical service level and global budget caps across 3 annual budget cap growth strategies over a 10-year timeframe in 2005-2015 for 8 of the most commonly occurring conditions in the United States. Health was assessed by a measure of disease burden (disability-adjusted life years). Results: The results indicate that budget caps have the potential for creating savings but can also result in patient harm if not designed well. As a result of these findings, 5 principles were developed for designing budget caps and should guide the use of budget caps to address medical spending. Conclusions: As public discussion grows about the use of budget caps to constrain health spending, it is critical to recognize that the budget cap design and the resulting healthcare provider behavior will determine whether there is potential harm to public health. Budget cap design should consider variability at the condition level, including patient population, improvements in health, treatment costs, and the innovations available, to both create savings and maximize patient health. In assessing the impact of healthcare spending caps on costs and disease burden, we demonstrate that budget cap design determines potential harm to public health.	[Ciarametaro, Michael; Dubois, Robert] Natl Pharmaceut Council, Washington, DC USA; [Houghton, Katherine; Wamble, David] Res Triangle Inst Hlth Solut RTI HS, 3040 East Cornwallis Rd, Res Triangle Pk, NC 27709 USA; [Wamble, David] Bristol Myers Squibb, Lawrence Township, NJ USA		Houghton, K (通讯作者)，Res Triangle Inst Hlth Solut RTI HS, 3040 East Cornwallis Rd, Res Triangle Pk, NC 27709 USA.	kstull@rti.org		Houghton, Katherine/0000-0003-4416-6080	National Pharmaceutical Council	This study was funded by the National Pharmaceutical Council.	Adams S, 2019, JAMA ONCOL, V5, P1205, DOI 10.1001/jamaoncol.2018.7147; [Anonymous], 2016, DIABETES CARE, V39, pS1, DOI 10.2337/dc16-S001; Anumudu SJ, 2020, SEMIN DIALYSIS, V33, P5, DOI 10.1111/sdi.12856; Appendix A, 2020, MASSACHUSETTS HLTH P; Bailit M, BALANCING HLTH CARES, DOI [10.1377/hblog20180717.572276/full/, DOI 10.1377/HBLOG20180717.572276/FULL]; Ballinger TJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00308; Block R, STATE MODELS HLTH CA; Centers for Medicare and Medicaid Services, NHE FACT SHEET; Clyde AT, 2008, HEALTH AFFAIR, V27, P1632, DOI 10.1377/hlthaff.27.6.1632; Connecticut State Office of Health Strategy, COST GROWTH BENCHMAR; Daly R, GLOBAL HOSP BUDGETS; De Silva S, 2019, BREAST CANCER-TARGET, V11, P71, DOI 10.2147/BCTT.S185870; Dubios RW, CVS RESTRICT PATIENT, DOI [10.1377/hblog20180913.889578/full/, DOI 10.1377/HBLOG20180913.889578/FULL]; Elam AR, 2017, OPHTHALMOLOGY, V124, P1442, DOI 10.1016/j.ophtha.2017.05.003; Emanuel E, 2012, NEW ENGL J MED, V367, P949, DOI 10.1056/NEJMsb1205901; Evert AB, 2019, DIABETES CARE, V42, P731, DOI 10.2337/dci19-0014; Gaspar K, 2020, EUR J HEALTH ECON, V21, P105, DOI 10.1007/s10198-019-01114-6; Glickman A, 2020, PENN LDI ISSUE BRIEF, V23; He RB, 2017, J MED ECON, V20, P903, DOI 10.1080/13696998.2017.1336448; Iwamoto Y, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7166-6; Kazemian P, 2019, JAMA INTERN MED, V179, P1376, DOI 10.1001/jamainternmed.2019.2396; Kerasidou A, 2019, HEALTH CARE ANAL, V27, P171, DOI 10.1007/s10728-019-00373-x; Liu SB, 2019, THER CLIN RISK MANAG, V15, P861, DOI 10.2147/TCRM.S207515; Mechanic R., HLTH CARE COST CONTR; Mills M, 2020, HEALTH POLICY, V124, P239, DOI 10.1016/j.healthpol.2019.12.002; Mirza S, 2018, MAYO CLIN PROC, V93, P1488, DOI 10.1016/j.mayocp.2018.05.026; Niedzwiecki MJ, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008152; OECD Directorate for Employment Labour and Social Affairs Health Division, IMPR FOR PHARM SPEND; Organisation for Economic Co-operation and Development, HLTH SPEND; Pew Trust, NEW YORKS MEDICAID D; Sastow DL, 2019, J SURG RES, V235, P190, DOI 10.1016/j.jss.2018.09.056; Sisko AM, 2019, HEALTH AFFAIR, V38, P491, DOI 10.1377/hlthaff.2018.05499; Srinivasan BT, 2019, MEDICINE, V47, P32, DOI DOI 10.1016/J.MPMED.2018.10.009; Stolyar L., THESIS GEORGETOWN U; Taylor YJ, 2020, J WOMENS HEALTH, V29, P29, DOI 10.1089/jwh.2019.7658; Tuckson R, 2019, HLTH SPENDING MOVING; Wamble D, 2019, HEALTH AFFAIR, V38, P68, DOI 10.1377/hlthaff.2018.05158	37	2	2	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAR	2021	24	3					388	396		10.1016/j.jval.2020.10.024		FEB 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QM9NG	33641773	Bronze			2022-04-28	WOS:000622099500011
J	Keetharuth, AD; Rowen, D; Bjorner, JB; Brazier, J				Keetharuth, Anju Devianee; Rowen, Donna; Bjorner, Jakob Bue; Brazier, John			Estimating a Preference-Based Index for Mental Health From the Recovering Quality of Life Measure: Valuation of Recovering Quality of Life Utility Index	VALUE IN HEALTH			English	Article						mental health; preference-based measure; QALYs; ReQoL-10; ReQoL-20		Background: There are increasing concerns about the appropriateness of generic preference-based measures to capture health benefits in the area of mental health. Objectives: The aim of this study is to estimate preference weights for a new measure, Recovering Quality of Life (ReQoL-10), to better capture the benefits of mental healthcare. Methods: Psychometric analyses of a larger sample of mental health service users (n = 4266) using confirmatory factor analyses and item response theory were used to derive a health state classification system and inform the selection of health states for utility assessment. A valuation survey with members of the UK public representative in terms of age, sex, and region was conducted using face-to-face interviewer administered time-trade-off with props. A series of regression models were fitted to the data and the best performing model selected for the scoring algorithm. Results: The ReQoL-Utility Index (UI) classification system comprises 6 mental health items and 1 physical health item. Sixty-four health states were valued by 305 participants. The preferred model was a random effects model, with significant and consistent coefficients and best model fit. Estimated utilities modeled for all health states ranged from -0.195 (state worse than dead) to 1 (best possible state). Conclusions: The development of the ReQoL-UI is based on a novel application of item response theory methods for generating the classification system and selecting health states for valuation. Conventional time-trade-off was used to elicit utility values that are modeled to enable the generation of QALYs for use in cost-utility analysis of mental health interventions.	[Keetharuth, Anju Devianee; Rowen, Donna; Brazier, John] Univ Sheffield, Sch Hlth Related Res, 208 West Court,2 Mappin St, Sheffield S1 4DT, S Yorkshire, England; [Bjorner, Jakob Bue] Optum Patient Insights, Johnston, RI USA; [Bjorner, Jakob Bue] Univ Copenhagen, Copenhagen, Denmark		Keetharuth, AD (通讯作者)，Univ Sheffield, Sch Hlth Related Res, 208 West Court,2 Mappin St, Sheffield S1 4DT, S Yorkshire, England.	d.keetharuth@sheffield.ac.uk		Keetharuth, Anju/0000-0001-8889-6806; Brazier, John/0000-0001-8645-4780	National Institute for Health Research Policy Research Program [PRP 104/0001]	This research was funded by the National Institute for Health Research Policy Research Program (Ref: PRP 104/0001). The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.	Attema AE, 2013, EUR J HEALTH ECON, V14, pS53, DOI 10.1007/s10198-013-0508-x; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Brazier J, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18340; Brazier J, 2010, HEALTH ECON, V19, P125, DOI 10.1002/hec.1580; Cai L., 2017, IRTPRO FLEXIBLE MULT; Connell J, 2018, QUAL LIFE RES, V27, P1893, DOI 10.1007/s11136-018-1847-y; Connell J, 2014, SOC SCI MED, V120, P12, DOI 10.1016/j.socscimed.2014.08.026; Connell J, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-138; Devlin NJ, 2011, HEALTH ECON, V20, P348, DOI 10.1002/hec.1596; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Grundy A, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1123-z; Keetharuth AD, 2021, QUAL LIFE RES, V30, P267, DOI 10.1007/s11136-020-02622-2; Keetharuth AD, 2019, QUAL LIFE RES, V28, P1005, DOI 10.1007/s11136-018-2091-1; Keetharuth AD, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071342; Keetharuth AD, 2018, BRIT J PSYCHIAT, V212, P42, DOI 10.1192/bjp.2017.10; Mavranezouli I, 2013, MED DECIS MAKING, V33, P381, DOI 10.1177/0272989X12464431; Mavranezouli I, 2011, QUAL LIFE RES, V20, P321, DOI 10.1007/s11136-010-9768-4; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Mulhern B, 2017, DIABETIC MED, V34, P1264, DOI 10.1111/dme.13377; Mulhern B, 2014, BRIT J PSYCHIAT, V205, P236, DOI 10.1192/bjp.bp.112.122283; Muthen L.K., 2017, 1998 2012 MPLUS USER; NICE, 2013, GUID METH TECHN APPR; Norman R, 2019, HEALTH ECON, V28, P1385, DOI 10.1002/hec.3950; Oppe M, 2014, VALUE HEALTH, V17, P445, DOI 10.1016/j.jval.2014.04.002; Papaioannou D, 2011, VALUE HEALTH, V14, P907, DOI 10.1016/j.jval.2011.04.006; Rowen D, 2020, PHARMACOECONOMICS, P1; Rowen D, 2017, PHARMACOECONOMICS, V35, pS11, DOI 10.1007/s40273-017-0544-y; Rowen D, 2012, VALUE HEALTH, V15, P346, DOI 10.1016/j.jval.2011.10.016; Rowen D, 2011, VALUE HEALTH, V14, P721, DOI 10.1016/j.jval.2011.01.004; Saarni SI, 2010, BRIT J PSYCHIAT, V197, P386, DOI 10.1192/bjp.bp.109.076489; SAMEJIMA F, 1969, PSYCHOMETRIKA, V34, P1; StataCorp S, 2015, STAT SOFTWARE RELEAS; Stevens K, 2012, PHARMACOECONOMICS, V30, P729, DOI 10.2165/11599120-000000000-00000; Yang YL, 2011, MED DECIS MAKING, V31, P281, DOI 10.1177/0272989X10379646; Young TA, 2010, QUAL LIFE RES, V19, P907, DOI 10.1007/s11136-010-9646-0	35	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	FEB	2021	24	2					281	290		10.1016/j.jval.2020.10.012		JAN 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QJ1VI	33518035	hybrid, Green Published, Green Accepted			2022-04-28	WOS:000619478100016
J	Colson, AR; Morton, A; Ardal, C; Chalkidou, K; Davies, SC; Garrison, LP; Jit, M; Laxminarayan, R; Megiddo, I; Morel, C; Nonvignon, J; Outterson, K; Rex, JH; Sarker, AR; Sculpher, M; Woods, B; Xiao, Y				Colson, Abigail R.; Morton, Alec; Ardal, Christine; Chalkidou, Kalipso; Davies, Sally C.; Garrison, Louis P.; Jit, Mark; Laxminarayan, Ramanan; Megiddo, Itamar; Morel, Chantal; Nonvignon, Justice; Outterson, Kevin; Rex, John H.; Sarker, Abdur Razzaque; Sculpher, Mark; Woods, Beth; Xiao, Yue			Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?	VALUE IN HEALTH			English	Article						antibiotic agents; antimicrobial resistance; economic evaluation; health technology assessment	ARTEMISININ RESISTANCE; ANTIBIOTIC-RESISTANCE; REIMBURSEMENT; PATHOGENS; ECONOMICS	Antimicrobial resistance is a serious challenge to the success and sustainability of our healthcare systems. There has been increasing policy attention given to antimicrobial resistance in the last few years, and increased amounts of funding have been channeled into funding for research and development of antimicrobial agents. Nevertheless, manufacturers doubt whether there will be a market for new antimicrobial technologies sufficient to enable them to recoup their investment. Health technology assessment (HTA) has a critical role in creating confidence that if valuable technologies can be developed they will be reimbursed at a level that captures their true value. We identify 3 deficiencies of current HTA processes for appraising antimicrobial agents: a methods-centric approach rather than problem-centric approach for dealing with new challenges, a lack of tools for thinking about changing patterns of infection, and the absence of an approach to epidemiological risks. We argue that, to play their role more effectively, HTA agencies need to broaden their methodological tool kit, design and communicate their analysis to a wider set of users, and incorporate long-term policy goals, such as containing resistance, as part of their evaluation criteria alongside immediate health gains.	[Colson, Abigail R.; Morton, Alec; Megiddo, Itamar] Univ Strathclyde, Strathclyde Business Sch, Management Sci, Glasgow, Lanark, Scotland; [Ardal, Christine] Norwegian Inst Publ Hlth, Antimicrobial Resistance Ctr, Oslo, Norway; [Chalkidou, Kalipso] Imperial Coll London, Sch Publ Hlth, London, England; [Davies, Sally C.] UK Dept Hlth & Social Care, London, England; [Garrison, Louis P.] Univ Washington, Comparat Hlth Outcomes Policy & Econ Inst, Seattle, WA 98195 USA; [Jit, Mark] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England; [Laxminarayan, Ramanan] Ctr Dis Dynam Econ & Policy, Washington, DC USA; [Morel, Chantal] Univ Hosp Bonn, Inst Hyg & Publ Hlth, Bonn, Germany; [Morel, Chantal] Uppsala Univ, Dept Business Studies, Uppsala, Sweden; [Morel, Chantal] Univ Geneva, Sci Fac, Geneva Transformat Governance Lab, Geneva, Switzerland; [Nonvignon, Justice] Univ Ghana, Sch Publ Hlth, Dept Hlth Policy Planning & Management, Legon, Ghana; [Outterson, Kevin] Boston Univ, Sch Law, Boston, MA 02215 USA; [Rex, John H.] F2G Ltd, Eccles, Cheshire, England; [Rex, John H.] AMR Solut, Boston, MA USA; [Sarker, Abdur Razzaque] Bangladesh Inst Dev Studies, Dhaka, Bangladesh; [Sculpher, Mark; Woods, Beth] Univ York, Ctr Hlth Econ, York, N Yorkshire, England; [Xiao, Yue] Natl Ctr Med & Hlth Technol Assessment, China Natl Hlth Dev Res Ctr, Beijing, Peoples R China		Colson, AR (通讯作者)，Univ Strathclyde, Management Sci, 199 Cathedral St, Glasgow G4 0QU, Lanark, Scotland.	abigail.colson@strath.ac.uk	; Megiddo, Itamar/N-9839-2015; Colson, Abigail/H-6441-2017	Morton, Alec/0000-0003-3803-8517; Megiddo, Itamar/0000-0001-8391-6660; Colson, Abigail/0000-0002-3241-5855			[Anonymous], MOD EV PURCH ANT; [Anonymous], CHANC URG GLOB ACT T; [Anonymous], GUID TREATM MAL; [Anonymous], 2019, THE ECONOMIST 0502; [Anonymous], LEADERS DECLARATION; [Anonymous], VACC TACKL DRUG RES; [Anonymous], NOV HOLD LAUNCH USD; [Anonymous], NUZ WITHDR MARK AUTH; [Anonymous], 2018, G20 LEADERS DECLARAT; [Anonymous], 2019 ANT AG CLIN DEV; [Anonymous], ZEM WITHDR MARK AUTH; [Anonymous], HIGH LEV M ANT RES; [Anonymous], TUB MULT RES TUB MDR; [Anonymous], 2019, ANTIBIOTIC RESISTANC; [Anonymous], 2017, BERLIN DECLARATION G; [Anonymous], 2017, G20 LEADERS DECLARAT; [Anonymous], DEV NEW ANT ENC NEW; [Anonymous], WORLD LEAD JOIN FORC; [Anonymous], ANTIMICROBIAL RESIST; Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981; Beutels P, 2008, LANCET INFECT DIS, V8, P727, DOI 10.1016/S1473-3099(08)70258-5; Beyer P, 2020, B WORLD HEALTH ORGAN, V98, P151, DOI 10.2471/BLT.20.251751; Cassini A, 2019, LANCET INFECT DIS, V19, P56, DOI 10.1016/S1473-3099(18)30605-4; Coast J, 1998, SOC SCI MED, V46, P29, DOI 10.1016/S0277-9536(97)00132-9; Colson AR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219190; Colson AR, 2018, REV ENV ECON POLICY, V12, P113, DOI 10.1093/reep/rex022; Cooke R., 1991, EXPERTS UNCERTAINTY; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Drummond MF., 2015, METHODS EC EVALUATIO, P353; Gandra S, 2016, INT J INFECT DIS, V50, P75, DOI 10.1016/j.ijid.2016.08.002; Gessner BD, 2010, VACCINE, V28, pA1, DOI 10.1016/j.vaccine.2010.02.025; Glover D, NHS MODELTACKLE ANTI; Gotham D, 2021, HEALTH POLICY, V125, P296, DOI 10.1016/j.healthpol.2020.11.015; Kvalheim, UTREDNING HVORDAN SM; Lakdawalla DN, 2018, VALUE HEALTH, V21, P131, DOI 10.1016/j.jval.2017.12.007; Laxminarayan R, 2001, J ENVIRON ECON MANAG, V42, P183, DOI 10.1006/jeem.2000.1156; Laxminarayan R, 2016, LANCET, V387, P168, DOI 10.1016/S0140-6736(15)00474-2; MacQuilkan K, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2018.1527556; Marquez PV, DRUG RESISTANT INFEC, V2; McClellan MB, DELINKING US ANTIBIO; Megiddo I, 2019, HEALTH ECON, V28, P556, DOI 10.1002/hec.3867; Morton Alec, 2019, MDM Policy Pract, V4, p2381468319892237, DOI 10.1177/2381468319892237; National Institute for Health and Clinical Excellence, 2008, GUID METH TECHN APPR; Neumann P. J., 2016, Cost-effectiveness in health and medicine; Outterson K, NEW ANTIBIOTICS ARE; Outterson K, 2020, TRANSL RES, V220, P182, DOI 10.1016/j.trsl.2020.02.006; Outterson K, 2016, NAT REV DRUG DISCOV, V15, P589, DOI 10.1038/nrd.2016.155; Palmer Stephen, FRAMEWORK VALUE ASSE; Piddock LJV, 2019, MEDCHEMCOMM, V10, P1227, DOI 10.1039/c9md90010a; Piddock LJV, 2018, LANCET INFECT DIS, V18, P1304, DOI 10.1016/S1473-3099(18)30661-3; Plackett B, 2020, NATURE, V586, pS50, DOI 10.1038/d41586-020-02884-3; Powers JH, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k587; Pragasam AK, 2017, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02135; Quigley J., 2018, ELICITATION, P15; Rex JH, PRAISE NONINFERIORIT; Rex JH, 2017, CLIN INFECT DIS, V65, P141, DOI 10.1093/cid/cix246; Rex JH, 2016, LANCET INFECT DIS, V16, P500, DOI 10.1016/S1473-3099(15)00500-9; Savic, REVITALIZING ANTIBIO; Silverman R, WORLD NEEDS BETTER D; Steuten L, REALISING BROADER VA; Stevenson MD, 2009, J OPER RES SOC, V60, P506, DOI 10.1057/palgrave.jors.2602580; Tantivess Sripen, 2017, F1000Res, V6, P2119, DOI 10.12688/f1000research.13180.1; Teillant A, 2015, LANCET INFECT DIS, V15, P1429, DOI 10.1016/S1473-3099(15)00270-4; Theuretzbacher U, 2020, NAT REV MICROBIOL, V18, P275, DOI 10.1038/s41579-019-0288-0; Towse A, ASSESSING VALUE NEW; Woodrow CJ, 2017, FEMS MICROBIOL REV, V41, P34, DOI 10.1093/femsre/fuw037	66	1	1	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	DEC	2021	24	12					1828	1834		10.1016/j.jval.2021.06.002		NOV 2021	7	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	XC7VG	34838281	hybrid, Green Accepted, Green Published			2022-04-28	WOS:000722217200014
J	Cidav, Z; Marcus, S; Mandell, D; Hornbrook, MC; Mo, JJ; Sun, V; Ercolano, E; Wendel, CS; Weinstein, RS; Holcomb, MJ; Grant, M; Rock, M; Krouse, RS				Cidav, Zuleyha; Marcus, Steven; Mandell, David; Hornbrook, Mark C.; Mo, Julia J.; Sun, Virginia; Ercolano, Elizabeth; Wendel, Christopher S.; Weinstein, Ronald S.; Holcomb, Michael J.; Grant, Marcia; Rock, Matthew; Krouse, Robert S.			Programmatic Costs of the Telehealth Ostomy Self-Management Training: An Application of Time-Driven Activity-Based Costing	VALUE IN HEALTH			English	Article						Time-Driven Activity-Based Costing; Ostomy Self-Management Training; programmatic costs; cost assessment	CARE; STOMA	Objectives: Programmatic cost assessment of novel clinical interventions can inform their widespread dissemination and implementation. This study aimed to determine the programmatic costs of a telehealth Ostomy Self-Management Training (OSMT) intervention for cancer survivors using Time-Driven Activity-Based Costing (TDABC) methodology. Methods: We demonstrated a step-by-step application of TDABC based on a process map with core OSMT intervention activities and associated procedures and determined resource use and costs, per unit procedure. We also assessed per patient costs from a payer perspective and provided estimates of total hours and costs by personnel, activity, and procedure. Results: The per-patient cost of the OSMT was $1758. Personnel time accounted for 91% of the total cost. Site supervisor and information technology technician time were the most expensive personnel resources. Telehealth technical and communication equipment accounted for 8% of the total cost. Intervention coordination and monitoring efforts represented most of the total time cost (62%), followed by the intervention delivery (35%). The procedures with the highest cost were communication via phone or virtual meetings (24%), email exchanges (18%), and telehealth session delivery (18%). Conclusions: Future efforts to replicate, disseminate, and implement the OSMT intervention should anticipate funding for nonclinical components of the intervention, including coordination and monitoring, and consider how these activities can be performed most efficiently. For institutions without established telemedicine programs, selection of videoconferencing platforms and adequate staffing for participant technical support should be considered. Our step-by-step application of TDABC serves as a case study demonstrating how interventionists can gather data on resource use and costs of intervention activities concurrently with their collection of trial data.	[Cidav, Zuleyha; Marcus, Steven; Mandell, David; Mo, Julia J.; Rock, Matthew; Krouse, Robert S.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Hornbrook, Mark C.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA; [Sun, Virginia; Grant, Marcia] City Hope Natl Med Ctr, Div Nursing Res & Educ, Med Ctr, Duarte, CA USA; [Ercolano, Elizabeth] Yale Sch Nursing, New Haven, CT USA; [Wendel, Christopher S.; Weinstein, Ronald S.; Holcomb, Michael J.] Univ Arizona, Coll Med, Tucson, AZ USA		Cidav, Z (通讯作者)，Univ Penn, Dept Med, Philadelphia, PA 19104 USA.	zcidav@upenn.edu	Mandell, David S/H-2730-2012	Mandell, David S/0000-0001-8240-820X; Holcomb, Michael/0000-0003-1135-4237	Patient-Centered Outcomes Research InstitutePatient-Centered Outcomes Research Institute - PCORI [1507-31690]; Benjamin and Mary Siddons Measey Foundation	This work was supported by grant 1507-31690 from the Patient-Centered Outcomes Research Institute, and a grant from the Benjamin and Mary Siddons Measey Foundation.	Anderson S., 2007, TIME DRIVEN ACTIVITY; [Anonymous], WHAT IS OSTOMY; Areena S., 2019, J MOD MANUF SYST TEC, V2, P15; Etges APBD, 2019, EUR J HEALTH ECON, V20, P1133, DOI 10.1007/s10198-019-01085-8; Charles JM, 2013, PREV SCI, V14, P377, DOI 10.1007/s11121-012-0302-5; Cidav Z, 2020, IMPLEMENT SCI, V15, DOI 10.1186/s13012-020-00993-1; Faury S, 2017, PATIENT EDUC COUNS, V100, P1807, DOI 10.1016/j.pec.2017.05.034; Frick KD, 2009, MED CARE, V47, pS76, DOI 10.1097/MLR.0b013e31819bc064; Grant M, 2013, J CANCER EDUC, V28, P70, DOI 10.1007/s13187-012-0433-1; Hughes D, 2016, PHARMACOECONOMICS, V34, P447, DOI 10.1007/s40273-015-0371-y; Kaplan RS, 2014, J HEALTHC MANAG, V59, P399, DOI 10.1097/00115514-201411000-00005; Kaplan RS, 2004, HARVARD BUS REV, V82, P131, DOI 10.2139/ssrn.485443; Keel G, 2017, HEALTH POLICY, V121, P755, DOI 10.1016/j.healthpol.2017.04.013; Krouse RS, 2016, PSYCHO-ONCOLOGY, V25, P574, DOI 10.1002/pon.4078; Quigley E, 2020, TIME DRIVEN ACTIVITY, V1; Ridyard CH, 2015, HEALTH ECON, V24, P372, DOI 10.1002/hec.3029; Shabbir J, 2010, COLORECTAL DIS, V12, P958, DOI 10.1111/j.1463-1318.2009.02006.x; Speich B, 2018, J CLIN EPIDEMIOL, V96, P1, DOI 10.1016/j.jclinepi.2017.12.018; Sun V, 2020, SUPPORT CARE CANCER, V28, P1551, DOI 10.1007/s00520-019-05156-7; Sun V, 2018, CONTEMP CLIN TRIALS, V64, P167, DOI 10.1016/j.cct.2017.10.008; Thorn JC, 2014, EXPERT REV PHARM OUT, V14, P843, DOI 10.1586/14737167.2014.953934; U.S. Bureau of Labor Statistics, NAT OCC EMPL WAG EST; Vonk-Klaassen SM, 2016, QUAL LIFE RES, V25, P125, DOI 10.1007/s11136-015-1050-3	23	1	1	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	SEP	2021	24	9					1245	1253		10.1016/j.jval.2021.03.018		AUG 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	UG5RC	34452703				2022-04-28	WOS:000689308300003
J	Stone, JC; Gurunathan, U; Aromataris, E; Glass, K; Tugwell, P; Munn, Z; Doi, SAR				Stone, Jennifer C.; Gurunathan, Usha; Aromataris, Edoardo; Glass, Kathryn; Tugwell, Peter; Munn, Zachary; Doi, Suhail A. R.			Bias Assessment in Outcomes Research: The Role of Relative Versus Absolute Approaches	VALUE IN HEALTH			English	Article						meta-analysis; methodology; quality assessment; risk of bias	MOLECULAR-WEIGHT HEPARIN; CLINICAL-TRIALS; QUALITY; METAANALYSIS; EFFICACY; PAIN; STANDARD; THERAPY; CANCER	Objectives: Bias assessment tools vary in content and detail, and the method used for assessment may produce different assessment results in a study if not carefully considered. Therefore, taking an approach to the assessment of studies that produces a similar result regardless of the tool used for assessment (tool independence) is important. Methods: A preexisting study that used 25 different quality scales was assessed to examine tool dependence of 2 common approaches to bias assessments-absolute value judgments (defined as the qualitative risk of bias judgment based on a threshold across studies) and relative ranks (defined as the relative probability toward bias of a study relative to the best assessed study). Agreement between each of the 25 scales and a composite scale (that includes all unique safeguards across all scales) was computed (using the intraclass correlation coefficient [ICC]; consistency). Tool dependence was considered present when the ICCs were inconsistent across the 25 scales for the same study. Results: We found that using relative ranks for tools with different numbers and types of items produced consistent results, with only small differences in the agreement for the various tools with the composite tool, whereas consistency (measured by the ICC) varied considerably when using absolute judgments. Inconsistency is problematic because it means that the assessment result is linked to the scale and not to the study. Conclusions: Tool independence is an important attribute of a bias assessment tool. On the basis of this study, the use of relative ranks retains tool independence and therefore produces consistent ranks for the same study across tools.	[Stone, Jennifer C.] Australian Natl Univ, Res Sch Populat Hlth, Dept Hlth Serv Res & Policy, Canberra, ACT, Australia; [Stone, Jennifer C.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Systemat Review Ctr Lab Anim Experimentat SYRCLE, Nijmegen, Netherlands; [Gurunathan, Usha] Prince Charles Hosp, Dept Anaesthesia, Brisbane, Qld, Australia; [Aromataris, Edoardo; Munn, Zachary] Univ Adelaide, JBI, Adelaide, SA, Australia; [Glass, Kathryn] Australian Natl Univ, Res Sch Populat Hlth, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia; [Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Doi, Suhail A. R.] Qatar Univ, Coll Med, QU Hlth, Dept Populat Med, Doha, Qatar		Doi, SAR (通讯作者)，Qatar Univ, Coll Med, QU Hlth, Dept Populat Med, Doha, Qatar.; Stone, JC (通讯作者)，Australian Natl Univ, Res Sch Populat Hlth, 62 Mills Rd Acton, Canberra, ACT 2601, Australia.	jennifer.stone@anu.edu.au; sardoi@gmx.net	Aromataris, Edoardo C/G-2260-2012; Gurunathan, Usha/AAP-3301-2021	Aromataris, Edoardo C/0000-0001-7238-5833; Gurunathan, Usha/0000-0002-0336-872X			ANDREW E, 1984, ACTA RADIOL DIAGN, V25, P55, DOI 10.1177/028418518402500111; BECKERMAN H, 1992, PHYS THER, V72, P483, DOI 10.1093/ptj/72.7.483; Berard A, 1998, J CLIN EPIDEMIOL, V51, P801, DOI 10.1016/S0895-4356(98)00073-0; BROWN SA, 1991, NURS RES, V40, P352; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHO MK, 1994, JAMA-J AM MED ASSOC, V272, P101, DOI 10.1001/jama.272.2.101; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; Crowe M, 2011, J CLIN EPIDEMIOL, V64, P79, DOI 10.1016/j.jclinepi.2010.02.008; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; Doi SAR, 2015, CONTEMP CLIN TRIALS, V45, P130, DOI 10.1016/j.cct.2015.05.009; Doi SAR, 2015, CONTEMP CLIN TRIALS, V45, P123, DOI 10.1016/j.cct.2015.05.010; EVANS M, 1985, BRIT J SURG, V72, P256, DOI 10.1002/bjs.1800720403; FEINSTEIN AR, 1979, CLIN PHARMACOL THER, V26, P129; Fisher D, 2019, STAT SOFTWARE COMPON; FLEISS JL, 1991, J CLIN EPIDEMIOL, V44, P127, DOI 10.1016/0895-4356(91)90261-7; GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Greenland S, 2001, Biostatistics, V2, P463, DOI 10.1093/biostatistics/2.4.463; Haynes RB, 1997, EVIDENCE BASED MED P, V157, P788; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; IMPERIALE TF, 1990, ANN INTERN MED, V113, P299, DOI 10.7326/0003-4819-113-4-299; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jonas WB, 2003, ALTERN THER HEALTH M, V9, pA5; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; KAKKAR VV, 1985, BRIT J SURG, V72, P786, DOI 10.1002/bjs.1800721006; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI 10.4084/MJHID.2010.005; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KLEIN S, 1986, CANCER, V58, P1378, DOI 10.1002/1097-0142(19860915)58:6<1378::AID-CNCR2820580635>3.0.CO;2-S; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Levine J, 1991, GUIDE CLIN TRIALS; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Losilla JM, 2018, J CLIN EPIDEMIOL, V101, P61, DOI 10.1016/j.jclinepi.2018.05.021; Marusic MF, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-00966-4; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Minozzi S, 2019, J CLIN EPIDEMIOL, V112, P28, DOI 10.1016/j.jclinepi.2019.04.001; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; O'Connor Sean R, 2015, BMC Res Notes, V8, P224, DOI 10.1186/s13104-015-1181-1; ONGHENA P, 1992, PAIN, V49, P205, DOI 10.1016/0304-3959(92)90144-Z; POYNARD T, 1988, PRESSE MED, V17, P315; REISCH JS, 1989, PEDIATRICS, V84, P815; SAMAMA M, 1988, BRIT J SURG, V75, P128, DOI 10.1002/bjs.1800750213; SMITH K, 1992, AM REV RESPIR DIS, V145, P533, DOI 10.1164/ajrccm/145.3.533; SPITZER WO, 1990, CLIN INVEST MED, V13, P17; Stone J, 2019, J CLIN EPIDEMIOL, V107, P51, DOI 10.1016/j.jclinepi.2018.11.015; Stone JC, 2020, J CLIN EPIDEMIOL, V117, P36, DOI 10.1016/j.jclinepi.2019.09.010; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; Tritchler D, 1999, STAT MED, V18, P2135, DOI 10.1002/(SICI)1097-0258(19990830)18:16<2135::AID-SIM183>3.0.CO;2-5; Welcome to PEDro, PHYS EV DAT; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD	54	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	AUG	2021	24	8					1145	1149		10.1016/j.jval.2021.02.011		AUG 2021	5	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TY1SX	34372980				2022-04-28	WOS:000683567300008
J	Jiao, BS; Basu, A				Jiao, Boshen; Basu, Anirban			Catalog of Age- and Medical Condition-Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis	VALUE IN HEALTH			English	Article						cost-effectiveness analysis; costs of death; future costs; medical condition; United States	LAST YEAR; ECONOMIC EVALUATIONS; LIFE; END; EXPENDITURES; LONGEVITY; PREVENTION; UTILITY; IMPACT; DEATH	Objectives: This study aims to develop a catalog of annual age-and medical condition-specific healthcare costs per capita among those who are living at a certain age (survivors) and the costs attributable to death itself for those who die at that age (decedents) in the United States. These estimates can be used to inform future cost calculations in cost-effectiveness analysis (CEA). Methods: We discussed a theoretical framework to incorporate futures costs in CEA. We used the nationally representative Medical Expenditure Panel Survey data to estimate costs among survivors and death costs. For survivors, we obtained cost estimates nonparametrically using kernel-based regression and locally weighted scatterplot smoothing. We estimated costs attributable to death using inverse probability weights comparing decedents with appropriately weighted survivors at a given age after controlling for more than 270 clinical condition classifications, demographics, and interactions. Cost estimates were expressed in 2019 US dollar and also separately by sex and specific clinical conditions. Results: Average healthcare costs per capita among survivors, expectedly, rose over age from $2062 (95% confidence interval [CI] $1553-$2478) during the first year of life to $14307 (95% CI $13 706-$14 956) at 85 years or older. Average costs of death were $44569 (95% CI $14 304-$67 369) during the first year of life and declined by -$321 (95% CI -$620 to -$22) per 1 year older. Conclusions: The US catalog of healthcare costs among survivors and decedents can facilitate calculations of future costs in CEA as recommended by the Second Panel on Cost-Effectiveness in Health and Medicine.	[Jiao, Boshen; Basu, Anirban] Univ Washington, Sch Pharm, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Box 357630, Seattle, WA 98195 USA		Jiao, BS (通讯作者)，Univ Washington, Sch Pharm, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Box 357630, Seattle, WA 98195 USA.	bjiao@uw.edu					Aldridge MD, 2015, AM J PUBLIC HEALTH, V105, P2411, DOI 10.2105/AJPH.2015.302889; Alemayehu B, 2004, HEALTH SERV RES, V39, P627, DOI 10.1111/j.1475-6773.2004.00248.x; [Anonymous], MEPS HC 180 2015 MED; [Anonymous], MED EXP PAN SURV HOU; [Anonymous], ANT THER NONM CASTR; [Anonymous], CONS PRIC IND; Basu A, 2020, J HEALTH ECON, V70, DOI 10.1016/j.jhealeco.2020.102287; Briggs ADM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197257; Calfo S., LAST YEAR LIFE STUDY; de Vries LM, 2019, PHARMACOECONOMICS, V37, P119, DOI 10.1007/s40273-018-0749-8; Duncan I, 2019, AM J HOSP PALLIAT ME, V36, P705, DOI 10.1177/1049909119836204; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Feenstraa TL, 2008, J HEALTH ECON, V27, P1645, DOI 10.1016/j.jhealeco.2008.07.007; Gandjour A, 2005, J HEALTH ECON, V24, P715, DOI 10.1016/j.jhealeco.2004.11.009; Garber AM, 1997, J HEALTH ECON, V16, P1, DOI 10.1016/S0167-6296(96)00506-1; Hogan C, 2001, HEALTH AFFAIR, V20, P188, DOI 10.1377/hlthaff.20.4.188; Hoover DR, 2002, HEALTH SERV RES, V37, P1625, DOI 10.1111/1475-6773.01113; Johannesson M, 1997, MED DECIS MAKING, V17, P382, DOI 10.1177/0272989X9701700403; Kellerborg K, 2020, VALUE HEALTH, V23, P1453, DOI 10.1016/j.jval.2020.07.004; Kruse M, 2012, EUR J HEALTH ECON, V13, P63, DOI 10.1007/s10198-010-0280-0; Lee RH, 2008, J HEALTH ECON, V27, P809, DOI 10.1016/j.jhealeco.2007.09.011; Levinsky NG, 2001, JAMA-J AM MED ASSOC, V286, P1349, DOI 10.1001/jama.286.11.1349; Liu K, 2006, HEALTH CARE FINANC R, V27, P95; Long MJ, 2000, J EVAL CLIN PRACT, V6, P63, DOI 10.1046/j.1365-2753.2000.00219.x; Manns B, 2003, HEALTH ECON, V12, P949, DOI 10.1002/hec.790; Meltzer D, 2000, MED CARE, V38, P679, DOI 10.1097/00005650-200006000-00009; Meltzer D, 1997, J HEALTH ECON, V16, P33, DOI 10.1016/S0167-6296(96)00507-3; Meltzer D, 2008, J HEALTH ECON, V27, P822, DOI 10.1016/j.jhealeco.2008.05.001; Meltzer D, 2006, ELGAR ORIG REF, P447; Miller T, 2001, DEMOGRAPHY, V38, P215, DOI 10.1353/dem.2001.0018; Nyman JA, 2004, HEALTH ECON, V13, P417, DOI 10.1002/hec.850; Payne G, 2007, MILBANK Q, V85, P213, DOI 10.1111/j.1468-0009.2007.00485.x; Perry-Duxbury M, 2020, VALUE HEALTH, V23, P1027, DOI 10.1016/j.jval.2020.05.006; Ratushnyak S, 2019, AM J PREV MED, V57, P792, DOI 10.1016/j.amepre.2019.07.027; Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195; Spillman BC, 2000, NEW ENGL J MED, V342, P1409, DOI 10.1056/NEJM200005113421906; Van Baal PHM, 2007, HEALTH ECON, V16, P421, DOI 10.1002/hec.1181; van Baal PHM, 2011, PHARMACOECONOMICS, V29, P175, DOI 10.2165/11586130-000000000-00000; Van Baala P, 2016, HEALTH ECON, V25, P237, DOI 10.1002/hec.3138; Yang Z, 2003, J GERONTOL B-PSYCHOL, V58, pS2, DOI 10.1093/geronb/58.1.S2	40	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUL	2021	24	7					957	965		10.1016/j.jval.2021.03.006		JUL 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TE7UB	34243839				2022-04-28	WOS:000670212100006
J	King, MT; Norman, R; Mercieca-Bebber, R; Costa, DSJ; McTaggart-Cowan, H; Peacock, S; Janda, M; Muller, F; Viney, R; Pickard, AS; Cella, D				King, Madeleine T.; Norman, Richard; Mercieca-Bebber, Rebecca; Costa, Daniel S. J.; McTaggart-Cowan, Helen; Peacock, Stuart; Janda, Monika; Mueller, Fabiola; Viney, Rosalie; Pickard, Alan Simon; Cella, David		Multi-Attribute Utility Canc	The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set	VALUE IN HEALTH			English	Article						condition-specific; health-related quality of life; multi-attribute utility; preference-based; QALY; quality of life; quality-adjusted life-year; utility; value set	DISCRETE-CHOICE EXPERIMENT; PREFERENCE-BASED MEASURE; HEALTH; EQ-5D; POPULATION; VALUATION; QLU-C10D; VALIDITY; WEIGHTS; DEPRESSION	Objectives: To develop a cancer-specific multi-attribute utility instrument derived from the Functional Assessment of Cancer Therapy General (FACT-G) health-related quality of life (HRQL) questionnaire. Methods: We derived a descriptive system based on a subset of the 27-item FACT-G. Item selection was informed by psychometric analyses of existing FACT-G data (n = 6912) and by patient input (n = 82). We then conducted an online valuation survey, with participants recruited via an Australian general population online panel. A discrete choice experiment (DCE) was used, with attributes being the HRQL dimensions of the descriptive system and survival duration, and 16 choice-pairs per participant. Utility decrements were estimated with conditional logit and mixed logit modeling. Results: Eight HRQL dimensions were included in the descriptive system: pain, fatigue, nausea, sleep, work, social support, sadness, and future health worry; each with 5 levels. Of 1737 panel members who accessed the valuation survey, 1644 (95%) completed 1 or more DCE choice-pairs and were included in analyses. Utility decrements were generally monotonic; within each dimension, poorer HRQL levels generally had larger utility decrements. The largest utility decrements were for the highest levels of pain (-0.40) and nausea (-0.28). The worst health state had a utility of-0.54, considerably worse than dead. Conclusions: A descriptive system and preference-based scoring approach were developed for the FACT-8D, a new cancer specific multi-attribute utility instrument derived from the FACT-G. The Australian value set is the first of a series of country-specific value sets planned that can facilitate cost-utility analyses based on items from the FACT-G and related FACIT questionnaires containing FACT-G items.	[King, Madeleine T.; Mercieca-Bebber, Rebecca; Costa, Daniel S. J.; Mueller, Fabiola] Univ Sydney, Fac Sci, Sch Psychol, Sydney, NSW, Australia; [Norman, Richard] Curtin Univ, Perth City Campus, Perth, ACT, Australia; [Norman, Richard] Dept Hlth Policy & Management, Bentley Campus, Perth, ACT, Australia; [Mercieca-Bebber, Rebecca] Univ Sydney, Fac Med & Hlth, NHMRC Clin Trials Ctr, Sydney, NSW, Australia; [Costa, Daniel S. J.] Pain Management Res Inst, St Leonards, NSW, Australia; [Costa, Daniel S. J.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [McTaggart-Cowan, Helen; Peacock, Stuart] Canadian Ctr Appl Res Canc Control, Vancouver, BC, Canada; [McTaggart-Cowan, Helen] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada; [Janda, Monika] Queensland Univ Technol, Sch Publ Hlth, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia; [Mueller, Fabiola] Univ Amsterdam, Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Med Psychol, Amsterdam, Noord Holland, Netherlands; [Viney, Rosalie] Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW, Australia; [Pickard, Alan Simon] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA; [Cella, David] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA		King, MT (通讯作者)，Univ Sydney, Sch Psychol, Griffith Taylor Bldg A19, Sydney, NSW 2006, Australia.	madeleine.king@sydney.edu.au	; Peacock, Stuart/P-2437-2018	Muller, Fabiola/0000-0002-0412-7469; Brazier, John/0000-0001-8645-4780; Viney, Rosalie/0000-0002-0039-9635; Pickard, A. Simon/0000-0001-5645-7091; Peacock, Stuart/0000-0002-8243-8721			Australian Bureau of Statistics, 2013, AUSTR DEM STAT; Australian Bureau of Statistics, 2013, 2011 AUSTR CENS; Bansback N, 2012, J HEALTH ECON, V31, P306, DOI 10.1016/j.jhealeco.2011.11.004; Bleichrodt H, 1997, J RISK UNCERTAINTY, V15, P107, DOI 10.1023/A:1007726117003; Bleichrodt H, 1997, MED DECIS MAKING, V17, P21, DOI 10.1177/0272989X9701700103; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Brazier JE, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16320; Brazier JE, 2004, MED CARE, V42, P851, DOI 10.1097/01.mlr.0000135827.18610.0d; Brucker PS, 2005, EVAL HEALTH PROF, V28, P192, DOI 10.1177/0163278705275341; Canadian Agency for Drugs and Technology in Healthcare, GUID EC EV HLTH TECH, V4th; Cella D.F, 1997, MANUAL FUNCTIONAL AS; Cella D, 2011, J NATL COMPR CANC NE, V9, P268, DOI 10.6004/jnccn.2011.0026; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Chen G, 2020, QUAL LIFE RES, V29, P3119, DOI 10.1007/s11136-020-02576-5; Finch AP, 2019, VALUE HEALTH, V22, P50, DOI 10.1016/j.jval.2018.07.001; French National Authority for Health, CHOIC METH EC EV MET; Gamper EM, 2020, QUAL LIFE RES, V29, P2485, DOI 10.1007/s11136-020-02536-z; Gandhi M, 2020, EUR J HEALTH ECON, V21, P501, DOI 10.1007/s10198-019-01156-w; Greenberg Donna B, 2004, J Natl Cancer Inst Monogr, P127; Herdman M, 2020, J PATIENT-REP OUTCOM, V4, DOI 10.1186/s41687-020-0185-3; Hole AR, 2007, STATA J, V7, P388, DOI 10.1177/1536867X0700700306; Kangwanrattanakul K, 2019, QUAL LIFE RES, V28, P1207, DOI 10.1007/s11136-018-2072-4; Kemmler G, 2019, QUAL LIFE RES, V28, P3197, DOI 10.1007/s11136-019-02283-w; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; King MT, 2016, QUAL LIFE RES, V25, P625, DOI 10.1007/s11136-015-1217-y; King MT, 2018, PHARMACOECONOMICS, V36, P225, DOI 10.1007/s40273-017-0582-5; Kolenikov S, 2012, STATA J, V12, P29, DOI 10.1177/1536867X1201200103; Lancsar E, 2008, PHARMACOECONOMICS, V26, P661, DOI 10.2165/00019053-200826080-00004; McTaggart-Cowan Helen, 2019, MDM Policy Pract, V4, p2381468319842532, DOI 10.1177/2381468319842532; McTaggart-Cowan H, 2013, EXPERT REV PHARM OUT, V13, P753, DOI 10.1586/14737167.2013.850420; Mukuria C, 2015, VALUE HEALTH, V18, P846, DOI 10.1016/j.jval.2015.07.004; Mulhern B, 2013, VALUE HEALTH, V16, P104, DOI 10.1016/j.jval.2012.09.001; Mulhern B, 2012, EPILEPSY BEHAV, V24, P36, DOI 10.1016/j.yebeh.2012.02.025; National Instituate for Health and Clinical Excellence, 2013, GUID METH TECHN APPR; Norman R, 2016, QUAL LIFE RES, V25, P637, DOI 10.1007/s11136-015-1115-3; Norman R, 2019, HEALTH ECON, V28, P1385, DOI 10.1002/hec.3950; Norman R, 2016, VALUE HEALTH, V19, P1033, DOI 10.1016/j.jval.2016.07.003; Norman R, 2014, MED DECIS MAKING, V34, P773, DOI 10.1177/0272989X13503499; Norman R, 2013, APPL HEALTH ECON HEA, V11, P287, DOI 10.1007/s40258-013-0035-z; Pharmaceutical Benefits Advisory Committee, 2016, GUID PREP SUBM PHARM; Reavley NJ, 2011, AUST NZ J PSYCHIAT, V45, P780, DOI 10.3109/00048674.2011.607130; Revelt D., 1999, CUSTOMER SPECIFIC TA; Rowen D, 2017, PHARMACOECONOMICS, V35, pS33, DOI 10.1007/s40273-017-0546-9; Rowen D, 2012, VALUE HEALTH, V15, P346, DOI 10.1016/j.jval.2011.10.016; Rowen D, 2011, VALUE HEALTH, V14, P721, DOI 10.1016/j.jval.2011.01.004; Schulz KF, 2010, BMJ-BRIT MED J, V340, pC332, DOI DOI 10.1136/bmj.c332; Scottish Medicines Consortium, 2016, GUID MAN COMPL NEW P; Simon GE, 2006, PSYCHOL MED, V36, P27, DOI 10.1017/S0033291705006136; Slade T, 2007, AUST NZ J PSYCHIAT, V41, P403, DOI 10.3109/00048674.2010.543653; StataCorp, 2013, STATA STAT SOFTW REL; SurveyEngine P/L, 2015, SURVEYENGINE CHOICE; Viney R, 2014, HEALTH ECON, V23, P729, DOI 10.1002/hec.2953; Viney R, 2011, VALUE HEALTH, V14, P928, DOI 10.1016/j.jval.2011.04.009; Wailoo A, 2010, INCORPORATION HLTH B; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895-4356(98)00081-X; Xie F, 2015, PHARMACOECONOMICS, V33, P867, DOI 10.1007/s40273-015-0292-9; Yanez B, 2013, ANN ONCOL, V24, P1073, DOI 10.1093/annonc/mds539	57	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24	6					862	873		10.1016/j.jval.2021.01.007		JUN 2021	12	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SP8AF	34119085				2022-04-28	WOS:000659884900015
J	Aggarwal, S; Bela, A; Kumar, S; Topaloglu, H				Aggarwal, S.; Bela, A.; Kumar, S.; Topaloglu, H.			COMPARISON OF BURDEN OF HOSPITALIZATIONS IN RHEUMATOID ARTHRITIS (RA), CROHNS DISEASE (CD) AND ULCERATIVE COLITIS (CD) PATIENTS INSURED BY MEDICAID: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE	VALUE IN HEALTH			English	Meeting Abstract									[Aggarwal, S.; Bela, A.; Topaloglu, H.] NOVEL Hlth Strategies, Chevy Chase, MD USA; [Kumar, S.] NOVEL Hlth Strategies, Columbia, MD USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU19	S148	S148					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400645
J	Ahmad, H; van der Mei, I; Taylor, BV; Chen, J; Zhao, T; Palmer, A				Ahmad, H.; van der Mei, I; Taylor, B., V; Chen, J.; Zhao, T.; Palmer, A.			IMPACT OF REMOTENESS ON COST OF ILLNESS OF AUSTRALIANS WITH MULTIPLE SCLEROSIS	VALUE IN HEALTH			English	Meeting Abstract									[Ahmad, H.; van der Mei, I; Taylor, B., V; Chen, J.; Zhao, T.; Palmer, A.] Univ Tasmania, Hobart, Tas, Australia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND38	S166	S166					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400722
J	Ali, EE; Asmamaw, G				Ali, E. E.; Asmamaw, G.			SOCIOECONOMIC FACTORS AND INSURANCE COVERAGE AS PREDICTORS OF ACCESS TO HEALTHCARE AMONG WOMEN IN ETHIOPIA	VALUE IN HEALTH			English	Meeting Abstract									[Ali, E. E.] Addis Ababa Univ, Addis Ababa 1, Ethiopia; [Asmamaw, G.] Arba Minch Univ, Addis Ababa, Ethiopia					Asmamaw, Getahun/0000-0002-3617-6361				0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS40	S179	S179					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401044
J	Althobaiti, H; Rodriguez-Monguio, R; Lewis, J; Brown, L; Seoane-Vazquez, E				Althobaiti, H.; Rodriguez-Monguio, R.; Lewis, J.; Brown, L.; Seoane-Vazquez, E.			TRENDS IN PRICES OF INSULIN MARKETED IN THE U.S	VALUE IN HEALTH			English	Meeting Abstract									[Althobaiti, H.; Lewis, J.; Brown, L.; Seoane-Vazquez, E.] Chapman Univ, Sch Pharm, Irvine, CA USA; [Rodriguez-Monguio, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB3	S78	S78					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400342
J	Alvis-Zakzuk, N; Florez-Tanus, A; Diaz-Jimenez, D; Chaparro-Narvaez, P; Castaneda-Orjuela, C; De La Hoz, F; Castell, CD; Alvis-Guzman, N				Alvis-Zakzuk, N.; Florez-Tanus, A.; Diaz-Jimenez, D.; Chaparro-Narvaez, P.; Castaneda-Orjuela, C.; De La Hoz, F.; Duenas Castell, C.; Alvis-Guzman, N.			DIRECT MEDICAL COSTS RELATED TO COVID-19 IN COLOMBIA	VALUE IN HEALTH			English	Meeting Abstract									[Alvis-Zakzuk, N.] Univ Costa CUC, Observ Nacl Salud, Inst Nacl Salud, Bogota, Colombia; [Florez-Tanus, A.] Coosalud EPS, Cartagena, Colombia; [Diaz-Jimenez, D.; Chaparro-Narvaez, P.; Castaneda-Orjuela, C.] Inst Nacl Salud, Bogota, Colombia; [De La Hoz, F.] Univ Nacl Colombia, Bogota, Colombia; [Duenas Castell, C.] Univ Cartagena, Cartagena, Colombia; [Alvis-Guzman, N.] Univ Cartagena, ALZAK Fdn, Cartagena, Bol, Colombia				Alvis-Guzman, Nelson/D-4913-2013; Zakzuk, Nelson J. Alvis/AAV-3171-2021	Alvis-Guzman, Nelson/0000-0001-9458-864X; 				0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS14	S175	S175					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401024
J	Asmamaw, G; Ali, EE				Asmamaw, G.; Ali, E. E.			THE FINANCIAL BURDEN OF MEDICINE OUT OF POCKET PAYMENT AMONG HOUSEHOLDS IN ETHIOPIA: AN ANALYSIS OF TRENDS AND DETERMINANTS	VALUE IN HEALTH			English	Meeting Abstract									[Asmamaw, G.] Arba Minch Univ, Addis Ababa, Ethiopia; [Ali, E. E.] Addis Ababa Univ, Addis Ababa 1, Ethiopia					Asmamaw, Getahun/0000-0002-3617-6361				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS42	S180	S180					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401046
J	Basson, A; Chodick, G				Basson, A.; Chodick, G.			DIAGNOSED PREVALENCE, PATIENT CHARACTERISTICS, AND TREATMENT AMONG ADULT PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS IN MACCABI HEALTH SERVICES	VALUE IN HEALTH			English	Meeting Abstract									[Basson, A.; Chodick, G.] Maccabi Healthcare Serv, Tel Aviv, Israel; [Chodick, G.] Tel Aviv Univ, Tel Aviv, Israel									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS20	S216	S216					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401210
J	Brook, R; Kleinman, NL; Beren, IA				Brook, R.; Kleinman, N. L.; Beren, I. A.			ABSENCE BENEFIT UTILIZATION, DURATION OF LEAVES, AND PAYMENTS VARY BY BENEFIT AND OVER TIME FOR SHORT- AND LONG-TERM DISABILITY AND WORKERS' COMPENSATION FOR EMPLOYEES WITH HEADACHES AND MIGRAINES IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Brook, R.] Better Hlth Worldwide NPRT NASP, Newfoundland, NJ USA; [Kleinman, N. L.; Beren, I. A.] WorkPartners LLC, Loveland, CO USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND69	S172	S172					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401011
J	Callea, G; Federici, C; Freddi, R; Tarricone, R				Callea, G.; Federici, C.; Freddi, R.; Tarricone, R.			RECOMMENDATIONS FOR THE DESIGN AND IMPLEMENTATION OF AN EARLY FEASIBILITY STUDIES PROGRAM IN ITALY	VALUE IN HEALTH			English	Meeting Abstract									[Callea, G.] SDA Bocconi Sch Management, Rome, RM, Italy; [Federici, C.; Freddi, R.; Tarricone, R.] SDA Bocconi Sch Management, Milan, MI, Italy									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS33	S178	S178					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401037
J	Cozad, M; Tabassum, M; Nourse, A; Merchant, G; Lindley, LC; Horner, RD				Cozad, M.; Tabassum, M.; Nourse, A.; Merchant, G.; Lindley, L. C.; Horner, R. D.			PREFERENCES OF PATIENTS WITH RHEUMATOID ARTHRITIS ARE DIVERSE AND CHANGEABLE	VALUE IN HEALTH			English	Meeting Abstract									[Cozad, M.] Univ South Carolina, Taylors, SC USA; [Tabassum, M.] Univ South Carolina, Columbia, SC 29208 USA; [Nourse, A.] Univ South Carolina, Sch Med, Columbia, SC 29208 USA; [Merchant, G.] Prisma Hlth Upstate, Greenville, SC USA; [Lindley, L. C.] Univ Tennessee Knoxville, Knoxville, TN USA; [Horner, R. D.] Univ Nebraska Med Ctr, Omaha, NE USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMS23	S142	S142					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400620
J	Demma, F; Di Martino, G				Demma, F.; Di Martino, G.			EXTENDED HALF-LIFE (EHL) RECOMBINANT FACTOR VIII (RFVIII) FOR THE TREATMENT OF HEMOPHILIA A IN ITALY: COST OF TREATMENT COMPARISON	VALUE IN HEALTH			English	Meeting Abstract									[Demma, F.; Di Martino, G.] Takeda, Rome, RM, Italy									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO32	S203	S203					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401151
J	Desai, K; Chandwani, S; Ru, B; Reynolds, M; Christian, JB; Estiri, H				Desai, K.; Chandwani, S.; Ru, B.; Reynolds, M.; Christian, J. B.; Estiri, H.			AN ONCOLOGY REAL-WORLD DATA ASSESSMENT FRAMEWORK FOR OUTCOMES RESEARCH	VALUE IN HEALTH			English	Meeting Abstract									Merck & Co Inc, Cranbury, NJ USA; [Chandwani, S.; Ru, B.] Merck & Co Inc, Kenilworth, NJ USA; [Reynolds, M.; Christian, J. B.] IQVIA, Durham, NC USA; [Estiri, H.] Harvard Med Sch, Boston, MA 02115 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN37	S25	S25					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400101
J	Di Maio, D; Wu, J; Stavropoulos, A; Alvarez, JS; Diles, D				Di Maio, D.; Wu, J.; Stavropoulos, A.; Alvarez, Sanchez J.; Diles, D.			SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS	VALUE IN HEALTH			English	Meeting Abstract									[Di Maio, D.; Alvarez, Sanchez J.] F Hoffman La Roche Ltd, Basel, Switzerland; [Wu, J.; Stavropoulos, A.; Diles, D.] Hoffmann La Roche Ltd, Mississauga, ON, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND39	S166	S166					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400723
J	Dong, L; Nian, D; Huang, Y; Lin, S; Zhong, L; Xu, X				Dong, L.; Nian, D.; Huang, Y.; Lin, S.; Zhong, L.; Xu, X.			EVALUATION OF TUCATINIB FOR HER2-POSITIVE BREAST CANCER PATIENTS WITH BRAIN METASTASES: A UNITED STATES-BASED COST-EFFECTIVENESS ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Dong, L.] Fujian Med Univ, Fuzhou, Peoples R China; [Nian, D.; Huang, Y.; Lin, S.; Xu, X.] Fujian Med Univ, Affiliated Hosp 1, Fuzhou, Peoples R China; [Zhong, L.] Texas A&M Univ, College Stn, TX USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		HT2	S9	S9					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400034
J	Fatoye, F; Gebrye, T				Fatoye, F.; Gebrye, T.			GLOBAL AND REGIONAL PREVALENCE AND INCIDENCE OF LUPUS IN LOW AND-MIDDLE INCOME COUNTRIES: A SYSTEMATIC REVIEW AND META-ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Fatoye, F.; Gebrye, T.] Manchester Metropolitan Univ, Manchester, Lin, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSY10	S230	S230					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401271
J	Gandola, A; Ait, SR; Orfanos, P; Bouisset, F; Licitra, L				Gandola, A.; Ait, Sarkouh R.; Orfanos, P.; Bouisset, F.; Licitra, L.			AN EARLY COST-EFFECTIVENESS ANALYSIS OF XEVINAPANT IN COMBINATION WITH CHEMO-RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Gandola, A.; Ait, Sarkouh R.; Bouisset, F.] Debiopharm Int SA, Lausanne, VD, Switzerland; [Orfanos, P.] Debiopharm Int SA, Basel, Switzerland; [Licitra, L.] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol, Milan, Italy					Chirila, Costel/0000-0002-7495-382X; Mladsi, Deirdre/0000-0001-8113-1149				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN72	S32	S32					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400133
J	Glover, S; Ray, G; Borrego, M; Roberts, M				Glover, S.; Ray, G.; Borrego, M.; Roberts, M.			COST-BENEFIT ANALYSIS OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR USE FOR PATIENTS < 65 YEARS WITH TYPE 2 DIABETES AND HEART FAILURE WITH REDUCED EJECTION FRACTION	VALUE IN HEALTH			English	Meeting Abstract									[Glover, S.; Roberts, M.] Univ New Mexico, Albuquerque, NM 87131 USA; [Ray, G.] Coll Pharm, Albuquerque, NM USA; [Borrego, M.] Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU12	S147	S147					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400640
J	Hunter, T; Nowak, C; Shan, M; Hoyt, M; Choong, C; Mills, K				Hunter, T.; Nowak, C.; Shan, M.; Hoyt, M.; Choong, C.; Mills, K.			TRENDS IN DIAGNOSTIC PREVALENCE, TREATMENT PATTERNS, AND HEALTHCARE RESOURCE UTILIZATION OF ADULT PATIENTS WITH FOOD ALLERGIES IN THE UNITED STATES, 2008-2018	VALUE IN HEALTH			English	Meeting Abstract									[Hunter, T.; Nowak, C.; Shan, M.; Hoyt, M.; Choong, C.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Shan, M.] Univ Cincinnati, Div Pharmaceut Sci, Indianapolis, IN USA; [Mills, K.] Eli Lilly & Co, Ramsey, MN USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS19	S216	S216					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401209
J	Kamgar, F; Hughes, R; Lucherini, S				Kamgar, F.; Hughes, R.; Lucherini, S.			DEVELOPING A PREDICTIVE ALGORITHM TO IDENTIFY THE KEY FACTORS IMPACTING ON THE TRANSMISSION AND FATALITIES FROM COVID-19	VALUE IN HEALTH			English	Meeting Abstract									[Kamgar, F.; Hughes, R.; Lucherini, S.] Adelphi Values Ltd, Bollington, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN49	S114	S114					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400499
J	Lima, PVP; van der Werf, L; Ferreira, R; Kashiura, D; Ono, L; Julian, G; Barbour, JC; Hernandez, F				Lima, P. V. P.; van der Werf, L.; Ferreira, R.; Kashiura, D.; Ono, L.; Julian, G.; Barbour, J. C.; Hernandez, F.			COVID-19 IMPACT ON BREAST AND PROSTATE CANCER SCREENING, DIAGNOSIS, AND SURGERY: A REAL-WORLD STUDY FROM THE BRAZILIAN AND COLOMBIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVES	VALUE IN HEALTH			English	Meeting Abstract									[Lima, P. V. P.; Ferreira, R.; Kashiura, D.; Ono, L.; Julian, G.; Barbour, J. C.] IQVIA Brasil, Sao Paulo, SP, Brazil; [van der Werf, L.] IQVIA Brasil, No Aplica, Cun, Brazil; [Hernandez, F.] IQVIA Colombia, Bogota, Colombia									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN238	S64	S64					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400280
J	Lin, FJ; Jhang, JG; Kuo, YH; Yeh, E; Pinto, L; Wu, CC				Lin, F. J.; Jhang, J. G.; Kuo, Y. H.; Yeh, E.; Pinto, L.; Wu, C. C.			COST ANALYSIS OF MYOCARDIAL INFARCTION AND ISCHEMIC STROKE USING THE NATIONAL CLAIMS DATABASE IN TAIWAN	VALUE IN HEALTH			English	Meeting Abstract									[Lin, F. J.; Jhang, J. G.; Kuo, Y. H.; Wu, C. C.] Natl Taiwan Univ, Taipei, Taiwan; [Yeh, E.; Pinto, L.] Amgen Inc, Thousand Oaks, CA 91320 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV17	S69	S69					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400303
J	Lin, J; Wong, CKH; Cheung, JPY; Cheung, PWH; Luo, N				Lin, J.; Wong, C. K. H.; Cheung, J. P. Y.; Cheung, P. W. H.; Luo, N.			PERFORMANCE OF PROXY-REPORTED EQ-5D YOUTH VERSION 5-LEVEL (EQ-5D-Y-5L) IN COMPARISON WITH THREE-LEVEL (EQ-5D-Y-3L) IN CHINESE PATIENTS WITH ADOLESCENT IDIOPATHIC SCOLIOSIS	VALUE IN HEALTH			English	Meeting Abstract									[Lin, J.] Chinese Univ Hong Kong, Sha Tin, Hong Kong, Peoples R China; [Wong, C. K. H.; Cheung, J. P. Y.; Cheung, P. W. H.] Univ Hong Kong, Hong Kong, Peoples R China; [Luo, N.] Natl Univ Singapore, Singapore, Singapore				Cheung, Jason Pui Yin/AAJ-2016-2020	Cheung, Jason Pui Yin/0000-0002-7052-0875				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH38	S105	S105					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400457
J	Liu, Y				Liu, Y.			IMPACT OF RECOGNIZED AND UNRECOGNIZED IATROGENIC LOWER URETERAL INJURY AT TIME OF HYSTERECTOMY: A NATIONWIDE POPULATIONAL DATABASE STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Liu, Y.] Intuit Surg, Sunnyvale, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSU2	S224	S224					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401244
J	Liu, Y; Patterson, ME; Sahil, S; Stoner, SC				Liu, Y.; Patterson, M. E.; Sahil, S.; Stoner, S. C.			EXAMINING ALL-CAUSE ADMISSION COUNTS AFTER INITIAL ANTIPSYCHOTICS ADMINISTRATION DURING HOSPITALIZATION FOR SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, OR BIPOLAR DISORDER	VALUE IN HEALTH			English	Meeting Abstract									[Liu, Y.; Patterson, M. E.; Sahil, S.; Stoner, S. C.] Univ Missouri, Kansas City, MO 64110 USA									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH1	S128	S128					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400557
J	Menon, SS; Yadav, N; Yeddala, SP; Doucette, J; Harris, C; Murimi-Worstell, IB				Menon, S. S.; Yadav, N.; Yeddala, S. P.; Doucette, J.; Harris, C.; Murimi-Worstell, I. B.			EFFECTS OF METFORMIN USE ON PROGRESSION-FREE AND OVERALL SURVIVAL OF GLIOBLASTOMA CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Menon, S. S.] MCPHS Univ, Brighton, MA USA; [Yadav, N.; Yeddala, S. P.; Doucette, J.; Harris, C.; Murimi-Worstell, I. B.] MCPHS Univ, Boston, MA USA									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN6	S19	S20					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400078
J	Mihajlovic, J; Loncar, I; Zeevat, F; van der Schans, J; Standaert, B; Postma, MJ				Mihajlovic, J.; Loncar, I; Zeevat, F.; van der Schans, J.; Standaert, B.; Postma, M. J.			SYSTEMATIC LITERATURE REVIEW ON MODELLING OF INFECTIOUS DISEASES IN ELDERLY	VALUE IN HEALTH			English	Meeting Abstract									[Mihajlovic, J.; Loncar, I] Mihajlovic Hlth Analyt, Novi Sad, Serbia; [Zeevat, F.; Standaert, B.] Univ Groningen, Univ Med Ctr Groningen, Groningen, GR, Netherlands; [van der Schans, J.] Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands; [Postma, M. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN65	S118	S118					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400515
J	Naoi, I; Baba, K; Shibahara, H; Inoue, S; Aino, H				Naoi, I; Baba, K.; Shibahara, H.; Inoue, S.; Aino, H.			DIRECT MEDICAL COSTS OF PARKINSON'S DISEASE IN JAPAN	VALUE IN HEALTH			English	Meeting Abstract									[Naoi, I; Baba, K.; Aino, H.] Sumitomo Dainippon Pharma Co Ltd, Tokyo, Japan; [Shibahara, H.; Inoue, S.] CRECON Med Assessment Inc, Tokyo, Japan									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND41	S166	S166					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400725
J	Patel, H; Budhia, S; Bathija, S				Patel, H.; Budhia, S.; Bathija, S.			PROJECT ORBIS/ACCESS CONSORTIUM - ARE QUICKER REGULATORY APPROVALS LEADING TO FASTER REIMBURSEMENT?	VALUE IN HEALTH			English	Meeting Abstract									[Patel, H.] Parexel, London, Lon, England; [Budhia, S.] PAREXEL Int, Waltham, MA USA; [Bathija, S.] PAREXEL Int, Horsham, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS62	S184	S184					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401065
J	Phatak, H; Pena, JDO; Patel, K; Patel, D				Phatak, H.; Pena, J. D. O.; Patel, K.; Patel, D.			A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC BURDEN AND COST DRIVERS IN PULMONARY ARTERIAL HYPERTENSION	VALUE IN HEALTH			English	Meeting Abstract									[Phatak, H.; Pena, J. D. O.] Acceleron Pharma Inc, Cambridge, MA USA; [Patel, K.] Market Access Solut LLC LTD MKTXS, Raritan, NJ USA; [Patel, D.] Market Access Solut LLC LTD MKTXS, Somerset, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO18	S200	S201					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401140
J	Pistollato, M; Ross-Stewart, K; Ahir, H				Pistollato, M.; Ross-Stewart, K.; Ahir, H.			THE CONSEQUENCES OF GREATER NET PRICE TRANSPARENCY FOR INNOVATIVE MEDICINES: INSIGHTS FROM EUROPEAN EXPERTS AND PAYERS	VALUE IN HEALTH			English	Meeting Abstract									[Pistollato, M.; Ross-Stewart, K.] Charles River Associates Inc, London, Lon, England; [Ahir, H.] MSD Ltd, Hoddesdon, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS4	S173	S173					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401016
J	Shin, M; D'Attilio, D				Shin, M.; D'Attilio, D.			HEALTH RESOURCE UTILIZATION AND COSTS OF RECTAL CANCER SURGERY IN KOREA	VALUE IN HEALTH			English	Meeting Abstract									[Shin, M.] Intuit Surg, Sunnyvale, CA USA; [D'Attilio, D.] Intuit Surg, Deerfield, IL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSU21	S228	S228					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401262
J	Skroumpelos, A; Freddi, M; Akcicek, H; Cohen, J; Driessen, MT				Skroumpelos, A.; Freddi, M.; Akcicek, H.; Cohen, J.; Driessen, M. T.			THE COST-EFFECTIVENESS OF FREMANEZUMAB IN PATIENTS WITH MIGRAINE WHO HAVE FAILED TWO OR MORE PREVIOUS MIGRAINE PREVENTIVE THERAPIES FROM A UK HEALTHCARE SYSTEM PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Skroumpelos, A.; Akcicek, H.; Driessen, M. T.] Teva Pharmaceut, Amsterdam, Netherlands; [Freddi, M.] Strategen, Winchester, Hants, England; [Cohen, J.] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND26	S163	S163					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400710
J	Song, C; Kreaden, U; Cheng, L; Yankovsky, A; Li, Y				Song, C.; Kreaden, U.; Cheng, L.; Yankovsky, A.; Li, Y.			SYSTEMATIC LITERATURE REVIEW ON COST-EFFECTIVENESS ANALYSIS OF ROBOTIC-ASSISTED RADICAL PROSTATECTOMY FOR PROSTATE CANCER	VALUE IN HEALTH			English	Meeting Abstract									[Song, C.] Intuit Surg, Duluth, GA USA; [Kreaden, U.; Cheng, L.; Li, Y.] Intuit Surg, Sunnyvale, CA USA; [Yankovsky, A.] Intuit Surg, Palo Alto, CA USA									0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN188	S54	S54					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400234
J	Tran, J; Zimmermann, M				Tran, J.; Zimmermann, M.			THE CLINICAL AND ECONOMIC IMPACTS OF PHARMACIST-INITIATED PRE-EXPOSURE PROPHYLAXIS FOR MEN WHO HAVE SEX WITH MEN IN THE UNITED STATES: A COST-UTILITY ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Tran, J.] Univ Washington, Seattle, WA 98195 USA; [Zimmermann, M.] Inst Dis Modeling, Bellevue, WA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		SC4	S240	S241					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401316
J	Tran, J; Khosropour, CM; Mena, L; Johnson, K; Sharma, M				Tran, J.; Khosropour, C. M.; Mena, L.; Johnson, K.; Sharma, M.			BUDGET IMPACT ANALYSIS OF HIV PRE-EXPOSURE PROPHYLAXIS TELEMEDICINE IN MISSISSIPPI	VALUE IN HEALTH			English	Meeting Abstract									[Tran, J.; Khosropour, C. M.; Sharma, M.] Univ Washington, Seattle, WA 98195 USA; [Mena, L.; Johnson, K.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN16	S108	S108					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400470
J	Turcu-Stiolica, A; Gheonea, DI; Ungureanu, BS; Doica, IP; Subtirelu, MS; Rogoveanu, I				Turcu-Stiolica, A.; Gheonea, D., I; Ungureanu, B. S.; Doica, I. P.; Subtirelu, M. S.; Rogoveanu, I			TRANSLATION AND CULTURAL ADAPTATION OF THE TELEMEDICINE SATISFACTION QUESTIONNAIRE FOR USE IN ROMANIA	VALUE IN HEALTH			English	Meeting Abstract									[Turcu-Stiolica, A.; Gheonea, D., I; Ungureanu, B. S.; Doica, I. P.; Subtirelu, M. S.; Rogoveanu, I] Univ Med & Pharm Craiova, Craiova, Romania				Turcu-Stiolica, Adina/C-5968-2017	Turcu-Stiolica, Adina/0000-0003-1374-276X				0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS113	S193	S193					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401107
J	Valerio, M; Veintimilla, C; Rodriguez, C; De la Villa, S; Somolinos, MS; Cerezales, M; Crespo, C; Rossello, I; Munoz, P				Valerio, M.; Veintimilla, C.; Rodriguez, C.; De la Villa, S.; Sanchez Somolinos, M.; Cerezales, M.; Crespo, C.; Rossello, I; Munoz, P.			ECONOMIC BURDEN OF PATIENTS TREATED WITH DALBAVANCIN IN A SPANISH HOSPITAL: ECODAL ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Valerio, M.; Veintimilla, C.; Rodriguez, C.; De la Villa, S.; Sanchez Somolinos, M.; Munoz, P.] Hosp Gen Univ Gregorio Maranon, Madrid, Spain; [Cerezales, M.] Axentiva Solut SL, Oviedo, O, Spain; [Crespo, C.] Axentiva Solut SL, Barcelona, B, Spain; [Rossello, I] Angelini Pharma Espana SLU, Barcelona, Spain									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG8	S88	S88					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400384
J	Wang, H; Ho, AF; Sambamoorthi, U				Wang, H.; Ho, A. F.; Sambamoorthi, U.			REDUCING THE RACIAL/ETHNIC DISPARITIES IN PERSONAL HEALTH RECORD (PHR) ADOPTION IN THE US	VALUE IN HEALTH			English	Meeting Abstract									[Wang, H.] JPS Hlth Network, Dallas, TX USA; [Ho, A. F.] JPS Hlth Network, Ft Worth, TX USA; [Sambamoorthi, U.] Univ North Texas, Hlth Sci Ctr, Ft Worth, TX USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS109	S192	S192					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401104
J	Zhang, J; He, X; Wu, J				Zhang, J.; He, X.; Wu, J.			THE IMPACT OF HYPERKALEMIA ON SURVIVAL AND HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE IN CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Zhang, J.; Wu, J.] Tianjin Univ, Tianjin, Peoples R China; [He, X.] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin, Peoples R China									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PUK23	S237	S238					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401303
J	Hubens, K; Krol, M; Coast, J; Drummond, MF; Brouwer, WBF; Uyl-de Groot, CA; Hakkaart-van Roijen, L				Hubens, Kimberley; Krol, Marieke; Coast, Joanna; Drummond, Michael F.; Brouwer, Werner B. F.; Uyl-de Groot, Carin A.; Hakkaart-van Roijen, Leona			Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective	VALUE IN HEALTH			English	Review						economic evaluation; indirect costs; measurement; measurement instruments; productivity costs; productivity loss; questionnaire; survey; systematic review	STANFORD PRESENTEEISM SCALE; INDIRECT COSTS; CARE; VALIDATION; ABSENCE; RECOMMENDATIONS; INTERVENTIONS; VERSION	Objectives: This study aimed (1) to perform a systematic literature review of instruments for measuring productivity loss of paid and unpaid work and (2) to assess the suitability (in terms of identification, measurement, and valuation) of these instruments for use in health economic evaluations from a societal perspective. Methods: Articles published from 2018 were sourced from PubMed/Medline, PsycInfo, Embase, and Econlit. Using 2 separate search strategies, eligible economic evaluations and validation studies were selected and unique measurement instruments identified. A data-extraction form was developed by studying previous literature and consulting an international panel of experts in the field of productivity costs. This data-extraction form was applied to assess the suitability of instruments for use in economic evaluations. Results: A total of 5982 articles were retrieved from the databases, of which 99 economic evaluations and 9 validation studies were included in the review. A total of 42 unique measurement instruments were identified. Nine instruments provided quantified measures of absenteeism, presenteeism, and unpaid work. Five instruments supplied the necessary information to enable the use of at least 1 common valuation method. The Health and Labour Questionnaire-Short Form, Health and Labour Questionnaire, and Institute for Medical Technology Assessment Productivity Cost Questionnaire met both criteria. Nevertheless, the developers replaced the Health and Labour Questionnaire-Short Form and Health and Labour Questionnaire by the more recently developed Institute for Medical Technology Assessment Productivity Cost Questionnaire. Conclusions: Although many instruments for measuring productivity loss were identified, most were not suitable for capturing productivity changes for economic evaluations from a societal perspective. Future research can benefit from this study by making an informed instrument choice for the measurement of productivity loss of paid and unpaid work.	[Hubens, Kimberley; Brouwer, Werner B. F.; Uyl-de Groot, Carin A.; Hakkaart-van Roijen, Leona] Erasmus Univ, Erasmus Sch Hlth Policy & Management, POB 1738, NL-300 DR Rotterdam, Netherlands; [Krol, Marieke] IQVIA, Amsterdam, Netherlands; [Coast, Joanna] Univ Bristol, Bristol Med Sch, Hlth Econ Bristol, Populat Hlth Sci, Bristol, Avon, England; [Drummond, Michael F.] Univ York, Ctr Hlth Econ, York, N Yorkshire, England; [Uyl-de Groot, Carin A.] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands		Hubens, K (通讯作者)，Erasmus Univ, Erasmus Sch Hlth Policy & Management, POB 1738, NL-300 DR Rotterdam, Netherlands.	k.hubens@gmail.com		Hakkaart-van Roijen, Leona/0000-0003-0635-7388; Coast, Joanna/0000-0002-3537-5166	European Union's Horizon 2020 research and innovation program [779292]	This study was part of the PECUNIA project and has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 779292.	Abbott JH, 2019, OSTEOARTHR CARTILAGE, V27, P424, DOI 10.1016/j.joca.2018.12.004; Abma FI, 2012, SCAND J WORK ENV HEA, V38, P5, DOI 10.5271/sjweh.3190; Agboola AA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202396; Agency for Quality and Accreditation in Health Care. Department for Development Research and Health Technology Assessment, 2011, CROAT GUID HLTH TECH, P1; Allen D, 2018, HUM RESOUR HEALTH, V16, DOI 10.1186/s12960-018-0321-9; Aronsson G, 2000, J EPIDEMIOL COMMUN H, V54, P502, DOI 10.1136/jech.54.7.502; Auquier P., FRENCH GUIDELINES EC; Beecham J, 2019, INTERNET INTERV, V16, P12, DOI 10.1016/j.invent.2018.02.009; Bhandari A, 2006, MED CARE RES REV, V63, P217, DOI 10.1177/1077558705285298; Bouwmans C, 2015, VALUE HEALTH, V18, P753, DOI 10.1016/j.jval.2015.05.009; Bouwmans C, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-217; Breckons M, 2018, J DENT RES, V97, P1200, DOI 10.1177/0022034518773310; Brouwer WBF, 1997, HEALTH ECON, V6, P253, DOI 10.1002/(SICI)1099-1050(199705)6:3<253::AID-HEC266>3.0.CO;2-6; Brouwer WBF, 1999, HEALTH POLICY, V48, P13, DOI 10.1016/S0168-8510(99)00028-7; Brouwer WBF, 2002, HEALTH POLICY, V61, P173, DOI 10.1016/S0168-8510(01)00233-0; BROWN NR, 1985, COGNITIVE PSYCHOL, V17, P139, DOI 10.1016/0010-0285(85)90006-4; Capri S, 2001, DRUG INF J, V35, P189, DOI 10.1177/009286150103500122; Centre for Health Evaluation & Outcome Sciences, VOLP TRANSL; Cicolini G, 2016, J NURS MANAGE, V24, P598, DOI 10.1111/jonm.12362; CLARK DM, 1982, J ABNORM PSYCHOL, V91, P87, DOI 10.1037/0021-843X.91.2.87; Cleemput I., 2015, BELGIAN GUIDELINES E; Dang Amit, 2016, Value Health Reg Issues, V9, P78, DOI 10.1016/j.vhri.2015.11.005; de Groot S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019864; de Putter CE, 2012, J BONE JOINT SURG AM, V94A, DOI 10.2106/JBJS.K.00561; Drummond MF., 2015, METHODS EC EVALUATIO, P353; EISENHOWER D, 1991, WILEY S PRO, P127; EULAR OML, EULAR OUTC MEAS LIB; European Headache Federation, LIFT BURD EUR PRINC; Fassbinder E, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1905-6; Fernandez-Ballesteros R, 2011, RES AGING, V33, P205, DOI 10.1177/0164027510395398; Frauendorf R, 2014, CLIN RHEUMATOL, V33, P1751, DOI 10.1007/s10067-013-2429-6; Gartner FR, 2012, INT ARCH OCC ENV HEA, V85, P125, DOI 10.1007/s00420-011-0649-0; Gillespie GL, 2010, ADV EMERG NURS J, V32, P258, DOI 10.1097/TME.0b013e3181e97510; Goetzel RZ, 2003, J OCCUP ENVIRON MED, V45, P743, DOI 10.1097/01.jom.0000079085.95532.32; Goossens MEJB, 2000, J CLIN EPIDEMIOL, V53, P688, DOI 10.1016/S0895-4356(99)00177-8; Gracia F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204681; Hakkaart-Van Roijen L, 2016, KOSTENHANDLEIDING ME; Hakkaart-van Roijen L., 2000, MANUAL HLTH LABOUR Q; Harvard Medical School, WHO HLTH WORK PERF Q; Hooshmand MA., COMP TELEMEDICINE TR; Hutting N, 2014, J OCCUP REHABIL, V24, P268, DOI 10.1007/s10926-013-9453-x; iMTA, QUEST IMTA; Institute for Quality and Efficiency in Healthcare (IQWiG) [Institut fur Qualitat und Wirtschaftlichkeit im Gesundheitswesen] Institute for Quality and Efficiency in Health Care (IQWiG), 2009, GEN METH ASS REL BEN, P74; Jonsson B, 2009, EUR J HEALTH ECON, V10, P357, DOI 10.1007/s10198-009-0173-2; Kamat N, 2019, POSTGRAD MED, V131, P60, DOI 10.1080/00325481.2019.1549458; Karimi, 2012, INT J LEADERSHIP STU, V7, P114; Khanmohammadi M, 2018, WORK, V61, P339, DOI 10.3233/WOR-182813; Kigozi J, 2017, VALUE HEALTH, V20, P496, DOI 10.1016/j.jval.2016.12.006; Kjellsson G, 2014, J HEALTH ECON, V35, P34, DOI 10.1016/j.jhealeco.2014.01.007; Knies S, 2013, VALUE HEALTH, V16, P740, DOI 10.1016/j.jval.2013.03.1624; Koopman C, 2002, J OCCUP ENVIRON MED, V44, P14, DOI 10.1097/00043764-200201000-00004; Koopmanschap M, 2005, PHARMACOECONOMICS, V23, P47, DOI 10.2165/00019053-200523010-00004; Koopmanschap M, 2004, TOEPASBAAR BIJ EC EV; KOOPMANSCHAP MA, 1995, J HEALTH ECON, V14, P171, DOI 10.1016/0167-6296(94)00044-5; Krol M., 2012, PRODUCTIVITY COSTS E; Krol M, 2016, EUR J HEALTH ECON, V17, P391, DOI 10.1007/s10198-015-0685-x; Krol M, 2013, PHARMACOECONOMICS, V31, P537, DOI 10.1007/s40273-013-0056-3; Krol M, 2011, PHARMACOECONOMICS, V29, P601, DOI 10.2165/11539970-000000000-00000; Lam RW, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-78; Loeppke R, 2003, J OCCUP ENVIRON MED, V45, P349, DOI 10.1097/01.jom.0000063619.37065.e2; Lofland Jennifer H, 2002, Expert Rev Pharmacoecon Outcomes Res, V2, P485, DOI 10.1586/14737167.2.5.485; Lofland JH, 2004, PHARMACOECONOMICS, V22, P165, DOI 10.2165/00019053-200422030-00003; Luengo-Fernandez R, 2013, LANCET ONCOL, V14, P1165, DOI 10.1016/S1470-2045(13)70442-X; Mapi research trust (MRT), WORK LIM QUEST WLQ; Mattke S, 2007, AM J MANAG CARE, V13, P211; Mumford V, 2018, J PAEDIATR CHILD H, V54, P987, DOI 10.1111/jpc.13923; National Headache Foundation, HEAD TESTS; Noben CYG, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-115; Ospina MB, 2015, AM J MANAG CARE, V21, pE171; Prasad M, 2004, PHARMACOECONOMICS, V22, P225, DOI 10.2165/00019053-200422040-00002; Reid M.G., 1934, EC HOUSEHOLD PRODUCT; Reilly Associates, WPAI GH V2 0; Reilly Associates, WPAI GEN INF; Severens JL, 2000, SOC SCI MED, V51, P243, DOI 10.1016/S0277-9536(99)00452-9; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; Statens legemiddelverk (Norwegian Medicines Agency), 2012, GUID HOW COND PHARM, V974, P1; Steiner TJ, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0837-3; Stull DE, 2009, CURR MED RES OPIN, V25, P929, DOI 10.1185/03007990902774765 ; Tan-Torres Edejer T., 2003, MAKING CHOICES HLTH; Tang K, 2015, PHARMACOECONOMICS, V33, P31, DOI 10.1007/s40273-014-0209-z; Tanvejsilp P, 2018, PHARMACOECON-OPEN, V2, P281, DOI 10.1007/s41669-017-0057-9; Thompson AH, 2018, VALUE HEALTH, V21, P650, DOI 10.1016/j.jval.2017.10.014; Trang S, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-0737; Uegaki K, 2011, J OCCUP REHABIL, V21, P90, DOI 10.1007/s10926-010-9258-0; Ungar W. J., 2018, CLIN PRACT PEDIAT PS, V6, P164, DOI [10.1037/c, DOI 10.1037/C, 10.1037/cpp0000226., DOI 10.1037/CPP0000226]; Vanni KJ, 2018, OCCUP MED-OXFORD, V68, P512, DOI 10.1093/occmed/kqy124; vanRoijen L, 1996, INT J TECHNOL ASSESS, V12, P405, DOI 10.1017/S0266462300009764; Walker S, 2019, APPL HEALTH ECON HEA, V17, P577, DOI 10.1007/s40258-019-00481-8; Wimo A, 2013, ALZHEIMERS DEMENT, V9, P429, DOI 10.1016/j.jalz.2012.06.008; Wynne-Jones G, 2018, PAIN, V159, P128, DOI 10.1097/j.pain.0000000000001075; Zethraeus N, 2009, OFFICE HLTH EC RES B, DOI [10.2139/ssrn.2640123, DOI 10.2139/SSRN.2640123]; Zhang W, 2011, SOC SCI MED, V72, P185, DOI 10.1016/j.socscimed.2010.10.026; Zhu Q, 2019, ANN OTO RHINOL LARYN, V128, P5, DOI 10.1177/0003489418803961	93	3	3	6	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	NOV	2021	24	11					1686	1699		10.1016/j.jval.2021.05.002		OCT 2021	14	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	XF1GI	34711370	Green Published, hybrid			2022-04-28	WOS:000723825200017
J	Boriani, G; Kennergren, C; Tarakji, KG; Wright, DJ; Ahmed, FZ; McComb, JM; Goette, A; Blum, T; Biffi, M; Green, M; Shore, J; Carion, PL; Wilkoff, BL				Boriani, Giuseppe; Kennergren, Charles; Tarakji, Khaldoun G.; Wright, David J.; Ahmed, Fozia Z.; McComb, Janet M.; Goette, Andreas; Blum, Thomas; Biffi, Mauro; Green, Michelle; Shore, Judith; Carion, Phuong Lien; Wilkoff, Bruce L.			Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England	VALUE IN HEALTH			English	Article						antibacterial envelope; cardiac implantable electronic device; cost-utility analysis; infection; randomized controlled trial	RESYNCHRONIZATION THERAPY; PREVENTION; GUIDELINES; MORTALITY; SOCIETY; HEALTH	Objectives: To model the cost-effectiveness of the TYRX Absorbable Antibacterial Envelope when used in patients at increased risk of cardiac implantable electronic device (CIED) infection in the context of 3 European healthcare systems: Germany, Italy, and England.& nbsp; Methods: A decision tree model with a lifetime horizon was populated using data from the Worldwide Randomized Antibiotic Envelope Infection Prevention Trial, a large multicenter randomized controlled trial. Use of the antibacterial envelope adjunctive to standard of care was compared to standard of care infection prevention alone. Patients in the model were divided into subgroups based on presence of factors known to increase infection risk. Results: The antibacterial envelope had the most favorable cost-effectiveness profile when patients had previously experienced CIED infection, had a history of immunosuppressive therapy, or had a Prevention of Arrhythmia Device Infection Trial (PADIT) score indicating high risk of infection (scores $6) at cost-effectiveness thresholds of & euro;50 000 in Germany (assumed in the absence of an official threshold), & euro;40 000 in Italy, and 30 pound 000 in England. Probabilistic sensitivity analysis indicated that the antibacterial envelope was likely to be cost-effective in patients with other risk factors (including replacement of high power CIEDs, generator replacement with lead modification, and PADIT scores indicating intermediate risk of infection) when used with some device types and in some countries. Conclusions: The absorbable antibacterial envelope was associated with cost-effectiveness ratios below European benchmarks in selected patients at increased risk of infection, suggesting the envelope provides value for European healthcare systems by reducing CIED infections.	[Boriani, Giuseppe] Univ Modena & Reggio Emilia, Policlin Modena, Dept Biomed Metab & Neural Sci, Modena, Italy; [Kennergren, Charles] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Tarakji, Khaldoun G.; Wilkoff, Bruce L.] Cleveland Clin, Cleveland, OH 44106 USA; [Wright, David J.] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England; [Ahmed, Fozia Z.] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England; [McComb, Janet M.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England; [Goette, Andreas] St Vincenz Hosp, Dept Cardiol & Intens Care Med, Paderborn, Germany; [Blum, Thomas] Univ Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany; [Biffi, Mauro] Policlin St Orsola Malpighi, Bologna, Italy; [Green, Michelle; Shore, Judith] York Hlth Econ Consortium, York, N Yorkshire, England; [Carion, Phuong Lien] Medtron Int Trading Sarl, Tolochenaz, Switzerland		Boriani, G (通讯作者)，Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Cardiol Div, Policlin Modena, Via Pozzo 71, I-41125 Modena, Italy.	giuseppe.boriani@unimore.it	Boriani, Giuseppe/AAC-3406-2022	Boriani, Giuseppe/0000-0002-9820-4815	Medtronic Inc.Medtronic	Financial support for this article was provided by Medtronic Inc.	Ahmed FZ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0206611; Ahsan SY, 2014, EUROPACE, V16, P1482, DOI 10.1093/europace/euu126; Attema AE, 2018, PHARMACOECONOMICS, V36, P745, DOI 10.1007/s40273-018-0672-z; Birnie DH, 2019, J AM COLL CARDIOL, V74, P2845, DOI 10.1016/j.jacc.2019.09.060; Blomstrom-Lundqvist C, 2020, EUROPACE, V22, P515, DOI 10.1093/europace/euz246; Boriani G, 2013, EUR HEART J, V34, P1869, DOI 10.1093/eurheartj/eht031; Briggs A, 2006, DECISION MODELLING H; Brignole M, 2013, EUR HEART J, V34, P2281, DOI 10.1093/eurheartj/eht150; Brough CEP, 2019, EUROPACE, V21, P290, DOI 10.1093/europace/euy291; Burnhope E, 2019, J MED ECON, V22, P464, DOI 10.1080/13696998.2019.1581621; Cameron D, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2018.1447828; Clementy N, 2018, EUROPACE, V20, P1974, DOI 10.1093/europace/eux387; de Bie MK, 2012, HEART RHYTHM, V9, P494, DOI 10.1016/j.hrthm.2011.10.034; Eby EL, 2020, J MED ECON, V23, P698, DOI 10.1080/13696998.2020.1751649; Egea M, 2018, EUROPACE, V20, pI180; Fattore G, 2009, PHARMACOECONOMICS IT, V11, P83, DOI [10.1007/BF03320660, DOI 10.1007/BF03320660]; Greenspon AJ, 2011, J AM COLL CARDIOL, V58, P1001, DOI 10.1016/j.jacc.2011.04.033; Kay G, 2018, J MED ECON, V21, P294, DOI 10.1080/13696998.2017.1409227; Kennergren C, 2020, EHRA PRESENTATION; Kirkfeldt RE, 2014, EUR HEART J, V35, P1186, DOI 10.1093/eurheartj/eht511; Ludwig S, 2018, J COMP EFFECT RES, V7, P483, DOI 10.2217/cer-2017-0080; Maniadakis N, 2011, EUROPACE, V13, pII3, DOI 10.1093/europace/eur088; Mittal S., 2020, HEART RHYTHM; NICE, 2013, GUID METH TECHN APPR; NICE, 2014, IMPL CARD DEF CARD R; Olsen T, 2019, EUR HEART J, V40, P1862, DOI 10.1093/eurheartj/ehz316; Polyzos KA, 2015, EUROPACE, V17, P767, DOI 10.1093/europace/euv053; Romeyer-Bouchard C, 2010, EUR HEART J, V31, P203, DOI 10.1093/eurheartj/ehp421; Sandoe JAT, 2015, J ANTIMICROB CHEMOTH, V70, P325, DOI 10.1093/jac/dku383; Shariff N, 2015, J CARDIOVASC ELECTR, V26, P783, DOI 10.1111/jce.12684; Sohail MR, 2011, ARCH INTERN MED, V171, P1821, DOI 10.1001/archinternmed.2011.441; Stadhouders N, 2019, HEALTH ECON, V28, P1331, DOI 10.1002/hec.3946; Tarakji KG, 2019, NEW ENGL J MED, V380, P1895, DOI 10.1056/NEJMoa1901111; Tarakji KG, 2016, AM HEART J, V180, P12, DOI 10.1016/j.ahj.2016.06.010; van Baal P, 2019, HEALTH ECON, V28, P87, DOI 10.1002/hec.3831; Wilkoff BL, 2020, CIRC-ARRHYTHMIA ELEC, V13, P1073, DOI 10.1161/CIRCEP.120.008503; Wilkoff BL, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.119.008280	37	5	5	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUL	2021	24	7					930	938		10.1016/j.jval.2020.12.021		JUL 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TE7UB	34243836	Green Published, hybrid			2022-04-28	WOS:000670212100003
J	Bernauer, M; Zaidi, O; Yeh, YC; Valencia, C; Pan, X				Bernauer, M.; Zaidi, O.; Yeh, Y. C.; Valencia, C.; Pan, X.			A LITERATURE REVIEW OF RECURRENT OR METASTATIC CERVICAL CANCER DISEASE BURDEN, TREATMENT OUTCOMES, AND UNMET NEEDS	VALUE IN HEALTH			English	Meeting Abstract									[Bernauer, M.] Pharmerit Int, Bethesda, MD USA; [Zaidi, O.; Yeh, Y. C.] Pharmerit Int, Newton, MA USA; [Valencia, C.; Pan, X.] EMD Serono Res & Dev Inst Inc, Billerica, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN38	S25	S25					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400102
J	Cao, D; Liu, J; Liu, J; He, X; Wu, J				Cao, D.; Liu, J.; Liu, J.; He, X.; Wu, J.			COST-UTILITY ANALYSIS OF LURASIDONE FOR THE TREATMENT OF SCHIZOPHRENIA IN CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Cao, D.; Liu, J.; He, X.; Wu, J.] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin, Peoples R China; [Liu, J.] Sumitomo Pharma Suzhou Co Ltd, Shanghai, Peoples R China									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH33	S133	S133					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400582
J	Fan, Y; Jimenez, M; Zhang, L; Bohn, R; Thompson, J; Brodovicz, KG; Gray, S; Melmed, G				Fan, Y.; Jimenez, M.; Zhang, L.; Bohn, R.; Thompson, J.; Brodovicz, K. G.; Gray, S.; Melmed, G.			ECONOMIC BURDEN ASSOCIATED WITH STRICTURES AND/OR FISTULAE AMONG COMMERCIALLY INSURED PATIENTS DIAGNOSED WITH CROHN?S DISEASE IN THE US	VALUE IN HEALTH			English	Meeting Abstract									[Fan, Y.; Zhang, L.] Boehringer Ingelheim GmbH & Co KG, Ingelheim, CT, Germany; [Jimenez, M.; Bohn, R.; Gray, S.] Bohn Epidemiol, Boston, MA USA; [Thompson, J.] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA; [Brodovicz, K. G.] Boehringer Ingelheim Int GmbH, Ridgefield, CT USA; [Melmed, G.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PGI13	S96	S96					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400418
J	Goodyer, P; Manso, M; Guittet, C; Bertholet-Thomas, A				Goodyer, P.; Manso, M.; Guittet, C.; Bertholet-Thomas, A.			ADV7103 TREATMENT ADHERENCE IN PATIENTS WITH DISTAL RENAL TUBULAR ACIDOSIS (DRTA)	VALUE IN HEALTH			English	Meeting Abstract									[Goodyer, P.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Manso, M.; Guittet, C.] Advicenne, Nimes 30, France; [Bertholet-Thomas, A.] Ctr Reference Malad Renales Rares, Nephrogones, Bron, France									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO9	S199	S199					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401131
J	Graham, S; Laurent, T; Simeone, J; Kuwatsuru, R; Hirano, T; Phillips, R; Isomura, T				Graham, S.; Laurent, T.; Simeone, J.; Kuwatsuru, R.; Hirano, T.; Phillips, R.; Isomura, T.			REAL-WORLD EVIDENCE GENERATION IN JAPAN - USES AND CHALLENGES	VALUE IN HEALTH			English	Meeting Abstract									[Graham, S.] Evidera, London, Ken, England; [Laurent, T.; Hirano, T.; Phillips, R.; Isomura, T.] Clin Study Support Inc, Nagoya, Aichi, Japan; [Simeone, J.] Evidera, Waltham, MA USA; [Kuwatsuru, R.] Juntendo Univ, Tokyo, Japan									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS119	S194	S194					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401113
J	Henry, A; Stricker-Shaver, J; Cork, D; Curry, A; Ralston, S				Henry, A.; Stricker-Shaver, J.; Cork, D.; Curry, A.; Ralston, S.			A RETROSPECTIVE REVIEW OF HTA OUTCOMES FOR ONCOLOGY TREATMENTS ASSESSED IN FRANCE AND GERMANY FROM 2018 TO 2020	VALUE IN HEALTH			English	Meeting Abstract									[Henry, A.; Stricker-Shaver, J.; Cork, D.; Curry, A.; Ralston, S.] Genesis Res, Newcastle Upon Tyne, Tyne & Wear, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN169	S51	S51					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400218
J	Hull, M; Anupindi, R; He, J; Danchenko, N; DeKoven, M; Bouchard, JR				Hull, M.; Anupindi, R.; He, J.; Danchenko, N.; DeKoven, M.; Bouchard, J. R.			BOTULINUM TOXIN UTILIZATION AND TREATMENT COST IN ADULT AND PEDIATRIC PATIENTS WITH SPASTICITY OR CERVICAL DYSTONIA IN THE US: ADMINISTRATIVE HEALTHCARE CLAIMS DATA	VALUE IN HEALTH			English	Meeting Abstract									[Hull, M.; Anupindi, R.; He, J.; DeKoven, M.] IQVIA, Falls Church, VA USA; [Danchenko, N.] Ipsen Global, Boulogne, France; [Bouchard, J. R.] Ipsen, Cambridge, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU7	S146	S146					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400635
J	Kamal-Bahl, S; Puckett, J; Willke, R				Kamal-Bahl, S.; Puckett, J.; Willke, R.			PATIENT HETEROGENEITY AND THE LIMITATIONS OF ONE-SIZE-FITS-ALL VALUE-BASED PRICING: A SYSTEMATIC REVIEW AND FUTURE DIRECTIONS	VALUE IN HEALTH			English	Meeting Abstract									[Kamal-Bahl, S.] COVIA Hlth Solut, Lansdale, PA USA; [Puckett, J.] COVIA Hlth Solut, Philadelphia, PA USA; [Willke, R.] ISPOR, Lawrenceville, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU49	S153	S153					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400667
J	Kamat, S; Descoteaux, AM; Vyas, A				Kamat, S.; Descoteaux, A. M.; Vyas, A.			IMPACT OF GUIDELINE-CONCORDANT TREATMENT ON SURVIVAL AMONG OLDER WOMEN WITH ADVANCED	VALUE IN HEALTH			English	Meeting Abstract									[Kamat, S.; Descoteaux, A. M.; Vyas, A.] Univ Rhode Isl, Kingston, RI 02881 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN147	S46	S46					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400198
J	Ko, G; Hansen, R				Ko, G.; Hansen, R.			COST-EFFECTIVENESS ANALYSIS OF OLAPARIB AND NOVEL HORMONAL THERAPIES IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER	VALUE IN HEALTH			English	Meeting Abstract									[Ko, G.] Univ Washington, Bellevue, WA USA; [Hansen, R.] Univ Washington, Seattle, WA 98195 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN178	S52	S52					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400225
J	Kocaata, Z; Muller, S; Maywald, U; Wilke, T				Kocaata, Z.; Mueller, S.; Maywald, U.; Wilke, T.			REAL-WORLD NON-PERSISTENCE WITH ORAL MULTIPLE MYELOMA TREATMENTS: A COMPARATIVE ANALYSIS OF METHODOLOGIES USING CLAIMS DATA	VALUE IN HEALTH			English	Meeting Abstract									[Kocaata, Z.] Ingress Hlth HWM GmbH, Wismar, MV, Germany; [Mueller, S.] Ingress Hlth, Wismar, Germany; [Maywald, U.] AOK PLUS, Dresden, Germany; [Wilke, T.] IPAM eV, Wismar, Germany									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN156	S48	S48					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400207
J	Kovacs, S; Bendes, R; Kalo, Z; Kolasa, K; Hren, R; Tesar, T; Reckers-Droog, V; Brouwer, W; Federici, C; Torbica, A; Drummond, M; Zemplenyi, A				Kovacs, S.; Bendes, R.; Kalo, Z.; Kolasa, K.; Hren, R.; Tesar, T.; Reckers-Droog, V; Brouwer, W.; Federici, C.; Torbica, A.; Drummond, M.; Zemplenyi, A.			TRANSFERRING HEALTH TECHNOLOGY ASSESSMENTS FROM EARLY ADOPTER TO LATE ADOPTER COUNTRIES: RECOMMENDATIONS FOR THE IMPLEMENTATION OF CED SCHEMES IN CENTRAL AND EASTERN EUROPEAN COUNTRIES	VALUE IN HEALTH			English	Meeting Abstract									[Kovacs, S.; Bendes, R.; Kalo, Z.; Zemplenyi, A.] Syreon Res Inst, Budapest, PE, Hungary; [Kalo, Z.] Semmelweis Univ, Ctr Hlth Technol Assessment, Budapest, Hungary; [Kolasa, K.] Kozminski Univ, Warsaw, Poland; [Hren, R.] Univ Ljubljana, Ljubljana, Slovenia; [Tesar, T.] Union Hlth Insurance Fund, Bratislava, Slovakia; [Reckers-Droog, V] PHMR Ltd, Rotterdam, ZH, Netherlands; [Brouwer, W.] Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands; [Federici, C.] SDA Bocconi Sch Management, Milan, MI, Italy; [Torbica, A.] Bocconi Univ, Milan, MI, Italy; [Drummond, M.] Univ York, York, N Yorkshire, England; [Zemplenyi, A.] Univ Pecs, Div Pharmacoecon, Fac Pharm, Budapest, Hungary				Kalo, Zoltan/G-7582-2011; Tesar, Tomas/AAW-4975-2021	Kalo, Zoltan/0000-0001-7762-2607; Tesar, Tomas/0000-0002-0023-4574				0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS77	S187	S187					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401078
J	Lin, CW; To, TM; Ng, C; Gupta, R; Ogale, S				Lin, C. W.; To, T. M.; Ng, C.; Gupta, R.; Ogale, S.			HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS RECEIVING ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS	VALUE IN HEALTH			English	Meeting Abstract									[Lin, C. W.] Genentech Inc, Millbrae, CA USA; [To, T. M.; Ng, C.; Gupta, R.; Ogale, S.] Genentech Inc, San Francisco, CA 94080 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN70	S32	S32					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400131
J	Liu, S; DeClue, R; Nisbett, A; Gautam, S; Fisher, MD; Shenolikar, R				Liu, S.; DeClue, R.; Nisbett, A.; Gautam, S.; Fisher, M. D.; Shenolikar, R.			REAL-WORLD PROGRESSION-FREE SURVIVAL BY TIMING OF MOLECULAR PROFILING TESTING AMONG METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS IN A COMMUNITY SETTING	VALUE IN HEALTH			English	Meeting Abstract									[Liu, S.; Shenolikar, R.] AstraZeneca, Gaithersburg, MD USA; [DeClue, R.; Gautam, S.; Fisher, M. D.] ConcertAI, Memphis, TN USA; [Nisbett, A.] ConcertAI, Tampa, FL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN33	S24	S24					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400097
J	Madariaga, H; Reyes, SJM; Gutierrez, AM; Ponce, DLD; Lukic, T; Amador, L				Madariaga, H.; Reyes, Sanchez J. M.; Gutierrez, Ardila M.; Ponce, de Leon D.; Lukic, T.; Amador, L.			PATIENT-REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB OR BIOLOGICAL DMARDS IN REAL LIFE CONDITIONS: COLOMBIAN AND PERU PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Madariaga, H.] SANNA Clin Sur, Arequipa, Peru; [Reyes, Sanchez J. M.; Amador, L.] Pfizer SAS, Bogota, Cun, Colombia; [Gutierrez, Ardila M.] Pfizer Chile SA, Santiago, RM, Chile; [Ponce, de Leon D.] Pfizer, Lima, Peru; [Lukic, T.] Pfizer, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMS2	S138	S138					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400602
J	Majd, Z; Mohan, A; Serna, O; Abughosh, S				Majd, Z.; Mohan, A.; Serna, O.; Abughosh, S.			USING GROUP-BASED TRAJECTORY MODELING (GBTM) TO CHARACTERIZE THE ASSOCIATION OF PAST ACEI/ARBS ADHERENCE TRAJECTORIES WITH SUBSEQUENT STATIN ADHERENCE TRAJECTORIES AMONG NEW STATIN USERS	VALUE IN HEALTH			English	Meeting Abstract									[Majd, Z.; Mohan, A.; Abughosh, S.] Univ Houston, Coll Pharm, Houston, TX 77030 USA; [Serna, O.] CareAllies, Houston, TX USA									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB38	S84	S84					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400368
J	da Silva, BM; Regis, C				Mendes da Silva, B.; Regis, C.			BUDGET IMPACT ANALYSIS OF EXPANDING USE OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS IG INFUSION IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PID) IN BRAZIL	VALUE IN HEALTH			English	Meeting Abstract									[Mendes da Silva, B.; Regis, C.] Takeda Farmaceut Brasil, Sao Paulo, SP, Brazil									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU9	S146	S146					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400637
J	Miller-Wilson, LA; Rutten, LJF; Van Thomme, J; Ozbay, AB; Limburg, PJ				Miller-Wilson, L. A.; Rutten, Finney L. J.; Van Thomme, J.; Ozbay, A. B.; Limburg, P. J.			CROSS-SECTIONAL ADHERENCE WITH THE MULTI-TARGET STOOL DNA TEST FOR COLORECTAL CANCER SCREENING IN A MEDICAID POPULATION	VALUE IN HEALTH			English	Meeting Abstract									[Miller-Wilson, L. A.] Exact Sci Corp, Montgomery, TX USA; [Rutten, Finney L. J.; Limburg, P. J.] Mayo Clin, Coll Med, Rochester, MN USA; [Van Thomme, J.; Ozbay, A. B.] Exact Sci Corp, Madison, WI USA									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMD22	S127	S127					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400555
J	Pistollato, M; Wilsdon, T; Steele, R; Bercher, J; Van Meerveld, M; Roediger, A; Schulz, S; Hartevelt, M; Calvetto, M				Pistollato, M.; Wilsdon, T.; Steele, R.; Bercher, J.; Van Meerveld, M.; Roediger, A.; Schulz, S.; Hartevelt, M.; Calvetto, M.			ONCOLOGY COMBINATIONS: HOW TO ENSURE TIMELY ACCESS?	VALUE IN HEALTH			English	Meeting Abstract									[Pistollato, M.; Wilsdon, T.; Steele, R.] Charles River Associates Inc, London, Lon, England; [Bercher, J.] Charles River Associates Inc, Munich, Germany; [Van Meerveld, M.; Schulz, S.] MSD, Zurich, Switzerland; [Roediger, A.] MSD, Luzern, Switzerland; [Hartevelt, M.; Calvetto, M.] Merck & Co Inc, Kenilworth, NJ USA				Roediger, Alexander/ABC-6370-2021					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN36	S25	S25					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400100
J	Polimeni, JM; Iorgulescu, RI				Polimeni, J. M.; Iorgulescu, R. I.			LINKING PERSONAL HEALTH TO THE LIVING ENVIRONMENT AND POVERTY: A CASE STUDY OF SCHENECTADY, NY	VALUE IN HEALTH			English	Meeting Abstract									[Polimeni, J. M.; Iorgulescu, R. I.] Albany Coll Pharm & Hlth Sci, Schenectady, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS44	S180	S180					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401048
J	Posada, K; Rojas, DG; Marin, J				Posada, K.; Garcia Rojas, D.; Marin, J.			CORRELATION BETWEEN SELF-REPORTED AND CLINICAL MEASURES OF WEIGHT, HEIGHT AND BODY MASS INDEX IN ADULTS MEMBERS OF A PRIVATE HEALTH INSURANCE COMPANY IN COLOMBIA, 2019	VALUE IN HEALTH			English	Meeting Abstract									[Posada, K.] Seguros SURA Colombia, Medellin, Colombia; [Garcia Rojas, D.; Marin, J.] EPS & Med Prepagada Suramer SA, Medellin, Ant, Colombia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS117	S194	S194					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401111
J	Qu, Y; Friedman, HS; Navaratnam, P; Xiao, H; Gricar, J				Qu, Y.; Friedman, H. S.; Navaratnam, P.; Xiao, H.; Gricar, J.			REAL-WORLD ASSESSMENT OF THE TREATMENT PATTERNS ASSOCIATED WITH UN-RESECTABLE ADVANCED AND METASTATIC ESOPHAGEAL CANCER IN CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Qu, Y.] Digital Hlth China Technol Ltd, Beijing 11, Peoples R China; [Friedman, H. S.; Navaratnam, P.] DataMed Solut LLC, New York, NY USA; [Xiao, H.; Gricar, J.] Bristol Myers Squibb, Lawrenceville, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN143	S45	S46					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400194
J	Ronquest, N; Paret, K; Gould, I; Barnett, CL; Mladsi, D				Ronquest, N.; Paret, K.; Gould, I; Barnett, C. L.; Mladsi, D.			EFFECTS OF STAKEHOLDER ENGAGEMENT WITH ICER ON COST-EFFECTIVENESS OF NEW INTERVENTIONS: LESSONS LEARNED FROM A CRITICAL REVIEW OF EVALUATIONS FROM 2018 TO 2019	VALUE IN HEALTH			English	Meeting Abstract									[Ronquest, N.; Gould, I] RTI Hlth Solut, Durham, NC USA; [Paret, K.; Barnett, C. L.] RTI Hlth Solut, Res Triangle Pk, NC USA; [Mladsi, D.] RTI Hlth Solut, Waltham, NC USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		HT1	S8	S9					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400033
J	Sanchez, L; Okumura, L; Dias, AMR; Deckert, J				Sanchez, L.; Okumura, L.; Dias, Alves M. R.; Deckert, J.			COST-EFFECTIVENESS ANALYSIS OF PERIOPERATIVE GOAL-DIRECTED FLUID THERAPY (PGDT) FOR HIGH-RISK HIP REPLACEMENT SURGERY FROM THE PUBLIC HEALTHCARE PERSPECTIVE IN MEXICO	VALUE IN HEALTH			English	Meeting Abstract									[Sanchez, L.] Edwards Lifesci Mexico, Mexico City, DF, Mexico; [Okumura, L.; Dias, Alves M. R.] Edwards Lifesci Brazil, Sao Paulo, Brazil; [Deckert, J.] Edwards Lifesci Europe, Nyon, Switzerland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSU8	S225	S225					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401249
J	Shah, C; Zafari, Z				Shah, C.; Zafari, Z.			DIRECT MEDICAL AND MORTALITY RELATED COSTS AMONG COPD PATIENTS IN THE UNITED STATES, 2017-2018	VALUE IN HEALTH			English	Meeting Abstract									[Shah, C.; Zafari, Z.] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS5	S213	S213					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401197
J	Shah, F; Huey, K; Deshpande, S; Turner, M; Chitnis, M; Schiller, E; Yucel, A; Bueno, LM; Oliva, E				Shah, F.; Huey, K.; Deshpande, S.; Turner, M.; Chitnis, M.; Schiller, E.; Yucel, A.; Bueno, Moro L.; Oliva, E.			A SYSTEMATIC LITERATURE REVIEW OF THE RELATIONSHIP BETWEEN SERUM FERRITIN AND OUTCOMES IN BETA-THALASSEMIA	VALUE IN HEALTH			English	Meeting Abstract									[Shah, F.] Whittington Hlth NHS Trust, Isleworth, Lon, England; [Huey, K.; Yucel, A.; Bueno, Moro L.] Bristol Myers Squibb Co, Princeton, NJ USA; [Deshpande, S.] Evidera, London, England; [Turner, M.; Chitnis, M.; Schiller, E.] Evidera, Waltham, MA USA; [Oliva, E.] Grande Osped Metropolitano Bianchi Melacrino More, Reggio Di Calabria, Italy									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSY16	S232	S232					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401277
J	Soloman, N; Amin, M; Cox, K; Helfgott, SM; Hu, A; Huston, K; Leonard, J; Milligan, S; Singh, JA; Tesser, J; Edgerton, C; Wick, N				Soloman, N.; Amin, M.; Cox, K.; Helfgott, S. M.; Hu, A.; Huston, K.; Leonard, J.; Milligan, S.; Singh, J. A.; Tesser, J.; Edgerton, C.; Wick, N.			GOUT MANAGEMENT WITH PEGLOTICASE IN US CLINICAL CARE; OBSERVATIONS FROM TRIO HEALTH AND THE AMERICAN RHEUMATOLOGY NETWORK	VALUE IN HEALTH			English	Meeting Abstract									[Soloman, N.; Amin, M.; Hu, A.; Leonard, J.; Tesser, J.] Arizona Arthrit & Rheumatol Associates, Phoenix, AZ USA; [Cox, K.; Milligan, S.] Trio Hlth Analyt, Louisville, CO USA; [Helfgott, S. M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Huston, K.] Ctr Rheumat Dis & Allergy Immunol, Kansas City, MO USA; [Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA; [Edgerton, C.] Articularis Healthcare, Summerville, SC USA; [Wick, N.] Trio Hlth Analyt, La Jolla, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMS4	S138	S138					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400604
J	Strassels, S; Moss, KO; Mallow, PJ; Tamer, RM; Monroe, TB; Williams, NO; Levine, AS; Muench, U				Strassels, S.; Moss, K. O.; Mallow, P. J.; Tamer, R. M.; Monroe, T. B.; Williams, N. O.; Levine, A. S.; Muench, U.			HOSPITAL ADMISSIONS ASSOCIATED WITH CANCER PAIN AND DEMENTIA IN OLDER ADULTS	VALUE IN HEALTH			English	Meeting Abstract									[Strassels, S.; Moss, K. O.; Tamer, R. M.; Monroe, T. B.; Williams, N. O.] Ohio State Univ, Columbus, OH 43210 USA; [Mallow, P. J.] Xavier Univ, Cincinnati, OH 45207 USA; [Levine, A. S.] Nationwide Childrens Hosp, Columbus, OH USA; [Muench, U.] Univ Calif San Francisco, San Francisco, CA 94143 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN123	S41	S41					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400175
J	Su, D; Zhou, R				Su, D.; Zhou, R.			INFLUENCING FACTORS AND ECONOMIC BURDEN OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE PULMONARY INFECTION IN NEUROSURGICAL PATIENTS	VALUE IN HEALTH			English	Meeting Abstract									[Su, D.; Zhou, R.] Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, Hefei 34, Peoples R China									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN71	S119	S119					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400521
J	Wagner, P; Zlateva, J; van Engen, A; Plantor, S				Wagner, P.; Zlateva, J.; van Engen, A.; Plantoer, S.			THE IMPACT OF COVID-19 ON EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS	VALUE IN HEALTH			English	Meeting Abstract									[Wagner, P.] IQVIA, Frankfurt, Germany; [Zlateva, J.] IQVIA, Sofia, Bulgaria; [van Engen, A.] IQVIA Consulting Serv, Amsterdam, NH, Netherlands; [Plantoer, S.] IQVIA Commercial GmbH & Co OHG, Munich, Germany									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU48	S153	S153					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400666
J	Xiong, X; Dalziel, K; Huang, L; Mulhern, B; Carvalho, N				Xiong, X.; Dalziel, K.; Huang, L.; Mulhern, B.; Carvalho, N.			HOW DO DIFFERENT HEALTH CONDITIONS IMPACT DIMENSIONS OF PEDIATRIC PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE MEASURES?	VALUE IN HEALTH			English	Meeting Abstract									[Xiong, X.; Dalziel, K.; Huang, L.; Carvalho, N.] Univ Melbourne, Melbourne, Vic, Australia; [Mulhern, B.] Univ Technol Sydney, Sydney, NSW, Australia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH33	S104	S104					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400453
J	Manski, CF; Tetenov, A				Manski, Charles F.; Tetenov, Aleksey			Statistical Decision Properties of Imprecise Trials Assessing Coronavirus Disease 2019 (COVID-19) Drugs	VALUE IN HEALTH			English	Article						COVID-19; decision criteria; near optimality; randomized trials	CHOICE; SIZE	Objectives: Researchers studying treatment of coronavirus disease 2019 (COVID-19) have reported findings of randomized trials comparing standard care with care augmented by experimental drugs. Many trials have small sample sizes, so estimates of treatment effects are imprecise. Hence, clinicians may find it difficult to decide when to treat patients with experimental drugs. A conventional practice when comparing standard care and an innovation is to choose the innovation only if the estimated treatment effect is positive and statistically significant. This practice defers to standard care as the status quo. We study treatment choice from the perspective of statistical decision theory, which considers treatment options symmetrically when assessing trial findings. Methods: We use the concept of near-optimality to evaluate criteria for treatment choice. This concept jointly considers the probability and magnitude of decision errors. An appealing criterion from this perspective is the empirical success rule, which chooses the treatment with the highest observed average patient outcome in the trial. Results: Considering the design of some COVID-19 trials, we show that the empirical success rule yields treatment choices that are much closer to optimal than those generated by prevailing decision criteria based on hypothesis tests. Conclusion: Using trial findings to make near-optimal treatment choices rather than perform hypothesis tests should improve clinical decision making.	[Manski, Charles F.] Northwestern Univ, Dept Econ, 2211 Campus Dr, Evanston, IL 60208 USA; [Manski, Charles F.] Northwestern Univ, Inst Policy Res, Evanston, IL 60208 USA; [Tetenov, Aleksey] Univ Geneva, Geneva Sch Econ & Management, Geneva, Switzerland		Manski, CF (通讯作者)，Northwestern Univ, Dept Econ, 2211 Campus Dr, Evanston, IL 60208 USA.	cfmanski@northwestern.edu	Manski, Charles/AAV-7497-2021		Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [100018-192580]	Funding/Support: This work was supported by grant 100018-192580 from the Swiss National Science Foundation.	Berry DA, 2004, STAT SCI, V19, P175, DOI 10.1214/088342304000000044; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Claxton K, 1996, HEALTH ECON, V5, P513, DOI 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9; Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Hirano K, 2009, ECONOMETRICA, V77, P1683, DOI 10.3982/ECTA6630; Lindley DV, 1998, STAT SCI, V13, P136; Manski CF, 2004, ECONOMETRICA, V72, P1221, DOI 10.1111/j.1468-0262.2004.00530.x; Manski CF, 2019, AM STAT, V73, P305, DOI 10.1080/00031305.2018.1543617; Manski CF, 2018, HEALTH ECON, V27, P1397, DOI 10.1002/hec.3803; Manski CF, 2016, P NATL ACAD SCI USA, V113, P10518, DOI 10.1073/pnas.1612174113; Meltzer D, 2001, J HEALTH ECON, V20, P109, DOI 10.1016/S0167-6296(00)00071-0; NIH, 2020, POT ANT DRUGS EV TRE; Nuffield Department of Population Health, RECOVERY; SAVAGE LJ, 1951, J AM STAT ASSOC, V46, P55, DOI 10.2307/2280094; Spiegelhalter DJ, 2004, STAT SCI, V19, P156, DOI 10.1214/088342304000000080; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; Stoye J, 2009, J ECONOMETRICS, V151, P70, DOI 10.1016/j.jeconom.2009.02.013; Tetenov A., 2016, CEMMAP WORKING PAPER; World Health Organization, SOLIDARITY	20	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAY	2021	24	5					641	647		10.1016/j.jval.2020.11.019		APR 2021	7	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	RU9KC	33933232	Bronze, Green Published			2022-04-28	WOS:000645457500006
J	Beck, E; Klint, J; Neine, M; Garcia, S; Meszaros, K				Beck, Ekkehard; Klint, Johan; Neine, Mohamed; Garcia, Stephanie; Meszaros, Kinga			Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease	VALUE IN HEALTH			English	Article						4CMenB; cost-effectiveness; meningococcal; vaccination	INTRODUCING VACCINATION; EPIDEMIOLOGIC IMPACT; ECONOMIC-EVALUATION; SEVERE MENINGITIS; ADOLESCENTS; BEXSERO(R); CARRIAGE; CHILDREN; WALES; LIFE	Objectives: This cost-effectiveness analysis (CEA) of 4CMenB infant vaccination in England comprehensively considers the broad burden of serogroup B invasive meningococcal disease (MenB IMD), which has not been considered, or was only partially considered in previous CEAs. Methods: A review of previous MenB vaccination CEAs was conducted to identify aspects considered in the evaluation of costs and health outcomes of the disease burden of MenB IMD. To inform the model structure and comprehensive analysis, the aspects were grouped into 5 categories. A stepwise analysis was conducted to analyze the impact of each category, and the more comprehensive consideration of disease burden, on the incremental cost-effectiveness ratio (ICER). Results: MenB IMD incidence decreased by 46.0% in infants and children 0-4 years old within 5 years after introduction of the program. Stepwise inclusion of the 5 disease burden categories to a conventional narrow CEA setting reduced the ICER from 360 pound 595 to 18 pound 645-that is, considering the impact of all 5 categories, 4CMenB infant vaccination is cost-effective at a threshold of 20 pound 000 per QALY gained. Conclusions: When considering comprehensively the MenB IMD burden, 4CMenB infant vaccination can be cost-effective, a finding contrary to previous CEAs. This analysis allows policy decision-makers globally to infer the impact of current disease burden considerations on the cost-effectiveness and the comprehensive assessment necessary for MenB IMD. Although this comprehensive CEA can help inform decision making today, it may be limited in capturing the full disease burden and complex interactions of health and economics of MenB IMD.	[Beck, Ekkehard; Meszaros, Kinga] GSK, Value Evidence, Ave Fleming 20, B-1300 Wavre, Belgium; [Klint, Johan] ICON Plc, Stockholm, Sweden; [Neine, Mohamed] GSK, Freelance, Wavre, Belgium; [Garcia, Stephanie] GSK, Business & Decis Life Sci, Wavre, Belgium		Beck, E (通讯作者)，GSK, Value Evidence, Ave Fleming 20, B-1300 Wavre, Belgium.	ekkehard.x.beck@gsk.com			GlaxoSmithKline Biologicals SAGlaxoSmithKline	GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also funded all costs associated with the development and the publishing of the present article.	Al-Janabi H, 2016, HEALTH ECON, V25, P1529, DOI 10.1002/hec.3259; Beck E, 2020, VACCINE, V38, P7558, DOI 10.1016/j.vaccine.2020.08.007; Benard S, 2016, J INFECT PUBLIC HEAL, V9, P339, DOI 10.1016/j.jiph.2015.10.016; Bettinger JA, 2013, PEDIATR INFECT DIS J, V32, pE20, DOI 10.1097/INF.0b013e3182706b89; Black S, 2013, LANCET, V382, P858, DOI 10.1016/S0140-6736(13)61863-2; Bos JM, 2006, PHARMACOECONOMICS, V24, P141, DOI 10.2165/00019053-200624020-00004; Bos JM, 2001, VACCINE, V20, P202, DOI 10.1016/S0264-410X(01)00254-7; Brown CC, 2019, PHARMACOECONOMICS, V37, P609, DOI 10.1007/s40273-019-00789-2; CADTH, GUID EC EV HLTH TECH; Christensen H, 2020, EUR J HEALTH ECON, V21, P297, DOI 10.1007/s10198-019-01129-z; Christensen H, 2017, VACCINE, V35, P208, DOI 10.1016/j.vaccine.2016.11.076; Christensen H, 2016, VACCINE, V34, P3412, DOI 10.1016/j.vaccine.2016.04.004; Christensen H, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5725; Christensen H, 2013, VACCINE, V31, P2638, DOI 10.1016/j.vaccine.2013.03.034; Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6; College des Economistes de la Sante ( CES), CONS PUBL HAS ACT GU; Darba J, 2014, VACCINE, V32, P5006, DOI 10.1016/j.vaccine.2014.07.019; Department of Health and Social Care, COST EFF METH IMM PR; European Centre for Disease Prevention and Control (ECDC), 2017, INV MEN DIS ANN EP R; European Centre for Disease Prevention and Control (ECDC), FACTSH MEN DIS; European Medicines Agency (EMA), BEXS SUMM PROD CHAR; European Network for Health Technology Assessment (EUnetHTA), DRAFT METH GUID PRAC; Gani R, 2008, PHARMACOECONOMICS, V26, P617, DOI 10.2165/00019053-200826070-00008; Gasparini R, 2016, HUM VACC IMMUNOTHER, V12, P2148, DOI 10.1080/21645515.2016.1160177; Ginsberg GM, 2016, INT J PUBLIC HEALTH, V61, P683, DOI 10.1007/s00038-016-0821-0; Halperin SA, 2012, VACCINE, V30, pB26, DOI 10.1016/j.vaccine.2011.12.032; Hanquet G, 2014, 231 HTA KCE; Health Council of The Netherlands, 2018, VACC MEN DIS; HernandezVillafuerte K, MENINGOCOCCAL VACCIN; Huels J, 2014, EPIDEMIOL INFECT, V142, P2000, DOI 10.1017/S095026881300294X; Institut National de Sante Publique du Quebec (INSPQ), ASS REP EP IMP VACC; Istituto per la Sicurezza Sociale (ISS), CAL VACC PED; Joint Committe on Vaccination and Immunisation (JCVI), 2013, COD PRACT JUN 2013; Joint Committee on Vaccination and Immunisation (JCVI), JCVI POS STAT US BEX; Joint Committee on Vaccination and Immunisation (JCVI), M 11 12 FEBR; Joint Committee on Vaccination and Immunisation (JCVI), JCVI INT POS STAT US; Joint Committee on Vaccination and Immunisation (JCVI), STAT HPV VACC; Kennedy ITR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177082; Ladhani S., 2019, 15 EUR MEN HAEM DIS; Ladhani SN, 2020, NEW ENGL J MED, V382, P309, DOI 10.1056/NEJMoa1901229; Ladhani SN, 2012, VACCINE, V30, P3710, DOI 10.1016/j.vaccine.2012.03.011; Lasseter G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197374; Lecocq H, 2016, VACCINE, V34, P2240, DOI 10.1016/j.vaccine.2016.03.020; Marshall HS, 2020, NEW ENGL J MED, V382, P318, DOI 10.1056/NEJMoa1900236; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; NICE, GUID METH TECHN APPR; Nord E, 2014, HEALTH POLICY, V116, P281, DOI 10.1016/j.healthpol.2014.02.009; Norwegian Ministry of Health and Care Services, PRINC PRIOR SETT HLT; Office for National Statistics (ONS), PRINC PROJ ENGL SUMM; Office for National Statistics (ONS), ANN SURV HOURS EARN; Office for National Statistics (ONS), EST POP UK ENGL WAL; Olbrich KJ, 2018, INFECT DIS THER, V7, P421, DOI 10.1007/s40121-018-0213-2; Parikh S., 2018, UK PHE PROGR REPORT; Parikh SR, 2018, VACCINE, V36, P3876, DOI 10.1016/j.vaccine.2018.02.038; Pizza M, EUR SOC PAED INF DIS; Plotkin SA, 2013, LANCET, V382, P858, DOI 10.1016/S0140-6736(13)61862-0; Pouwels KB, 2013, HUM VACC IMMUNOTHER, V9, P1129, DOI 10.4161/hv.23888; Public Health England (PHE), ROUT IMM SCHED AUT; Robert Koch Institute (RKI), 2016, MOD METH PRED EP HLT; Robert Koch Institute (RKI), 2018, STAND OP PROC GERM S; Robert Koch Institute (RKI), METH STIKO DEV VACC; Rodrigues F., 15 EUR MEN HAEM DIS; Scholz S, 2019, VACCINE, V37, P1692, DOI 10.1016/j.vaccine.2019.01.013; Sevilla J, ISPOR2019 COP DENM; Shigematsu M, 2002, EPIDEMIOL INFECT, V129, P459, DOI 10.1017/S0950268802007549; Song J, 2010, FAM RELAT, V59, P269, DOI 10.1111/j.1741-3729.2010.00601.x; Strauss D, 2008, DEV MED CHILD NEUROL, V50, P487, DOI 10.1111/j.1469-8749.2008.03000.x; Tirani M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123383; Tu HAT, 2014, VACCINE, V32, P5436, DOI 10.1016/j.vaccine.2014.07.096; Ultsch B, 2016, PHARMACOECONOMICS, V34, P227, DOI 10.1007/s40273-015-0335-2; Verguet S, 2016, PHARMACOECONOMICS, V34, P913, DOI 10.1007/s40273-016-0414-z; Viner RM, 2012, LANCET NEUROL, V11, P774, DOI 10.1016/S1474-4422(12)70180-1; Wang B, 2014, PEDIATR INFECT DIS J, V33, P316, DOI 10.1097/INF.0000000000000043; WeilOlivier C, 2019, ISPOR EUR 2019 COP; Whelan J, 2015, EXPERT REV VACCINES, V14, P713, DOI 10.1586/14760584.2015.1004317; Wright C, 2013, PEDIATR DRUGS, V15, P49, DOI 10.1007/s40272-012-0006-0	76	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JAN	2021	24	1					91	104		10.1016/j.jval.2020.09.004		JAN 2021	14	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QC0YJ	33431159	hybrid			2022-04-28	WOS:000614560000013
J	Huo, ZH; Chan, JYC; Lin, J; Bat, BKK; Chan, TK; Tsoi, KKF; Yip, BHK				Huo, Zhaohua; Chan, Joyce Y. C.; Lin, Jiaer; Bat, Baker K. K.; Chan, Tak Kit; Tsoi, Kelvin K. F.; Yip, Benjamin H. K.			Supporting Informal Caregivers of People With Dementia in Cost-Effective Ways: A Systematic Review and Meta-Analysis	VALUE IN HEALTH			English	Review						caregiver; cost; cost-effectiveness; dementia; economic evaluation	CARE MANAGEMENT; PSYCHOSOCIAL INTERVENTION; FAMILY CAREGIVERS; THERAPY; COMMUNITY; ALZHEIMERS; SERVICES; ANXIETY; IMPACT	Objectives: Caring for persons with dementia is a heavy burden for informal caregivers. This study aimed to appraise the economic evidence of interventions supporting informal caregivers of people with dementia. Methods: Literature was searched, and trial-based studies evaluating the costs and effects of interventions supporting informal caregivers of people with dementia were included. Cost data were analyzed from both healthcare and societal perspectives. Random-effects models were used to synthesize cost and effect data, based on mean differences (MDs) or standardized MDs. Results: Of 33 eligible studies identified from 48588 records, 14 (42.4%) showed net savings in total cost regardless of analytical perspectives. Among 22 studies included in meta-analyses, caregiver-focused psychosocial interventions showed improvements in caregivers' psychological health (n = 4; standardized MD 0.240; 95% confidence interval 0.094-0.387); nevertheless, the increases in societal cost were significant (n = 5; MD 3144; 95% confidence interval 922-5366). Psychological intervention and behavioral management engaging patient-caregiver dyads showed positive effects on caregivers' subjective burden, also with increases in total cost. Subgroup analyses indicated that the inclusion of different intervention components, the caregiver characteristics, and the follow-up periods could affect the costs and effects of interventions supporting informal caregivers. Conclusions: Psychosocial interventions directed at informal caregivers and dyad-based psychological and behavioral interventions are effective but also expensive. The use of these interventions depends on the society's willingness to pay. More comprehensive economic evidence of interventions supporting informal caregivers is required, and the design of intervention should focus more on different intervention components, characteristics of patients and caregivers, and healthcare systems.	[Huo, Zhaohua; Chan, Joyce Y. C.; Lin, Jiaer; Bat, Baker K. K.; Chan, Tak Kit; Tsoi, Kelvin K. F.; Yip, Benjamin H. K.] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Shatin, Hong Kong, Peoples R China; [Chan, Joyce Y. C.] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [Tsoi, Kelvin K. F.] Chinese Univ Hong Kong, Stanley Ho Big Data Decis Analyt Res Ctr, Shatin, Hong Kong, Peoples R China		Yip, BHK (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, JC Sch Publ Hlth & Primary Care, Shatin, Hong Kong, Peoples R China.; Tsoi, KKF (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, JC Sch Publ Hlth & Primary Care, Shatin, Hong Kong, Peoples R China.	kelvintsoi@cuhk.edu.hk; benyip@cuhk.edu.hk		Chan, Joyce YC/0000-0001-6329-7727			All-Party Parliamentary Group (APPG) on Dementia, 20 BILL QUEST INQ IM; [Anonymous], The epidemiology and impact of dementia: current state and future trends; [Anonymous], CRDS GUIDANCE UNDERT; Bahar-Fuchs A, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013069.pub2; Barth J, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001454; BLACK WC, 1990, MED DECIS MAKING, V10, P212, DOI 10.1177/0272989X9001000308; Brodaty H, 1991, Int Psychogeriatr, V3, P11, DOI 10.1017/S1041610291000479; Challis D, 2002, INT J GERIATR PSYCH, V17, P315, DOI 10.1002/gps.595; Charlesworth G, 2008, HEALTH TECHNOL ASSES, V12; Cheng ST, 2020, PSYCHOL AGING, V35, P55, DOI 10.1037/pag0000401; Chiao CY, 2015, INT NURS REV, V62, P340, DOI 10.1111/inr.12194; Chodosh J, 2015, J AGING HEALTH, V27, P864, DOI 10.1177/0898264315569454; Clare L, 2019, HEALTH TECHNOL ASSES, V23, P1, DOI 10.3310/hta23100; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cooper C, 2007, INT PSYCHOGERIATR, V19, P175, DOI 10.1017/S1041610206004297; D'Amico F, 2016, INT J GERIATR PSYCH, V31, P656, DOI 10.1002/gps.4376; Dahlrup B, 2014, DEMENT GERIATR COGN, V37, P181, DOI 10.1159/000355365; Dickinson C, 2017, INT PSYCHOGERIATR, V29, P31, DOI 10.1017/S1041610216001447; Drummond M F, 1991, Int J Technol Assess Health Care, V7, P209; Drummond MF., 2015, METHODS EC EVALUATIO, P353; Duggleby W, 2018, J MED INTERNET RES, V20, DOI 10.2196/10484; Duru OK, 2009, AM J MANAG CARE, V15, P521; Ebrahem AS, 2018, EXPERT OPIN PHARMACO, V19, P1245, DOI 10.1080/14656566.2018.1499727; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Evers S, 2005, INT J TECHNOL ASSESS, V21, P240, DOI 10.1017/S0266462305050324; Gaugler JE, 2003, J APPL GERONTOL, V22, P118, DOI 10.1177/0733464802250049; Geldmacher David S, 2008, Neuropsychiatr Dis Treat, V4, P549; Gitlin LN, 2010, AM J GERIAT PSYCHIAT, V18, P510, DOI 10.1097/JGP.0b013e3181c37d13; Graff MJL, 2008, BMJ-BRIT MED J, V336, P134, DOI 10.1136/bmj.39408.481898.BE; Guerchet M., WORLD ALZHEIMER REPO; Roijen LHV, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-370; Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486; Henderson C, 2021, HEALTH SOC CARE COMM, V29, P1756, DOI 10.1111/hsc.13281; Higgins JPT., 2021, COCHRANE HDB SYSTEMA; Joling KJ, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-305; Jones C, 2012, INT PSYCHOGERIATR, V24, P6, DOI 10.1017/S1041610211001207; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI 10.4084/MJHID.2010.005; Laakkonen ML, 2016, J AM GERIATR SOC, V64, P752, DOI 10.1111/jgs.14055; Lavis John, 2005, J Health Serv Res Policy, V10 Suppl 1, P35, DOI 10.1258/1355819054308549; Lin JS, 2013, ANN INTERN MED, V159, P601, DOI 10.7326/0003-4819-159-9-201311050-00730; Lin PJ, 2019, PHARMACOECONOMICS, V37, P597, DOI 10.1007/s40273-019-00788-3; Livingston G, 2014, LANCET PSYCHIAT, V1, P539, DOI 10.1016/S2215-0366(14)00073-X; Meng HD, 2019, ETHNIC HEALTH, DOI 10.1080/13557858.2019.1590536; Menn P, 2012, VALUE HEALTH, V15, P851, DOI 10.1016/j.jval.2012.06.007; Michalowsky B, 2019, ALZHEIMERS DEMENT, V15, P1296, DOI 10.1016/j.jalz.2019.05.008; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; National Institute for Health and Clinical Excellence, 2008, GUID METH TECHN APPR; Nichols LO, 2008, J AM GERIATR SOC, V56, P413, DOI 10.1111/j.1532-5415.2007.01569.x; Nickel F, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0751-1; O'Brien JT, 2021, MOVEMENT DISORD, V36, P143, DOI 10.1002/mds.28282; Oremus Mark, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P273, DOI 10.1586/14737167.8.3.273; Orgeta V, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19640; Pena-Longobardo LM, 2019, EUR J HEALTH ECON, V20, P1207, DOI 10.1007/s10198-019-01087-6; Pusey H, 2001, AGING MENT HEALTH, V5, P107, DOI 10.1080/13607860120038302; Roberts J, 1999, NURS RES, V48, P162, DOI 10.1097/00006199-199905000-00006; Shaw CA, 2021, RES NURS HEALTH, V44, P60, DOI 10.1002/nur.22076; Shemilt I, 2010, EVID POLICY, V6, P51, DOI 10.1332/174426410X482999; Sogaard R, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004105; Spector A, 2015, BRIT J PSYCHIAT, V206, P509, DOI 10.1192/bjp.bp.113.140087; Sterne JA, 2009, META ANAL STATA UPDA; Sutton AJ., 2000, METHODS META ANAL ME; Tacconelli E., 2010, THE LANCET INFECTIOU, V10, P226, DOI 10.1016/S1473-3099(10)70065-7; Tanajewski L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140662; Thompson Carl A, 2007, BMC Geriatr, V7, P18, DOI 10.1186/1471-2318-7-18; Van Houtven CH, 2013, GERONTOLOGIST, V53, P60, DOI 10.1093/geront/gns045; Vandepitte S, 2016, INT J GERIATR PSYCH, V31, P1277, DOI 10.1002/gps.4504; Vandepitte S, 2016, J ALZHEIMERS DIS, V52, P929, DOI 10.3233/JAD-151011; WEINBERGER M, 1993, J AM GERIATR SOC, V41, P153, DOI 10.1111/j.1532-5415.1993.tb02050.x; Wimo A, 2017, ALZHEIMERS DEMENT, V13, P1, DOI 10.1016/j.jalz.2016.07.150; Woods RT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152843; Wray LO, 2010, GERONTOLOGIST, V50, P623, DOI 10.1093/geront/gnq040; Xu JF, 2017, LANCET, V390, pS47, DOI 10.1016/S0140-6736(17)33185-9; Zweifel P., 2009, HEALTH ECON	73	1	1	4	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	DEC	2021	24	12					1853	1862		10.1016/j.jval.2021.05.011		NOV 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	XC7VG	34838284				2022-04-28	WOS:000722217200017
J	Sullivan, T; Turner, RM; Derrett, S; Hansen, P				Sullivan, Trudy; Turner, Robin M.; Derrett, Sarah; Hansen, Paul			New Zealand Population Norms for the EQ-5D-5L Constructed From the Personal Value Sets of Participants in a National Survey	VALUE IN HEALTH			English	Article						EQ-VAS; EQ-5D-5L; health-related quality of life; New Zealand; population norms; utility value; value set	QUALITY-OF-LIFE; HEALTH; SAMPLE; MODEL	Objectives: To derive New Zealand (NZ) population norms for the EQ-5D-5L and to examine the association between participants' sociodemographic characteristics and their health-related quality of life. Methods: Data from the 2018 NZ EQ-5D-5L valuation study (n = 2468) were used. Each participant's 5-digit profile was converted to a single utility value using their personal value set. The profiles, mean utility values, and mean EuroQol visual analog scale (EQ-VAS) scores were summarized by dimension and disaggregated by age group and gender. Multivariable logistic and Tobit regressions were used to investigate the association between participants' sociodemographic characteristics and the EQ-5D-5L dimensions, utility values, and EQ-VAS scores. Results: The mean utility value was 0.847 and the mean EQ-VAS score was 74.8. Of the 3125 possible EQ-5D-5L profiles, 25 profiles represented the current health status of the majority of participants (78%). The odds of having problems with anxiety or depression was greatest for people aged 18 to 24 years and decreased with age. People with a long-term disability or chronic illness had greater odds of problems on all dimensions and lower (poorer) utility values and EQ-VAS scores. Age, ethnicity, employment status, long-term disability, and chronic illness were associated with utility. Conclusion: EQ-5D-5L population norms were derived for the NZ population using the personal value sets of 2468 participants. Consistent with other countries' population norms, EQ-5D-5L utility values and EQ-VAS scores were associated with age, employment status, long-term disability, and chronic illness. These norms will support resource allocation decision making and help in understanding the health-related quality of life of the NZ population.	[Sullivan, Trudy; Derrett, Sarah] Univ Otago, Dept Prevent & Social Med, 18 Frederick St, Dunedin 9016, New Zealand; [Turner, Robin M.] Univ Otago, Biostat Ctr, Div Hlth Sci, Dunedin, New Zealand; [Hansen, Paul] Univ Otago, Dept Econ, Dunedin, New Zealand		Sullivan, T (通讯作者)，Univ Otago, Dept Prevent & Social Med, 18 Frederick St, Dunedin 9016, New Zealand.	trudy.sullivan@otago.ac.nz			Department of Preventive and Social Medicine, University of Otago; Health Research Council of New ZealandHealth Research Council of New Zealand [HRC19/640]	The Department of Preventive and Social Medicine, University of Otago provided funding for data collection and software administration; 1000minds Ltd supplied the software; the Health Research Council of New Zealand provided funding for the analysis (HRC19/640).	Abdin E, 2013, QUAL LIFE RES, V22, P2983, DOI 10.1007/s11136-013-0405-x; Austin PC, 2000, QUAL LIFE RES, V9, P901, DOI 10.1023/A:1008938326604; Brazier J., 2017, MEASURING VALUING HL; Cabases, 2014, SELF REPORTED POPULA; Devlin N., 2020, METHODS ANAL REPORTI; Devlin NJ, 2017, APPL HEALTH ECON HEA, V15, P127, DOI 10.1007/s40258-017-0310-5; Devlin NJ, 2003, HEALTH ECON, V12, P529, DOI 10.1002/hec.741; EuroQol Research Foundation, 2019, EQ 5D 5L USER GUIDE; Garcia-Gordillo MA, 2016, QUAL LIFE RES, V25, P1313, DOI 10.1007/s11136-015-1164-7; Golicki D, 2019, PHARMACOECONOMICS, V37, P1165, DOI 10.1007/s40273-019-00811-7; Golicki D, 2017, ARCH MED SCI, V13, P191, DOI 10.5114/aoms.2015.52126; Grochtdreis T, 2019, EUR J HEALTH ECON, V20, P933, DOI 10.1007/s10198-019-01054-1; Hansen P, 2008, J MULTI-CRITERIA DEC, V15, P87, DOI 10.1002/mcda.428; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Nguyen LH, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0771-0; Ludwig K, 2018, PHARMACOECONOMICS, V36, P663, DOI 10.1007/s40273-018-0615-8; McCaffrey N, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0537-0; Ministry of Education, 2020, ED COUNTS; Ministry of Health, 2019, ANN DAT EXPL 2018 19; OECD, 2019, Health at a Glance 2019:�OECD Indicators, DOI 10.1787/4dd50c09-en; Oppe M, 2014, VALUE HEALTH, V17, P445, DOI 10.1016/j.jval.2014.04.002; Pharmaceutical Management Agency (PHARMAC), 2019, GUID FUN APPL PHARMA; Poder TG, 2020, VALUE HEALTH, V23, P251, DOI 10.1016/j.jval.2019.08.008; Ramos-Goni JM, 2018, VALUE HEALTH, V21, P596, DOI 10.1016/j.jval.2017.10.023; Scalone L, 2015, EPIDEMIOL BIOSTAT PU, V12, DOI 10.2427/11457; Shiroiwa T, 2016, QUAL LIFE RES, V25, P707, DOI 10.1007/s11136-015-1108-2; Shuker C, 2017, NEW ZEAL MED J, V130, P11; Stanley J, 2018, BMJ OPEN, V8; Statistics New Zealand, 2013, DISABILITY; Sullivan T, 2020, SOC SCI MED, V246, DOI 10.1016/j.socscimed.2019.112707; Van den Berg B, 2012, HEALTH ECON, V21, P1508, DOI 10.1002/hec.1823; Wong ELY, 2018, PATIENT, V11, P235, DOI 10.1007/s40271-017-0278-0; Wong ELY, 2019, VALUE HEALTH, V22, P916, DOI 10.1016/j.jval.2019.02.014; Yang ZH, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-1036-2	34	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	SEP	2021	24	9					1308	1318		10.1016/j.jval.2021.04.1280		AUG 2021	11	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	UG5RC	34452711	hybrid			2022-04-28	WOS:000689308300011
J	Wang, MM; Loh, EW; Chou, JF; Sung, PM; Chou, YY; Lin, YK; Chen, SF; Tam, KW				Wang, Mo-Mei; Loh, El-Wui; Chou, Ju-Fen; Sung, Pei-Man; Chou, Yun-Yun; Lin, Yen-Kuang; Chen, Shu-Fen; Tam, Ka-Wai			Influence of Shared Decision Making on Decisional Conflict and Regret in Postpartum Mother-Infant Care: A Randomized Controlled Trial	VALUE IN HEALTH			English	Article						decisional conflicts; mother-infant care; patient decision aids; postpartum; rooming-in; shared decision making	SKIN CONTACT; HEALTH-CARE; LACTATION; BENEFITS; BELIEFS; CHINESE	Objectives: Although postpartum rooming-in is encouraged by the World Health Organization, independent separated nursery care is still widely adopted in Eastern countries. Our aim is to evaluate the effect of shared decision making (SDM) assisted by patient decision aids on subjective decisional conflict and regret among women who are required to make choices regarding postpartum infant care. Methods: A total of 196 pregnant women who came for routine checkups 1 month before delivery were randomly assigned to the SDM group or the classic group. Before the mothers were discharged after delivery, their decision-making difficulties were evaluated. The primary outcome was the decisional conflict, which was assessed using the SURE (Sure of myself; Understand information; Risk-benefit ratio; Encouragement) scale. The secondary outcome was the decisional regret, which was measured using the Decision Regret scale. Results: Compared with the classic group, SDM group had surer feelings about the choice (P<.001), felt more confident about knowing the benefits and risks of each option (P<.001), had a clearer understanding of the benefits and risks (P<.001), and felt sufficiently supported with enough advice to make a suitable choice (P<.001). No significant difference was noted in the Decision Regret scores between groups. The choice of 24-hour rooming-in, 12-hour rooming-in, and separated nursery care was not significantly different between groups. Conclusions: SDM reduced the decisional conflict and uncertainty of the mothers. Available choices of postpartum mother- infant care should be provided to mothers through SDM that includes individual values, health goals, and clear knowledge and transparency.	[Wang, Mo-Mei; Chou, Ju-Fen; Sung, Pei-Man; Chen, Shu-Fen] Taipei Med Univ, Shuang Ho Hosp, Dept Nursing, 291 Zhongzheng Rd, New Taipei 23561, Taiwan; [Loh, El-Wui; Chou, Yun-Yun; Tam, Ka-Wai] Taipei Med Univ, Shuang Ho Hosp, Shared Decis Making Resource Ctr, 291 Zhongzheng Rd, New Taipei 23561, Taiwan; [Loh, El-Wui] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Loh, El-Wui; Tam, Ka-Wai] Taipei Med Univ, Cochrane Taiwan, Taipei, Taiwan; [Lin, Yen-Kuang] Taipei Med Univ, Coll Nursing, Biostat & Res Consultat Ctr, Taipei, Taiwan; [Lin, Yen-Kuang] Taipei Med Univ, Coll Nursing, Sch Nursing, Taipei, Taiwan; [Tam, Ka-Wai] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan; [Tam, Ka-Wai] Taipei Med Univ, Coll Med, Sch Med, Div Gen Surg,Dept Surg, Taipei, Taiwan		Chen, SF (通讯作者)，Taipei Med Univ, Shuang Ho Hosp, Dept Nursing, 291 Zhongzheng Rd, New Taipei 23561, Taiwan.; Tam, KW (通讯作者)，Taipei Med Univ, Shuang Ho Hosp, Shared Decis Making Resource Ctr, 291 Zhongzheng Rd, New Taipei 23561, Taiwan.	13459@s.tmu.edu.tw; kelvintam@h.tmu.edu.tw					Andreas NJ, 2015, EARLY HUM DEV, V91, P629, DOI 10.1016/j.earlhumdev.2015.08.013; Boue G, 2018, CRIT REV FOOD SCI, V58, P126, DOI 10.1080/10408398.2016.1138101; Brehaut JC, 2003, MED DECIS MAKING, V23, P281, DOI 10.1177/0272989X03256005; Bystrova K, 2009, BIRTH-ISS PERINAT C, V36, P97, DOI 10.1111/j.1523-536X.2009.00307.x; Chen CY, 2017, J CHIN MED ASSOC, V80, P747, DOI 10.1016/j.jcma.2017.04.010; Chiou ST, 2014, BIRTH-ISS PERINAT C, V41, P33, DOI 10.1111/birt.12090; Colombo L, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010048; Del Ciampo LA, 2018, REV BRAS GINECOL OBS, V40, P354, DOI 10.1055/s-0038-1657766; Dumas L, 2013, CLIN NURS RES, V22, P310, DOI 10.1177/1054773812468316; Elwyn G, 2014, ANN FAM MED, V12, P270, DOI 10.1370/afm.1615; Fok D, 2016, BIRTH-ISS PERINAT C, V43, P247, DOI 10.1111/birt.12233; Gertosio C, 2016, MINERVA PEDIATR, V68, P201; Guillaumon A, 2013, GYNECOL OBSTET FERTI, V41, P351, DOI 10.1016/j.gyobfe.2012.09.026; Gustin Allen N Jr, 2019, Anesthesiol Clin, V37, P573, DOI 10.1016/j.anclin.2019.05.001; Holroyd E, 2004, WOMEN HEALTH, V40, P109, DOI 10.1300/J013v40n03_08; Jaafar SH, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006641.pub3; Kim SK, 2017, INT J NURS STUD, V80, P94, DOI 10.1016/j.ijnurstu.2018.01.004; Lai YL, 2015, APPL NURS RES, V28, P116, DOI 10.1016/j.apnr.2014.08.002; Legare F, 2010, CAN FAM PHYSICIAN, V56, pE308; Liamputtong Pranee, 2004, Health Care Women Int, V25, P454, DOI 10.1080/07399330490267468; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1016/j.ijsu.2011.10.001, 10.1136/bmj.c869]; Ng CA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215869; O'Connor A M, 1999, Eff Clin Pract, V2, P163; Patel S, 2016, J HUM LACT, V32, P530, DOI 10.1177/0890334415618668; Tonelli MR, 2019, J EVAL CLIN PRACT, V25, P1057, DOI 10.1111/jep.13260; Turck D, 2013, ARCH PEDIATRIE, V20, P529, DOI 10.1016/S0929-693X(13)72251-6; Withers M, 2018, MIDWIFERY, V56, P158, DOI 10.1016/j.midw.2017.10.019	27	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	SEP	2021	24	9					1335	1342		10.1016/j.jval.2021.03.011		AUG 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	UG5RC	34452714				2022-04-28	WOS:000689308300014
J	Holdford, D; Vendetti, N; Sop, DM; Johnson, S; Smith, WR				Holdford, David; Vendetti, Nicholas; Sop, Daniel M.; Johnson, Shirley; Smith, Wally R.			Indirect Economic Burden of Sickle Cell Disease	VALUE IN HEALTH			English	Article						anemia; cost of illness; costs and cost analysis; economics; health expenditures; sickle cell	QUALITY-OF-LIFE; HEALTH-CARE; PRODUCTIVITY COSTS; YOUNG-ADULTS; PAIN; CHILDREN; ADOLESCENTS; EMPLOYMENT; RISK; PREDICTORS	Objective: This study aimed to quantify the indirect costs of sickle cell disease in the United States. Methods: Adult patients from a sickle cell disease clinic at an urban academic healthcare system completed an adapted Institute for Medical Technology Assessment Productivity Cost Questionnaire related to the impact of their disorder on absenteeism, presenteeism, ability to contribute through unpaid work outside of employment, and other aspects of life. Additional data were collected from patient records about each participant's genotype, total hemoglobin level, and pain level. Results: Of the 192 individuals, 187 who completed the survey reported experiencing vaso-occlusive crisis pain events during the last year that negatively affected their productivity at work and in daily roles. Three-fourths of respondents reported impairment in their ability to complete everyday tasks, such as caring for children, running errands, doing housework, shopping for groceries, and volunteer (unpaid) work. Only 30% of respondents reported being employed or self-employed. Of those employed, estimated costs of absenteeism and presenteeism attributable to pain events averaged $15103 per person annually. Estimated total annual losses in unpaid work productivity averaged $3145 862 for the study respondents and another $2 870 652 for their caregivers. Conclusions: Sickle cell disease affected the work productivity, nonwork productivity, and the daily lives of adults seen with the disorder in an academic medical center.	[Holdford, David; Sop, Daniel M.; Johnson, Shirley; Smith, Wally R.] Virginia Commonwealth Univ, Richmond, VA USA; [Vendetti, Nicholas] Pfizer Inc, Collegeville, PA USA		Smith, WR (通讯作者)，Virginia Commonwealth Univ, Vice Chair Res, Sickle Cell Dis, Div Gen Internal Med, Box 980306,730 E Broad St,Suite 430, Richmond, VA 23219 USA.	wally.smith@vcuhealth.org			Pfizer Inc.Pfizer	Funding and editorial support were provided by Pfizer Inc.	Adegbola Maxine, 2015, J Natl Black Nurses Assoc, V26, P15; Ameringer S, 2014, J PEDIATR ONCOL NURS, V31, P6, DOI 10.1177/1043454213514632; Anderson LM, 2015, J PEDIAT HEMATOL ONC, V37, P584, DOI 10.1097/MPH.0000000000000431; Anie KA, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001274; Ballas SK, 2010, J NATL MED ASSOC, V102, P993, DOI 10.1016/S0027-9684(15)30725-2; Ballas SK, 2005, AM J HEMATOL, V79, P17, DOI 10.1002/ajh.20336; Bediako SM, 2010, J HEALTH CARE POOR U, V21, P1124, DOI 10.1353/hpu.2010.0945; Bouwmans C, 2015, VALUE HEALTH, V18, P753, DOI 10.1016/j.jval.2015.05.009; Brandow AM, 2010, PEDIATR BLOOD CANCER, V54, P92, DOI 10.1002/pbc.22222; Brousseau DC, 2010, AM J HEMATOL, V85, P77, DOI 10.1002/ajh.21570; Centers for Disease Control and Prevention, DAT STAT SICKL CELL; Citero VD, 2007, PAIN, V133, P39, DOI 10.1016/j.pain.2007.02.008; Dampier C, 2002, J PAIN, V3, P461, DOI 10.1054/jpai.2002.128064; Dampier C, 2002, J PEDIAT HEMATOL ONC, V24, P643, DOI 10.1097/00043426-200211000-00008; Dampier C, 2017, J PAIN, V18, P490, DOI 10.1016/j.jpain.2016.12.016; Drummond MF., 2015, METHODS EC EVALUATIO, P353; Field JJ, 2019, J PAIN, V20, P746, DOI 10.1016/j.jpain.2018.12.003; Fisher K, 2018, J BEHAV MED, V41, P416, DOI 10.1007/s10865-018-9918-7; Gil KM, 2004, HEALTH PSYCHOL, V23, P267, DOI 10.1037/0278-6133.23.3.267; Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022; Howard Jo, 2009, Expert Rev Pharmacoecon Outcomes Res, V9, P347, DOI 10.1586/erp.09.32; Idowu M, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.2244.2244; Jacobs P, 2005, PHARMACOECONOMICS, V23, P143, DOI 10.2165/00019053-200523020-00006; Job Accommodation Network, SICKL CELL AN ACC CO SICKL CELL AN ACC CO; Kato GJ, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.10; Katz T, 2018, SLEEP BREATH, V22, P797, DOI 10.1007/s11325-018-1630-x; Kauf TL, 2009, AM J HEMATOL, V84, P323, DOI 10.1002/ajh.21408; Krol M, 2015, SOC SCI MED, V144, P127, DOI 10.1016/j.socscimed.2015.09.008; Krol M, 2014, PHARMACOECONOMICS, V32, P335, DOI 10.1007/s40273-014-0132-3; Krol M, 2013, PHARMACOECONOMICS, V31, P537, DOI 10.1007/s40273-013-0056-3; Levenson JL, 2008, PSYCHOSOM MED, V70, P192, DOI 10.1097/PSY.0b013e31815ff5c5; Lovett PB, 2014, EMERG MED CLIN N AM, V32, P629, DOI 10.1016/j.emc.2014.04.011; McClish DK, 2009, PAIN, V145, P246, DOI 10.1016/j.pain.2009.06.029; Moscou-Jackson G, 2016, PAIN MANAG NURS, V17, P38, DOI 10.1016/j.pmn.2015.09.002; Pells J, 2007, CLIN J PAIN, V23, P707, DOI 10.1097/AJP.0b013e31814da3eb; Piel FB, 2017, NEW ENGL J MED, V376, P1561, DOI 10.1056/NEJMra1510865; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; Raphael JL, 2012, PEDIATR BLOOD CANCER, V58, P584, DOI 10.1002/pbc.23181; Smith WR, 2008, ANN INTERN MED, V148, P94, DOI 10.7326/0003-4819-148-2-200801150-00004; Smith WR, 2005, J NATL MED ASSOC, V97, P183; Sogutlu A, 2011, PSYCHOSOMATICS, V52, P272, DOI 10.1016/j.psym.2011.01.010; Stone PW, 2000, INT J TECHNOL ASSESS, V16, P111, DOI 10.1017/S0266462300161100; Thomas VJ, 2002, BRIT J HEALTH PSYCH, V7, P345, DOI 10.1348/135910702760213724; Tranmer JE, 2005, PHARMACOECONOMICS, V23, P449, DOI 10.2165/00019053-200523050-00005; U.S. Bureau of Labor Statistics, 2019, CIV LAB FORC PART RA; U.S. Bureau of Labor Statistics, 2016, OCC EMPL STAT; Valrie CR, 2018, J PEDIAT HEMATOL ONC, V40, P116, DOI 10.1097/MPH.0000000000001067; Verbooy K, 2018, VALUE HEALTH, V21, P1428, DOI 10.1016/j.jval.2018.04.1828; Vichinsky E, 2017, HEMATOL-AM SOC HEMAT, P435, DOI 10.1182/asheducation-2017.1.435; Whitesell PL, 2016, SLEEP MED, V22, P47, DOI 10.1016/j.sleep.2016.05.006; Williams H, 2018, J HEALTH CARE POOR U, V29, P814, DOI 10.1353/hpu.2018.0060; Zhang W, 2011, SOC SCI MED, V72, P185, DOI 10.1016/j.socscimed.2010.10.026	52	0	0	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	AUG	2021	24	8					1095	1101		10.1016/j.jval.2021.02.014		AUG 2021	7	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TY1SX	34372974	Bronze			2022-04-28	WOS:000683567300002
J	Ward, T; Medina-Lara, A; Mujica-Mota, RE; Spencer, AE				Ward, Thomas; Medina-Lara, Antonieta; Mujica-Mota, Ruben E.; Spencer, Anne E.			Accounting for Heterogeneity in Resource Allocation Decisions: Methods and Practice in UK Cancer Technology Appraisals	VALUE IN HEALTH			English	Article						cancer; economic; heterogeneity; HTA; modeling; NICE; review	ECONOMIC-EVALUATION; PATIENT HETEROGENEITY; SUBGROUP ANALYSIS; CLINICAL-TRIALS; COST; PROJECTIONS; SURVIVAL; MODELS; CARE	Objectives: The availability of novel, more efficacious and expensive cancer therapies is increasing, resulting in significant treatment effect heterogeneity and complicated treatment and disease pathways. The aim of this study is to review the extent to which UK cancer technology appraisals (TAs) consider the impact of patient and treatment effect heterogeneity. Methods: A systematic search of National Institute for Health and Care Excellence TAs of colorectal, lung and ovarian cancer was undertaken for the period up to April 2020. For each TA, the pivotal clinical studies and economic evaluations were reviewed for considerations of patient and treatment effect heterogeneity. The study critically reviews the use of subgroup analysis and real-world translation in economic evaluations, alongside specific attributes of the economic modeling framework. Results: The search identified 49 TAs including 49 economic models. In total, 804 subgroup analyses were reported across 69 clinical studies. The most common stratification factors were age, gender, and Eastern Cooperative Oncology Group performance score, with 15% (119 of 804) of analyses demonstrating significantly different clinical outcomes to the main population; economic subgroup analyses were undertaken in only 17 TAs. All economic models were cohort-level with the majority described as partitioned survival models (39) or Markov/semi-Markov models. The impact of real-world heterogeneity on disease progression estimates was only explored in 2 models. Conclusion: The ability of current modeling approaches to capture patient and treatment effect heterogeneity is constrained by their limited flexibility and simplistic nature. This study highlights a need for the use of more sophisticated modeling methods that enable greater consideration of real-world heterogeneity.	[Ward, Thomas; Medina-Lara, Antonieta; Mujica-Mota, Ruben E.; Spencer, Anne E.] Univ Exeter, Coll Med & Hlth, Hlth Econ Grp, St Lukes Campus,Heavitree Rd, Exeter EX1 2LU, Devon, England; [Mujica-Mota, Ruben E.] Univ Leeds, Acad Unit Hlth Econ, Sch Med, Leeds, W Yorkshire, England		Ward, T (通讯作者)，Univ Exeter, Coll Med & Hlth, Hlth Econ Grp, St Lukes Campus,Heavitree Rd, Exeter EX1 2LU, Devon, England.	tw494@exeter.ac.uk			Dennis and Mereille Gillings Foundation	: This research has been supported by a PhD studentship grant for Mr Ward from the Dennis and Mereille Gillings Foundation.	Abner EL, 2013, J BIOM BIOSTAT; Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Arnold M, 2019, LANCET ONCOL, V20, P1493, DOI 10.1016/S1470-2045(19)30456-5; Brennan A, 2006, HEALTH ECON, V15, P1295, DOI 10.1002/hec.1148; Briggs ADM, 2016, POPUL HEALTH METR, V14, DOI 10.1186/s12963-016-0085-1; Bullement A, 2019, APPL HEALTH ECON HEA, V17, P771, DOI 10.1007/s40258-019-00513-3; Cancer Research UK, CANC INC STAT; Caro JJ, 2010, PHARMACOECONOMICS, V28, P957, DOI 10.2165/11537420-000000000-00000; Cichosz Simon Lebech, 2015, J Diabetes Sci Technol, V10, P27, DOI 10.1177/1932296815611680; Clinical Practice Research Datalink. CPRD Governance, CLIN PRACTICE RES DA; Collins GS, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-103; Cook DI, 2004, MED J AUSTRALIA, V180, P289, DOI 10.5694/j.1326-5377.2004.tb05928.x; Cookson R, 2016, FISC STUD, V37, P371, DOI 10.1111/j.1475-5890.2016.12109; Cui Lu, 2002, J Biopharm Stat, V12, P347, DOI 10.1081/BIP-120014565; DAGOSTINO RB, 1995, MED CARE, V33, pAS95; Damen JAAG, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2416; Davis S., 2014, NICE DSU TECHNICAL S; Di Tanna GL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0224135; Espinoza MA, 2014, MED DECIS MAKING, V34, P951, DOI 10.1177/0272989X14538705; Exarchakou A, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k764; Falzone L, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01300; Foster HME, 2018, LANCET PUBLIC HEALTH, V3, pE576, DOI 10.1016/S2468-2667(18)30200-7; Fowler H, 2020, BMC CANCER, V20, DOI 10.1186/s12885-019-6472-9; Geifman N, 2016, BIOCOMPUT-PAC SYM, P309; Grouin JM, 2005, J BIOPHARM STAT, V15, P869, DOI 10.1081/BIP-200067988; Grutters JPC, 2013, PHARMACOECONOMICS, V31, P111, DOI 10.1007/s40273-012-0015-4; Hawkes N, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l408; Kolovos S, 2019, J BONE ONCOL, V17, DOI 10.1016/j.jbo.2019.100243; Lakdawalla DN, 2017, VALUE HEALTH, V20, P866, DOI 10.1016/j.jval.2017.04.003; Laudicella M, 2016, BRIT J CANCER, V114, P1286, DOI 10.1038/bjc.2016.77; Macmillan, 2019, STAT FACT SHEET; Macmillan cancer support, 2019, HLTH IN TIM TALK; Maddams J, 2012, BRIT J CANCER, V107, P1195, DOI 10.1038/bjc.2012.366; McConnell H, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016797; Mitchell AP, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.6510; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Muller P, 2018, CANCER EPIDEMIOL, V56, P161, DOI 10.1016/j.canep.2018.07.010; National Institute for Health and Care Excellence, CERVICAL SCREENING; National Institute for Health and Care Excellence, BOW SCREEN; National Institute for Health and Care Excellence, BREAST SCREEN; Nguyen A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11246; NHS Digital, HOSP EP STAT HES; NHS England, 2019, NHS LONG TERM PLAN; NICE NIfHaCE, NICE DSU TECHNICAL S; Noble D, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7163; Pfizer, 2020, CANC COSTS RIPPL EFF; Public Health England, 2019, HLTH PROF ENGL 2019; Public Health England, CANC REG DAT; Public Health England, 2018, HLTH PROF ENGL 2018; Ramaekers BLT, 2013, VALUE HEALTH, V16, P855, DOI 10.1016/j.jval.2013.02.013; Ramspek CL, 2020, NEPHROL DIAL TRANSPL, V35, P1527, DOI 10.1093/ndt/gfz018; Sculpher M, 2008, PHARMACOECONOMICS, V26, P799, DOI 10.2165/00019053-200826090-00009; Signorovitch JE, 2010, PHARMACOECONOMICS, V28, P935, DOI 10.2165/11538370-000000000-00000; Smittenaar CR, 2016, BRIT J CANCER, V115, P1147, DOI 10.1038/bjc.2016.304; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Tangri N, 2013, ANN INTERN MED, V158, P596, DOI 10.7326/0003-4819-158-8-201304160-00004; UK Biobank, BIOB DAT; Unger JM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju002; Varadhan R, 2013, DEV PROTOCOL OBSERVA; Ward SE, 2019, CLIN ONCOL-UK, V31, P444, DOI 10.1016/j.clon.2019.03.005; Yu JX, 2019, NAT REV DRUG DISCOV, V18, P821, DOI 10.1038/d41573-019-00090-z; Yuan M, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0099-9	62	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUL	2021	24	7					995	1008		10.1016/j.jval.2020.12.022		JUL 2021	14	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TE7UB	34243843				2022-04-28	WOS:000670212100010
J	Abushanab, D; Al-Badriyeh, D				Abushanab, D.; Al-Badriyeh, D.			EFFICACY AND SAFETY OF IBUPROFEN PLUS PARACETAMOL IN A FIXED-DOSE COMBINATION FOR ACUTE POSTOPERATIVE PAIN IN ADULTS: META-ANALYSIS AND A TRIAL SEQUENTIAL ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Abushanab, D.] Hamad Med Corp, Doha, Qatar; [Al-Badriyeh, D.] Qatar Univ, Doha, Qatar									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSS1	S220	S220					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401226
J	Angayen, M; Lopez, S; Shin, DY; Chang, J				Angayen, M.; Lopez, S.; Shin, D. Y.; Chang, J.			ASSOCIATION OF HEALTH RELATED QUALITY OF LIFE WITH BREAST CANCER SURVIVAL AMONG HISPANIC POPULATION USING MEDICAL EXPENDITURE PANEL SURVEY DATA (2006-2015)	VALUE IN HEALTH			English	Meeting Abstract									[Angayen, M.; Lopez, S.; Chang, J.] Univ Texas El Paso, El Paso, TX 79968 USA; [Shin, D. Y.] New Mexico State Univ, Las Cruces, NM 88003 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN146	S46	S46					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400197
J	Armeni, P; Meregaglia, M; Borsoi, L; Torbica, A; Callea, G				Armeni, P.; Meregaglia, M.; Borsoi, L.; Torbica, A.; Callea, G.			WHAT FACTORS DO CLINICIANS VALUE MOST IN SELECTING PHYSICIAN PREFERENCE ITEMS? A SURVEY IN ORTHOPEDICS USING DISCRETE CHOICE EXPERIMENT AND BEST-WORST SCALING	VALUE IN HEALTH			English	Meeting Abstract									[Armeni, P.; Meregaglia, M.; Borsoi, L.] SDA Bocconi Sch Management, Milan, MI, Italy; [Torbica, A.] Bocconi Univ, Milan, MI, Italy; [Callea, G.] SDA Bocconi Sch Management, Rome, RM, Italy									0	0	0	4	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMD16	S126	S126					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400550
J	Berdunov, V; Millen, S; Paramore, A; Reynia, S; Fryer, N; Griffin, J; Floros, L; Georges, N				Berdunov, V; Millen, S.; Paramore, A.; Reynia, S.; Fryer, N.; Griffin, J.; Floros, L.; Georges, N.			BUDGET IMPACT ANALYSIS OF THE ONCOTYPE DX BREAST CANCER RECURRENCE SCORE TEST TO GUIDE CHEMOTHERAPY USE IN ER+/HER2-NODE-NEGATIVE EARLY INVASIVE BREAST CANCER	VALUE IN HEALTH			English	Meeting Abstract									[Berdunov, V; Floros, L.] PHMR Ltd, London, England; [Millen, S.; Paramore, A.; Reynia, S.; Fryer, N.; Georges, N.] Exact Sci, London, England; [Griffin, J.] Jane Griffin Associates, East Molesey, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN42	S26	S26					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400106
J	Bosnic, N; Zhang, Y; Foroutan, N				Bosnic, N.; Zhang, Y.; Foroutan, N.			CHANGES IN CANADIAN GUIDELINES FOR CONDUCTING BUDGET IMPACT ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Bosnic, N.; Zhang, Y.; Foroutan, N.] PMPRB, Ottawa, ON, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG5	S87	S87					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400381
J	Brook, R; Kleinman, NL; Beren, IA				Brook, R.; Kleinman, N. L.; Beren, I. A.			EMPLOYEES WITH DIABETES IN THE UNITED STATES USED DIFFERENT ABSENCE BENEFITS (SHORT- AND LONG-TERM DISABILITY AND WORKERS' COMPENSATION) OVER TIME WITH VARYING LEAVE LENGTHS AND PAYMENTS	VALUE IN HEALTH			English	Meeting Abstract									[Brook, R.] Better Hlth Worldwide NPRT NASP, Newfoundland, NJ USA; [Kleinman, N. L.; Beren, I. A.] WorkPartners LLC, Loveland, CO USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB50	S86	S86					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400377
J	Chakladar, S; Hait, A; Singh, A; Kathe, N; Aparasu, RR				Chakladar, S.; Hait, A.; Singh, A.; Kathe, N.; Aparasu, R. R.			ECONOMIC BURDEN AMONG BREAST CANCER PATIENTS IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Chakladar, S.; Hait, A.; Singh, A.; Kathe, N.] Complete HEOR Solut CHEORS, N Wales, PA USA; [Aparasu, R. R.] Univ Houston, Coll Pharm, Houston, TX 77030 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN232	S63	S63					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400274
J	Curteis, T; Chandiwana, D; Pathak, P; Lanoue, B; Buehler, A; Pencheva, R; Smith-Tilley, J				Curteis, T.; Chandiwana, D.; Pathak, P.; Lanoue, B.; Buehler, A.; Pencheva, R.; Smith-Tilley, J.			ANALYSIS OF SOCIETAL COSTS DUE TO WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT FROM THE MONALEESA-7 TRIAL OF RIBOCICLIB plus ENDOCRINE THERAPY (ET) IN PREMENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER (ABC) IN BRAZIL	VALUE IN HEALTH			English	Meeting Abstract									[Curteis, T.] Costello Med, Manchester, Lancs, England; [Chandiwana, D.; Lanoue, B.] Novartis Pharmaceut, E Hanover, NJ USA; [Pathak, P.] Novartis Ireland Ltd, Dublin, D, Ireland; [Buehler, A.] Novartis Biociencias SA, Sao Paulo, SP, Brazil; [Pencheva, R.; Smith-Tilley, J.] Costello Med, Cambridge, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN45	S27	S27					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400109
J	Dawamne, T; Zhong, L				Dawamne, T.; Zhong, L.			NEONATAL ABSTINENCE SYNDROME INCIDENCE RATE, CLINICAL CHARACTERISTICS & HEALTHCARE RESOURCE UTILIZATION IN TEXAS DURING 2006-2017	VALUE IN HEALTH			English	Meeting Abstract									[Dawamne, T.] Texas A&M Univ, Houston, TX USA; [Zhong, L.] Texas A&M Univ, College Stn, TX USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG20	S91	S91					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400395
J	Diaz-Ortega, M; Vergara, S; Montenegro, E; Barbosa, D				Diaz-Ortega, M.; Vergara, S.; Montenegro, E.; Barbosa, D.			COST PER OBJECTIVE RESPONSE WITH DABRAFENIB plus TRAMETINIB AS THE FIRST LINE OF TREATMENT IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600 MUTATION IN COLOMBIA	VALUE IN HEALTH			English	Meeting Abstract									[Diaz-Ortega, M.; Vergara, S.; Montenegro, E.; Barbosa, D.] NOVARTIS, Bogota, Cun, Colombia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN64	S31	S31					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400127
J	Erim, D; Pollack, M; Feigler, N				Erim, D.; Pollack, M.; Feigler, N.			A MODEL FOR DETERMINING THE BUDGET IMPACT OF INTRODUCING A NEW SINGLE-INHALER TRIPLE COMBINATION THERAPY FOR MANAGING MODERATE TO VERY SEVERE COPD IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Erim, D.] Parexel Int, Lexington, MA USA; [Pollack, M.; Feigler, N.] AstraZeneca LP, Wilmington, DE USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS6	S213	S214					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401198
J	Ghosh, S; Richards, K; Rascati, K; Lawson, K				Ghosh, S.; Richards, K.; Rascati, K.; Lawson, K.			PRESCRIPTION OPIOID USE IN WOMEN DURING PREGNANCY - A RETROSPECTIVE ANALYSIS USING TEXAS MEDICAID PRESCRIPTION CLAIMS DATA	VALUE IN HEALTH			English	Meeting Abstract									[Ghosh, S.; Rascati, K.] Univ Texas Austin, Austin, TX 78712 USA; [Richards, K.; Lawson, K.] Univ Texas Austin, Coll Pharm, Texas Ctr Hlth Outcomes Res & Educ TxCORE, Austin, TX 78712 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG19	S90	S90					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400394
J	Jeppesen, P; Shahraz, S; Hopkins, T; Worsfold, A				Jeppesen, P.; Shahraz, S.; Hopkins, T.; Worsfold, A.			COMPLICATIONS AND HEALTHCARE UTILIZATION IN ADULT PATIENTS RECEIVING PARENTERAL SUPPORT FOR INTESTINAL FAILURE ASSOCIATED WITH SHORT BOWEL SYNDROME	VALUE IN HEALTH			English	Meeting Abstract									[Jeppesen, P.] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark; [Shahraz, S.] ICON Plc, Oakland, CA USA; [Hopkins, T.] Takeda, Cambridge, MA USA; [Worsfold, A.] Takeda, Zurich, Switzerland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PGI24	S98	S98					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400427
J	Jommi, C; Pantellini, F; Stagi, L; Cavazza, M				Jommi, C.; Pantellini, F.; Stagi, L.; Cavazza, M.			ECONOMIC IMPACT OF COMPASSIONATE USE OF MEDICINES	VALUE IN HEALTH			English	Meeting Abstract									[Jommi, C.; Cavazza, M.] Bocconi Univ, Milan, Italy; [Pantellini, F.; Stagi, L.] Roche Spa, Monza, MI, Italy									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		EM2	S7	S7					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400027
J	Kindilien, S; Goldberg, E				Kindilien, S.; Goldberg, E.			PRESCRIPTION MEDICATION USE IN A REPRESENTATIVE US SAMPLE OF PREGNANT WOMEN	VALUE IN HEALTH			English	Meeting Abstract									[Kindilien, S.; Goldberg, E.] Univ New Mexico, Albuquerque, NM 87131 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH17	S102	S102					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400443
J	Kruger, E; Nedzesky, J; Thomas, NA; Poma, A; Valayannopoulos, V				Kruger, E.; Nedzesky, J.; Thomas, N. A.; Poma, A.; Valayannopoulos, V.			COMMON AND SERIOUS COMORBIDITIES AMONG ADULTS WITH GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA)	VALUE IN HEALTH			English	Meeting Abstract									[Kruger, E.] Ultragenyx Pharmaceut Ltd, San Francisco, CA USA; [Nedzesky, J.; Thomas, N. A.] Ultragenyx Pharmaceut Inc Ltd, Brisbane, CA USA; [Poma, A.; Valayannopoulos, V.] Ultragenyx Pharmaceut Ltd, Cambridge, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO71	S210	S211					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401186
J	Kwon, C; Grieve, S; Wyckmans, J; Forsythe, A; Senatore, A				Kwon, C.; Grieve, S.; Wyckmans, J.; Forsythe, A.; Senatore, A.			SYSTEMATIC LITERATURE REVIEW (SLR) OF EVIDENCE ON CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN FOR PATIENTS WHO HAVE UNDERGONE THE FONTAN PROCEDURE	VALUE IN HEALTH			English	Meeting Abstract									[Kwon, C.] Purple Squirrel Econ, Southborough, MA USA; [Grieve, S.] Purple Squirrel Econ, Montreal, PQ, Canada; [Wyckmans, J.; Senatore, A.] Johnson & Johnson, Janssen Pharmaceut Co, Allschwil, BL, Switzerland; [Forsythe, A.] Purple Squirrel Econ, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO3	S197	S198					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401126
J	Lim, KK; Koleva-Kolarova, R; Fox-Rushby, J				Lim, K. K.; Koleva-Kolarova, R.; Fox-Rushby, J.			A COMPARISON OF THE CONTENT AND CONSISTENCY OF QUALITY AND TRANSFERABILITY CHECKLISTS FOR REVIEWING ECONOMIC EVALUATIONS	VALUE IN HEALTH			English	Meeting Abstract									[Lim, K. K.; Fox-Rushby, J.] Kings Coll London, London, England; [Koleva-Kolarova, R.] Univ Oxford, Oxford, Oxf, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PPM3	S195	S195					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401115
J	Lyu, N; Chen, H				Lyu, N.; Chen, H.			IMPACT OF PCP SCREENING ON EARLY DETECTION OF PEDIATRIC MENTAL DISORDER	VALUE IN HEALTH			English	Meeting Abstract									[Lyu, N.; Chen, H.] Univ Houston, Coll Pharm, Houston, TX 77030 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH18	S102	S102					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400444
J	Mazumder, D; Lele, A; Tyagi, R; Ghosh, A				Mazumder, D.; Lele, A.; Tyagi, R.; Ghosh, A.			IMMUNE-RELATED ADVERSE EVENTS (IRAES) IN NSCLC PATIENTS TREATED WITH PROGRAMMED CELL DEATH 1 (PD-1) INHIBITORS: AN ANALYSIS USING THE DATA FROM FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)	VALUE IN HEALTH			English	Meeting Abstract									[Mazumder, D.; Lele, A.; Tyagi, R.; Ghosh, A.] SmartAnalyst India Pvt Ltd, Gurugram, HR, India									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN117	S40	S41					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400171
J	Morlock, R; Aiyer, L; Culwell, K; Howard, B				Morlock, R.; Aiyer, L.; Culwell, K.; Howard, B.			ASSESSING THE UNDERSTANDABILITY AND IMPORTANCE OF PATIENT REPORTED OUTCOMES IMPACTING ADHERENCE AND OUTCOMES OF A NON-HORMONAL VAGINAL MICROBICIDE TO PREVENT AND PROTECT AGAINST CHLAMYDIA TRACHOMATIS (CT) AND NEISSERIA GONORRHOEAE (GC)	VALUE IN HEALTH			English	Meeting Abstract									[Morlock, R.] YourCareChoice, Ann Arbor, MI USA; [Aiyer, L.; Culwell, K.; Howard, B.] Evofem Biosci Inc, San Diego, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH34	S104	S104					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400454
J	Osterland, A; Widmer, RJ; Godley, PJ				Osterland, A.; Widmer, R. J.; Godley, P. J.			REAL-WORLD OUTCOMES OF ANTITHROMBOTIC THERAPIES IN PATIENTS WITH CORONARY ARTERY DISEASE THAT REQUIRE LONG-TERM ORAL ANTICOAGULATION	VALUE IN HEALTH			English	Meeting Abstract									[Osterland, A.; Widmer, R. J.; Godley, P. J.] Baylor Scott & White Hlth, Austin, TX USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV2	S67	S67					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400291
J	Polyzoi, M; Sandhu, H; Maervoet, J; Yuan, Y; Chaudhary, M; Varol, N; Lee, A; Dale, P; Jones, C; Lubinga, SJ; Penrod, JR				Polyzoi, M.; Sandhu, H.; Maervoet, J.; Yuan, Y.; Chaudhary, M.; Varol, N.; Lee, A.; Dale, P.; Jones, C.; Lubinga, S. J.; Penrod, J. R.			A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS IPILIMUMAB PLUS TWO CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY VERSUS PLATINUM DOUBLET CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Polyzoi, M.] PAREXEL Int, Strangnas, D, Sweden; [Sandhu, H.; Maervoet, J.; Dale, P.] Parexel Int, London, Ess, England; [Yuan, Y.; Chaudhary, M.; Lubinga, S. J.; Penrod, J. R.] Bristol Myers Squibb Co, Princeton, NJ USA; [Varol, N.; Lee, A.] Bristol Myers Squibb Co, Uxbridge, Middx, England; [Jones, C.] PAREXEL Int, Stockholm, Sweden									0	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		EC1	S5	S5					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400018
J	Porter, K; Fischer, R; Peay, H				Porter, K.; Fischer, R.; Peay, H.			DECISION-MAKING AND EXPERIENCED BENEFITS AND RISKS OF CORTICOSTEROIDS AS A TREATMENT FOR DUCHENNE MUSCULAR DYSTROPHY	VALUE IN HEALTH			English	Meeting Abstract									[Porter, K.; Peay, H.] RTI Int, Res Triangle Pk, NC USA; [Fischer, R.] Parent Project Muscular Dystrophy, Hackensack, NJ USA					Peay, Holly/0000-0002-3053-7453; Porter, Katherine/0000-0002-5544-8369				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMS26	S143	S143					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400623
J	Simpson, K; Wase, L; Fossler, MJ; Demitrack, MA				Simpson, K.; Wase, L.; Fossler, M. J.; Demitrack, M. A.			BUDGET IMPACT ANALYSIS FOR OLICERIDINE IN THE MANAGEMENT OF MODERATE TO SEVERE ACUTE POSTOPERATIVE PAIN	VALUE IN HEALTH			English	Meeting Abstract									[Simpson, K.] Med Univ South Carolina, Charleston, SC 29425 USA; [Wase, L.; Fossler, M. J.; Demitrack, M. A.] Trevena Inc, Chesterbrook, PA USA									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG6	S87	S88					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400382
J	Sokolova, V; Mladov, V; Tolkacheva, D				Sokolova, V; Mladov, V; Tolkacheva, D.			BIOLOGICS TO TREAT ADULTS WITH ACTIVE RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN THE RUSSIAN FEDERATION: NUMBER NEEDED TO TREAT AND COST PER RESPONDER	VALUE IN HEALTH			English	Meeting Abstract									[Sokolova, V; Mladov, V; Tolkacheva, D.] BIOCAD, St Petersburg, Spe, Russia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PBI15	S17	S17					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400068
J	Sun, F; Jeyakumar, S; Smith, N				Sun, F.; Jeyakumar, S.; Smith, N.			ECONOMIC VALUE AND HEALTH SYSTEM IMPACT OF REMDESIVIR IN TREATING HOSPITALIZED COVID-19 PATIENTS IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Sun, F.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA; [Jeyakumar, S.; Smith, N.] Maple Hlth Grp LLC, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		IN3	S10	S10					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400039
J	Tanudtanud, K; Vinculado, R; Lasquite, KM; Catlett, K; Dacosta, BS				Tanudtanud, K.; Vinculado, R.; Lasquite, K. M.; Catlett, K.; Dacosta, Byfield S.			HEALTHCARE COSTS FOR ELDERLY PATIENTS WITH LUNG CANCER AND COMORBID MAJOR DEPRESSIVE DISORDER (MDD)	VALUE IN HEALTH			English	Meeting Abstract									[Tanudtanud, K.; Vinculado, R.; Lasquite, K. M.; Catlett, K.; Dacosta, Byfield S.] Optum Labs, Minnetonka, MN USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN99	S37	S38					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400157
J	Vurgun, N; Whiting, CG; Sandman, K				Vurgun, N.; Whiting, C. G.; Sandman, K.			CAREGIVER-REPORTED OUTCOMES IN ALZHEIMER'S DISEASE AND OTHER DEMENTIAS: A SURVEY OF INTERVENTIONAL CLINICAL TRIALS OF PHARMACOLOGIC THERAPIES	VALUE IN HEALTH			English	Meeting Abstract									[Vurgun, N.] Purple Squirrel Econ, Montreal, PQ, Canada; [Whiting, C. G.] Natl Alliance Caregiving, Washington, DC USA; [Sandman, K.] Purple Squirrel Econ, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND61	S170	S170					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401003
J	Xiong, S; Wu, J; Li, M; Lu, K				Xiong, S.; Wu, J.; Li, M.; Lu, K.			ASSOCIATION BETWEEN SATISFACTION WITH QUALITY OF CARE AND ANTI-DEMENTIA MEDICATION ADHERENCE AMONG ELDERLY ADULTS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS	VALUE IN HEALTH			English	Meeting Abstract									[Xiong, S.; Lu, K.] Univ South Carolina, Columbia, SC 29208 USA; [Wu, J.] Presbyterian Coll, Clinton, SC USA; [Li, M.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG38	S93	S93					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400407
J	Bovenberg, J; Penton, H; Buyukkaramikli, N				Bovenberg, Josien; Penton, Hannah; Buyukkaramikli, Nasuh			10 Years of End-of-Life Criteria in the United Kingdom	VALUE IN HEALTH			English	Article						end of life; NICE; cost-effectiveness analyses; modeling	NICES; THRESHOLD; HEALTH	Objectives: In January 2009, the National Institute for Health and Care Excellence introduced supplementary guidance for end-of-life (EoL) treatments, which allowed treatments with an incremental cost-effectiveness ratio over the regular threshold (20 pound 000-30 pound 000) to be recommended, if they satisfied the EoL criteria. The aims of this study were (1) to systematically review 10 years of EoL supplementary guidance implementation and explore how it could be improved, and (2) to create a framework for incorporating the uncertainty relating to EoL criteria satisfaction into model-based costeffectiveness analyses for decision making. Methods: All appraisals between January 2009 and 2019 were screened for EoL discussions. Data were extracted on the EoL criteria and cost-effectiveness assessment details. Additionally, a quantitative method was developed to include the EoL criteria satisfaction uncertainty into model-based cost-effectiveness analyses. A stylized example was created to provide a case study for the inclusion of EoL criteria satisfaction uncertainty. Results: An EoL discussion was identified in 35% of appraisals, 57% of which led to a positive EoL decision. Only 5.7% of technologies with positive EoL decisions were not recommended, versus 43.8% of technologies with negative EoL decisions. EoL criteria assessment was often reported insufficiently and evaluated inconsistently and nontransparently. A total of 54.9% of EoL decisions were made while at least 1 criterion was surrounded by considerable uncertainty. By applying the proposed quantitative method, this EoL criteria satisfaction uncertainty was accounted for in decision making. The stylized example demonstrated that the impact of EoL criteria satisfaction uncertainty can be substantial enough to reverse the reimbursement decision. Conclusions: To improve consistency/transparency and correct reimbursement decisions' likelihood, new guidelines on the implementation of the EoL criteria are needed.	[Bovenberg, Josien; Penton, Hannah] Erasmus Univ, Rotterdam, Netherlands; [Buyukkaramikli, Nasuh] Inst Med Technol Assessment, Rotterdam, Netherlands		Bovenberg, J (通讯作者)，Albregt Engelmanstr 53-A, NL-3025 BC Rotterdam, Netherlands.	josienbovenberg@hotmail.com		Penton, Hannah/0000-0001-9492-7875			Appleby J, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2449; Bojke L, 2009, VALUE HEALTH, V12, P739, DOI 10.1111/j.1524-4733.2008.00502.x; Buyukkaramikli NC, 2019, PHARMACOECONOMICS, V37, P1391, DOI 10.1007/s40273-019-00844-y; Collins M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1363; Griffiths EA, 2016, VALUE HEALTH, V19, pA489, DOI 10.1016/j.jval.2016.09.825; Hamerslag L, 2011, VALUE HEALTH, V14, pA243, DOI 10.1016/j.jval.2011.08.070; Jackson CH, 2009, J R STAT SOC A STAT, V172, P383, DOI 10.1111/j.1467-985X.2008.00573.x; Jones L, 2004, HEALTH TECHNOL ASSES, V8, P1; Linley WG, 2013, HEALTH ECON, V22, P948, DOI 10.1002/hec.2872; McHugh N, 2018, SOC SCI MED, V198, P61, DOI 10.1016/j.socscimed.2017.12.019; Moise P, 2011, VALUE HEALTH, V14, pA173, DOI 10.1016/j.jval.2011.02.959; National Institute for Health and Care Excellence, 2018, TA515 ERIB TREAT LOC; National Institute for Health and Care Excellence, 2013, GUID METH TECHN APPR; National Institute for Health and Care Excellence, 2016, TA414 COB COMB VEM T; National Institute for Health and Care Excellence, 2018, TA530 NIV TREAT LOC; National Institute for Health and Care Excellence, 2016, TA403 RAM PREV TREAT; National Institute for Health and Care Excellence, 2016, CONS PROP NEW CANC D; National Institute for Health and Care Excellence Decision Support Unit, END LIF; National institute for Health and Clinical Excellence, 2009, APPR LIF EXT END LIF; Price MJ, 2011, VALUE HEALTH, V14, P205, DOI 10.1016/j.jval.2010.08.001; Rothery C, 2020, VALUE HEALTH, V23, P277, DOI 10.1016/j.jval.2020.01.004; Shah KK, 2015, SOC SCI MED, V124, P48, DOI 10.1016/j.socscimed.2014.11.022; Strong M, 2014, SIAM-ASA J UNCERTAIN, V2, P106, DOI 10.1137/120889563; Strong M, 2012, J R STAT SOC C-APPL, V61, P25, DOI 10.1111/j.1467-9876.2011.01014.x; Vemer P, 2016, PHARMACOECONOMICS, V34, P349, DOI 10.1007/s40273-015-0327-2; Versteegh MM, 2019, PHARMACOECONOMICS, V37, P1155, DOI 10.1007/s40273-019-00810-8	26	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAY	2021	24	5					691	698		10.1016/j.jval.2020.11.015		APR 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	RU9KC	33933238	hybrid			2022-04-28	WOS:000645457500012
J	Hornberger, J; Chhatwal, J				Hornberger, John; Chhatwal, Jagpreet			Opioid Misuse: A Global Crisis	VALUE IN HEALTH			English	Editorial Material									[Hornberger, John] Acumen LLC, 500 Airport Blvd,STE 100, Burlingame, CA 94010 USA; [Chhatwal, Jagpreet] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA; [Chhatwal, Jagpreet] Harvard Med Sch, Boston, MA 02115 USA		Hornberger, J (通讯作者)，Acumen LLC, 500 Airport Blvd,STE 100, Burlingame, CA 94010 USA.	jhornberger@acumenllc.com					Amiri S, 2021, VALUE HEALTH, V24, P188, DOI 10.1016/j.jval.2020.08.2098; Ballreich J, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.23677; Barenie RE, 2021, VALUE HEALTH, V24, P182, DOI 10.1016/j.jval.2020.04.1840; Beaulieu E, 2021, VALUE HEALTH, V24, P158, DOI 10.1016/j.jval.2020.07.013; Chen QS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7621; Kim S, 2021, VALUE HEALTH, V24, P174, DOI 10.1016/j.jval.2020.12.002; Knipe DM, 2020, SCIENCE, V370, P1274, DOI 10.1126/science.abf0357; Kurteva S, 2021, VALUE HEALTH, V24, P147, DOI 10.1016/j.jval.2020.07.015; Linas BP, 2021, J SUBST ABUSE TREAT, V120, DOI 10.1016/j.jsat.2020.108158; US Department of Health and Human Services, HHS ACT SECR DECL PU; Zhou LL, 2021, VALUE HEALTH, V24, P196, DOI 10.1016/j.jval.2020.12.001	11	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	FEB	2021	24	2					145	146		10.1016/j.jval.2020.12.003		JAN 2021	2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QJ1VI	33518020	Bronze			2022-04-28	WOS:000619478100001
J	Seddik, AH; Schiener, C; Ostwald, DA; Schramm, S; Huels, J; Katsarava, Z				Seddik, Ahmed H.; Schiener, Claudio; Ostwald, Dennis A.; Schramm, Sara; Huels, Jasper; Katsarava, Zaza			Social Impact of Prophylactic Migraine Treatments in Germany: A State-Transition and Open Cohort Approach	VALUE IN HEALTH			English	Article						Aimovig; erenumab; migraine disorders; population model; societal cost; unpaid work; work productivity	HEADACHE; ERENUMAB; BURDEN; DISEASE; TRIAL	Objectives: Migraine is a highly prevalent neurological disorder. The most characteristic symptom of migraine is moderate to severe recurrent headache along with other neurological symptoms. In this study, we modeled the potential reduction in migraine days and corresponding avoided productivity losses if erenumab was prescribed to the patient population indicated for prophylactic migraine treatment ($ 4 monthly migraine days [MMDs]) in Germany from 2020 to the end of 2027. Methods: We simulated the incremental benefits of erenumab against the standard of care. Response rates, transition probabilities, discontinuation rates, and productivity estimates were derived from the erenumab clinical trial program. Patients had a probability of residing in 1 of 7 states, given the MMDs in addition to the probability of death. Based on accrued MMDs in every cycle, days of absenteeism and presenteeism for paid and unpaid work were derived. Paid work was monetized according to gross value added using the human capital approach, whereas unpaid work was valuated according to the proxy good method. In addition, downstream macroeconomic effects were captured using value-added multipliers. Direct medical costs were concomitantly calculated. Results: Our results show that prescribing erenumab for the indicated population in Germany could lead to a reduction of 166 million migraine days annually and reduce productivity losses in the range of euro 27 billion. This includes euro 13.1 billion from direct productivity and euro 13.5 billion from economic value chain effects. Conclusions: This study highlights the macroeconomic effects of a systematic introduction of novel inhibitors of the calcitonin gene-related peptide pathway for migraine in Germany.	[Seddik, Ahmed H.; Schiener, Claudio; Ostwald, Dennis A.] WifOR Inst, Darmstadt, Germany; [Seddik, Ahmed H.] Dauchi Sankyo Europe GmbH, Munich, Germany; [Ostwald, Dennis A.] Steinbeis Univ, Grad Sch, Fac Leadership & Management, SIBE, Berlin, Germany; [Schramm, Sara] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Informat Biometry & Epidemiol, Essen, Germany; [Katsarava, Zaza] Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, Essen, Germany; [Huels, Jasper] Novartis Pharma AG, Basel, Switzerland; [Katsarava, Zaza] Evangelical Hosp Unna, Unna, Germany; [Katsarava, Zaza] EVEX Med Corp, Tbilisi, Georgia; [Katsarava, Zaza] IM Sechenov First Moscow State Med Univ Sechenov, Moscow, Russia		Schiener, C (通讯作者)，WifOR GmbH, Rheinstr 22, D-64283 Darmstadt, Hesse, Germany.	claudio.schiener@wifor.com			Novartis Pharma AG Basel; German Federal Ministry of Education and Research (BMBF), GermanyFederal Ministry of Education & Research (BMBF)	This study was funded by Novartis Pharma AG Basel. The GHC Study was supported by the German Federal Ministry of Education and Research (BMBF), Germany.	Agosti R, 2018, HEADACHE, V58, P17, DOI 10.1111/head.13301; Ashina M, 2019, CEPHALALGIA, V39, P1455, DOI 10.1177/0333102419854082; Becker C, 2008, CEPHALALGIA, V28, P57, DOI 10.1111/j.1468-2982.2007.01469.x; Benz T, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0871-5; Buse DC, 2018, CEPHALALGIA, V38, P1622, DOI 10.1177/0333102418789072; Diener H-C., PROPHYLAXE MIGRANE M; Dodick DW, 2018, CEPHALALGIA, V38, P1026, DOI 10.1177/0333102418759786; European Medicines Agency, ASS REP AIM INT PROP; Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI [10.1016/S1474-4422(18)30499-X, 10.1016/S1474-4422(18)30295-3]; Global Health Data Exchange, GBD RES TOOL; Goadsby PJ, 2017, NEW ENGL J MED, V377, P2123, DOI 10.1056/NEJMoa1705848; Goodman CS, HTA 101 INTRO HLTH T; Grosse SD, 2009, ENCY MED DECISION MA, P603; Haag G, 2009, NERVENHEILKUNDE, V6, P382; Himmler S, 2021, J COMP EFFECT RES, V10, P143, DOI 10.2217/cer-2020-0077; Himmler S, 2020, EXPERT REV PHARM OUT, V20, P369, DOI 10.1080/14737167.2019.1644169; International Monetary Fund, 2020, WORLD EC OUTLOOK; Kantar Health, GLOB HLTH WELL REP F; Lampl C, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0599-8; Linde M, 2004, CEPHALALGIA, V24, P455, DOI 10.1111/j.1468-2982.2004.00703.x; Linde M, 2012, EUR J NEUROL, V19, P703, DOI 10.1111/j.1468-1331.2011.03612.x; Lipton RB, 2015, HEADACHE, V55, P103, DOI 10.1111/head.12505_2; Raffaelli B, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-1018-8; reimbursement.info, FALLP DRG B77Z KOPFC; Reuter U, 2018, LANCET, V392, P2280, DOI 10.1016/S0140-6736(18)32534-0; Scuteri D, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00363; Seddik AH, 2020, CEPHALALGIA, V40, P1551, DOI 10.1177/0333102420944842; Severens JL, 2004, VALUE HEALTH, V7, P397, DOI 10.1111/j.1524-4733.2004.74002.x; Silberstein Stephen D, 2015, Continuum (Minneap Minn), V21, P973, DOI 10.1212/CON.0000000000000199; Sirven J. I., 2008, CLIN NEUROLOGY OLDER, V2nd; Statistisches Bundesamt (Destatis), 2015, BEV DTSCH 2060 TAB E; Stovner LJ, 2007, CEPHALALGIA, V27, P193, DOI 10.1111/j.1468-2982.2007.01288.x; Sullivan SD, 2014, VALUE HEALTH, V17, P5, DOI 10.1016/j.jval.2013.08.2291; Tepper S, 2017, LANCET NEUROL, V16, P425, DOI 10.1016/S1474-4422(17)30083-2; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Vo P, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0907-6; Yoon MS, 2012, J HEADACHE PAIN, V13, P215, DOI 10.1007/s10194-012-0425-x	37	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	OCT	2021	24	10					1446	1453		10.1016/j.jval.2021.04.1281		SEP 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	WE3WV	34593167	hybrid			2022-04-28	WOS:000705561100008
J	Maas, ET; Juch, JNS; Ostelo, RWJG; Groeneweg, JG; Kallewaard, JW; Koes, BW; Verhagen, AP; van Dongen, JM; van Tulder, MW; Huygen, FJPM				Maas, Esther T.; Juch, Johan N. S.; Ostelo, Raymond W. J. G.; Groeneweg, J. George; Kallewaard, Jan-Willem; Koes, Bart W.; Verhagen, Arianne P.; van Dongen, Johanna M.; van Tulder, Maurits W.; Huygen, Frank J. P. M.			Inadequate Selection and Treatment Results in Poor Outcomes and Lack of Cost-Effectiveness Reply	VALUE IN HEALTH			English	Letter							PAIN		[Maas, Esther T.; Ostelo, Raymond W. J. G.; van Dongen, Johanna M.; van Tulder, Maurits W.] Vrije Univ Amsterdam, Movement Sci Res Inst, Fac Sci, Dept Hlth Sci, Boelelaan 1081, NL-1081 HV Amsterdam, Netherlands; [Juch, Johan N. S.; Groeneweg, J. George; Huygen, Frank J. P. M.] Erasmus Univ, Med Ctr, Dept Anesthesiol, Rotterdam, Netherlands; [Ostelo, Raymond W. J. G.; van Dongen, Johanna M.; van Tulder, Maurits W.] Univ Amsterdam, Med Ctr, Dept Epidemiol & Data Sci, Amsterdam Movement Sci Res Inst, Amsterdam, Netherlands; [Koes, Bart W.; Verhagen, Arianne P.] Erasmus Univ, Med Ctr, Dept Gen Practice, Rotterdam, Netherlands; [Kallewaard, Jan-Willem] Rijnstate Hosp, Dept Anesthesiol, Velp, Netherlands; [Ostelo, Raymond W. J. G.] Vrije Univ, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands		Maas, ET (通讯作者)，Vrije Univ Amsterdam, Movement Sci Res Inst, Fac Sci, Dept Hlth Sci, Boelelaan 1081, NL-1081 HV Amsterdam, Netherlands.	e.t.maas@vu.nl	Kallewaard, Jan/AAD-4467-2022; van Tulder, Maurits/AAB-9785-2022; Koes, Bart/K-4614-2016	van Tulder, Maurits/0000-0002-7589-8471; Koes, Bart/0000-0002-0450-9969; van Dongen, Johanna Maria/0000-0002-1606-8742; Verhagen, Arianne/0000-0002-6195-0128; Groeneweg, Johannes George/0000-0001-6072-0446; Ostelo, Raymond/0000-0001-7679-7210	Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development	Drs Ostelo, Groenewegand, van Tulder, and Huygen reported receiving grants from The Netherlands Organisation for Health Research and Development during the conduct of the study. Dr Ostelo reported receiving grants from The Netherlands Organisation Scientific Research, Wetenschappelijk College Fysiotherapie/KNGF, Ned Ver Manuele Therapie, European Chiropractors' Union, Amsterdam Movement Sciences, National Health Care Institute, and De Friesland Zorgverzekeraar outside the submitted work. No other disclosures were reported.	[Anonymous], GUIDELINE LUMBAR SPI; Ares JD, 2020, PAIN PRACT, V20, P889, DOI 10.1111/papr.12928; Bogduk N, 2000, PAIN MED, V1, P24, DOI 10.1046/j.1526-4637.2000.99104.x; Burnham RS, 2009, ARCH PHYS MED REHAB, V90, P201, DOI 10.1016/j.apmr.2008.07.021; Cohen SP, 2020, REGION ANESTH PAIN M, V45, P424, DOI 10.1136/rapm-2019-101243; Maas ET, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-260; Schneider BJ, 2020, PAIN MED, V21, P1122, DOI 10.1093/pm/pnz349; van Kleef M, 2010, PAIN PRACT, V10, P459, DOI 10.1111/j.1533-2500.2010.00393.x	8	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	AUG	2021	24	8					1235	1236		10.1016/j.jval.2021.02.013		AUG 2021	2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TY1SX	34372990	Green Published			2022-04-28	WOS:000683567300018
J	Mok, CH; Kwok, HHY; Ng, CS; Leung, GM; Quan, JC				Mok, Chiu Hang; Kwok, Harley H. Y.; Ng, Carmen S.; Leung, Gabriel M.; Quan, Jianchao			Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis	VALUE IN HEALTH			English	Review						Asia; diabetes; meta-analysis; quality of life; systematic review; utility	QUALITY-OF-LIFE; STANDARD GAMBLE; VALUE SET; EQ-5D; EUROQOL; VALIDATION; MELLITUS; VALUATION; DISEASE; MODELS	Objectives: East and Southeast Asia has the greatest burden of diabetes in the world. We sought to derive a reference set of utility values for type 2 diabetes without complication and disutility (utility decrement) values for important diabetes-related complications to better inform economic evaluation. Methods: A systematic review to identify utility values for diabetes and related complications reported in East and Southeast Asia. We searched MEDLINE (OVID) from inception to May 26, 2020 for utility values elicited using direct and indirect methods. Identified studies were assessed for quality based on the National Institute of Health and Care Excellence guidelines. Utility and disutility estimates were pooled by meta-analyses with subgroup analyses to evaluate differences by nationality and valuation instrument. (PROSPERO: CRD42020191075). Results: We identified 17 studies for the systematic review from a total of 13 035 studies in the initial search, of which 13 studies met the quality criteria for inclusion in the meta-analyses. The pooled utility value for diabetes without complication was 0.88 (95% CI 0.83-0.93), with the pooled utility decrement for associated complications ranged from 0.00 (for excess BMI) to 0.18 (for amputation). The utility values were consistently more conservative than previous estimates derived in Western populations. Utility decrements were comparable for SF-6D and EQ-5D valuation instruments and for Chinese and other Asian groups. Conclusions: A reference set of pooled disutility and utility values for type 2 diabetes and its complications in East and Southeast Asian populations yielded more conservative estimates than Western populations.	[Mok, Chiu Hang; Kwok, Harley H. Y.; Ng, Carmen S.; Leung, Gabriel M.; Quan, Jianchao] Univ Hong Kong, LKS Fac Med, Sch Publ Hlth, Div Hlth Econ Policy & Management, 7 Sassoon Rd, Hong Kong, Peoples R China; [Leung, Gabriel M.] Lab Data Discovery Hlth, Hong Kong Sci Pk, Hong Kong, Peoples R China		Ng, CS; Quan, JC (通讯作者)，LKS Fac Med, Sch Publ Hlth, Pokfulam, 7 Sassoon Rd, Hong Kong, Peoples R China.	csng14@hku.hk; jquan@hku.hk	Quan, Jianchao/N-2761-2017	Quan, Jianchao/0000-0002-8386-8512; Mok, Chiu Hang/0000-0002-8527-016X; Kwok, Harley Hiu-Yung/0000-0001-5901-1407	Research Grants Council of the Hong Kong Special Administrative Region, ChinaHong Kong Research Grants Council [27112518]	This work was supported by grant 27112518 from the Research Grants Council of the Hong Kong Special Administrative Region, China.	Bagust A, 2005, HEALTH ECON, V14, P217, DOI 10.1002/hec.910; Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117; Beaudet A, 2014, VALUE HEALTH, V17, P462, DOI 10.1016/j.jval.2014.03.003; Bleichrodt H, 2002, HEALTH ECON, V11, P447, DOI 10.1002/hec.688; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Brazier J, 2017, INT ENCY PUBLIC HLTH, P586; Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7; Clarke P, 2002, MED DECIS MAKING, V22, P340, DOI 10.1177/027298902400448902; Conner-Spady B, 2003, MED CARE, V41, P791, DOI 10.1097/00005650-200307000-00003; Currie CJ, 2006, CURR MED RES OPIN, V22, P1523, DOI 10.1185/030079906X115757; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Dolan P, 1996, HEALTH ECON, V5, P141, DOI 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N; Eddy DM, 2003, DIABETES CARE, V26, P3102, DOI 10.2337/diacare.26.11.3102; Feng Y, 2014, QUAL LIFE RES, V23, P977, DOI 10.1007/s11136-013-0537-z; Fenwick EK, 2012, INVEST OPHTH VIS SCI, V53, P677, DOI 10.1167/iovs.11-8992; Glasziou P, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-21; Gu SY, 2020, QUAL LIFE RES, V29, P2695, DOI 10.1007/s11136-020-02524-3; Hayes AJ, 2013, DIABETOLOGIA, V56, P1925, DOI 10.1007/s00125-013-2940-y; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hoerger TJ, 2009, VALIDATION CDC RTI D; Ikeda S., 2015, Journal of the National Institute of Public Health, V64, P47; International Diabetes Federation, 2019, IDF ATL, Vninth; Japanese EuroQol Translation Team, 1997, J HLTH CARE SOC, V8, P109, DOI DOI 10.4091/IKEN1991.8.1_109; Jiao FF, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0699-4; Jo MW, 2008, VALUE HEALTH, V11, P1186, DOI 10.1111/j.1524-4733.2008.00348.x; Juniper EF, 2001, EUR RESPIR J, V18, P38, DOI 10.1183/09031936.01.00088301; Kim BY, 2019, DIABETES METAB J, V43, P487, DOI 10.4093/dmj.2019.0067; Kim SS, 2014, DIABETES RES CLIN PR, V103, P522, DOI 10.1016/j.diabres.2013.12.003; Lam CLK, 2008, VALUE HEALTH, V11, P295, DOI 10.1111/j.1524-4733.2007.00233.x; Lam CLK, 2005, QUAL LIFE RES, V14, P539, DOI 10.1007/s11136-004-0704-3; Lee WJ, 2012, J KOREAN MED SCI, V27, P255, DOI 10.3346/jkms.2012.27.3.255; Li YZ, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m997; Lin YJ, 2019, CURR MED RES OPIN, V35, P7, DOI 10.1080/03007995.2018.1470970; Liu GG, 2014, VALUE HEALTH, V17, P597, DOI 10.1016/j.jval.2014.05.007; Luk AOY, 2014, J DIABETES METAB, V5, DOI 10.4172/2155-6156.1000333; Luo N, 2003, QUAL LIFE RES, V12, P87, DOI 10.1023/A:1022063721237; Luo N, 2017, VALUE HEALTH, V20, P662, DOI 10.1016/j.jval.2016.11.016; Mai VQ, 2020, QUAL LIFE RES, V29, P1923, DOI 10.1007/s11136-020-02469-7; McEwan P, 2014, VALUE HEALTH, V17, P714, DOI 10.1016/j.jval.2014.07.007; McGhee S M, 2011, Hong Kong Med J, V17 Suppl 6, P17; Moher D, 2015, SYST REV, V4, DOI [10.1186/s13643-015-0087-2, 10.1186/2046-4053-4-1]; Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873; Neumann PJ, 2018, VALUE HEALTH, V21, pS56, DOI 10.1016/j.jval.2018.07.424; Pan CW, 2018, QUAL LIFE RES, V27, P2087, DOI 10.1007/s11136-018-1876-6; Pan CW, 2016, MED DECIS MAKING, V36, P234, DOI 10.1177/0272989X15606903; Papaioannou D, 2010, NICE DSU TECHNICAL S; Papaioannou D, 2013, VALUE HEALTH, V16, P686, DOI 10.1016/j.jval.2013.02.017; Quah JHM, 2011, ANN ACAD MED SINGAP, V40, P276; Quan J, 2017, DIABETIC MED, V34, P902, DOI 10.1111/dme.13284; Quan J., CHIME MODEL CHINESE; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Riddle MC, 2018, DIABETES CARE, V41, P929, DOI 10.2337/dci18-0012; Safita N, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0530-7; Sakamaki H, 2006, VALUE HEALTH, V9, P47, DOI 10.1111/j.1524-4733.2006.00080.x; Sakthong P, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-71; Saramago P, 2012, VALUE HEALTH, V15, P639, DOI 10.1016/j.jval.2012.02.009; Schramm W, 2016, STUD HEALTH TECHNOL, V226, P115, DOI 10.3233/978-1-61499-664-4-115; Shao H, 2019, PHARMACOECONOMICS, V37, P921, DOI 10.1007/s40273-019-00775-8; Shao H, 2018, PHARMACOECONOMICS, V36, P1125, DOI 10.1007/s40273-018-0662-1; Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003; Si L, 2020, VALUE HEALTH, V23, P1163, DOI 10.1016/j.jval.2020.04.1832; Sintonen H, 2001, ANN MED, V33, P328, DOI 10.3109/07853890109002086; Smolen HJ., 2015, VALUE HEALTH, V18; Takahara M, 2019, ACTA DIABETOL, V56, P309, DOI 10.1007/s00592-018-1244-6; Tan MC, 2014, SINGAP MED J, V55, P209; Tee ES, 2017, EUR J CLIN NUTR, V71, P844, DOI 10.1038/ejcn.2017.44; Terauchi Y, 2019, DIABETES RES CLIN PR, V149, P115, DOI 10.1016/j.diabres.2019.01.019; Thomas C, 2014, VALUE HEALTH, V17, pA556, DOI 10.1016/j.jval.2014.08.1826; Tsuchiya A, 2002, HEALTH ECON, V11, P341, DOI 10.1002/hec.673; Tung TH, 2005, DIABETES RES CLIN PR, V68, P265, DOI 10.1016/j.diabres.2004.10.003; Pham TB, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/4360804; van der Heijden AAWA, 2015, DIABETIC MED, V32, P1580, DOI 10.1111/dme.12811; Venkataraman K, 2013, CLIN ENDOCRINOL, V78, P865, DOI 10.1111/j.1365-2265.2012.04480.x; Walters Stephen J, 2003, Health Qual Life Outcomes, V1, P4, DOI 10.1186/1477-7525-1-4; Wan EYF, 2016, QUAL LIFE RES, V25, P2957, DOI 10.1007/s11136-016-1324-4; Ware JE, 2008, QUALITY METRIC; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Xie F, 2015, PHARMACOECONOMICS, V33, P867, DOI 10.1007/s40273-015-0292-9; Ye W, 2015, DIABETES TECHNOL THE, V17, P701, DOI 10.1089/dia.2014.0304; Zhang YL, 2014, QUAL LIFE RES, V23, P2319, DOI 10.1007/s11136-014-0674-z; Zhang YC, 2020, DIABETES THER, V11, P939, DOI 10.1007/s13300-020-00788-z; Zheng Y, 2018, NAT REV ENDOCRINOL, V14, P88, DOI 10.1038/nrendo.2017.151; Zsolyom A, 2013, VALUE HEALTH, V16, pA590, DOI 10.1016/j.jval.2013.08.1640	83	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUL	2021	24	7					1059	1067		10.1016/j.jval.2020.12.019		JUL 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TE7UB	34243830				2022-04-28	WOS:000670212100017
J	Petersohn, S; Grimm, SE; Ramaekers, BLT; ten Cate-Hoek, AJ; Joore, MA				Petersohn, Svenja; Grimm, Sabine E.; Ramaekers, Bram L. T.; ten Cate-Hoek, Arina J.; Joore, Manuela A.			Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study	VALUE IN HEALTH			English	Article						uncertainty analysis	DECISION-ANALYTIC MODELS; COST-EFFECTIVENESS; STRUCTURAL UNCERTAINTY; EXPECTED VALUE; INFORMATION; ASPIRIN; GUIDELINES; PERFECT; EVENTS; SAMPLE	Objectives: Decision makers adopt health technologies based on health economic models that are subject to uncertainty. In an ideal world, these models parameterize all uncertainties and reflect them in the cost-effectiveness probability and risk associated with the adoption. In practice, uncertainty assessment is often incomplete, potentially leading to suboptimal reimbursement recommendations and risk management. This study examines the feasibility of comprehensive uncertainty assessment in health economic models. Methods: A state transition model on peripheral arterial disease treatment was used as a case study. Uncertainties were identified and added to the probabilistic sensitivity analysis if possible. Parameter distributions were obtained by expert elicitation, and structural uncertainties were either parameterized or explored in scenario analyses, which were model averaged. Results: A truly comprehensive uncertainty assessment, parameterizing all uncertainty, could not be achieved. Expert elicitation informed 8 effectiveness, utility, and cost parameters. Uncertainties were parameterized or explored in scenario analyses and with model averaging. Barriers included time and resource constraints, also of clinical experts, and lacking guidance regarding some aspects of expert elicitation, evidence aggregation, and handling of structural uncertainty. The team's multidisciplinary expertise and existing literature and tools were facilitators. Conclusions: While comprehensive uncertainty assessment may not be attainable, improvements in uncertainty assessment in general are no doubt desirable. This requires the development of detailed guidance and hands-on tutorials for methods of uncertainty assessment, in particular aspects of expert elicitation, evidence aggregation, and handling of structural uncertainty. The issue of benefits of uncertainty assessment versus time and resources needed remains unclear.	[Petersohn, Svenja; Grimm, Sabine E.; Ramaekers, Bram L. T.; Joore, Manuela A.] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Oxfordgebouw 10, NL-6229 EV Maastricht, Netherlands; [ten Cate-Hoek, Arina J.] Maastricht Univ, Dept Internal Med, Med Ctr, Maastricht, Netherlands		Grimm, SE (通讯作者)，Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Oxfordgebouw 10, NL-6229 EV Maastricht, Netherlands.	sabine.grimm@mumc.nl		Joore, Manuela/0000-0002-5649-6768			Anand SS, 2018, LANCET, V391, P219, DOI 10.1016/S0140-6736(17)32409-1; [Anonymous], 2016, GUID EC EV HEALTHC; Arnold RJG, 2010, PHARMACOECONOMICS, V28, P609, DOI 10.2165/11537580-000000000-00000; Bilcke J, 2011, MED DECIS MAKING, V31, P675, DOI 10.1177/0272989X11409240; Bojke L, 2017, PHARMACOECONOMICS, V35, P867, DOI 10.1007/s40273-017-0525-1; Bojke L, 2010, VALUE HEALTH, V13, P557, DOI 10.1111/j.1524-4733.2010.00709.x; Bojke L, 2009, VALUE HEALTH, V12, P739, DOI 10.1111/j.1524-4733.2008.00502.x; Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003; Briggs AH, 2012, MED DECIS MAKING, V32, P722, DOI 10.1177/0272989X12458348; Claxton K, 2008, PHARMACOECONOMICS, V26, P781, DOI 10.2165/00019053-200826090-00008; Eddy DM, 2012, MED DECIS MAKING, V32, P733, DOI 10.1177/0272989X12454579; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Ghabri S, 2018, PHARMACOECONOMICS, V36, P127, DOI 10.1007/s40273-017-0603-4; Ghabri S, 2016, PHARMACOECONOMICS, V34, P617, DOI 10.1007/s40273-016-0381-4; Greving JP, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1672; Grigore B, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0527-0; Grimm SE, 2020, PHARMACOECONOMICS, V38, P205, DOI 10.1007/s40273-019-00855-9; Grimm SE, 2017, PHARMACOECONOMICS, V35, P1287, DOI 10.1007/s40273-017-0562-9; Grutters JPC, 2015, PHARMACOECONOMICS, V33, P1, DOI 10.1007/s40273-014-0201-7; Harremoes P., 2003, INTEGR ASSESS, V4, P5, DOI DOI 10.1076/IAIJ.4.1.5.16466; Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002; Iglesias CP, 2016, PHARMACOECONOMICS, V34, P1161, DOI 10.1007/s40273-016-0425-9; Knol AB, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-19; Kunst N, 2020, VALUE HEALTH, V23, P734, DOI 10.1016/j.jval.2020.02.010; National Institute for Health and Care Excellence, 2013, GUID METH TECHN APPR; O'Hagan A, 2004, RELIAB ENG SYST SAFE, V85, P239, DOI 10.1016/j.ress.2004.03.014; O'Leary RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141697; Oostenbrink JB, 2001, J VASC SURG, V34, P254, DOI 10.1067/mva.2001.115961; Petersohn S, 2020, EUR J PREV CARDIOL, V27, P1354, DOI 10.1177/2047487320913380; Petersohn S, 2019, QUAL LIFE RES, V28, P2257, DOI 10.1007/s11136-019-02166-0; Rothery C, 2020, VALUE HEALTH, V23, P277, DOI 10.1016/j.jval.2020.01.004; Sampson CJ, 2017, PHARMACOECON-OPEN, V1, P73, DOI 10.1007/s41669-017-0019-2; Soares MO, 2020, MED DECIS MAKING, V40, P448, DOI 10.1177/0272989X20916450; Soares MO, 2018, VALUE HEALTH, V21, P715, DOI 10.1016/j.jval.2018.01.019; Spiegelhalter D.J., 2004, BAYESIAN APPROACHES, VVolume 13; Spronk S, 2008, J VASC SURG, V48, P1472, DOI 10.1016/j.jvs.2008.06.016; Strong M, 2014, MED DECIS MAKING, V34, P311, DOI 10.1177/0272989X13505910; Strong M, 2012, J R STAT SOC C-APPL, V61, P25, DOI 10.1111/j.1467-9876.2011.01014.x; Sullivan PW, 2011, MED DECIS MAKING, V31, P800, DOI 10.1177/0272989X11401031; van Asselt ADI, 2011, EUR J VASC ENDOVASC, V41, P97, DOI 10.1016/j.ejvs.2010.06.024; van Hout BA, 2001, EUR HEART J, V22, P751, DOI 10.1053/euhj.2000.2308; van Stel HF, 2012, VALUE HEALTH, V15, P175, DOI 10.1016/j.jval.2011.09.004; Willan AR, 2010, HEALTH ECON, V19, P549, DOI 10.1002/hec.1493	43	3	3	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUL	2021	24	7					983	994		10.1016/j.jval.2021.01.004		JUL 2021	12	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TE7UB	34243842	hybrid			2022-04-28	WOS:000670212100009
J	Keeney, E; Welton, NJ; Stevenson, M; Dalili, MN; Lopez-Lopez, JA; Caldwell, DM; Phillippo, DM; Munafo, MR; Thomas, KH				Keeney, Edna; Welton, Nicky J.; Stevenson, Matt; Dalili, Michael N.; Lopez-Lopez, Jose A.; Caldwell, Deborah M.; Phillippo, David M.; Munafo, Marcus R.; Thomas, Kyla H.			Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events	VALUE IN HEALTH			English	Article						cost-effectiveness; economic model; smoking cessation; value of information	NICOTINE-REPLACEMENT THERAPY; UNAIDED CESSATION; VARENICLINE; UTILITY; BUPROPION; HEALTH; STRATEGIES; RELAPSE; COHORT; MODEL	Objectives: Smoking is a leading cause of death worldwide. Cessation aids include varenicline, bupropion, nicotine replacement therapy (NRT), and e-cigarettes at various doses (low, standard and high) and used alone or in combination with each other. Previous cost-effectiveness analyses have not fully accounted for adverse effects nor compared all cessation aids. The objective was to determine the relative cost-effectiveness of cessation aids in the United Kingdom. Methods: An established Markov cohort model was adapted to incorporate health outcomes and costs due to depression and self-harm associated with cessation aids, alongside other health events. Relative efficacy in terms of abstinence and major adverse neuropsychiatric events was informed by a systematic review and network meta-analysis. Base case results are reported for UK-licensed interventions only. Two sensitivity analyses are reported, one including unlicensed interventions and another comparing all cessation aids but removing the impact of depression and self-harm. The sensitivity of conclusions to model inputs was assessed by calculating the expected value of partial perfect information. Results: When limited to UK-licensed interventions, varenicline standard-dose and NRT standard-dose were most costeffective. Including unlicensed interventions, e-cigarette low-dose appeared most cost-effective followed by varenicline standard-dose + bupropion standard-dose combined. When the impact of depression and self-harm was excluded, varenicline standard-dose + NRT standard-dose was most cost-effective, followed by varenicline low-dose + NRT standard-dose. Conclusion: Although found to be most cost-effective, combined therapy is currently unlicensed in the United Kingdom and the safety of e-cigarettes remains uncertain. The value-of-information analysis suggested researchers should continue to investigate the long-term effectiveness and safety outcomes of e-cigarettes in studies with active comparators.	[Keeney, Edna; Welton, Nicky J.; Dalili, Michael N.; Lopez-Lopez, Jose A.; Caldwell, Deborah M.; Phillippo, David M.; Thomas, Kyla H.] Univ Bristol, Populat Hlth Sci, Bristol Med Sch, Bristol, Avon, England; [Stevenson, Matt] Univ Sheffield, Hlth Econ & Decis Sci, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Munafo, Marcus R.] Univ Bristol, Sch Psychol Sci, Bristol, Avon, England; [Munafo, Marcus R.] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Lopez-Lopez, Jose A.] Univ Murcia, Dept Basic Psychol & Methodol, Fac Psychol, Murcia, Spain		Keeney, E (通讯作者)，Univ Bristol, 1-5 Whiteladies Rd, Bristol BS8 1NU, Avon, England.	edna.keeney@bristol.ac.uk	Munafo, Marcus/AAE-2306-2020	Munafo, Marcus/0000-0002-4049-993X; , Deborah/0000-0001-8014-7480; Dalili, Michael/0000-0002-6687-5374; Welton, Nicky/0000-0003-2198-3205; Thomas, Kyla/0000-0001-5418-4034	National Institute for Health Research Health Technology Assessment ProgrammeNational Institute for Health Research (NIHR) [NIHR HTA 15/58/18]	This project presents independent research that was funded by the National Institute for Health Research Health Technology Assessment Programme (project number NIHR HTA 15/58/18).	Action on Smoking and Health, 2017, EC TOBACCO; Action on Smoking and Health, 2018, USE E CIGARETTES VAP; Allender S, 2009, TOB CONTROL, V18, P262, DOI 10.1136/tc.2008.026294; Annemans L, 2009, CLIN DRUG INVEST, V29, P655, DOI 10.2165/11317730-000000000-00000; Anthenelli RM, 2016, LANCET, V387, P2507, DOI 10.1016/S0140-6736(16)30272-0; Ara R, 2010, VALUE HEALTH, V13, P509, DOI 10.1111/j.1524-4733.2010.00700.x; Athanasakis K, 2012, CLIN THER, V34, P1803, DOI 10.1016/j.clinthera.2012.07.002; Bae JY, 2009, VALUE HEALTH, V12, pS70, DOI 10.1111/j.1524-4733.2009.00631.x; Bertranou E, 2018, J MED ECON, V21, P113, DOI 10.1080/13696998.2017.1377718; Bolin K, 2008, RESP MED, V102, P699, DOI 10.1016/j.rmed.2007.12.018; Bolin K, 2009, EUR J PUBLIC HEALTH, V19, P650, DOI 10.1093/eurpub/ckp075; Bolin K, 2009, J EVAL CLIN PRACT, V15, P478, DOI 10.1111/j.1365-2753.2008.01045.x; Briggs A, 2006, DECISION MODELLING H; British Heart Foundation, 2014, CVD STAT; Byford S, 2003, PSYCHOL MED, V33, P977, DOI 10.1017/S0033291703008183; Cassino C, 1999, AM J RESP CRIT CARE, V159, P1773, DOI 10.1164/ajrccm.159.6.9809042; Claxton K, 1996, HEALTH ECON, V5, P513, DOI 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9; Customs HR, 2019, MONTHLY EXCHANGE RAT; Earnshaw J, 2008, NICE GUIDE METHODS T; Epstein D, 2019, HEALTH ECON, V28, P801, DOI 10.1002/hec.3884; European Medicines Agency (EMA), 2016, CHAMP PROC STEPS TAK; Haacke C, 2006, STROKE, V37, P193, DOI 10.1161/01.STR.0000196990.69412.fb; Hawkins J, 2010, NICOTINE TOB RES, V12, P1228, DOI 10.1093/ntr/ntq175; Health Information and Quality Authority, 2017, HLTH TECHNOLOGY ASSE; HIQA, 2017, HLTH TECHNOLOGY ASSE; Hoogendoorn M, 2008, CURR MED RES OPIN, V24, P51, DOI 10.1185/030079907X242917; Howard P, 2008, PHARMACOECONOMICS, V26, P497, DOI 10.2165/00019053-200826060-00004; Hunter RM, 2014, PSYCHOL MED, V44, P1381, DOI 10.1017/S0033291713002067; Jha P, 2014, NEW ENGL J MED, V370, P60, DOI 10.1056/NEJMra1308383; Knight C, 2010, VALUE HEALTH, V13, P209, DOI 10.1111/j.1524-4733.2009.00672.x; Kotz D, 2015, LANCET RESP MED, V3, P761, DOI 10.1016/S2213-2600(15)00320-3; Krall Elizabeth A, 2002, Nicotine Tob Res, V4, P95, DOI 10.1080/14622200110098428; Leaviss J, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18330; Li JS, 2020, ADDICTION, V115, P507, DOI 10.1111/add.14829; Linden K, 2010, CURR MED RES OPIN, V26, P549, DOI 10.1185/03007990903542666; Lloyd Andrew, 2007, Prim Care Respir J, V16, P22, DOI 10.3132/pcrj.2007.00002; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Medicines and Healthcare products Regulatory Agency, 2008, DRUG SAF UPDATE, V2, P2; National Institute for Health and Clinical Excellence, 2018, NICE GUID NG92 STOP; NHS D, 2017, STAT SMOKING ENGLAND; NHS Digital, 2019, STAT SMOK ENGL 2019; NICE, 2013, GUID METH TECHN APPR; Office for National Statistics (ONS), 2017, POPULATION ESTIMATES; ONS, 2016, DEATHS SINGLE YEAR A; Orme ME, 2001, TOB CONTROL, V10, P55, DOI 10.1136/tc.10.1.55; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Pickard AS, 2008, RESP MED, V102, P519, DOI 10.1016/j.rmed.2007.11.016; Public Health England, 2017, COST SMOK NHS ENG EN; Rasmussen CE, 2004, LECT NOTES ARTIF INT, V3176, P63, DOI 10.1007/978-3-540-28650-9_4; Sheffield Uo, 2015, ACCEL VAL INF REL VE; Stevanovic J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152030; Taylor GMJ, 2020, NICOTINE TOB RES, V22, P48, DOI 10.1093/ntr/ntz072; Taylor GMJ, 2017, INT J EPIDEMIOL, V46, P1948, DOI 10.1093/ije/dyx109; Thomas KH DM, IN PRESS; Unrod M, 2016, NICOTINE TOB RES, V18, P298, DOI 10.1093/ntr/ntv079; US Food and Drug Administration, 2009, FDA DRUG SAFETY NEWS, V2; US Food and Drug Administration, FDA DRUG SAFETY COMM; Vemer P, 2010, VALUE HEALTH, V13, P230, DOI 10.1111/j.1524-4733.2009.00612.x; von Wartburg M, 2014, INT J CLIN PRACT, V68, P639, DOI 10.1111/ijcp.12363; Xu XM, 2018, EUR STROKE J, V3, P82, DOI 10.1177/2396987317746516	60	1	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24	6					780	788		10.1016/j.jval.2020.12.012		JUN 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SP8AF	34119075	Green Published, Green Accepted, hybrid			2022-04-28	WOS:000659884900005
J	Aggarwal, S; Kumar, S; Bela, A; Topaloglu, H				Aggarwal, S.; Kumar, S.; Bela, A.; Topaloglu, H.			HOSPITAL LENGTH OF STAY, TOTAL COSTS AND COMORBIDITIES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE	VALUE IN HEALTH			English	Meeting Abstract									[Aggarwal, S.; Bela, A.; Topaloglu, H.] NOVEL Hlth Strategies, Chevy Chase, MD USA; [Kumar, S.] NOVEL HLTH STRATEGIES, Columbia, MD USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO22	S201	S201					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401142
J	Arora, P; Ha, J; Mehta, D				Arora, P.; Ha, J.; Mehta, D.			IMPACT OF TELEHEALTH UTILIZATION DURING THE COVID-19 PANDEMIC ON HEALTH CARE RESOURCE UTILIZATION	VALUE IN HEALTH			English	Meeting Abstract									[Arora, P.; Ha, J.] Butler Univ, Indianapolis, IN 46208 USA; [Mehta, D.] Sunovion Pharmaceut Inc, Waltham, MA USA									0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU5	S145	S145					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400633
J	Berdunov, V; Sammon, C; Ramagopalan, S				Berdunov, V; Sammon, C.; Ramagopalan, S.			RECOMMENDATIONS FOR HANDLING UNCERTAINTY IN ECONOMIC EVALUATION: A TARGETED REVIEW OF PHARMACOECONOMIC GUIDELINES	VALUE IN HEALTH			English	Meeting Abstract									[Berdunov, V; Sammon, C.] PHMR Ltd, London, England; [Ramagopalan, S.] F Hoffmann La Roche, Basel, BS, Switzerland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		EM4	S7	S8					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400029
J	Challagulla, S; Lee, P; Kistler, K; Douyon, L; Lai, D; Iyengar, R				Challagulla, S.; Lee, P.; Kistler, K.; Douyon, L.; Lai, D.; Iyengar, R.			REAL-WORLD ECONOMIC OUTCOMES OF FIRST-LINE (1L) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)	VALUE IN HEALTH			English	Meeting Abstract									[Challagulla, S.] Pharmacyclics LLC, Fremont, CA USA; [Lee, P.; Lai, D.; Iyengar, R.] Pharmacyclics LLC, Sunnyvale, CA USA; [Kistler, K.; Douyon, L.] Xcenda, Palm Harbor, FL USA									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN101	S38	S38					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400159
J	Chen, Y; Carlson, J				Chen, Y.; Carlson, J.			PERFORMANCE-BASED RISK-SHARING ARRANGEMENTS IN DIAGNOSTICS AND DEVICES IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Chen, Y.; Carlson, J.] Univ Washington, Seattle, WA 98195 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		RE1	S238	S238					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401305
J	Clarke, CA; Kurian, A; Hubbell, E; Gomez, S				Clarke, C. A.; Kurian, A.; Hubbell, E.; Gomez, S.			POTENTIAL FOR EARLIER CANCER DIAGNOSIS TO REDUCE CANCER DEATHS:DIFFERENCES BY SEX AND RACE/ETHNICITY	VALUE IN HEALTH			English	Meeting Abstract									[Clarke, C. A.; Hubbell, E.] GRAIL Inc, Menlo Pk, CA USA; [Kurian, A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Gomez, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN124	S42	S42					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400176
J	Cook, S; Loos, AM; Tan, R; Tennant, L				Cook, S.; Loos, A. M.; Tan, R.; Tennant, L.			THE EVOLUTION OF PAYER PERCEPTIONS OF ICER	VALUE IN HEALTH			English	Meeting Abstract									[Cook, S.] Xcenda LLC, Clearwater, FL USA; [Loos, A. M.; Tennant, L.] Xcenda LLC, Palm Harbor, FL USA; [Tan, R.] Xcenda LLC, San Diego, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS75	S186	S186					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401076
J	Forma, F; Chiu, K; Boskovic, DH; Shafrin, J; Veeranki, P				Forma, F.; Chiu, K.; Boskovic, Hadzi D.; Shafrin, J.; Veeranki, P.			DIGITAL HEALTH TOOLS TO MONITOR MEDICATION ADHERENCE AMONG BIPOLAR DISORDER, MAJOR DEPRESSIVE DISORDER AND SCHIZOPHRENIA	VALUE IN HEALTH			English	Meeting Abstract									[Forma, F.; Boskovic, Hadzi D.] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA; [Chiu, K.; Shafrin, J.] PRECISIONheor, Los Angeles, CA USA; [Veeranki, P.] PRECISIONheor, Cypress, TX USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH34	S133	S134					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400583
J	Forsythe, A; Pick, C; Sandman, K				Forsythe, A.; Pick, C.; Sandman, K.			THE HUMANISTIC AND ECONOMIC COSTS OF CONVERSION THERAPY: A SYSTEMATIC LITERATURE REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Forsythe, A.; Sandman, K.] Purple Squirrel Econ, New York, NY USA; [Pick, C.] Trevor Project, West Hollywood, CA USA									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS30	S177	S177					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401034
J	Granger, E; Daral, S; Van Caster, K; Chopra, A; Tibrewal, A; Owens, G				Granger, E.; Daral, S.; Van Caster, K.; Chopra, A.; Tibrewal, A.; Owens, G.			THE USE OF NALOXONE IN OPIOID OVERDOSE AND OVERDOSE AT-RISK POPULATIONS: A RETROSPECTIVE MEDICAL CLAIMS ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Granger, E.] THE 5Ps LLC, Centennial, CO USA; [Daral, S.; Chopra, A.; Tibrewal, A.] Optum India, Gurugram, Haryana, India; [Van Caster, K.] Optum Lifesci, Eden Prairie, MN USA; [Owens, G.] Emergent Biosolut, Hilton Head Isl, SC USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH22	S131	S132					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400575
J	Graves, E; Gerber, B; Shaw, E; Mayer, M; Cowling, T; Bougie, JK; Ladouceur, MP				Graves, E.; Gerber, B.; Shaw, E.; Mayer, M.; Cowling, T.; Bougie, J. K.; Ladouceur, M. P.			EPIDEMIOLOGY, TREATMENT LANDSCAPE, AND HEALTHCARE UTILIZATION FOR PATIENTS WITH MIGRAINE IN CANADA: A LITERATURE REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Graves, E.; Gerber, B.; Shaw, E.; Mayer, M.; Cowling, T.] Medlior Hlth Outcomes Res Ltd, Calgary, AB, Canada; [Bougie, J. K.; Ladouceur, M. P.] Lundbeck Canada, Montreal, PQ, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND45	S167	S167					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400729
J	Green, J; Williamson, N; Bradley, H; Barclay, M; Sims, J; Arbuckle, R; Patalano, F; Spera, C; Viriato, D; Naujoks, C; Banhazi, J				Green, J.; Williamson, N.; Bradley, H.; Barclay, M.; Sims, J.; Arbuckle, R.; Patalano, F.; Spera, C.; Viriato, D.; Naujoks, C.; Banhazi, J.			QUALITATIVE EXPLORATION OF PATIENT EXPERIENCES OF VISUAL FUNCTION IMPAIRMENTS AND HEALTH-RELATED QUALITY OF LIFE IMPACTS ASSOCIATED WITH RLBP1 RETINITIS PIGMENTOSA IN A SAMPLE OF CANADIAN PATIENTS	VALUE IN HEALTH			English	Meeting Abstract									[Green, J.] Mem Univ Newfoundland, St John, NF, Canada; [Williamson, N.; Bradley, H.; Barclay, M.; Sims, J.; Arbuckle, R.] Adelphi Values Ltd, Bollington, Cheshire, England; [Patalano, F.; Spera, C.; Viriato, D.] Novartis Pharma AG, Basel, Switzerland; [Naujoks, C.; Banhazi, J.] Novartis Pharma AG, Basel, Bs, Switzerland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSS14	S222	S223					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401238
J	Guzauskas, G; Carlson, J; Dann, R; Ramsey, S				Guzauskas, G.; Carlson, J.; Dann, R.; Ramsey, S.			BUDGET IMPACT OF THE DIVITUM (R) TKA ASSAY IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER	VALUE IN HEALTH			English	Meeting Abstract									[Guzauskas, G.; Carlson, J.; Ramsey, S.] Univ Washington, Seattle, WA 98195 USA; [Dann, R.] Biovica Int AB, Boston, MA USA; [Ramsey, S.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA									0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN190	S55	S55					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400236
J	Hildreth, C; Infante, K; Eslami, N; Garfield, S				Hildreth, C.; Infante, K.; Eslami, N.; Garfield, S.			HOW US CLINICAL TRIALS ARE BEING REIMAGINED IN A COVID-19 WORLD	VALUE IN HEALTH			English	Meeting Abstract									[Hildreth, C.; Infante, K.] Ernst & Young, New York, NY USA; [Eslami, N.] Ernst & Young, Malden, MA USA; [Garfield, S.] Ernst & Young, Wayland, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS86	S188	S188					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401085
J	Iloanusi, NJR; Iloanusi, S; Mgbere, O; Ajayi, AI; Essien, EJ				Iloanusi, N. J. R.; Iloanusi, S.; Mgbere, O.; Ajayi, A., I; Essien, E. J.			COVID-19 RELATED KNOWLEDGE, ATTITUDE AND PRACTICES IN A SOUTHEASTERN CITY IN NIGERIA: A CROSS-SECTIONAL SURVEY	VALUE IN HEALTH			English	Meeting Abstract									[Iloanusi, N. J. R.] Gen Hosp, Onitsha, Anambra State, Nigeria; [Iloanusi, S.; Mgbere, O.; Essien, E. J.] Univ Houston, Houston, TX USA; [Ajayi, A., I] African Populat & Hlth Res Ctr, Populat Dynam & Sexual & Reprod Hlth & Rights Uni, APHRC Campus, Nairobi, Kenya				Mgbere, Osaro/O-2702-2018	Mgbere, Osaro/0000-0002-2863-6284				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN34	S111	S112					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400487
J	Jiao, B; Gulati, R; Hendrix, N; Gore, JL; Rais-Bahrami, S; Tosoian, JJ; Kattan, MW; Morgan, TM; Etzioni, R				Jiao, B.; Gulati, R.; Hendrix, N.; Gore, J. L.; Rais-Bahrami, S.; Tosoian, J. J.; Kattan, M. W.; Morgan, T. M.; Etzioni, R.			COMPARATIVE EFFECTIVENESS AND COST-EFFECTIVENESS OF REFLEX TESTING MEN WITH INTERMEDIATE PSA LEVELS: A SYSTEMATIC MODEL-BASED ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Jiao, B.; Gore, J. L.] Univ Washington, Seattle, WA 98195 USA; [Gulati, R.; Etzioni, R.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Hendrix, N.] Harvard Univ, Boston, MA 02115 USA; [Rais-Bahrami, S.] Univ Alabama Birmingham, Birmingham, AL USA; [Tosoian, J. J.; Morgan, T. M.] Univ Michigan, Ann Arbor, MI 48109 USA; [Kattan, M. W.] Cleveland Clin, Cleveland, OH 44106 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN166	S50	S50					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400216
J	Kim, V; Lodaya, K; Marinaro, X; Zhang, X; Hayashida, DK; Munson, S; D'Souza, F				Kim, V; Lodaya, K.; Marinaro, X.; Zhang, X.; Hayashida, D. K.; Munson, S.; D'Souza, F.			INVESTIGATING LENGTH OF STAY IN GASTROINTESTINAL PATIENT SURGICAL CLUSTERS IN THE NATIONAL INPATIENT SAMPLE WITH MACHINE LEARNING	VALUE IN HEALTH			English	Meeting Abstract									[Kim, V] Winchester Hosp, Winchester, MA USA; [Lodaya, K.; Marinaro, X.; Zhang, X.; Hayashida, D. K.; Munson, S.; D'Souza, F.] Boston Strateg Partners Inc, Boston, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PGI28	S99	S99					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400431
J	Kotschevar, C; Gabriel, M; Mastrangelo, V; Campbell, P				Kotschevar, C.; Gabriel, M.; Mastrangelo, V; Campbell, P.			SPECIALTY PHARMACY TURNAROUND TIME: IMPEDIMENTS, FACILITATORS, AND BEST PRACTICES	VALUE IN HEALTH			English	Meeting Abstract									[Kotschevar, C.; Mastrangelo, V; Campbell, P.] Pharm Qual Alliance, Alexandria, VA USA; [Gabriel, M.] Pharm Qual Alliance, Winter Springs, FL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG29	S92	S92					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400400
J	Macaulay, R				Macaulay, R.			IMPACT OF COVID ON HEALTH TECHNOLOGY ASSESSMENT BODIES	VALUE IN HEALTH			English	Meeting Abstract									[Macaulay, R.] Precis Advisors, London, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS78	S187	S187					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401079
J	Mills, K; Nowak, C; Choong, C; Shan, M; Hoyt, M; Hunter, T				Mills, K.; Nowak, C.; Choong, C.; Shan, M.; Hoyt, M.; Hunter, T.			TRENDS IN DIAGNOSTIC PREVALENCE, TREATMENT PATTERNS, AND HEALTHCARE RESOURCE UTILIZATION OF PEDIATRIC FOOD ALLERGY PATIENTS IN THE UNITED STATES, 2008-2018	VALUE IN HEALTH			English	Meeting Abstract									[Mills, K.] Eli Lilly & Co, Ramsey, MN USA; [Nowak, C.; Choong, C.; Shan, M.; Hoyt, M.; Hunter, T.] Eli Lilly & Co, Indianapolis, IN 46285 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		SC2	S240	S240					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401314
J	Molaei, M; Crawford, A; Schubert, P; Goldfarb, N; Silberstein, SD				Molaei, M.; Crawford, A.; Schubert, P.; Goldfarb, N.; Silberstein, S. D.			ECONOMIC IMPACT OF COMORBIDITIES IN AN EMPLOYER-INSURED MIGRAINE POPULATION	VALUE IN HEALTH			English	Meeting Abstract									[Molaei, M.] Thomas Jefferson Univ, Conshohocken, PA USA; [Crawford, A.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Schubert, P.] Gallagher Benefit Serv, Wayne, PA USA; [Goldfarb, N.] Greater Philadelphia Business Coalit Hlth, Philadelphia, PA USA; [Silberstein, S. D.] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU13	S147	S147					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400641
J	Nash, C; Duttagupta, S; Cheung, ZLH				Nash, C.; Duttagupta, S.; Cheung, Z. L. H.			INFLUENCE OF PATIENT POPULATION & HTA ASSESSMENT ON PRICE EROSION DUE TO INDICATION EXPANSION IN EUROPE: EVALUATION ACROSS ONCOLOGY & NON-ONCOLOGY BIOPHARMACEUTICAL INNOVATIONS	VALUE IN HEALTH			English	Meeting Abstract									[Nash, C.; Duttagupta, S.; Cheung, Z. L. H.] Decis Resources Grp, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU37	S150	S151					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400656
J	Paul, A; Abulannaz, O; Chhabra, M; Le, ML; Kelly, LE				Paul, A.; Abulannaz, O.; Chhabra, M.; Le, M. L.; Kelly, L. E.			DOSING AND SAFETY OF MEDICAL CANNABIS IN CHILDREN: PRELIMINARY FINDINGS FROM A LIVING SYSTEMATIC REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Paul, A.; Abulannaz, O.; Chhabra, M.; Le, M. L.; Kelly, L. E.] Univ Manitoba, Winnipeg, MB, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH19	S102	S102					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400445
J	Piniazhko, O; Masheiko, A; Serediuk, V; Kovtun, L; Babenko, M; Honchar, Y; Hrytsenko, O; Komarida, O; Ivashchenko, I; Kahveci, R; Voitenko, A				Piniazhko, O.; Masheiko, A.; Serediuk, V; Kovtun, L.; Babenko, M.; Honchar, Y.; Hrytsenko, O.; Komarida, O.; Ivashchenko, I.; Kahveci, R.; Voitenko, A.			MILESTONES FOR HTA INSTITUTIONALIZATION IN UKRAINE DUE TO INTERNATIONAL PRACTICE	VALUE IN HEALTH			English	Meeting Abstract									[Piniazhko, O.; Masheiko, A.; Serediuk, V; Kovtun, L.; Babenko, M.] Minist Hlth Ukraine, State Expert Ctr, Kiev, Ukraine; [Honchar, Y.; Hrytsenko, O.; Komarida, O.; Ivashchenko, I.] Minist Hlth Ukraine, Kiev, Ukraine; [Kahveci, R.; Voitenko, A.] Management Sci Hlth, USAIDs SAFEMed, Kiev, Ukraine									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS79	S187	S187					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401080
J	Qin, M; Cao, W; Zheng, L; Chen, X; Wang, X				Qin, M.; Cao, W.; Zheng, L.; Chen, X.; Wang, X.			COST COMPARISON BETWEEN LEUPROLIDE 3-MONTH FORMULATION AND OTHER GONADOTROPIN-RELEASING HORMONE AGONISTS AS THERAPY FOR CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY IN CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Qin, M.; Cao, W.; Wang, X.] Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Beijing, Peoples R China; [Zheng, L.; Chen, X.] Takeda China, Shanghai 31, Peoples R China									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH10	S101	S101					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400438
J	Rane, A; Pohlman, S				Rane, A.; Pohlman, S.			CONTRAST ENHANCED MAMMOGRAPHY (CEM) VS CONTRAST ENHANCED BREAST MRI AS A PREOPERATIVE STAGING EXAM IN WOMEN WITH NEWLY DIAGNOSED BREAST CANCER: A BUDGET IMPACT ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Rane, A.; Pohlman, S.] Hologic Inc, Marlborough, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN56	S29	S29					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400119
J	Ratto, B; Das, J; Kalra, M; Banerjee, H				Ratto, B.; Das, J.; Kalra, M.; Banerjee, H.			COMPARATIVE EFFICACY OF COMBINATION OF DABRAFENIB AND TRAMETINIB AGAINST OTHER ADJUVANT THERAPIES FOR MELANOMA	VALUE IN HEALTH			English	Meeting Abstract									[Ratto, B.; Banerjee, H.] Novartis Pharmaceut, New Jersey, NJ USA; [Das, J.; Kalra, M.] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN32	S24	S24					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400096
J	Roman, GA; Rojas, W; Ribon, GG; Reyes, SJM; Castano, GN				Roman, Gonzalez A.; Rojas, W.; Ribon, G. G.; Reyes, Sanchez J. M.; Castano, Gamboa N.			BUDGET IMPACT ANALYSIS OF PEGVISOMANT IN THE TREATMENT ACROMEGALY IN COLOMBIA	VALUE IN HEALTH			English	Meeting Abstract									[Roman, Gonzalez A.] Hosp Univ San Vicente Fdn, Dept Endocrinol, Medellin, Colombia; [Rojas, W.] Fdn Santa Fe Bogota, Dept Endocrinol, Bogota, Colombia; [Ribon, G. G.; Reyes, Sanchez J. M.; Castano, Gamboa N.] Pfizer SAS, Bogota, Cun, Colombia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO27	S202	S202					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401147
J	Ruzich, E; Meyers, O				Ruzich, E.; Meyers, O.			ASSESSING THE READABILITY OF PATIENT-REPORTED OUTCOME MEASURES IN TRIALS FOR DRUGS WITH RECENT FDA APPROVAL	VALUE IN HEALTH			English	Meeting Abstract									[Ruzich, E.] IQVIA, Cambridge, MA USA; [Meyers, O.] IQVIA, Beachwood, OH USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU60	S155	S155					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400675
J	Semenov, O; Zaliska, O; Maksymovych, N; Huz, V; Zabolotnya, Z				Semenov, O.; Zaliska, O.; Maksymovych, N.; Huz, V; Zabolotnya, Z.			SURVEY OF THE AWARENESS OF PHARMACISTS ABOUT QUARANTINE MEASURES DURING THE COVID-19 PANDEMIC	VALUE IN HEALTH			English	Meeting Abstract									[Semenov, O.; Zaliska, O.; Maksymovych, N.; Huz, V; Zabolotnya, Z.] Danylo Halytsky Lviv Natl Med Univ, Lvov, Ukraine				Zaliska, Olha/AAN-6078-2020	Zaliska, Olha/0000-0003-1845-7909				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS56	S183	S183					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401059
J	Shamseddine, N; DeBoer, E; Chirikov, V; Shah, P; Poirier, I; Potenziano, J				Shamseddine, N.; DeBoer, E.; Chirikov, V; Shah, P.; Poirier, I; Potenziano, J.			THE ECONOMIC BURDEN OF OUT-OF-HOSPITAL CARDIAC ARREST INCREASES WITH SEVERITY OF PROGNOSIS AMONG US MEDICARE OLDER ADULTS (2017-2019)	VALUE IN HEALTH			English	Meeting Abstract									[Shamseddine, N.; DeBoer, E.; Poirier, I; Potenziano, J.] Mallinckrodt Pharmaceut, Bedminster, NJ USA; [Chirikov, V; Shah, P.] Pharmerit Int, Bethesda, MD USA									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV12	S68	S68					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400299
J	Shcherbakova, N; Hong, M; Tereso, G				Shcherbakova, N.; Hong, M.; Tereso, G.			TEN YEAR TRENDS IN HIGH COST OUTPATIENT PHARMACY CLAIMS AMONG COMMERCIALLY INSURED US POPULATION BY THERAPEUTIC CATEGORY AND DATE OF INITIAL APPROVAL	VALUE IN HEALTH			English	Meeting Abstract									[Shcherbakova, N.] Western New England Univ, Coll Pharm & Hlth Sci, Agawam, MA USA; [Hong, M.] Western New England Univ, Coll Pharm & Hlth Sci, Springfield, MA USA; [Tereso, G.] Hlth New England, Springfield, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS114	S193	S193					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401108
J	Shukla, S; Shah, D; Martin, A; Risebrough, NA; Kendall, R; Vogelmeier, CF; Boucot, I; Tombs, L; Bjermer, L; Jones, P; Kerwin, E; Compton, C; Maltais, F; Lipson, D; Ismaila, A				Shukla, S.; Shah, D.; Martin, A.; Risebrough, N. A.; Kendall, R.; Vogelmeier, C. F.; Boucot, I; Tombs, L.; Bjermer, L.; Jones, P.; Kerwin, E.; Compton, C.; Maltais, F.; Lipson, D.; Ismaila, A.			ECONOMIC EVALUATION OF UMECLIDINIUM/VILANTEROL VERSUS UMECLIDINIUM OR SALMETEROL IN A UK COPD POPULATION AT LOW RISK OF EXACERBATIONS USING THE GALAXY MODEL	VALUE IN HEALTH			English	Meeting Abstract									[Shukla, S.] GSK, Paramus, NJ USA; [Shah, D.] ICON Plc, New York, NY USA; [Martin, A.; Boucot, I; Tombs, L.; Jones, P.; Compton, C.] GSK, Brentford, Middx, England; [Risebrough, N. A.] ICON, Toronto, ON, Canada; [Kendall, R.] ICON Plc, Toronto, ON, Canada; [Vogelmeier, C. F.] Philipps Univ Marburg, Marburg, Germany; [Bjermer, L.] Lund Univ, Lund, Sweden; [Kerwin, E.] Clin Res Inst, Medford, OR USA; [Kerwin, E.] Altitude Clin Consulting, Medford, OR USA; [Maltais, F.] Univ Laval, Quebec City, PQ, Canada; [Lipson, D.; Ismaila, A.] GSK, Collegeville, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRS10	S214	S214					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401201
J	Sieluk, J; Haiderali, A; Huang, M; Hirshfield, K; Signorovitch, J; Song, Y; Freimark, J; Wang, T				Sieluk, J.; Haiderali, A.; Huang, M.; Hirshfield, K.; Signorovitch, J.; Song, Y.; Freimark, J.; Wang, T.			PRODUCTIVITY COSTS ASSOCIATED WITH DISEASE RECURRENCE AMONG SURGICALLY-TREATED PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER	VALUE IN HEALTH			English	Meeting Abstract									[Sieluk, J.; Haiderali, A.; Huang, M.; Hirshfield, K.] Merck & Co Inc, Kenilworth, NJ USA; [Signorovitch, J.; Song, Y.; Freimark, J.; Wang, T.] Anal Grp, Boston, MA USA									0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN248	S66	S66					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400289
J	Singh, A; Campbell, J; Venn, A; Jones, G; Blizzard, L; Palmer, A; Dwyer, T; Cicuttini, F; Ding, C; Antony, B				Singh, A.; Campbell, J.; Venn, A.; Jones, G.; Blizzard, L.; Palmer, A.; Dwyer, T.; Cicuttini, F.; Ding, C.; Antony, B.			ASSOCIATION BETWEEN KNEE SYMPTOMS, CHANGE IN KNEE SYMPTOMS OVER 6-9 YEARS AND SF-6D HEALTH STATE UTILITY AMONG MIDDLE-AGED AUSTRALIANS	VALUE IN HEALTH			English	Meeting Abstract									[Singh, A.; Campbell, J.; Venn, A.; Jones, G.; Blizzard, L.; Palmer, A.; Ding, C.; Antony, B.] Univ Tasmania, Hobart, Tas, Australia; [Dwyer, T.] Univ Oxford, Oxford, England; [Cicuttini, F.] Monash Univ, Clayton, Vic, Australia				Singh, Ambrish/W-2163-2017	Singh, Ambrish/0000-0002-4618-7507				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMS6	S139	S139					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400606
J	Singh, S; Hoch, JS; Hearps, SJC; Dalziel, K; Cheek, JA; Holmes, JF; Anderson, V; Babl, FE; Kuppermann, N				Singh, S.; Hoch, J. S.; Hearps, S. J. C.; Dalziel, K.; Cheek, J. A.; Holmes, J. F.; Anderson, V; Babl, F. E.; Kuppermann, N.			ACUTE CARE COSTS OF PEDIATRIC SPORTS-RELATED HEAD INJURIES IN AUSTRALIA: THE AUSTRALASIAN PAEDIATRIC HEAD INJURY STUDY (APHIRST)	VALUE IN HEALTH			English	Meeting Abstract									[Singh, S.] Univ Melbourne, Sacramento, CA USA; [Hoch, J. S.] Univ Calif Davis, Sacramento, CA 95817 USA; [Hearps, S. J. C.; Anderson, V] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Dalziel, K.; Babl, F. E.] Univ Melbourne, Melbourne, Vic, Australia; [Cheek, J. A.] Royal Childrens Hosp, Parkville, Vic, Australia; [Holmes, J. F.; Kuppermann, N.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIT2	S122	S122					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400533
J	Skroumpelos, A; Freddi, M; Akcicek, H; Cohen, JM; Driessen, MT				Skroumpelos, A.; Freddi, M.; Akcicek, H.; Cohen, J. M.; Driessen, M. T.			THE COST-EFFECTIVENESS OF FREMANEZUMAB IN PATIENTS WITH MIGRAINE AND PREVIOUS INADEQUATE RESPONSE TO ONABOTULINUMTOXINA FROM A UK HEALTHCARE SYSTEM PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Skroumpelos, A.; Akcicek, H.; Driessen, M. T.] Teva Pharmaceut, Amsterdam, Netherlands; [Freddi, M.] Strategen, Winchester, Hants, England; [Cohen, J. M.] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND20	S162	S162					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400705
J	Sundaram, M; Song, Y; Rogerio, JW; Zhang, S; Adejoro, O; Carley, C; Zhu, J; Signorovitch, J; Haas, NB				Sundaram, M.; Song, Y.; Rogerio, J. W.; Zhang, S.; Adejoro, O.; Carley, C.; Zhu, J.; Signorovitch, J.; Haas, N. B.			ECONOMIC AND CLINICAL BURDENS OF RECURRENCE FOLLOWING NEPHRECTOMY FOR INTERMEDIATE-HIGH OR HIGH-RISK RENAL CELL CARCINOMA (RCC): A RETROSPECTIVE ADMINISTRATIVE CLAIMS ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Sundaram, M.; Rogerio, J. W.; Adejoro, O.] Merck & Co Inc, Kenilworth, NJ USA; [Song, Y.; Zhang, S.; Carley, C.; Signorovitch, J.] Anal Grp, Boston, MA USA; [Zhu, J.] Anal Grp, Somerville, MA USA; [Haas, N. B.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN40	S25	S26					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400104
J	Teigland, C; Pulungan, Z; Mohammadi, I				Teigland, C.; Pulungan, Z.; Mohammadi, I			HEALTHCARE UTILIZATION, COST, AND QUALITY AMONG HIGH-NEED, HIGH-COST MEDICARE BENEFICIARIES IN MEDICARE FEE-FOR-SERVICE VERSUS MEDICARE ADVANTAGE	VALUE IN HEALTH			English	Meeting Abstract									[Teigland, C.; Pulungan, Z.; Mohammadi, I] Avalere Hlth, Washington, DC USA									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		CO2	S4	S4					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400015
J	Williams, K; Skrobanski, H; Buesch, K; Acaster, S				Williams, K.; Skrobanski, H.; Buesch, K.; Acaster, S.			MEASURING CARER UTILITY IN RARE PAEDIATRIC DISEASE: A MIXED METHODS CASE STUDY IN AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY (AADCD)	VALUE IN HEALTH			English	Meeting Abstract									[Williams, K.; Skrobanski, H.; Acaster, S.] Acaster Lloyd Consulting Ltd, London, Lon, England; [Buesch, K.] PTC Therapeut Switzerland GmbH, Zug, Switzerland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO46	S205	S205					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401162
J	Zhao, H; Zhang, L; Ford, J; Li, Z; Zhong, S; Ye, W; Li, J; Tockhorn-Heidenreich, A; Cotton, S; Chen, C				Zhao, H.; Zhang, L.; Ford, J.; Li, Z.; Zhong, S.; Ye, W.; Li, J.; Tockhorn-Heidenreich, A.; Cotton, S.; Chen, C.			TREATMENT PATTERNS AND REAL-WORLD OUTCOMES AMONG PATIENTS WITH EPISODIC MIGRAINE IN CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Zhao, H.] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China; [Zhang, L.; Li, Z.; Zhong, S.; Ye, W.; Li, J.] Eli Lilly China, Shanghai 31, Peoples R China; [Ford, J.; Tockhorn-Heidenreich, A.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Cotton, S.] Adelphi Real World, Bollington, England; [Chen, C.] Shandong Univ, Cheeloo Coll Med, Shandong Prov Hosp, Dept Neurol, Jinan, Shandong, Peoples R China									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND64	S171	S171					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401006
J	Vogel, WB; Morris, HL; Muller, K; Huo, TY; Parish, A; Stoner, D; Shenkman, E				Vogel, Walter Bruce; Morris, Heather L.; Muller, Keith; Huo, Tianyao; Parish, Alice; Stoner, Dena; Shenkman, Elizabeth			Cost-Effectiveness of the Wellness Incentives and Navigation (WIN) Program	VALUE IN HEALTH			English	Article						chronic illness; cost-effectiveness; Medicaid; motivational interviewing; patient activation		Objectives: Promoting patient involvement in managing co-occurring physical and mental health conditions is increasingly recognized as critical to improving outcomes and controlling costs in this growing chronically ill population. The main objective of this study was to conduct an economic evaluation of the Wellness Incentives and Navigation (WIN) intervention as part of a longitudinal randomized pragmatic clinical trial for chronically ill Texas Medicaid enrollees with co-occurring physical and mental health conditions. Methods: The WIN intervention used a personal navigator, motivational interviewing, and a flexible wellness expense account to increase patient activation, that is, the patient's knowledge, skills, and confidence in managing their self-care and co-occurring physical and mental health conditions. Regression models were fit to both participant-level quality-adjusted life years (QALYs) and total costs of care (including the intervention) controlling for demographics, health status, poverty, Medicaid managed care plan, intervention group, and baseline health utility and costs. Incremental costs and QALYs were calculated based on the difference in predicted costs and QALYs under intervention versus usual care and were used to calculate the incremental cost-effectiveness ratios (ICERs). Confidence intervals were calculated using Fieller's method, and sensitivity analyses were performed. Results: The mean ICER for the intervention compared with usual care was $12 511 (95% CI $8971-$16 842), with a sizable majority of participants (70%) having ICERs below $40 000. The WIN intervention also produced higher QALY increases for participants who were sicker at baseline compared to those who were healthier at baseline. Conclusion: The WIN intervention shows considerable promise as a cost-effective intervention in this challenging chronically ill population.	[Vogel, Walter Bruce; Morris, Heather L.; Muller, Keith; Huo, Tianyao; Shenkman, Elizabeth] Univ Florida, Coll Med, Dept Hlth Outcomes & Biomed Informat, Clin & Translat Sci Inst, Gainesville, FL USA; [Vogel, Walter Bruce; Morris, Heather L.; Muller, Keith; Huo, Tianyao; Shenkman, Elizabeth] Inst Child Hlth Policy, Gainesville, FL USA; [Parish, Alice] Duke Univ, Dept Biostat & Bioinformat, BERD Methods Core, Durham, NC USA; [Stoner, Dena] Texas Dept State Hlth Serv, Austin, TX USA		Vogel, WB (通讯作者)，2004 Mowry Rd,Suite 2240,POB 100177, Gainesville, FL 32610 USA.	bvogel@ufl.edu			US Department of Health and Human Services, Centers for Medicare & Medicaid Services [CMS-1B1-11-001]	The WIN project is supported by Funding Opportunity Number CMS-1B1-11-001 from the US Department of Health and Human Services, Centers for Medicare & Medicaid Services.	[Anonymous], TEXAS STAR1PLUS; [Anonymous], 2017, CMS CONTRACT NO HHSM; Bayliss EA, 2007, ANN FAM MED, V5, P395, DOI 10.1370/afm.722; Case K, 2019, MED CARE RES REV, V76, P444, DOI 10.1177/1077558717709419; COX C, 1990, BIOMETRICS, V46, P709, DOI 10.2307/2532090; Delcher C, 2017, INT J EMERG MED, V10, DOI 10.1186/s12245-017-0157-4; Dentzer S, 2013, HEALTH AFFAIR, V32, P202, DOI 10.1377/hlthaff.2013.0037; DiClemente CC, 2017, PSYCHOL ADDICT BEHAV, V31, P862, DOI 10.1037/adb0000318; Eisenhandler J., DEV EVALUATION CLIN; Feeny D, 2006, MED DECIS MAKING, V26, P307, DOI 10.1177/0272989X06290975; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; Gandek B., 2009, USERS MANUAL SF 12V2; Greene J, 2012, J GEN INTERN MED, V27, P520, DOI 10.1007/s11606-011-1931-2; Guo Y, 2019, HEALTH SERV RES, V54, P1156, DOI 10.1111/1475-6773.13235; Hendriks M, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-393; Hibbard JH, 2007, HEALTH SERV RES, V42, P1443, DOI 10.1111/j.1475-6773.2006.00669.x; Hibbard JH, 2017, HEALTH SERV RES, V52, P1297, DOI 10.1111/1475-6773.12545; Horsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54; Hughes JS, 2004, MED CARE, V42, P81, DOI 10.1097/01.mlr.0000102367.93252.70; Hunter RM, 2015, PHARMACOECONOMICS, V33, P355, DOI 10.1007/s40273-014-0247-6; Huo T, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0858-2; Jolles MP, 2015, MED CARE, V53, P708, DOI 10.1097/MLR.0000000000000389; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; MILLER DM, 1984, AM STAT, V38, P124, DOI 10.2307/2683247; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Salyers MP, 2000, MED CARE, V38, P1141, DOI 10.1097/00005650-200011000-00008; Severens JL, 1999, INT J TECHNOL ASSESS, V15, P608, DOI 10.1017/S0266462399153157; Shenkman E, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1245-x; Sullivan PW, 2006, MED DECIS MAKING, V26, P401, DOI 10.1177/0272989X06290496; Van Vleet A, 2014, OVERVIEW MEDICAID IN; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	31	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAR	2021	24	3					361	368		10.1016/j.jval.2020.06.019		FEB 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QM9NG	33641770	Bronze			2022-04-28	WOS:000622099500008
J	Portnoy, A; Resch, SC; Suharlim, C; Brenzel, L; Menzies, NA				Portnoy, Allison; Resch, Stephen C.; Suharlim, Christian; Brenzel, Logan; Menzies, Nicolas A.			What We Do Not Know About the Costs of Immunization Programs in Low- and Middle-Income Countries	VALUE IN HEALTH			English	Article									[Portnoy, Allison; Resch, Stephen C.; Suharlim, Christian; Menzies, Nicolas A.] Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA 02115 USA; [Suharlim, Christian] Management Sci Hlth, Boston, MA USA; [Brenzel, Logan] Bill & Melinda Gates Fdn, Seattle, WA USA; [Menzies, Nicolas A.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA		Menzies, NA (通讯作者)，Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.	nmenzies@hsph.harvard.edu			Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1158709]	This work was supported by grant OPP1158709 from the Bill & Melinda Gates Foundation	Adam T, 2003, INT J TECHNOL ASSESS, V19, P407, DOI 10.1017/S0266462303000369; Andersson N, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S8; Batt K, 2004, B WORLD HEALTH ORGAN, V82, P689; Bishai D, 2006, HEALTH AFFAIR, V25, P348, DOI 10.1377/hlthaff.25.2.348; Brenzel L, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P389; Brenzel L, 2015, VACCINE, V33, pA93, DOI 10.1016/j.vaccine.2014.12.076; Brenzel L, 2015, VACCINE, V33, pA13, DOI 10.1016/j.vaccine.2014.12.066; Clement FM, 2009, HEALTH ECON, V18, P377, DOI 10.1002/hec.1363; EPIC Project (Harvard), WORK PAP COST IMM PR; Frappier J, 2015, J MED ECON, V18, P596, DOI 10.3111/13696998.2015.1033423; Graves N, 2002, HEALTH ECON, V11, P735, DOI 10.1002/hec.683; Hargreaves JR, 2011, LANCET, V378, P1885, DOI 10.1016/S0140-6736(11)60687-9; Immunization Costing Action Network (ICAN), 2019, IMM DEL COST CAT IDC IMM DEL COST CAT IDC; Johns Hopkins University-International Vaccine Access Center (IVAC), METH REP DEC VACC EC; Johri M, 2015, B WORLD HEALTH ORGAN, V93, P339, DOI 10.2471/BLT.14.146951; LaFond A, 2015, HEALTH POLICY PLANN, V30, P298, DOI 10.1093/heapol/czu011; Ludwig J, 2011, J ECON PERSPECT, V25, P17, DOI 10.1257/jep.25.3.17; Lydon P, 2008, VACCINE, V26, P6706, DOI 10.1016/j.vaccine.2008.10.015; Menzies NA, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0942-1; Munk C, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4468-4; Nelson KN, 2016, VACCINE, V34, P5495, DOI 10.1016/j.vaccine.2016.09.038; Owais A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-239; Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3; Ozawa S, 2019, VACCINE, V37, P5525, DOI 10.1016/j.vaccine.2019.06.081; Ozawa S, 2018, VACCINE, V36, P3641, DOI 10.1016/j.vaccine.2018.05.030; Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086; Pandey P, 2007, JAMA-J AM MED ASSOC, V298, P1867, DOI 10.1001/jama.298.16.1867; Pegurri E, 2005, VACCINE, V23, P1624, DOI 10.1016/j.vaccine.2004.02.029; Portnoy A, 2020, PHARMACOECONOMICS, V38, P995, DOI 10.1007/s40273-020-00930-6; Powell-Jackson T, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002519; Ryman TK, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-134; Sridhar S, 2014, VACCINE, V32, P6870, DOI 10.1016/j.vaccine.2014.10.063; Vassall A, GLOBAL HLTH COST CON; Vaughan K, 2019, VACCINE-X, V2, DOI 10.1016/j.jvacx.2019.100034; WHO, GLOB VACC ACT PLAN 2	35	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JAN	2021	24	1					67	69		10.1016/j.jval.2020.08.2097		JAN 2021	3	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QC0YJ	33431155	Green Published, hybrid			2022-04-28	WOS:000614560000009
J	Mao, ZX; Ahmed, S; Graham, C; Kind, P				Mao, Zhuxin; Ahmed, Shenaz; Graham, Christopher; Kind, Paul			The Unfolding Method to Explore Health-Related Quality of Life Constructs in a Chinese General Population	VALUE IN HEALTH			English	Article						China; HRQOL; multidimensional scaling; ranking data; subjective health status; unfolding	ADAPTATION; MODEL	Objectives: Health-related quality of life (HRQOL) is a complicated concept that can be measured using multiple health items. Although HRQOL is closely associated with people's subjective assessment of their own health, a limited number of studies have investigated which health items are considered most important and relevant by the general population. Even fewer empirical studies have investigated how HRQOL is understood in non-Western populations. This study used multidimensional unfolding analysis in a Chinese general population to explore the constructs of HRQOL. Methods: A scoping review of Chinese generic HRQOL measures and a series of qualitative interviews produced a list of 42 potentially important health items in a Chinese cultural setting; 110 Chinese participants in face-to-face interviews ranked the health items from most important to least important. Responses were coded into a rectangular 110 3 42 matrix, and multidimensional unfolding was conducted to analyze participants' preferences for health items. Results: It was found that demographic characteristics and one's health condition affected views of HRQOL. Meanwhile, 3 health items were considered to be most important across the whole sample: sleep quality, body constitution, and spiritual appearance. Conclusion: This study used a novel approach to explore how people coming from a Chinese cultural setting may perceive HRQOL and which aspects of HRQOL are most important to them. The study shows that multidimensional unfolding is a feasible approach to assess preferences in a general population. Future studies using this approach are recommended to further explore the constructs of HRQOL in other general populations.	[Mao, Zhuxin] Southwestern Univ Finance & Econ, Sch Insurance, Chengdu, Sichuan, Peoples R China; [Mao, Zhuxin; Ahmed, Shenaz; Kind, Paul] Univ Leeds, Inst Hlth Sci, Leeds, W Yorkshire, England; [Graham, Christopher] Queens Univ Belfast, Dept Psychol, Belfast, Antrim, North Ireland		Mao, ZX (通讯作者)，Southwestern Univ Finance & Econ, Sch Insurance, Chengdu, Sichuan, Peoples R China.	zhuxin.mao@hotmail.com		Mao, Zhuxin/0000-0002-7444-1584	China Scholarship Council - University of Leeds Joint Scholarship	Zhuxin Mao's contribution to this research was supported by the China Scholarship Council - University of Leeds Joint Scholarship.	BENNETT JF, 1960, PSYCHOMETRIKA, V25, P27, DOI 10.1007/BF02288932; Borg I., 2018, APPL MULTIDIMENSIONA; Bowden A, 2003, SOC SCI MED, V57, P1289, DOI 10.1016/S0277-9536(02)00503-8; Busing FMTA, 2005, PSYCHOMETRIKA, V70, P71, DOI 10.1007/s11336-001-0908-1; Chan WTC, 2013, WORLD J TRANSL MED, V2, P56, DOI DOI 10.5528/WJTM.V2.I3.56; Chen AW, 2009, TRANSCULT PSYCHIATRY, V46, P623, DOI 10.1177/1363461509351374; Coombs CH, 1964, THEORY DATA; Cui S, 1993, SHANGHAI ARCH PSYCHI, V5, P24; Depp CA, 2006, AM J GERIAT PSYCHIAT, V14, P6, DOI 10.1097/01.JGP.0000192501.03069.bc; Devlin NJ, 2017, APPL HEALTH ECON HEA, V15, P127, DOI 10.1007/s40258-017-0310-5; Ding CodyS., 2018, FUNDAMENTALS APPL MU; Fielding R, 1997, QUAL LIFE RES, V6, P35; Groenen, 2005, MORDEN MULTIDIMENSIO; GUYATT G, 1991, CONTROL CLIN TRIALS, V12, pS81, DOI 10.1016/S0197-2456(05)80014-5; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V272, P630, DOI 10.1001/jama.272.8.630; Haas BK, 1999, WESTERN J NURS RES, V21, P728, DOI 10.1177/01939459922044153; Haraldstad K, 2019, QUAL LIFE RES, V28, P2641, DOI 10.1007/s11136-019-02214-9; HAYS WL, 1961, PSYCHOMETRIKA, V26, P221, DOI 10.1007/BF02289716; Herdman M, 1998, QUAL LIFE RES, V7, P323, DOI 10.1023/A:1008846618880; Hsu E, 2000, CULT MED PSYCHIAT, V24, P197, DOI 10.1023/A:1005529514427; Hu M., 2000, CHINESE J BEHAV MED, V9, P65; KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k; Lew-Ting CY, 1998, SOC SCI MED, V47, P821, DOI 10.1016/S0277-9536(98)00140-3; Li X., 2007, THESIS GUANGZHOU U C; Liang Y-j, 2011, ANHUI ZHONG YI XUE Y, V30, P18; [刘凤斌 Liu FB], 2007, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V11, P10492; [刘凤斌 LIU Fengbin], 2008, [中山大学学报. 医学科学版, Journal of Sun Yat-sen University. Medical Sciences], V29, P332; Mair P, 2016, MULTIVAR BEHAV RES, V51, P772, DOI 10.1080/00273171.2016.1235966; Mansour A A, 1994, J Community Health, V19, P165, DOI 10.1007/BF02260377; Mao Z., 2019, IHEA WORLD C; Mao ZX, 2020, HEALTH QUAL LIFE OUT, V18, DOI 10.1186/s12955-020-01414-z; McColl E., 2005, ASSESSING QUALITY LI, P9; McDowell I, 2006, MEASURING HLTH GUIDE; Prakash V, 2019, ANN PHYS REHABIL MED, V62, P174, DOI 10.1016/j.rehab.2019.01.006; Prior L, 2000, SOCIOL HEALTH ILL, V22, P815, DOI 10.1111/1467-9566.00232; Schipper H, 1996, QUALITY LIFE PHARMAC; Shumaker S, 1995, INT ASSESSMENT HLTH, P3; Stephenson W, 1935, NATURE, V136, P297, DOI 10.1038/136297b0; Tripathy S, 2020, INTENS CARE MED, V46, P1746, DOI 10.1007/s00134-020-06007-4; Wang X., 2009, ZHONG HUA JIAN KANG, V3, P216; WARE JE, 1987, J CHRON DIS, V40, P473; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watts S., 2005, QUAL RES PSYCHOL, V2, P67, DOI DOI 10.1191/1478088705QP022OA; Wei H., 1995, CHINA MENT HLTH J, V9, P227; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; World Health Organization, INT STAT CLASS DIS R; Wu Da-Rong, 2007, Zhongguo Zhong Xi Yi Jie He Za Zhi, V27, P847; [武阳丰 Wu Yangfeng], 2005, [中华流行病学杂志, Chinese Journal of Epidemiology], V26, P751; Zhang HM, 2017, CHIN J INTEGR MED, V23, P350, DOI 10.1007/s11655-014-1853-z; Zhou X, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/863685	50	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24	6					846	854		10.1016/j.jval.2020.12.014		JUN 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SP8AF	34119083	Green Accepted, Bronze			2022-04-28	WOS:000659884900013
J	Alsumali, A; Lautsch, D; Liu, R; Patel, D; Nanji, S; Djatche, L				Alsumali, A.; Lautsch, D.; Liu, R.; Patel, D.; Nanji, S.; Djatche, L.			BUDGET IMPACT ANALYSIS OF VERICIGUAT FOR THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION FOLLOWING A WORSENING HEART FAILURE EVENT IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Alsumali, A.] Merck & Co Inc, Blue Bell, PA USA; [Lautsch, D.; Djatche, L.] Merck & Co Inc, Kenilworth, NJ USA; [Liu, R.; Patel, D.; Nanji, S.] Pharmerit, Bethesda, MD USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV9	S68	S68					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400297
J	Bin Sawad, A; Pothukuchy, A; Badeaux, M; Hodson, V; Bubb, G; Lindsley, K; Uyei, J; Diaz, GA				Bin Sawad, A.; Pothukuchy, A.; Badeaux, M.; Hodson, V; Bubb, G.; Lindsley, K.; Uyei, J.; Diaz, G. A.			THE NATURAL HISTORY, CLINICAL OUTCOMES AND UNMET NEEDS OF PATIENTS WITH ARGINASE 1 DEFICIENCY (ARG1-D): A SYSTEMATIC REVIEW OF CASE REPORTS	VALUE IN HEALTH			English	Meeting Abstract									[Bin Sawad, A.; Pothukuchy, A.; Badeaux, M.; Hodson, V; Bubb, G.] Aeglea BioTherapeut, Austin, TX USA; [Lindsley, K.] IQVIA, Windsor Mill, MD USA; [Uyei, J.] IQVIA, San Francisco, CA USA; [Diaz, G. A.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Div Med Genet & Genom, New York, NY 10029 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		CO1	S4	S4					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400014
J	Bohn, J; Simoneau, G; Shen, C; Pellegrini, F; de Moor, C				Bohn, J.; Simoneau, G.; Shen, C.; Pellegrini, F.; de Moor, C.			ESTIMANDS AND THE CHOICE OF METHODOLOGY IN MULTI-GROUP COMPARATIVE EFFECTIVENESS RESEARCH	VALUE IN HEALTH			English	Meeting Abstract									[Bohn, J.; Simoneau, G.; Shen, C.; de Moor, C.] Biogen, Cambridge, MA USA; [Pellegrini, F.] Biogen Int GmbH, Baar, Switzerland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND52	S168	S169					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400735
J	Carter, JE; Carson, JS; Hickerson, W; Walsh, T; Becker, R; Sparks, J				Carter, J. E.; Carson, J. S.; Hickerson, W.; Walsh, T.; Becker, R.; Sparks, J.			COST SAVINGS OF AUTOLOGOUS CELL HARVESTING DEVICE FOR THE TREATMENT OF BURNS REQUIRING HOSPITALIZATION: AN ECONOMIC EVALUATION USING REAL-WORLD DATA	VALUE IN HEALTH			English	Meeting Abstract									[Carter, J. E.] Univ Med Ctr New Orleans, New Orleans, FL USA; [Carson, J. S.] Univ Florida Hlth Shands Burn Ctr, Gainesville, FL USA; [Hickerson, W.] Reg One Hlth, Memphis, FL USA; [Walsh, T.] Avita Med, Valencia, FL USA; [Becker, R.] Russell Consulting, Chicago, IL USA; [Sparks, J.] Avita Med, Valencia, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIT5	S122	S122					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400536
J	Chong, KC; Wang, J				Chong, K. C.; Wang, J.			WILLINGNESS TO PAY FOR SUGAR-SWEETENED BEVERAGES TAX IN AN AFFLUENT SETTING OF ASIA: A PRELIMINARY FINDING	VALUE IN HEALTH			English	Meeting Abstract									[Chong, K. C.] Chinese Univ Hong Kong, Hong Kong, Peoples R China; [Wang, J.] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China				Chong, Marc Ka-chun/S-7258-2019	Chong, Marc Ka-chun/0000-0001-5610-1298				0	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PAM1	S12	S12					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400048
J	Conner, T; Raju, D; Hauser, R; Gyory, T				Conner, T.; Raju, D.; Hauser, R.; Gyory, T.			INCORPORATING A PATIENT-REPORTED SYMPTOM BURDEN TOOL IN CANCER CARE SETTINGS	VALUE IN HEALTH			English	Meeting Abstract									[Conner, T.] Vidence LLC, San Antonio, TX USA; [Raju, D.; Hauser, R.; Gyory, T.] Vidence LLC, Boca Raton, FL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN224	S61	S62					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400267
J	Danchenko, N; Johnston, K; Bolatova, T; Whalen, J				Danchenko, N.; Johnston, K.; Bolatova, T.; Whalen, J.			COST-EFFECTIVENESS OF BONT-A PRODUCTS FOR TREATMENT OF PEDIATRIC SPASTICITY IN THE UNITED KINGDOM	VALUE IN HEALTH			English	Meeting Abstract									[Danchenko, N.] Ipsen Global, Boulogne, France; [Johnston, K.; Bolatova, T.] Broadst Hlth Econ & Outcomes Res, Vancouver, BC, Canada; [Whalen, J.] Ipsen Biopharm Ltd, Slough, Berks, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND37	S165	S166					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400721
J	dos Santos, SS; Nars, M; Girola, N; Mussolino, F; Salgado, J				dos Santos, S. S.; Nars, M.; Girola, N.; Mussolino, F.; Salgado, J.			TREATMENT PATTERN AND COST ESTIMATION OF MELANOMA IN BRAZILIAN PUBLIC HEALTHCARE SYSTEM	VALUE IN HEALTH			English	Meeting Abstract									[dos Santos, S. S.; Girola, N.; Salgado, J.] Novartis Biociencias SA, Sao Paulo, SP, Brazil; [Nars, M.; Mussolino, F.] Moka Info, Sao Paulo, Brazil									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN126	S42	S42					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400178
J	Dzingirai, B; Chavunduka, T; Manyau, P; van Hulst, M; Postma, MJ; Mafirakureva, N				Dzingirai, B.; Chavunduka, T.; Manyau, P.; van Hulst, M.; Postma, M. J.; Mafirakureva, N.			ESTIMATING THE COSTS OF THE MANAGEMENT OF NON-HODGKINA'S LYMPHOMA AT A TERTIARYA HEALTH INSTITUTION	VALUE IN HEALTH			English	Meeting Abstract									[Dzingirai, B.; Manyau, P.] Univ Zimbabwe, Harare, HA, Zimbabwe; [Chavunduka, T.] Univ Zimbabwe, Rusape, MA, Zimbabwe; [van Hulst, M.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Postma, M. J.] Isala Hosp, Zwolle, Netherlands; [Mafirakureva, N.] Univ Sheffield, Sheffield, S Yorkshire, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN89	S36	S36					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400149
J	Emerson, S; Johnston, K; Howarth, A; Schneider, J; Friesen, M; Szabo, S				Emerson, S.; Johnston, K.; Howarth, A.; Schneider, J.; Friesen, M.; Szabo, S.			LEVERAGING PUBLICLY AVAILABLE DATA TO ESTIMATE A REAL-TIME REPRODUCTION NUMBER (RT) FOR COVID-19: A COMPARISON OF TWO METHODS	VALUE IN HEALTH			English	Meeting Abstract									[Emerson, S.; Friesen, M.; Szabo, S.] Broadstreet Hlth Econ & Outcomes Res, Vancouver, BC, Canada; [Johnston, K.] Mem Univ, Vancouver, BC, Canada; [Howarth, A.; Schneider, J.] Avalon Hlth Econ, Morristown, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN50	S114	S114					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400500
J	Holanda, P; De Santana, CS; Senna, T; Carmo, L; Alexandre, RF				Holanda, P.; Salgado De Santana, C.; Senna, T.; Carmo, L.; Alexandre, R. F.			COST-EFFECTIVENESS OF PALBOCICLIB IN COMBINATION WITH LETROZOLE VERSUS LETROZOLE ALONE FOR PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER HR+ / HER2-IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM	VALUE IN HEALTH			English	Meeting Abstract									[Holanda, P.; Senna, T.; Carmo, L.; Alexandre, R. F.] Pfizer, Sao Paulo, Brazil; [Salgado De Santana, C.] Pfizer, Santos, SP, Brazil									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN103	S38	S38					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400161
J	Hsiao, C; Furnback, W; Pan, SM				Hsiao, C.; Furnback, W.; Pan, S. M.			THE CURRENT BURDEN OF CATARACT SURGERY AND OUTCOMES OF IMAGE-GUIDED SYSTEMS: A TARGETED LITERATURE REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Hsiao, C.; Pan, S. M.] Alcon Vis LLC, Ft Worth, TX USA; [Furnback, W.] Elysia Grp LLC, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMD3	S123	S123					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400539
J	Huang, S; Wang, MJ; DerSarkissian, M; Gu, YM; Benson, J; Vu, J; Duh, MS; Bell, C				Huang, S.; Wang, M. J.; DerSarkissian, M.; Gu, Y. M.; Benson, J.; Vu, J.; Duh, M. S.; Bell, C.			HEALTHCARE COSTS, RESOURCE UTILIZATION, AND ADVERSE EVENTS ASSOCIATED WITH LONG-TERM ORAL CORTICOSTEROID USE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Huang, S.; Bell, C.] GlaxoSmithKline, Res Triangle Pk, NC USA; [Wang, M. J.; DerSarkissian, M.; Gu, Y. M.; Benson, J.; Vu, J.; Duh, M. S.] Anal Grp, Boston, MA USA						GSKGlaxoSmithKline	GSK.		0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSY26	S233	S233					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401283
J	Jones, T; McNair, A; Morley, J; McLeod, H; Hollingworth, W				Jones, T.; McNair, A.; Morley, J.; McLeod, H.; Hollingworth, W.			A LONGITUDINAL STUDY TO IDENTIFY POTENTIALLY LOW-VALUE CLINICAL PROCEDURES USING HOSPITAL EPISODE STATISTICS LINKED TO DEPRIVATION AND ETHNICITY IN ENGLAND, 2014/15-2018/19	VALUE IN HEALTH			English	Meeting Abstract									[Jones, T.; McNair, A.; Morley, J.; McLeod, H.; Hollingworth, W.] Univ Bristol, Bristol, Avon, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS63	S184	S184					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401066
J	Kindilien, S; Goldberg, E				Kindilien, S.; Goldberg, E.			30 DAY READMISSIONS OF PATIENTS WITH A MALNUTRITION DIAGNOSIS: EXPLORATION OF THE US HOSPITAL POPULATION	VALUE IN HEALTH			English	Meeting Abstract									[Kindilien, S.; Goldberg, E.] Univ New Mexico, Albuquerque, NM 87131 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PAM2	S12	S13					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400049
J	Lenahan, K; Gertler, RM; Nichols, D; Chambers, JD				Lenahan, K.; Gertler, R. M.; Nichols, D.; Chambers, J. D.			EXAMINING US COMMERCIAL HEALTH PLANS' USE OF STEP THERAPY PROTOCOLS FOR SPECIALTY DRUGS: AN EMPIRICAL ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Lenahan, K.; Gertler, R. M.; Chambers, J. D.] Tufts Med Ctr, Boston, MA 02111 USA; [Nichols, D.] Genentech Inc, San Francisco, CA 94080 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS52	S182	S182					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401056
J	Lylyk, P; Cirio, J; Toranzo, C; Aiello, EC; Paredes, D; Valencia, J				Lylyk, P.; Cirio, J.; Toranzo, C.; Aiello, E. C.; Paredes, D.; Valencia, J.			COST-UTILITY OF MECHANICAL THROMBECTOMY AFTER THROMBOLYSIS IN ISCHEMIC-STROKE DUE TO LARGE VESSEL OCLUSSION IN PROGRAMA DE ATENCION MEDICA INTEGRAL PAMI IN ARGENTINA	VALUE IN HEALTH			English	Meeting Abstract									[Lylyk, P.; Toranzo, C.] ENERI Equipo Neurocirugia Endovasc & Radiol Inter, Buenos Aires, DF, Argentina; [Lylyk, P.; Toranzo, C.] Clin La Sagrada Familia, Buenos Aires, DF, Argentina; [Cirio, J.] Clin La Sagrada Familia, Acute Stroke Unit, Buenos Aires, B, Argentina; [Cirio, J.] ENERI, Dept Neurol, Buenos Aires, B, Argentina; [Paredes, D.] Medtronic, Hlth Econ & Reimbursement, Santiago, RM, Chile; [Valencia, J.] Medtronic, Miami, FL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND24	S163	S163					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400709
J	Nedzesky, J; Kruger, E; Thomas, NA; Valayannopoulos, V; Poma, A				Nedzesky, J.; Kruger, E.; Thomas, N. A.; Valayannopoulos, V.; Poma, A.			RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA)	VALUE IN HEALTH			English	Meeting Abstract									[Nedzesky, J.] Ultragenyx Pharmaceut Ltd, Brisbane, CA USA; [Kruger, E.] Ultragenyx Pharmaceut Ltd, San Francisco, CA USA; [Thomas, N. A.] Ultragenyx Pharmaceut Inc Ltd, Brisbane, CA USA; [Valayannopoulos, V.; Poma, A.] Ultragenyx Pharmaceut Ltd, Cambridge, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO76	S212	S212					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401191
J	Orsini, I; Gricar, J; Bertwistle, D; Kim, I; Kurt, M				Orsini, I; Gricar, J.; Bertwistle, D.; Kim, I; Kurt, M.			COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA REFRACTORY OR INTOLERANT TO PREVIOUS CHEMOTHERAPY: A UNITED-STATES PAYER PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Orsini, I] Parexel Int, London, Lon, England; [Gricar, J.; Kim, I; Kurt, M.] Bristol Myers Squibb Co, Lawrenceville, NJ USA; [Bertwistle, D.] Bristol Myers Squibb Co, Uxbridge, Middx, England									0	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN43	S26	S26					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400107
J	Osuna, A; Figueroa-Lara, A				Osuna, A.; Figueroa-Lara, A.			COST-EFFECTIVENESS ANALYSIS OF VISCOELASTIC POINT-OF-CARE TESTING VERSUS STANDARD LABORATORY TESTS FOR GUIDING TRANSFUSION THERAPY IN BRAZILIAN PATIENTS WHO UNDERWENT COMPLEX CARDIAC SURGERY	VALUE IN HEALTH			English	Meeting Abstract									[Osuna, A.] French Sch Publ Hlth, Paris 75, France; [Figueroa-Lara, A.] Werfen, Mexico City, DF, Mexico									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV28	S72	S72					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400314
J	Pabon, B; Tellez, J; Arcos, J; Jones, K; Valencia, J				Pabon, B.; Tellez, J.; Arcos, J.; Jones, K.; Valencia, J.			COST-EFFECTIVENESS ANALYSIS OF THE PIPELINE EMBOLIZATION DEVICE (PED) COMPARED WITH STENT ASSISTED COILING AND NEUROSURGICAL CLIPPING FOR TREATMENT OF INTRACRANIAL ANEURYSMS IN COLOMBIA	VALUE IN HEALTH			English	Meeting Abstract									[Pabon, B.] Angiodinamia, Medellin, Colombia; [Tellez, J.; Arcos, J.] Medtron Colombia, Bogota, Cun, Colombia; [Jones, K.] Medtronic, Napoles, Mex, Mexico; [Valencia, J.] Medtronic, Miami, FL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV19	S70	S70					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400305
J	Patel, V; Davis, K; Merikle, E; McClure, E; Patroneva, A				Patel, V; Davis, K.; Merikle, E.; McClure, E.; Patroneva, A.			THE EPWORTH SLEEPINESS SCALE FOR CHILDREN AND ADOLESCENTS IS A FIT-FOR-PURPOSE MEASURE OF DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME: A QUALITATIVE INTERVIEW STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Patel, V] Covance Labcorp, Chicago, IL USA; [Davis, K.; Patroneva, A.] Harmony Biosci LLC, Plymouth Meeting, PA USA; [Merikle, E.; McClure, E.] Covance Labcorp, Gaithersburg, MD USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO60	S208	S208					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401175
J	Podolsky, M; Kim, D; Neumann, PJ				Podolsky, M.; Kim, D.; Neumann, P. J.			NON-HEALTH CONSIDERATIONS IN ECONOMIC EVALUATIONS OF COVID-19 INTERVENTIONS: A SYSTEMIC REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Podolsky, M.; Kim, D.; Neumann, P. J.] Tufts Med Ctr, Boston, MA 02111 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		IN4	S10	S10					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400040
J	Poretta, T; Alhasani, H; Broughton, E; Stwalley, B; Hao, Y; Le, TK; Zhang, Y				Poretta, T.; Alhasani, H.; Broughton, E.; Stwalley, B.; Hao, Y.; Le, T. K.; Zhang, Y.			REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE COSTS AMONG PATIENTS WITH MUSCLE-INVASIVE UROTHELIAL CARCINOMA UNDERGOING RADICAL SURGERY IN MARKETSCAN DATABASES	VALUE IN HEALTH			English	Meeting Abstract									[Poretta, T.] Bristol Myers Squibb, West Newbury, MA USA; [Alhasani, H.; Broughton, E.; Stwalley, B.; Hao, Y.; Le, T. K.; Zhang, Y.] Bristol Myers Squibb, Princeton, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN85	S35	S35					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400146
J	Rajagopalan, K; Rashid, N; Abler, V; Shah, A				Rajagopalan, K.; Rashid, N.; Abler, V; Shah, A.			SOCIETAL BURDEN OF DEMENTIA-RELATED PSYCHOSIS IN THE US: A COST OF ILLNESS ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Rajagopalan, K.] An L It Iks Inc, Framingham, MA USA; [Rashid, N.; Abler, V] ACADIA Pharmaceut Inc, San Diego, CA USA; [Shah, A.] An L It Iks Inc, Somerville, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		ED3	S6	S6					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400024
J	Ramond, A; Carroll, R; Vekeria, S; Nordstrom, B				Ramond, A.; Carroll, R.; Vekeria, S.; Nordstrom, B.			INVESTIGATING SECULAR TRENDS IN THE SURVIVAL OF MELANOMA PATIENTS IN ENGLAND	VALUE IN HEALTH			English	Meeting Abstract									[Ramond, A.] Evidera, London, England; [Carroll, R.; Vekeria, S.] Bristol Myers Squibb Pharmaceut Ltd, Uxbridge, Middx, England; [Nordstrom, B.] Evidera, Waltham, MD USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN114	S40	S40					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400170
J	Staret, J; Goodin, A; Bhagwandass, H; Hincapie-Castillo, JM				Staret, J.; Goodin, A.; Bhagwandass, H.; Hincapie-Castillo, J. M.			CHANGES IN SCHEDULE II OPIOID PRESCRIPTIONS DISPENSED BY MEDICAID IN FOLLOWING ACUTE PAIN OPIOID RESTRICTION LAWS	VALUE IN HEALTH			English	Meeting Abstract									[Staret, J.] Univ Florida, Coll Pharm, Jacksonville, FL USA; [Goodin, A.; Bhagwandass, H.] Univ Florida, Gainesville, FL USA; [Hincapie-Castillo, J. M.] Univ Florida, Coll Pharm, Gainesville, FL USA				Hincapie-Castillo, Juan/J-5499-2019	Hincapie-Castillo, Juan/0000-0002-6945-2713				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU26	S149	S149					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400649
J	Stercho, T; Kamal, K				Stercho, T.; Kamal, K.			HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION AND THEIR CAREGIVERS: A REVIEW OF EVIDENCE	VALUE IN HEALTH			English	Meeting Abstract									[Stercho, T.; Kamal, K.] West Virginia Univ, Morgantown, WV 26506 USA									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO45	S205	S205					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401161
J	Sukonthasarn, A; Thongtang, N; Ektare, V; Du, F; Brizuela, G; Rustagi, S; Gao, X				Sukonthasarn, A.; Thongtang, N.; Ektare, V; Du, F.; Brizuela, G.; Rustagi, S.; Gao, X.			COST-EFFECTIVENESS OF ATORVASTATIN VERSUS SIMVASTATIN IN PREVENTION OF CARDIOVASCULAR EVENTS FROM A THAILAND SOCIETAL PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Sukonthasarn, A.] Bangkok Hosp Chiang Mai, Bangkok, Thailand; [Thongtang, N.] Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok, Thailand; [Ektare, V] Pharmerit India Private Ltd, Andheri East, MH, India; [Du, F.] Pharmerit Shanghai Co Ltd, Shanghai 31, Peoples R China; [Brizuela, G.] A Viatris Co, Antipolo, Philippines; [Rustagi, S.] A Viatris Co, Bangkok, Thailand; [Gao, X.] Pharmerit, Waban, MA USA									0	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV21	S70	S70					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400307
J	Venner, CP; Majer, IM; Rogoza, R; Yusuf, A				Venner, C. P.; Majer, I. M.; Rogoza, R.; Yusuf, A.			CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE (KD) VERSUS POMALIDOMIDE IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE (PVD): A MATCHING ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC)	VALUE IN HEALTH			English	Meeting Abstract									[Venner, C. P.] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada; [Majer, I. M.] Amgen Inc, Rotkreuz, Switzerland; [Rogoza, R.] Amgen Canada Inc, Mississauga, ON, Canada; [Yusuf, A.] Amgen Inc, Thousand Oaks, CA 91320 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN4	S19	S19					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400076
J	Yang, S; Boren, M; Lipe, A; Hincapie-Castillo, JM; Brown, J; Park, H; Guo, S; Chang, CY; Wilson, DL; Adkins, LE; Lo-Ciganic, W				Yang, S.; Boren, M.; Lipe, A.; Hincapie-Castillo, J. M.; Brown, J.; Park, H.; Guo, S.; Chang, C. Y.; Wilson, D. L.; Adkins, L. E.; Lo-Ciganic, W.			TRENDS AND CHARACTERISTICS IN OPIOID ANALGESIC USE FOR MIGRAINE IN US EMERGENCY DEPARTMENTS: ANALYSIS OF NATIONAL HOSPITAL AMBULATORY MEDICAL CARE SURVEY 2007-2018 DATA	VALUE IN HEALTH			English	Meeting Abstract									[Yang, S.] Univ Florida, Ocala, FL USA; [Boren, M.; Lipe, A.; Brown, J.; Park, H.; Wilson, D. L.; Lo-Ciganic, W.] Univ Florida, Gainesville, FL USA; [Hincapie-Castillo, J. M.; Chang, C. Y.] Univ Florida, Coll Pharm, Gainesville, FL USA; [Guo, S.] Univ Florida, Pittsburgh, PA USA; [Adkins, L. E.] Univ Florida Hlth Sci Ctr Lib, Gainesville, FL USA				Hincapie-Castillo, Juan/J-5499-2019	Hincapie-Castillo, Juan/0000-0002-6945-2713				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND51	S168	S168					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400734
J	Mouter, N; Collewet, M; de Wit, GA; Rotteveel, A; Lambooij, MS; Kessels, R				Mouter, Niek; Collewet, Marion; de Wit, G. Ardine; Rotteveel, Adrienne; Lambooij, Mattijs S.; Kessels, Roselinde			Societal Effects Are a Major Factor for the Uptake of the Coronavirus Disease 2019 (COVID-19) Digital Contact Tracing App in The Netherlands	VALUE IN HEALTH			English	Article						digital contact tracing app; discrete choice experiment; COVID-19; coronavirus; preferences; societal effects; SARS-CoV-2	BAYESIAN OPTIMAL DESIGNS	Objectives: Our study investigates the extent to which uptake of a COVID-19 digital contact-tracing (DCT) app among the Dutch population is affected by its configurations, its societal effects, and government policies toward such an app. Methods: We performed a discrete choice experiment among Dutch adults including 7 attributes, that is, who gets a noti-fication, waiting time for testing, possibility for shops to refuse customers who have not installed the app, stopping condition for contact tracing, number of people unjustifiably quarantined, number of deaths prevented, and number of households with financial problems prevented. The data were analyzed by means of panel mixed logit models. Results: The prevention of deaths and financial problems of households had a very strong influence on the uptake of the app. Predicted app uptake rates ranged from 24% to 78% for the worst and best possible app for these societal effects. We found a strong positive relationship between people's trust in government and people's propensity to install the DCT app. Conclusions: The uptake levels we find are much more volatile than the uptake levels predicted in comparable studies that did not include societal effects in their discrete choice experiments. Our finding that the societal effects are a major factor in the uptake of the DCT app results in a chicken-or-the-egg causality dilemma. That is, the societal effects of the app are severely influenced by the uptake of the app, but the uptake of the app is severely influenced by its societal effects.	[Mouter, Niek] Delft Univ Technol, Fac Technol Policy & Management, Transport & Logist Grp, Delft, Netherlands; [Collewet, Marion] Leiden Univ, Leiden Law Sch, Inst Tax Law & Econ, Dept Econ, Leiden, Netherlands; [de Wit, G. Ardine; Rotteveel, Adrienne; Lambooij, Mattijs S.] Ctr Nutr Prevent & Hlth Serv, Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands; [de Wit, G. Ardine] Univ Utrecht, Univ Med Ctr Utrecht, Juliusctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Kessels, Roselinde] Maastricht Univ, Dept Data Analyt & Digitalizat, POB 616, NL-6200 Maastricht, Netherlands; [Kessels, Roselinde] Univ Antwerp, Dept Econ, Antwerp, Belgium		Mouter, N (通讯作者)，Maastricht Univ, Dept Data Analyt & Digitalizat, POB 616, NL-6200 Maastricht, Netherlands.	n.mouter@tudelft.nl	Kessels, Roselinde/N-8479-2016	Kessels, Roselinde/0000-0002-4534-0047; Collewet, Marion/0000-0002-8289-847X; de Wit, G. Ardine/0000-0002-1375-7657	Maastricht University; JMP Division of SAS Institute	Dr Kessels acknowledges her Elinor Ostrom research grant from Maastricht University which was used to collect the data. Also, she thanks the JMP Division of SAS Institute for further financial support.	Albert H, 2020, FORBES; Altmann S, SUPPORT APP BASED CO, DOI [10.1101/2020.05.05.20091587v1, DOI 10.1101/2020.05.05.20091587V1]; Brazell JD, 2006, MARKET LETT, V17, P255, DOI 10.1007/s11002-006-7943-8; Carson RT, 2007, ENVIRON RESOUR ECON, V37, P181, DOI 10.1007/s10640-007-9124-5; Bekker-Grob EW, 2020, SOC SCI MED, V246, DOI 10.1016/j.socscimed.2019.112736; de Bekker-Grob EW, 2019, VALUE HEALTH, V22, P1050, DOI 10.1016/j.jval.2019.04.1924; Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505; Diener C, 2006, DUAL RESPONSE NONE A; Dignum F, SIMULATIES TONEN DAT; ECDPC (European Centre for Disease Prevention and Control), 2020, TECHNICAL REPORT; Eynon R, DIGITAL SKILLS TANGI; Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936; Frimpong J, FINANCIAL INCENTIVES; Hensher DA, 2015, APPLIED CHOICE ANALYSIS, 2ND EDITION, P1, DOI 10.1017/CBO9781316136232; Hoogink J, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08844-w; Jonker M, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/20741; Jonker MF, 2019, HEALTH ECON, V28, P350, DOI 10.1002/hec.3846; Kessels R, 2015, APPL STOCH MODEL BUS, V31, P626, DOI 10.1002/asmb.2065; Kessels R, 2011, J CHOICE MODEL, V4, P52, DOI 10.1016/S1755-5345(13)70042-3; Kessels R, 2011, APPL STOCH MODEL BUS, V27, P173, DOI 10.1002/asmb.906; LANCASTER KJ, 1966, J POLIT ECON, V74, P132, DOI 10.1086/259131; Organisation for Economic Co-operation and Development, GOVT GLANCE 2019; Sabat I, 2020, HEALTH POLICY, V124, P909, DOI 10.1016/j.healthpol.2020.06.009; Sattler F, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00340-0; Train KE, 2009, DISCRETE CHOICE METHODS WITH SIMULATION, 2ND EDITION, P1, DOI 10.1017/CBO9780511805271; Veldwijk J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111805; Venkatesh V, 2000, MANAGE SCI, V46, P186, DOI 10.1287/mnsc.46.2.186.11926; Venkatesh V, 2003, MIS QUART, V27, P425, DOI 10.2307/30036540; Wiertz C, PREDICTED ADOPTION R; Williams S, 2020, PUBLIC ATTITUDES COV, DOI [10.1101/2020.05.14.20102269v1.full.pdf, DOI 10.1101/2020.05.14.20102269V1.FULL.PDF]; Xu J, 2005, STATA J, V5, P537, DOI 10.1177/1536867X0500500405	31	4	4	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAY	2021	24	5					658	667		10.1016/j.jval.2021.01.001		APR 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	RU9KC	33933234	hybrid, Green Published			2022-04-28	WOS:000645457500008
J	Shlomai, A; Leshno, A; Sklan, EH; Leshno, M				Shlomai, Amir; Leshno, Ari; Sklan, Ella H.; Leshno, Moshe			Modeling Social Distancing Strategies to Prevent SARS-CoV-2 Spread in Israel: A Cost-Effectiveness Analysis	VALUE IN HEALTH			English	Article						cost-effectiveness; SARS-CoV-2; SEIR model		Objectives: While highly effective in preventing SARS-CoV-2 spread, national lockdowns come with an enormous economic price. Few countries have adopted an alternative ?testing, tracing, and isolation? approach to selectively isolate people at high exposure risk, thereby minimizing the economic impact. To assist policy makers, we performed a cost-effectiveness analysis of these 2 strategies. Methods: A modified Susceptible, Exposed, Infectious, Recovered, and Deceased (SEIRD) model was employed to assess the situation in Israel, a small country with w9 million people. The incremental cost-effectiveness ratio (ICER) of these strategies as well as the expected number of infected individuals and deaths were calculated. Results: A nationwide lockdown is expected to save, on average, 274 (median 124, interquartile range: 71-221) lives compared to the ?testing, tracing, and isolation? approach. However, the ICER will be, on average, $45 104 156 (median $49.6 million, interquartile range: 22.7-220.1) to prevent 1 case of death. Conclusion: A national lockdown has a moderate advantage in saving lives with tremendous costs and possible overwhelming economic effects. These findings should assist decision makers dealing with additional waves of this pandemic.	[Shlomai, Amir] Beilinson Med Ctr, Rabin Med Ctr, Dept Med D, Petah Tiqwa, Israel; [Shlomai, Amir; Leshno, Ari] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Leshno, Ari] Sheba Med Ctr, Goldschleger Eye Inst, Ramat Gan, Israel; [Sklan, Ella H.] Tel Aviv Univ, Sackler Fac Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel; [Leshno, Moshe] Tel Aviv Univ, Coller Sch Management, Tel Aviv, Israel		Sklan, EH (通讯作者)，Tel Aviv Univ, Sackler Fac Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel.	sklan@tauex.tau.ac.il					[Anonymous], Living, working and COVID-19 dataset. Eurofound.; [Anonymous], Coronavirus disease (COVID-19) outbreak.; [Anonymous], 2020 value assessment framework: final framework.; [Anonymous], Economic indicators: Israeli economic data.; Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5; Bonaccorsi G, 2020, P NATL ACAD SCI USA, V117, P15530, DOI 10.1073/pnas.2007658117; Chernozhukov V, 2020, OPTIMAL TARGETED LOC, V27102, DOI 10.3386/w27102; Cohen J, 2020, SCIENCE, V367, P1287, DOI 10.1126/science.367.6484.1287; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Gopinath G., GREAT LOCKDOWN WORST; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMoa2002032, 10.1056/NEJMc2005203]; Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100; Kip VW., 2005, VALUE LIFE, V517; Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Li MY, 1999, MATH BIOSCI, V160, P191, DOI 10.1016/S0025-5564(99)00030-9; Mckee M, 2020, NAT MED, V26, P640, DOI 10.1038/s41591-020-0863-y; Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Roser M, OUR WORLD DATA; When to quarantine, CTR DIS CONTR PREV; Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017; Xu Y, 2020, NAT MED, V26, P502, DOI 10.1038/s41591-020-0817-4	23	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAY	2021	24	5					607	614		10.1016/j.jval.2020.09.013		APR 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	RU9KC	33933228	Green Published, Bronze			2022-04-28	WOS:000645457500002
J	Luyten, J; van Hoek, AJ				Luyten, Jeroen; van Hoek, Albert Jan			Integrating Alternative Social Value Judgments Into Cost-Effectiveness Analysis of Vaccines: An Application to Varicella-Zoster Virus Vaccination	VALUE IN HEALTH			English	Article						assumption; cost-effectiveness analysis; distribution; equity; population preference; QALY; QALY-equivalence assumption; sensitivity analysis; social value		Objectives: Cost-effectiveness analyses (CEA) are based on the value judgment that health outcomes (eg, quantified in quality adjusted life-years; QALYs) are all equally valuable irrespective of their context. Whereas most published CEAs perform extensive sensitivity analysis on various parameters and assumptions, only rarely is the influence of the QALY-equivalence assumption on cost-effectiveness results investigated. We illustrate how the integration of alternative social value judgments in CEA can be a useful form of sensitivity analysis. Methods: Because varicella-zoster virus (VZV) vaccination affects 2 distinct diseases (varicella zoster and herpes zoster) and likely redistributes infections across different age groups, the program has an important equity dimension. We used a costeffectiveness model and disentangled the share of direct protection and herd immunity within the total projected QALYs resulting from a 50-year childhood VZV program in the UK. We use the UK population's preferences for QALYs in the vaccine context to revalue QALYs accordingly. Results: Revaluing different types of QALYs for different age groups in line with public preferences leads to a 98% change in the projected net impact of the program. The QALYs gained among children through direct varicella protection become more important, whereas the QALYs lost indirectly through zoster in adults diminish in value. Weighting of vaccine-related side effects made a large difference. Conclusions: Our study shows that a sensitivity analysis in which alternative social value judgments about the value of health outcomes are integrated into CEA of vaccines is relatively straightforward and provides important additional information for decision makers to interpret cost-effectiveness results.	[Luyten, Jeroen] KULeuven, Leuven Inst Healthcare Policy, Kapucijnenvoer 35, B-3000 Leuven, Belgium; [Luyten, Jeroen] London Sch Econ, Dept Hlth Policy, Personal Social Serv Res Unit, Houghton St, London, England; [van Hoek, Albert Jan] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, Keppel St, London, England; [van Hoek, Albert Jan] Antonie van Leeuwenhoeklaan, Natl Inst Publ Hlth & Environm, Ctr Infect Dis, Bilthoven, Netherlands		van Hoek, AJ (通讯作者)，London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, Keppel St, London, England.; van Hoek, AJ (通讯作者)，Antonie van Leeuwenhoeklaan, Natl Inst Publ Hlth & Environm, Ctr Infect Dis, Bilthoven, Netherlands.; van Hoek, AJ (通讯作者)，Natl Inst Publ Hlth & Environm, Ctr Infect Dis, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands.	albert.jan.van.hoek@rivm.nl		Luyten, Jeroen/0000-0001-6398-4025	National Institute for Health Research Health Protection Research Unit in Immunisation at London School of Hygiene & Tropical Medicine; Public Health England; National Institute for Health Research Health Protection Research Unit in Immunization at the London School of Hygiene and Tropical Medicine	This research was supported by the National Institute for Health Research Health Protection Research Unit in Immunisation at London School of Hygiene & Tropical Medicine in partnership with Public Health England. Dr van Hoek was partly funded by the National Institute for Health Research Health Protection Research Unit in Immunization at the London School of Hygiene and Tropical Medicine, in partnership with Public Health England. The views expressed are those of the authors and not necessarily those of the National Health Service, National Institute for Health Research, Department of Health, or Public Health England.	Asaria M, 2016, MED DECIS MAKING, V36, P8, DOI 10.1177/0272989X15583266; Barnighausen T, 2014, P NATL ACAD SCI USA, V111, P12313, DOI 10.1073/pnas.1400475111; Bilcke J, 2012, EPIDEMIOL INFECT, V140, P2096, DOI 10.1017/S0950268811002640; Coast J, 2009, SOC SCI MED, V69, P786, DOI 10.1016/j.socscimed.2009.06.026; Cooper LZ, 2008, PEDIATRICS, V122, P149, DOI 10.1542/peds.2008-0987; Culyer, 2020, DISTRIBUTIONAL COST; Dolan P, 2005, HEALTH ECON, V14, P197, DOI 10.1002/hec.924; Field RI, 2012, VACCINE, V30, P1009, DOI 10.1016/j.vaccine.2011.12.053; Forbes H, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6987; Granstrom M, 2011, HISTORY OF VACCINE DEVELOPMENT, P73, DOI 10.1007/978-1-4419-1339-5_10; Gu YY, 2015, SOC SCI MED, V146, P41, DOI 10.1016/j.socscimed.2015.10.005; Harder T, 2019, CLIN INFECT DIS, V69, P1329, DOI 10.1093/cid/ciy1099; Hausman D, 2015, VALUING HLTH; Lancsar E, 2011, J HEALTH ECON, V30, P466, DOI 10.1016/j.jhealeco.2011.01.003; Luyten J, 2020, AM J BIOETHICS, V20, P58, DOI 10.1080/15265161.2020.1795533; Luyten J, 2019, VACCINE, V37, P2494, DOI 10.1016/j.vaccine.2019.03.041; Luyten J, 2019, SOC SCI MED, V228, P181, DOI 10.1016/j.socscimed.2019.03.025; Luyten J, 2016, HEALTH AFFAIR, V35, P212, DOI 10.1377/hlthaff.2015.1088; Luyten J, 2015, VALUE HEALTH, V18, P224, DOI 10.1016/j.jval.2014.12.007; Luyten J, 2014, VACCINE, V32, P7175, DOI 10.1016/j.vaccine.2014.10.015; Lynch M, 2006, PEDIATRICS, V117, pE827, DOI 10.1542/peds.2005-1556; Malm H, 2020, IN PRESS; May T, 2005, BIOETHICS, V19, P407, DOI 10.1111/j.1467-8519.2005.00452.x; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; Nord E, 2015, PHARMACOECONOMICS, V33, P89, DOI 10.1007/s40273-014-0212-4; Nord E, 2009, VALUE HEALTH, V12, pS10, DOI 10.1111/j.1524-4733.2009.00516.x; Ogunjimi B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066485; Petrovsky N, 2015, DRUG SAFETY, V38, P1059, DOI 10.1007/s40264-015-0350-4; Phelps CE, 2017, VACCINE, V35, pA50, DOI 10.1016/j.vaccine.2016.09.072; Ricciardi GW, 2015, VACCINE, V33, P3, DOI 10.1016/j.vaccine.2014.09.023; Schokkaert E, 2015, INT J TECHNOL ASSESS, V31, P111, DOI 10.1017/S0266462315000306; Shah KK, 2009, HEALTH POLICY, V93, P77, DOI 10.1016/j.healthpol.2009.08.005; Standaert B, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1147-4; Tsuchiya A, 2000, HEALTH ECON, V9, P57, DOI 10.1002/(SICI)1099-1050(200001)9:1<57::AID-HEC484>3.0.CO;2-N; Uebe B, 2002, EUR J PEDIATR, V161, P442, DOI 10.1007/s00431-002-0981-1; van Hoek AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111807; van Hoek AJ, 2012, VACCINE, V30, P1225, DOI 10.1016/j.vaccine.2011.11.026; van Hoek AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017030; WAGSTAFF A, 1991, J HEALTH ECON, V10, P21, DOI 10.1016/0167-6296(91)90015-F; WEINSTEIN MC, 1988, J HEALTH ECON, V7, P289, DOI 10.1016/0167-6296(88)90030-6; Wilder-Smith A, 2019, LANCET, V394, P2151, DOI 10.1016/S0140-6736(19)32525-5; Wolfson LJ, 2020, CLIN INFECT DIS, V70, P995, DOI 10.1093/cid/ciz305	42	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JAN	2021	24	1					41	49		10.1016/j.jval.2020.07.011		JAN 2021	9	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QC0YJ	33431152	Bronze			2022-04-28	WOS:000614560000006
J	Farkas, M; Huynh, E; Gulacsi, L; Zrubka, Z; Dobos, A; Kovacs, L; Baji, P; Pentek, M				Farkas, Miklos; Huynh, Elisabeth; Gulacsi, Laszlo; Zrubka, Zsombor; Dobos, Agota; Kovacs, Levente; Baji, Petra; Pentek, Marta			Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs	VALUE IN HEALTH			English	Article						best-worst scaling; EQ-5D-5L; Hungary; ICEpop CAPability measure for Adults; population tariffs; preferences; value set	ECONOMIC EVALUATIONS; CAPABILITY	Objectives: The ICEpop CAPability measure for Adults (ICECAP-A) was developed to assess the capability well-being of adults for use in economic evaluations. Currently, ICECAP-A tariffs are available only for the UK population. The objectives of this study were to develop a Hungarian tariff set for the ICECAP-A instrument and to explore intercountry differences between the Hungarian and the UK value sets. Methods: A survey was conducted by computer-assisted personal interviews on a sample representative of the Hungarian adult population (N = 1000) to elicit their preferences regarding ICECAP-A attributes with the use of a best-worst scaling choice task. A latent class multinomial logit model with continuous variance scale was used to estimate the weights for each of the 4 capability levels of all 5 ICECAP-A attributes, namely, attachment, stability, achievement, enjoyment, and autonomy. Results: The model identified 2 preference classes with approximately equal share. The first class had a stronger relative preference for autonomy and achievement, whereas the second class had a strong preference for attachment. Multivariate analysis of the classes revealed that women, pensioners, people who are married or living in a partnership, and people with poorer health status are characteristics associated with the latter class membership (preference for attachment). Population tariffs were estimated from the model. Overall, attachment was found to be the most important attribute, followed by stability, enjoyment, achievement, and autonomy. Conclusions: Hungarian tariffs are largely consistent with those found for the United Kingdom; nevertheless, autonomy seems to be less important in Hungary compared with the United Kingdom.	[Farkas, Miklos] Univ Bristol, Sch Accounting & Finance, Bristol, Avon, England; [Huynh, Elisabeth] Australian Natl Univ, Res Sch Populat Hlth, Dept Hlth Serv Res & Policy, Acton, Australia; [Gulacsi, Laszlo; Zrubka, Zsombor; Pentek, Marta] Obuda Univ, Univ Res & Innovat Ctr, Hlth Econ Res Ctr, Budapest, Hungary; [Kovacs, Levente] Obuda Univ, Univ Res & Innovat Ctr, Physiol Controls Res Ctr, Budapest, Hungary; [Gulacsi, Laszlo; Zrubka, Zsombor] Corvinus Univ Budapest, Corvinus Inst Adv Studies, Budapest, Hungary; [Dobos, Agota] Corvinus Univ Budapest, Corvinus Ctr Foreign Language Educ & Res, Budapest, Hungary; [Baji, Petra] Corvinus Univ Budapest, Dept Hlth Econ, 8 Fovam Ter, H-1093 Budapest, Hungary		Baji, P (通讯作者)，Corvinus Univ Budapest, Dept Hlth Econ, 8 Fovam Ter, H-1093 Budapest, Hungary.	petra.baji@uni-corvinus.hu		Gulacsi, Laszlo/0000-0002-9285-8746	Higher Education Institutional Excellence Program 2020 of the Ministry of Innovation and Technology [TKP2020-IKA-02]	This research was supported by the Higher Education Institutional Excellence Program 2020 of the Ministry of Innovation and Technology in the framework of the "Financial and Public Services" research project (TKP2020-IKA-02) at the Corvinus University of Budapest.	Al-Janabi H, 2012, QUAL LIFE RES, V21, P167, DOI 10.1007/s11136-011-9927-2; Baji P, 2020, QUAL LIFE RES, V29, P2863, DOI 10.1007/s11136-020-02542-1; Baji P, 2020, PHARMACOECONOMICS, V38, P633, DOI 10.1007/s40273-020-00899-2; Bierlaire M, 200605 TRANSPOR; Bray N, 2017, ACTA OPHTHALMOL, V95, pE415, DOI 10.1111/aos.13255; EVS, 2011, 19812008EVS19812008; Flynn TN, 2007, J HEALTH ECON, V26, P171, DOI 10.1016/j.jhealeco.2006.04.002; Flynn TN, 2015, HEALTH ECON, V24, P258, DOI 10.1002/hec.3014; Goranitis I, 2017, MED DECIS MAKING, V37, P498, DOI 10.1177/0272989X16678844; Helter TM, 2020, QUAL LIFE RES, V29, P1433, DOI 10.1007/s11136-019-02393-5; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Himmler S, 2020, MED DECIS MAKING, V40, P498, DOI 10.1177/0272989X20923015; Hoefman RJ, 2017, PHARMACOECONOMICS, V35, P469, DOI 10.1007/s40273-016-0477-x; Hungarian Central Statistical Office, POP CENS 2011 NAT DA; Kinghorn P, 2019, SOC SCI MED, V240, DOI 10.1016/j.socscimed.2019.112546; McFadden D., 1973, FRONTIERS ECONOMETRI, P105; Mitchell PM, 2015, SOC SCI MED, V139, P71, DOI 10.1016/j.socscimed.2015.06.037; Proud L, 2019, QUAL LIFE RES, V28, P1429, DOI 10.1007/s11136-019-02114-y; Rencz F, 2020, VALUE HEALTH, V23, P1235, DOI 10.1016/j.jval.2020.03.019; Schwartz SH, 2004, J RES PERS, V38, P230, DOI 10.1016/S0092-6566(03)00069-2; Thurstone LL, 1927, PSYCHOL REV, V34, P273, DOI 10.1037/h0070288; Versteegh M, 2016, PHARMACOECONOMICS, V34, P1071, DOI 10.1007/s40273-016-0431-y; Wild D, 2005, VALUE HEALTH, V8, P94, DOI 10.1111/j.1524-4733.2005.04054.x	23	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	DEC	2021	24	12					1845	1852		10.1016/j.jval.2021.06.011		NOV 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	XC7VG	34838283	hybrid, Green Accepted			2022-04-28	WOS:000722217200016
J	Kennedy, C; McCullagh, L; Adams, R; Trela-Larsen, L; Tilson, L; Barry, M				Kennedy, Cormac; McCullagh, Laura; Adams, Roisin; Trela-Larsen, Lea; Tilson, Lesley; Barry, Michael			Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective	VALUE IN HEALTH			English	Article						cost-effectiveness threshold; drug cost; drug pricing; health expenditure; Health Technology Assessment-opportunity cost; pharmacoeconomics	HEALTH TECHNOLOGY-ASSESSMENT; UNITED-STATES; REIMBURSEMENT RECOMMENDATIONS; PHARMACEUTICAL-INDUSTRY; CANCER DRUG; MARKET; CARE	This study aims to estimate the theoretical excess expenditure that would be incurred by the Irish state-payer, should drugs be reimbursed at their original asking ("list") price rather than at a price at which the drug is considered cost-effective. In Ireland, all new drugs are evaluated by the National Centre for Pharmacoeconomics. For this study, drugs that were submitted by pharmaceutical companies from 2012 to 2017 and considered not cost-effective at list price were reviewed. A total of 43 such drugs met our inclusion criteria, and their pharmacoeconomic evaluations were further assessed. The price at which the drug could be considered cost-effective (cost-effective price) at the upper cost-effectiveness threshold used in Ireland (euro 45 000/quality adjusted life-year) was estimated for 18 drugs with an available cost-effectiveness model. Then, for each drug, the list price and cost-effective price (both per unit) were both individually applied to 1 year of national real-world drug utilization data. This allowed the estimation of the expected expenditures under the assumptions of list price paid and costeffective price paid. The resulting theoretical excess expenditure, the expenditure at list price minus the expenditure at the cost-effective price, was estimated to be euro108.2 million. This estimate is theoretical because of the confidentiality of actual drug prices. The estimation is calculated using the list price and likely overestimates the actual excess expenditure, which would reduce to zero if cost-effective prices are agreed. Nevertheless, this estimate illustrates the importance of a process to assess the value of new drugs so that potential excess drug expenditure is identified.	[Kennedy, Cormac; McCullagh, Laura; Adams, Roisin; Tilson, Lesley; Barry, Michael] Trinity Coll Dublin, Trinity Ctr Hlth Sci, Dept Pharmacol & Therapeut, Dublin 8, Ireland; [McCullagh, Laura; Adams, Roisin; Trela-Larsen, Lea; Tilson, Lesley; Barry, Michael] St James Hosp, Natl Ctr Pharmacoecon, Dublin 8, Ireland		Kennedy, C (通讯作者)，St James Hosp, Dept Pharmacol & Therapeut, Trinity Ctr Hlth Sci, Dublin 8, Ireland.	kennec30@tcd.ie	Kennedy, Cormac/AAP-6770-2020	Kennedy, Cormac/0000-0002-2577-0242			Allen N, 2017, VALUE HEALTH, V20, P320, DOI 10.1016/j.jval.2016.10.014; [Anonymous], 2015, FISC SUST HLTH SYST; Brouwer W, 2019, EUR J HEALTH ECON, V20, P175, DOI 10.1007/s10198-018-1000-4; Carter L, 2021, DEMENTIA-LONDON, V20, P47, DOI 10.1177/1471301219863580; Claxton K, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19140; Claxton KP, PHARM PRICING EARLY; Culyer AJ, 2016, HEALTH ECON POLICY L, V11, P415, DOI 10.1017/S1744133116000049; DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012; Divino V, 2016, HEALTH AFFAIR, V35, P1588, DOI 10.1377/hlthaff.2016.0030; Edney LC, 2018, PHARMACOECONOMICS, V36, P239, DOI 10.1007/s40273-017-0585-2; Griffiths EA, 2015, CLINICOECONOMIC OUTC, V7, P463, DOI 10.2147/CEOR.S87462; Hartung DM, 2015, NEUROLOGY, V84, P2185, DOI 10.1212/WNL.0000000000001608; Health, PRIC SUPPL MED GOODS; Hong SJ, 2018, J ONCOL PRACT, V14, P685, DOI 10.1200/JOP.1800069; Howard DH, 2015, J ECON PERSPECT, V29, P139, DOI 10.1257/jep.29.1.139; IQVIA, GLOBAL ONCOLOGY TREN; IQVIA, GLOB US MED 2019 OUT; Kamal R, 2016, JAMA-J AM MED ASSOC, V315, P1326; Kantarjian H, 2014, J ONCOL PRACT, V10, pE208, DOI 10.1200/JOP.2013.001351; Kawalec P, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0501-4; Kusel J, 2016, BR J HEALTHC MANAG, V22, P267; Light DW, 2011, BIOSOCIETIES, V6, P34, DOI 10.1057/biosoc.2010.40; Linley WG, 2012, PHARMACOECONOMICS, V30, P779, DOI 10.2165/11591530-000000000-00000; McCullagh L, 2016, PHARMACOECONOMICS, V34, P1267, DOI 10.1007/s40273-016-0437-5; O'Sullivan BP, 2013, JAMA-J AM MED ASSOC, V310, P1343, DOI 10.1001/jama.2013.278129; Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150; Picavet E, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-62; Prasad V, 2017, JAMA INTERN MED, V177, P1569, DOI 10.1001/jamainternmed.2017.3601; Roos JCP, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6471; Schmitz S, 2016, PHARMACOECONOMICS, V34, P925, DOI 10.1007/s40273-016-0406-z; Simoens S, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-42; Vallejo-Torres L, 2018, HEALTH ECON, V27, P746, DOI 10.1002/hec.3633	32	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	OCT	2021	24	10					1402	1406		10.1016/j.jval.2021.03.012		SEP 2021	5	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	WE3WV	34593162	hybrid			2022-04-28	WOS:000705561100003
J	Karimi, M; van der Zwaan, L; Islam, K; van Genabeek, J; Rutten-van Molken, M				Karimi, Milad; van der Zwaan, Lennart; Islam, Kamrul; van Genabeek, Joost; Rutten-van Molken, Maureen			Evaluating Complex Health and Social Care Program Using Multi-Criteria Decision Analysis: A Case Study of "Better Together in Amsterdam North"	VALUE IN HEALTH			English	Article						complex care; discrete choice experiment; health technology assessment; multi-criteria decision analysis; well-being	PSYCHOMETRIC PROPERTIES; MCDA; DUTCH; FRAMEWORK; SERVICES; VERSION; K10	Objectives: Multi-criteria decision analysis (MCDA) has been recommended to support policy making in healthcare. However, practical applications of MCDA are sparse. One potential use for MCDA is for the evaluation of programs for complex and vulnerable patients. These complex patients benefit from integrated care programs that span healthcare and social care and aim to improve more than just health outcomes. MCDA can evaluate programs that aim to improve broader outcomes because it allows the evaluation of multiple outcomes alongside each other. In this study, we evaluate an innovative integrated care program in the Netherlands using MCDA. Methods: We used an innovative MCDA framework with broad outcomes of health, well-being, and cost to evaluate the Better Together in Amsterdam North (BSiN) program using preferences of patients, partners, providers, payers, and policy makers in the Netherlands. BSiN provides case management support for a period of 6 months. Seven outcomes that previous research has deemed important to complex patients were measured, including physical functioning and social relationships and participation. Results: We find that the program improved the overall MCDA score marginally, and, thus, after 6 and after 12 months, BSiN was preferred to usual care by all stakeholders. BSiN was preferred to usual care, mostly owing to improvements in psychological well-being and social relationships and participation. Conclusions: The integrated healthcare and social care program BSiN in the Netherlands was preferred to usual care according to an MCDA evaluation. MCDA seems a useful method to evaluate complex programs with benefits beyond health.	[Karimi, Milad; Rutten-van Molken, Maureen] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands; [van der Zwaan, Lennart; van Genabeek, Joost] Netherlands Org Appl Sci Res TNO, Unit Hlth Living, Leiden, Netherlands; [Islam, Kamrul] Univ Bergen, Dept Econ, Bergen, Norway; [Islam, Kamrul] NORCE Norwegian Res Ctr, Bergen, Norway; [Rutten-van Molken, Maureen] Erasmus Univ, Inst Med Technol Assessment iMTA, Rotterdam, Netherlands		Karimi, M (通讯作者)，OPEN Health, Marten Meesweg 107, NL-3068 AV Rotterdam, Netherlands.	miladkarimi@openhealthgroup.com		Islam, M. Kamrul/0000-0003-4751-1513	European UnionEuropean Commission [634288]	This work was supported by grants 634288 from the European Union's Horizon 2020 research and innovation program.	Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Baser O, 2006, VALUE HEALTH, V9, P377, DOI 10.1111/j.1524-4733.2006.00130.x; Bhaskaran K, 2014, INT J EPIDEMIOL, V43, P1336, DOI 10.1093/ije/dyu080; Bjorkquist C, 2018, J MULTIDISCIP HEALTH, V11, P233, DOI 10.2147/JMDH.S157769; Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013; Crossman S, 2019, HEALTH SOC CARE COMM, V27, P409, DOI 10.1111/hsc.12659; Donker T, 2010, PSYCHIAT RES, V176, P45, DOI 10.1016/j.psychres.2009.01.012; Fassaert T, 2009, INT J METH PSYCH RES, V18, P159, DOI 10.1002/mpr.288; Fassaert T, 2014, COMMUNITY MENT HLT J, V50, P583, DOI 10.1007/s10597-013-9683-6; Feinglass J, 2018, POPUL HEALTH MANAG, V21, P96, DOI 10.1089/pop.2017.0026; GGD Amsterdam, 2016, GEZ BEEL RES AMST GE; Hall W, 2018, VALUE HEALTH, V21, P1355, DOI 10.1016/j.jval.2018.06.004; Hudon C, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012353; Kempen GIJM, 1996, SOC SCI MED, V43, P1601, DOI 10.1016/S0277-9536(96)00057-3; Khanassov V, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0459-9; Kuluski K, 2017, INT J INTEGR CARE, V17, DOI 10.5334/ijic.2944; Leijten FRM, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021072; Leijten FRM, 2018, HEALTH POLICY, V122, P12, DOI 10.1016/j.healthpol.2017.06.002; Looman WM, 2019, HEALTH SOC CARE COMM, V27, P1, DOI 10.1111/hsc.12571; Lukersmith S, 2016, INT J INTEGR CARE, V16, DOI 10.5334/ijic.2477; Marsh K, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0125-8; Marsh K, 2016, VALUE HEALTH, V19, P125, DOI 10.1016/j.jval.2015.12.016; Marsh K, 2014, PHARMACOECONOMICS, V32, P345, DOI 10.1007/s40273-014-0135-0; Marsh KD, 2018, VALUE HEALTH, V21, P394, DOI 10.1016/j.jval.2017.10.001; McShane BB, 2019, AM STAT, V73, P235, DOI 10.1080/00031305.2018.1527253; Naversnik K, 2012, VALUE HEALTH, V15, P540, DOI 10.1016/j.jval.2011.12.008; Nolte E, 2012, HEALTH ECON POLICY L, V7, P125, DOI 10.1017/S1744133111000338; Rubin D.B., 2001, HEALTH SERV OUTCOME, V2, P169, DOI DOI 10.1023/A:1020363010465; Rutten-van Molken M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037547; Rutten-van Molken M, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3367-4; Strijk JE., 2014, EUR J PUBLIC HEALTH, V24; Thokala P, 2016, VALUE HEALTH, V19, P1, DOI 10.1016/j.jval.2015.12.003; Tsiachristas A, 2016, INT J INTEGR CARE, V16, DOI 10.5334/ijic.2472; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Wodchis Walter P, 2015, Int J Integr Care, V15, pe021	35	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUL	2021	24	7					966	975		10.1016/j.jval.2021.02.007		JUL 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TE7UB	34243840	Green Published, hybrid			2022-04-28	WOS:000670212100007
J	Aggarwal, S; Kumar, S; Bela, A; Topaloglu, H				Aggarwal, S.; Kumar, S.; Bela, A.; Topaloglu, H.			COMPARISON OF BURDEN OF HOSPITALIZATIONS IN ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD) PATIENTS WITH AND WITHOUT SURGERY: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE	VALUE IN HEALTH			English	Meeting Abstract									[Aggarwal, S.; Bela, A.; Topaloglu, H.] NOVEL Hlth Strategies, Chevy Chase, MD USA; [Kumar, S.] Novel Hlth Strategies, Columbia, MD USA									0	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PGI15	S97	S97					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400420
J	Azimpour, K; Tremblay, G; Wolitski, D; Forsythe, A				Azimpour, K.; Tremblay, G.; Wolitski, D.; Forsythe, A.			THE APPROPRIATE HEALTH ECONOMIC MODELING APPROACH IN CANCER SCREENING TESTS	VALUE IN HEALTH			English	Meeting Abstract									[Azimpour, K.; Tremblay, G.; Wolitski, D.] Purple Squirrel Econ, Montreal, PQ, Canada; [Forsythe, A.] Purple Squirrel Econ, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN104	S39	S39					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400162
J	Borrelli, E; McGladrigan, CG				Borrelli, E.; McGladrigan, C. G.			CYCLIN DEPENDENT KINASE (CDK) 4/6 INHIBITORS AND LUNG INFLAMMATION: AN ANALYSIS OF THE UNITED STATES FOOD AND DRUG ADMINISTRATIONS' ADVERSE EVENT REPORTING SYSTEM	VALUE IN HEALTH			English	Meeting Abstract									[Borrelli, E.] Univ Rhode Isl, Coll Pharm, Cranston, RI USA; [McGladrigan, C. G.] Mass Gen North Shore Canc Ctr, Danvers, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN112	S40	S40					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400168
J	Brockbank, T; Sotou, D; Barkauskaite, E; Patel, P				Brockbank, T.; Sotou, D.; Barkauskaite, E.; Patel, P.			EARLY PRICING AND ACCESS FORECASTING FOR ORPHAN ASSETS - LEVERAGING A VALUE-DRIVEN APPROACH TO PRICE FORECASTING	VALUE IN HEALTH			English	Meeting Abstract									[Brockbank, T.; Sotou, D.; Barkauskaite, E.; Patel, P.] Global Pricing Innovat, London, Lon, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO12	S199	S199					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401134
J	Caballol-Avendano, F; Flores-Hoyos, A; Guerra-Cruz, J; Merillu-Gonzalez, V; Morales-Vizcarra, F; Reynaldos-Grandon, K				Caballol-Avendano, F.; Flores-Hoyos, A.; Guerra-Cruz, J.; Merillu-Gonzalez, V; Morales-Vizcarra, F.; Reynaldos-Grandon, K.			BURNOUT SYNDROME PREVENTION IN NURSING AT PANDEMIC (COVID-19): A LITERATURE REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Caballol-Avendano, F.; Flores-Hoyos, A.; Guerra-Cruz, J.; Merillu-Gonzalez, V; Morales-Vizcarra, F.; Reynaldos-Grandon, K.] Andres Bello Univ, Santiago, RM, Chile									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS69	S185	S185					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401071
J	Dai, D; Fernandes, J; Samiian, A; Coetzer, H				Dai, D.; Fernandes, J.; Samiian, A.; Coetzer, H.			PATIENT CHARACTERISTICS AND COMORBIDITIES IN PATIENTS WITH ESSENTIAL TREMOR: A RETROSPECTIVE OBSERVATIONAL STUDY IN A UNITED STATES COMMERCIALLY INSURED AND MEDICARE ADVANTAGE POPULATION	VALUE IN HEALTH			English	Meeting Abstract									[Dai, D.; Fernandes, J.; Coetzer, H.] CVS Clin Trial Serv, New York, NY USA; [Samiian, A.] Cala Hlth, San Mateo, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND44	S167	S167					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400728
J	Dallabrida, S; Linke, H; Shah, P; Culbreth-Notaro, M				Dallabrida, S.; Linke, H.; Shah, P.; Culbreth-Notaro, M.			PATIENT PREFERENCES AND FEEDBACK REGARDING DAILY REPORTING OF COVID-19 SYMPTOMS USING PERSONAL SMARTPHONES FOR THE OBVIO-19 STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Dallabrida, S.; Shah, P.; Culbreth-Notaro, M.] Obviohealth, Orlando, FL USA; [Linke, H.] Obviohealth, Columbus, OH USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS105	S192	S192					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401101
J	Dickson, J; Pierre, M; Lockhart, L; McCormack, J				Dickson, J.; Pierre, M.; Lockhart, L.; McCormack, J.			GAINING TRUST IN THE USE OF VIRTUAL MEETINGS FOR HEALTH TECHNOLOGY ASSESSMENT DURING THE COVID-19 PANDEMIC	VALUE IN HEALTH			English	Meeting Abstract									[Dickson, J.; Pierre, M.; Lockhart, L.; McCormack, J.] Healthcare Improvement Scotland, Glasgow, Lanark, Scotland									0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS67	S185	S185					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401069
J	Drozd, M; Wex, J; Szkultecka-Debek, M; Zibelnik, N				Drozd, M.; Wex, J.; Szkultecka-Debek, M.; Zibelnik, N.			UNCERTAINTY IN CLINICAL OUTCOMES IN THE TREATMENT OF PAEDIATRIC ORPHAN INDICATIONS WITH LICENSED THERAPIES	VALUE IN HEALTH			English	Meeting Abstract									[Drozd, M.] Med Univ Lublin, Lublin, Poland; [Wex, J.; Szkultecka-Debek, M.; Zibelnik, N.] EUSA Pharma, Hemel Hempstead, Hrt, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO4	S198	S198					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401127
J	Exuzides, A; Gholizadeh, S; Lewis, K; Palmer, C; Waltz, M; Rose, J; Jolley, A; Behne, JM; Behne, MK; Blaschke, TF; Smith, TJ; Sinnott, J; Cook, L; Yeaman, MR				Exuzides, A.; Gholizadeh, S.; Lewis, K.; Palmer, C.; Waltz, M.; Rose, J.; Jolley, A.; Behne, J. M.; Behne, M. K.; Blaschke, T. F.; Smith, T. J.; Sinnott, J.; Cook, L.; Yeaman, M. R.			DEMOGRAPHICS AND RELAPSE PROFILE CORRELATES WITH TREATMENT CHANGE IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) PATIENTS: ANALYSIS OF THE CIRCLES STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Exuzides, A.; Gholizadeh, S.] Genentech Inc, San Francisco, CA 94080 USA; [Lewis, K.; Palmer, C.; Waltz, M.; Rose, J.; Jolley, A.; Sinnott, J.; Cook, L.] Univ Utah, Salt Lake City, UT USA; [Behne, J. M.; Behne, M. K.] Guthy Jackson Charitable Fdn, Beverly Hills, CA USA; [Blaschke, T. F.] Stanford Univ, Stanford, CA 94305 USA; [Smith, T. J.] Univ Michigan, Ann Arbor, MI 48109 USA; [Yeaman, M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO75	S211	S212					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401190
J	Feng, G; Huang, F; Chen, Q; Zhong, Q; Liu, T; Hao, D; Yan, N; Jian, T; Ming, WK				Feng, G.; Huang, F.; Chen, Q.; Zhong, Q.; Liu, T.; Hao, D.; Yan, N.; Jian, T.; Ming, W. K.			INNOVATIVE APPLICATION OF A MOBILE APP FOR GESTATIONAL DIABETES HEALTH EDUCATION IN THE ERA OF THE COVID-19 PANDEMIC AND BIG DATA	VALUE IN HEALTH			English	Meeting Abstract									[Feng, G.; Huang, F.; Chen, Q.; Zhong, Q.; Liu, T.; Hao, D.; Yan, N.; Jian, T.] Jinan Univ, Guangzhou 44, Peoples R China; [Ming, W. K.] Jinan Univ, Sch Med, Dept Publ Hlth & Prevent Med, Guangzhou, Peoples R China				Ming, Wai-kit/AAH-5989-2019	Ming, Wai-kit/0000-0002-8846-7515				0	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB28	S82	S83					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400361
J	Gressler, L; Marinac-Dabic, D; Dosreis, S; Goodney, P; Mullins, CD; Shaya, FT				Gressler, L.; Marinac-Dabic, D.; Dosreis, S.; Goodney, P.; Mullins, C. D.; Shaya, F. T.			COMPARING MACHINE-LEARNING METHODS FOR THE PREDICTION OF MAJOR ADVERSE LIMB EVENTS AND MORTALITY AFTER A PERCUTANEOUS INTERVENTION	VALUE IN HEALTH			English	Meeting Abstract									[Gressler, L.] Univ Maryland, Baltimore, MD 21201 USA; [Marinac-Dabic, D.] US FDA, Silver Spring, MD USA; [Dosreis, S.; Mullins, C. D.] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA; [Goodney, P.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; [Shaya, F. T.] Univ Maryland Baltimore, Baltimore, MD USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		AI4	S1	S2					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400005
J	Iloanusi, S; Mgbere, O; Essien, EJ				Iloanusi, S.; Mgbere, O.; Essien, E. J.			PIN1 POLYPHARMACY AMONG COVID-19 PATIENTS: A PRISMA-BASED SYSTEMATIC REVIEW OF AVAILABLE LITERATURE	VALUE IN HEALTH			English	Meeting Abstract									[Iloanusi, S.; Mgbere, O.; Essien, E. J.] Univ Houston, Houston, TX USA				Mgbere, Osaro/O-2702-2018	Mgbere, Osaro/0000-0002-2863-6284				0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN1	S106	S106					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400460
J	Lo, SH; Lloyd, A; Elkhalifa, S; Sisic, Z; Van Nooten, F				Lo, S. H.; Lloyd, A.; Elkhalifa, S.; Sisic, Z.; Van Nooten, F.			TIME TRADE-OFF UTILITIES FOR HEREDITARY ANGIOEDEMA HEALTH STATES	VALUE IN HEALTH			English	Meeting Abstract									[Lo, S. H.; Lloyd, A.] Acaster Lloyd Consulting Ltd, London, Lon, England; [Elkhalifa, S.] Salford Royal NHS Fdn Trust, Salford, Lancs, England; [Sisic, Z.; Van Nooten, F.] BioCryst, London, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSY17	S232	S232					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401278
J	Macaulay, R				Macaulay, R.			THE "NICENESS" OF NICE: A TIME-TREND ANALYSIS	VALUE IN HEALTH			English	Meeting Abstract									[Macaulay, R.] Precis Advisors, London, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS73	S186	S186					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401075
J	Mittler, J; Danchenko, N; Bouchard, J				Mittler, J.; Danchenko, N.; Bouchard, J.			MODELING THE ECONOMIC IMPACT OF INCORPORATING ABOBOTULINUMTOXINA INTO AN INSTITUTIONAL FORMULARY FOR FDA-APPROVED INDICATIONS	VALUE IN HEALTH			English	Meeting Abstract									[Mittler, J.] Peregrine Market Access, Saratoga Springs, NY USA; [Danchenko, N.] Ipsen Global, Boulogne, France; [Bouchard, J.] Ipsen, Cambridge, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND35	S165	S165					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400719
J	Mozaffari, E; Chandak, A; Liang, S; Gayle, J; Haubrich, R; Thrun, M; Hodgkins, P				Mozaffari, E.; Chandak, A.; Liang, S.; Gayle, J.; Haubrich, R.; Thrun, M.; Hodgkins, P.			REAL-WORLD UTILIZATION OF REMDESIVIR IN 2020: A RETROSPECTIVE COHORT STUDY	VALUE IN HEALTH			English	Meeting Abstract									[Mozaffari, E.; Liang, S.; Haubrich, R.; Thrun, M.; Hodgkins, P.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA; [Chandak, A.] Certara, New York, NY USA; [Gayle, J.] Premier Inc, Charlotte, NC USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN82	S121	S121					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400530
J	Amaral, LM; Barros, M; Freitas, G; Martins, C; Rovere, R; Oliveira, M; Girola, N; Sallum, F; Arinelli, R; Pepe, C; Salgado, J				Murta Amaral, L.; Barros, M.; Freitas, G.; Martins, C.; Rovere, R.; Oliveira, M.; Girola, N.; Sallum, F.; Arinelli, R.; Pepe, C.; Salgado, J.			A PARTIAL MCDA APPROACH TO IDENTIFY KEY CRITERIA FOR BRAZILIAN PUBLIC REIMBURSEMENT DECISION IN MELANOMA ADJUVANT TREATMENT SETTING	VALUE IN HEALTH			English	Meeting Abstract									[Murta Amaral, L.; Sallum, F.; Arinelli, R.] ORIGIN Hlth Intelligence, Rio De Janeiro, RJ, Brazil; [Barros, M.] AC Camargo Hosp, Sao Paulo, Brazil; [Freitas, G.] Secretaria Espirito Santo, Espirito Santo, Brazil; [Martins, C.] Amer Ctr Oncol Integrado, Rio De Janeiro, Brazil; [Rovere, R.] Hosp Santa Catarina, Blumenau, SC, Brazil; [Oliveira, M.] Inst Lado Lado Pela Vida, Sao Paulo, Brazil; [Girola, N.; Salgado, J.] Novartis Biociencias SA, Sao Paulo, SP, Brazil; [Pepe, C.] ORIGIN Hlth Intelligence, Sao Paulo, Brazil									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN182	S53	S53					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400228
J	Okumura, L; Sanchez, L; Alves, M; Candolfi, P				Okumura, L.; Sanchez, L.; Alves, M.; Candolfi, P.			BALLOON-EXPANDABLE VERSUS SELF-EXPANDABLE TRANSCATHETER AORTIC VALVE REPLACEMENT	VALUE IN HEALTH			English	Meeting Abstract									[Okumura, L.; Alves, M.] Edwards LLC, Sao Paulo, Brazil; [Sanchez, L.] Edwards Lifesci Mexico, Mexico City, DF, Mexico; [Candolfi, P.] Edwards Lifesci Inc, Irvine, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCV8	S68	S68					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400296
J	Ourhaan, N; Bhagwandass, H; Goodin, A; Hincapie-Castillo, JM				Ourhaan, N.; Bhagwandass, H.; Goodin, A.; Hincapie-Castillo, J. M.			TRENDS IN UTILIZATION OF AMPHETAMINE-CONTAINING MEDICATIONS FOLLOWING STATE LEVEL RESTRICTION LAWS FOR ACUTE PAIN OPIOID PRESCRIPTIONS	VALUE IN HEALTH			English	Meeting Abstract									[Ourhaan, N.; Bhagwandass, H.; Goodin, A.] Univ Florida, Gainesville, FL USA; [Hincapie-Castillo, J. M.] Univ Florida, Coll Pharm, Gainesville, FL USA				Hincapie-Castillo, Juan/J-5499-2019	Hincapie-Castillo, Juan/0000-0002-6945-2713				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG15	S89	S90					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400390
J	Paredes, D; Zamarin, J; Vallejos, C; Valencia, J				Paredes, D.; Zamarin, J.; Vallejos, C.; Valencia, J.			DIFFERENCES IN COSTING METHODS IN BARIATRIC SURGERY IN CHILE: DRG STRATEGY AND BOTTOM UP STRATEGY	VALUE IN HEALTH			English	Meeting Abstract									[Paredes, D.] Medtronic, Hlth Econ & Reimbursement, Santiago, RM, Chile; [Zamarin, J.; Vallejos, C.] Hosp Reg Coyhaique, Coyhaique, Chile; [Zamarin, J.; Vallejos, C.] IFSO, Coyhaique, Chile; [Valencia, J.] Medtronic, Miami, FL USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB10	S79	S79					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400346
J	Park, S; Oh, HW				Park, S.; Oh, H. W.			COST-MINIMIZATION ANALYSIS OF INTRODUCING HEXAXIM (R) INTO KOREAN NATIONAL IMMUNIZATION PROGRAM	VALUE IN HEALTH			English	Meeting Abstract									[Park, S.] Sanofi Aventis Korea Co Ltd, Seoul, South Korea; [Oh, H. W.] Sanofi Pasteur Ltd, Seoul, South Korea									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN13	S107	S107					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400468
J	Patel, S; Crawford, A; Maio, V; Schubert, P; Goldfarb, N				Patel, S.; Crawford, A.; Maio, V; Schubert, P.; Goldfarb, N.			IMPACT OF METFORMIN ADHERENCE ON HEALTHCARE EXPENDITURES IN AN EMPLOYED POPULATION	VALUE IN HEALTH			English	Meeting Abstract									[Patel, S.; Crawford, A.; Maio, V] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Schubert, P.] Gallagher Benefit Serv, Wayne, PA USA; [Goldfarb, N.] Greater Philadelphia Business Coalit Hlth, Philadelphia, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB41	S85	S85					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400371
J	Pradhan, A; Oates, T; Shaya, FT				Pradhan, A.; Oates, T.; Shaya, F. T.			PREDICTING OPIOID USE DISORDER USING MACHINE LEARNING METHODOLOGIES	VALUE IN HEALTH			English	Meeting Abstract									[Pradhan, A.; Shaya, F. T.] Univ Maryland, Baltimore, MD 21201 USA; [Oates, T.] Univ Maryland Baltimore Cty, Baltimore, MD 21228 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG36	S93	S93					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400405
J	Reis, NJP; Busch, J				Reis, Neto J. P.; Busch, J.			MODIFIABLE LIFESTYLE RISK FACTORS FOR ARTERIAL HYPERTENSION AND DIABETES MELLITUS IN BENEFICIARIES OF A HEALTH PLAN IN BRAZIL: A RETROSPECTIVE COHORT	VALUE IN HEALTH			English	Meeting Abstract									[Reis, Neto J. P.] Univ Fed Maranhao, Rio De Janeiro, RJ, Brazil; [Busch, J.] Souza Marques Univ, Rio De Janeiro, RJ, Brazil									0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU69	S157	S157					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400684
J	Skrobanski, H; Williams, K; Werner, C; O'Neill, S; Buesch, K; Acaster, S				Skrobanski, H.; Williams, K.; Werner, C.; O'Neill, S.; Buesch, K.; Acaster, S.			A QUALITATIVE STUDY ON THE IMPACT OF CARING FOR AN INDIVIDUAL WITH AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY (AADCD)	VALUE IN HEALTH			English	Meeting Abstract									[Skrobanski, H.; Williams, K.; Acaster, S.] Acaster Lloyd Consulting Ltd, London, Lon, England; [Werner, C.] PTC Therapeut, Frankfurt, Germany; [O'Neill, S.] PTC Therapeut Int Ltd, Dublin, Ireland; [Buesch, K.] PTC Therapeut Switzerland GmbH, Zug, Switzerland									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO52	S206	S206					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401167
J	Stenson, K; O'Callaghan, L; Mellor, J; Husbands, J; Hatchell, N; Wright, J; Barlow, S				Stenson, K.; O'Callaghan, L.; Mellor, J.; Husbands, J.; Hatchell, N.; Wright, J.; Barlow, S.			HEALTHCARE RESOURCE UTILIZATION (HCRU) FOR EARLY-, MIDDLE- AND LATE-STAGE AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS: RESULTS FROM A REAL-WORLD POINT-IN-TIME SURVEY	VALUE IN HEALTH			English	Meeting Abstract									[Stenson, K.; O'Callaghan, L.] Biogen, Cambridge, MA USA; [Mellor, J.; Husbands, J.; Hatchell, N.; Wright, J.; Barlow, S.] Adelphi Real World, Bollington, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND68	S172	S172					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401010
J	Vieira, FM; Ribeiro, GN; Brito, C; Travassos, A				Vieira, F. M.; Ribeiro, G. N.; Brito Filho, C.; Travassos, A.			COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF VENETOCLAX PLUS OBINUTUZUMAB VERSUS IBRUTINIB IN PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM	VALUE IN HEALTH			English	Meeting Abstract									[Vieira, F. M.] Inst COI Educ & Pesquisa, Rio De Janeiro, Go, Brazil; [Ribeiro, G. N.] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil; [Brito Filho, C.] AbbVie Brazil, Sao Paulo, SP, Brazil; [Travassos, A.] AbbVie, Sao Paulo, SP, Brazil									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN106	S39	S39					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400163
J	Wallace, E; Sacks, N; Cyr, P; Baker-Wagner, M				Wallace, E.; Sacks, N.; Cyr, P.; Baker-Wagner, M.			AN OBSERVATIONAL COHORT ANALYSIS ON THE ECONOMIC IMPACT OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH FABRY DISEASE	VALUE IN HEALTH			English	Meeting Abstract									[Wallace, E.] Univ Alabama Birmingham, Vestavia, AL USA; [Sacks, N.; Baker-Wagner, M.] Precis HEOR, Boston, MA USA; [Cyr, P.] Precis Value & Hlth, Boston, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO23	S201	S201					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401143
J	Zhang, M; Mansfield, V				Zhang, M.; Mansfield, V			COMPARING COMPLEX MACHINE LEARNING MODELS TO PREDICT LIKELIHOOD OF OVARIAN CANCER USING MEDICARE CLAIMS DATA	VALUE IN HEALTH			English	Meeting Abstract									[Zhang, M.] North Carolina State Univ, Apex, NC USA; [Mansfield, V] UnitedHlth Grp, Minneapolis, MN USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN194	S56	S56					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400240
J	Zhao, J; Jin, G; Yang, L				Zhao, J.; Jin, G.; Yang, L.			ECONOMIC EVALUATION OF AVATROMBOPAG FOR ELECTIVE DIAGNOSTIC PROCEDURE OR SURGERY OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE (CLD) IN CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Zhao, J.; Yang, L.] Peking Univ, Beijing, Peoples R China; [Jin, G.] Peking Univ, London, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU11	S147	S147					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400639
J	Rodriguez-Mireles, S; Lopez-Valcarcel, BG; Serra-Majem, L				Rodriguez-Mireles, Silvia; Lopez-Valcarcel, Beatriz G.; Serra-Majem, Lluis			When Industrial Policies Conflict With Population Health: Potential Impact of Removing Food Subsidies on Obesity Rates	VALUE IN HEALTH			English	Article						food subsidies; obesity; sugar/economics; cheese/economics; butter/economics; industrial subsidies; health policy	SUGAR-SWEETENED BEVERAGES; TAX; OVERWEIGHT; DEMAND; PRICES; PREVENTION; MORTALITY; DRINKS	Objectives: To model the potential impact on obesity of removing butter, cheese, and sugar subsidies in the Canary Islands. Methods: A simulation model was applied based on a local data set of subsidies and retail prices (2007-2016), data on own-price elasticity estimates, and representative nutritional and health surveys. We estimated marginal obesity prevalence and population attributable fraction to assess the potential impact of the butter, cheese, and sugar subsidies intervention. Results: The intervention was predicted to avoid 10 363 obese adults over the study period, because of the reduction of the obesity prevalence by -0.7 percentage points. Overall, the predicted effect was largest in elderly and male groups, although females with a low socioeconomic status experienced the greatest decrease in the prevalence. The population attributable fraction predicted that 4.0% of population with obesity were attributable to the existence of these subsidies. Conclusions: This analysis provides policy makers with the predicted impact on obesity of the butter, cheese, and sugar subsidies disposal, enabling them to incorporate this health impact into decision making across policy areas in the economic and health field. This study aims to model the potential impact on obesity of removing industrial subsidies for butter, cheese and sugar in the Canary Islands.	[Rodriguez-Mireles, Silvia; Lopez-Valcarcel, Beatriz G.] Univ Las Palmas Gran Canaria, Dept Quantitat Methods Econ & Management, Las Palmas Gran Canaria 35017, Spain; [Rodriguez-Mireles, Silvia] Hosp Univ Gran Canaria Dr Negrin, Canary Hlth Serv, Las Palmas Gran Canaria, Spain; [Serra-Majem, Lluis] Univ Las Palmas Gran Canaria, Res Inst Biomed & Hlth Sci, Las Palmas Gran Canaria, Spain; [Serra-Majem, Lluis] Complejo Hosp Univ Insular Maternoinfantil, Canary Hlth Serv, Las Palmas Gran Canaria, Spain; [Serra-Majem, Lluis] Inst Salud Carlos III, CIBER OBN, Madrid, Spain		Rodriguez-Mireles, S (通讯作者)，Univ Las Palmas Gran Canaria, Dept Quantitat Methods Econ & Management, Las Palmas Gran Canaria 35017, Spain.	silvia.rodriguezmireles@ulpgc.es	Rodriguez Mireles, Silvia/F-2835-2019	Rodriguez Mireles, Silvia/0000-0002-6928-9493	National Plan for Scientific Research and Technical Innovation 2017-2020 - Ministry of Economy and Competitiveness of Spain [ECO2017-83771-C3-2]; Fundacion Canaria Colegio de Medicos de Las Palmas [I18/20]	This paper forms part of the research funded by Grant ECO2017-83771-C3-2 under the National Plan for Scientific Research and Technical Innovation 2017-2020 funded by the Ministry of Economy and Competitiveness of Spain. Rodriguez-Mireles received a research grant (I18/20) from the Fundacion Canaria Colegio de Medicos de Las Palmas.	Afshin A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMoa1614362; Allcott H, 2019, J ECON PERSPECT, V33, P202, DOI 10.1257/jep.33.3.202; Aranceta J, 2003, MED CLIN-BARCELONA, V120, P608, DOI 10.1157/13046926; Aranceta J, 2007, PUBLIC HEALTH NUTR, V10, P1187, DOI 10.1017/S1368980007000699; Bach-Faig A, 2011, PUBLIC HEALTH NUTR, V14, P2274, DOI 10.1017/S1368980011002515; Briggs ADM, 2017, LANCET PUBLIC HEALTH, V2, pE15, DOI 10.1016/S2468-2667(16)30037-8; Briggs ADM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-860; Brouwer-Brolsma EM, 2018, NUTR METAB CARDIOVAS, V28, P451, DOI 10.1016/j.numecd.2018.01.008; Camacho S, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1289650; Chinea-Martin A, 2012, ACTIVIDAD AGROALIMEN, P129; Consejeria de Economia Industria Comercio y Conocimiento del Gobierno de Canarias, BALANCES AYUDAS REGI; Cornelsen L, 2015, HEALTH ECON, V24, P1548, DOI 10.1002/hec.3107; Dreher ML, 2020, NUTRIENTS, V12, DOI 10.3390/nu12071919; DUARTE AAL, 2009, J FLUID MECH, V4, P1; Duarte F, 1998, INVESTIG AGRAR PROD, V13; Elinder LS, 2005, BMJ-BRIT MED J, V331, P1333, DOI 10.1136/bmj.331.7528.1333; Escobar MAC, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1072; Eyles H, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001353; Godenau D, 2019, GRADO AUTOABASTECIMI; Goettler A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014632; Gordis L, 2000, EPIDEMIOLOGY; GOULD BW, 1991, AM J AGR ECON, V73, P212, DOI 10.2307/1242897; Green R, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3703; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Harkanen T, 2014, FOOD POLICY, V49, P196, DOI 10.1016/j.foodpol.2014.07.001; Hawkes C, 2015, LANCET, V385, P2410, DOI 10.1016/S0140-6736(14)61745-1; Hernandez PA, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10093057; Instituto Canario de Estadistica, METODOLOGIA; Instituto de Informacion Sanitaria del Ministerio de Sanidad Consumo y Bienestar Social, MORTALIDAD CAUSA MUE; Navamuel EL, 2014, APPL ECON, V46, P1624, DOI 10.1080/00036846.2013.868593; Lloyd-Williams F, 2008, B WORLD HEALTH ORGAN, V86, P535, DOI 10.2471/BLT.08.053728; Lucan SC, 2015, PUBLIC HEALTH NUTR, V18, P571, DOI 10.1017/S1368980014002559; Majem LS, 2000, ARCH LATINOAM NUTR, V50, P62; Manyema M, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3085-y; Manyema M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105287; Mozaffarian D, 2019, ADV NUTR, V10, p917S, DOI 10.1093/advances/nmz053; Mytton OT, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2931; Niebylski ML, 2015, NUTRITION, V31, P787, DOI 10.1016/j.nut.2014.12.010; Powell LM, 2013, OBES REV, V14, P110, DOI 10.1111/obr.12002; Powell LM, 2009, MILBANK Q, V87, P229, DOI 10.1111/j.1468-0009.2009.00554.x; Roberto CA, 2015, LANCET, V385, P2400, DOI 10.1016/S0140-6736(14)61744-X; Ruiz E, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030275; Sacks FM, 1999, CLIN CARDIOL, V22, P6, DOI 10.1002/clc.4960221503; Scheelbeek PFD, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4786; Schwendicke F, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3938-4; Schwingshackl L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157461; Schwingshackl L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140846; Shumow L, 2015, DIETARY SUGARS AND HEALTH, P43; Smed S, 2007, FOOD POLICY, V32, P624, DOI 10.1016/j.foodpol.2007.03.002; Subdireccion General de Comercializacion y Relaciones Internacionales, SUBDIRECCION GEN DE; Swinburn BA, 2011, LANCET, V378, P804, DOI 10.1016/S0140-6736(11)60813-1; Swinburn BA, 2009, AM J CLIN NUTR, V89, P1723, DOI 10.3945/ajcn.2008.27061; The Council of the European Communities, 1992, COUNCIL REGULATION E; Waterlander WE, 2013, AM J CLIN NUTR, V97, P886, DOI 10.3945/ajcn.112.041632; World Health Organization, GLOBAL HLTH OBSERVAT; Wright A, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4497-z	56	2	2	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAR	2021	24	3					336	343		10.1016/j.jval.2020.12.005		FEB 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QM9NG	33641766	hybrid			2022-04-28	WOS:000622099500004
J	Lakdawalla, DN; Phelps, CE				Lakdawalla, Darius N.; Phelps, Charles E.			Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach	VALUE IN HEALTH			English	Article						CEA for disabled persons; value of hope; value of insurance; optimal CE decision threshold; severity of illness		Objectives: Cost-effectiveness analysis (CEA) embeds an assumption at odds with most economic analysis-that of constant returns to health in the creation of happiness (utility). We aim to reconcile it with the bulk of economic theory. Methods: We generalize the traditional CEA approach, allow diminishing returns to health, and align CEA with the rest of the health economics literature. Results: This simple change has far-reaching implications for the practice of CEA. First, optimal cost-effectiveness thresholds should systematically rise for more severe diseases and fall for milder ones. We provide formulae for estimating how these thresholds vary with health-related quality of life (QoL) in the sick state. Practitioners can also use our approach to account for treatment outcome uncertainty. Holding average benefits fixed, risk-averse consumers value interventions more when they reduce outcome uncertainty ('insurance value') and/or when they provide a chance at positively skewed outcomes (Value of hope'). Finally, we provide a coherent way to combine improvements in QoL and life expectancy (LE) when people have diminishing returns to QoL. Conclusion: This new approach obviates the need for increasingly prevalent and ad hoc exceptions to CEA for end-of-life care, rare disease, and very severe disease (eg, cancer). Our methods also show that the value of improving QoL for disabled people is greater than for comparable non-disabled people, thus resolving an ongoing and mathematically legitimate objection to CEA raised by advocates for disabled people. Our Generalized Risk-Adjusted Cost-Effectiveness (GRACE) approach helps align HTA practice with realistic preferences for health and risk.	[Lakdawalla, Darius N.] Univ Southern Calif, Quintiles Prof Pharmaceut Dev & Regulatory Innova, Leonard Schaeffer Ctr Hlth Policy & Econ, Price Sch Publ Policy,Sch Pharm, Los Angeles, CA 90007 USA; [Lakdawalla, Darius N.] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Phelps, Charles E.] Univ Rochester, Rochester, NY USA		Lakdawalla, DN (通讯作者)，Univ Southern Calif, Schaeffer Ctr Hlth Policy & Econ, 635 Downey Way,VPD 414K, Los Angeles, CA 90089 USA.	dlakdawa@usc.edu	Lakdawalla, Darius/B-4409-2011	Lakdawalla, Darius/0000-0001-5934-8042	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1R01AG062277-01]	The National Institute on Aging (1R01AG062277-01) provided funding for this research.	Anderson JL, 2014, J AM COLL CARDIOL, V63, P2304, DOI 10.1016/j.jacc.2014.03.016; Basu A, 2020, VALUE HEALTH, V23, P96, DOI 10.1016/j.jval.2019.10.014; Buckingham K, 2006, HEALTH ECON, V15, P1149, DOI 10.1002/hec.1122; Cather DA, 2010, RISK MANAG INSUR REV, V13, P127; Center for the Evaluation of Value and Risk in Health, COST EFFECTIVENESS A; Chetty R, 2006, AM ECON REV, V96, P1821, DOI 10.1257/aer.96.5.1821; Easterlin RA, 2004, DAEDALUS-US, V133, P26, DOI 10.1162/001152604323049361; Garber AM, 1997, J HEALTH ECON, V16, P1, DOI 10.1016/S0167-6296(96)00506-1; Garrison LP, 2018, VALUE HEALTH, V21, P161, DOI 10.1016/j.jval.2017.12.009; Groot W, 2000, J HEALTH ECON, V19, P403, DOI 10.1016/S0167-6296(99)00037-5; Institute for Clinical and Economic Review, 2020, 2020 2023 VALUE ASSE; KIMBALL MS, 1990, ECONOMETRICA, V58, P53, DOI 10.2307/2938334; Lakdawalla D, 2017, J PUBLIC ECON, V145, P94, DOI 10.1016/j.jpubeco.2016.11.012; Lakdawalla DN, 2018, VALUE HEALTH, V21, P131, DOI 10.1016/j.jval.2017.12.007; Lakdawalla DN, 2012, HEALTH AFFAIR, V31, P676, DOI 10.1377/hlthaff.2011.1300; Neumann PG., 2017, COST EFFECTIVENESS H, V2nd; Nord E, 2001, Expert Rev Pharmacoecon Outcomes Res, V1, P85, DOI 10.1586/14737167.1.1.85; Nord E, 1999, HEALTH ECON, V8, P25; Noussair CN, 2014, REV ECON STUD, V81, P325, DOI 10.1093/restud/rdt032; Paulden M, 2017, EXPERT REV PHARM OUT, V17, P239, DOI 10.1080/14737167.2017.1330152; Phelps CE, 2020, GEN METHOD ESTIMATIN; Phelps CE, 2019, VALUE HEALTH, V22, P785, DOI 10.1016/j.jval.2019.03.003; Phelps CE, 2017, VALUE HEALTH, V20, P251, DOI 10.1016/j.jval.2016.11.011; Rice N., 2013, CTR HLTH EC RES PAPE; Shafrin J, 2017, VALUE HEALTH, V20, P217, DOI 10.1016/j.jval.2016.11.028; Tan-Torres Edjerer R, 2003, MAKING CHOICES HLTH; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	27	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	FEB	2021	24	2					244	249		10.1016/j.jval.2020.10.003		JAN 2021	6	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QJ1VI	33518031	Bronze			2022-04-28	WOS:000619478100012
J	Crown, WH; Bierer, BE				Crown, William H.; Bierer, Barbara E.			Real-World Evidence: Understanding Sources of Variability Through Empirical Analysis	VALUE IN HEALTH			English	Editorial Material									[Crown, William H.] Brandeis Univ, Florence Heller Grad Sch, Waltham, MA USA; [Bierer, Barbara E.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Bierer, Barbara E.] Harvard Med Sch, Boston, MA 02115 USA		Bierer, BE (通讯作者)，Brigham & Womens Hosp, Dept Med, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA.	bbierer@bwh.harvard.edu					Anglemyer A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000034.pub2; Bartlett VL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.12869; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; FDA, 2018, FRAM FDAS REAL WORLD; Forbes SP, 2020, J GEN INTERN MED, V35, P1396, DOI 10.1007/s11606-020-05713-5; Franklin JM, 2017, CLIN PHARMACOL THER, V102, P924, DOI 10.1002/cpt.857; Goodman SN, 2017, JAMA-J AM MED ASSOC, V317, P705, DOI 10.1001/jama.2016.19970; Hernan MA, 2008, EPIDEMIOLOGY, V19, P766, DOI 10.1097/EDE.0b013e3181875e61; Madigan D, 2013, AM J EPIDEMIOL, V178, P645, DOI 10.1093/aje/kwt010; Noseworthy PA, 2019, EUR HEART J, V40, P1257, DOI 10.1093/eurheartj/ehz085; Packer DL, 2019, JAMA-J AM MED ASSOC, V321, P1261, DOI 10.1001/jama.2019.0693; Petersen ML, 2014, EPIDEMIOLOGY, V25, P418, DOI 10.1097/EDE.0000000000000078; RCT Duplicate, RAND CONTR TRIALS DU; Schneeweiss S, 2008, NEW ENGL J MED, V358, P771, DOI 10.1056/NEJMoa0707571; Seeger JD, 2015, THROMB HAEMOSTASIS, V114, P1277, DOI 10.1160/TH15-06-0497; Sentinel, FOOD DRUG ADM FDA SE; Thompson D, 2021, VALUE HLTH, V24; US Food and Drug Administration, US REAL WORLD EV SUP; Yale School of Medicine, CTR OUTC RES EV CORE; Zarin DA, 2020, J CLIN EPIDEMIOL, V121, P29, DOI 10.1016/j.jclinepi.2020.01.007	21	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JAN	2021	24	1					116	117		10.1016/j.jval.2020.11.003		JAN 2021	2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QC0YJ	33431144	Bronze			2022-04-28	WOS:000614560000016
J	Vasquez, WF; Trudeau, JM				Vasquez, William F.; Trudeau, Jennifer M.			Will Americans Get Vaccinated? Predicting COVID-19 Vaccine Uptake Rates Under Contingent Scenarios	VALUE IN HEALTH			English	Article						contingent scenarios; preference heterogeneity; vaccine uptake	INFLUENZA VACCINATION; ETHNIC DISPARITIES; PREFERENCES; POPULATIONS; VALUATION; COVERAGE; CHILDREN	Objectives: Amid a pandemic, vaccines represent a promising solution for mitigating public health and economic crises, and an improved understanding of individuals' vaccination intentions is crucial to design optimal immunization campaigns. This study predicts uptake rates for different COVID-19 vaccine specifications and identifies personal characteristics that moderate an individual's responsiveness to vaccine attributes. Methods: We developed an online survey with contingent specifications of a COVID-19 vaccine, varying in effectiveness, risks of side effects, duration of immunity, and out-of-pocket cost. Using population-averaged logit models, we estimated vaccine uptake rates that account for uncertainty, heterogeneity across respondents, and interactions between vaccine and personal characteristics. Results: We obtained 3047 completed surveys. The highest uptake rate for an annual vaccine, 62%, is predicted when vaccine effectiveness is 80% to 90%, side effects are minimal, and the vaccine is provided at zero cost, with decreases seen in the uptake rate for less effective vaccines, for example, 50% for 50% to 60% effectiveness. Moreover, we found that Americans' response to vaccine effectiveness depends on their self-reported concern, that is, concerned respondents report a higher willingness to get vaccinated. Our findings also indicate that COVID-19 vaccine uptake rates decrease with vaccine cost and that responsiveness to vaccine cost is moderated by income. Conclusions: Although providing the COVID-19 vaccine at zero cost will motivate many individuals to get vaccinated, a policy focused exclusively on vaccine cost may not be enough to reach herd immunity thresholds. Although those concerned with COVID-19 will participate, further evidence is needed on how to incentivize participation among the unconcerned (43%) to prevent further pandemic spread.	[Vasquez, William F.] Fairfield Univ, Dept Econ, Fairfield, CT 06430 USA; [Trudeau, Jennifer M.] Sacred Heart Univ, Dept Business Econ, West Campus,E-1127,3135 Easton Turnpike, Fairfield, CT 06825 USA		Trudeau, JM (通讯作者)，Sacred Heart Univ, Dept Business Econ, West Campus,E-1127,3135 Easton Turnpike, Fairfield, CT 06825 USA.	trudeauj@sacredheart.edu			Fairfield University's Mahoney Fund	This research was supported by a grant from Fairfield University's Mahoney Fund.	Almario CV, 2016, AM J INFECT CONTROL, V44, P1004, DOI 10.1016/j.ajic.2016.03.064; Arana JE, 2008, J HEALTH ECON, V27, P753, DOI 10.1016/j.jhealeco.2007.10.003; Bandilla W, 2003, SOC SCI COMPUT REV, V21, P235, DOI [10.1177/0894439303021002009, 10.1177/0894439303251573]; Boas TC, 2020, POLIT SCI RES METH, V8, P232, DOI 10.1017/psrm.2018.28; Boyle KJ, 2017, ECON NON-MARK GOOD, V13, P83, DOI 10.1007/978-94-007-7104-8_4; de Bekker-Grob EW, 2018, VACCINE, V36, P1467, DOI 10.1016/j.vaccine.2018.01.054; de Bekker-Grob EW, 2012, HEALTH ECON, V21, P145, DOI 10.1002/hec.1697; de Bekker-Grob EW, 2010, VACCINE, V28, P6692, DOI 10.1016/j.vaccine.2010.08.001; Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505; Eilers R, 2017, VACCINE, V35, P2823, DOI 10.1016/j.vaccine.2017.04.014; Fadda M, 2020, INT J PUBLIC HEALTH, V65, P711, DOI 10.1007/s00038-020-01404-4; Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068; Hall J, 2002, HEALTH ECON, V11, P457, DOI 10.1002/hec.694; Iboi EA, 2020, INFECT DIS MODEL, V5, P510, DOI 10.1016/j.idm.2020.07.006; Johnston RJ, 2017, J ASSOC ENVIRON RESO, V4, P319, DOI 10.1086/691697; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kim D, 2008, VALUE HEALTH, V11, P119, DOI 10.1111/j.1524-4733.2007.00220.x; Kim S.-y., 2014, ANN VACCINES IMMUN, V1, P1001; Kolenikov S, 2014, STATA J, V14, P22, DOI 10.1177/1536867X1401400104; Leng AL, 2021, VACCINE, V39, P247, DOI 10.1016/j.vaccine.2020.12.009; Liao CH, 2009, VALUE HEALTH, V12, pS74, DOI 10.1111/j.1524-4733.2009.00632.x; Lu PJ, 2015, VACCINE, V33, pD83, DOI 10.1016/j.vaccine.2015.09.031; Marin MG, 2002, PREV MED, V34, P235, DOI 10.1006/pmed.2001.0983; Mercer A, WEIGHTING ONLINE OPT; Neuhaus J M, 1992, Stat Methods Med Res, V1, P249, DOI 10.1177/096228029200100303; NEUHAUS JM, 1991, INT STAT REV, V59, P25, DOI 10.2307/1403572; NPR/PBS NewsHour/Marist poll, MAR COLL I PUBL OPN; OKeefe MS, ONE 3 AM WOULD NOT G; Omer SB, 2020, JAMA-J AM MED ASSOC, V324, P2095, DOI 10.1001/jama.2020.20892; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Ruggles S, IPUMS US VERSION 100; Sadique MZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054149; Shono A, 2014, VACCINE, V32, P5071, DOI 10.1016/j.vaccine.2014.07.002; Tyson A, US PUBLIC NOW DIV WH; Veldwijk J, 2014, VACCINE, V32, P6277, DOI 10.1016/j.vaccine.2014.09.004; Verelst F, 2019, VACCINE, V37, P2079, DOI 10.1016/j.vaccine.2019.02.056; Wong CKH, 2018, VALUE HEALTH, V21, P622, DOI 10.1016/j.jval.2017.10.012	37	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	NOV	2021	24	11					1543	1550		10.1016/j.jval.2021.05.007		OCT 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	XF1GI	34711354	Green Published, Bronze			2022-04-28	WOS:000723825200001
J	Pauly, MV; Comanor, WS; Frech, HE; Martinez, JR				Pauly, Mark, V; Comanor, William S.; Frech, H. E., III; Martinez, Joseph R.			Cost-Effectiveness Analysis of Branded Drugs With Market Demand and Insurance	VALUE IN HEALTH			English	Article						branded drugs; cost-effectiveness analysis; insurance	COVERAGE; US	Objectives: Cost-effectiveness analysis of branded pharmaceuticals presumes that both cost (or price) and marginal effectiveness levels are exogenous. This assumption underlies most judgments of the cost-effectiveness of specific drugs. In this study, we show the theoretical implications of letting both factors be endogenous by modeling pharmaceutical price setting with and without health insurance, along with patient response to the prices that depend on marginal effectiveness. We then explore the implications of these models for cost-effectiveness ratios. Methods: We used simple textbook models of patient demand and pricing behavior of drug firms to predict market equilibria in the drug and insurance markets and to generate calculations of the cost-effectiveness ratios in those settings. Results: We found that ratios in market settings can be much different from those calculated in cost-effectiveness studies based on exogenous prices and treatment of all patients at risk rather than those who would demand treatment in a market setting. We also found that there may be considerable similarity in these market cost-effectiveness ratios across different products because drug firms with market power set profit-maximizing prices. Conclusions: We found that market cost-effectiveness ratios will always indicate an excess of benefits over cost. Insurance will lead to less favorable ratios than without insurance, but when insurers bargain with drug firms, rather than taking their prices as given, cost-effectiveness ratios will be more favorable.	[Pauly, Mark, V; Martinez, Joseph R.] Univ Penn, Wharton Sch, 208 CPC,3641 Locust Walk, Philadelphia, PA 19104 USA; [Comanor, William S.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA; [Frech, H. E., III] Univ Calif Santa Barbara, Dept Econ, Santa Barbara, CA USA		Pauly, MV (通讯作者)，Univ Penn, Wharton Sch, 208 CPC,3641 Locust Walk, Philadelphia, PA 19104 USA.	pauly@wharton.upenn.edu					Bach PB, 2014, JAMA-J AM MED ASSOC, V312, P1629, DOI 10.1001/jama.2014.13235; Besanko D, INSURANCE HIGH PRICE; Chambers JD, 2018, HEALTH AFFAIR, V37, P1041, DOI 10.1377/hlthaff.2017.1553; Chambers JD, 2017, AM J PHARM BENEFIST, V9, P155; Chambers JD, 2014, HEALTH AFFAIR, V33, P1751, DOI 10.1377/hlthaff.2014.0574; Chandra A, 2017, NEW ENGL J MED, V377, P103, DOI 10.1056/NEJMp1705035; Comanor WS, 2018, REV IND ORGAN, V52, P589, DOI 10.1007/s11151-018-9616-1; Einav L, 2018, AM ECON J-ECON POLIC, V10, P122, DOI 10.1257/pol.20160355; FRECH HET, 1975, ECON INQ, V13, P55; Garber AM, INSURANCE INCENTIVES; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; IQVIA, MED USE SPENDING US; IQVIA, MED SPENDING AFFORDA; Kaiser Family Foundation, 2018 EMPLOYER HLTH B; Lakdawalla D, 2013, J PUBLIC ECON, V102, P1, DOI 10.1016/j.jpubeco.2013.03.001; Lakdawalla DN, EVALUATION MED TECHN; LEIBOWITZ A, 1985, SOC SCI MED, V21, P1063, DOI 10.1016/0277-9536(85)90161-3; Lu ZJ, 2020, INT J ECON BUS, V27, P1, DOI 10.1080/13571516.2019.1651150; Lu ZJ, 1998, REV ECON STAT, V80, P108, DOI 10.1162/003465398557212; Ma Q, 2011, PHARMACOL REV, V63, P437, DOI 10.1124/pr.110.003533; Pauly M, 2015, HEALTH ECON, V24, P506, DOI 10.1002/hec.3044; Pauly MV, 2017, VALUE HEALTH, V20, P278, DOI 10.1016/j.jval.2016.11.017; Pauly MV, 2012, OXFORD HDB EC BIOPHA; Pauly MV, 2019, EC DIMENSIONS PERSON; Philipson TJ, WHO BENEFITS NEW MED; Wamble D, 2019, HEALTH AFFAIR, V38, P68, DOI 10.1377/hlthaff.2018.05158	26	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	OCT	2021	24	10					1476	1483		10.1016/j.jval.2021.04.1289		SEP 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	WE3WV	34593171	Bronze			2022-04-28	WOS:000705561100012
J	Wu, Q; Gilbody, S; Li, JS; Wang, HI; Parrott, S				Wu, Qi; Gilbody, Simon; Li, Jinshuo; Wang, Han-, I; Parrott, Steve			Long-Term Cost-Effectiveness of Smoking Cessation Interventions in People With Mental Disorders: A Dynamic Decision Analytical Model	VALUE IN HEALTH			English	Article						decision analytical model; long-term cost-effectiveness; mental disorders; smoking cessation	EXCESS MORTALITY; UNITED-STATES; HEALTH; DEPRESSION; SMOKERS; INDIVIDUALS; VARENICLINE; RELAPSE; RISK	Objectives: People with mental disorders are more likely to smoke than the general population. The objective of this study is to develop a decision analytical model that estimates long-term cost-effectiveness of smoking cessation interventions in this population. Methods: A series of Markov models were constructed to estimate average lifetime smoking-attributable inpatient cost and expected quality-adjusted life-years. The model parameters were estimated using a variety of data sources. The model incorporated uncertainty through probabilistic sensitivity analysis using Monte Carlo simulations. It also generated tables presenting incremental cost-effectiveness ratios of the proposed interventions with varying incremental costs and incremental quit rates. We used data from 2 published trials to demonstrate the model's ability to make projections beyond the observational time frame. Results: The average smoker's smoking-attributable inpatient cost was 3 times higher and health utility was 5% lower than ex smokers. The intervention in the trial with a statistically insignificant difference in quit rate (19% vs 25%; P=.2) showed a 45% to 49% chance of being cost-effective compared with the control at willingness-to-pay thresholds of 20 pound 000 to 30 pound 000/ quality-adjusted life-years. The second trial had a significant outcome (quit rate 35.9% vs 15.6%; P,.001), and the corresponding probability of the intervention being cost-effective was 65%. Conclusions: This model provides a consistent platform for clinical trials to estimate the potential lifetime cost-effectiveness of smoking cessation interventions for people with mental disorders and could help commissioners direct resources to the most cost-effective programs. However, direct comparisons of results between trials must be interpreted with caution owing to their different designs and settings.	[Wu, Qi; Gilbody, Simon; Li, Jinshuo; Wang, Han-, I; Parrott, Steve] Univ York, Dept Hlth Sci, York, N Yorkshire, England		Wu, Q (通讯作者)，Univ York, Dept Hlth, Mental Hlth & Addict Res Grp, York YO10, N Yorkshire, England.	qi.wu@york.ac.uk	Gilbody, Simon/AAY-3720-2021	Gilbody, Simon/0000-0002-8236-6983; Parrott, Steven James/0000-0002-0165-1150			[Anonymous], 1990, HLTH BEN SMOK CESS; Anthenelli RM, 2013, ANN INTERN MED, V159, P390, DOI 10.7326/0003-4819-159-6-201309170-00005; Arcelus J, 2011, ARCH GEN PSYCHIAT, V68, P724, DOI 10.1001/archgenpsychiatry.2011.74; Barnett PG, 2008, ADDICTION, V103, P834, DOI 10.1111/j.1360-0443.2008.02167.x; Barnett PG, 2015, J CLIN PSYCHIAT, V76, pE1285, DOI 10.4088/JCP.14m09016; Batterham PJ, 2013, J AFFECT DISORDERS, V150, P855, DOI 10.1016/j.jad.2013.03.018; Berg ML, 2017, ADDICTION, V112, P946, DOI 10.1111/add.13748; Bergen H, 2012, LANCET, V380, P1568, DOI 10.1016/S0140-6736(12)61141-6; Bjorkenstam E, 2015, BRIT J PSYCHIAT, V207, P339, DOI 10.1192/bjp.bp.114.149583; Bolin K, 2012, PHARMACOECONOMICS, V30, P551, DOI 10.2165/11590120-000000000-00000; Bolin K, 2009, EUR J PUBLIC HEALTH, V19, P650, DOI 10.1093/eurpub/ckp075; Boscarino JA, 2006, ANN EPIDEMIOL, V16, P248, DOI 10.1016/j.annepidem.2005.03.009; Brazier J., 2017, MEASURING VALUING HL; Brazier JE, 2004, MED CARE, V42, P851, DOI 10.1097/01.mlr.0000135827.18610.0d; Brazier JE, 2008, PRO NEWSLETT, V40, P14, DOI DOI 10.4135/9781412971980.N298; Briggs A, 2006, DECISION MODELLING H; Cuijpers P, 2002, J AFFECT DISORDERS, V72, P227, DOI 10.1016/S0165-0327(01)00413-X; Curtis L.A, 2020, UNIT COSTS HLTH SOCI; Dalsgaard S, 2015, LANCET, V385, P2190, DOI 10.1016/S0140-6736(14)61684-6; Department of Health and Social Services, REF COSTS 2015 16; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Drummond MF., 2015, METHODS EC EVALUATIO, P353; Fenwick E, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-52; Gierisch JM, 2012, J GEN INTERN MED, V27, P351, DOI 10.1007/s11606-011-1915-2; Gonzalez-Roz A, 2021, NICOTINE TOB RES, V23, P320, DOI 10.1093/ntr/ntaa146; Hall SM, 2006, AM J PUBLIC HEALTH, V96, P1808, DOI 10.2105/AJPH.2005.080382; Harker K, STOLEN YEARS MENTAL; Hawkins J, 2010, NICOTINE TOB RES, V12, P1228, DOI 10.1093/ntr/ntq175; Hughes JR, 2008, ADDICT BEHAV, V33, P1516, DOI 10.1016/j.addbeh.2008.05.012; Humphreys K, 2015, J PSYCHIATR RES, V70, P28, DOI 10.1016/j.jpsychires.2015.08.005; Hyland A, 2004, NICOTINE TOB RES, V6, P363, DOI 10.1080/14622200412331320761; John A, 2018, SCHIZOPHR RES, V199, P154, DOI 10.1016/j.schres.2018.04.009; Kharroubi SA, 2007, J HEALTH ECON, V26, P597, DOI 10.1016/j.jhealeco.2006.09.002; Laramee P, 2015, EBIOMEDICINE, V2, P1394, DOI 10.1016/j.ebiom.2015.08.040; Lasser K, 2000, JAMA-J AM MED ASSOC, V284, P2606, DOI 10.1001/jama.284.20.2606; Li JS, 2020, ADDICTION, V115, P2113, DOI 10.1111/add.15086; McManus S, 2016, MENTAL HLTH ANDWELLB; Meier SM, 2016, JAMA PSYCHIAT, V73, P268, DOI 10.1001/jamapsychiatry.2015.3105; NatCen social research University of Leicester, 2019, MENTAL HLTH WELLBEIN; National Institute for Health and Care Excellence, 2013, GUID METH TECHN APPR; NHS Digital, 2009, ADULT PSYCH MORB ENG; NHS Digital, PRESCRIPTION COST AN; NHS Digital, CODE GROUP HRG41 201; NHS Digital, HOSP EPIS STAT HOSP; Office for National Statistics, 2018, ADULT SMOK HAB UK; Office of the National Statistics, DEATH REG SUMM TABL; Ostbye T, 2002, PREV MED, V34, P334, DOI 10.1006/pmed.2001.0991; Parrott S, 1998, Thorax, V53 Suppl 5 Pt 2, pS1; Pratt LA, 2016, GEN HOSP PSYCHIAT, V39, P39, DOI 10.1016/j.genhosppsych.2015.12.003; Richardson G, 2004, HEALTH ECON, V13, P1203, DOI 10.1002/hec.901; Richardson S, 2019, ADDICT BEHAV, V90, P14, DOI 10.1016/j.addbeh.2018.10.011; Royal College of Physicians, 2015, 50 YEARS SMOK HLTH; Royal college of physicians, 2013, SMOK MENT HLTH; Royal College of Physicians, 2018, HID PLA SIGHT TRE TO; Secades-Villa R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188849; Tillmann M, 1997, J PUBLIC HEALTH MED, V19, P268, DOI 10.1093/oxfordjournals.pubmed.a024629; Vogl M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-203; Walker ER, 2017, DRUG ALCOHOL DEPEN, V171, P31, DOI 10.1016/j.drugalcdep.2016.11.026; World Health Organization, EC TOB TOOLK ASS EC; World Health Organization, 2019, WHO REPORT GLOBAL TO; Wu Q, 2015, TOB CONTROL, V24, P462, DOI 10.1136/tobaccocontrol-2013-051464	61	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	SEP	2021	24	9					1263	1272		10.1016/j.jval.2021.04.002		AUG 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	UG5RC	34452705	Green Accepted, Green Published, hybrid			2022-04-28	WOS:000689308300005
J	Conteh, L; Shuford, K; Agboraw, E; Kont, M; Kolaczinski, J; Patouillard, E				Conteh, Lesong; Shuford, Kathryn; Agboraw, Efundem; Kont, Mara; Kolaczinski, Jan; Patouillard, Edith			Costs and Cost-Effectiveness of Malaria Control Interventions: A Systematic Literature Review	VALUE IN HEALTH			English	Review						cost-effectiveness; disease control interventions; malaria; unit cost	RAPID DIAGNOSTIC-TESTS; INTERMITTENT PREVENTIVE TREATMENT; UNCOMPLICATED MALARIA; EFFECTIVENESS THRESHOLDS; ECONOMIC-EVALUATION; LOW-TRANSMISSION; MOSQUITO-CONTROL; ELIMINATION; MANAGEMENT; DELIVERY	Objectives: To systematically review the literature on the unit cost and cost-effectiveness of malaria control. Methods: Ten databases and gray literature sources were searched to identify evidence relevant to the period 2005 to 2018. Studies with primary financial or economic cost data from malaria endemic countries that took a provider, provider and household, or societal perspective were included. Results: We identified 103 costing studies. The majority of studies focused on individual rather than combined interventions, notably insecticide-treated bed nets and treatment, and commonly took a provider perspective. A third of all studies took place in 3 countries. The median provider economic cost of protecting 1 person per year ranged from $1.18 to $5.70 with vector control and from $0.53 to $5.97 with chemoprevention. The median provider economic cost per case diagnosed with rapid diagnostic tests was $6.06 and per case treated $9.31 or $89.93 depending on clinical severity. Other interventions did not share enough similarities to be summarized. Cost drivers were rarely reported. Cost-effectiveness of malaria control was reiterated, but care in methodological and reporting standards is required to enhance data transferability. Conclusions: Important information that can support resource allocation was reviewed. Given the variability in methods and reporting, global efforts to follow existing standards are required for the evidence to be most useful outside their study context, supplemented by guidance on options for transferring existing data across settings.	[Conteh, Lesong; Shuford, Kathryn] London Sch Econ & Polit Sci, Dept Hlth Policy, London, England; [Conteh, Lesong] Imperial Coll London, Sch Publ Hlth, St Marys Campus, Paddington, England; [Agboraw, Efundem] Univ Liverpool Liverpool Sch Trop Med, Vector Biol, Liverpool, Merseyside, England; [Kont, Mara] Imperial Coll London, MRC Ctr Global Infect Dis Anal, Dept Infect Dis Epidemiol, London, England; [Kolaczinski, Jan] WHO, Dept Global Malaria Programme, Geneva, Switzerland; [Patouillard, Edith] WHO, Dept Hlth Syst Governance & Financing, Ave Appia 20, CH-1202 Geneva, Switzerland		Patouillard, E (通讯作者)，WHO, Dept Hlth Syst Governance & Financing, Ave Appia 20, CH-1202 Geneva, Switzerland.	patouillarde@who.int	Conteh, Lesong/ABE-9550-2020	Conteh, Lesong/0000-0002-0719-3672; Patouillard, Edith/0000-0001-7347-2824	United States Agency for International DevelopmentUnited States Agency for International Development (USAID); Bill and Melinda Gates FoundationBill & Melinda Gates Foundation	This work was supported by several grants from the United States Agency for International Development and the Bill and Melinda Gates Foundation.	Abotsi AK., 2012, U CAPE COAST J ARTS; Ansah EK, 2013, AM J TROP MED HYG, V89, P724, DOI 10.4269/ajtmh.13-0033; Ayieko Philip, 2009, Cost Eff Resour Alloc, V7, P3, DOI 10.1186/1478-7547-7-3; Batwala V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-372; Becker-Dreps SI, 2009, AM J TROP MED HYG, V81, P496, DOI 10.4269/ajtmh.2009.81.496; Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418; Bojang KA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000409; Bonner K, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-73; Botto-Menezes C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004494; Boutron I., 2020, COCHRANE HDB SYSTEMA; Cameron DB, 2019, AJAR-AFR J AIDS RES, V18, P277, DOI 10.2989/16085906.2019.1679200; Chaki PP, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-172; Chanda P, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-21; Chanda P, 2011, MALARIA J, V10, DOI [10.1186/1475-2875-10-158, 10.1186/1475-2875-10-159]; Chanda Pascalina, 2009, Cost Eff Resour Alloc, V7, P5, DOI 10.1186/1478-7547-7-5; Cico A, 2018, PMI IRS COUNTRY PROG; Collins D, 2014, J GLOB HEALTH, V4, P129, DOI 10.7189/jogh.04.020407; Comfort AB, 2014, AM J TROP MED HYG, V90, P20, DOI 10.4269/ajtmh.13-0019; Conteh L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012223; Conteh L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010313; Dambach P, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1438-8; Daviaud E, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.010403; Davis WA, 2011, B WORLD HEALTH ORGAN, V89, P211, DOI 10.2471/BLT.10.084103; De Allegri M, 2010, HEALTH POLICY PLANN, V25, P28, DOI 10.1093/heapol/czp031; de Oliveira MRF, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-390; Drake TL, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-273; Drucker AM, 2016, J INVEST DERMATOL, V136, pE109, DOI 10.1016/j.jid.2016.08.021; Edoka IP, 2020, HEALTH POLICY PLANN, V35, P546, DOI 10.1093/heapol/czz152; Eisele TP, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-93; Evers S, 2005, INT J TECHNOL ASSESS, V21, P240, DOI 10.1017/S0266462305050324; Ezenduka CC, 2017, PHARMACOECON-OPEN, V1, P185, DOI 10.1007/s41669-017-0021-8; Faye A, 2010, SANTE PUBLIQUE, V22, P617, DOI 10.3917/spub.106.0617; Feachem RGA, 2019, LANCET, V394, P1056, DOI 10.1016/S0140-6736(19)31139-0; de Oliveira MRF, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-277; Fernandes S, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1539-4; Ferrari G, 2015, TROP MED INT HEALTH, V20, P91; Ferrer BE, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1906-9; FPemba D, 2008, MALAWI MED J, V20, P86; Girón Sandra Lorena, 2006, Biomed., V26, P379; Grabowsky M, 2005, TROP MED INT HEALTH, V10, P1151, DOI 10.1111/j.1365-3156.2005.01502.x; Gueye CS, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1190; Hailu A, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0164-1; Hamainza B, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-128; Hansen KS, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0696-1; Hansen KS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189758; Hansen KS, 2012, INT HEALTH, V4, P38, DOI 10.1016/j.inhe.2011.10.001; Hansen KS., 2017, COST EFFECTIVENESS A, V15, P15; Haque U, 2014, LANCET GLOB HEALTH, V2, pE98, DOI 10.1016/S2214-109X(13)70176-1; Howard N, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005935; Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002; Hutton G, 2009, B WORLD HEALTH ORGAN, V87, P123, DOI 10.2471/BLT.08.051961; Kolaczinski JH, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-102; Kusumawathie PHD, 2008, T ROY SOC TROP MED H, V102, P705, DOI 10.1016/j.trstmh.2008.03.013; Kyaw SS, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-416; Larson BA, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1457-5; Leech AA, 2018, VALUE HEALTH, V21, P759, DOI 10.1016/j.jval.2017.12.016; Lemma Hailemariam, 2011, Cost Eff Resour Alloc, V9, P2, DOI 10.1186/1478-7547-9-2; Lubell Y, 2007, AM J TROP MED HYG, V77, P128, DOI 10.4269/ajtmh.2007.77.128; Maccario R, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4490-6; Maheu-Giroux M, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-477; Maka DE, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1639-1; Makoutode CP, 2014, COST EFFECT RESOUR A, V12, DOI 10.1186/1478-7547-12-21; Manzi F, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-165; Matangila JR, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-132; Mbonye AK, 2008, T ROY SOC TROP MED H, V102, P685, DOI 10.1016/j.trstmh.2008.04.016; Moore BR, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2081-8; Morel CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058205; Mori AT, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-363; Mueller DH, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-17; Mueller DH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-73; Mulligan JA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-32; Nonvignon J, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1418-z; Nonvignon J, 2012, TROP MED INT HEALTH, V17, P951, DOI 10.1111/j.1365-3156.2012.03018.x; Ntuku HM, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1671-1; Ofman Joshua J, 2003, J Manag Care Pharm, V9, P53; Ogunniyi Abiodun, 2016, Malar Res Treat, V2016, P5242498, DOI 10.1155/2016/5242498; Onwujekwe O, 2007, ACTA TROP, V101, P95, DOI 10.1016/j.actatropica.2006.07.013; Onwujekwe O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078362; Orobaton N, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1578-x; Paintain LS, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-71; Parikh R, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-371; Patouillard E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024871; Pitt C, 2017, HEALTH POLICY PLANN, V32, P1256, DOI 10.1093/heapol/czx084; Plosky WD, 2019, AJAR-AFR J AIDS RES, V18, P263, DOI 10.2989/16085906.2019.1680398; Rahman R, 2016, TROP MED INT HEALTH, V21, P1468, DOI 10.1111/tmi.12767; RBM Partnership, 2015, ACT INV DEF MAL 2016 ACT INV DEF MAL 2016; Rehfuess EA, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-000844; Renggli S, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-85; Rezaei-Hemami M, 2014, J ARTHROPOD-BORNE DI, V8, P43; Rolland E, 2006, TROP MED INT HEALTH, V11, P398, DOI 10.1111/j.1365-3156.2006.01580.x; Scates S, 2017, SCH NET PROGRAM ROUN; Scates S JY, 2016, MASS CAMPAIGNS ROUTI; Sedlmayr R, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-102; Sicuri E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013407; Sikaala CH, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-225; Silumbe K, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0722-3; Stelmach R., 2018, AM J TROP MED HYG, V16, P16; Stevens W, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-22; Sun DW, 2015, AM J TROP MED HYG, V93, P1240, DOI 10.4269/ajtmh.14-0486; Tawiah T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164055; Tediosi F., 2013, MAJOR INFECT DIS, V3rd; Thokala P, 2018, PHARMACOECONOMICS, V36, P509, DOI 10.1007/s40273-017-0606-1; Vassall A., REFERENCE CASE ESTIM; Watts RD, 2019, VALUE HEALTH, V22, P377, DOI 10.1016/j.jval.2018.10.006; White MT, 2016, AM J TROP MED HYG, V95, P52, DOI 10.4269/ajtmh.16-0182; White MT, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-337; WHO, 2013, WORLD MALARIA REPORT 2013, P1; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2009, COST PSI KEN ITN PRO COST PSI KEN ITN PRO; WHO, 2015, GLOB TECHN STRAT MAL; WHO, 2009, COST UG ITN ACT REP COST UG ITN ACT REP; WHO, 2009, COST ZMCP ITN PROGR COST ZMCP ITN PROGR; WHO, 2019, MAL ER BEN FUT SCEN; WHO, 2018, MAL SURV MON EV REF; Willcox ML, 2009, ANN TROP MED PARASIT, V103, P3, DOI 10.1179/136485909X384983; Wiseman V, 2006, PLOS MED, V3, P1844, DOI 10.1371/journal.pmed.0030373; Wisniewski J., 2017, COST ANAL SERIES ROU; Wisniewski J, 2020, ACTA TROP, V202, DOI 10.1016/j.actatropica.2019.105229; Worrall E, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-338; Worrall E, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-263; Yeung S, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-84; Yukich J., 2016, CONTINUOUS DISTRIBUT; Yukich J., 2007, OPERATIONS COSTS COS; Yukich J., 2014, GHANA LLIN CONTINUOU; Yukich J, 2010, AM J TROP MED HYG, V83, P61, DOI 10.4269/ajtmh.2010.09-0632; Yukich JO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-51; Yukich JO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-258; Zelman BW, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2361-y	128	2	2	7	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	AUG	2021	24	8					1213	1222		10.1016/j.jval.2021.01.013		AUG 2021	10	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	TY1SX	34372987	Green Accepted, hybrid, Green Published			2022-04-28	WOS:000683567300015
J	Abubakar, U; Sulaiman, SAS; Aly, A; Elhag, EAA				Abubakar, U.; Sulaiman, Syed S. A.; Aly, A.; Elhag, Abdelhameed Ahmad E.			IMPACT OF ANTIMICROBIAL STEWARDSHIP INTERVENTIONS ON COMPLIANCE WITH SURGICAL ANTIBIOTIC PROPHYLAXIS: A SYSTEMATIC REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Abubakar, U.] Int Islamic Univ Malaysia, Kuantan 06, Malaysia; [Sulaiman, Syed S. A.; Aly, A.] Univ Sains Malaysia, George Town, Malaysia; [Elhag, Abdelhameed Ahmad E.] Univ Khartoum, Khartoum, Sudan									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN3	S106	S106					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400462
J	Abubakar, U; Hammad, M				Abubakar, U.; Hammad, M.			ROLE OF ASYMPTOMATIC CARRIERS IN THE TRANSMISSION OF COVID-19: A REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Abubakar, U.] Int Islamic Univ Malaysia, Kuantan 06, Malaysia; [Hammad, M.] Albaha Univ, Albaha, Saudi Arabia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN51	S114	S115					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400501
J	Appukkuttan, S; Fu, C; Du, Y; Parkin, J; Gaiser, A; Partridge, J; Kong, S; Freedland, S				Appukkuttan, S.; Fu, C.; Du, Y.; Parkin, J.; Gaiser, A.; Partridge, J.; Kong, S.; Freedland, S.			POTENTIAL DRUG-DRUG INTERACTIONS TO NOVEL ANTI-ANDROGEN THERAPIES AMONG NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS	VALUE IN HEALTH			English	Meeting Abstract									[Appukkuttan, S.; Fu, C.; Du, Y.; Parkin, J.; Partridge, J.; Kong, S.] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA; [Gaiser, A.] Xcenda, Tampa, FL USA; [Freedland, S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN158	S49	S49					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400209
J	Boateng-Kuffour, A; Okumura, S; Neben, C; Servais, L; Wallace, S; Law, S; Lilligren, H; Chua, A; Lee, D; Gerwig, K; Topper, S; Zhou, A				Boateng-Kuffour, A.; Okumura, S.; Neben, C.; Servais, L.; Wallace, S.; Law, S.; Lilligren, H.; Chua, A.; Lee, D.; Gerwig, K.; Topper, S.; Zhou, A.			CLOSING THE KNOWLEDGE GAP IN GENOMICS RESEARCH: A PATIENT-CENTERED APPROACH TO REPORT DEVELOPMENT IN THE ALL OF US RESEARCH PROGRAM	VALUE IN HEALTH			English	Meeting Abstract									[Boateng-Kuffour, A.; Okumura, S.; Neben, C.; Servais, L.; Wallace, S.; Law, S.; Lilligren, H.; Chua, A.; Lee, D.; Gerwig, K.; Topper, S.; Zhou, A.] Color, Burlingame, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PPM4	S195	S195					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401116
J	Buesch, K; Smith, A; Hanbury, A; Beitia, ODI; Hammes, F; de Pouvourville, G				Buesch, K.; Smith, A.; Hanbury, A.; Beitia, Ortiz de Zarate, I; Hammes, F.; de Pouvourville, G.			UTILITIES IN A RARE DISEASE COLLECTED VIA VIGNETTES IN GENERAL POPULATION SAMPLES FROM THE UK AND FRANCE: COMPARISON OF RESULTS	VALUE IN HEALTH			English	Meeting Abstract									[Buesch, K.] PTC Therapeut Switzerland GmbH, Zug, Switzerland; [Smith, A.] RB, Kingston Upon Hull, Ery, England; [Hanbury, A.] York Hlth Econ Consortium, York, N Yorkshire, England; [Beitia, Ortiz de Zarate, I; Hammes, F.] PTC Therapeut France, Paris 75, France; [de Pouvourville, G.] ESSEC Business Sch, Cergy Pontoise, France									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO48	S206	S206					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401164
J	D'Souza, A; Abonour, R; Zonder, J; Hoffman, J; Wong, SW; Liedtke, M; Dispenzieri, A; Cote, S; Nair, S; Potluri, R; Weiss, BM; Vermeulen, J; Lam, A; Mehra, M				D'Souza, A.; Abonour, R.; Zonder, J.; Hoffman, J.; Wong, S. W.; Liedtke, M.; Dispenzieri, A.; Cote, S.; Nair, S.; Potluri, R.; Weiss, B. M.; Vermeulen, J.; Lam, A.; Mehra, M.			BURDEN OF ILLNESS IN PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS: A REAL WORLD STUDY USING OPTUM CLAIMS DATABASE	VALUE IN HEALTH			English	Meeting Abstract									[D'Souza, A.] Froedtert & Med Coll Wisconsin Canc Ctr, Milwaukee, WI USA; [Abonour, R.] Indiana Canc Pavil, Indianapolis, IN USA; [Zonder, J.] Barbara Ann Karmanos Canc Inst, Detroit, MI USA; [Hoffman, J.] Sylvester Comprehens Canc Ctr, Miami, FL USA; [Wong, S. W.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Liedtke, M.] Stanford Univ, Stanford, CA 94305 USA; [Dispenzieri, A.] Mayo Clin, Rochester, MN USA; [Cote, S.; Lam, A.] Janssen Global Serv, Raritan, NJ USA; [Nair, S.] Janssen Pharmaceut NV, Beerse, Belgium; [Potluri, R.] SmartAnalyst Inc, New York, NY USA; [Weiss, B. M.; Vermeulen, J.; Mehra, M.] Janssen Global Med Affairs, Horsham, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO21	S201	S201					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401141
J	Dedhia, M; Nadpara, P				Dedhia, M.; Nadpara, P.			PREDICTORS AND HEALTH RELATED QUALITY OF LIFE ASSOCIATED WITH RENAL DISEASES IN CANCER PATIENTS IN UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Dedhia, M.; Nadpara, P.] Virginia Commonwealth Univ, Richmond, VA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU59	S155	S155					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400674
J	Fischer, C; Genestier, V; Gauthier, A				Fischer, C.; Genestier, V; Gauthier, A.			HOW TO BETTER TAKE INTO ACCOUNT TREATMENT SWITCH IN RANDOMIZED CONTROLLED TRIALS?	VALUE IN HEALTH			English	Meeting Abstract									[Fischer, C.; Genestier, V] Amaris, Levallois Perret, France; [Gauthier, A.] Amaris Consulting, Barcelona, Spain									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN196	S56	S56					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400242
J	Gabay, C; Diaz, MC; Ismael, J; Caro, L				Gabay, C.; Diaz, M. C.; Ismael, J.; Caro, L.			RECOMMENDATIONS FOR COLON CANCER (CC) SCREENING IN INDIVIDUALS WITH AVERAGE RISK BASED ON IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST (IFOBT) IN ARGENTINA USING GRADE-ADOLOPMENT TOOL	VALUE IN HEALTH			English	Meeting Abstract									[Gabay, C.; Ismael, J.; Caro, L.] Fdn Gedyt, Buenos Aires, DF, Argentina; [Diaz, M. C.] Angel H Roffo Canc Inst, Buenos Aires, DF, Argentina									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN186	S54	S54					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400232
J	Greenleaf, R; Grossi, P; Erb, M; El-Sayegh, R; Pracyk, JB; Marcini, A				Greenleaf, R.; Grossi, P.; Erb, M.; El-Sayegh, R.; Pracyk, J. B.; Marcini, A.			REDUCTION IN PEDICLE SCREW PLACEMENT TIME WITH A GUIDEWIRELESS PEDICLE SCREW SYSTEM FOR MINIMALLY INVASIVE SPINE SURGERY	VALUE IN HEALTH			English	Meeting Abstract									[Greenleaf, R.] Reconstruct Orthoped, Sewell, NJ USA; [Grossi, P.] Duke Hlth, Raleigh, NC USA; [Erb, M.] DePuy Synthes Inc, Markham, ON, Canada; [El-Sayegh, R.] Johnson & Johnson Med Devices, Markham, ON, Canada; [Pracyk, J. B.; Marcini, A.] Johnson & Johnson, Raynham, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMD18	S126	S126					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400552
J	Harricharan, S; Richard, ME; Roman, J; Forsythe, A				Harricharan, S.; Richard, M. E.; Roman, J.; Forsythe, A.			THE ECONOMIC AND HUMANISTIC BURDEN OF DYSTROPHIC EPIDERMOLYSIS BULLOSA (DEB): A SYSTEMATIC LITERATURE REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Harricharan, S.; Richard, M. E.] Purple Squirrel Econ, Montreal, PQ, Canada; [Roman, J.] Krystal Biotech, Pittsburgh, PA USA; [Forsythe, A.] Purple Squirrel Econ, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PSS7	S221	S221					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401232
J	Huang, PL; Levy, J				Huang, P. L.; Levy, J.			IN-HOME IV ANTIBIOTICS COST AND UTILIZATION FOLLOWING TIBIA FRACTURES	VALUE IN HEALTH			English	Meeting Abstract									[Huang, P. L.] Univ Florida, Gainesville, FL USA; [Levy, J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIT4	S122	S122					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400535
J	Jandu, J; Naylor, F; McAughey, E; Samiian, A; Blackney, M; Khosla, D				Jandu, J.; Naylor, F.; McAughey, E.; Samiian, A.; Blackney, M.; Khosla, D.			BUDGET IMPACT ANALYSIS OF TRANSCUTANEOUS AFFERENT PATTERNED STIMULATION THERAPY FOR THE TREATMENT OF ESSENTIAL TREMOR IN THE UNITED STATES	VALUE IN HEALTH			English	Meeting Abstract									[Jandu, J.] FIECON, St Albans, England; [Naylor, F.; McAughey, E.; Blackney, M.] FIECON, London, England; [Samiian, A.] Cala Hlth, San Mateo, CA USA; [Khosla, D.] Cala Hlth, Burlingame, CA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMD7	S124	S124					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400543
J	Kim, SW; Ishii, T; Takeno, S; Kado, Y; Tamai, Y; Akiyama, T; Yu, E; Demiya, S				Kim, S. W.; Ishii, T.; Takeno, S.; Kado, Y.; Tamai, Y.; Akiyama, T.; Yu, E.; Demiya, S.			COVID-19 PATIENTS ANALYSIS UTILIZING JAPAN AND US CLAIMS DATABASES	VALUE IN HEALTH			English	Meeting Abstract									[Kim, S. W.; Ishii, T.; Takeno, S.; Kado, Y.; Tamai, Y.; Akiyama, T.; Yu, E.; Demiya, S.] IQVIA Solut Japan, Minato Ku, Tokyo 13, Japan									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN46	S114	S114					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400497
J	Kruger, E; Nedzesky, J; Thomas, NA; Cataldo, J				Kruger, E.; Nedzesky, J.; Thomas, N. A.; Cataldo, J.			COMMON AND SERIOUS COMORBIDITIES AMONG ADULTS WITH WILSON DISEASE	VALUE IN HEALTH			English	Meeting Abstract									[Kruger, E.] Ultragenyx Pharmaceut Ltd, San Francisco, CA USA; [Nedzesky, J.; Thomas, N. A.] Ultragenyx Pharmaceut Inc Ltd, Brisbane, CA USA; [Cataldo, J.] Ultragenyx Pharmaceut Ltd, Cambridge, MA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO72	S211	S211					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401187
J	Layton, JB; Ritchey, MB; Huang, Z; Anderson-Smits, C				Layton, J. B.; Ritchey, M. B.; Huang, Z.; Anderson-Smits, C.			REPLICATING CLINICAL TRIAL EXCLUSION CRITERIA IN A CLAIMS-BASED COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) INITIATING INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENT	VALUE IN HEALTH			English	Meeting Abstract									[Layton, J. B.] RTI Hlth Solut, Res Triangle Pk, NC USA; [Ritchey, M. B.] Med Tech Epi LLC, Philadelphia, PA USA; [Huang, Z.] Takeda Pharmaceut Int Co, Cambridge, MA USA; [Anderson-Smits, C.] Shire US Inc, Cambridge, MA USA				Layton, J. Bradley/B-4950-2018	Layton, J. Bradley/0000-0003-0994-5820				0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PBI19	S18	S18					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400072
J	Li, V; Costantino, H; Rowland, J; Yue, L; Gupta, S				Li, V; Costantino, H.; Rowland, J.; Yue, L.; Gupta, S.			LASSO (LEAST ABSOLUTE SHRINKAGE AND SELECTION OPERATOR) AND XGBOOST (EXTREME GRADIENT BOOSTING) MODELS FOR PREDICTING DEPRESSION-RELATED WORK IMPAIRMENT IN US WORKING ADULTS	VALUE IN HEALTH			English	Meeting Abstract									[Li, V; Costantino, H.; Gupta, S.] Kantar, New York, NY USA; [Rowland, J.] Kantar, Bronx, NY USA; [Yue, L.] Kantar, Jersey City, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		ML3	S11	S11					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400043
J	Meng, W; Qureshi, Z; Khandker, R				Meng, W.; Qureshi, Z.; Khandker, R.			TOPIC LANDSCAPE ANALYSIS OF REDDIT SOCIAL MEDIA SUBMISSIONS IN INSOMNIA	VALUE IN HEALTH			English	Meeting Abstract									[Meng, W.] Merck & Co Inc, Boston, MA USA; [Qureshi, Z.] Merck & Co Inc, Kenilworth, NJ USA; [Khandker, R.] Merck & Co Inc, N Wales, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PND66	S171	S171					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401008
J	Ming, J; Li, HJ; Wang, Y; Ge, Y; Liu, J; Hu, S				Ming, J.; Li, H. J.; Wang, Y.; Ge, Y.; Liu, J.; Hu, S.			CLINICAL PERFORMANCE AND COST ANALYSIS OF DIFFERENT PERIPHERAL INTRAVENOUS CATHETERS WITH THE IMPLEMENTATION OF VOLUME-BASED PROCUREMENT IN CHINA	VALUE IN HEALTH			English	Meeting Abstract									[Ming, J.; Li, H. J.; Wang, Y.; Ge, Y.] IQVIA, Shanghai, Peoples R China; [Liu, J.] IQVIA, Beijing, Peoples R China; [Hu, S.] Fudan Univ, Sch Publ Hlth, Shanghai, Peoples R China									0	1	1	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMD1	S123	S123					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400537
J	Mladov, V; Sokolova, V; Tolkacheva, D				Mladov, V; Sokolova, V; Tolkacheva, D.			NUMBER NEEDED TO TREAT AND INCREMENTAL COSTS PER RESPONDER FOR BIOLOGICS IN ADULT PATIENTS WITH ACTIVE RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN THE RUSSIAN FEDERATION	VALUE IN HEALTH			English	Meeting Abstract									[Mladov, V; Sokolova, V; Tolkacheva, D.] BIOCAD, St Petersburg, Spe, Russia									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PBI16	S17	S17					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400069
J	Nichols, D; Toliver, J; Wang, R				Nichols, D.; Toliver, J.; Wang, R.			MODELING THE IMPACT OF DRUG PRICING POLICIES ON INNOVATION	VALUE IN HEALTH			English	Meeting Abstract									[Nichols, D.; Wang, R.] Genentech Inc, San Francisco, CA 94080 USA; [Toliver, J.] Univ Texas Austin, Austin, TX 78712 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		RE2	S238	S238					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401306
J	Norrbacka, K; Divino, V; Lebrec, J; Vadher, K; DeKoven, M				Norrbacka, K.; Divino, V; Lebrec, J.; Vadher, K.; DeKoven, M.			DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN FRANCE AND THE NETHERLANDS	VALUE IN HEALTH			English	Meeting Abstract									[Norrbacka, K.] Eli Lilly Finland, Helsinki, Finland; [Divino, V; DeKoven, M.] IQVIA, Falls Church, VA USA; [Lebrec, J.] HaaPACS GmbH, Schriesheim, Germany; [Vadher, K.] Eli Lilly UK, Bracknell, Berks, England									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDB39	S84	S84					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400369
J	O'Gorman, C; Feliz, S; Jones, A; Streicher, C; Thomas, Z; Tabuteau, H				O'Gorman, C.; Feliz, S.; Jones, A.; Streicher, C.; Thomas, Z.; Tabuteau, H.			EFFECTS OF AXS-05 ON PATIENT REPORTED DEPRESSIVE SYMPTOMS IN MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE GEMINI TRIAL	VALUE IN HEALTH			English	Meeting Abstract									[O'Gorman, C.; Feliz, S.; Jones, A.; Streicher, C.; Thomas, Z.; Tabuteau, H.] Axsome Therapeut, New York, NY USA									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMH40	S135	S135					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400588
J	Oladapo, O; D'Alessio, D; Vallow, S				Oladapo, O.; D'Alessio, D.; Vallow, S.			RECOMMENDATIONS FOR THE COLLECTION OF PATIENT-REPORTED OUTCOMES (PRO) DATA IN THE POST-PROGRESSION AND POST-TREATMENT SETTING FOLLOWING ONCOLOGY CLINICAL TRIALS	VALUE IN HEALTH			English	Meeting Abstract									[Oladapo, O.; D'Alessio, D.; Vallow, S.] Novartis Pharmaceut, E Hanover, NJ USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PCN223	S61	S61					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400266
J	Panzer, A; Margaretos, N; Kim, D; Cohen, JT; Chambers, JD				Panzer, A.; Margaretos, N.; Kim, D.; Cohen, J. T.; Chambers, J. D.			THE INFLUENCE OF EXPEDITED APPROVAL DESIGNATIONS ON HEALTH PLAN COVERAGE: AN EMPIRICAL EVALUATION	VALUE IN HEALTH			English	Meeting Abstract									[Panzer, A.; Margaretos, N.; Kim, D.; Cohen, J. T.; Chambers, J. D.] Tufts Med Ctr, Boston, MA 02111 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PMU34	S150	S150					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400654
J	Rojanasarot, S; Bhattacharyya, SK; Burnett, AL				Rojanasarot, S.; Bhattacharyya, S. K.; Burnett, A. L.			THE IMPACT OF AN EMPLOYER BENEFIT EXCLUSION FOR ERECTILE DYSFUNCTION TREATMENTS: US EMPLOYER PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Rojanasarot, S.; Bhattacharyya, S. K.] Boston Sci, Marlborough, MA USA; [Burnett, A. L.] Johns Hopkins Univ, Baltimore, MD USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH20	S102	S103					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400446
J	Sandman, K; Vieweg, DC; Forsythe, A				Sandman, K.; Vieweg, D. C.; Forsythe, A.			ECONOMIC EVALUATIONS OF DIGITAL THERAPEUTICS (DTX) FROM A US PERSPECTIVE	VALUE IN HEALTH			English	Meeting Abstract									[Sandman, K.; Vieweg, D. C.; Forsythe, A.] Purple Squirrel Econ, New York, NY USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PNS85	S188	S188					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401084
J	Shah, K; Szczotka, A; Belazi, D; Kogut, SJ				Shah, K.; Szczotka, A.; Belazi, D.; Kogut, S. J.			REAL-WORLD UTILIZATION OF TOP-DOWN AND STEP-UP PHARMACOLOGIC THERAPY IN CROHN'S DISEASE AND ULCERATIVE COLITIS	VALUE IN HEALTH			English	Meeting Abstract									[Shah, K.; Kogut, S. J.] Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA; [Szczotka, A.; Belazi, D.] AscellaHealth, Berwyn, PA USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PGI19	S97	S97					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400423
J	Shepard, D; Kulchyckyj, M; Furere, SM				Shepard, D.; Kulchyckyj, M.; Furere, Musange S.			COST-EFFECTIVENESS OF RAPID SCREENING IN ANTENATAL CARE IN BUGESERA DISTRICT, RWANDA	VALUE IN HEALTH			English	Meeting Abstract									[Shepard, D.] Brandeis Univ, Wellesley Hills, MA USA; [Kulchyckyj, M.] Brandeis Univ, Waltham, MA USA; [Furere, Musange S.] Natl Univ Rwanda, Kigali, Rwanda									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIH4	S100	S100					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400433
J	Vysotska, O; Piniazhko, O; Vysotskyi, V; Masheiko, A; Serediuk, V; Leleka, M				Vysotska, O.; Piniazhko, O.; Vysotskyi, V.; Masheiko, A.; Serediuk, V; Leleka, M.			REAL-WORLD DATA ANALYSIS OF ANTIRETROVIRAL TREATMENT FOR HIV-INFECTED CHILDREN IN UKRAINE	VALUE IN HEALTH			English	Meeting Abstract									[Vysotska, O.; Vysotskyi, V.] Bogomolets Natl Med Univ, Ukrainian Family Med Training Ctr, Educ & Res Ctr, Kiev, Ukraine; [Piniazhko, O.] Minist Hlth Ukraine, State Expert Ctr, Lvov, Ukraine; [Masheiko, A.] Minist Hlth Ukraine, State Expert Ctr, Kyiv, BC, Canada; [Serediuk, V; Leleka, M.] Minist Hlth Ukraine, State Expert Ctr, Kiev, Ukraine									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN78	S120	S120					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400526
J	Willms, K; Jamet, N; Shek, N; Achrafie, L; Haddlesey, A; Bureau, M				Willms, K.; Jamet, N.; Shek, N.; Achrafie, L.; Haddlesey, A.; Bureau, M.			EXPECTATIONS VERSUS REALITY: HOW REAL-WORLD DATA FITS INTO BUDGET IMPACT ANALYSES	VALUE IN HEALTH			English	Meeting Abstract									[Willms, K.; Jamet, N.; Achrafie, L.] Amaris Consulting Inc, Toronto, ON, Canada; [Shek, N.; Haddlesey, A.; Bureau, M.] Hoffman La Roche Ltd, Mississauga, ON, Canada									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		RE3	S238	S238					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401307
J	Xiong, Y; Liu, Y; Hu, Q; Long, E; Bian, Y				Xiong, Y.; Liu, Y.; Hu, Q.; Long, E.; Bian, Y.			EVALUATING THE EFFECTIVENESS AND SAFETY AND ECONOMY OF DOMESTIC AND ORIGINAL TIGECYCLINE FOR INJECTION IN REAL-WORLD BASED ON PSM METHOD	VALUE IN HEALTH			English	Meeting Abstract									[Xiong, Y.; Hu, Q.] Univ Elect Sci & Technol China, Chengdu, Peoples R China; [Liu, Y.] Southwest Med Univ, Luzhou, Peoples R China; [Long, E.; Bian, Y.] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Sch Med, Chengdu, Peoples R China									0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PDG41	S94	S94					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400410
J	Yang, H; Hall, A; Qian, J; Ngorsuraches, S; Garza, KB				Yang, H.; Hall, A.; Qian, J.; Ngorsuraches, S.; Garza, K. B.			THE APPLICATION OF SHARED DECISION MAKING IN THE CHRONIC NON-CANCER PAIN MANAGEMENT: A SYSTEMATIC REVIEW	VALUE IN HEALTH			English	Meeting Abstract									[Yang, H.] Auburn Univ, Harrison Sch Pharm, Dazhu 51, Peoples R China; [Hall, A.; Qian, J.; Ngorsuraches, S.; Garza, K. B.] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PPM5	S195	S195					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401117
J	Yuasa, A; Yonemoto, N; LoPresti, M; Ikeda, S				Yuasa, A.; Yonemoto, N.; LoPresti, M.; Ikeda, S.			A SYSTEMATIC REVIEW OF THE USE OF PRODUCTIVITY LOSS/GAIN IN COST-EFFECTIVENESS ANALYSES FOR VACCINES	VALUE IN HEALTH			English	Meeting Abstract									[Yuasa, A.] Pfizer Japan Inc, Shibuya Ku, Tokyo 13, Japan; [Yonemoto, N.] Pfizer Japan Inc, Tokyo 13, Japan; [LoPresti, M.] INTAGE Healthcare Inc, Tokyo 13, Japan; [Ikeda, S.] Int Univ Hlth & Welf, Chiba, Japan									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PIN25	S109	S110					2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039400478
J	[Anonymous]				[Anonymous]			COST OF ILLNESS OF SICKLE CELL DISEASE IN THE US, PAYER'S PERSPECTIVE: (CRESCENT)	VALUE IN HEALTH			English	Meeting Abstract																		0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JUN	2021	24			1		PRO26	S202	S202					1	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	SQ0GK					2022-04-28	WOS:000660039401146
J	Chhatwal, J; Postma, MJ				Chhatwal, Jagpreet; Postma, Maarten J.			Health Economics of Interventions to Tackle the Coronavirus 2019 Pandemic	VALUE IN HEALTH			English	Editorial Material							COVID-19		[Chhatwal, Jagpreet] Harvard Med Sch, Massachusetts Gen Hosp, Inst Technol Asssessment, 101 Merrimac St,Floor 10th, Boston, MA 02114 USA; [Postma, Maarten J.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands; [Postma, Maarten J.] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, Groningen, Netherlands		Chhatwal, J (通讯作者)，Harvard Med Sch, Massachusetts Gen Hosp, Inst Technol Asssessment, 101 Merrimac St,Floor 10th, Boston, MA 02114 USA.	jagchhatwal@mgh.harvard.edu		Postma, Maarten/0000-0002-6306-3653			Basu A, 2021, VALUE HEALTH, V24, P632, DOI 10.1016/j.jval.2020.11.013; Campbell JD, ALTERNATIVE PRICING; Dawoud DM, 2020, VALUE HEALTH, V23, P1409, DOI 10.1016/j.jval.2020.07.002; Forsythe S, 2020, VALUE HEALTH, V23, P1427, DOI 10.1016/j.jval.2020.04.1824; Gravesteijn B, 2021, VALUE HEALTH, V24, P648, DOI 10.1016/j.jval.2020.12.010; Leahy J, 2020, VALUE HEALTH, V23, P1423, DOI 10.1016/j.jval.2020.09.003; Ma SY, 2020, VALUE HEALTH, V23, P1405, DOI 10.1016/j.jval.2020.06.002; Manski CF, 2021, VALUE HEALTH, V24, P641, DOI 10.1016/j.jval.2020.11.019; Mouter N, 2021, VALUE HEALTH, V24, P658, DOI 10.1016/j.jval.2021.01.001; Mullins CD, 2020, VALUE HEALTH, V23, P1403, DOI 10.1016/j.jval.2020.09.009; National Institute of Health, COVID 19 TREATM GUID; Reed S, 2020, VALUE HEALTH, V23, P1438, DOI 10.1016/j.jval.2020.07.003; Shlomai A, 2021, VALUE HEALTH, V24, P607, DOI 10.1016/j.jval.2020.09.013; Towse A, 2021, VALUE HEALTH, V24, P625, DOI 10.1016/j.jval.2020.12.008; Zala D, 2020, VALUE HEALTH, V23, P1432, DOI 10.1016/j.jval.2020.07.001; Zhao JD, 2021, VALUE HEALTH, V24, P615, DOI 10.1016/j.jval.2020.12.009	16	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	MAY	2021	24	5					605	606		10.1016/j.jval.2021.03.002		APR 2021	2	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	RU9KC	33933227	Green Submitted, Green Published, Bronze			2022-04-28	WOS:000645457500001
J	Watts, E; Sim, SY; Constenla, D; Sriudomporn, S; Brenzel, L; Patenaude, B				Watts, Elizabeth; Sim, So Yoon; Constenla, Dagna; Sriudomporn, Salin; Brenzel, Logan; Patenaude, Bryan			Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches	VALUE IN HEALTH			English	Article						cost of illness; immunization; productivity loss; value-of-statistical-life	JAPANESE ENCEPHALITIS VACCINE; PNEUMONIA; CHILDREN; DEATHS; IMPACT	Objectives: Vaccination has prevented millions of deaths and cases of disease in lowand middle-income countries (LMICs). During the Decade of Vaccines (2011-2020), international organizations, including the World Health Organization and Gavi, the Vaccine Alliance, focused on new vaccine introduction and expanded coverage of existing vaccines. As Gavi, other organizations, and country governments look to the future, we aimed to estimate the economic benefits of immunization programs made from 2011 to 2020 and potential gains in the future decade. Methods: We used estimates of cases and deaths averted by vaccines against 10 pathogens in 94 LMICs to estimate the economic value of immunization. We applied 3 approaches-cost of illness averted (COI), value of statistical life (VSL), and value of statistical life-year (VSLY)-to estimate observable and unobservable economic benefits between 2011 and 2030. Results: From 2011 to 2030, immunization would avert $1510.4 billion ($674.3-$2643.2 billion) (2018 USD) in costs of illness in the 94 modeled countries, compared with the counterfactual of no vaccination. Using the VSL approach, immunization would generate $3436.7 billion ($1615.8-$5657.2 billion) in benefits. Applying the VSLY approach, $5662.7 billion ($2547.2-$9719.4) in benefits would be generated. Conclusion: Vaccination has generated significant economic benefits in LMICs in the past decade. To reach predicted levels of economic benefits, countries and international donor organizations need to meet coverage projections outlined in the Gavi Operational Forecast. Estimates generated using the COI, VSL, or VSLY approach may be strategically used by donor agencies, decision makers, and advocates to inform investment cases and advocacy campaigns.	[Watts, Elizabeth; Sriudomporn, Salin; Patenaude, Bryan] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Baltimore, MD USA; [Watts, Elizabeth; Sriudomporn, Salin; Patenaude, Bryan] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Sim, So Yoon] World Hlth Org, Dept Immunizat Vaccines & Biol IVB, Geneva, Switzerland; [Constenla, Dagna] GlaxoSmithKline Plc, Panama City, Panama; [Brenzel, Logan] Bill & Melinda Gates Fdn, Seattle, WA USA		Watts, E (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Int Vaccine Access Ctr, 415 N Washington St,Off 530, Baltimore, MD 21231 USA.	ewatts13@jhu.edu		Patenaude, Bryan/0000-0002-5180-3626	Bill and Melinda Gates Foundation, United States [OPP1128214]	Bill and Melinda Gates Foundation, United States, OPP1128214 Multi Project Grant.	[Anonymous], 2020, DOUBL COUNT LIV SAV; [Anonymous], 2018, LANCET, V392, P2139, DOI DOI 10.1016/S0140-6736(18)32862-9; Bishai D, 2011, J INFECT DIS, V204, pS107, DOI 10.1093/infdis/jir131; Chang AY, 2018, HEALTH AFFAIR, V37, P316, DOI 10.1377/hlthaff.2017.0861; de Broucker G, 2020, PHARMACOECONOMICS, V38, P1071, DOI 10.1007/s40273-020-00940-4; Dieleman JL, 2018, LANCET, V391, P1783, DOI 10.1016/S0140-6736(18)30697-4; Ding D, 2003, B WORLD HEALTH ORGAN, V81, P334; Drummond JM, 2005, J HIGH ENERGY PHYS; Gargano LM, 2017, VACCINE, V35, P435, DOI 10.1016/j.vaccine.2016.11.070; Gavi the Vaccine Alliance, GAVI V16; Gavi the Vaccine Alliance, VACC ALL PREV PROT P; Gavi the Vaccine Alliance, INV CAS TECHN APP; International Labour Office, 2018, WOM MEN INF EC STAT; Kim SY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-260; Kim SY, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-253; Lee BY, 2011, AM J TROP MED HYG, V84, P764, DOI 10.4269/ajtmh.2011.10-0624; Li X, 2019, ESTIMATING HLTH IMPA, DOI [10.1101/19004358v1, DOI 10.1101/19004358, 10.1101/19004358.]; Liu W, 2008, VACCINE, V26, P4456, DOI 10.1016/j.vaccine.2008.06.050; Lusvan ME, 2019, VACCINE, V37, P798, DOI 10.1016/j.vaccine.2018.12.056; Masterman CJ, 2018, J BENEFIT-COST ANAL, V9, P407, DOI 10.1017/bca.2018.20; Ojal J, 2019, LANCET GLOB HEALTH, V7, pE644, DOI 10.1016/S2214-109X(18)30562-X; Ozawa S, 2011, HLTH AFF, V30; Ozawa S, 2017, B WORLD HEALTH ORGAN, V95, P629, DOI 10.2471/BLT.16.178475; Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562; Robinson LA, REFERENCE CASE GUIDE; Robinson LA, 2019, J BENEFIT-COST ANAL, V10, P15, DOI 10.1017/bca.2018.26; Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895; Sim SY, 2020, HEALTH AFFAIR, V39, P1343, DOI 10.1377/hlthaff.2020.00103; Sim SY, VALUE HLTH; Sinha A, 2008, REV PANAM SALUD PUBL, V24, P304, DOI 10.1590/S1020-49892008001100002; Stack ML, 2011, HEALTH AFFAIR, V30, P1021, DOI 10.1377/hlthaff.2011.0382; Stenberg K, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0095-x; Strategic Advisory Group of Experts on Immunization, 2019, WHOIVB1907; The United Nations, WORLD POP PROSP 2017; Touch S, 2010, VACCINE, V28, P4593, DOI 10.1016/j.vaccine.2010.04.086; U.S. Department of State, COUNTR REP HUM RIGHT; UNICEF, MULT IND CLUST SURV; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; World Health Organization, IMM MON; Yin ZD, 2012, VACCINE, V30, P5569, DOI 10.1016/j.vaccine.2012.05.068	40	5	5	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1098-3015	1524-4733		VALUE HEALTH	Value Health	JAN	2021	24	1					78	85		10.1016/j.jval.2020.07.009		JAN 2021	8	Economics; Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Health Care Sciences & Services	QC0YJ	33431157	Bronze			2022-04-28	WOS:000614560000011
